

Sunday, 22. March 2026*Non-Profit Symposium*

08:30 - 10:00

R2

IS01 - Innovations in allogeneic stem cell transplantation and immunotherapy | SORBONNE-ATERHIT

Bipin Savani (Nashville, United States of America (the))

Eolia Brissot (Paris, France)

| | | |
|--------|---|---------------|
| IS01-1 | Rejuvenating cord blood transplantation Annalisa Ruggeri (Milano, Italy) | 08:30 - 08:45 |
| IS01-2 | EU guidelines for the prevention of GVHD Zinaida Peric (Rijeka, Croatia) | 08:45 - 09:00 |
| IS01-3 | Management of refractory acute GVHD Florent Malard (Paris, France) | 09:00 - 09:15 |
| IS01-4 | Chemo-free therapy for Ph + ALL He Huang (Hangzhou, China) | 09:15 - 09:30 |
| IS01-5 | Allo-HCT for T-ALL Eolia Brissot (Paris, France) | 09:30 - 09:45 |
| IS01-6 | Round table discussion - How to improve QoL after allo-HCT - All speakers and moderators | 09:45 - 10:00 |

Non-Profit Symposium

08:30 - 10:00

R3

IS02 - Donor selection for Allo-SCT: does HLA matching still matter? | SFGM-TC

Maud D'Aveni (Nancy, France)

Anne Huynh (Toulouse, France)

| | | |
|--------|--|---------------|
| IS02-1 | Clinical case about donor selection Etienne Daguindau (BESANCON, France) Simona Pagliuca (Nancy, France) | 08:30 - 09:00 |
| IS02-2 | What does HLA matching mean in 2026? Roberto Crocchiolo (Milano, Italy) | 09:00 - 09:30 |
| IS02-3 | Impact of donor type on outcome: is HLA matching still the most relevant factor? Raynier Devillier (Marseille, France) | 09:30 - 10:00 |

Non-Profit Symposium

08:30 - 10:00

R4

IS03 - Modern strategies to improve outcome after allogeneic stem cell transplantation in Myelofibrosis | University Hospital Essen

Nicolaus Kröger (Essen, Germany)

Thomas Schroeder (Essen, Germany)

Nico Gagelmann (Hamburg, Germany)

| | | |
|--------|--|---------------|
| IS03-1 | Welcome Nicolaus Kröger (Essen, Germany) | 08:30 - 08:35 |
| IS03-2 | Optimizing conditioning to reduce toxicity and improve outcome Nico Gagelmann (Hamburg, Germany) | 08:35 - 08:50 |
| IS03-3 | Optimizing GvHD prevention in sibling and MUD transplantation Patrizia Chiusolo (Roma, Italy) | 08:50 - 09:05 |
| IS03-4 | Optimal Haplo Strategy alternative donor strategies in patients lacking HLA compatible Donor | 09:05 - 09:20 |

| | | |
|--|--|---------------|
| | Thomas Schroeder (Essen, Germany) | |
| IS03-5 | Defining remission criteria after allograft for myelofibrosis Rachel Salit (Seattle, United States of America (the)) | 09:20 - 09:45 |
| IS03-6 | Podium discussion: All faculty | 09:45 - 10:00 |
| <i>Non-Profit Symposium</i> | | |
| 08:30 - 10:00 | | R5 |
| IS04 - Latest advances in multiple myeloma - With the institutional support of H.A.C. Pharma IFM | | |
| Mohamad Mohty (Paris, France) | | |
| IS04-1 | Immunotherapy for elderly patients Thierry Facon (Lille, France) | 08:30 - 08:50 |
| IS04-2 | Should MRD be the endpoint for clinical trials and routine practice? Jesús San-Miguel (Pamplona, Spain) | 08:50 - 09:10 |
| IS04-3 | Milestones in auto-SCT for myeloma Joaquín Martínez (Madrid, Spain) | 09:10 - 09:30 |
| IS04-4 | CAR-T cells in myeloma: current status Mohamad Mohty (Paris, France) | 09:30 - 09:50 |
| IS04-5 | Round table discussion - All Speakers | 09:50 - 10:00 |
| <i>Nurses Group</i> | | |
| 08:30 - 10:00 | | R7 |
| NG01 - Nurses Education Day 1: Advancing the art of nursing care in HSCT and cell therapy Transplantation challenges throughout the generations | | |
| Marijke Quaghebeur (Ghent, Belgium) | | |
| Isabel Salcedo (Madrid, Spain) | | |
| NG01-1 | A case of age specific challenges in infants Julia Ruiz Pato (Madrid, Spain) | 08:30 - 08:51 |
| NG01-2 | A case of age specific challenges in AYA Thomas Jezequel (Nantes, France) | 08:51 - 09:12 |
| NG01-3 | A case of age specific challenges in adults Solveig Adalsteinsdottir (Stockholm, Sweden) | 09:12 - 09:33 |
| NG01-4 | A case of age specific challenges in the older adult Berta Solé Tomàs (Barcelona, Spain) | 09:33 - 09:54 |
| NG01-5 | Q&A | 09:54 - 10:00 |
| <i>Non-Profit Symposium</i> | | |
| 08:30 - 10:00 | | R8 |
| IS05 - Enhancing Efficacy and Safety in Hematopoietic Stem Cell Transplantation: Insights from Cooperative Research Spanish Society for HSCT & Cell Therapy (GETH-TC) | | |
| Mi Kwon (Madrid, Spain) | | |
| Montserrat Rovira (Barcelona, Spain) | | |
| IS05-1 | Viral infections after allo-HCT. How much should we be concerned in 2026? José Luis Piñana (VALENCIA, Spain) | 08:30 - 08:55 |
| IS05-2 | Graft manipulation in the PTCy-era Antonio Pérez Martínez (Madrid, Spain) | 08:55 - 09:20 |
| IS05-3 | Post-Transplant Cyclophosphamide, Frailty, and Cardiomyopathy: A | 09:20 - 09:45 |

| | | |
|---------------------------------|--|---------------|
| | Challenging Triad in modern Allogeneic HCT procedures | |
| | M Queralt Salas (Barcelona, Spain) | |
| IS05-4 | Discussion - All | 09:45 - 10:00 |
| <i>Non-Profit Symposium</i> | | |
| | | 08:30 - 10:00 |
| | | R12 |
| | IS06 - GMMG symposium | |
| | Christof Scheid (Cologne, Germany) | |
| | Hans Salwender (Hamburg, Germany) | |
| IS06-1 | Therapy of newly-diagnosed multiple myeloma patients | 08:30 - 08:43 |
| | Marc Raab (Heidelberg, Germany) | |
| IS06-2 | Treatment of high-risk multiple myeloma | 08:43 - 08:56 |
| | Ricardo Kosch (Hamburg, Germany) | |
| IS06-3 | Role of CART therapy and bispecific antibodies in multiple myeloma | 08:56 - 09:09 |
| | Christof Scheid (Cologne, Germany) | |
| IS06-4 | Therapy of relapsed multiple myeloma patients outside of immunotherapies | 09:09 - 09:22 |
| | Hans Salwender (Hamburg, Germany) | |
| IS06-5 | Immune deficiencies and infections in myeloma therapy | 09:22 - 09:35 |
| | Igor Blau (Berlin, Germany) | |
| IS06-6 | Update on AL Amyloidosis | 09:35 - 09:48 |
| | Alexander Carpinteiro (Essen, Germany) | |
| IS06-7 | Q&A | 09:48 - 10:00 |
| <i>ePoster</i> | | |
| | | 08:30 - 18:00 |
| | | R20 |
| | Gene Therapy - Clinical | |
| A278 | LONG-TERM CLINICAL OUTCOMES OF ATIDARSAGENE AUTOTEMCEL, AUTOLOGOUS HEMATOPOIETIC STEM CELL GENE THERAPY (HSC-GT) FOR EARLY-ONSET METACHROMATIC LEUKODYSTROPHY, WITH UP TO 13 YEARS OF FOLLOW-UP | 08:30 - 08:30 |
| | Salvatore Recupero (Milan, Italy) | |
| A279 | REFRAMING PAIN AND VOES AFTER TRANSFORMATIVE THERAPIES FOR SICKLE CELL DISEASE: INSIGHTS FROM GENE THERAPY WITH LOVOTIBEGLOGENE AUTOTEMCEL | 08:30 - 08:30 |
| | Julie Kanter (Birmingham, United States Minor Outlying Islands (the)) | |
| A280 | FIRST-IN-WORLD EXPERIENCE OF IMMUNOMODULATION TO PROMOTE RECIPIENT TOLERANCE TO GENE MODIFIED AUTOLOGOUS STEM CELL TRANSPLANT FOR MPS II | 08:30 - 08:30 |
| | Nathan Jeffreys (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| A281 | GALLBLADDER ABNORMALITIES IN METACHROMATIC LEUKODYSTROPHY: PRELIMINARY ANALYSIS IN PATIENTS TREATED WITH HEMATOPOIETIC STEM CELL GENE THERAPY AND UNTREATED PATIENTS | 08:30 - 08:30 |
| | Salvatore Recupero (Milan, Italy) | |
| A282 | BRIDGING READINESS AND REALITY: U.S. PEDIATRIC HEMATOLOGISTS' PERSPECTIVES ON GENE THERAPY FOR SICKLE CELL DISEASE IN THE POST-APPROVAL ERA | 08:30 - 08:30 |
| | Alexander Ngwube (Houston, United States Minor Outlying Islands (the)) | |

| | | |
|---------------------------------|---|---------------|
| A283 | A CASE OF LACK OF ENGRAFTMENT OF GENE-CORRECTED CELLS AFTER LENTIVIRAL HEMATOPOIETIC STEM CELL GENE THERAPY FOR METACHROMATIC LEUKODYSTROPHY: AN INTEGRATED CLINICAL AND IMMUNOLOGICAL INVESTIGATION Valeria Calbi (Milan, Italy) | 08:30 - 08:30 |
| A284 | STEM CELL MOBILISATION FOR GENE THERAPY IN ADOLESCENT PATIENTS WITH SICKLE CELL DISEASE: EXPERIENCE FROM THE FIRST THREE PATIENTS IN THE UK Sarah Lawson (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A285 | THE USE OF GCSF FOR STEM CELLS MOBILIZATION IN PATIENTS WITH SICKLE CELL DISEASE TREATED WITH GENE THERAPY Mohammed Essa (Riyadh, Saudi Arabia) | 08:30 - 08:30 |
| P098 | EXPLORING THE REIMBURSEMENT OF CAR-T CELL THERAPY FOR MULTIPLE MYELOMA AND B-CELL LYMPHOMA PATIENTS UNDER TURKIYE'S SOCIAL SECURITY SYSTEM (SGK) Meltem Kurt Yuksel (Ankara, Turkey) | 08:30 - 08:30 |
| <i>ePoster</i> 08:30 - 18:00 | | R20 |
| Autoimmune Diseases | | |
| B337 | REAL-WORLD ANALYSIS OF RAVULIZUMAB SAFETY AND EFFECTIVENESS IN ADVANCED AGE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: INSIGHTS FROM THE INTERNATIONAL PNH REGISTRY Philippe Gustovic (Baar, Switzerland) | 08:30 - 08:30 |
| B338 | DANICOPAN ADD-ON THERAPY DEMONSTRATES POSITIVE EFFICACY AND SAFETY IN ADVANCED AGE ADULTS WITH PNH AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS: PHASE 3 ALPHA TRIAL SUB-ANALYSIS Austin Kulasekararaj (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B339 | HETEROGENEOUS NON-HEMATOLOGIC AUTOIMMUNE COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC LEUKEMIA: INCIDENCE, SPECTRUM, AND OUTCOMES IN A SINGLE-CENTER COHORT Amir Ali Hamidieh (Tehran, Iran (Islamic Republic of)) | 08:30 - 08:30 |
| B340 | FROM VISION TO REALITY: EVALUATING SAFETY OF THE FIRST IN HOUSE IMPLEMENTED CD19 CAR-T IN UNITED ARAB EMIRATES FOR SLE PATIENTS Mohamed Abu-Haleeqa (Abu Dhabi, United Arab Emirates (the)) | 08:30 - 08:30 |
| B341 | REDUCTION OF INTERLEUKIN-6 AND INTERLEUKIN-8-MEDIATED INFLAMMATION AND PROLIFERATION IN SKIN FIBROBLASTS IN SYSTEMIC SCLEROSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION MEASURED BY GENE EXPRESSION ANALYSES Gunter Assmann (Minden, Germany) | 08:30 - 08:30 |
| B342 | SAFETY OF RAVULIZUMAB USE IN PREGNANCY: INSIGHTS FROM A GLOBAL PHARMACOVIGILANCE ANALYSIS Cory Williams (New Haven, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B343 | MMR SEROLOGIC STATUS IN MULTIPLE SCLEROSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION Edoardo Simonetti (Florence, Italy) | 08:30 - 08:30 |
| B344 | INFECTIOUS COMPLICATIONS IN DUTCH MS-PATIENTS WITHIN THE FIRST YEAR AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A FOREIGN COUNTRY | 08:30 - 08:30 |

| | | |
|----------------------------|---|---------------|
| | Lara Suzanne Oosterom (Groningen, Netherlands (the)) | |
| B345 | NUMBER OF CD34 CELLS EMPLOYED IN AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR PERSONS WITH MULTIPLE SCLEROSIS IS NOT RELATED TO THE NEUROLOGICAL OUTCOME OF THE PROCEDURE Guillermo J. Ruiz-Argüelles (Puebla, Mexico) | 08:30 - 08:30 |
| B346 | BEYOND STEM CELLS; DUAL NK-CELL POPULATION IN STEM CELL GRAFT MAY CONTRIBUTE TO IMMUNE RESET POST AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS Shahna Barrett (Kingston, Jamaica) | 08:30 - 08:30 |
| B347 | AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ANTI-SYNTHEASE SYNDROME: LONG-TERM OUTCOMES FROM TWO REFRACTORY CASES Michel Lu (Sydney, Australia) | 08:30 - 08:30 |
| B348 | OUTCOMES OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE SCLEROSIS: EXPERIENCE FROM SOUTH AFRICA Adam Setzer (Johannesburg, South Africa) | 08:30 - 08:30 |
| B349 | ANTI-CD38 MONOCLONAL ANTIBODY FOR TREATING IMMUNE THROMBOCYTOPENIA:A CASE REPORT | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Bone Marrow Failure | | |
| B334 | EFFICACY AND SAFETY OF IPTACOPAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REAL-WORLD STUDY OF 37 PATIENTS IN CHINA | 08:30 - 08:30 |
| B335 | T CELL-DEPLETED HAPLOIDENTICAL AND MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION REPRESENT SAFE AND EFFICIENT THERAPEUTIC APPROACHES FOR PEDIATRIC PATIENTS WITH BONE MARROW FAILURE SYNDROMES Anja Troeger (Regensburg, Germany) | 08:30 - 08:30 |
| P264 | GROWTH IMPAIRMENT AND PROGRESSIVE SHORT STATURE IN PEARSON SYNDROME Ayami Yoshimi (Freiburg, Germany) | 08:30 - 08:30 |
| P265 | OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS THE ONLY TREATMENT AVAILABLE FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN VENEZUELA Marcos Hernandez (Valencia, Venezuela (Bolivarian Republic of)) | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Aplastic Anaemia | | |
| B320 | PREVIOUS ANTITHYMOCYTE-BASED IMMUNOSUPPRESSIVE THERAPY INCREASED THE RISK OF VIRUS REACTIVATION IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA Zhengli Xu (Beijing, China) | 08:30 - 08:30 |
| B321 | IMPROVING THE OUTCOME OF STEM CELL TRANSPLANTATION IN PATIENTS WITH SEVERE APLASTIC ANEMIA | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | Sabrina Giammarco (Rome, Italy) | |
| B323 | ASSESSMENT OF DONOR ENGRAFTMENT KINETICS FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT OF SEVERE APLASTIC ANEMIA Ganesh Raman (Seattle, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B324 | QUALITY OF LIFE IN PATIENTS WITH APLASTIC ANEMIA IMPROVES DURING IMMUNOSUPPRESSIVE THERAPY AND CORRELATES WITH DEPTH OF RESPONSE: ANALYSIS OF THE SAAWP EBMT RACE STUDY Iris Lommerse (Leiden, Netherlands (the)) | 08:30 - 08:30 |
| B325 | QUALITATIVE ASSESSMENT OF PREDICTORS OF RESPONSE TO IMMUNOSUPPRESSIVE THERAPY IN APLASTIC ANAEMIA: A SYSTEMATIC LITERATURE REVIEW Phillip Scheinberg (Sao Paulo, Brazil) | 08:30 - 08:30 |
| B326 | AB T-CELL DEPLETION VERSUS PTCY IN UNRELATED DONOR HSCT FOR PEDIATRIC PATIENTS WITH APLASTIC ANEMIA Daria Shasheleva (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| B327 | EXCELLENT OUTCOMES AFTER HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA SUPPORT EARLY TRANSPLANTATION Gisele Loth (Curitiba, Brazil) | 08:30 - 08:30 |
| B328 | AN EPIGENOME-WIDE ASSOCIATION (EWAS) STUDY IN FANCONI ANEMIA AND APLASTIC ANEMIA Maura Faraci (Genova, Italy) | 08:30 - 08:30 |
| B329 | HIGH CD34+ CELL DOSE SIGNIFICANTLY REDUCES EBV REACTIVATION AND IMPROVES SURVIVAL IN APLASTIC ANEMIA PATIENTS UNDERGOING UCBT Jing Long (Beijing, China) | 08:30 - 08:30 |
| B330 | A SYSTEMATIC REVIEW OF REAL-WORLD EVIDENCE ON THERAPIES FOR MODERATE APLASTIC ANAEMIA Britta Hoechsmann (Ulm, Germany) | 08:30 - 08:30 |
| B331 | HAPLOIDENTICAL VS MATCHED UNRELATED DONOR TRANSPLANTATION IN SEVERE APLASTIC ANEMIA: A SINGLE-CENTER COHORT Mohamed I. Sharif (Toronto, Canada) | 08:30 - 08:30 |
| B332 | THIOTEPA-BASED BUSULFAN-SPARING CONDITIONING OPTIMIZES ENGRAFTMENT AND MITIGATES CHRONIC GVHD IN PEDIATRIC HAPLOIDENTICAL HSCT FOR SAA: A MATCHED CASE-CONTROL STUDY Shaoyan Hu (Suzhou, China) | 08:30 - 08:30 |
| B333 | SECOND ALLOGENEIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA: REAL-WORLD OUTCOMES FROM A SINGLE CENTRE IN PAKISTAN Bushra Ahsan (Lahore, Pakistan) | 08:30 - 08:30 |
| P260 | PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN FANCONI ANEMIA: A CASE SERIES OF SINGLE CENTER EXPERIENCE Bulent Antmen (Adana, Turkey) | 08:30 - 08:30 |
| P261 | EXPERIENCE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACQUIRED APLASTIC ANEMIA BETWEEN 2010-2015 IN A SINGLE CENTER Blanca Vegas (Madrid, Spain) | 08:30 - 08:30 |

| | | |
|--|--|---------------|
| P262 | CASE REPORT: THE USE OF PEGCETACOPLAN PERI-HAEMATOPOIETIC STEM CELL TRANSPLANT FOR PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA / APLASTIC ANAEMIA Alma Corker (Sydney, Australia) | 08:30 - 08:30 |
| P263 | AUTOLOGOUS UMBILICAL CORD BLOOD TRANSPLANTATION WITHOUT CHEMOTHERAPY-BASED CONDITIONING IN A CHILD WITH SEVERE APLASTIC ANEMIA: A CASE REPORT Katarzyna Bobeff (Lodz, Poland) | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Late complications, quality of life, fertility and survivorship | | |
| A414 | CARDIOVASCULAR HEALTH OF HAEMATOPOIETIC STEM CELL TRANSPLANT SURVIVORS IN THE UK BIOBANK Dorina-Gabriela Condurache (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A415 | SOCIAL IMPACT AND PATIENT-CAREGIVER EXPERIENCE IN CHRONIC GVHD: RESULTS FROM A NATIONAL SURVEY IN SPAIN Marta Fernandez (Barcelona, Spain) | 08:30 - 08:30 |
| A416 | SURVEY ON FERTILITY MANAGEMENT AND OUTCOMES AFTER CAR T, ON BEHALF OF THE EBMT CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY Giorgio Orofino (Milan, Italy) | 08:30 - 08:30 |
| A417 | SECOND PRIMARY MALIGNANCIES AFTER T-CELL ENGAGING BISPECIFIC ANTIBODY THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS Jaromir Tomasik (Warsaw, Poland) | 08:30 - 08:30 |
| A418 | QUALITY OF LIFE RECOVERY FOLLOWING CHRONIC GRAFT-VERSUS-HOST DISEASE RESOLUTION IN LONG-TERM ALLOGENEIC TRANSPLANT SURVIVORS Genevieve Douglas (Melbourne, Australia) | 08:30 - 08:30 |
| A419 | LONGITUDINAL ASSESSMENT OF FRAILTY AND FUNCTIONAL RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE PROPHYLAXIS Adriana Cuartas (Barcelona, Spain) | 08:30 - 08:30 |
| A420 | EXTENSIVE OR SEVERE CHRONIC GVHD IS ASSOCIATED WITH SUSTAINED AND WORSENING IMPAIRMENTS IN SYMPTOMS AND WELL-BEING UP TO 5 YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Pleun Schonewille (Utrecht, Netherlands (the)) | 08:30 - 08:30 |
| A421 | SIGNIFICANT IMPROVEMENT OF SURVIVAL AND GVHD- AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OVER TIME Hanna A. Knaus (Vienna, Austria) | 08:30 - 08:30 |
| A422 | POST-HCT EMPLOYMENT AND ASSOCIATED FACTORS AMONG CHILDHOOD, ADOLESCENT, AND YOUNG ADULT PATIENTS AT THE TIME OF TRANSPLANTATION Saiko Kurosawa (Nagano, Japan) | 08:30 - 08:30 |
| A423 | GONADAL FUNCTION OF CHILDREN AND ADOLESCENTS AFTER ALLOGENEIC HSCT WITH TREOSULFAN- AND TBI-BASED CONDITIONING Susanna Arakelyan (Moscow, Russian Federation (the)) | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| A424 | LONG-TERM SURVIVAL AND QUALITY OF LIFE IN OLDER ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANT Kyra A. Oosterink (Leiden, Netherlands (the)) | 08:30 - 08:30 |
| A425 | GONADAL TOXICITY AND PREMATURE OVARIAN INSUFFICIENCY AFTER HEMATOPOIETIC STEM CELL GENE-THERAPY IN FEMALE PATIENTS WITH METACHROMATIC LEUKODYSTROPHY Salvatore Recupero (Milan, Italy) | 08:30 - 08:30 |
| A426 | MAPPING QUALITY OF LIFE OVER TIME: INSIGHTS FROM THE ACCESS TRIAL USING MISMATCHED UNRELATED DONORS Rachel Cusatis (Milwaukee, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A427 | EVALUATING THE POTENTIAL OF E-HEALTH TO IMPROVE POST-TRANSPLANT CARE: PRELIMINARY RESULTS OF THE MY-MEDULA RANDOMIZED TRIAL Irene García-Cadenas (Barcelona, Spain) | 08:30 - 08:30 |
| A429 | IMPACT OF REDUCED-INTENSITY CONDITIONING REGIMENS ON FEMALE GONADAL FUNCTION IN SICKLE CELL DISEASE Tamara Diesch-Furlanetto (Basel, Switzerland) | 08:30 - 08:30 |
| A430 | NOT JUST SURVIVING BUT THRIVING - A PEDSQL-MEASURED QUALITY OF LIFE IN LONG TERM SURVIVORS WHO UNDERWENT HSCT FOR IBMFS Krithika Krishnakumar (Chennai, India) | 08:30 - 08:30 |
| A431 | INCIDENCE, RISK FACTORS AND OUTCOMES OF AVASCULAR NECROSIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS DEVELOPING GRAFT-VERSUS-HOST DISEASE Rohan Jacob Verghese (Navi Mumbai, India) | 08:30 - 08:30 |
| A432 | SECOND PRIMARY MALIGNANCY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION - LONG-TERM FOLLOW-UP AT A SINGLE INSTITUTE EXPERIENCE Lun-Wei Chiou (Taipei, Taiwan (Province of China)) | 08:30 - 08:30 |
| A433 | NON-INFECTIOUS COMPLICATIONS AFTER CAR-T CELL THERAPY Juan Manuel Cerezo-Martín (Santander, Spain) | 08:30 - 08:30 |
| A434 | FROM CHILDHOOD TO ADOLESCENCE: LONG-TERM RISKS AND RECOVERY MORE THAN FIVE YEARS AFTER NON-TBI HSCT Amir Ali Hamidieh (Tehran, Iran (Islamic Republic of)) | 08:30 - 08:30 |
| A435 | BRONCHIOLITIS OBLITERANS SYNDROME AFTER PAEDIATRIC ALLOGENEIC HSCT: A SYSTEMATIC REVIEW OF THERAPEUTIC STRATEGIES Hannah Walker (Melbourne, Australia) | 08:30 - 08:30 |
| A436 | LATE MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION SURVIVORS Yun-Jung Huang (Taipei, Taiwan (Province of China)) | 08:30 - 08:30 |
| P235 | SEXUAL ACTIVITY DURING NEUTROPENIA AND IMMUNOSUPPRESSION: WHAT DO YOU TELL YOUR PATIENT? Sigrun Einarsdottir Anna Nordlander (Stockholm, Sweden) | 08:30 - 08:30 |
| P236 | LONG-TERM RESULTS OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AUTO-HCT AND ALLO-HCT) - REAL-LIFE DATA FROM A SINGLE CENTER ANALYSIS OF 15- AND 20-YEAR SURVIVALS Kajetan Karaszewski (Warsaw, Poland) | 08:30 - 08:30 |
| P237 | MORBIDITY BURDEN, SOCIAL REHABILITATION AND QUALITY OF LIFE IN LONG-TERM SURVIVORS OF HAEMATOPOIETIC CELL | 08:30 - 08:30 |

| | | |
|--|---|---------------|
| | TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE FROM INDIA | |
| | Sachin Punatar (Navi Mumbai, India) | |
| P238 | DE NOVO DONOR-DERIVED PDGFRA-REARRANGED EOSINOPHILIA AFTER HAPLOIDENTICAL HSCT IN A PATIENT WITH PRIOR AML AND T-LBL: A CASE OF SEQUENTIAL MULTILINEAGE MALIGNANCIES | 08:30 - 08:30 |
| | Angelica Cabbuag (Taguig City, Philippines (the)) | |
| P239 | KIDNEY TRANSPLANTATION FOLLOWING HSCT, COMPLICATED BY TA-TMA WITH PROGRESSION TO END-STAGE RENAL DISEASE | 08:30 - 08:30 |
| | Evelina Lyudovskikh (Moscow, Russian Federation (the)) | |
| P240 | COST EFFECTIVENESS EVALUATION OF THE IMPLEMENTATION OF AN ON-LINE EXTRACORPOREAL PHOTOCHEMOTHERAPY TECHNOLOGY FOR POST BMT C-GVHD PREVIOUSLY TREATED WITH AN OFF-LINE TECHNOLOGY IN ANOTHER HOSPITAL | 08:30 - 08:30 |
| | Paola Maria Manzini (Cuneo, Italy) | |
| P241 | ERYTHROCYTOSIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE | 08:30 - 08:30 |
| | Ajda Gunes (Izmir, Turkey) | |
| P242 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH SEVERE CARDIOVASCULAR COMORBIDITY | 08:30 - 08:30 |
| | Ilya Potapov (Saint-Petersburg, Russian Federation (the)) | |
| P244 | SUCCESSFUL TREATMENT OF SECONDARY HISTIOCYTIC SARCOMA AFTER B-ALL TRANSPLANTATION WITH TARGETED THERAPY COMBINED WITH RADIOTHERAPY: A CASE REPORT | 08:30 - 08:30 |
| | Jing Long (Beijing, China) | |
| <i>ePoster</i> | | |
| | 08:30 - 18:00 | R20 |
| Paediatrics - Basic and translational | | |
| B268 | PRE-TRANSPLANT RESISTOME DISRUPTION PREDICTS ESBL GENE ACCUMULATION IN PEDIATRIC TRANSPLANT RECIPIENTS: A PROSPECTIVE MULTI-CENTER STUDY | 08:30 - 08:30 |
| | Edoardo Muratore (Bologna, Italy) | |
| B269 | REGULATORY T CELL RECONSTITUTION IS ASSOCIATED WITH ONSET AND SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC AND YOUNG ADULT HCT RECIPIENTS | 08:30 - 08:30 |
| | Jaap-Jan Boelens (New York, United States Minor Outlying Islands (the)) | |
| B270 | CAR-T PHENOTYPE AND HOST IMMUNE PROFILES AT APHERESIS AND POST-INFUSION DRIVE CD19 CAR-T PERSISTENCE IN PAEDIATRIC B ALL | 08:30 - 08:30 |
| B272 | ROLE OF PHARMACOGENETICS IN THE EFFICACY OF LOW-DOSE METHOTREXATE ADMINISTERED AS GVHD PROPHYLAXIS IN PEDIATRIC ALL PATIENTS: A FORUM STUDY | 08:30 - 08:30 |
| | Yvonne Gloor (Geneva, Switzerland) | |
| B273 | POTENTIAL FOR PHARMACOGENOMICS TO IMPROVE MEDICATION SAFETY AND EFFICACY IN AUSTRALIAN HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS | 08:30 - 08:30 |
| | Hannah Walker (Melbourne, Australia) | |
| B274 | HEMATOPOIETIC STEM CELL TRANSPLANTATION AND GUT MICROBIOME DIVERSITY IN CHILDREN | 08:30 - 08:30 |
| | Gustav Ørting Jørgensen (Copenhagen, Denmark) | |

ePoster

08:30 - 18:00

R20

Paediatrics - Clinical

- B203 **COMPARATIVE ANALYSIS ON ANTI-THYMOCYTE GLOBULIN (ATG) VS ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) IN PEDIATRIC PATIENTS WITH MALIGNANT DISEASES RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY** 08:30 - 08:30
 Francesco Saglio (Torino, Italy)
- B204 **PRETRANSPLANT ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) PREDICTS NON-RELAPSE MORTALITY AFTER ALLO-HSCT IN A MULTICENTRIC PEDIATRIC ALL COHORT WITH INCREASING RISK FOR OLDER PATIENTS** 08:30 - 08:30
 Dorothea Bauer (Vienna, Austria)
- B205 **IMPACT OF RECIPIENT AGE AND CYCLOSPORIN A TARGET LEVEL ON MIXED CHIMERISM AFTER TREOSULFAN-BASED MATCHED FAMILY DONOR HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE** 08:30 - 08:30
 Barbara Meissner (Hannover, Germany)
- B206 **OUTCOMES OF PATIENTS WITH AML UNDER 18 YEARS WHO RELAPSE WITHIN 6 MONTHS FROM ALLOGENEIC HSCT- A RETROSPECTIVE STUDY FROM THE EBMT PDWP** 08:30 - 08:30
 Claire Horgan (Manchester, United Kingdom of Great Britain and Northern Ireland (the))
- B207 **COMPARISON OF BONE MARROW VS PERIPHERAL BLOOD STEM CELLS FOR HAPLOIDENTICAL HSCT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN: A CIBMTR ANALYSIS** 08:30 - 08:30
 Joerg Krueger (Toronto, Canada)
- B208 **EFFICACY ANALYSIS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA: A 15-YEAR CLINICAL STUDY FROM CHINA** 08:30 - 08:30
 Shaoyan Hu (Suzhou, China)
- B209 **THE COMBINATION OF VENETOCLAX AND DECITABINE AS MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH VERY HIGH-RISK ACUTE MYELOID LEUKEMIA** 08:30 - 08:30
 Jonathan P. Gross (Berlin, Germany)
- B210 **MMUD VS MATCHED DONORS IN PEDIATRIC HSCT SETTING: TIME TO RE-THINK GVHD PROPHYLAXIS STRATEGIES?** 08:30 - 08:30
 Chiara Mainardi (Padova, Italy)
- B211 **BELUMOSUDIL USE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN: EXPERIENCE FROM THE PEDIATRIC SUBCOMMITTEE OF THE SPANISH GROUP FOR HSCT AND CELL THERAPY (GETH)** 08:30 - 08:30
 Marta González (Madrid, Spain)
- B212 **A PILOT MULTICENTRE FEASIBILITY STUDY OF REAL-TIME PHARMACOKINETIC-GUIDED FLUDARABINE DOSING IN CHILDREN RECEIVING CD19-DIRECTED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL LEUKAEMIA** 08:30 - 08:30
 Emma Barlow (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the))
- B213 **SURFACTANT PROTEIN D IN PLASMA MAY PREDICT BRONCHIOLITIS OBLITERANS AFTER PEDIATRIC HSCT** 08:30 - 08:30
 Amalie Christence Sennels (Copenhagen, Denmark)
- B214 **HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN USING CD3/CD19 DEPLETED GRAFTS: RESULTS OF A MULTICENTRE PHASE I/II STUDY** 08:30 - 08:30

| | | |
|------|--|---------------|
| | Thomas Eichholz (Tuebingen, Germany) | |
| B215 | EMAPALUMAB FOR THE TREATMENT OR PROPHYLAXIS FOR GRAFT FAILURE AFTER HSCT IN CHILDREN Blanca Molina (Madrid, Spain) | 08:30 - 08:30 |
| B216 | TREOSULFAN OR BUSULFAN: DETERMINANTS OF RELAPSE RISK WITH DIFFERENT CONDITIONING REGIMEN IN CHILDREN WITH ACUTE MYELOID LEUKEMIA Emanuele Lanino (Monza, Italy) | 08:30 - 08:30 |
| B217 | PROADRENOMEDULLIN (PRO-ADM) FOR EARLY IDENTIFICATION OF INFECTIOUS AND TRANSPLANT-RELATED COMPLICATIONS AFTER PEDIATRIC HCT: A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY Manuela Spadea (Turin, Italy) | 08:30 - 08:30 |
| B218 | REAL-WORLD EXPERIENCE WITH ISAVUCONAZOLE IN ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS IN SPAIN Blanca Molina (Madrid, Spain) | 08:30 - 08:30 |
| B219 | BANDICOOT: AN ADAPTIVE PLATFORM TRIAL DESIGNED TO IMPROVE THE COMPLICATIONS, COST-EFFECTIVENESS AND HEALTH OUTCOMES FOR CHILDREN RECEIVING A STEM CELL TRANSPLANT Hannah Walker (Melbourne, Australia) | 08:30 - 08:30 |
| B220 | ORAL SUPPLEMENTATION VS ENTERAL VIA NASO-GASTRIC TUBE VS PARENTERAL NUTRITION AS NUTRITIONAL SUPPORT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY Francesco Paolo Tambaro (Naples, Italy) | 08:30 - 08:30 |
| B221 | POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC PATIENTS RECEIVING LETERMОВIR AS CMV INFECTION PROPHYLAXIS Katarzyna Smalisz (Cracow, Poland) | 08:30 - 08:30 |
| B222 | TREOSULFAN-BASED CONDITIONING REGIMENS ARE SAME EFFECTIVE, BUT LESS TOXIC IN COMPARISON WITH BUSULFAN-BASED IN PEDIATRIC SOLID TUMORS: RESULTS OF RETROSPECTIVE ANALYSIS FROM 148 PATIENTS Teimur Aliev (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| B223 | COMPARATIVE STUDY OF CORD BLOOD TRANSPLANTATION FOR PEDIATRIC ACUTE LEUKEMIA: JOINT ANALYSIS BY EUROCORD AND JSTCT Itaru Kato (Kyoto, Japan) | 08:30 - 08:30 |
| B225 | ENTERAL VERSUS PARENTERAL NUTRITION IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE EVALUATION OF FEASIBILITY, CLINICAL OUTCOMES, AND RESOURCE UTILIZATION Hawazen Alsaedi (Riyadh, Saudi Arabia) | 08:30 - 08:30 |
| B227 | DAY +60 B LYMPHOCYTES POST-TRANSPLANT AS AN EARLY PREDICTOR OF CHRONIC GVHD Marta González (Madrid, Spain) | 08:30 - 08:30 |
| B228 | CURRENT USE OF BELUMOSUDIL FOR PEDIATRIC STEROID-REFRACTORY CHRONIC GVHD IN EUROPE: RESULTS OF RETROSPECTIVE SURVEY OF THE PEDIATRIC DISEASES WORKING PARTY (PDWP) OF THE EBMT Kirill Kirgizov (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| B229 | THE DONOR'S FINGERPRINT: PEDIATRIC DONOR CELL | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | LEUKEMIA | |
| | Aharon Gefen (Haifa, Israel) | |
| B230 | REAL-WORLD EXPERIENCE WITH BELUMOSUDIL FOR STEROID-REFRACTORY CHRONIC GVHD IN CHILDREN: A MULTICENTER STUDY ON BEHALF OF RUSBMT PAEDIATRIC WORKING PARTY | 08:30 - 08:30 |
| | Tatiana Bykova (Saint-Petersburg, Russian Federation (the)) | |
| B231 | PLATFORM-SPECIFIC PATTERNS OF IMMUNE RECONSTITUTION AFTER PEDIATRIC ALLOGENEIC HSCT: COMPARATIVE ANALYSIS OF TCRAB/CD19+ DEPLETION AND POST-TRANSPLANT CYCLOPHOSPHAMIDE | 08:30 - 08:30 |
| | Larisa Vakhonina (Ekaterinburg, Russian Federation (the)) | |
| B233 | ROMIPLOSTIM IN PEDIATRIC PATIENTS POST HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR EARLY PLATELET ENGRAFTMENT- AN OPEN LABEL RANDOMISED CONTROLLED TRIAL | 08:30 - 08:30 |
| | Sanjana Sarangarajan (New Delhi, India) | |
| B234 | ACUTE GRAFT-VERSUS-HOST DISEASE REQUIRING SECOND-LINE THERAPY AFTER PEDIATRIC ALLOGENEIC HCT IN THE PRE-RUXOLITINIB ERA: A RETROSPECTIVE AIEOP ANALYSIS | 08:30 - 08:30 |
| | Stella Boghen (Pavia, Italy) | |
| B235 | POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC HEMOGLOBINOPATHIES: EXPANDING ACCESS TO ALLOGENEIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |
| | Manon Queudeville (Hamburg, Germany) | |
| B236 | MULTIFACETED ROLE OF ELTROMBOPAG FOR POOR GRAFT FUNCTION IN PEDIATRIC ALLOGENEIC HSCT RECIPIENTS | 08:30 - 08:30 |
| | Natalia Maximova (Trieste, Italy) | |
| B237 | HIGH VIRAL LOAD BK VIRURIA IS COMMON AFTER PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANT AND DOES NOT PREDICT SYMPTOMATIC HAEMORRHAGIC CYSTITIS | 08:30 - 08:30 |
| | Hilary Cahill (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B238 | DONOR SELECTION STRATEGY IS CRITICAL IN DETERMINING OUTCOMES OF HIGH-RISK, PAEDIATRIC, RELAPSED, MRD POSITIVE T-ALL HSCT | 08:30 - 08:30 |
| | Srividhya Senthil (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B239 | BORN TO HEAL? PSYCHOSOCIAL AND ETHICAL DIMENSIONS OF SAVIOR SIBLINGS AND RECIPIENT CHILDREN IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |
| | İbrahim Eker (Afyonkarahisar, Turkey) | |
| B240 | SECONDARY MALIGNANCIES IN SURVIVORS OF CHILDHOOD CANCER | 08:30 - 08:30 |
| | Hilary Cahill (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B241 | PERI-TRANSPLANT RUXOLITINIB FOR GRAFT-VS-HOST-DISEASE (GVHD) PREVENTION IN PEDIATRIC AND YOUNG ADULT PATIENTS UNDERGOING MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION (HCT): INTERIM ANALYSIS | 08:30 - 08:30 |
| | Nicole Karras (Duarte, United States Minor Outlying Islands (the)) | |
| B242 | PROPHYLACTIC DLI IN PEDIATRIC PATIENTS WITH HIGH RISK HEMATOLOGICAL MALIGNANCIES - A SINGLE CENTER EXPERIENCE | 08:30 - 08:30 |
| | Denise Epple (Munich, Germany) | |
| B243 | FEASIBILITY OF CADAVERIC DONOR-DERIVED HEMATOPOIETIC GRAFTS TO INDUCE MIXED CHIMERISM AS A STRATEGY TO | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | ACHIEVE TOLERANCE IN MULTIVISCERAL TRANSPLANTATION Antonio Pérez Martínez (Madrid, Spain) | |
| B244 | IMPACT OF ANTI-THYMOCYTE GLOBULIN DOSE ON SURVIVAL, RELAPSE AND IMMUNE RECOVERY IN PEDIATRIC ALLOGENEIC HSCT FOR MYELOID MALIGNANCIES Marek Ussowicz (Wrocław, Poland) | 08:30 - 08:30 |
| B245 | THE EFFECT OF ALLOGENEIC HSCT ON PEDIATRIC NON-DOWN SYNDROME AMKL: RESULTS FROM A MULTICENTER CALD-AMKL-18 TRIAL Shaoyan Hu (Suzhou, China) | 08:30 - 08:30 |
| B246 | PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN BRAZIL: A REGIONAL CHALLENGE Beatrice Duarte (São Paulo, Brazil) | 08:30 - 08:30 |
| B247 | DOSE REDUCTION IMPROVES THE OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH WILMS TUMOR: DATA FROM RETROSPECTIVE TRIAL FROM TWO CENTRS Teimur Aliev (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| B248 | NEUROIMMUNOLOGICAL MORBIDITY AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER ANALYSIS ON BEHALF OF THE PEDIATRIC SUBCOMMITTEE OF GETH (GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO) Angelica Villanueva-Freije (Madrid, Spain) | 08:30 - 08:30 |
| B249 | THE RESULTS OF ALLOGENIC HSCT IN PAEDIATRIC PATIENTS DIAGNOSED WITH MYELOID SARCOMA - A SINGLE CENTRE EXPERIENCE Jacek Wachowiak (Poznań, Poland) | 08:30 - 08:30 |
| B250 | POPULATION PHARMACOKINETIC EVALUATION OF EXTENDED INFUSION ACYCLOVIR IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS Natalia Maximova (Trieste, Italy) | 08:30 - 08:30 |
| B251 | EXCELLENT OUTCOMES OF UNMANIPULATED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS AFTER MINIMALLY INTENSIVE CONDITIONING FOR SALVAGE HSCT IN CHILDREN Ulrike Zeilhofer (Zurich, Switzerland) | 08:30 - 08:30 |
| B252 | EFFICACY OF PROPHYLACTIC LEVOFLOXACIN IN PEDIATRIC AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER, RETROSPECTIVE ANALYSIS Melanie Klemond (Rochester, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B254 | POST-TRANSPLANT COMPLICATIONS AND MAINTENANCE THERAPY IN CHILDREN UNDERGOING AUTOHSCT DUE TO RELAPSE/PROGRESSION OF HODGKIN'S LYMPHOMA Katarzyna Smalisz (Cracow, Poland) | 08:30 - 08:30 |
| B255 | LYMPHOMATOID GRANULOMATOSIS OF A CENTRAL NERVOUS SYSTEM AS THE ONLY MANIFESTATION OF POST- TRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A PEDIATRIC CASE REPORT Maria Polacik (Dresden, Germany) | 08:30 - 08:30 |
| B256 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A POLISH PEADIATRIC EXPERIENCE Jowita Fraczkiewicz (Wroclaw, Poland) | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| B257 | MANAGEMENT OF TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IN CHILDREN AFTER HSCT WITH RAVULIZUMAB: SINGLE CENTER EXPERIENCE Irina Kostareva (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| B258 | OUTCOME OF SALVAGE SECOND HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CHILDREN WITH HIGH-RISK HEMATOLOGICAL DISORDERS: A SINGLE CENTER EXPERIENCE FROM JORDAN Ayad Ahmed Hussein (Amman, Jordan) | 08:30 - 08:30 |
| B259 | CMV AND BK VIRUS REACTIVATION AFTER ALLOGENEIC HSCT ACCORDING TO DONOR TYPE: A SINGLE-CENTER PEDIATRIC EXPERIENCE Cristina Jercan (Bucharest, Romania) | 08:30 - 08:30 |
| B260 | THE CLINICAL COURSE OF HAPLOHSCT + DINUTUXIMAB BETA IMMUNOTHERAPY IN POLISH CHILDREN WITH RELAPSING NEUROBLASTOMA Katarzyna Smalisz (Cracow, Poland) | 08:30 - 08:30 |
| B261 | ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH DIAMOND-BLACKFAN ANAEMIA: A SINGLE-CENTER EXPERIENCE Renata Formankova (Prague, Czechia) | 08:30 - 08:30 |
| B262 | CHRONIC GRAFT VERSUS HOST DISEASE DURING 20-YEAR OF MONOCENTRIC EXPERIENCE Maura Faraci (Genova, Italy) | 08:30 - 08:30 |
| B263 | THE ACHILLES HEEL OF KMT2A-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA IN INFANTS Larisa Fechina (Ekaterinburg, Russian Federation (the)) | 08:30 - 08:30 |
| B264 | EXTRACORPOREAL PHOTOPHERESIS INWITH DIFFERENT SYSTEMS PERFORMED; A REAL WORLD SINGLE CENTER REPORT Volker Witt (Vienna, Austria) | 08:30 - 08:30 |
| B265 | TACKLING MIXED CHIMERISM WITH WHOLE BLOOD DONOR LYMPHOCYTE INFUSION IN RESOURCE LIMITED SETTING - CASE SERIES Ranjit Kumar Chatada Srivaishnava (Hyderabad, India) | 08:30 - 08:30 |
| B266 | DEVELOPMENT OF A NOVEL SCORING INDEX TO QUANTIFY THE NEED FOR NUTRITIONAL SUPPORT INTERVENTIONS DURING STEM CELL TRANSPLANT AND GENE THERAPY IN CHILDREN Gerard Gurumurthy (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B267 | POOR OUTCOMES FOR CHILDREN WITH REFRACTORY POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER Hannah Walker (Melbourne, Australia) | 08:30 - 08:30 |
| P214 | ULTRA-RAPID CD3/CD45RA-DEPLETED HAPLOIDENTICAL HSCT FOR PEDIATRIC CEREBRAL ALD: FEASIBILITY, ENGRAFTMENT KINETICS, CHIMERISM BEHAVIOR, AND EARLY NEUROLOGIC OUTCOMES IN THREE CASES Poh Lin Tan (Singapore, Singapore) | 08:30 - 08:30 |
| P215 | TORQUE TENO VIRUS IN PEDIATRIC CAR-T RECIPIENTS Yasmina Mozo (Madrid, Spain) | 08:30 - 08:30 |
| P217 | A PILOT RANDOMIZED STUDY OF SMOFLIPID VERSUS INTRALIPID IN PEDIATRIC ACUTE LEUKEMIA UNDERGOING HSCT: EARLY ANTHROPOMETRIC, METABOLIC, INFLAMMATORY, AND CLINICAL EFFECTS Amir Ali Hamidieh (Tehran, Iran (Islamic Republic of)) | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| P219 | ETOPOSIDE OR FLUDARABINE MAY BE COMBINED WITH 1.200CGY TOTAL BODY IRRADIATION FOR PEDIATRIC HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION TO TREAT ACUTE LYMPHOBLASTIC LEUKEMIA Ana Carolina Ribeiro Correa (SÃO PAULO, Brazil) | 08:30 - 08:30 |
| P220 | REDUCTION OF TOTAL BODY IRRADIATION DOSE IN THE CONDITIONING OF CHILDREN WITH ALL AND ITS IMPACT ON SURVIVAL AND TOXICITY Alberto Olaya-Vargas (Mexico City, Mexico) | 08:30 - 08:30 |
| P221 | CLINICAL EFFICACY OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 20 JMML CASES: A SINGLE-CENTER STUDY XINGYU Cao (Langfang, China) | 08:30 - 08:30 |
| P222 | THRASSA, A MULTICENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF MAAT013 IN RUXOLITINIB-REFRACTORY OR INTOLERANT PAEDIATRIC/ADOLESCENT PARTICIPANTS WITH GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE Marion Bruelle (Lyon, France) | 08:30 - 08:30 |
| P223 | ONE SIZE DOESN'T FIT ALL: MODIFICATION OF CONDITIONING REGIMEN IN METABOLIC DISEASE HSCT IN PEDIATRIC TRANSPLANTS Ranjit Kumar Chatada Srivaishnava (Hyderabad, India) | 08:30 - 08:30 |
| P224 | NON HAEMATOLOGICAL AUTOIMMUNE MANIFESTATIONS FOLLOWING PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANT Hilary Cahill (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P225 | CHALLENGES AND ACHIEVEMENTS OF BUILDING PEDIATRIC BONE MARROW TRANSPLANT PROGRAM IN A DEVELOPING COUNTRY; SINGLE CENTER EXPERIENCE IN IRAQ Hanafy Hafez (Karbala, Iraq) | 08:30 - 08:30 |
| P226 | TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY DRIVES MORTALITY IN PEDIATRIC HSCT: INSIGHTS FROM A SINGLE-CENTER COHORT Simone Schrauth (Würzburg, Germany) | 08:30 - 08:30 |
| P228 | LINEAGE SWITCH FROM B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TO T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN A PAEDIATRIC PATIENT WITH HOX11 EXPRESSION AFTER 11 YEARS□A CASE REPORT Shaoyan Hu (Suzhou, China) | 08:30 - 08:30 |
| P229 | BEYOND NUMBERS: SUPERIOR PEDIATRIC BONE MARROW TRANSPLANT OUTCOMES THROUGH STANDARDIZED, RISK-ADAPTIVE CARE AND PROACTIVE COMPLICATION MANAGEMENT İbrahim Eker (Afyonkarahisar, Turkey) | 08:30 - 08:30 |
| P230 | PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHRONIC GRANULOMATOUS DISEASE: A CASE SERIES OF SINGLE CENTER EXPERIENCE İlgen Sasmaz (Adana, Turkey) | 08:30 - 08:30 |
| P231 | CONCENTRATION OF TOTAL NUCLEATED CELLS IN HARVESTED BONE MARROW FROM PEDIATRIC DONORS Cristian Manuel Sotomayor Fahrenkrog (Santiago, Chile) | 08:30 - 08:30 |
| P232 | TRANSFUSION PRACTICES AND COMPLICATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CUBAN EXPERIENCE | 08:30 - 08:30 |

| | | |
|--|---|---------------|
| | Juan Carlos Jaime Fagundo (Havana, Cuba) | |
| P233 | HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) - MY EXPERIENCE OVER 2 YEARS FOR VARIED HEMATOLOGICAL ONCOLOGICAL CONDITIONS Priti Mehta (Mumbai, India) | 08:30 - 08:30 |
| P234 | BUSULFAN ASSOCIATED PULMONARY TOXICITY AND INFECTIOUS COMPLICATIONS FOLLOWING AUTOLOGOUS SCT IN A 3-YEAR-OLD CHILD WITH NEUROBLASTOMA Ines Goppelt (Dresden, Germany) | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Infections and vaccination - Clinical | | |
| B072 | RISK STRATIFICATION SYSTEM FOR CMV MONITORING AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION Alicja Sadowska-Klasa (Seattle, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B073 | REAL-WORLD USE, EFFECTIVENESS AND SAFETY OF MARIBAVIR IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT CMV OR INTOLERANCE TO ANTI-CMV AGENTS: INTERIM ARISE RESULTS Johan Maertens (Leuven, Belgium) | 08:30 - 08:30 |
| B074 | INFECTION BURDEN IN MISMATCHED UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION USING REDUCED-DOSE POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: RESULTS FROM THE OPTIMIZE TRIAL Jeffery J. Auletta (Minneapolis, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B075 | RISK STRATIFICATION FOR EARLY EBV REACTIVATION AFTER PEDIATRIC ALLO-HSCT: DEVELOPMENT OF A CLINICAL SCORING SYSTEM Shaoyan Hu (Suzhou, China) | 08:30 - 08:30 |
| B076 | ADENOVIRUS IN THE ERA OF INCREASING ALTERNATE DONOR HSCT: OUTCOMES, PREDICTORS, AND THERAPEUTIC RESPONSE OVER THE LAST DECADE Krithika Krishnakumar (Chennai, India) | 08:30 - 08:30 |
| B077 | IMPACT OF INTERLEUKIN-6 DYNAMICS ON INFECTION SEVERITY AND CLINICAL OUTCOMES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES UNDERGOING INTENSIVE THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION Ben-Niklas Baermann (Düsseldorf, Germany) | 08:30 - 08:30 |
| B078 | PRE-TRANSPLANT CLOSTRIDIODES DIFFICILE INFECTION: A TIMING-DEPENDENT PREDICTOR OF GI GVHD AND EARLY MORTALITY IN ALLOGENEIC HSCT RECIPIENTS Wenyi Wang (Hangzhou, China) | 08:30 - 08:30 |
| B079 | HHV-6B INFECTION ADVERSELY IMPACTS OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER, CASE-CONTROL STUDY Jiayu Huang (Shanghai, China) | 08:30 - 08:30 |
| B080 | VIROLOGIC OUTCOMES BY BASELINE CMV VIRAL LOAD IN HCT RECIPIENTS TREATED WITH MARIBAVIR: POST HOC ANALYSIS OF PHASE 2 AND 3 TRIALS Genovefa Papanicolaou (New York, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B081 | PROGNOSTIC IMPLICATIONS OF CMV INFECTION/DISEASE AND HHV-6 ENCEPHALITIS IN CORD BLOOD TRANSPLANT | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | RECIPIENTS RECEIVING FOSCARNET Shogo Matsui (Tokyo, Japan) | |
| B082 | BRONCHOALVEOLAR LAVAGE PRACTICES IN ALLO-HCT RECIPIENTS WITH LOWER RESPIRATORY TRACT INFECTIONS: A SURVEY OF INFECTIOUS DISEASES WORKING PARTY (IDWP) EBMT Agnieszka Piekarska (Gdansk, Poland) | 08:30 - 08:30 |
| B083 | MOST PATIENTS DON'T NEED COMPLETE REVACCINATION AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION Sabine Dressler (Nürnberg, Germany) | 08:30 - 08:30 |
| B084 | OUTCOME OF CMV PNEUMONIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION IN THE ERA OF MODERN TRANSPLANTATION AND CMV PREVENTION PRACTICES Alicja Sadowska-Klasa (Seattle, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B086 | EBV REACTIVATION AND PTLD IN THE LETERMOVIR ERA: BEYOND ANTIVIRAL PROPHYLAXIS Ilaria Cutini (Florence, Italy) | 08:30 - 08:30 |
| B087 | IMPACT OF EBMT 2025 DEFINITIONS ON THE IDENTIFICATION OF CATHETER-RELATED BLOODSTREAM INFECTIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Juan Manuel Cerezo-Martín (Santander, Spain) | 08:30 - 08:30 |
| B089 | INCREASED INCIDENCE OF INFECTIONS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS IN MATCHED SIBLING AND UNRELATED DONOR STEM CELL TRANSPLANTATION Athanasios Gakopoulos (Athens, Greece) | 08:30 - 08:30 |
| B090 | EFFICACY AND SAFETY OF MARIBAVIR IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS BY BASELINE NEUTROPENIA STATUS: A POST HOC ANALYSIS OF PHASE 2 AND 3 CLINICAL TRIALS Alicja Sadowska-Klasa (Seattle, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B091 | THE ORAL MICROBIOME IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS Rajinder Bajwa (Columbus, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B092 | SURVEY BY THE INFECTIOUS DISEASES WORKING PARTY OF EBMT ON THE USE OF RECOMBINANT HERPES ZOSTER VACCINE AFTER AUTOLOGOUS AND ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANTATION Maria Stamouli (Athens, Greece) | 08:30 - 08:30 |
| B093 | ANAKINRA TO REDUCE FEVER DURING NEUTROPENIA AND MUCOSITIS IN MULTIPLE MYELOMA PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER HIGH-DOSE MELPHALAN - A RANDOMIZED CONTROLLED TRIAL Eva Molendijk (Nijmegen, Netherlands (the)) | 08:30 - 08:30 |
| B094 | THE IMPACT OF CMV-SEROPOSITIVITY ON OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF LETERMOVIR IN AML AND MDS PATIENTS Lina Kolloch (Muenster, Germany) | 08:30 - 08:30 |
| B095 | MARIBAVIR FOR TREATMENT OF REFRACTORY/RECURRENT CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HSCT RECIPIENTS Aleksandr Siniaev (St. Petersburg, Russian Federation (the)) | 08:30 - 08:30 |
| B096 | EFFECTIVENESS OF A STRUCTURED PREVENTION STRATEGY | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | FOR HBV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING HBSAG-POSITIVE DONORS | |
| | Jinya Lin (Hangzhou, China) | |
| B097 | LETERMOVIR PRIMARY PROPHYLAXIS IS A PROTECTIVE FACTOR FOR SURVIVAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS. DATA FROM THE FIRST PROSPECTIVE MULTICENTER STUDY IN LATIN AMERICA | 08:30 - 08:30 |
| | Fabian Herrera (Buenos Aires, Argentina) | |
| B098 | SAFETY OF OMITTING ANTIBACTERIAL PROPHYLAXIS IN ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: EXPERIENCE FROM A SINGLE CANADIAN CENTER | 08:30 - 08:30 |
| | Omar Eduardo Fernandes Vargas (Montreal, Canada) | |
| B099 | EARLY ADMINISTRATION OF LETERMOVIR PROPHYLAXIS POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IS ASSOCIATED WITH DELAYED ENGRAFTMENT | 08:30 - 08:30 |
| | Dionysios Neofytos (Geneva, Switzerland) | |
| B100 | EXHALED-BREATH VOLATILE MARKERS OF INVASIVE PULMONARY ASPERGILLOSIS IN PEDIATRIC CANCER AND STEM CELL TRANSPLANT PATIENTS: A PILOT STUDY | 08:30 - 08:30 |
| | Laura Rotte (Utrecht, Netherlands (the)) | |
| B101 | CMV INFECTION AFTER ALLOGENEIC HSCT IN SERONEGATIVE RECIPIENTS TRANSPLANTED FROM A SEROPOSITIVE DONOR: A MONOCENTRIC RETROSPECTIVE STUDY | 08:30 - 08:30 |
| | Alienor Xhaard (Paris, France) | |
| B103 | CYTOMEGALOVIRUS REACTIVATION IN A SINGLE CENTER PAEDIATRIC COHORT UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION AND USE OF LETERMOVIR | 08:30 - 08:30 |
| | Teresa Martín Aláez (Madrid, Spain) | |
| B104 | PRESERVATION OF ADAPTIVE IMMUNITY AFTER NONMYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION IN ADULTS WITH SICKLE CELL DISEASE (PROTECT STUDY) | 08:30 - 08:30 |
| | Erfan Nur (Amsterdam, Netherlands (the)) | |
| B105 | CAN RECTAL SWABS PREDICT POST-HCT PSEUDOMONAS AERUGINOSA INFECTIONS? - A PRELIMINARY SINGLE-CENTER ANALYSIS | 08:30 - 08:30 |
| | Giovanni Grillo (Milan, Italy) | |
| B106 | INTRODUCING MIPI-RADS, MOLD-ASSOCIATED INVASIVE PULMONARY INFECTION - REPORTING AND DATA SYSTEM, FOR UNIFORM ASSESSMENT AND REPORTING OF CHEST CT-IMAGING OF PULMONARY INVASIVE MOULD INFECTIONS | 08:30 - 08:30 |
| | Elizabeth De Kort (Nijmegen, Netherlands (the)) | |
| B107 | HUMAN HERPES VIRUS 6 INFECTION IN ALLOGENEIC STEM CELL TRANSPLANTATION RECEIVING POST-TRASPLANT CYCLOPHOSPHAMIDE | 08:30 - 08:30 |
| | Maria Suárez-Lledó (Barcelona, Spain) | |
| B108 | IMPACT OF DONOR CMV-SPECIFIC HUMORAL AND CELL-MEDIATED IMMUNITY ON CMV-IMMUNE RECONSTITUTION AND INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION | 08:30 - 08:30 |
| | Guillermo Ramos Moreno (Madrid, Spain) | |
| B109 | INCIDENCE OF EBV DNAEMIA AND POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) AMONG HCT WITH | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | POSTTRANSPLANT CYCLOPHOSPHAMIDE (PTCY). A SINGLE CENTER EXPERIENCE | |
| | Genovefa Papanicolaou (New York, United States Minor Outlying Islands (the)) | |
| B110 | MONITORING MATTERS - SUPRATHERAPEUTIC LEVEL OF TACROLIMUS IS A PREDICTOR OF BK VIRUS REACTIVATION IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |
| | Revathi Raj (Chennai, India) | |
| B111 | ERAVACYCLINE IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS: A REAL-WORLD STUDY OF DRUG-DRUG INTERACTIONS WITH CYCLOSPORINE/TACROLIMUS AND ANTI-INFECTIVE EFFICACY | 08:30 - 08:30 |
| | Jieya Luo (Tianjin, China) | |
| B112 | GASTROINTESTINAL MUCOSITIS AS CONTRIBUTOR TO FEVER IN AUTOLOGOUS STEM CELL TRANSPLANT RECIPIENTS CONDITIONED WITH HIGH-DOSE MELPHALAN | 08:30 - 08:30 |
| | Björn Reijnders (Nijmegen, Netherlands (the)) | |
| B113 | CMV AND EBV REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | 08:30 - 08:30 |
| | Yuqing Tu (Suzhou, China) | |
| B114 | EARLY DISCONTINUATION OF EMPIRIC ANTIBIOTIC THERAPY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS | 08:30 - 08:30 |
| | Aleksandr Siniaev (St. Petersburg, Russian Federation (the)) | |
| B116 | THE ROLE OF PCR DETECTION OF CARBAPENEMASE GENES IN NATIVE SPECIMENS FOR ROUTINE COLONIZATION SCREENING IN THE EARLY POST-ALLO-HCT PERIOD | 08:30 - 08:30 |
| | Aleksandr Siniaev (St. Petersburg, Russian Federation (the)) | |
| B117 | CURRENT TRENDS IN THE MANAGEMENT OF CYTOMEGALOVIRUS IN CELL THERAPIES RECIPIENTS IN SPAIN: RESULTS OF THE 2025 GETH-TC SURVEY | 08:30 - 08:30 |
| | Irene García-Cadenas (Barcelona, Spain) | |
| B118 | RISK OF BACTEREMIA IN LEVOFLOXACIN-RESISTANT EXTENDED-SPECTRUM B-LACTAMASE-PRODUCING ENTEROBACTERIALES COLONIZED RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT | 08:30 - 08:30 |
| | Dario Schiavo (Treviso, Italy) | |
| B120 | DETERMINANTS OF EARLY AND LATE INFECTIONS AFTER CAR-T IN SECOND- AND THIRD-LINE LBCL | 08:30 - 08:30 |
| | Ilaria Cutini (Florence, Italy) | |
| B121 | MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY | 08:30 - 08:30 |
| | Francesco Paolo Tambaro (Naples, Italy) | |
| B122 | SURGICAL TREATMENT OF PULMONARY INVASIVE FUNGAL DISEASE IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION | 08:30 - 08:30 |
| | Alexander Kulagin (Saint Petersburg, Russian Federation (the)) | |
| B123 | NOT ALL AUTOLOGOUS TRANSPLANTS ARE LOW RISK: DELAYED PLATELET ENGRAFTMENT SIGNALS THE NEED FOR CMV MONITORING | 08:30 - 08:30 |
| | Ibrahim Ethem Pinar (Bursa, Turkey) | |

| | | |
|------|---|---------------|
| B124 | RESPIRATORY VIRAL INFECTIONS AND NONINFECTIOUS PULMONARY COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Frédéric Rivière (Caen, France) | 08:30 - 08:30 |
| B125 | HHV6 MONITORING AND DONOR ASSESSMENT IN PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANT - A SINGLE CENTRE PROSPECTIVE STUDY Antonio Grasso (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B126 | CHANGES IN ANTIBODY TITERS AND PREDICTIVE FACTORS FOR SEROCONVERSION FOLLOWING LIVE VACCINATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS Misaki Hada (Kyoto, Japan) | 08:30 - 08:30 |
| B127 | MANAGEMENT OF CMV INFECTION WITH MARIBAVIR IN PATIENTS TREATED WITH CAR-T THERAPY Cristian Gutierrez-Padilla (Madrid, Spain) | 08:30 - 08:30 |
| B128 | NORMAL IGG DOES NOT EQUATE TO IMMUNE COMPETENCE AFTER HSCT IN PEDIATRIC SICKLE CELL DISEASE Alexander Ngwube (Houston, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B129 | PHYSICIAN SURVEY OF REAL-WORLD MARIBAVIR USE AND TREATMENT DECISION MAKING IN REFRACTORY CYTOMEGALOVIRUS INFECTION AFTER TRANSPLANTATION Johan Maertens (Leuven, Belgium) | 08:30 - 08:30 |
| B130 | COMPARATIVE ANALYSIS OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL VS MATCHED SIBLING DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Marco Alejandro Jiménez-Ochoa (Mexico City, Mexico) | 08:30 - 08:30 |
| B131 | HOSPITAL EXEMPTION USE OF VIRUS-SPECIFIC T-LYMPHOCYTES IN CHILDREN: EARLY EXPERIENCE WITHIN THE ALLOVISTA FRAMEWORK Marek Ussowicz (Wrocław, Poland) | 08:30 - 08:30 |
| B132 | IMPACT OF LETERMIVIR PROPHYLAXIS ON CYTOMEGALOVIRUS EVENTS AND RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR AML AND MDS Sin Young Park (Seoul, Korea (the Republic of)) | 08:30 - 08:30 |
| B133 | ADDITION OF ANTITHYMOCYTE GLOBULIN TO CYCLOSPORIN AND MYCOPHENOLATE IN UNMANIPULATED HAPLO-TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN AND TEENAGERS. RESULTS OF A SERIE OF 40 PATIENTS Angela Trujillo-Gaviria (Medellin, Colombia) | 08:30 - 08:30 |
| B134 | OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS REQUIRING INTENSIVE CARE: A RETROSPECTIVE COHORT STUDY Andrés Yesid Bonilla-Salcedo (Mexico City, Mexico) | 08:30 - 08:30 |
| B135 | LONG TERM COVID-19 VACCINE EFFECTIVENESS AND ANTY-SARS-COV-2 IGG DYNAMICS IN CHILDREN AND YOUNG ADULTS AFTER ALLOGENEIC HSCT Marek Ussowicz (Wrocław, Poland) | 08:30 - 08:30 |
| B136 | RISK OF INFECTIONS AFTER CAR-T CELLS IS HIGH AND DIFFICULT-TO-PREDICT Héctor Cruz Barquín (Santander, Spain) | 08:30 - 08:30 |
| B137 | METAGENOMIC NEXT-GENERATION SEQUENCING AS A | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | DIAGNOSTIC TOOL TO DETECT PATHOGENS IN IMMUNOCOMPROMISED PATIENTS WITH PULMONARY INFECTIONS - A SINGLE CENTER PROSPECTIVE STUDY Anna Ruckdeschel (Würzburg, Germany) | |
| B139 | TRANSPLANTING THROUGH UNCERTAINTY: SINGLE CENTER EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SEVERE APLASTIC ANEMIA AND POSSIBLE PULMONARY INVASIVE FUNGAL INFECTION Ayad Ahmed Hussein (Amman, Jordan) | 08:30 - 08:30 |
| B140 | ACCURATE CMV IGG DETECTION USING BUCCAL SWABS IN STEM CELL DONOR SCREENING Alejandra Martinez Trillos (Barcelona, Spain) | 08:30 - 08:30 |
| B141 | LATE CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HSCT PERSISTS IN THE ERA OF LETERMОВIR PROPHYLAXIS - A SINGLE-CENTRE REAL WORLD STUDY Kirsty Sharplin (Oxford, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B142 | IMPACT OF HUMAN PARVOVIRUS B19 INFECTION ON THE OUTCOME OF PEDIATRIC HCT FOR HEMOGLOBINOPATHIES AND OTHER HEREDITARY ANEMIAS Stella Muscianisi (Pavia, Italy) | 08:30 - 08:30 |
| B143 | COMPARATIVE STUDY OF RESPIRATORY SYNCYTIAL VIRUS BURDEN AND TREATMENT POLICIES IN HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Justin du Toit (Johannesburg, South Africa) | 08:30 - 08:30 |
| B144 | HOW DO DEFINITIONS FOR NOSOCOMIAL INVASIVE ASPERGILLOSIS PERFORM IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS? Paulina Vega (Seattle, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B145 | CANADIAN SURVEY ON ANTIBACTERIAL PROPHYLAXIS AND FEBRILE NEUTROPENIA MANAGEMENT IN ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS Omar Eduardo Fernandes Vargas (Montreal, Canada) | 08:30 - 08:30 |
| B146 | MANAGEMENT OF PROTRACTED CLOSTRIDIODES DIFFICILE INFECTION IN CHILDREN WITH GI-GVHD AFTER ALLOGENEIC HSCT: A SINGLE-CENTER PEDIATRIC EXPERIENCE Jaroslava Adamčáková (Bratislava, Slovakia) | 08:30 - 08:30 |
| B147 | MICAFUNGIN AS ANTIFUNGAL PROPHYLAXIS DURING THE PRE-ENGRAFTMENT PERIOD OF ALLO-HSCT. ANALYSIS OF A 450-PATIENT COHORT Bernardo Soto Román (Madrid, Spain) | 08:30 - 08:30 |
| B148 | SEROPREVALENCE OF HBV IN UNRELATED DONORS AT CONFIRMATORY TYPING STAGE AND ITS IMPACT ON THE CHOICE OF HEMATOPOIETIC CELL DONOR - DATA OF DKMS POLAND Przemyslaw Szymanski (Warsaw, Poland) | 08:30 - 08:30 |
| B149 | EPIDEMIOLOGY OF CATHETER-RELATED BLOODSTREAM INFECTIONS IN STEM CELL TRANSPLANTATION Elba Vélez Blanco (Santander, Spain) | 08:30 - 08:30 |
| B150 | REAL-WORLD UTILIZATION AND EFFICACY OF BIOEQUIVALENT GENERIC LETERMОВIR PROPHYLAXIS IN ALLOGENEIC HSCT RECIPIENTS: PEDIATRIC SUBGROUP ANALYSIS FROM DEFENDER STUDY Santanu Sen (Mumbai, India) | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| B151 | LETERMOVIR CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENIC HEMATOPOIETIC-CELL TRANSPLANTATION: REAL-WORLD EVIDENCE FROM HIGH-ENDEMIC REGION Vaibhav Chadha (New Delhi, India) | 08:30 - 08:30 |
| P150 | HHV-6 REPLICATION AS A RISK FACTOR FOR GRAFT LOSS IN ALLO-HSCT: A COHORT STUDY AT A REFERENCE CENTER Leslie González Pinedo (Las Palmas de Gran Canaria, Spain) | 08:30 - 08:30 |
| P151 | VIRUS-SPECIFIC LYMPHOCYTE THERAPY FOR PHARMACOLOGICALLY REFRACTORY VIRAL REACTIVATIONS IN PEDIATRIC IMMUNOCOMPROMISED PATIENTS: A 13-YEAR SINGLE-CENTER EXPERIENCE Maura Faraci (Genova, Italy) | 08:30 - 08:30 |
| P152 | PREDICTIVE BIOMARKERS OF SARS-COV-2 VACCINE SEROCONVERSION IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES Andrea Henden (Brisbane, Australia) | 08:30 - 08:30 |
| P153 | EARLY INFECTIOUS COMPLICATIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: MICROBIOLOGICAL PROFILE AND ANTIMICROBIAL RESISTANCE PATTERNS Manuela Estrada-Schweineberg (Bogotá, Colombia) | 08:30 - 08:30 |
| P154 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIAS AND HIV INFECTION Aleksandr Siniaev (St. Petersburg, Russian Federation (the)) | 08:30 - 08:30 |
| P156 | REAL-WORLD UTILIZATION, CMV REACTIVATION OUTCOMES AND SURVIVAL ANALYSIS OF BIOEQUIVALENT GENERIC LETERMIVIR PROPHYLAXIS IN INDIAN ALLOGENEIC HSCT RECIPIENTS: DEFENDER STUDY Gaurav Kharya (New Delhi, India) | 08:30 - 08:30 |
| P157 | DECOLONIZATION OF MULTIDRUG-RESISTANT BACTERIA BY FECAL MICROBIOTA TRANSPLANTATION IN A PATIENT BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Deepa Nanayakkara (Duarte, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| P158 | ANTIBACTERIAL PROPHYLAXIS IN AUTOLOGOUS STEM CELL TRANSPLANTATION: CEFPODOXIME VERSUS FLUOROQUINOLONES Sinem Civriz Bozdag (Istanbul, Turkey) | 08:30 - 08:30 |
| P159 | DIAGNOSTIC VALUE OF CMV PCR ON GASTROINTESTINAL BIOPSIES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Nour Ben Abdeljelil (Tunis, Tunisia) | 08:30 - 08:30 |
| P160 | ACICLOVIR-RESISTANT HERPES SIMPLEX VIRUS IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT: A CASE SERIES Jenna Nunn (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P161 | A BUNDLED INTERVENTION TO REDUCE RISK OF CATHETER CENTRAL LINE ASSOCIATED BLOODSTREAM INFECTIONS (CLABSIS) FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION Dario Schiavo (Treviso, Italy) | 08:30 - 08:30 |
| P163 | THE RELEVANCE OF PREVIOUSLY KNOWN BACTERIAL COLONIZATION IN DETERMINING THE ETIOLOGY OF BLOODSTREAM INFECTION IN HEMATO-ONCOLOGY PATIENTS: A TIMEFRAME ANALYSIS | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | Ilya Potapov (Saint-Petersburg, Russian Federation (the)) | |
| P164 | CLINICAL IMPACT OF HERPES ZOSTER INFECTION IN PATIENTS WITH PLASMA CELL DISORDERS: A RETROSPECTIVE STUDY Ajda Gunes (Izmir, Turkey) | 08:30 - 08:30 |
| P165 | ACYCLOVIR PROPHYLAXIS FOR VARICELLA ZOSTER VIRUS REACTIVATION IN HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS: WHAT IS THE TRULY EFFECTIVE LOW DOSE? Ayşe Hilal Eroğlu Küçükçdiler (Aydın, Turkey) | 08:30 - 08:30 |
| P166 | PERSISTING FEVER AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE REPORT OF A RARE INFECTION WITH LOMENTOSPORA PROLIFICANS Janne Frömmichen (Freiburg im Breisgau, Germany) | 08:30 - 08:30 |
| P167 | PULMONARY COMPLICATION AFTER ALLO-HCT WITH EBV DETECTION IN BALF - A STUDY ON BEHALF OF THE PALG Agnieszka Piekarska (Gdansk, Poland) | 08:30 - 08:30 |
| P168 | VERY EARLY-ONSET PULMONARY TUBERCULOSIS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT Leylagül Kaynar (Istanbul, Turkey) | 08:30 - 08:30 |
| P169 | REAL-WORLD UTILIZATION AND EFFICACY OF LETERMОВIR PROPHYLAXIS IN ADULT ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: SUBGROUP ANALYSIS DEFENDER STUDY Nataraj KS (Bangalore, India) | 08:30 - 08:30 |
| P170 | POSTINFLAMMATORY HYPERPIGMENTATION AND ATROPHIC SCARS AFTER HERPES ZOSTER IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENT: CLINICAL CASE REPORT AND COSMETOLOGY TREATMENT OPTIONS Anna Dmitrova (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| P171 | HRCT LUNG FINDINGS OF HUMAN METAPNEUMOVIRUS (HMPV) IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES POST BMT: THE GREAT MIMICKER Amrita Guha (Navi Mumbai, India) | 08:30 - 08:30 |
| P172 | ASTROVIRUS ENCEPHALITIS STATUS POST STEM CELL TRANSPLANT David Jacobsohn (Washington, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| P173 | NOCARDIOSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: DIAGNOSTIC PITFALLS, THERAPEUTIC CHALLENGES, AND DIVERGENT CLINICAL OUTCOMES—A DECADE-LONG CASE SERIES Shahbaz Memon (Riyadh, Saudi Arabia) | 08:30 - 08:30 |
| P174 | LATE CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AFTER COMPLETING LETERMОВIR PRIMARY PROPHYLAXIS - A SINGLE-CENTER PRELIMINARY ANALYSIS Agnieszka Tomaszewska (Warsaw, Poland) | 08:30 - 08:30 |
| P176 | TRIAL IN PROGRESS: A PHASE 2, SINGLE-ARM, MULTICENTER STUDY OF MARIBAVIR FOR CYTOMEGALOVIRUS INFECTION IN PATIENTS WITH LYMPHOID MALIGNANCIES UNDERGOING BISPECIFIC ANTIBODIES (MALMBA) Soyean Kwon (Seoul, Korea (the Republic of)) | 08:30 - 08:30 |
| P177 | OUTCOMES OF USING GENERIC LETERMОВIR FOR CMV PROPHYLAXIS IN HSCT: RETROSPECTIVE ANALYSIS | 08:30 - 08:30 |

| | | |
|---|--|---------------|
| | Anil Aribandi (Hyderabad, India) | |
| P178 | MYCOBACTERIUM ABSCESSUS AS A COMPLICATION OF IMMUNOSUPPRESSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR CONGENITAL NEUTROPENIA Ruben Van Paemel (Ghent, Belgium) | 08:30 - 08:30 |
| P179 | GRAFT REJECTION AND POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRICS: BEWARE OF PARVOVIRUS INFECTIONS Mayara Satsuki Kunii (Sao Paulo, Brazil) | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Infections and vaccination - Basic and Translational | | |
| B070 | IMMUNOGENICITY AND REACTOGENICITY OF REPEATED COVID-19 VACCINATION IN IMMUNOCOMPROMISED PATIENTS (AUTO-COVID-VACC): PRELIMINARY RESULTS FROM A MULTICENTRE, PROSPECTIVE, NON-INTERVENTIONAL STUDY Louise M. Cremer (Cologne, Germany) | 08:30 - 08:30 |
| B071 | IMPACT OF EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV-PTLD) ON DONOR T-CELL CHIMERISM IN ALLOGRAFT RECIPIENTS RECEIVING THYMOGLOBULIN AS GVHD PROPHYLAXIS Kirsty Sharplin (Oxford, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Relapse and Graft-versus-Leukemia | | |
| A342 | MUTATIONAL LANDSCAPE CHANGES OF AML IN PATIENTS RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Kristina Maas-Bauer (Freiburg, Germany) | 08:30 - 08:30 |
| A343 | GRANULOCYTE TRANSFUSION DURING CORD-BLOOD TRANSPLANT PRODUCES EARLY, REPRODUCIBLE, EFFECTOR MEMORY CD8+ T-CELL EXPANSION WITH CLINICALLY SIGNIFICANT CLINICAL RESPONSES IN REFRACTORY AML Nathan Jeffreys (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A345 | PROGNOSTIC IMPACT OF PRE-TRANSPLANT MEASURABLE RESIDUAL DISEASE AND GVHD PROPHYLAXIS IN AML PATIENTS UNDERGOING ALLO-HCT Huxlhey Cabrera-García (Medellín, Colombia) | 08:30 - 08:30 |
| A346 | AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HIGH-RISK AML: A SINGLE-CENTER RETROSPECTIVE STUDY Sadia Falcioni (Bologna, Italy) | 08:30 - 08:30 |
| A348 | CLINICAL OUTCOMES OF AZACITIDINE-VENETOCLAX IN RELAPSED AML AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE ASOVASNA CELLULAR THERAPY GROUP Maria de la Cruz Viguria (San Sebastián, Spain) | 08:30 - 08:30 |
| A349 | OUTCOMES OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE AND A DIFFERENT DONOR AFTER RELAPSE FOLLOWING A FIRST ALLOGRAFT: A SINGLE-CENTER RETROSPECTIVE STUDY | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | Lucia Castilla-Garcia (Madrid, Spain) | |
| A350 | DONOR DERIVED LEUKEMIA, SINGLE CENTRE EXPERIENCE Markéta Šťastná Marková (Praha 2, Czechia) | 08:30 - 08:30 |
| A351 | EFFICACY AND TOXICITY OF DONOR LYMPHOCYTE INFUSION IN A FIXED-DOSE COHORT: CLINICAL OUTCOMES AND PATIENT-REPORTED BURDEN Julian Greß (Munich, Germany) | 08:30 - 08:30 |
| A352 | EFFECT OF MINIMAL RESIDUAL DISEASE GUIDED POSTTRANSPLANT 6-MERCAPTOPYRIMIDINE AND METHOTREXATE MAINTENANCE ON PROGNOSIS OF HIGH-RISK PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE Zühre Kaya (Ankara, Turkey) | 08:30 - 08:30 |
| A353 | CLINICAL COURSE AND SURVIVAL OF AML PATIENTS WITH CLONAL EVOLUTION AT RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Lukas Schaefer (Berlin, Germany) | 08:30 - 08:30 |
| A355 | MONOCYTE-T CELLS CROSSTALK ORCHESTRATES EARLY GRAFT-VERSUS-LEUKEMIA IMMUNITY IN AML PATIENTS AFTER TRANSPLANTATION Sha Hao (Tianjin, China) | 08:30 - 08:30 |
| A356 | APPLICATION OF PLASMA FOURIER-TRANSFORM INFRARED SPECTROSCOPY (FT-IR) FOR MONITORING OF ACUTE MYELOID LEUKEMIA AND EXTRAMEDULLARY RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Besjana Khahysa (Brescia, Italy) | 08:30 - 08:30 |
| A357 | REFINED DISEASE RISK INDEX OUTWEIGHS PRE-TRASPLANT RESPONSE IN PREDICTING RELAPSE AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULTS FROM THE NATIONAL CANCER INSTITUTE IN LIMA, PERÚ Naty López-Córdova (Lima, Peru) | 08:30 - 08:30 |
| A358 | VENETOCLAX AND HYPOMETHYLATING AGENT WITH DONOR LYMPHOCYTE INFUSION FOR RELAPSED ACUTE MYELOID LEUKAEMIA POST ALLOGENEIC STEM CELL TRANSPLANTATION William George Giusti Fischer (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P113 | MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF SOLITARY EXTRAMEDULLARY RELAPSE OF AML AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Julia Frimmel (Kiel, Germany) | 08:30 - 08:30 |
| P114 | AZACITIDINE AS POST-TRANSPLANT MAINTENANCE THERAPY IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: EFFECTS, SAFETY AND IMMUNE RECONSTITUTION DYNAMICS Silvia Viola (Monza, Italy) | 08:30 - 08:30 |
| P115 | DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC TRANSPLANTATION FOR MYELOID MALIGNANCIES: CLINICAL OUTCOMES AND THE ROLE OF CD3+ CELL DOSE Lina Rüsing (Vienna, Austria) | 08:30 - 08:30 |
| P116 | RETROSPECTIVE ANALYSIS OF THE INCIDENCE OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES: TREATMENT CHALLENGES FOR PATIENTS IN NORTH MACEDONIA Aleksandra Pivkova Veljanovska (Skopje, Republic of North Macedonia) | 08:30 - 08:30 |
| P118 | HIGH-DOSE CRYOPRESERVED BONE MARROW FROM DECEASED | 08:30 - 08:30 |

| | | |
|---|---|---------------|
| | DONORS MAY REDUCE RELAPSE IN HLA-MISMATCHED ALLOGENEIC TRANSPLANTATION: DAY 180 POST-TRANSPLANT HOPE UPDATE | |
| | Sagar Munjal (San Francisco, United States Minor Outlying Islands (the)) | |
| P119 | COMPARISON OF UMBILICAL CORD BLOOD TRANSPLANTATION OUTCOMES BETWEEN FLT3-MUTATED AND -WILD-TYPE AML IN A MATCHED-PAIR COHORT | 08:30 - 08:30 |
| | Aya Nishida (Tokyo, Japan) | |
| P120 | POST-TRANSPLANT RELAPSE AS A MAJOR DETERMINANT OF OVERALL SURVIVAL AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULTS FROM A SINGLE CENTER IN AN UPPER-MIDDLE INCOME COUNTRY | 08:30 - 08:30 |
| | Naty López-Córdova (Lima, Peru) | |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Gene Therapy - Basic and Translational | | |
| A273 | PHARMACODYNAMIC INSIGHTS INTO ADAPTER CAR TECHNOLOGIES | 08:30 - 08:30 |
| | Patrick Schlegel (Regensburg, Germany) | |
| A274 | A SINGLE-STEP STRATEGY FOR SIMULTANEOUS T-CELL ACTIVATION AND B-CELL ELIMINATION IN CAR-T PRODUCTION USING BISPECIFIC ANTIBODIES | 08:30 - 08:30 |
| | Ivan Gaponenko (Saint Petersburg, Russian Federation (the)) | |
| A275 | SYSTEMATIC TARGET ANTIGEN VALIDATION AND ANTIBODY VALIDATION FOR CELLULAR IMMUNOTHERAPY | 08:30 - 08:30 |
| | Patrick Schlegel (Regensburg, Germany) | |
| A276 | A COMPARATIVE PHENOTYPIC AND FUNCTIONAL STUDY OF WT-1 AND TERT SPECIFIC TCR-ENGINEERED T CELLS WITH MODULAR RECEPTOR DESIGNS | 08:30 - 08:30 |
| | Emilia Jaskuła (Wroclaw, Poland) | |
| A277 | IMPROVING LENTIVIRAL TRANSDUCTION EFFICIENCY OF CD34+ HEMATOPOIETIC STEM CELLS USING POLOXAMERS OR LENTIBLAST PREMIUM®: OPTIMIZATION TOWARD A GENE THERAPY PROCEDURE FOR SICKLE CELL DISEASE | 08:30 - 08:30 |
| | Elisa Magrin (Paris, France) | |
| P097 | HIGH-THROUGHPUT SINGLE-CELL CYTOGENETIC DETECTION OF SMALL GENOMIC TARGETS AND TRANSGENES TO ASSESS HETEROGENEITY AND GENOMIC STABILITY IN GENE-MODIFIED CELL THERAPIES | 08:30 - 08:30 |
| | Erin Cross (Boulder, United States Minor Outlying Islands (the)) | |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Transplant and Cellular Therapies - Clinical | | |
| A037 | EMAPALUMAB INDUCES RAPID, DURABLE RESPONSES AND RELIABLE BRIDGING TO CURATIVE HSCT IN PATIENTS WITH PRIMARY HLH: POOLED ANALYSIS OF PROSPECTIVE TRIALS NI-0501-04, NI-0501-05 AND NI-0501-09 | 08:30 - 08:30 |
| | Franco Locatelli (Rome, Italy) | |
| A038 | INTERIM CLINICAL OUTCOMES IN ORCA-T WITH REDUCED INTENSITY CONDITIONING: AN OBSERVATIONAL COMPARISON TO REGISTRY-BASED POST-TRANSPLANT CYCLOPHOSPHAMIDE PATIENTS | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | Anna Pavlova (Menlo Park, United States Minor Outlying Islands (the)) | |
| A039 | CONTEMPORARY CAUSES OF ACUTE TRANSPLANT-RELATED MORTALITY (TRM) AFTER ALLOGRAFT IN A COHORT OF 2312 PAEDIATRIC PATIENTS: A REPORT FROM THE BSBMTCT, PAEDIATRIC GROUP | 08:30 - 08:30 |
| | Gustavo de Oliveira Canedo (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| A040 | CLINICAL BENEFITS OF RUXOLITINIB IN MODERATE-TO-SEVERE CRS: REDUCED SEVERE ICANS AND STEROID USE WITH PRESERVED SURVIVAL AFTER PEDIATRIC CAR-T THERAPY | 08:30 - 08:30 |
| | Shaoyan Hu (Suzhou, China) | |
| A041 | RELAPSED OR REFRACTORY POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: REAL-LIFE MULTICENTER ITALIAN EXPERIENCE WITH TABELCELEUCEL | 08:30 - 08:30 |
| | Chiara Consoli (Torino, Italy) | |
| A042 | LISOCABTAGENE MARALEUCEL VERSUS AXICABTAGENE CILOLEUCEL IN R/R LARGE B-CELL LYMPHOMA: A META-ANALYSIS OF REAL-WORLD COMPARATIVE STUDIES | 08:30 - 08:30 |
| | Fernando Gibran-Nunes (São Paulo, Brazil) | |
| A043 | PRELIMINARY SAFETY AND EFFICACY OF MYELOABLATIVE ORCA-Q IN PATIENTS WITH HAPLOIDENTICAL DONORS | 08:30 - 08:30 |
| | Amandeep Salhotra (Duarte, United States of America (the)) | |
| A044 | FIRST-LINE ANAKINRA FOR CYTOKINE RELEASE SYNDROME AFTER ANTI-CD19 CAR-T CELLS: A SINGLE-CENTER EXPERIENCE | 08:30 - 08:30 |
| A045 | CAR-T-CELL-INDUCED PSEUDOPROGRESSION (CARTIPP): AN EBMT TCWP STUDY | 08:30 - 08:30 |
| | Torsten Schroeder (Kiel, Germany) | |
| A046 | CLINICAL BIOMARKERS FOR EARLY RECOGNITION OF SUBOPTIMAL ECULIZUMAB RESPONSE IN TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY | 08:30 - 08:30 |
| | Kristie Ramos (Cincinnati, United States Minor Outlying Islands (the)) | |
| A047 | B CELL APLASIA POST CD28 AND 41BB CONTAINING CD19 TARGETING CAR-T CELL THERAPY - SINGLE CENTRE RETROSPECTIVE EXPERIENCE | 08:30 - 08:30 |
| | Nida Shafique (Sutton, United Kingdom of Great Britain and Northern Ireland (the)) | |
| A048 | LONG-TERM CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA TREATED WITH PRIZLONCABTAGENE AUTOLEUCEL | 08:30 - 08:30 |
| | Aibin Liang (Shanghai, China) | |
| A049 | OUTCOME OF AGGRESSIVE B-CELL LYMPHOMA ADMINISTERED WITH CAR T-CELL ALONE OR IN COMBINATION WITH ASCT: A PROPENSITY SCORE MATCHING COHORT STUDY | 08:30 - 08:30 |
| | Yan Gao (Beijing, China) | |
| A050 | INFLUENCE OF THE HLA MISMATCHED LOCUS ON OUTCOMES IN MISMATCHED UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE GVHD PROPHYLAXIS: A CIBMTR RETROSPECTIVE ANALYSIS | 08:30 - 08:30 |
| | Stephen R. Spellman (Minneapolis, United States Minor Outlying Islands (the)) | |
| A051 | DONOR SELECTION AND CLINICAL OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS OLDER THAN 50 YEARS - A SINGLE CENTRE RETROSPECTIVE REVIEW | 08:30 - 08:30 |
| | Thomas Chan (Hong Kong, China) | |

| | | |
|------|--|---------------|
| A052 | BCMA CAR T-CELL THERAPY DEMONSTRATES EARLY SAFETY AND EFFICACY SIGNALS IN REFRACTORY SYSTEMIC SCLEROSIS AND ANTIPHOSPHOLIPID SYNDROME: PHASE I RESULTS IN AUTOIMMUNE DISEASES Shlomo Elias (Jerusalem, Israel) | 08:30 - 08:30 |
| A053 | CAR⁺ EXTRACELLULAR VESICLES PREDICT ANTI-CD19 CAR-T CELL THERAPY RESPONSE IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS Margherita Ursi (Bologna, Italy) | 08:30 - 08:30 |
| A054 | FLUDARABINE EXPOSURE IMPACTS BCMA-DIRECTED CAR-T THERAPY EFFICACY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA Eugene Brailovski (New York City, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A055 | OUTCOME OF CAR-T CELL THERAPY IN OLDER PATIENTS. A STUDY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY Guillaume Dachy (Brussels, Belgium) | 08:30 - 08:30 |
| A056 | HAPLOIDENTICAL DONOR-DERIVED CAR-T CELLS CO-INFUSED WITH THE ALLOGENIC GRAFT ON THE PLATFORM OF T CELL DEPLETION OR POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN WITH ADVANCED B-CELL NEOPLASMS Larisa Shelikhova (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| A059 | COMPARATIVE VALIDATION OF NEUTROPHIL-BASED MODELS (CAR-HEMATOTOX, ALL-HEMATOTOX, AND E-IPM) FOR PREDICTING EARLY T-ICAHT-DEFINED PLATELET RECOVERY AFTER CAR-T THERAPY Meng Lv (Beijing, China) | 08:30 - 08:30 |
| A060 | IMPACT OF THIOTEPA-BUSULFAN CONDITIONING ON CMML TRANSPLANT SCORE PERFORMANCE Maraike Harfmann (Hamburg, Germany) | 08:30 - 08:30 |
| A061 | TRUNCATING GENE ALTERATIONS AND PROMOTER HYPERMETHYLATION DRIVE CD7⁻ RELAPSE AFTER CD7 CAR-T THERAPY: A PATIENT-INFORMED MECHANISM STUDY Rongrong Chen (Hangzhou, China) | 08:30 - 08:30 |
| A062 | BU/CY/FLU-ATG VERSUS BU/CY-ATG CONDITIONING REGIMEN IN HAPLOIDENTICAL CELL TRANSPLANTATION FOR SEVERE ACQUIRED APLASTIC ANEMIA Zhengli Xu (Beijing, China) | 08:30 - 08:30 |
| A063 | THE CAST STRATEGY (CAR-T/ASCT/SEQUENTIAL CAR-T) WITH LOW-DOSE FRACTIONATED RT BRIDGING IN HEAVILY PRE-TREATED R/R CNSL □A PROOF-OF-CONCEPT STUDY Yajing Zhang (Beijing, China) | 08:30 - 08:30 |
| A064 | L-IPM: A NOVEL SCORE SYSTEM FOR PREDICTING LATE IMMUNE EFFECTOR CELL-ASSOCIATED HEMATOTOXICITY (ICAHT) AFTER CAR-T THERAPY AND COMPARISON WITH CAR-HEMATOTOX, ALL-HEMATOTOX, AND E-IPM Meng Lv (Beijing, China) | 08:30 - 08:30 |
| A065 | IMPACT OF TREATMENT SEQUENCE OF GLOFITAMAB AND CAR-T THERAPY ON EFFICACY, SURVIVAL, AND TARGET ANTIGEN EXPRESSION IN RELAPSED/REFRACTORY B-NHL Yan Gao (Beijing, China) | 08:30 - 08:30 |
| A066 | CD19 CAR-T THERAPY IN TRANSFORMED FOLLICULAR LYMPHOMA: A REAL-WORLD COHORT OF 43 PATIENTS Yan Gao (Beijing, China) | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| A067 | ANTIBIOTIC TIMING AND IMPACT ON SURVIVAL OUTCOMES IN ANTI-CD19 AND ANTI-BCMA CAR-T CELL THERAPY Uroosa Ibrahim (New York, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A068 | IMMUNOGENETIC AND CLINICAL DETERMINANTS OF CYTOKINE RELEASE SYNDROME AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POSTTRANSPLANTATION CYCLOPHOSPHAMIDE Rodrigo Gil Manso (Salamanca, Spain) | 08:30 - 08:30 |
| A070 | SALVAGE STRATEGIES AND OUTCOMES AFTER EARLY-LINE CD19 CAR T-CELL THERAPY FAILURE IN LARGE B-CELL LYMPHOMA Silvia Escribano Serrat (New York, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A071 | INCIDENCE OF SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSED BY DOPPLER ULTRASOUND/LIVER ELASTOGRAPHY IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Maud D'Aveni (Nancy, France) | 08:30 - 08:30 |
| A072 | PERI-TRANSPLANT PALLIATIVE CARE AND/OR COMORBIDITY MANAGEMENT FOR OLDER, MEDICALLY INFIRM, AND/OR FRAIL RECIPIENTS OF ALLOGENEIC TRANSPLANTS - PHASE II AND INTERIM PHASE III TRIAL ANALYSES Mohamed Sorrow (Seattle, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A073 | POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSE REDUCTION ENABLES FASTER GRANULOCYTE ENGRAFTMENT WHILE MAINTAINING EFFICACY IN PREVENTING GVHD Václav Heřman (Prague, Czechia) | 08:30 - 08:30 |
| A075 | OUTCOME OF PATIENTS TREATED FOR T-ALL WITH HSCT IN THE FORUM-1 STUDY Jeanne Martin (Paris, France) | 08:30 - 08:30 |
| A076 | AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (AUTOHCT) FOR PLASMA BLASTIC LYMPHOMA (PBL): AN EBMT LYMPHOMA WORKING PARTY STUDY Peter Dreger (Heidelberg, Germany) | 08:30 - 08:30 |
| A077 | EXCELLENT OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC AND ADULT NUP98-REARRANGED ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER REAL-WORLD STUDY Baiqing Sun (Langfang, China) | 08:30 - 08:30 |
| A078 | OUTCOMES OF ALLO-HCT IN AML PATIENTS HARBORING NUP98 REARRANGEMENTS: A STUDY OF THE EBMT GLOBAL COMMITTEE, ACUTE LEUKEMIA WORKING PARTY, AND PEDIATRIC DISEASES WORKING PARTY Lin Li (Hangzhou, China) | 08:30 - 08:30 |
| A079 | IMPORTANCE OF GRAFT COMPOSITION ON EBV REACTIVATION RISK FOLLOWING MODERN GVHD PROPHYLAXIS Jean Roy (Montréal, Canada) | 08:30 - 08:30 |
| A080 | PATIENTS WITH RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS ACHIEVE DEEP HEMATOLOGIC AND ORGAN RESPONSES WITH THE NOVEL MDC-CAR-BCMA001 Kiasvasch Mohammad Nejad Farid (Heidelberg, Germany) | 08:30 - 08:30 |
| A081 | PRE-LYMPHODEPLETION CIRCULATING MICRORNA SIGNATURES PREDICT OUTCOMES OF PATIENTS TREATED WITH ANTI-CD19 CAR-T CELL THERAPY Margherita Ursi (Bologna, Italy) | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| A082 | ARE TRANSPLANT-DERIVED COMORBIDITY INDICES FIT FOR CAR-T THERAPY? A MULTICENTER COMPARATIVE ANALYSIS Silvia Escribano Serrat (New York, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A083 | INCIDENCE AND RISK FACTORS OF PRIMARY GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Tatiana Rudakova (St.Petersburg, Russian Federation (the)) | 08:30 - 08:30 |
| A085 | CLINICAL OUTCOMES IN MYELODYSPLASTIC SYNDROME PATIENTS TREATED WITH ORCA-T OR POST-TRANSPLANT CYCLOPHOSPHAMIDE PATIENTS: A REGISTRY-BASED COMPARISON Arpita Gandhi (Portland, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A086 | MACROPHAGE ACTIVATION BEFORE LYMPHODEPLETION CAN PREDICT CRS, ICANS, AND LATE CYTOPENIA AFTER CD19 CAR-T CELL THERAPY FOR HEMATOLOGICAL CANCER Monica Da-My Tran (Copenhagen, Denmark) | 08:30 - 08:30 |
| A087 | CAR-T BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA Xiaoxi Lu (Chengdu, China) | 08:30 - 08:30 |
| A088 | OUTCOMES OF DONOR LYMPHOCYTE INFUSION FOR MEASURABLE RESIDUAL DISEASE AND RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE RETROSPECTIVE ANALYSIS Safia Belbachir (Murdoch, Australia) | 08:30 - 08:30 |
| A089 | SECONDARY MALIGNANCY RISK AFTER ALLOGENEIC HSCT WITH PTCY OR ATG PROPHYLAXIS: A RETROSPECTIVE STUDY Daniele Mannina (Rozzano, Italy) | 08:30 - 08:30 |
| A090 | NOVEL PRECISION ALEMTUZUMAB DOSING RESULTS IN BETTER DAY 0 TARGET RANGE ACHIEVEMENT AND IMPROVED HSCT OUTCOMES IN IEI PATIENTS Pooja Khandelwal (Cincinnati, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A091 | PRELIMINARY BASIS FOR A PREDICTIVE ALGORITHM OF REHABILITATION REQUIREMENTS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS Riccardo Marmoni (Brescia, Italy) | 08:30 - 08:30 |
| A092 | EMAPALUMAB IS ASSOCIATED WITH RAPID AND SUSTAINED BENEFITS IN PHLH SUBGROUPS, INCLUDING CNS INVOLVEMENT AND PREVIOUSLY UNTREATED PATIENTS: ANALYSIS OF TRIALS NI-0501-04, NI-0501-05 AND NI-0501-09 Franco Locatelli (Rome, Italy) | 08:30 - 08:30 |
| A093 | MAAT033 FOR GUT MICROBIOTA OPTIMIZATION TO IMPROVE SURVIVAL AFTER ALLOGENEIC HCT: THE PHOEBUS TRIAL Natalia Gemperle Ortiz (Lyon, France) | 08:30 - 08:30 |
| A094 | DYNAMIC MONITORING OF THE PROGNOSTIC NUTRITIONAL INDEX (PNI) IN CAR-T THERAPY FOR RELAPSED/REFRACTORY LYMPHOMA: A RETROSPECTIVE STUDY Jing Liu (Beijing, China) | 08:30 - 08:30 |
| A095 | CIRCULATING TUMOR DNA (CTDNA) AND IL-10 OR IL-10/IL-6 RATIO DYNAMIC MONITORING FOR PREDICTING RELAPSE IN RELAPSED/REFRACTORY CNS LYMPHOMA: A RETROSPECTIVE COHORT STUDY Yan Gao (Beijing, China) | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| A096 | A FIRST-IN-HUMAN STUDY OF HLA-PARTIALLY TO FULLY MATCHED ALLOGENEIC CRYOPRESERVED DECEASED DONOR BONE MARROW TRANSPLANTATION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES Sagar Munjal (San Fransisco, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A097 | UPFRONT TRANSPLANTATION VS. INTENSIVE REMISSION INDUCTION IN MDS/AML, MDS-EB AND OLIGOBLASTIC AML - LIMITED PREDICTIVE VALUE OF BLAST COUNT AT DIAGNOSIS Lisa-Marie Necke (Tübingen, Germany) | 08:30 - 08:30 |
| A098 | IMPACT OF POST-TRANSPLANT INTRATHECAL THERAPY ON CENTRAL NERVOUS SYSTEM RELAPSE IN ACUTE LYMPHOBLASTIC LEUKEMIA Julia Bannatyne Undabeitia (Santander, Spain) | 08:30 - 08:30 |
| A099 | TIMING OF CALCINEURIN INHIBITOR-MMF AFTER HAPLOIDENTICAL TRANSPLANTATION WITH PTCY: RESULTS OF A PHASE II RANDOMIZED STUDY Mithun Abraham Prakash (Ranipet, India) | 08:30 - 08:30 |
| A101 | HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACQUIRED APLASTIC ANEMIA IN 2024: A CROSS-SECTIONAL STUDY FROM THE CHINESE BLOOD AND MARROW TRANSPLANTATION REGISTRY GROUP (CBMTRG) Zhengli Xu (Beijing, China) | 08:30 - 08:30 |
| A103 | IRON OVERLOAD (IO) IS ASSOCIATED WITH AN INCREASED RISK OF INFECTIOUS COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) WITH POST TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) BASED PROPHYLAXIS Monzr Al Malki (Duarte, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A106 | OPTIMIZING ALTERNATIVE DONOR SELECTION IN ALLOGENEIC HSCT: DISEASE- AND CONDITIONING-SPECIFIC ADVANTAGES OF UMBILICAL CORD BLOOD TRANSPLANTS Eun-Jeong Jeong (Seongnam-si, Korea (the Republic of)) | 08:30 - 08:30 |
| A107 | INFLUENCE OF TIME-OF-DAY OF GRAFT INFUSION ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES: A VALIDATION COHORT STUDY Chiara Bernardi (Geneva, Switzerland) | 08:30 - 08:30 |
| A108 | CLINICAL CHARACTERISTICS, PROGNOSTIC FACTORS, AND TRANSPLANT OUTCOMES IN HEMATOLOGICAL MALIGNANCIES WITH BEHÇET'S DISEASE: A RETROSPECTIVE STUDY OF 114 PATIENTS Xiaoyu Cao (Hangzhou, China) | 08:30 - 08:30 |
| A109 | CUMULATIVE CYCLOSPORINE A EXPOSURE AND LONG-TERM OUTCOMES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA Hauke Wilcken (Freiburg, Germany) | 08:30 - 08:30 |
| A110 | ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ACUTE LEUKEMIA: LESSONS TO LEARN FROM MULTIMODAL CLUSTERING Thomas Luft (Heidelberg, Germany) | 08:30 - 08:30 |
| A111 | TRANSPLANT OUTCOMES WITH SPANISH CORD BLOOD UNITS: SIGNIFICANT IMPROVEMENT OVER TIME Sergi Querol (Barcelona, Spain) | 08:30 - 08:30 |
| A112 | EFFICACY OF THE TRIPLET THERAPY WITH VENETOCLAX, AZACITIDINE AND GILTERITINIB FOR THE TREATMENT OF | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | FLT3-ITD MUTATED R/R AML PATIENTS BRIDGING TO ALLOGENEIC STEM CELL TRANSPLANTATION | |
| | Chen Liang (Tianjin, China) | |
| A113 | THE EFFICACY OF MEMORY T CELL DONOR LYMPHOCYTE INFUSION IN AUGMENTING IMMUNE FUNCTION FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION | 08:30 - 08:30 |
| | Jiayu Huang (Shanghai, China) | |
| A114 | LONG-TERM SURVIVAL AND HIGH-RISK DETERMINANTS FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT IN MANTLE CELL LYMPHOMA | 08:30 - 08:30 |
| | Muhammad Azeem Khan (Rochester, United States Minor Outlying Islands (the)) | |
| A115 | LINK BETWEEN NON DONOR-SPECIFIC ANTI-HLA ANTIBODIES AND INFERIOR KEY OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION -THE "LAIKA" STUDY- | 08:30 - 08:30 |
| | Roberto Crocchiolo (Milano, Italy) | |
| A116 | V-DELTA-2 UNCONVENTIONAL T CELLS IN THE DONOR GRAFT ARE ASSOCIATED WITH IMPROVED OVERALL SURVIVAL AFTER UNRELATED DONOR ALLO-HCT FOR AML AND MDS | 08:30 - 08:30 |
| | Kate A. Markey (Seattle, United States Minor Outlying Islands (the)) | |
| A117 | DAN-CART 1901: PRELIMINARY RESULTS OF SAFE AND FEASIBLE ADMINISTRATION OF THE FRESH AUTOLOGOUS ANTI-CD19 CAR-T PRODUCT DK-CLIC-1901 | 08:30 - 08:30 |
| | Katrine Kielsen (Copenhagen, Denmark) | |
| A118 | OUTCOMES OF CRYOPRESERVED VERSUS NON-CRYOPRESERVED STEM CELL ALLOGRAFTS: A COMPARATIVE ANALYSIS | 08:30 - 08:30 |
| | Jenny Miethke (Jena, Germany) | |
| A119 | COMPARISON OF OUTCOMES OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR ALK-POSITIVE AND ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: AN ANALYSIS OF THE EBMT LWP | 08:30 - 08:30 |
| | Evgenii Shumilov (Muenster, Germany) | |
| A120 | TREATMENT OUTCOMES WITH OUT-OF-SPECIFICATION PRODUCTS AND REMANUFACTURING SUCCESS IN CAR T-CELL THERAPY FOR AGGRESSIVE B-CELL LYMPHOMAS: A MULTICENTRE REAL-WORLD STUDY GETH/GELTAMO | 08:30 - 08:30 |
| | Lucía Lopez Corral (Salamanca, Spain) | |
| A122 | INCIDENCE AND RISK FACTORS FOR POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN A MULTICENTER COHORT | 08:30 - 08:30 |
| | Olivia Gelo (Buenos Aires, Argentina) | |
| A123 | ALLOGENEIC STEM CELL TRANSPLANTATION WITH 3-DAYS BUSULFAN PLUS FLUDARABINE AS CONDITIONING REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY T- AND NK/T-CELL LYMPHOMAS | 08:30 - 08:30 |
| | Ji Hyun Lee (Busan, Korea (the Republic of)) | |
| A124 | THE IMPACT OF HLA-DPB1 PERMISSIVE AND NON-PERMISSIVE MISMATCH ON OUTCOMES IN MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THALASSEMIA | 08:30 - 08:30 |
| | Mohana Reddy (Bengaluru, India) | |
| A125 | CLINICAL OUTCOMES OF FULLY HLA-MATCHED SIBLING VERSUS PARENTAL HSCT IN CHILDREN WITH HEMOGLOBINOPATHIES | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| A126 | PATIENTS WITH HIGH GRADE TRANSFORMATION OF WALDENSTRÖM'S MACROGLOBULINEMIA CAN BE RESCUED WITH TRANSPLANTATION. REPORT FROM THE LYMPHOMA WORKING PARTY OF THE EBMT Charalampia Kyriakou (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A128 | IMPACT OF PRE-APHERESIS HOLDING THERAPY ON EFFICACY AND HEMATOLOGIC TOXICITY AFTER CD19 CAR T-CELL THERAPY IN LARGE B-CELL LYMPHOMA Marina Gomez-Llobell (New York, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A129 | EFFECT OF DEFERASIROX INITIATED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ON OUTCOMES IN AML AND MDS: A PROSPECTIVE OBSERVATIONAL STUDY WITH PROPENSITY-SCORE MATCHED CONTROLS Mauricette Michallet (Lyon, France) | 08:30 - 08:30 |
| A130 | HIGHER BODY MASS INDEX IS ASSOCIATED WITH IMPROVED OUTCOMES AFTER CAR-T CELL THERAPY IN PATIENTS WITH LARGE B-CELL LYMPHOMA Mirko Farina (Brescia, Italy) | 08:30 - 08:30 |
| A131 | POPULATION PHARMACOKINETICS AND OPTIMAL EXPOSURE OF ANTI-THYMOCYTE GLOBULIN IN MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION Hamid Ghazal (Calgary, Canada) | 08:30 - 08:30 |
| A132 | EXPLORING BASELINE COGNITIVE FUNCTION ASSESSMENTS AS A PREDICTOR OF ICANS IN CAR-T CELL THERAPY PATIENTS Safia Belbachir (Murdoch, Australia) | 08:30 - 08:30 |
| A133 | EASIX OUTPERFORMS EBMT AND CIBMTR RISK MODELS IN PREDICTING VOD/SOS DESPITE DEFIBROTIDE USE IN ALLOGENEIC HSCT Güldane Cengiz Seval (Ankara, Turkey) | 08:30 - 08:30 |
| A134 | NON-CRYOPRESERVED HEMATOPOIETIC STEM CELLS FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA: REDUCED TOXICITY AND DISTINCT INFLAMMATORY PROFILE AS COMPARED TO CRIOPRESERVED PRODUCTS Mauricio Sarmiento Maldonado (Santiago, Chile) | 08:30 - 08:30 |
| A136 | CLINICAL OUTCOMES OF LISOCABTAGENE MARALEUCEL (LISOCEL) IN YOUNGER PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) Miguel Angel Perales (New York, United States of America (the)) | 08:30 - 08:30 |
| A137 | OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN T-CELL NON-HODGKIN LYMPHOMA EXPERIENCE AT UNIVESITARY HOSPITAL OF SALAMANCA-SPAIN Jaime Daniel Pallo Espinoza (Salamanca, Spain) | 08:30 - 08:30 |
| A139 | "REAL WORLD" INCIDENCE AND CHARACTERISTICS OF IMMUNE EFFECTOR CELL-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTICYTOSIS: A GOCART COALITION STUDY ON BEHALF OF THE EBMT ADWP, CTIWP AND TCWP Matteo Doglio (Milan, Italy) | 08:30 - 08:30 |
| A140 | RISK STRATIFICATION FOR HIGHER GRADE ICANS IN ANTI CD19 CAR T-CELL THERAPY TO GUIDE MANAGEMENT OF HIGH RISK PATIENTS Jonas Wißkirchen (Mainz, Germany) | 08:30 - 08:30 |
| A141 | VENETOCLAX PLUS HIGH-DOSE CYTARABINE AND MITOXANTRONE (HAM-VEN) AS BRIDGE TO OR SALVAGE THERAPY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | IN RELAPSED/REFRACTORY AML Sara Jennrich (Essen, Germany) | |
| A142 | SARCOPENIA ASSESSMENT BY BIOELECTRICAL IMPEDANCE AND FUNCTIONAL TESTS PREDICTS CLINICAL OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Silvia Zanon (Brescia, Italy) | 08:30 - 08:30 |
| A143 | POOR GRAFT FUNCTION AND GRAFT FAILURE AFTER ALLOGENEIC HSCT: FOCUS ON CELLULAR THERAPY. A RETROSPECTIVE SINGLE-CENTER ANALYSIS Natalia Zubarovskaya (Vienna, Austria) | 08:30 - 08:30 |
| A145 | SCALABLE MANUFACTURING AND NATIONWIDE DISTRIBUTION OF ORCA-T: A PRECISION-ENGINEERED ALLOGENEIC IMMUNE CELL THERAPY Anna Pavlova (Menlo Park, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A146 | OUTCOMES AFTER STANDARD- VS. REDUCED-DOSE TREOSULFAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Johanne Schovsbo (Copenhagen, Denmark) | 08:30 - 08:30 |
| A147 | REAL-WORLD EXPERIENCE WITH TABELECLEUCEL Kiavasch Mohammad Nejad Farid (Heidelberg, Germany) | 08:30 - 08:30 |
| A148 | MESENCHYMAL STEM CELLS DERIVED FROM DIFFERENT SOURCES AND THEIR SECRETOMES IN MULTIPLE SCLEROSIS THERAPY: A SINGLE CENTER EXPERIENCE Ahmad Ibrahim (Beirut, Lebanon) | 08:30 - 08:30 |
| A149 | TREOSULFAN-FLUDARABINE AS A REDUCED INTENSITY CONDITIONING ALTERNATIVE TO BUSULFAN-FLUDARABINE FOR ADULT ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE-CENTER, EARLY REAL-LIFE CLINICAL AND ECONOMICAL COMPARATIVE OUTCOMES Clémence Delaye (Villejuif, France) | 08:30 - 08:30 |
| A150 | CD72-GATED PRE-CAR-T MRD AS A NOVEL PREDICTOR OF POST-TRANSPLANT OUTCOMES IN R/R B-ALL ACHIEVING MRD-NEGATIVE REMISSION AFTER CD19 CAR-T THERAPY Man Chen (Beijing, China) | 08:30 - 08:30 |
| A151 | NON-MYELOABLATIVE CONDITIONING FLUCYTBI WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IS SAFE AND EFFECTIVE FOR BOTH HAPLOIDENTICAL AND UNRELATED DONOR ALLOGENEIC TRANSPLANTATION IN OLDER PATIENTS WITH AML OR MDS Charlotte Nykolyszyn (Marseille, France) | 08:30 - 08:30 |
| A152 | HYPOMETHYLATING AGENTS PLUS VENETOCLAX VS INTENSIVE CHEMOTHERAPY PRIOR TO TRANSPLANT IN HIGH-RISK ACUTE MYELOID LEUKEMIA Charlotte Nykolyszyn (Marseille, France) | 08:30 - 08:30 |
| A153 | PROGNOSIS ANALYSIS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF MYELOID SARCOMA: A SINGLE-CENTER STUDY Na Zhang (Beijing, China) | 08:30 - 08:30 |
| A154 | PATTERNS AND PREDICTORS OF HEMATOLOGIC TOXICITY AFTER BCMA- AND CD19-TARGETED CAR-T THERAPY Shlomo Elias (Jerusalem, Israel) | 08:30 - 08:30 |
| A156 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA: A | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | RETROSPECTIVE STUDY ON PROGNOSTIC FACTORS AND A NOVEL SCORING SYSTEM | |
| | Na Tao (Hangzhou, China) | |
| A157 | OUTCOME OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) AFTER PEMBROLIZUMAB IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS: A RETROSPECTIVE ANALYSIS OF THE KING HUSSEIN CANCER CENTER | 08:30 - 08:30 |
| | Khalid Halahleh (Amman, Jordan) | |
| A158 | A PILOT RANDOMIZED CLINICAL TRIAL OF A VIRTUAL REALITY SUPPORTIVE CARE INTERVENTION FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION | 08:30 - 08:30 |
| | Hermioni Amonoo (Boston, United States Minor Outlying Islands (the)) | |
| A161 | HARMONIZING HAPLOIDENTICAL STRATEGIES: A FOUR-YEAR COMPARATIVE ANALYSIS OF T-CELL-DEPLETED AND REPLETE PEDIATRIC TRANSPLANTS FROM A DEVELOPING COUNTRY | 08:30 - 08:30 |
| | Chintan Tarunkumar Vyas (Mumbai, India) | |
| A164 | PERFORMANCE AND VALIDATION OF THE SIMPLIFIED COMORBIDITY INDEX IN PREDICTING NON-RELAPSE MORTALITY AFTER ALLOGENEIC HCT IN THE CURRENT ERA | 08:30 - 08:30 |
| | Omar Eduardo Fernandes Vargas (Montreal, Canada) | |
| A165 | GRAFT-VERSUS-HOST DISEASE, RELAPSE, AND A SIMPLE GRFS RISK GROUPING IN HAPLOIDENTICAL TRANSPLANTATION WITH PTCY | 08:30 - 08:30 |
| | Gonzalo Bentolila (Ciudad Autonoma de Buenos Aires, Argentina) | |
| A166 | CD45RA-DEPLETED T-CELL ADOPTIVE CELL THERAPY FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS WITH REFRACTORY/RESISTANT EBV INFECTIONS: A MULTICENTER, RETROSPECTIVE STUDY | 08:30 - 08:30 |
| | Chuanhe Jiang (Shanghai, China) | |
| A167 | HCT-CI FAILS TO PREDICT OUTCOMES OR TOXICITY IN A LARGE REAL-WORLD LBCL COHORT TREATED WITH AXICABTAGENE CILOLEUCEL: THE AUSTRALIAN CAR-T REAL-WORLD CONSORTIUM EXPERIENCE | 08:30 - 08:30 |
| | Safia Belbachir (Murdoch, Australia) | |
| A169 | SURVIVAL OUTCOMES FOLLOWING ALLOGENEIC TRANSPLANT FOR TP53-MUTATED MYELOID MALIGNANCY IN IRELAND | 08:30 - 08:30 |
| | Sarah Kelliher (Dublin, Ireland) | |
| A170 | OUTCOME AND TOXICITY PROFILE OF CAR T-CELL THERAPY IN PEDIATRIC RELAPSED/REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE-CENTER EXPERIENCE FROM SAUDI ARABIA | 08:30 - 08:30 |
| | Alaa Alzahrani (Riyadh, Saudi Arabia) | |
| A171 | INDIVIDUALIZED BUSULFAN COMPARED TO FIXED-DOSE IN HEMATOPOIETIC STEM CELL TRANSPLANT FOR AML/MDS: RESULTS FROM A SINGLE CENTER | 08:30 - 08:30 |
| | Roberto Bono (Palermo, Italy) | |
| A172 | IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) IN PAEDIATRIC PATIENTS FOLLOWING CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY: EXPERIENCE FROM A TERTIARY CARE CENTER | 08:30 - 08:30 |
| | Nazaret Sanchez-Sierra (Barcelona, Spain) | |
| A173 | A SINGLE CENTRE RETROSPECTIVE REVIEW OF DONOR LYMPHOCYTE INFUSION - INDICATIONS, OUTCOMES AND TOXICITY | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | Catharina Tao (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | |
| A174 | REAL-WORLD OUTCOMES OF AUTOLOGOUS BONE MARROW TRANSPLANTATION IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER RETROSPECTIVE ANALYSIS FROM THE UKRAINIAN NATIONAL BMT REGISTRY Serhii Horbachov (Cherkasy, Ukraine) | 08:30 - 08:30 |
| A175 | TREOSULFAN COMPARED WITH BUSULFAN-BASED CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HEMATOLOGICAL MALIGNANCIES Anna Czyż (Wrocław, Poland) | 08:30 - 08:30 |
| A176 | UTILIZING GVHD BIOMARKERS TO PREDICT POOR ENGRAFTMENT: THE GOLDBLOCKS PHENOMENON OF ALLOREACTIVE T CELLS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION Clayton Long (Phoenix, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A177 | IMMUNE EFFECTOR CELL ASSOCIATED HAEMATOTOXICITY (ICAH) AND CORRELATION WITH CLINICAL OUTCOMES POST CD19 CAR-T; A SINGLE CENTRE RETROSPECTIVE EXPERIENCE FROM THE ROYAL MARSDEN HOSPITAL Nida Shafique (Sutton, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A178 | DUAL T-CELL DEPLETION WITH ANTITHYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PERIPHERAL BLOOD ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME Soyean Kwon (Seoul, Korea (the Republic of)) | 08:30 - 08:30 |
| A179 | IMPACT OF HLA B LEADER GENOTYPE ON SINGLE HLA MISMATCHED ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER COHORT STUDY Elcin Erdogan Yucel (Izmir, Turkey) | 08:30 - 08:30 |
| A180 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION USING DECEASED DONOR DERIVED CRYOPRESERVED BONE MARROW: A FIRST-IN-HUMAN REPORT OF SUCCESSFUL ENGRAFTMENT IN PRESERVE 1 Sagar Munjal (San Francisco, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A181 | EFFICACY OF UNRELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SEVERE APLASTIC ANEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY OF 206 PATIENTS Jinrong Zhao (Guangzhou, China) | 08:30 - 08:30 |
| A184 | UMBILICAL CORD BLOOD MICROTRANSPLANTATION PLUS CHEMOTHERAPY FOR AML AND HIGH-RISK MDS POST-CR1 Jing Zheng (Hangzhou, China) | 08:30 - 08:30 |
| A185 | CLINICAL IMPACT OF IN-SILICO HISTOCOMPATIBILITY ALGORITHMS IN 9/10 MISMATCHED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Rodrigo Gil Manso (Salamanca, Spain) | 08:30 - 08:30 |
| A186 | INTRARENAL ARTERIAL INFUSION OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF TRANSPLANTATION-ASSOCIATED ACUTE RENAL FAILURE: A CASE REPORT Yuanying Zeng (Dongguan, China) | 08:30 - 08:30 |
| A187 | CLINICAL STUDY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION PLUS UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR THE RELAPSED AND REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Zhengchang He (Chongqing, China) | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| A188 | POST-TRANSPLANT MONITORING OF NGS-BASED MINIMAL RESIDUAL DISEASE AND DONOR CHIMERISM AS A PROGNOSTIC TOOL IN OLDERLY PATIENTS WITH AML/MDS Seong Kyu Park (Bucheon-Si, Korea (the Republic of)) | 08:30 - 08:30 |
| A189 | PTCY VERSUS ATLG IN ALLOGENEIC HSCT FOR ACUTE LEUKEMIA WITH HIGH DISEASE BURDEN: A REAL-WORLD STUDY Minglu Li (Beijing, China) | 08:30 - 08:30 |
| A190 | ADMISSION TO INTENSIVE CARE UNIT (ICU) OF ADULT HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE CENTER EXPERIENCE Laura Contreras Rujas (Madrid, Spain) | 08:30 - 08:30 |
| A191 | DETERMINANTS OF GVHD AND SURVIVAL AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER ANALYSIS OF 169 PATIENTS Fei Pan (Beijing, China) | 08:30 - 08:30 |
| A192 | A RETROSPECTIVE ANALYSIS OF THE CLINICAL CHARACTERISTICS, RISK FACTORS, AND PROGNOSIS OF FUSARIUM INFECTION IN HEMATOLOGIC PATIENTS BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION JiCong Liu (LangFang, China) | 08:30 - 08:30 |
| A193 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR THERAPY-RELATED MYELOID NEOPLASMS: LONG-TERM OUTCOMES AND PROGNOSTIC DETERMINANTS FROM A SINGLE-CENTER COHORT Yunsuk Choi (Seoul, Korea (the Republic of)) | 08:30 - 08:30 |
| A194 | EFFICACY AND SAFETY OF COMBINING BCL-2 INHIBITORS WITH HYPOMETHYLATING AGENTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Larisa Kuzmina (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| A195 | SECONDARY MYELODYSPLASTIC SYNDROME AFTER CAR-T THERAPY: AN EMERGING LATE TOXICITY Juliana Bosco Santos (São Paulo, Brazil) | 08:30 - 08:30 |
| A196 | EARLY CYCLOSPORINE TAPERING AND PROPHYLACTIC DONOR LYMPHOCYTE INFUSION FOR POST-TRANSPLANT IMMUNOMODULATION IN HIGH-RISK HEMATOLOGIC MALIGNANCIES: A SINGLE-CENTER FEASIBILITY STUDY Roberto Bono (Palermo, Italy) | 08:30 - 08:30 |
| A198 | LONG-TERM OUTCOMES OF ADULT PH+ ALL TREATED WITH DASATINIB OR IMATINIB BEFORE THE BLINATUMOMAB ERA: A RETROSPECTIVE ANALYSIS OF 250 PATIENTS FROM THE PALG REGISTRY Ugo Giordano (Wroclaw, Poland) | 08:30 - 08:30 |
| A199 | OVERCOMING ULTIMATE RESISTANCE: EFFICACY AND SAFETY OF RECIPIENT-DERIVED (DONOR-CHIMERIC) CAR-T THERAPY COMBINED WITH MULTIMODAL STRATEGIES FOR EARLY RELAPSE POST-ALLO-HSCT: A SINGLE-CENTER CASE SERIES Yajing Zhang (Beijing, China) | 08:30 - 08:30 |
| A200 | GEMTUZUMAB OZOGAMICIN ENABLES BRIDGING TO 2ND/3RD ALLO-HSCT WITH FAVORABLE OUTCOMES IN CD33-HIGH RELAPSED/REFRACTORY AML WITH POST-ALLO-HSCT RELAPSE Xiaohong Liu (Beijing, China) | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| A201 | LONGITUDINAL IMPROVEMENT IN SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A 15-YEAR SINGLE-CENTRE EVALUATION OF QUALITY INITIATIVES Safia Belbachir (Murdoch, Australia) | 08:30 - 08:30 |
| A202 | THROMBOTIC MICROANGIOPATHY FOLLOWING CAR T-CELL THERAPY: A CASE SERIES FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY Guillaume Dachy (Brussels, Belgium) | 08:30 - 08:30 |
| A203 | THE IMPACT OF PRE-TRANSPLANT ISOAGGLUTININ REDUCTION IN MAJOR AND BIDIRECTIONAL ABO-MISMATCHED ALLOGENEIC STEM CELL TRANSPLANTATION - A TWO CENTRE COMPARISON Safia Belbachir (Murdoch, Australia) | 08:30 - 08:30 |
| A204 | SAFETY AND EMERGING CLINICAL IMPACT OF CD19 CAR T-CELL THERAPY IN SEVERE AUTOIMMUNE RHEUMATIC DISEASES: A SINGLE-CENTRE CASE SERIES Aitomi Bittner (Berlin, Germany) | 08:30 - 08:30 |
| A205 | SINGLE CENTRE EXPERIENCE OF USING A THERAPEUTIC PLATELET REGIME DURING AUTOLOGOUS STEM CELL TRANSPLANT Malik Saeed (Nottingham, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A206 | ALLOGENEIC HSCT FOR ADVANCED STAGE AND RELAPSED/REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA (ENKTCL): A SINGLE INSTITUTION EXPERIENCE IN L-ASPARAGINASE ERA Thomas Chan (Hong Kong, China) | 08:30 - 08:30 |
| A207 | EFFICACY AND SAFETY OF CD20XCD3 BISPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMAS: A SYSTEMATIC REVIEW AND META-ANALYSIS Fernando Gibran-Nunes (São Paulo, Brazil) | 08:30 - 08:30 |
| A208 | ACCESS TO CAR-T CELL THERAPY IN CENTRAL AND EASTERN EUROPE (CEE) - PERSISTENT DISPARITIES Karolina Liszka (Wrocław, Poland) | 08:30 - 08:30 |
| A209 | EFFICACY AND SAFETY ANALYSIS OF PD-1 INHIBITORS IN ACUTE LEUKEMIA PATIENTS WITH MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION BiXin Li (Langfang, China) | 08:30 - 08:30 |
| A211 | HYPOFIBRINOGENEMIA AND SYSTEMIC INFLAMMATION FOLLOWING BCMA-DIRECTED CAR-T THERAPY: A RETROSPECTIVE STUDY Almudena Zaratiegui (Madrid, Spain) | 08:30 - 08:30 |
| A212 | SURVIVAL AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER, DECADE-LONG ANALYSIS Noa Holtzman (Miami, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A213 | AGE AT TRANSPLANT DETERMINES OUTCOME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MITOCHONDRIAL NEURO-GASTROINTESTINAL ENCEPHALOPATHY (MNGIE) Patel Zeeshan Jameel (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A214 | LONG-TERM OUTCOMES OF HAPLOIDENTICAL AND MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN COMPLETE REMISSION NON-DS-AMKL: A | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | SINGLE-CENTER COHORT STUDY Fei Pan (Beijing, China) | |
| A215 | IMPACT OF HEPATITIS E VIRUS INFECTION ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CURRENT TREATMENT STATUS Ting Liu (Langfang City, China) | 08:30 - 08:30 |
| A216 | IMPACT OF THERAPEUTIC PLASMA EXCHANGE ON PAN-REACTIVE HLA ANTIBODY TITRES IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA UNDERGOING MATCHED RELATED DONOR HSCT: A SINGLE-CENTRE STUDY Santanu Sen (Mumbai, India) | 08:30 - 08:30 |
| A217 | RISK FACTORS FOR REFRACTORY CYTOMEGALOVIRUS INFECTION IN HEMATOPOIETIC STEM CELL AND SOLID ORGAN TRANSPLANT RECIPIENTS Shunqing Wang (Guangzhou, China) | 08:30 - 08:30 |
| A218 | PROGNOSTIC AND SAFETY PREDICTIVE VALUE OF THE SYSTEMIC IMMUNE-INFLAMMATION INDEX IN R/R B-CELL LYMPHOMA PATIENTS UNDERGOING CAR-T CELL THERAPY Jing Liu (Beijing, China) | 08:30 - 08:30 |
| A219 | BONE MARROW TRANSPLANTATION IN SICKLE, ACCORDING TO DONOR STATUS: COMPARISON AND DIFFERENCES IN CLINICAL OUTCOMES Eduardo J. Bardón-Cancho (Madrid, Spain) | 08:30 - 08:30 |
| A220 | THE PROGNOSTIC IMPACT OF CEBPA MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Erlic Jiang (Tianjin, China) | 08:30 - 08:30 |
| A221 | MESENCHYMAL STEM CELL TRANSPLANTATION IN PATIENTS WITH GRAFT HYPOFUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Tatsiana Talako (Minsk, Belarus) | 08:30 - 08:30 |
| A222 | REFINING HLA-DPB1 MISMATCH (PERMISSIVENESS/NON PERMISSIVENESS) ASSESSMENT IN ALLOGENEIC STEM CELL TRANSPLANTATION Chiara Camerini (Florence, Italy) | 08:30 - 08:30 |
| A223 | DYNAMIC CHANGES IN PHASE ANGLE ASSESSED BY BIOELECTRICAL IMPEDANCE ANALYSIS AS A MARKER OF TOXICITY IN PATIENTS UNDERGOING CAR-T CELL THERAPY Mirko Farina (Brescia, Italy) | 08:30 - 08:30 |
| A224 | HYPOMETHYLATING AGENTS AND VENETOCLAX FOR RELAPSE PREVENTION IN PATIENTS WITH HIGH-RISK MYELOID MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Huiying Qiu (Shanghai, China) | 08:30 - 08:30 |
| A225 | A SIMPLIFIED APPROACH TO GENERATE TREG-ENRICHED GRAFT: TECHNICAL AND EARLY CLINICAL DEVELOPMENT OF CD3-DEPLETION AND CD25-SELECTION Dmitry Pershin (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| A226 | REAL-WORLD OVERALL SURVIVAL OUTCOMES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA: EXPERIENCE FROM A MEXICAN CENTER Rosa Adriana Alvidrez-González (Mexico City, Mexico) | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| A227 | EFFICACY AND SAFETY OF GRANULOCYTE COLONY STIMULATING FACTOR (GCSF) USE FOLLOWING CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY (CAR-T): A SYSTEMATIC REVIEW Xiao Ran Luo (Singapore, Singapore) | 08:30 - 08:30 |
| A228 | COMPUTED TOMOGRAPHY-DERIVED MUSCLE QUALITY PREDICTS LENGTH OF HOSPITALIZATION AFTER STEM CELL TRANSPLANTATION Christianne Bourlon-De los Ríos (Mexico City, Mexico) | 08:30 - 08:30 |
| A229 | THE ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA Nikolai Tsvetkov (St. Petersburg, Russian Federation (the)) | 08:30 - 08:30 |
| A230 | TRANSITIONING CAR-T CELL THERAPY FOR MYELOMA TO THE OUTPATIENT SETTING: FIRST EXPERIENCE FROM A GERMAN CENTER Philipp Gödel (Cologne, Germany) | 08:30 - 08:30 |
| A231 | THE PRACTICAL DIFFICULTIES OF DLI THERAPY: A SINGLE-CENTRE AUDIT OF DLI COLLECTION AND USE William George Giusti Fischer (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A232 | EARLY STEROID PROPHYLAXIS AS A STRATEGY TO REDUCE CAR T-CELL TOXICITIES WITHOUT AFFECTING EFFICACY Simona Sammassimo (Milan, Italy) | 08:30 - 08:30 |
| A233 | SEQUENTIAL IMMUNOMODULATION WITH PRE-APHERESIS PRIMING AND POST-INFUSION BOOST TO RESTORE T-CELL FITNESS AND IMPROVE ANTI-CD19 CAR-T EXPANSION IN BENDAMUSTINE-EXPOSED R/R B-NHL: A PILOT STUDY Yajing Zhang (Beijing, China) | 08:30 - 08:30 |
| A234 | REDEFINING CURATIVE HORIZONS IN THALASSEMIA MAJOR: 100% SURVIVAL FOLLOWING ALTERNATIVE DONOR HSCT IN A RESOURCE-LIMITED SETTING Chintan Tarunkumar Vyas (Mumbai, India) | 08:30 - 08:30 |
| A235 | EXPERIENCE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH GATA2 MUTATION Larisa Kuzmina (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| A236 | ALLOGENEIC HSCT WITH MYELOABLATIVE CONDITIONING IN SICKLE CELL DISEASE: A SINGLE-CENTER EXPERIENCE Akif Yesilipek (Antalya, Turkey) | 08:30 - 08:30 |
| A238 | SHOULD FRAILTY SCORES BE CONSIDERED WHEN ASSESSING ELIGIBILITY FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION? THE EXPERIENCE OF THE SOUTH WALES BLOOD AND MARROW TRANSPLANT PROGRAMME Wendy Ingram (Cardiff, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A239 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF 38 PATIENTS Yang He (Langfang, China) | 08:30 - 08:30 |
| A240 | IS HLA MISMATCHING BECOMING A HISTORY IN THE ERA OF POST-TRANSPLANT CYCLOPHOSPHAMIDE? Elcin Erdogan Yucel (Izmir, Turkey) | 08:30 - 08:30 |
| A241 | INDUCING KETOSIS WITH B-HYDROXYBUTYRATE SUPPLEMENTATION DURING CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN RELAPSED/REFRACTORY INFANT ACUTE | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | LYMPHOBLASTIC LEUKEMIA Patrizia Lehr (Freiburg, Germany) | |
| A243 | OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY IN ADOLESCENTS AND YOUNG ADULTS: A SINGLE-CENTRE EXPERIENCE Yazeed Bajuaifer (Riyadh, Saudi Arabia) | 08:30 - 08:30 |
| A244 | CD34⁺ CELL DOSE ABOVE 10 MILLION PER KILOGRAM ON THE OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE Lun-Wei Chiou (Taipei, Taiwan (Province of China)) | 08:30 - 08:30 |
| A245 | OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN ACUTE LEUKEMIAS IN ECUADOR Luis Martillo-Maldonado (Guayaquil, Ecuador) | 08:30 - 08:30 |
| A246 | EVALUATING THE ROLE OF ELTROMBOPAG IN POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS WITH HEMATOLOGIC DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS April Joy Ong (Manila City, Philippines (the)) | 08:30 - 08:30 |
| A247 | TREATMENT OF RELAPSED/REFRACTORY HIGH-GRADE B-CELL LYMPHOMAS WITH POINT-OF-CARE MANUFACTURED ANTI-CD-MB-19.1 -CART-CELLS: A SINGLE CENTER, INTERIM ANALYSIS OF A PHASE 2 TRIAL FROM JORDAN Khalid Halahleh (Amman, Jordan) | 08:30 - 08:30 |
| A248 | FEASIBILITY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH MYELOID NEOPLASMS: SINGLE-CENTER EXPERIENCE Natalia López Esteban (Las Palmas de Gran Canaria, Spain) | 08:30 - 08:30 |
| A249 | OUTCOMES OF CORD BLOOD TRANSPLANTATION FOR AML-MR: PROGRESS AND REMAINING CHALLENGES Shunsuke Nishino (Minato-Ku, Tokyo, Japan) | 08:30 - 08:30 |
| A250 | HAPLOIDENTICAL VERSUS FULLY MATCHED RELATED DONOR STEM CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULTS WITH SEVERE APLASTIC ANEMIA: A SINGLE-CENTER EXPERIENCE FROM A RESOURCE-LIMITED SETTING Daniella Hodroj (Beirut, Lebanon) | 08:30 - 08:30 |
| A251 | PROGNOSTIC FACTORS FOR CYTOKINE RELEASE SYNDROME (CRS) AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY: A SINGLE-CENTER EXPERIENCE Aikaterini Benekou (Athens, Greece) | 08:30 - 08:30 |
| A252 | WHEN COMBINING ATG WITH PTCY, HIGHER ATG EXPOSURE MAY RESULT IN HIGHER SURVIVAL Hamid Ghazal (Calgary, Canada) | 08:30 - 08:30 |
| A253 | IMPACT OF CORTICOSTEROID THERAPY ON CLINICAL OUTCOMES, TOXICITY, AND CAR T-CELL KINETICS IN PATIENTS TREATED WITH ACADEMIC ANTI-BCMA CAR T CELLS (HBI0101) Sigal Grisariu (Jerusalem, Israel) | 08:30 - 08:30 |
| A254 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION POST-CAR-T THERAPY IN CHILDREN WITH PRE-B ACUTE LYMPHOBLASTIC LEUKAEMIA: NATIONAL POLISH EXPERIENCE Karolina Liszka (Wrocław, Poland) | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| A256 | MULTICENTER PILOT CLINICAL TRIAL OF OLUTASIDENIB AS MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH AML/MDS CARRYING IDH1 MUTATIONS Amandeep Salhotra (Duarte, United States of America (the)) | 08:30 - 08:30 |
| A257 | A SINGLE CENTRE EXPERIENCE OF ALLOGENEIC STEM CELL TRANSPLANT IN PATIENTS OVER 70 Catharina Tao (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A258 | LOW-LEVEL PRETRANSPLANT CMV DNAEMIA IS ALREADY A RISK FACTOR FOR POSTTRANSPLANT CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Dionysios Neofytos (Geneva, Switzerland) | 08:30 - 08:30 |
| A259 | ASSESSMENT OF COMPLEMENT PATHWAY DYNAMICS AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT: RESULTS FROM A MONOCENTRIC LONGITUDINAL MONITORING PROGRAM Camille Malbrun (Vandoeuvre-Les-Nancy, France) | 08:30 - 08:30 |
| A260 | HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR MALIGNANT AND NON-MALIGNANT HEMATOLOGIC DISORDERS: A REAL-WORLD EXPERIENCE FROM QATAR Afraa Fadul (Doha, Qatar) | 08:30 - 08:30 |
| A261 | OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHRONIC MYELOID LEUKEMIA IN TYROSINE KINASE INHIBITORS ERA: A SINGLE CENTRE STUDY FROM PAKISTAN Bushra Ahsan (Lahore, Pakistan) | 08:30 - 08:30 |
| A262 | ABT/CD19 DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION IS A SAFE AND EFFECTIVE SALVAGE THERAPY IN HEAVILY PRETREATED RELAPSED/REFRACTORY PATIENTS WITH HODGKIN LYMPHOMA Lucia Prezioso (Parma, Italy) | 08:30 - 08:30 |
| A264 | FACTORS AFFECTING QUALITY OF BONE MARROW HARVESTING: AN ANALYSIS OF ANTHONY NOLAN DONORS FROM 2019-2024 Tania Dexter (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A265 | FOR CAR T CELL, SIZE DOES SEEM TO MATTER! Susana Couto Irving (Porto, Portugal) | 08:30 - 08:30 |
| A267 | IMPACT OF SOCIODEMOGRAPHIC AND CLINICAL FACTORS ON ACCESS TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY FROM MEXICO Rosa Adriana Alvidrez-González (Mexico City, Mexico) | 08:30 - 08:30 |
| A268 | SINGLE-CENTER RETROSPECTIVE CLINICAL STUDY ON THE CONDITIONING REGIMEN OF DECITABINE, THIOTEPA, BUSULFAN, AND FLUDARABINE (DTBF) COMBINED WITH ATG/PTCY FOR ALTERNATIVE DONOR TRANSPLANTATION IN MYELODYSPLASTIC NEOPLASMS Yajing Xu (Changsha, China) | 08:30 - 08:30 |
| A269 | CONDITIONING MATTERS: A RETROSPECTIVE COMPARISON OF BUCY AND FLUBU IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Mistral Castellanos-Mares (Mexico City, Mexico) | 08:30 - 08:30 |
| A270 | MULTI-VIRUS SPECIFIC MEMORY T CELLS TARGETING CMV, BKV, AND EBV IN POST-HSCT VIRAL INFECTIONS | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | Seok-Goo Cho (Seoul, Korea (the Republic of)) | |
| A271 | LONG-TERM OUTCOMES OF HAPLOIDENTICAL, MATCHED SIBLING, AND MATCHED UNRELATED DONOR HSCT IN 133 ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A SINGLE-CENTER COMPARATIVE STUDY Yanli Zhao (Langfang, China) | 08:30 - 08:30 |
| A272 | ALEMTUZUMAB PROVIDES DURABLE DEPLETION OF CIRCULATING CAR-T CELLS IN A PATIENT WITH HYPOKINETIC MOVEMENT DISORDERS AFTER BCMA-TARGETING CAR-T CELL THERAPY Lea Miebach (Greifswald, Germany) | 08:30 - 08:30 |
| P008 | IMPACT OF ATG DOSE ON OUTCOMES FOLLOWING MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE COMPARISON OF 5 MG/KG VERSUS 10 MG/KG Cheongin Yang (Suwon, Korea (the Republic of)) | 08:30 - 08:30 |
| P009 | BONE MARROW TRANSPLANTATION IN TELOMERE BIOLOGY DISORDERS, THE EXPERIENCE OF PEDIATRIC BONE MARROW TRANSPLANT UNIT OF BRESCIA Marianna Maffeis (Brescia, Italy) | 08:30 - 08:30 |
| P010 | OUTCOME OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES Angeliki Georgopoulou (Patras, Greece) | 08:30 - 08:30 |
| P011 | THE USEFULNESS OF CULTURING APHERESIS PRODUCTS IN HEMATOPOIETIC STEM CELL AUTOTRANSPLANTS Guillermo J. Ruiz-Argüelles (Puebla, Mexico) | 08:30 - 08:30 |
| P012 | OUTCOME OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT IN RELAPSE/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A MULTI-CENTRE RETROSPECTIVE COHORT STUDY Xinxin Huang (Singapore, Singapore) | 08:30 - 08:30 |
| P013 | IMPACT OF CYCLOSPORINE A BLOOD LEVELS EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS ON OUTCOME Max Wichmann (Hamburg, Germany) | 08:30 - 08:30 |
| P016 | UTILITY OF IL-6, FERRITIN AND CRP LEVELS IN PREDICTING CAR T-CELL TOXICITIES IN PATIENTS TREATED WITH TISA-CEL FOR B CELL LYMPHOMA AND B-ALL Hanan AlQudairy (Riyadh, Saudi Arabia) | 08:30 - 08:30 |
| P018 | THE JOURNEY TO ALLOGENEIC STEM CELL TRANSPLANTATION OF PATIENTS TREATED WITH BCL2 INHIBITOR THERAPY IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA IN MIDDLE INCOME COUNTRY Fernando Barroso Duarte (Fortaleza, Brazil) | 08:30 - 08:30 |
| P019 | OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN INFANT LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY Xiaoxi Lu (Chengdu, China) | 08:30 - 08:30 |
| P021 | HEMATOPOIETIC STEM CELL TRANSPLANTATION IN APLASTIC ANAEMIA: EXPERIENCE FROM A TERTIARY CARE REFERRAL HOSPITAL K.K Radhika (Hyderabad, India) | 08:30 - 08:30 |
| P022 | A RARE CASE OF AUTOSOMAL DOMINANT OSTEOPETROSIS WITH CONCOMITANT CMML 1 TREATED WITH ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | Jenny Miethke (Jena, Germany) | |
| P023 | HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR JUVENILE MYELOMONOCYTIC LEUKAEMIA Frances Yeap (Singapore, Singapore) | 08:30 - 08:30 |
| P024 | OPTIMIZING PAEDIATRIC LYMPHAPHERESIS: KEY FACTORS FOR SAFE AND EFFECTIVE PROCEDURES Mercé Albert Bayo (Barcelona, Spain) | 08:30 - 08:30 |
| P026 | CLINICAL CHARACTERISTICS AND OUTCOMES OF HODGKIN LYMPHOMA PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A REAL-WORLD EXPERIENCE FROM A NATIONAL REFERRAL CENTER Vicky Margarita Moncada Gadea (Ciudad de Mexico, Mexico) | 08:30 - 08:30 |
| P028 | CD19 CAR-T THERAPY OUTCOMES IN OLDER ADULTS: A SINGLE-CENTER REAL-WORLD EXPERIENCE FROM ASIA Lawrence Cheng Kiat Ng (Singapore, Singapore) | 08:30 - 08:30 |
| P029 | DECEASED DONOR BONE MARROW TRANSPLANT: FIRST EVER HUMAN CASE REPORT OF SUCCESSFUL ENGRAFTMENT AFTER INFUSION OF A CRYOPRESERVED DECEASED DONOR BONE MARROW IN A PATIENT WITH AML Sagar Munjal (San Fransisco, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| P030 | COMPARATIVE EFFECTIVENESS OF RATG, PTCY, AND CNI/MTX FOR GVHD PROPHYLAXIS IN MATCHED SIBLING AND UNRELATED DONOR TRANSPLANTATION Gonzalo Bentolila (Ciudad Autonoma de Buenos Aires, Argentina) | 08:30 - 08:30 |
| P031 | EFFICACY OF ROMIPILOSTIM ON HASTENING PLATELET COUNT RECOVERY IN POST-TRANSPLANT PATIENTS: A SINGLE-CENTER EXPERIENCE N. Kaushik (Bengaluru, India) | 08:30 - 08:30 |
| P034 | ANALYSIS OF GRAFT-VERSUS-HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL (GRFS) IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Minia Grobas Sebio (Las Palmas de Gran Canaria, Spain) | 08:30 - 08:30 |
| P035 | CRYOPRESERVED LEUKAPHERESIS FOR CAR-T MANUFACTURING IN SPAIN: A NATIONAL SURVEY FROM THE SPANISH SOCIETY FOR BLOOD TRANSFUSION AND CELLULAR THERAPY (SETS) Jesus Fernandez-Sojo (Barcelona, Spain) | 08:30 - 08:30 |
| P036 | PERICATHETER AND SYSTEMIC THROMBOSIS DURING CAR-T LYMPHOCYTAPHERESIS: INCIDENCE AND CLINICAL CORRELATES Eugenio Galli (Rome, Italy) | 08:30 - 08:30 |
| P038 | T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSE AFTER CAR-T THERAPY Antonella Zanette (Curitiba, Brazil) | 08:30 - 08:30 |
| P039 | IMMUNE RECONSTITUTION AND INFECTIOUS COMPLICATIONS IN PATIENTS UNDERGOING CAR-T CELL THERAPY: A REAL-WORLD SINGLE-CENTER EXPERIENCE Maria Caterina Mico' (Reggio Calabria, Italy) | 08:30 - 08:30 |
| P040 | OUTCOMES OF CD19 CAR T-CELL THERAPY IN DOWN SYNDROME-ASSOCIATED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A THREE-PATIENT CASE SERIES FROM A CENTER IN THE MIDDLE EAST Nourah Alzaidy (Riyadh, Saudi Arabia) | 08:30 - 08:30 |
| P041 | AN UNSUPERVISED APPROACH TO PREDICTING EARLY POST- | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | TRANSPLANT FEVER IN ADULTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION USING ROUTINE LABORATORY AND CLINICAL PARAMETERS | |
| | Jaromir Tomasik (Warsaw, Poland) | |
| P043 | CLINICAL OUTCOMES FOLLOWING TREATMENT WITH CD19 CAR T-CELL THERAPY IN PATIENTS WITH DOWN SYNDROME-ASSOCIATED ALL: A SINGLE-INSTITUTION EXPERIENCE | 08:30 - 08:30 |
| | Brittany Ivory (Los Angeles, United States Minor Outlying Islands (the)) | |
| P045 | DEVELOPING PEDIATRIC ALLOGENIC STEM-CELL TRANSPLANTATION IN LOW-MIDDLE- INCOME COUNTRY: REPORT FROM MOROCCO | 08:30 - 08:30 |
| | Maria El Kababri (Rabat, Morocco) | |
| P046 | RARE EWSR1 REARRANGEMENT IN AML | 08:30 - 08:30 |
| | Shaoyan Hu (Suzhou, China) | |
| P047 | BETTER SURVIVAL FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY (>65 YEARS OLD) AML PATIENTS - RESULTS OF AN INTERNATIONAL, TWO-CENTER ANALYSES | 08:30 - 08:30 |
| | Karolina Beldzińska-Gądek (Gdańsk, Poland) | |
| P048 | BEYOND SUPPORTIVE CARE: ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN WITH FUCOSIDOSIS | 08:30 - 08:30 |
| | Akif Yesilipek (Antalya, Turkey) | |
| P049 | PATIENTS WITH MULTIPLE SCLEROSIS ABOVE AGE 60 HAVE NEUROLOGICAL RESPONSES TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTS SIMILAR TO YOUNGER INDIVIDUALS: A SINGLE-CENTER EXPERIENCE | 08:30 - 08:30 |
| | Guillermo J. Ruiz-Argüelles (Puebla, Mexico) | |
| P050 | RESULTS OF AN ITALIAN SURVEY FOR CELLULAR THERAPY PRODUCTS STORAGE AND DISPOSAL: NEED FOR AN UPDATE OF 2014 GUIDELINES | 08:30 - 08:30 |
| | Claudia Del Fante (Pavia, Italy) | |
| P051 | SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: A SINGLE-CENTER EXPERIENCE | 08:30 - 08:30 |
| | Teresa Bedoya Palop (Barcelona, Spain) | |
| P052 | IMPACT OF PRE-TRANSPLANT EVENTS ON THE FEASIBILITY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |
| | Nour Ben Abdeljelil (Tunis, Tunisia) | |
| P053 | FAVOURABLE SURVIVAL IN ALLOGENIC STEM CELL TRANSPLANT RECIPIENTS ADMITTED TO INTENSIVE CARE; 6-YEAR RETROSPECTIVE REVIEW FROM A UNIVERSITY HOSPITAL TRANSPLANT CENTRE IN THE UK | 08:30 - 08:30 |
| | Behnaz Mobashwera (Portsmouth, United Kingdom of Great Britain and Northern Ireland (the)) | |
| P054 | G-CSF ADMINISTRATION AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMAS TREATED WITH CAR-T CELLS: A MONOCENTRIC EXPERIENCE | 08:30 - 08:30 |
| | Serafina Barbato (Naples, Italy) | |
| P055 | ROLE OF GILTERITINIB IN PREVENTING RELAPSE IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT: A REAL-WORLD COHORT STUDY | 08:30 - 08:30 |
| | Laura Carral Fernandez (Madrid, Spain) | |

| | | |
|------|--|---------------|
| P056 | AN EVOLVING LANDSCAPE - HOW CHANGING CONDITIONING REGIMES CAN IMPROVE MYELOFIBROSIS TRANSPLANT OUTCOMES Tara Maisel (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P057 | VARIATIONS IN BLOOD TRANSFUSION PRACTICES AMONG SOUTH AFRICAN HAEMATOLOGY PROVIDERS: A SURVEY OF HAEMATO-ONCOLOGY AND HAEMATOPOIETIC STEM CELL TRANSPLANT PRESCRIBERS Justin du Toit (Johannesburg, South Africa) | 08:30 - 08:30 |
| P058 | VIRUS-SPECIFIC T CELL THERAPY FOR POST-TRANSPLANT VIRAL INFECTIONS: ONE YEAR OF CLINICAL-GRADE MANUFACTURING EXPERIENCE Rebecca Axelsson Robertson (Stockholm, Sweden) | 08:30 - 08:30 |
| P059 | COMBINATION ANTIVIRAL TREATMENT IS EFFECTIVE IN TREATING PARAINFLUENZA 3INFECTION IN THE IMMEDIATE POST-TRANSPLANT SETTING, INCLUDING IN PATIENTS WITH IN-VIVO T-CELL DEPLETION Antony Cousins (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P060 | GENETIC INSTABILITY IN BLOOM: A RARE CASE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION Angeliki Karagiannidou (Chaidari, Greece) | 08:30 - 08:30 |
| P061 | CLINICAL UTILIZATION OF CORD BLOOD UNITS IN THE FAMICORD GROUP Tomasz Baran (Warsaw, Poland) | 08:30 - 08:30 |
| P063 | EFFICACY AND SAFETY OF SHORT-COURSE BLINATUMOMAB FOR PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH MOLECULAR RECURRENCE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION Shaoyan Hu (Suzhou, China) | 08:30 - 08:30 |
| P065 | OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: EXPERIENCE FROM A TERTIARY CENTER IN SAUDI ARABIA Wael Alanazi (Dammam, Saudi Arabia) | 08:30 - 08:30 |
| P066 | SAFE DELIVERY OF BISPECIFIC ANTIBODIES AT CHRISTIE PRIVATE CARE: SERVICE IMPLEMENTATION AND EARLY SAFETY OUTCOMES Meena Afzal Lakha (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P067 | OUTCOMES OF THIRD ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AMONG HEMATOLOGICAL MALIGNANCY PATIENTS RELAPSE POST SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Song Xue (Beijing, China) | 08:30 - 08:30 |
| P068 | HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH LI-FRAUMENI SYNDROME AND HEMATOLOGIC MALIGNANCIES: A SINGLE-CENTER EXPERIENCE Maria Ilyushina (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| P069 | LATE-ONSET DONOR-DERIVED PDGFR-B-REARRANGED EOSINOPHILIC NEOPLASM FOLLOWING HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A SECONDARY ACUTE MYELOID LEUKEMIA Francien Bonifacia Lumauag (Taguig, Philippines (the)) | 08:30 - 08:30 |
| P070 | A SINGLE CENTRE EXPERIENCE OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DDX41-MUTATED MDS | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | AND AML | |
| | Catharina Tao (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | |
| P072 | SUCCESSFUL IMPLEMENTATION OF CAR-T CELL THERAPY AT THE ONCOLOGY INSTITUTE IN WARSAW Lukasz Targonski (Warszawa, Poland) | 08:30 - 08:30 |
| P073 | LASER DOPPLER-BASED MICROCIRCULATORY MONITORING AS AN EARLY PREDICTOR OF POOR VENOUS FLOW DURING LEUKAPHERESIS Ryu Yanagisawa (Matsumoto, Japan) | 08:30 - 08:30 |
| P074 | THE ILLUSION OF DEFEAT: PSEUDO-PROGRESSION FOLLOWING DUAL CD19/CD22 CAR-T THERAPY IN REFRACTORY DLBCL Sundar Shewale (Kolkata, India) | 08:30 - 08:30 |
| P075 | IMPACT OF REFRACTORY PRE-TRANSPLANT CYTOMEGALOVIRUS INFECTIONS ON SURVIVAL IN CHILDREN UNDERGOING STEM CELL TRANSPLANT FOR PRIMARY IMMUNODEFICIENCY DISORDERS Fatema Al-Hashem (Riyadh, Saudi Arabia) | 08:30 - 08:30 |
| P076 | INCIDENCE AND CHARACTERISTICS OF EXTREMELY RARE COMPLICATIONS OF POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A BICENTRIC SAUDI ARABIAN EXPERIENCE Shad Ahmed (Riyadh, Saudi Arabia) | 08:30 - 08:30 |
| P077 | CHALLENGES IN PERFORMING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RESOURCE-LIMITED COUNTRIES EXPERIENCE OF THE BONE MARROW TRANSPLANTATION CENTER IN TUNISIA Nour Ben Abdeljelil (Tunis, Tunisia) | 08:30 - 08:30 |
| P079 | USE OF ORAL AZACITIDINE AS BRIDGING THERAPY TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): A SINGLE TRANSPLANT PROGRAM EXPERIENCE Angela Carobene (Napoli, Italy) | 08:30 - 08:30 |
| P080 | MITIGATING RISK FACTORS FOR PROLONGED HOSPITALIZATION IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER QUALITY IMPROVEMENT STUDY IN SAUDI ARABIA Waad Alghamdi (Jeddah, Saudi Arabia) | 08:30 - 08:30 |
| P082 | ALLOGENEIC TRANSPLANT JOURNEY THROUGH THREE MALIGNANCIES: A 75-YEAR-OLD PATIENT DEFYING THE ODDS Ajda Gunes (Izmir, Turkey) | 08:30 - 08:30 |
| P083 | HARNESSING GRAFT-VERSUS-LEUKEMIA ALLOREACTIVITY TO TREAT MULTI-REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HSCT Rajinder Bajwa (Columbus, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| P084 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF SEVERE APLASTIC ANEMIA IN ADULTS: EXPERIENCE OF THE REPUBLIC OF BELARUS Tatsiana Talako (Minsk, Belarus) | 08:30 - 08:30 |
| P085 | FACTORS ASSOCIATED WITH OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL IN ADULTS WITH ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AT A CENTER IN COLOMBIA Claudia Sossa-Melo (Bucaramanga, Colombia) | 08:30 - 08:30 |
| P086 | AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |

| | | |
|--|---|---------------|
| | IN HODGKIN LYMPHOMA: A 16-YEAR SINGLE-CENTER EXPERIENCE FROM EHU 1ST NOVEMBER OF ORAN, ALGERIA | |
| | Amal Bendimerad (Oran, Algeria) | |
| P087 | EXPERIENCE OF MISMATCHED UNRELATED DONOR TRANSPLANTS WITH PTCY BASED GVHD PROPHYLAXIS IN BENIGN HEMATOLOGICAL DISORDERS | 08:30 - 08:30 |
| | Akanksha Garg (Ahmedabad, India) | |
| P088 | RISK FACTORS FOR RECURRENT CYTOMEGALOVIRUS INFECTION IN HEMATOPOIETIC STEM CELL AND SOLID ORGAN TRANSPLANT RECIPIENTS: A SCOPING REVIEW | 08:30 - 08:30 |
| | Shunqing Wang (Guangzhou, China) | |
| P089 | HAPLO-CORD HCT: SAVE THE SIBLING! | 08:30 - 08:30 |
| | Sundar Shewale (Kolkata, India) | |
| P090 | A CASE OF RESOLVED SEVERE HEMATOLOGICAL TOXICITY AFTER ANTI-BCMA CAR-T THERAPY FOR MULTIPLE MYELOMA | 08:30 - 08:30 |
| | Mikhail Uss (Minsk, Belarus) | |
| P091 | JUVENILE MYELOMONOCYTIC LEUKEMIA WITH THERAPY-RELATED AML: A COMPLEX CASE OF MULTIPLE HAPLOIDENTICAL TRANSPLANTS AND CHRONIC GVHD | 08:30 - 08:30 |
| | Esraa Abdelhakem (Muscat, Oman) | |
| P092 | THE ROLE OF APHERESIS PLATELETS IN SUPPORTIVE THERAPY FOR PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION - CASE REPORT | 08:30 - 08:30 |
| | Marina Sekulic (Podgorica, Montenegro) | |
| P093 | ALLOGENEIC STEM CELL TRANSPLANT WITH PERIPHERAL BLOOD SOURCE AS FRONTLINE THERAPY: A SINGLE CENTRE EXPERIENCE | 08:30 - 08:30 |
| | Guillermo Ramos Moreno (Madrid, Spain) | |
| P094 | FLAG-VENETOCLAX-ENASIDENIB SALVAGE FOR 7+3 FAILURE | 08:30 - 08:30 |
| | Kevin Sese (Taguig, Philippines (the)) | |
| P095 | CLINICAL IMPACT OF HLA-C*04:09 RECLASSIFICATION FROM NULL TO LOW-EXPRESSION ALLELE: A CASE AFTER APPARENTLY 10/10 MATCHED ALLOGENEIC HSCT | 08:30 - 08:30 |
| | Rodrigo Gil Manso (Salamanca, Spain) | |
| P096 | SUCCESSFUL MANAGEMENT OF POST-TRANSPLANT AML RELAPSE WITH SALVAGE CHEMOTHERAPY AND DONOR LYMPHOCYTE INFUSION | 08:30 - 08:30 |
| | Hakan Goker (Ankara, Turkey) | |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Immune Reconstitution and Chimerism | | |
| B186 | IMMUNE RECONSTITUTION DURING MAINTENANCE THERAPY WITH AZACITIDINE AFTER ALLOGENEIC HCT | 08:30 - 08:30 |
| | Laura Pedretti (Bologna, Italy) | |
| B187 | PREVALENCE AND LONG-TERM CLINICAL IMPACT OF SELECTIVE IGA DEFICIENCY FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY: A RETROSPECTIVE COHORT ANALYSIS | 08:30 - 08:30 |
| | Sravani Vemuri (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B188 | CHARACTERIZING THERAPEUTIC ENDPOINTS AND EFFICACY OF PRE-EMPTIVE DONOR LYMPHOCYTE INFUSION FOR MIXED | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | LYMPHOID CHIMERISM POST-ALLOGENEIC STEM CELL TRANSPLANT: A FOUR-YEAR SINGLE-CENTRE RETROSPECTIVE ANALYSIS | |
| | Kinda Al-Hourani (Glasgow, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B189 | BONE MARROW ASPIRATIONS (BMAS) AFTER DONOR LYMPHOCYTE INFUSION (DLI): ARE ROUTINE FOLLOW-UPS NECESSARY FOR ALL PATIENTS? | 08:30 - 08:30 |
| | Sophie Bertorelli (Cardiff, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B190 | LETERMOVIR PROPHYLAXIS RESHAPES EARLY IMMUNE RECONSTITUTION AND CMV/EBV REACTIVATION DYNAMICS AFTER ALLOGENEIC HSCT | 08:30 - 08:30 |
| | Wei Zhao (Beijing, China) | |
| B191 | DEEP IMMUNOPHENOTYPING IDENTIFIES DIFFERENTIAL IMMUNE PROFILES IN RECIPIENTS OF DONOR LYMPHOCYTE INFUSIONS | 08:30 - 08:30 |
| | Jennifer Vidler (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B192 | BONE MARROW GRAFTS SUPPORT BROADER EARLY T-CELL AND ANTIVIRAL REPERTOIRE RECOVERY AFTER HAPLOIDENTICAL HSCT WITH PTCY | 08:30 - 08:30 |
| | Amandine Pradier (Geneva, Switzerland) | |
| B193 | A RANDOMIZED PILOT TRIAL OF CLOSTRIDIUM BUTYRICUM MIYARI 588 IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS | 08:30 - 08:30 |
| | Ryotaro Nakamura (Duarte, United States Minor Outlying Islands (the)) | |
| B194 | DETERMINANTS OF ENGRAFTMENT INSTABILITY IN SICKLE CELL DISEASE: IDENTIFYING MODIFIABLE AND EARLY PREDICTORS OF MIXED CHIMERISM AFTER CURATIVE TRANSPLANTATION | 08:30 - 08:30 |
| | Alexander Ngwube (Houston, United States Minor Outlying Islands (the)) | |
| B195 | DIFFERENTIAL IMMUNE RECONSTITUTION ACROSS AGE GROUPS AFTER ALLO-HSCT: A LONGITUDINAL ANALYSIS OF PEDIATRIC, ADULT, AND ELDERLY PATIENTS | 08:30 - 08:30 |
| | Wei Zhao (Beijing, China) | |
| B196 | IMMUNE RECONSTITUTION AFTER HAPLOIDENTICAL PBSCT IN PAEDIATRIC B AND T-ALL: A COMPARATIVE STUDY OF PATIENTS WITH AND WITHOUT PRIOR CAR-T THERAPY | 08:30 - 08:30 |
| | Jann Adriel Sy (Singapore, Singapore) | |
| B197 | DAY 30 MIXED DONOR CHIMERISM DOES NOT PREDICT RELAPSE IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML AND MDS | 08:30 - 08:30 |
| | Carol Herrera Hernández (Las Palmas de Gran Canaria, Spain) | |
| B198 | PROLONGED HYPOGAMMAGLOBULINEMIA IN PATIENTS WITH INBORN ERRORS OF IMMUNITY (IEI) AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) | 08:30 - 08:30 |
| | Yulia Rodina (Moscow, Russian Federation (the)) | |
| B199 | THREE-MONTH WHOLE BLOOD AND T-CELL CHIMERISM INDEPENDENTLY PREDICT RELAPSE AND SURVIVAL FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTS FOR HAEMATOLOGICAL CANCERS: A MULTICENTRE ANALYSIS | 08:30 - 08:30 |
| | Rebecca Goodhew (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B200 | SUCCESSFUL TREATMENT OF TRANSPLANTED PID PATIENTS WITH SPLIT CHIMERISM USING CD34+POSITIVELY-SELECTED HSPCS AFTER CONDITIONING WITH REDUCED-TOXICITY TARGETED BUSULFAN ALONE | 08:30 - 08:30 |

| | | |
|---|---|---------------|
| | Pik Ki Chan (Zurich, Switzerland) | |
| B201 | FROM IMMUNODEFICIENCY TO MALIGNANCY: SUCCESSFUL ALLOGENEIC HSCT IN NIJMEGEN BREAKAGE SYNDROME WITH LATE RELAPSE T-ALL Sabina Kardovskaya (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| B202 | CLINICAL SIGNIFICANCE OF DONOR-RECIPIENT ABO MISMATCH IN SURVIVAL AND IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - SINGLE CENTRE EXPERIENCE (CIC 1085) Yavor Petrov (Varna, Bulgaria) | 08:30 - 08:30 |
| P208 | B-CELL IMMUNE RECONSTITUTION AFTER ALLO-HSCT IN PEDIATRIC PATIENTS: PRELIMINARY RESULTS FROM A LONGITUDINAL FLOW CYTOMETRY ANALYSIS Dmitry Pershin (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| P209 | IMMUNE RECONSTITUTION DYNAMICS AND CLINICAL CORRELATES AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER REAL-WORLD EXPERIENCE Suar Caki Kilic (İstanbul, Turkey) | 08:30 - 08:30 |
| P211 | IMMUNE RECONSTITUTION ASSESSMENT IN PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE Victor Iván Salinas-Herrera (Mexico City, Mexico) | 08:30 - 08:30 |
| P212 | PRELIMINARY ANALYSIS OF B-CELL IMMUNORECONSTITUTION IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE Susanna Arakelyan (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| P213 | TÜRKİYE TRANSPLANT CENTRES CHIMERISM APPROACH SURVEY STUDY Ayşe Hilal Eroğlu Küçükçıldiler (Aydın, Turkey) | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Health Economics and Technology Assessment | | |
| P328 | M-CSF-STIMULATED ALVEOLAR MACROPHAGES SAFEGUARD FROM INVASIVE ASPERGILLOSIS Dalia Sheta (Würzburg, Germany) | 08:30 - 08:30 |
| P330 | THE USE OF EFFICIENCY ANALYSIS TO EVALUATE UNRELATED BONE MARROW DONOR REGISTRIES Danielli Oliveira (Rio De Janeiro, Brazil) | 08:30 - 08:30 |
| P331 | CAR-T COST CONSTRAINTS IN GERMANY: BUDGET IMPACT, PATIENT ACCESS, AND EASYGEN'S POTENTIAL FOR COST-DRIVEN INNOVATION Rebecca Scheiwe (Bad Homburg, Germany) | 08:30 - 08:30 |
| P334 | THE ECONOMIC BENEFIT FOR PATIENTS AND CAREGIVERS OF EXPANDING CAR-T CENTRES IN SPAIN Carlos Pardo (Madrid, Spain) | 08:30 - 08:30 |
| P336 | ANALYSIS AND OPTIMIZATION POTENTIALS OF CURRENT CAR-T CELL THERAPY MANAGEMENT: A PROCESS MANAGEMENT PERSPECTIVE Anika Teichert (Leipzig, Germany) | 08:30 - 08:30 |
| P337 | FEASIBILITY OF SYSMEX XN-1000 HEMATOPOIETIC | 08:30 - 08:30 |

| | | |
|--|---|---------------|
| | PROGENITOR CELL COUNTS FOR REAL-TIME MONITORING OF ALLOGENEIC STEM CELL COLLECTION | |
| | Wedad S. Hamdi (Doha, Qatar) | |
| P338 | MEASUREMENT OF COST IN A VALUE-BASED PERSPECTIVE: COMPARATIVE ANALYSIS OF ONLINE AND OFFLINE EXTRACORPOREAL PHOTOPHERESIS (ECP) MODALITIES IN SPAIN | 08:30 - 08:30 |
| | Miguel Blanquer (Murcia, Spain) | |
| P339 | HEALTHCARE RESOURCE UTILISATION OF PATIENTS WITH DLBCL RECEIVING AXICABTAGENE CILOLEUCEL IN ENGLAND: A FEASIBILITY STUDY | 08:30 - 08:30 |
| | Eleonora Lovato (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| P340 | PATIENT CHARACTERISTICS IN A DLBCL COHORT RECEIVING AXICABTAGENE CILOLEUCEL IN ENGLAND: A REAL-WORLD FEASIBILITY STUDY | 08:30 - 08:30 |
| | Eleonora Lovato (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Myelofibrosis, Chronic Myeloid Leukaemia and Other Myeloproliferative Disorders | | |
| B422 | PELABRESIB PLUS RUXOLITINIB AS BRIDGING THERAPY TO HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: INSIGHTS FROM MANIFEST AND MANIFEST-2 STUDIES | 08:30 - 08:30 |
| | Michael Loschi (Nice, France) | |
| B424 | HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MYELOFIBROSIS: A CHINESE MULTICENTER RETROSPECTIVE STUDY | 08:30 - 08:30 |
| | Yuqian Sun (Beijing, China) | |
| B425 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS: PATTERNS AND OUTCOME AFTER RELAPSE AND LONG-TERM FOLLOW UP | 08:30 - 08:30 |
| | Avichai Shimoni (Tel-Hashomer, Israel) | |
| B426 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELOFIBROSIS USING POST-TRANSPLANT CYCLOPHOSPHAMIDE: PRELIMINARY RESULTS FROM THE GETH-TC CLINICAL PRACTICE PROTOCOL | 08:30 - 08:30 |
| | Juan Carlos Hernandez-Boluda (Valencia, Spain) | |
| B427 | MTSS PREDICTS OUTCOME OF HAPLO-SCT IN MYELOFIBROSIS | 08:30 - 08:30 |
| | Judith Metzdorf (Essen, Germany) | |
| B428 | LONG-TERM MINIMAL RESIDUAL DISEASE MONITORING BY DIGITAL DROPLET PCR AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS IS PREDICTIVE OF RELAPSE: A RETROSPECTIVE AND PROSPECTIVE STUDY | 08:30 - 08:30 |
| | Maria Chiara Finazzi (Bergamo, Italy) | |
| B429 | HAPLOIDENTICAL STEM CELL TRANSPLANTATION USING NOVEL PROTOCOL DEMONSTRATED EXCELLENT OUTCOMES FOR PATIENTS WITH MYELOFIBROSIS | 08:30 - 08:30 |
| | Yuqian Sun (Beijing, China) | |
| B430 | THE EFFICACY AND SAFETY OF PD-1 MONOCLONAL ANTIBODY IN THE TREATMENT OF HEMOPHAGOCYTIC SYNDROME □ SYSTEMATIC REVIEW | 08:30 - 08:30 |
| | Shaoyan Hu (Suzhou, China) | |

| | | |
|------|--|---------------|
| B431 | INCIDENCE, CLINICAL OUTCOME, AND THERAPEUTIC IMPLICATIONS OF RELAPSE AFTER ALLOGENIC STEM CELL TRANSPLANTATION FOR PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS Chiara Camerini (Florence, Italy) | 08:30 - 08:30 |
| B432 | REDUCED-INTENSITY HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH ADVANCED MYELOFIBROSIS Monzr Al Malki (Duarte, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B433 | INFLUENCE OF HLA-DPB MATCHING ON OUTCOMES AFTER ALLO-HSCT FOR MYELOFIBROSIS Mathias Schäfersküpper (Hamburg, Germany) | 08:30 - 08:30 |
| B434 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS: A SINGLE-CENTER RETROSPECTIVE STUDY | 08:30 - 08:30 |
| B435 | POOR GRAFT FUNCTION FOLLOWING ALLOGENIC STEM CELL TRANSPLANTATION FOR PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: INCIDENCE, RISK FACTORS, AND PROGNOSTIC IMPLICATIONS FROM A SINGLE-CENTER EXPERIENCE Edoardo Simonetti (Florence, Italy) | 08:30 - 08:30 |
| P306 | IMPACT OF SPLENIC RADIOTHERAPY BEFORE HAEMATOPOIETIC STEM CELL TRANSPLANT ON ENGRAFTMENT AND TRANSFUSION NEEDS IN PATIENTS WITH MYELOFIBROSIS Gerard Gurumurthy (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P308 | ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: SINGLE CENTRE EXPERIENCE Guillermo Morán Cortés (Madrid, Spain) | 08:30 - 08:30 |
| P309 | ASCIMINIB AS BRIDGE TO ALLOGENEIC-HEMOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) IN A MULTICENTER CHRONIC MYELOID LEUKEMIA (CML) PATIENTS' COHORT Stefania Leone (Naples, Italy) | 08:30 - 08:30 |
| P310 | ALLOGENEIC HSCT IN A 7-YEAR-OLD GIRL WITH ADULT-TYPE PRIMARY MYELOFIBROSIS: A RARE CASE REPORT Maria Ebbesen Soerum (Copenhagen, Denmark) | 08:30 - 08:30 |
| P311 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH PRIMARY MYELOFIBROSIS Malek Benakli (Algiers, Algeria) | 08:30 - 08:30 |
| P312 | THIRD-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH TKI IN THE POST-BMT SETTING IN PATIENT WITH POSITIVE MRD Felipe Lopez (Valdivia, Chile) | 08:30 - 08:30 |
| P313 | IMPACT OF DOSE-ESCALATION STRATEGIES ON CLINICAL OUTCOMES OF ROPEGINTERFERON ALFA-2B IN POLYCYTHEMIA VERA: A SYSTEMATIC REVIEW AND META-ANALYSIS Jong-Ho Won (Seoul, Korea (the Republic of)) | 08:30 - 08:30 |

ePoster

08:30 - 18:00

R20

Myelodysplastic Syndromes

| | | |
|------|--|---------------|
| B414 | IMPACT OF CONCURRENT GENETIC ALTERATIONS ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH TP53-MUTATED | 08:30 - 08:30 |
|------|--|---------------|

| | | |
|---------------------------------|---|---------------|
| | AML/MDS: A MULTI-CENTER COHORT STUDY Zhengli Xu (Beijing, China) | |
| B415 | A NOVEL TARGETED NGS ASSAY FOR TP53 LOH DETECTION FACILITATES ROUTINE MULTI-HIT CLASSIFICATION AND REFINES RISK STRATIFICATION IN MYELOID NEOPLASMS Yanmin Zhao (Hangzhou, China) | 08:30 - 08:30 |
| B416 | RISK-ADAPTED CONDITIONING REGIMEN IN MYELOYDYSPLASIA NEOPLASMS: A MULTICENTER STUDY USING THE TRANSPLANT CONDITIONING INTENSITY (TCI) SCORE | 08:30 - 08:30 |
| B419 | COMPARATIVE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MYELOYDYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS AND OTHER MYELOYDYSPLASTIC SYNDROMES: BRAZILIAN SBTMO/CIBMTR REGISTRY ANALYSIS Fernando Barroso Duarte (Fortaleza, Brazil) | 08:30 - 08:30 |
| B420 | OUTCOME OF UNRELATED AND HAPLOIDENTICAL HSCT AMONG CHILDREN WITH MYELOYDYSPLASTIC SYNDROME Mariya Ilyushina (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| P303 | IMPACT OF ALCOHOL CONSUMPTION AND SMOKING HISTORY ON OUTCOMES AFTER ALLO-HCT IN PATIENTS WITH MDS-RELATED DISEASES Tomohiro Kohmoto (Nagoya, Japan) | 08:30 - 08:30 |
| P304 | CASE REPORT: CLEARANCE OF TP53 MUTATION POST ALLOGENEIC STEM CELL TRANSPLANT IN THE SETTING OF CHRONIC GVHD, WITH SUBSEQUENT TP53 MYELOID SARCOMA Alma Corker (Sydney, Australia) | 08:30 - 08:30 |
| P305 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LOW-RISK MYELOYDYSPLASTIC SYNDROME: A CASE SERIES OF SINGLE-CENTER EXPERIENCE Nur Soyer (Izmir, Turkey) | 08:30 - 08:30 |
| <i>ePoster</i> 08:30 - 18:00 | | R20 |
| Multiple Myeloma | | |
| B406 | INTENSIFIED CONSOLIDATION WITH TANDEM AUTOLOGOUS VERSUS AUTOLOGOUS/REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION FROM RELATED OR UNRELATED DONORS IN FIRST-LINE THERAPY IN 149 HIGH-RISK MYELOMA PATIENTS Song-Yau Wang (Leipzig, Germany) | 08:30 - 08:30 |
| B407 | UPDATED EXPLORATORY MULTIVARIABLE ANALYSES DEMONSTRATE DIFFERENTIAL IMPACT OF DUFFY GENOTYPE ON PROGRESSION-FREE SURVIVAL WITH LENALIDOMIDE-BORTEZOMIB-DEXAMETHASONE (RVD) ALONE OR RVD+ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) Paul G. Richardson (Boston, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B408 | SOLUBLE BCMA AS AN EMERGING BIOMARKER IN BCMA T-CELL-REDIRECTING THERAPIES Adolfo Fernández Sánchez (Salamanca, Spain) | 08:30 - 08:30 |
| B409 | THE EXPERIENCE OF AUTOSCT IN PATIENTS WITH MULTIPLE MYELOMA ON DIALYSIS Ekaterina Karimova (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| B410 | BORTEZOMIB MAINTENANCE AFTER ALLOGENEIC TRANSPLANT | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | IN NEWLY DIAGNOSED MYELOMA PATIENTS: LESS CHRONIC GVHD BUT NO IMPACT ON SURVIVAL | |
| | Jean Roy (Montréal, Canada) | |
| B411 | AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: A 10-YEAR SINGLE-CENTER EXPERIENCE | 08:30 - 08:30 |
| | Evgeniia Zhelnova (Moscow, Russian Federation (the)) | |
| B412 | PROGNOSTIC DIFFERENCES AMONG PATIENTS WITH MULTIPLE MYELOMA UNDERGOING UPFRONT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPAN, TAIWAN, AND MALAYSIA: IMPACT OF PRE-TRANSPLANT PI/IMID-BASED THERAPIES | 08:30 - 08:30 |
| | Hiroyuki Takamatsu (Kanazawa, Japan) | |
| B413 | COMPARISON OF DARA-VTD AND TRIPLE THERAPY AS INDUCTION REGIMENS PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA | 08:30 - 08:30 |
| | Maciej Sławomir Tomaszewicz (Wrocław, Poland) | |
| P290 | IS THERE STILL A CURATIVE ROLE FOR ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA? LONG-TERM OUTCOMES IN YOUNG PATIENTS UNDERGOING HLA-IDENTICAL ALLOGENEIC HAEMATOPIETIC STEM CELL TRANSPLANT | 08:30 - 08:30 |
| | Daniele Avenoso (Brescia, Italy) | |
| P291 | ZERO PERCENT TREATMENT-RELATED MORTALITY, HIGH EFFICACY AND LONG-TERM SAFETY OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR MULTIPLE MYELOMA IN THE ERA OF QUADRUPLETS | 08:30 - 08:30 |
| | Chrysavgi-Elisavet Lalayanni (Thessaloniki, Greece) | |
| P293 | INTEGRATED PRE- AND POST-TRANSPLANT RISK SCORE FOR PROGRESSION AFTER A SINGLE AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA | 08:30 - 08:30 |
| | Leonid Khordzhasov (Moscow, Russian Federation (the)) | |
| P294 | CLINICAL OBSERVATION ON THE NKG2D AND CS1 TARGETED CAR-T TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENT WITH BCMA AND GPRC5D DELETION | 08:30 - 08:30 |
| | Shaomei Feng (Beijing, China) | |
| P295 | AUTOLOGOUS STEM CELL TRANSPLANTS NEGATE OUTCOME DIFFERENCES BETWEEN DUAL AND TRIPLE THERAPIES IN MULTIPLE MYELOMA: REAL-WORLD DATA FROM A MIDDLE-INCOME COUNTRY | 08:30 - 08:30 |
| | Guillermo J. Ruiz-Argüelles (Puebla, Mexico) | |
| P296 | SAFETY, ENGRAFTMENT KINETICS, AND TRANSPLANT-RELATED COMPLICATIONS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: INSIGHTS FROM A RESOURCE-CONSTRAINED REAL-WORLD COHORT | 08:30 - 08:30 |
| | Stalin Chowdary Bala (Visakhapatnam, India) | |
| P297 | PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN COLOMBIA | 08:30 - 08:30 |
| | Claudia Sossa-Melo (Bucaramanga, Colombia) | |
| P301 | DRUG INDUCED THROMBOTIC MICROANGIOPATHY (TMA) IN A CASE OF MULTIPLE MYELOMA | 08:30 - 08:30 |
| | Ganesan Subramanian (Chennai, India) | |
| P302 | OUTCOMES OF SECOND AUTOLOGOUS STEM CELL TRANSPLANTATION AS RESCUE THERAPY IN RELAPSED | 08:30 - 08:30 |

MULTIPLE MYELOMA PATIENT, WITHOUT CRYOPRESERVED CD34. CASE REPORT FROM TRANSPLANT CENTER IN VENEZUELA

Marcos Hernandez (Valencia, Venezuela (Bolivarian Republic of))

ePoster

08:30 - 18:00

R20

Chronic Lymphocytic Leukemia

- | | | |
|------|---|---------------|
| B405 | <p>OUTCOME OF SINGLE- AND DOUBLE-REFRACTORY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): THE IMPACT OF CELLULAR THERAPY</p> <p>Peter Dreger (Heidelberg, Germany)</p> | 08:30 - 08:30 |
| P289 | <p>THE ROLE OF GENETIC SUSCEPTIBILITY GENES IN THE NECESSITY OF ALLOGENEIC TRANSPLANTATION FOR RICHTER SYNDROME</p> <p>Shaomei Feng (Beijing, China)</p> | 08:30 - 08:30 |

ePoster

08:30 - 18:00

R20

B cell Non Hodgkin Lymphoma

- | | | |
|------|--|---------------|
| B394 | <p>PHASE 2 ELARA TRIAL FINAL ANALYSIS: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)</p> <p>Joaquín Martínez (Madrid, Spain)</p> | 08:30 - 08:30 |
| B395 | <p>REAL-WORLD STUDY OF SECOND-LINE LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL EFFECTIVENESS, SAFETY, AND HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA</p> <p>Farah Toron (Uxbridge, United Kingdom of Great Britain and Northern Ireland (the))</p> | 08:30 - 08:30 |
| B396 | <p>ALLOGENEIC TRANSPLANTATION AFTER FAILURE OF CAR-T CELLS AND EXPOSURE TO BISPECIFIC ANTIBODIES: FEASIBILITY, SAFETY AND SURVIVAL OUTCOMES</p> <p>Giorgia Gobbi</p> | 08:30 - 08:30 |
| B397 | <p>ALLOGENEIC TRANSPLANTATION OUTCOMES IN PATIENTS WITH HIGH-GRADE LYMPHOMA AFTER RELAPSE FOLLOWING CAR-T THERAPY: A MULTICENTER RETROSPECTIVE COMPARATIVE STUDY</p> <p>Araceli Salamanca Cuenca (Jerez de la Frontera, Spain)</p> | 08:30 - 08:30 |
| B398 | <p>AUTOLOGOUS STEM CELL TRANSPLANTATION WITH REDUCED-DOSE THIOTEPA CONDITIONING IN PRIMARY CNS LYMPHOMA: SAFETY AND OUTCOMES IN A REAL-WORLD COHORT</p> <p>Giovanni Grillo (Milan, Italy)</p> | 08:30 - 08:30 |
| B400 | <p>POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD): RESULTS OF THE MULTICENTER OBSERVATIONAL RETROSPECTIVE COHORT STUDY OF THE ITALIAN LYMPHOMA FOUNDATION (FIL_PTLD)</p> <p>Chiara Consoli (Torino, Italy)</p> | 08:30 - 08:30 |
| B401 | <p>PREDOMINANCE OF CD4+ T-CELLS IS ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL</p> <p>Jorge Illarramendi (Pessac, France)</p> | 08:30 - 08:30 |
| B402 | <p>EFFICACY AND SAFETY OF ENSARTINIB-BASED REGIMENS IN ALK-POSITIVE LYMPHOMA: A REAL-WORLD RETROSPECTIVE</p> | 08:30 - 08:30 |

| | | |
|---|---|---------------|
| | STUDY | |
| | Xiaorui Fu (Zhengzhou, China) | |
| B403 | LONG-TERM FOLLOW-UP OF CD19 CAR-T FOR R/R B-NHL: KI-67 AS A PROGNOSTIC FACTOR FOR SUSTAINED REMISSION | 08:30 - 08:30 |
| | Yinghui Yu (Hangzhou, China) | |
| P285 | CLINICAL OUTCOMES AND PREDICTORS OF INTENSIVE CARE ADMISSION IN LYMPHOMA PATIENTS TREATED WITH BISPECIFICS | 08:30 - 08:30 |
| | Guillermo Ramos Moreno (Madrid, Spain) | |
| P286 | MANAGEMENT OF RELAPSED/REFRACTORY (R/R) B-NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES (BSABS). A SINGLE CENTER EXPERIENCE | 08:30 - 08:30 |
| | Antonios Patrinos (Athens, Greece) | |
| P287 | MARIBAVIR TREATMENT IN AGGRESSIVE EBV-ASSOCIATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+ PTLD) | 08:30 - 08:30 |
| | Wei-Han Huang (Hualien, Taiwan (Province of China)) | |
| P288 | AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PRIMARY CNS LYMPHOMA: A SINGLE-CENTER EXPERIENCE OVER 10 YEARS | 08:30 - 08:30 |
| | Filiz Vural (İzmir, Turkey) | |
| <i>ePoster</i> | | |
| | 08:30 - 18:00 | R20 |
| Hodgkin Lymphoma and T cell Lymphoma | | |
| B387 | PD-1 INHIBITOR PROLGOLIMAB ACHIEVES HIGH RESPONSE RATE BUT AUTO-HCT REMAINS ESSENTIAL FOR SUSTAINED PROLONGED REMISSION IN SECOND-LINE TREATMENT OF RELAPSED/REFRACTORY HODGKIN LYMPHOMA (PROLGO-HL) | 08:30 - 08:30 |
| | Liudmila Fedorova (St. Petersburg, Russian Federation (the)) | |
| B388 | FIVE-YEAR FOLLOW-UP OF NIVOLUMAB-BASED COMBINATIONS AND TRANSPLANT STRATEGY AFTER PD-1 INHIBITOR FAILURE IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA | 08:30 - 08:30 |
| | Liudmila Fedorova (St. Petersburg, Russian Federation (the)) | |
| B389 | AUTOLOGOUS TRANSPLANT IN T-CELL LYMPHOMAS | 08:30 - 08:30 |
| | Cristian Rodriguez (Córdoba, Argentina) | |
| B391 | THE ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADVANCED PRIMARY CUTANEOUS T-CELL LYMPHOMA - A MULTICENTER RETROSPECTIVE ANALYSIS | 08:30 - 08:30 |
| | Moritz Schmidt (Munich, Germany) | |
| B392 | A COMPARATIVE ANALYSIS OF TRANSFORMED HODGKIN'S LYMPHOMAS FROM MARGINAL ZONE LYMPHOMA: A POPULATION-BASED COHORT STUDY | 08:30 - 08:30 |
| | Rongrong Chen (Hangzhou, China) | |
| B393 | ROLE OF TARGETED IMMUNE THERAPIES IN RELAPSED/REFRACTORY LYMPHOMA (HODGKINS): A MULTICENTER EXPERIENCE FROM VARIOUS TRANSPLANT CENTERS IN PAKISTAN. A LOWER MIDDLE INCOME COUNTRY PERSPECTIVE | 08:30 - 08:30 |
| | Bushra Ahsan (Lahore, Pakistan) | |
| P275 | SAFETY AND EFFICACY OF LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY ADULT T-CELL | 08:30 - 08:30 |

| | | |
|---|--|---------------|
| | LEUKEMIA/LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY | |
| | Makoto Yoshimitsu (Kagoshima, Japan) | |
| P276 | HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR T-CELL LYMPHOMAS IN A MIDDLE-INCOME COUNTRY: FEASIBILITY, DELAYS, AND REAL-WORLD OUTCOMES FROM A NATIONAL REFERRAL CENTER IN MEXICO | 08:30 - 08:30 |
| | Mistral Castellanos-Mares (Mexico City, Mexico) | |
| P277 | PEMBROLIZUMAB PLUS GEMCITABINE, VINOURELBINE, AND DOXORUBICIN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN 24 RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS | 08:30 - 08:30 |
| | Malek Benakli (Algiers, Algeria) | |
| P278 | IMMUNE RECONSTITUTION AND LONG-TERM OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN RELAPSED AND REFRACTORY T-CELL LYMPHOMAS | 08:30 - 08:30 |
| | Quentin Fichaux (Munich, Germany) | |
| P279 | NURSING MANAGEMENT OF A CHEMOTHERAPY PATIENT WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA AND AN INFECTED LOWER-LIMB WOUND: A CASE STUDY | 08:30 - 08:30 |
| | Jing Liu (Beijing, China) | |
| P280 | AUTOLOGOUS STEM CELL TRANSPLANTATION IN 175 PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA; LONG-TERM FOLLOW UP IN A SINGLE-CENTRE SERIES | 08:30 - 08:30 |
| | Malek Benakli (Algiers, Algeria) | |
| P283 | ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT AS SALVAGE THERAPY FOR MATURE T CELL LYMPHOMA: CLINICAL EXPERIENCE AND OUTCOMES | 08:30 - 08:30 |
| | Jan Miko Aaron Baybay (Quezon City, Philippines (the)) | |
| P284 | A CASE REPORT OF MULTI-DRUG COMBINATION THERAPY FOR RELAPSED/REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA | 08:30 - 08:30 |
| | Shaomei Feng (Beijing, China) | |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Inborn error of immunity, hematopoiesis and metabolism | | |
| B370 | HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCIES IN CHILDREN: THE UKRAINIAN EXPERIENCE (2018-2025) | 08:30 - 08:30 |
| | Oleksandr Istomin (Kyiv, Ukraine) | |
| B371 | OUTCOMES OF ALLOGENEIC HSCT IN NIJMEGEN BREAKAGE SYNDROME WITH TREOSULFAN-BASED CONDITIONING REGIMEN - A MULTICENTER STUDY | 08:30 - 08:30 |
| | Alexandra Laberko (Saint-Petersburg, Russian Federation (the)) | |
| B372 | FACTORS ASSOCIATED WITH MIXED CHIMERISM IN CHILDREN WITH NON-MALIGNANT DISEASES TRANSPLANTED WITH A TREOSULFAN- BASED REGIMEN | 08:30 - 08:30 |
| | Etai Adam (Tel Aviv, Israel) | |
| B373 | MULTICENTER EXPERIENCE OF HSCT IN RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISEASE (RALD) - IEWP EBMT STUDY | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | Alexandra Laberko (Saint-Petersburg, Russian Federation (the)) | |
| B374 | OUTCOMES OF LATE-ONSET KRABBE DISEASE TREATED WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE-CENTRE EXPERIENCE Callum Fernando (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B375 | HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IN NEUROPATHIC MUCOPOLYSACCHARIDOSIS TYPE-II (MPS-II) PRESERVES NEURODEVELOPMENT AND SHOULD BE ROUTINE PRACTICE Osama Mansour (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B376 | IMPAIRED P53-MEDIATED DNA DAMAGE RESPONSE IN A HUMAN ETV6::RUNX1 IPSC MODEL SHOWS GENOMIC INSTABILITY IN PRE-LEUKEMIC CELLS Petra Gesine Koegler (Düsseldorf, Germany) | 08:30 - 08:30 |
| B377 | GLOBALISING HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY: A UK-INDIA MULTICENTRE EXPERIENCE Divij Sachdeva (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B378 | FIRST REPORTED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) FOR RAD50 DEFICIENCY: INITIAL CLINICAL EXPERIENCE IN TWO PEDIATRIC PATIENTS Alexandra Shutova (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| B379 | SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH WOLMAN DISEASE REFRACTORY TO HIGH-DOSE ENZYME REPLACEMENT THERAPY: COMPLETE DONOR CHIMERISM AND SUSTAINED METABOLIC RECOVERY Burcu Akıncı (İstanbul, Turkey) | 08:30 - 08:30 |
| B380 | HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY: IMPACT OF CONDITIONING REGIMENS Gizem Zengin Ersoy (İstanbul, Turkey) | 08:30 - 08:30 |
| B381 | ALLOGENEIC STEM CELL TRANSPLANTATION AS A CURATIVE STRATEGY FOR PYRUVATE KINASE DEFICIENCY: A SINGLE-CENTER EXPERIENCE Anna Osipova (Saint-Petersburg, Russian Federation (the)) | 08:30 - 08:30 |
| B383 | SUCCESSFUL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH IMMUNODEFICIENCY ASSOCIATED WITH ITGB4 MUTATION: EXPANDING THE PHENOTYPE Neeraj Teotia (Gurugram, India) | 08:30 - 08:30 |
| B384 | SINGLE CENTER EXPERIENCE OF ALLOGENEIC HSCT WITH POSTTRANPLANT CYCLOPHOSPHAMIDE IN INBORN ERRORS OF IMMUNITY Alexandra Laberko (Saint-Petersburg, Russian Federation (the)) | 08:30 - 08:30 |
| B385 | CLINICAL PICTURE AND IMMUNE RECONSTITUTION POST-HAEMATOPOIETIC CELL TRANSPLANTATION IN PAEDIARIC PATIENTS WITH CHRONIC GRANULOMATOUS DISEASE - LATIN AMERICAN SINGLE EXPERIENCE Maria Pilar Tejada (Ciudad Autónoma de Buenos Aires, Argentina) | 08:30 - 08:30 |
| B386 | SUCCESSFUL CORD BLOOD TRANSPLANTATION IN AN INFANT WITH LEUKOCYTE ADHESION DEFICIENCY TYPE III: A CASE REPORT AND 1 YEAR FOLLOW-UP Marianna Maffei (Brescia, Italy) | 08:30 - 08:30 |
| P269 | HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT | 08:30 - 08:30 |

| | | |
|------------------------|---|---------------|
| | CONDITIONING IN IL2RG-MUTATED SCID AND SEVERE ACTIVE CMV INFECTION: RAPID IMMUNE RECONSTITUTION AND INFECTION CONTROL | |
| | Peter Svec (Bratislava, Slovakia) | |
| P271 | SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIAPH1 MUTATION: A CASE REPORT | 08:30 - 08:30 |
| | Burcu Akıncı (İstanbul, Turkey) | |
| P272 | CLINICAL CONSIDERATIONS FOR HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENT WITH CONCOMITANT CHRONIC GRANULOMATOUS DISEASE AND MCLEOD SYNDROME | 08:30 - 08:30 |
| | Kentaro Fujimori (Setagaya, Japan) | |
| P273 | EXPERIENCE IN PREPARING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT WITH WISKOTT-ALDRICH SYNDROME | 08:30 - 08:30 |
| | Volha Mishkova (Borovlyany, Belarus) | |
| P274 | HEMOPHAGOCYTING LYMPHOHISTIOCYTOSIS - ISOLATED CNS MANIFESTATION | 08:30 - 08:30 |
| | Kristína Poláková (Bratislava, Slovakia) | |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Acute Leukaemia | | |
| B281 | A NOVEL RISK STRATIFICATION FRAMEWORK FOR CEBPA MUTANT AML BASED ON CEBPA BZIP IN-FRAME INSERTION/DELETION AND NRAS/CSF3R CO-MUTATIONS | 08:30 - 08:30 |
| | Zhile Chen (Hangzhou, China) | |
| B282 | ALLOGENEIC TRANSPLANTATION OUTCOMES OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES AND COMPLEX KARYOTYPE: A STUDY FROM THE ALWP/EBMT | 08:30 - 08:30 |
| | Arnon Nagler (Ramat Gan, Israel) | |
| B283 | SURVIVAL BENEFIT OF ALLOGENEIC TRANSPLANT IN TP53-MUTATED AML ACROSS SINGLE- AND DOUBLE-HIT DISEASE | 08:30 - 08:30 |
| | Jaime Andres Suarez-Londono (Hempstead, United States Minor Outlying Islands (the)) | |
| B284 | INOTUZUMAB OZOGAMICIN AS A BRIDGE TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN RELAPSED/REFRACTORY B-ALL: A STUDY ON BEHALF OF GETH-TC | 08:30 - 08:30 |
| | Aitana Balaguer Rosello (Valencia, Spain) | |
| B285 | "LESS IS MORE"? PTCY+CNI WITH VS WITHOUT MMF IN 10/10 MUD HCT FOR AML IN CR1. FROM THE GLOBAL COMMITTEE AND ALWP OF EBMT | 08:30 - 08:30 |
| | Jia Chen (Suzhou, China) | |
| B286 | IMPACT OF INDUCTION RESPONSE AND CO-MUTATIONS ON TRANSPLANT OUTCOMES IN AML WITH MYELODYSPLASIA-RELATED GENE MUTATIONS: A MULTICENTER RETROSPECTIVE STUDY | 08:30 - 08:30 |
| | Xiaoxia Hu (Shanghai, China) | |
| B287 | TREOSULFAN-BASED CONDITIONING WITH PTCY IN AML: A COMPARISON BETWEEN HAPLOIDENTICAL AND 9/10 MUD TRANSPLANTS. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT | 08:30 - 08:30 |
| | Daniele Avenoso (Brescia, Italy) | |

| | | |
|------|---|---------------|
| B288 | RESULTS OF ALLOGENEIC HSCT IN CR1 FOR PEDIATRIC PATIENTS WITH <i>DE NOVO</i>, HIGH-RISK, ACUTE MYELOID LEUKEMIA (AML): A REPORT FROM AIEOP Pietro Merli (Rome, Italy) | 08:30 - 08:30 |
| B289 | MAINTENANCE THERAPY POST HEMATOPOIETIC STEM CELL TRANSPLANT IN ACUTE MYELOID LEUKEMIA WITH FLT3 INHIBITORS AND HYPOMETHYLATING AGENTS: INSIGHTS FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY Nour Moukalled (Beirut, Lebanon) | 08:30 - 08:30 |
| B290 | SUCCESSFUL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED AND RELAPSED/REFRACTORY ACUTE MYELOBLASTIC LEUKEMIA FOLLOWING A HIGHLY EFFICIENT REGIMEN, FLAG-MITOXANTRONE WITH LOW-DOSE 7 DAYS VENETOCLAX Ahmad Ibrahim (Beirut, Lebanon) | 08:30 - 08:30 |
| B291 | POST-TRANSPLANT OUTCOMES IN ACUTE MYELOID LEUKEMIA HARBORING NRAS AND/OR KRAS MUTATIONS: A STUDY ON BEHALF OF EBMT-ALWP Iman Abou Dalle (Beirut, Lebanon) | 08:30 - 08:30 |
| B292 | "STICK TO THE STANDARD": ADDITION OF THIOTEPA TO FLU/BU INCREASES NRM IN MSD/URD TRANSPLANTS FOR MRD+CR1 AML. FROM THE GLOBAL COMMITTEE AND ALWP OF EBMT Yuhua Ru (Suzhou, China) | 08:30 - 08:30 |
| B293 | COMBINED PRE-TRANSPLANT MRD DETECTION BY FACS AND NGS MAY ENHANCE RELAPSE PREDICTION IN AML PATIENTS RECEIVING ALLO-SCT IN COMPLETE REMISSION Evgeny Klyuchnikov (Hamburg, Germany) | 08:30 - 08:30 |
| B294 | ALLOGENEIC TRANSPLANTATION IN SECONDARY COMPARED TO DE NOVO ACUTE MYELOID LEUKEMIA- THE IMPACT OF NEXT-GENERATION SEQUENCING BASED MUTATION PROFILE: A STUDY FROM THE ALWP/EBMT Arnon Nagler (Ramat Gan, Israel) | 08:30 - 08:30 |
| B295 | OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL): LONG-TERM CLINICAL OUTCOMES IN ADULTS STRATIFIED BY AGE SUBGROUPS OF INTEREST | 08:30 - 08:30 |
| B296 | ICT01/IPN60340-AZACITIDINE-VENETOCLAX INDUCES HIGH REMISSION RATE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 1/2 STUDY EVICTION Sylvain Garciaz (Marseille, France) | 08:30 - 08:30 |
| B299 | FLAMSA-BASED CONDITIONING IS ASSOCIATED WITH LOWER NRM AND HIGHER SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY AML Evgeny Klyuchnikov (Hamburg, Germany) | 08:30 - 08:30 |
| B300 | OUTCOMES OF MORPHOLOGICAL VERSUS MINIMAL RESIDUAL DISEASE (MRD) RELAPSE AFTER ALLOGENEIC TRANSPLANTATION (ALLO-HCT) FOR ACUTE MYELOID LEUKEMIA (AML) Hassan B. Alkhateeb (Rochester, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B301 | PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKAEMIA UNDERGOING UNMANIPULATED G-CSF-PRIMED HAPLOIDENTICAL BONE MARROW TRANSPLANTATION: FAVOURABLE LONG-TERM OUTCOME IN FIRST REMISSION WITH POSITIVE MEASURABLE RESIDUAL DISEASE | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | Gottardo De Angelis (Rome, Italy) | |
| B302 | SYSTEMIC EVALUATION FOR EXTRAMEDULLARY DISEASE AND TREATMENT OUTCOMES IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Ruifeng Hou (Beijing, China) | 08:30 - 08:30 |
| B303 | SUPERIOR GVHD-FREE/RELAPSE-FREE SURVIVAL WITH HAPLOIDENTICAL TRANSPLANTATION USING TCRAB/CD45RA-DEPLETED GRAFTS IN AML: A COMPARATIVE ANALYSIS WITH MATCHED DONORS Huirong Han (Singapore, Singapore) | 08:30 - 08:30 |
| B304 | SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM DIFFERENT DONOR FOR PATIENTS WITH ACUTE LEUKEMIA RELAPSED AFTER FIRST TRANSPLANTATION—A SINGLE CENTER REAL WORLD STUDY Yue Lu (Langfang, China) | 08:30 - 08:30 |
| B305 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION MAY OVERCOME THE ADVERSE PROGNOSTIC IMPACT OF <i>IKZF1</i> ALTERATIONS IN ADULT PRECURSOR B-ALL Veronika Valkova (Prague, Czechia) | 08:30 - 08:30 |
| B306 | DEPTH OF REMISSION PREDICTS OUTCOME AFTER ALLOGENEIC HSCT FOR AML: A SINGLE-CENTER STUDY OF 263 PATIENTS Anna Maria Raiola (GE, Italy) | 08:30 - 08:30 |
| B307 | REAL-WORLD EXPERIENCE WITH GILTERITINIB MAINTENANCE FOLLOWING ALLOGENEIC TRANSPLANTATION IN RELAPSED/REFRACTORY AML PATIENTS HARBORING <i>FLT3</i> MUTATIONS Xavier Cheng-Hong Tsai (Taipei, Taiwan (Province of China)) | 08:30 - 08:30 |
| B309 | REAL-WORLD OUTCOMES OF DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC HCT FOR ACUTE LEUKEMIA: A 20-YEAR MULTICENTER STUDY Anna Paola Iori (Rome, Italy) | 08:30 - 08:30 |
| B310 | AGE OVER SIBLING: YOUNGER UNRELATED DONORS PROVIDE SUPERIOR OUTCOMES COMPARED TO SIBLING DONORS IN FULLY MATCHED HCT IN OLDER AML/MDS PATIENTS Jan Maciej Zaucha (Gdansk, Poland) | 08:30 - 08:30 |
| B311 | CHARACTERISTICS AND OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULTS WITH PHILADELPHIA-LIKE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER ANALYSIS Noa Holtzman (Miami, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B312 | ALLOGENEIC STEM CELL TRANSPLANTATION DURING FIRST REMISSION IMPROVES SURVIVAL IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA Congxiao Zhang (Hangzhou, China) | 08:30 - 08:30 |
| B313 | FACTORS PREDICTING OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH ACTIVE DISEASE UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Raffaella Cerretti (Rome, Italy) | 08:30 - 08:30 |
| B314 | AN EARLY MYELOID STEM CELLS-BASED IMMUNOPHENOTYPIC PANEL CAN RAPIDLY AND EFFICIENTLY DISTINGUISH APL FROM APL-LIKE Man Chen (Beijing, China) | 08:30 - 08:30 |
| B315 | STUDY OF BONE MARROW-INFILTRATING NK CELLS (BINK) AND | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | PERIPHERAL BLOOD NK CELL (PBNK) IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA | |
| | Antonio Pérez Martínez (Madrid, Spain) | |
| B316 | EARLY TRANSPLANTATION FOLLOWING INDUCTION CHEMOTHERAPY IN ADULT AML PATIENTS WITH A <i>NUP98</i> REARRANGEMENTS LEADS TO MRD-NEGATIVE REMISSION | 08:30 - 08:30 |
| | Hannah Al-Yousuf (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B317 | OUTCOMES OF SECOND ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA AT THE IRISH NATIONAL ADULT STEM CELL TRANSPLANT UNIT | 08:30 - 08:30 |
| | James Dillon (Dublin, Ireland) | |
| B318 | EFFICACY AND SAFETY OF BLINATUMOMAB AS COMBINATION OF INDUCTION OR EARLY CONSOLIDATION THERAPY IN NEWLY DIAGNOSED B CELL ACUTE LEUKEMIA | 08:30 - 08:30 |
| | Fang Xu (Lang Fang, China) | |
| B319 | PROGNOSTIC FACTORS FOR EARLY LEUKEMIA-FREE SURVIVAL IN NPM1-MUTATED AML UNDERGOING ALLOGENEIC TRANSPLANTATION WITH ACTIVE DISEASE | 08:30 - 08:30 |
| | Alessia Fraccaroli (Munich, Germany) | |
| P247 | REDUCED RELAPSE RATES IN LEUKEMIA PATIENTS UNDERGOING HAPLOIDENTICAL VERSUS MATCHED RELATED ALLOGENIC BONE MARROW TRANSPLANT: RESULTS FROM A COLOMBIAN BONE MARROW TRANSPLANTATION UNIT | 08:30 - 08:30 |
| | Jorge Cuervo-Sierra (Rionegro, Colombia) | |
| P248 | POST-TRANSPLANT OUTCOMES IN ADULT ALL: INSIGHTS FROM A SINGLE-CENTER EXPERIENCE | 08:30 - 08:30 |
| | Nour Ben Abdeljelil (Tunis, Tunisia) | |
| P249 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADULT AND PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | 08:30 - 08:30 |
| | Malek Benakli (Algiers, Algeria) | |
| P250 | DURABLE REMISSION AFTER ALLOGENEIC HSCT AND FLT3 INHIBITION IN PEDIATRIC REFRACTORY AML HARBORING A NOVEL FLT3 EXON 14 IN-FRAME INSERTION IDENTIFIED BY NEXT GENERATION SEQUENCING | 08:30 - 08:30 |
| | Walid Ballourah (Riyadh, Saudi Arabia) | |
| P251 | RISKS FACTORS FOR HEMORRHAGIC CYSTITIS IN LEUKEMIA PATIENTS FROM A COLOMBIAN BONE MARROW TRANSPLANTATION UNIT: A RETROSPECTIVE COHORT STUDY | 08:30 - 08:30 |
| | Jorge Cuervo-Sierra (Rionegro, Colombia) | |
| P252 | SAFETY AND EFFICACY OF LIPOSOMAL MITOXANTRONE-INTENSIFIED BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | 08:30 - 08:30 |
| | Yajing Xu (Changsha, China) | |
| P254 | IMPLEMENTING EBMT RISK SCORE AS A PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH ACUTE LEUKEMIA AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. SINGLE CENTER EXPERIENCE | 08:30 - 08:30 |
| | Lazar Chadievski (Skopje, Republic of North Macedonia) | |
| P255 | SUBGROUP ANALYSIS OF THE GREATER CHINA REGION IN THE RANDOMIZED PHASE 3 AGILE STUDY OF IVOSIDENIB+AZACITIDINE VERSUS PLACEBO+AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED MIDH AML | 08:30 - 08:30 |

| | | |
|---|---|---------------|
| | Su-Peng Yeh (Taichung, Taiwan (Province of China)) | |
| P257 | TARGETING FLT3: A REAL-LIFE, SINGLE-CENTER ANALYSIS OF FLT3 INHIBITORS USE IN THE ALLOGENEIC TRANSPLANT SETTING Francesca Duca (Monza, Italy) | 08:30 - 08:30 |
| P258 | CLINICAL CASE OF TREATMENT OF CONGENITAL ACUTE MYELOID LEUKEMIA Juliya Mareika (Borovlyany, Belarus) | 08:30 - 08:30 |
| P259 | REAL-WORLD EXPERIENCE WITH VENETOCLAX, AZACITIDINE, AND SORAFENIB IN RELAPSED/REFRACTORY FLT3-ITD AML: A SINGLE-CENTRE CASE SERIES Titas Tiškevičius (Kaunas, Lithuania) | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Artificial Intelligence and Computational Approaches | | |
| B275 | HLA STRUCTURAL PROFILES IDENTIFIED BY PROTEIN LANGUAGE MODELS PREDICT GRAFT FAILURE IN HAPLOIDENTICAL TRANSPLANTATION Rui Ma (Beijing, China) | 08:30 - 08:30 |
| B276 | MINOR HISTOCOMPATIBILITY ANTIGEN BURDEN AS A RISK FACTOR FOR ACUTE GVHD AFTER HLA-IDENTICAL UNRELATED DONOR TRANSPLANT Javier Sevilla-Montero (Madrid, Spain) | 08:30 - 08:30 |
| B277 | STACKED MACHINE-LEARNING SURVIVAL MODELING FOR MYELODYSPLASTIC SYNDROMES UNDERGOING ALLOGENEIC TRANSPLANTATION: AN EBMT REGISTRY STUDY Carmelo Gurnari (Rome, Italy) | 08:30 - 08:30 |
| B278 | PROTEIN LANGUAGE MODEL-DERIVED FUNCTIONAL DIVERSITY METRIC OF HLA ALLELES BETWEEN DONOR AND RECIPIENT PREDICTS GRAFT FAILURE IN SALVAGE SECOND HAPLO-HSCT USING THE SAME DONORS Rui Ma (Beijing, China) | 08:30 - 08:30 |
| B279 | AUTOMATED EXTRACTION AND VISUALIZATION OF PEDIATRIC BMT CLINICAL NOTES USING A COST-EFFICIENT GPT-4.1-MINI PIPELINE Dua'a Zandaki (Amman, Jordan) | 08:30 - 08:30 |
| B280 | CREATING A POOL OF READY-TO-USE CORD BLOOD UNITS BY SELECTING DONORS USING HLA-INFORMED ALGORITHMS Maude Dumont-Lagacé (Montréal, Canada) | 08:30 - 08:30 |
| P245 | DEVELOPMENT OF A MACHINE LEARNING MODEL TO PREDICT PROGRESSION FREE SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA AFTER CAR-T CELL THERAPY Anushri Soni (New York, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| P246 | AN EXPLORATORY STUDY EVALUATING TUMOUR RADIOMICS AS A MOLECULAR ADJUNCT IN DIFFUSE LARGE B-CELL LYMPHOMA (TRAMADOL STUDY) Amrita Guha (Navi Mumbai, India) | 08:30 - 08:30 |

ePoster

08:30 - 18:00

R20

Non-infectious Early Complications

| | | |
|------|---|---------------|
| A379 | DEFINING AND VALIDATING THE CD34+ CELL DOSE THRESHOLD REQUIRED FOR STEM CELL BOOST IN CHILDREN WITH POOR GRAFT FUNCTION. A REPORT FROM THE GETH-TC Maria Isabel Benitez Carabante (Barcelona, Spain) | 08:30 - 08:30 |
| A380 | ENGRAFTMENT SYNDROME IN PEDIATRIC ALLOGENEIC HSCT: RISK FACTORS AND OUTCOMES Anne B. Verbeek (Leiden, Netherlands (the)) | 08:30 - 08:30 |
| A381 | INCIDENCE OF VOD AND LONGITUDINAL DYNAMICS OF EASIX AND ENDOTHELIAL BIOMARKERS AFTER ALLO-HCT WITH PTCY Blanca De Moner Rafel (Barcelona, Spain) | 08:30 - 08:30 |
| A382 | SECOND ALLOGENEIC STEM CELL TRANSPLANTATION TO TREAT PRIMARY AND SECONDARY GRAFT FAILURE: A SINGLE CENTRE EXPERIENCE Ignacio Gómez-Centurión (Madrid, Spain) | 08:30 - 08:30 |
| A383 | REDUCED EARLY POST-TRANSPLANT GLUTAMINE LEVELS ARE ASSOCIATED WITH SYSTEMIC INFLAMMATION AND SEVERE AGVHD Sarah Weischendorff (Copenhagen, Denmark) | 08:30 - 08:30 |
| A384 | COMPARISON OF THE INFECTIOUS AND IMMUNOLOGICAL SAFETY OF A LOW-BACTERIAL AND MODIFIED DIET IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS Alexander Kulagin (Saint Petersburg, Russian Federation (the)) | 08:30 - 08:30 |
| A385 | NON-INFECTIOUS NON CARDIOGENIC INTERSTITIAL LUNG DISEASE-RELATED ACUTE RESPIRATORY FAILURE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE FRENCH MULTICENTER EXPERIENCE Jebnoun Naïm (Créteil, France) | 08:30 - 08:30 |
| A386 | INCIDENCE AND RISK FACTORS OF NON-INFECTIOUS PULMONARY COMPLICATIONS FOLLOWING LOW-DOSE-RATE TOTAL BODY IRRADIATION Zixuan Jin (Kyoto, Japan) | 08:30 - 08:30 |
| A387 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF CURCUMIN TO REDUCE MUCOSITIS IN AUTOLOGOUS TRANSPLANT SETTING Sachin Punatar (Navi Mumbai, India) | 08:30 - 08:30 |
| A388 | COMPREHENSIVE PAIN MANAGEMENT IN PAEDIATRIC ALLOGENIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): RETROSPECTIVE AUDIT OF SPECIALIST PAIN TEAM REFERRALS AND DEVELOPMENT OF A PILOT PAIN-MANAGEMENT PATHWAY Akshay Deshpande (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A389 | EARLY ACUTE KIDNEY INJURY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A 634-RECIPIENT COHORT STUDY Luiz Carlos da Costa-Junior (São Paulo, Brazil) | 08:30 - 08:30 |
| A390 | A PHASE 1 DOSE-ESCALATION STUDY OF UMBILICAL CORD BLOOD MONONUCLEAR CELL INFUSION FOR SECONDARY POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Erlie Jiang (Tianjin, China) | 08:30 - 08:30 |
| A391 | THE ROLE OF DEFIBROTIDE AS PROPHYLAXIS FOR VENOCCLUSIVE DISEASE IN PEDIATRIC THALASSEMIA STEM CELL TRANSPLANTATION USING IV BUSULFAN CONDITIONING. A RETROSPECTIVE SINGLE-CENTER 10-YEAR EXPERIENCE | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | Abdullah Alharbi (Riyadh, Saudi Arabia) | |
| A392 | IMPACT OF ANTIBIOTIC USE IN EARLY FEVER AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE María José Llácer Ferrandis (Madrid, Spain) | 08:30 - 08:30 |
| A393 | AUTOIMMUNE-LIKE HEPATITIS OF ALLOGENIC ORIGIN: A RARE BUT DISTINCT ENTITY IN POST-TRANSPLANT LIVER DYSFUNCTION Claudia Mosquera Rubal (Madrid, Spain) | 08:30 - 08:30 |
| A394 | TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY: INCIDENCE AND MANAGEMENT IN SETTINGS WITH LIMITED BIOMARKERS AND NO ACCESS TO TARGETED THERAPIES Nour Ben Abdeljelil (Tunis, Tunisia) | 08:30 - 08:30 |
| A395 | NARSOPLIMAB IN CRITICALLY ILL PATIENTS WITH TA-TMA REQUIRING INTENSIVE CARE: A SINGLE CENTER STUDY Ana Belén Bocanegra (Madrid, Spain) | 08:30 - 08:30 |
| A396 | RESELECT1&2: INTERVENTIONAL STUDIES FOR THE TREATMENT OF POOR GRAFT FUNCTION POST ALLOGENEIC STEM CELL TRANSPLANTATION Daniel North (Melbourne, Australia) | 08:30 - 08:30 |
| A397 | HEPATIC VENOUS PRESSURE GRADIENT TO DIAGNOSE VENO-OCCLUSIVE DISEASE AFTER HEMATOPOIETIC BONE MARROW TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS Luigi Colecchia (Bologna, Italy) | 08:30 - 08:30 |
| A400 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) IS AN EARLY BIOMARKER OF SEVERE SINUSOIDAL OBSTRUCTION SYNDROME AFTER PEDIATRIC HSCT Karoline Juul Grube (Copenhagen, Denmark) | 08:30 - 08:30 |
| A401 | DEFIBROTIDE RESCUE FOR PEDIATRIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME; A SINGLE-CENTER 10-YEAR EXPERIENCE Dua'a Zandaki (Amman, Jordan) | 08:30 - 08:30 |
| A402 | ASSESSMENT OF CARDIOVASCULAR RISK BURDEN AND ITS IMPACT ON OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Panagiota Gianni (Ulm, Germany) | 08:30 - 08:30 |
| A403 | TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY CLINICAL CHARACTERISTIC, RISK FACTORS, THERAPEUTIC MANAGEMENT AND OUTCOME: A SINGLE CENTER RETROSPECTIVE COHORT STUDY Memon Shahbaz (Riyadh, Saudi Arabia) | 08:30 - 08:30 |
| A404 | REAL-WORLD EFFICACY AND SAFETY OF DEFIBROTIDE FOR SINUSOIDAL OBSTRUCTION SYNDROME - NATIONWIDE SURVEY Souichi Shiratori (Sapporo, Japan) | 08:30 - 08:30 |
| A405 | EASIX SCORE AS A PREDICTOR FOR TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY IN PAEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Maria Isabel Benitez Carabante (Barcelona, Spain) | 08:30 - 08:30 |
| A406 | POSITIVE OUTCOMES AMONG PEDIATRIC HCT PATIENTS TREATED WITH DARATUMUMAB FOR AUTO-IMMUNE | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | HEMOLYTIC ANEMIA | |
| | Lauren Stafford (Durham, United States Minor Outlying Islands (the)) | |
| A408 | DAY 0 EASIX SCORE PREDICTS NON-RELAPSE MORTALITY, BUT NOT GRAFT-VERSUS HOST DISEASE OR RELAPSE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER REAL-WORLD ANALYSIS | 08:30 - 08:30 |
| | Ion Antohe (Iasi, Romania) | |
| A409 | ANAKINRA AS TREATMENT FOR SECONDARY HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS FOLLOWING ALLOGENIC STEM CELL TRANSPLANT: A RETROSPECTIVE ANALYSIS IN A UNIVERSITY HOSPITAL TRANSPLANT CENTRE | 08:30 - 08:30 |
| | Hwai Jing Hiew (Southampton, United Kingdom of Great Britain and Northern Ireland (the)) | |
| A410 | EARLY POST-TRANSPLANT ELECTROLYTE DISTURBANCES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: INCIDENCE AND SEVERITY | 08:30 - 08:30 |
| | Luiz Carlos da Costa-Junior (São Paulo, Brazil) | |
| A411 | HEMOSTATIC ALTERATIONS AND HISTOPATHOLOGICAL FINDINGS OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HSCT FROM A REFERENCE CENTER IN LATIN AMERICA | 08:30 - 08:30 |
| | Severiano Baltazar Arellano (Monterrey, Mexico) | |
| A412 | THE CLINICAL SIGNIFICANCE AND SAFETY OF BRONCHOSCOPY AFTER ALLO-HSCT | 08:30 - 08:30 |
| | Seiya Bamba (Kyoto, Japan) | |
| A413 | COLD AGGLUTININ SYNDROME FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | 08:30 - 08:30 |
| | Trym Døvik (Oslo, Norway) | |
| P180 | IMPACT OF NUTRITIONAL STATUS IN THE POPULATION OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ON TREATMENT OUTCOMES - VALIDATION OF NUTRITIONAL ASSESSMENT TOOLS | 08:30 - 08:30 |
| | Patrycja Mensah-Glanowska (Krakow, Poland) | |
| P181 | MELPHALAN-INDUCED INTESTINAL MUCOSITIS IN HEMATOPOIETIC STEM CELL TRANSPLANT: RAPID RESPONSE TO SHORT-COURSE ORAL BUDESONIDE | 08:30 - 08:30 |
| | Elias Tayar (Webster, United States Minor Outlying Islands (the)) | |
| P182 | IMPACT OF THERAPEUTIC PLASMA EXCHANGE ON IMPROVEMENT OF ERYTHROID ENGRAFTMENT IN MAJOR INCOMPATIBLE ABO-GROUP AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER ANALYSIS | 08:30 - 08:30 |
| | Maria Caterina Mico' (Reggio Calabria, Italy) | |
| P183 | EARLY POST-TRANSPLANT EOSINOPHILIC GASTROENTERITIS IN TWO ALLOGENIC HSCT RECIPIENTS | 08:30 - 08:30 |
| | Claudia Mosquera Rubal (Madrid, Spain) | |
| P184 | OPTIMIZED TREATMENT OF HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH ALLOGENEIC PLATELET-RICH PLASMA | 08:30 - 08:30 |
| | Tatsiana Talako (Minsk, Belarus) | |
| P185 | POST-TRANSPLANT PURE RED CELL APLASIA: A SINGLE CENTER EXPERIENCE WITH PLASMA EXCHANGE AND HIGH DOSE ERYTHROPOIETIN | 08:30 - 08:30 |
| | Ambra Taglietti (Ascoli Piceno, Italy) | |

| | | |
|---|---|---------------|
| P186 | LEVETIRACETAM FOR THE PREVENTION OF BUSULFAN-INDUCED SEIZURES IN HEMATOPOIETIC CELL TRANSPLANTATION Yongjune Lee (Busan, Korea (the Republic of)) | 08:30 - 08:30 |
| P187 | PATTERNS AND PREDICTORS OF ORAL MUCOSITIS FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): A PROSPECTIVE SINGLE-CENTRE EXPERIENCE N. Kaushik (Bengaluru, India) | 08:30 - 08:30 |
| P188 | ENGRAFTMENT SYNDROME IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION: INCIDENCE, ASSOCIATED FACTORS AND CLINICAL IMPACT Joud Zanabali al Sibai (Oviedo, Spain) | 08:30 - 08:30 |
| P189 | PROPHYLAXIS WITH DEFIBROTIDE VERSUS EARLY TREATMENT OF SEVERE VOD IN PEDIATRIC ONCO-HEMATOLOGICAL PATIENTS: A MONOCENTRIC EXPERIENCE Katia Perruccio (Perugia, Italy) | 08:30 - 08:30 |
| P190 | POSSIBLE ROLE OF FLUDARABINE IN EARLY POST TRANSPLANT CEREBRAL TOXICITY. A SINGLE CENTRE EXPERIENCE Elsa Masedu (Monza, Italy) | 08:30 - 08:30 |
| P191 | PAIN MANAGEMENT WITH NARCOTIC INFUSION IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY Eman Khattab (Amman, Jordan) | 08:30 - 08:30 |
| P192 | TAKOTSUBO CARDIOMYOPATHY MIMICKING ACUTE CORONARY SYNDROME DURING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION Domas Vaitiekus (Kaunas, Lithuania) | 08:30 - 08:30 |
| P193 | A CASE OF CAPILLARY LEAK SYNDROME FOLLOWING HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION IN A PATIENT WITH ACUTE MYELOID LEUKEMIA Jean Rachel Catapia (Makati City, Philippines (the)) | 08:30 - 08:30 |
| P194 | ALLOGENEIC STEM CELL TRANSPLANT FOR NEAR ETP ACUTE LYMPHOBLASTIC LEUKAEMIA IN A DECEASED-DONOR RENAL TRANSPLANT RECIPIENT: A CASE STUDY AND LITERATURE REVIEW Linda Lingxu Li (Auckland, New Zealand) | 08:30 - 08:30 |
| <i>ePoster</i> 08:30 - 18:00 | | R20 |
| Graft-versus-host Disease - Clinical | | |
| B001 | LOW-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FROM AN 10/10 HLA-IDENTICAL DONOR: A NEW PARADIGM? STUDY CONDUCTED ON BEHALF OF GETH-TC B. Herruzo (Málaga, Spain) | 08:30 - 08:30 |
| B002 | DECODING LONG-TERM IMMUNE SIGNATURE THROUGH AUTOANTIBODY EXPRESSION AS PERSISTENT IMMUNE SIGNALS IN POST-TRANSPLANT PAEDIATRIC ALL Anita Lawitschka (Vienna, Austria) | 08:30 - 08:30 |
| B003 | DUPILUMAB: EFFECTIVE AND SAFE ADDITION TO THE THERAPEUTIC ARMAMENTARIUM FOR PAEDIATRIC SKIN GVHD - A SINGLE CENTRE EXPERIENCE Kalasekhar Vijaya Sekharan (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| B004 | REAL-WORLD RESULTS ON THE USE OF BELUMOSUDIL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC GVHD: THE ITALIAN RETROSPECTIVE ANALYSIS Francesca Bonifazi (Bologna, Italy) | 08:30 - 08:30 |
| B005 | KEY RESULTS FROM THE CHRONOS MULTICENTRE RETROSPECTIVE COHORT STUDY DESCRIBING PATIENT OUTCOMES IN THIRD-LINE ACUTE GASTROINTESTINAL GVHD Johannes Clausen (Linz, Austria) | 08:30 - 08:30 |
| B006 | PHASE 2 STUDY OF EXTRACORPOREAL PHOTOPHERESIS WITH UVADEX™ PLUS STANDARD STEROID TREATMENT FOR HIGH-RISK ACUTE GRAFT-VERSUS-HOST DISEASE Francis Ayuketang Ayuk (Hamburg, Germany) | 08:30 - 08:30 |
| B007 | CLINICAL OUTCOMES AMONG PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE TREATED WITH AXATILIMAB: ANALYSIS OF AN EXPANDED ACCESS PROGRAM Anthony Stein (Duarte, CA, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B008 | TWO-AGENT GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS WITH CYCLOPHOSPHAMIDE AND RUXOLITINIB: EXPERIENCE BEYOND THE CLINICAL TRIALS Ivan Moiseev (Saint Petersburg, Russian Federation (the)) | 08:30 - 08:30 |
| B009 | ABATACEPT REDUCES ACUTE GVHD INCIDENCE AND IMPROVES GRFS IN PEDIATRIC PATIENTS TRANSPLANTED FROM AN HLA-MISMATCHED DONOR: A REAL-WORLD, MULTICENTER, RETROSPECTIVE STUDY Pietro Merli (Rome, Italy) | 08:30 - 08:30 |
| B011 | A MULTICENTRE STUDY ON IN VIVO T-CELL DEPLETION PLATFORMS IN REDUCED-INTENSITY ALLOGENEIC STEM CELL TRANSPLANTS FOR HAEMATOLOGICAL MALIGNANCIES Rebecca Goodhew (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B012 | RESULTS OF ABATACEPT ADDITION TO POST TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS IN ALLOGENEIC HEMATOPOYETIC STEM CELL TRANSPLANTATION Lucia Castilla-Garcia (Madrid, Spain) | 08:30 - 08:30 |
| B013 | BELUMOSUDIL FOR ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE: A SINGLE-CENTER REAL-WORLD STUDY OF EFFICACY AND SAFETY Heng Mei (Wuhan, China) | 08:30 - 08:30 |
| B014 | REAL-WORLD SINGLE-CENTER EXPERIENCE OF ANTI-THYMOCYTE/ ANTI-T-LYMPHOCYTE GLOBULINS IN POST-TRANSPLANT CYCLOPHOSPHAMIDE CONDITIONINGS OF HAPLOIDENTICAL AND UNRELATED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SAFETY, EFFICACY, AND ENDOTHELIAL INJURY PROFILE Eleni Gavriilaki (Thessaloniki, Greece) | 08:30 - 08:30 |
| B015 | ASSOCIATION BETWEEN ORAL CHRONIC GRAFT-VERSUS-HOST DISEASE AND THE GRAFT-VERSUS-LEUKEMIA EFFECT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE, SINGLE-CENTER OBSERVATIONAL STUDY Michael Loschi (Nice, France) | 08:30 - 08:30 |
| B016 | THE COMBINATION OF RUXOLITINIB AND EXTRACORPOREAL PHOTOPHERESIS IS A HIGHLY EFFECTIVE SECOND LINE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE Nikolett Wohner (Budapest, Hungary) | 08:30 - 08:30 |
| B017 | OUTCOMES IN TCRAB-DEPLETED HAPLOIDENTICAL | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | TRANSPLANTATION WITH UPFRONT CD45RA-DEPLETED MEMORY T-CELL ADD-BACK: ANALYSIS OF 127 ADULTS WITH HEMATOLOGICAL MALIGNANCIES TREATED AT NATIONAL UNIVERSITY CANCER INSTITUTE, SINGAPORE | |
| | Victor Wei Teik Ling (Singapore, Singapore) | |
| B018 | MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN | 08:30 - 08:30 |
| | Krzysztof Czyzewski (Bydgoszcz, Poland) | |
| B019 | BEYOND STATIC SNAPSHOTS: A DYNAMIC PREDICTION MODEL FOR ACUTE GRAFT-VERSUS-HOST DISEASE INTEGRATING SERIAL MEASUREMENTS OF SIX INFLAMMATORY BIOMARKERS | 08:30 - 08:30 |
| | Xiaoyu Zhang (Tianjin, China) | |
| B020 | THE ROLE OF ADDING ANTITHYMOCYTE GLOBULIN TO STANDARD GVHD PROPHYLAXIS IN HLA ONE-LOCUS-MISMATCHED UNRELATED BONE MARROW TRANSPLANTATION: A RANDOMIZED MULTICENTER PHASE III TRIAL | 08:30 - 08:30 |
| | Junya Kanda (Kyoto, Japan) | |
| B021 | 3X3 COMPARISON OF TACROLIMUS, SIROLIMUS AND MYCOPHENOLATE MOPHETIL (MMF) VS POSTRASPLANT CYCLOPHOSPHAMIDE (PT-CY), TACROLIMUS AND MMF VS PT-CY, SIROLIMUS AND MMF. A RETROSPECTIVE ANALYSIS (GETH-TC) | 08:30 - 08:30 |
| | José Antonio Pérez Simón (Sevilla, Spain) | |
| B022 | ST2 AND REG3A IN GRAFT VERSUS HOST DISEASE | 08:30 - 08:30 |
| | Dan Le (Melbourne, Australia) | |
| B023 | GRAFT-VERSUS-HOST DISEASE IN THE CENTRAL NERVOUS SYSTEM - EMERGING PROBLEM OF MODERN HSCT TECHNOLOGY | 08:30 - 08:30 |
| | Natalia Bronina (Moscow, Russian Federation (the)) | |
| B024 | SKIN RESPONSES USING MODIFIED CRITERIA AMONG PATIENTS WITH SCLEROTIC CHRONIC GRAFT-VERSUS-HOST DISEASE TREATED WITH AXATILIMAB IN THE AGAVE-201 TRIAL | 08:30 - 08:30 |
| | Britnie Thomas (Wilmington, United States Minor Outlying Islands (the)) | |
| B028 | A MODIFIED PEDIATRIC DAY 100 SCORE TO PREDICT MODERATE TO SEVERE CGVHD, TRANSPLANT-RELATED MORTALITY, AND OUTCOME AFTER HEMATOPOIETIC CELL TRANSPLANTATION | 08:30 - 08:30 |
| | Sonia Bonanomi (Monza, Italy) | |
| B029 | SERUM CHOLINESTERASE AS A LOW-COST, ROUTINELY AVAILABLE BIOMARKER FOR ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE IN CHILDREN | 08:30 - 08:30 |
| | Wiebke Jünemann (Hamburg, Germany) | |
| B030 | HUMANIZED ANTI-CD25 MONOCLONAL ANTIBODY FOR GVHD PROPHYLAXIS IN ELDERLY HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION: A PHASE II STUDY | 08:30 - 08:30 |
| | Xiaoyu Zhang (Tianjin, China) | |
| B031 | ABSOLUTE LYMPHOCYTE COUNT AT ANTI-T-LYMPHOCYTE GLOBULIN DOES NOT PREDICT GVHD INCIDENCE AND GVHD/RELAPSE FREE SURVIVAL AFTER MATCHED UNRELATED DONOR TRANSPLANTATION: A TWO-CENTER VALIDATION STUDY | 08:30 - 08:30 |
| | Radwan Massoud (Hamburg, Germany) | |
| B033 | SAFETY AND FEASIBILITY OF 0.6 MG/KG EVERY 4 WEEKS DOSING OF AXATILIMAB IN PATIENTS TREATED IN THE | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | AGAVE-201 STUDY María Sola Soto (Barcelona, Spain) | |
| B034 | ASSESSMENTS OF BONE HEALTH AMONG PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE RECEIVING AXATILIMAB IN THE AGAVE-201 TRIAL Doris M. Ponce (New York, NY, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B035 | OUTCOMES OF PATIENTS DIAGNOSED WITH STEROID-REFRACTORY OR DEPENDENT ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE RESISTANT OR INTOLERANT TO SECOND-LINE RUXOLITINIB: A RETROSPECTIVE STUDY FROM THE GETH-TC María Sola Soto (Barcelona, Spain) | 08:30 - 08:30 |
| B036 | IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSE REDUCTION ON THE INCIDENCE OF COMPLICATIONS AND RELAPSE AFTER ALLOGENEIC TRANSPLANTATION María Panizo-Inogés (Pamplona, Spain) | 08:30 - 08:30 |
| B037 | MISSED AND DELAYED GENITAL GVHD: ORAL INVOLVEMENT AS A CLINICAL BIOMARKER FOR EARLY DETECTION Valle Gómez-García de Soria (Madrid, Spain) | 08:30 - 08:30 |
| B039 | REDUCED-DOSE POST TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: LEARNINGS FOR THE FUTURE Rohan Halder (New Delhi, India) | 08:30 - 08:30 |
| B042 | A SINGLE TRANSPLANT PROGRAM EXPERIENCE IN TERMS OF GVHD PROPHYLAXIS: IS LESS DOSES OF METHOTREXATE BETTER THAN MORE? Cristina Luise (Naples, Italy) | 08:30 - 08:30 |
| B043 | SYSTEMIC TREATMENT WITH THE ROCK2 INHIBITOR BELUMOSUDIL IN OCULAR CHRONIC GRAFT VERSUS HOST DISEASE Yibo Wu (Hangzhou, China) | 08:30 - 08:30 |
| B044 | DONOR- AND DOSE- SPECIFIC ENDOTHELIAL ACTIVATION AND CLINICAL OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE M Queralt Salas (Barcelona, Spain) | 08:30 - 08:30 |
| B045 | EFFICACY OF CNI-FREE GVHD PROPHYLAXIS IN PEDIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER PRIOR MONOCLONAL ANTIBODY THERAPY Tatiana Bykova (Saint-Petersburg, Russian Federation (the)) | 08:30 - 08:30 |
| B046 | VIRAL INFECTION WITHIN STEROID REFRACTORY/DEPENDENT GVHD PATIENTS TREATED WITH RUXOLITINIB: A SINGLE CENTER ANALYSIS Silvia Zanon (Brescia, Italy) | 08:30 - 08:30 |
| B047 | BENEFITS OF A MULTIDISCIPLINARY COMMITTEE FOR THE TREATMENT OF CHRONIC GVHD: CASE REPORTS AS A PARADIGM FOR COLLABORATIVE CARE David Gomez Rocha (Madrid, Spain) | 08:30 - 08:30 |
| B048 | EFFICACY AND SAFETY OF BELUMOSUDIL-ECP (EXTRACORPOREAL PHOTOPHERESIS) COMBINATION THERAPY IN REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AND CORRELATION WITH CYTOKIN KINETIC: A SINGLE-CENTER RETROSPECTIVE STUDY | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | Patrizia Chiusolo (Roma, Italy) | |
| B049 | BELUMOSUDIL TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: REAL-WORLD CLINICAL DATA FROM FRANCE Florent Malard (Paris, France) | 08:30 - 08:30 |
| B050 | MORTALITY BY ORGAN-SPECIFIC FIBROTIC MANIFESTATIONS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE IN THE UNITED STATES Alyshah Abdul Sultan (Morristown, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B051 | SAFETY AND TOLERABILITY OF A CANNABIS-BASED OIL EXTRACT IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION - A PHASE I STUDY Juliana Matos Pessoa (São Paulo, Brazil) | 08:30 - 08:30 |
| B052 | PROPHYLACTIC TOCILIZUMAB FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN MATERNAL HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-ARM STUDY Yibo Wu (Hangzhou, China) | 08:30 - 08:30 |
| B053 | ABATACEPT FOR GVHD PROPHYLAXIS IN PEDIATRIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM SAUDI ARABIA Hawazen Alsaedi (Riyadh, Saudi Arabia) | 08:30 - 08:30 |
| B054 | PET-CT AND CHRONIC GVHD: A DIAGNOSTIC TOOL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ? A PROSPECTIVE INTERVENTIONAL STUDY WITHIN CHU CAEN NORMANDY, FRANCE Quentin Levesque (Caen, France) | 08:30 - 08:30 |
| B055 | REAL-WORLD EFFICACY AND TOXICITY PROFILE OF RUXOLITINIB IN PEDIATRIC ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE: A MULTICENTER RETROSPECTIVE STUDY Andrea Buonsante (Monza, Italy) | 08:30 - 08:30 |
| B056 | "EFFECT OF REDUCING THE DOSES OF CYCLOPHOSPHAMIDE ON OUTCOMES AND ON IMMUNE RECOVERY" Francisco Manuel Martín Domínguez (Seville, Spain) | 08:30 - 08:30 |
| B057 | RUXOLITINIB UTILIZATION IN STEROID-REFRACTORY GVHD DURING THE PTCY ERA: A COMPARATIVE ANALYSIS WITH AN HISTORICAL ATG COHORT Riccardo Marnoni (Brescia, Italy) | 08:30 - 08:30 |
| B058 | CLINICAL FEATURES AND OUTCOME OF CHRONIC GVHD IN PEDIATRIC PATIENTS: A MULTICENTER STUDY ON BEHALF OF THE SPANISH GROUP FOR HEMATOPOIETIC TRANSPLANTATION AND CELL THERAPY(GETH-TC) Laura Alonso Garcia (Barcelona, Spain) | 08:30 - 08:30 |
| B059 | CHARACTERISTICS OF CLINICAL TRIALS IN GRAFT-VERSUS-HOST DISEASE: LANDSCAPE OF STUDY DRUGS AND ASSESSMENT OF OUTCOME MEASURES Hanna A. Knaus (Vienna, Austria) | 08:30 - 08:30 |
| B060 | IMPACT OF ANTI-T-LYMPHOCYTE GLOBULIN DOSING ON GRAFT VERSUS HOST DISEASE IN MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION Radwan Massoud (Hamburg, Germany) | 08:30 - 08:30 |
| B061 | SAFETY AND EFFICACY OF ABATACEPT IN THE MANAGEMENT OF STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | DISEASE. A SINGLE CENTER EXPERIENCE Panagiotis Dolgyras (Thessaloniki, Greece) | |
| B064 | OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS WITH PERI-TRANSPLANT-RUXOLITINIB PROPHYLAXIS Miriam Mozaffari Jovein (Freiburg im Breisgau, Germany) | 08:30 - 08:30 |
| B065 | IMPACT OF PULMONARY FUNCTION TESTING ON BRONCHIOLITIS OBLITERANS SYNDROME AND OUTCOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANT Rosa De Francesco (Tricase, Italy) | 08:30 - 08:30 |
| B066 | LOW-DOSE WEEKLY CIDOFOVIR AS AN EFFECTIVE PROPHYLACTIC ALTERNATIVE TO LETERMOVIR FOR PRE-ENGRAFTMENT CMV IN ALLOGENEIC HSCT Santanu Sen (Mumbai, India) | 08:30 - 08:30 |
| B067 | DESCRIPTION OF CHRONIC GRAFT VERSUS HOST DISEASE USING AN INNOVATIVE ARTIFICIAL INTELLIGENCE NATURAL LANGUAGE PROCESSING ON ELECTRONIC MEDICAL RECORDS FROM 8 CENTERS IN FRANCE Darko Kiprijanovski (Paris, France) | 08:30 - 08:30 |
| B068 | EFFECTIVENESS AND SAFETY OF BELUMOSUDIL FOR CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE STUDY FROM CHINA Hailong Yuan (Xinjiang, China) | 08:30 - 08:30 |
| B069 | EARLY RUXOLITINIB USE IN MODERATE-TO-SEVERE PULMONARY CHRONIC GRAFT-VERSUS-HOST DISEASE: A CASE SERIES Andrés Yesid Bonilla-Salcedo (Mexico City, Mexico) | 08:30 - 08:30 |
| P123 | FAECAL MICROBIAL TRANSPLANTATION FOR GRAFT-VERSUS-HOST DISEASE Andrea Henden (Brisbane, Australia) | 08:30 - 08:30 |
| P124 | GRADE YOUR GVHD YOURSELF - DEVELOPMENT OF AN APP TO DOCUMENT CHRONIC GRAFT -VERSUS-HOST DISEASE BY PATIENTS AND CAREGIVERS Daniel Wolff (Regensburg, Germany) | 08:30 - 08:30 |
| P125 | TREATMENT PATTERN AND EFFECTIVENESS OF BELUMOSUDIL FOR CHRONIC GVHD: A SINGLE-CENTRE, RETROSPECTIVE STUDY IN CHINA Jinsong Yan (Dalian, China) | 08:30 - 08:30 |
| P126 | ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) VS. ANTI-THYMOCYTE GLOBULIN (ATG) IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PRELIMINARY COMPETING-RISK ANALYSIS Patricia Flüchter (Würzburg, Germany) | 08:30 - 08:30 |
| P127 | REAL-WORLD IMPACT OF RUXOLITINIB IN GRAFT-VERSUS-HOST DISEASE: EXPERIENCE FROM A NATIONAL REFERRAL CANCER CENTER IN MEXICO Mistral Castellanos-Mares (Mexico City, Mexico) | 08:30 - 08:30 |
| P128 | ETANERCEPT AS SECOND-LINE THERAPY FOR STEROID-REFRACTORY GVHD: FEASIBILITY, SAFETY, AND OUTCOMES Michel Lu (Sydney, Australia) | 08:30 - 08:30 |
| P130 | IN VIVO T CELL DEPLETION IN COMPLETE REMISSION ACUTE LEUKEMIA PATIENTS RECEIVING PERIPHERAL STEM CELL TRANSPLANTATION FROM HLA IDENTICAL SIBLING WITH | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | MYELOABLATIVE CONDITIONING REGIMEN Luca Castagna (Palermo, Italy) | |
| P131 | ECP BASED COMBINATIONS FOR TREATING ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE Simon Bulley (Leeds, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P132 | BELUMOSUDIL FOR REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE IN CHILDREN AND YOUNG ADULTS: REPORT OF 4 CASES Burcu Akinci (İstanbul, Turkey) | 08:30 - 08:30 |
| P134 | OCULAR GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A 10-YEAR SINGLE CENTER EXPERIENCE Cristina Tecchio (Verona, Italy) | 08:30 - 08:30 |
| P135 | COMPARATIVE OUTCOMES OF THREE DIFFERENT ATLG REGIMENS IN ALLO-HSCT FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE STUDY Xiaohong Liu (Beijing, China) | 08:30 - 08:30 |
| P137 | BELUMOSUDIL IN SEVERE PROGRESSIVE OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE: A CASE SERIES Filippo Frioni (Rome, Italy) | 08:30 - 08:30 |
| P138 | EFFECTS OF EXTRACORPOREAL PHOTOPHERESIS (ECP) ON LEUKEMIA-SPECIFIC AND ANTI-LEUKEMIC IMMUNE CELL SUBSETS IN LEUKEMIA PATIENTS AFTER STEM CELL TRANSPLANTATION (HSCT) WITH ACUTE OR CHRONIC GRAFT-VERSUS-HOST-DISEASE Helga Schmetzer (Munich, Germany) | 08:30 - 08:30 |
| P140 | REDUCED-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR GVHD PROPHYLAXIS IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION: REAL-WORLD OUTCOMES FROM A LATIN AMERICAN TRANSPLANT CENTER Severiano Baltazar Arellano (Monterrey, Mexico) | 08:30 - 08:30 |
| P142 | CLINICAL CHARACTERISTICS AND SURVIVAL OUTCOMES OF GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE COHORT ANALYSIS Naty López-Córdova (Lima, Peru) | 08:30 - 08:30 |
| P143 | DUPILUMAB AS EFFECTIVE TREATMENT IN ADULT AD-LIKE GVHD: A CASE REPORT Margherita Malchiodi (Siena, Italy) | 08:30 - 08:30 |
| P146 | VERY LATE ONSET ACUTE GVHD AFTER COVID19 VACCINE AND INFECTION: A CASE REPORT Margherita Malchiodi (Siena, Italy) | 08:30 - 08:30 |
| P147 | COMPOSITION OF PERIPHERAL BLOOD IMMUNE-CELLS IN PATIENTS WITH LEUKEMIA AFTER ALLOGENEIC STEM-CELL-TRANSPLANTATION(HSCT) IN PATIENTS WITH VS. WITHOUT CHRONIC(C) OR ACUTE(A) GRAFT-VERSUS-HOST-DISEASE(GVHD) AND HEALTHY DONORS Helga Schmetzer (Munich, Germany) | 08:30 - 08:30 |
| P148 | DYNAMIC MODULATION OF NATURAL KILLER (NK) AND CYTOKINE INDUCED KILLER (CIK) CELLS BY EXTRACORPOREAL PHOTOPHERESIS IN CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOETIC STEM CELL TRANSPLANTATION Anying Huang (Munich, Germany) | 08:30 - 08:30 |

| | | |
|--|--|---------------|
| P149 | REPORT ON THE EFFICACY OF MESENCHYMAL STROMAL CELLS (MSC-OBTINIX™) IN STEROID AND RUXOLITINIB-REFRACTORY GVHD (SRR-GVHD) WITHIN A COMPASSIONATE USE PROGRAM: AN ITALIAN SINGLE-CENTER EXPERIENCE Daniele Avenoso (Brescia, Italy) | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Graft-versus-host Disease - Basic and Translational | | |
| A360 | ATG EXPOSURE AND IMMUNE RECONSTITUTION IN CHILDREN WITH HEMOGLOBINOPATHIES FOLLOWING HSCT: DIFFERENT PATTERNS FOR ATG-GRAFALON AND THYMOGLOBULINE Ysabel Alessa Schwietzer (Hamburg, Germany) | 08:30 - 08:30 |
| A361 | SKIN TAPE STRIPPING ENABLES NON-INVASIVE MONITORING OF INFLAMMATORY CYTOKINES IN ACUTE SKIN GVHD Nakisa Kamari-Kany (Copenhagen, Denmark) | 08:30 - 08:30 |
| A363 | THERAPEUTIC TARGETING OF CCR7 IMPROVES OUTCOMES IN A PRECLINICAL MODEL OF ACUTE GRAFT-VERSUS-HOST DISEASE Andrea Hoyos Domingo (Madrid, Spain) | 08:30 - 08:30 |
| A364 | PRE-TRANSPLANT T/NK-LIKE DERIVED EXTRACELLULAR VESICLES ASSOCIATE WITH GVHD AND DISTINCT IMMUNE RECONSTITUTION PATTERNS, INFLUENCED BY GUT MICROBIOME AND CHEMOTHERAPY EXPOSURE IN PEDIATRIC STEM CELL TRANSPLANTATION Francesca Gottardi (Bologna, Italy) | 08:30 - 08:30 |
| A365 | HIGH THROUGHPUT METABOLIC ANALYSES DEMONSTRATE AMINO ACID PATHWAY PERTURBATIONS IN ACUTE GRAFT-VERSUS-HOST DISEASE Dan Le (Melbourne, Australia) | 08:30 - 08:30 |
| A369 | COMPARATIVE ANALYSIS OF GRAFT-VERSUS-HOST DISEASE INCIDENCE AND PATTERNS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS STANDARD PROPHYLAXIS M Queralt Salas (Barcelona, Spain) | 08:30 - 08:30 |
| A371 | IMPAIRED CIRCULATING T_{FH} SUBSETS AS EARLY INDICATORS OF CHRONIC GVHD PATHOGENESIS Silvia Spoerl (Erlangen, Germany) | 08:30 - 08:30 |
| A372 | PERTURBATIONS IN THE MICROBIAL DERIVED TRYPTOPHAN METABOLITES UNDERLIE ACUTE GRAFT-VERSUS-HOST DISEASE Dan Le (Melbourne, Australia) | 08:30 - 08:30 |
| A374 | PRE-TRANSPLANT TREC LEVELS MODULATE POST-TRANSPLANT GUT INTRINSIC DNA-DAMAGE AND IMMUNE RESPONSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Adam Kuba (Olomouc, Czechia) | 08:30 - 08:30 |
| A375 | SYNERGISTIC EFFECTS OF AXATILIMAB AND RUXOLITINIB IN AN INFLAMMATORY IN VITRO MODEL OF GVHD Shannon Kahan (Wilmington, DE, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A376 | VON WILLEBRAND FACTOR-ENHANCED EASIX FORMULA CORRELATES WITH CGVHD SEVERITY IN THE INFLAMMATORY CGVHD PHENOTYPE AND CYTOKINE CONCENTRATIONS Ana Zelić Kerep (Zagreb, Croatia) | 08:30 - 08:30 |

| | | |
|---------------------------------|--|---------------|
| A377 | THE INTERPLAY BETWEEN CYTOMEGALOVIRUS REACTIVATION, CONDITIONING REGIMENS, AND GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HSCT: A 10-YEAR RETROSPECTIVE ANALYSIS FROM RESOURCE-LIMITED SETTING Bushra Ahsan (Lahore, Pakistan) | 08:30 - 08:30 |
| A378 | SINGLE-AGENT CSF-1R OR JAK INHIBITION REDUCES FIBROSIS IN A MURINE MODEL OF CHRONIC GRAFT-VERSUS-HOST DISEASE Paul Wilson (Wilmington, DE, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| P121 | ADAPTIVE AND MYELOID DYNAMICS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE OR CHRONIC GRAFT-VERSUS-HOST DISEASE UNDERGOING EXTRACORPOREAL PHOTOPHERESIS VERSUS NON-GRAFT-VERSUS-HOST DISEASE AND HEALTHY DONORS Helga Schmetzer (Munich, Germany) | 08:30 - 08:30 |
| P122 | EXPERIENCE IN HAPLOIDENTICAL TRANSPLANTATION OVER THE LAST 3 YEARS, IN THE TRANSPLANT UNIT OF MEXICO'S NATIONAL REFERENCE MEDICAL CENTER Alba Edna Morales Hernandez (Ciudad de México, Mexico) | 08:30 - 08:30 |
| <i>ePoster</i> 08:30 - 18:00 | | R20 |
| Data management | | |
| P315 | MULTI-MISMATCH SEARCHES IN HAP-E SEARCH Christine Urban (Tuebingen, Germany) | 08:30 - 08:30 |
| P316 | EVALUATING 2.5 YEARS OF OMOP IMPLEMENTATION IN THE EBMT REGISTRY: APPROACH, CHALLENGES AND OUTCOMES Annelot van Amerongen (Leiden, Netherlands (the)) | 08:30 - 08:30 |
| P317 | HLA: A MICROSCOPIC MARVEL CREATING A MACROSCOPIC CHALLENGE IN HSCT DATA MANAGEMENT - UNDERSTANDING THE STRUGGLE AND THE CASE FOR AUTOMATION Marie Wilson (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P318 | A STRONGER EUROPEAN VOICE TO SUPPORT GENE AND CELL THERAPIES: EUROGCT AS A COMMON TOOL Aurélie Mahalatchimy (Aix-en-Provence, France) | 08:30 - 08:30 |
| P319 | PBMT DATA MANAGEMENT GROUP: BUILDING FOUNDATIONS AND FOSTERING NATIONAL COLLABORATION Shahid Iqbal (Rawalpindi, Pakistan) | 08:30 - 08:30 |
| P321 | THE STRATEGIC ROLE OF BRAZIL IN THE INTERNATIONAL SUPPLY OF STEM CELLS: THE CONTRIBUTION OF REDOME TO LATIN AMERICA AND THE WORLD Natiele Tavares (Rio de Janeiro, Brazil) | 08:30 - 08:30 |
| P322 | STRENGTHENING NATIONAL TRANSPLANT INFRASTRUCTURE THROUGH INTERNATIONAL COLLABORATION: LESSONS FROM THE DKMS EXPERIENCE IN COLOMBIA Sandra G. Salamanca Pinzón (Tübingen, Germany) | 08:30 - 08:30 |
| P323 | DETERMINANTS AND TRENDS IN UNRELATED ALLOGENEIC HSCT CANCELLATIONS: A 10-YEAR SINGLE-CENTER ANALYSIS Pinelopi Samara (Athens, Greece) | 08:30 - 08:30 |
| P324 | MONITORING OF BKV DNAEMIA AND HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Clarisse Martins Machado (São Paulo, Brazil) | 08:30 - 08:30 |

| | | |
|----------------------------|---|---------------|
| P325 | IMPLEMENTATION OF THE BRAZILIAN SOCIETY OF CELLULAR THERAPY AND BONE MARROW TRANSPLANTATION EDUCATIONAL PLATFORM: PRELIMINARY RESULTS AND CHALLENGES Fernando Barroso Duarte (Fortaleza, Brazil) | 08:30 - 08:30 |
| P326 | BUILDING THE LOCAL EVIDENCE BASE: DEMOGRAPHIC PROFILE OF DLBCL PATIENTS IN WALES Ceri Jones (Cardiff, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P327 | LEVERAGING MACHINE LEARNING TO PREDICT POST-TRANSPLANT COMPLICATIONS IN ALLOGENEIC HSCT Monia Zidane (Paris, France) | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Solid Tumours | | |
| B436 | SEQUENCE ORDER IN BU MEL CONDITIONING FAILS TO PREDICT SURVIVAL: PK AND OUTCOME DATA FROM A PEDIATRIC NEUROBLASTOMA AND EWING SARCOMA COHORT Srijib Mukherjee (Westmead, Australia) | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Haemoglobinopathies | | |
| B350 | THE NEED FOR A SUBSEQUENT HCT IS A LATE & CONTINUOUS RISK AND WITH SIGNIFICANT IMPACT IN OVERALL SURVIVAL IN HAEMOGLOBINOPATHIES: AN ANALYSIS OF HWP Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B351 | EARLY DETECTION OF CLONAL HEMATOPOIESIS IN SICKLE CELL DISEASE: RESULTS FROM AN ACTIVELY MONITORED COHORT Alice Corsia (Paris, France) | 08:30 - 08:30 |
| B352 | TREOSULFAN-BASED CONDITIONING IS ASSOCIATED WITH BETTER OUTCOMES IN ADOLESCENTS AND YOUNG ADULTS UNDERGOING MATCHED RELATED DONOR TRANSPLANTATION FOR THALASSEMIA MAJOR Mithun Abraham Prakash (Ranipet, India) | 08:30 - 08:30 |
| B354 | POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS ATG AS GVHD PROPHYLAXIS IN MATCHED SIBLING DONOR PBSC TRANSPLANTATION FOR B-THALASSEMIA MAJOR - A SINGLE CENTER EXPERIENCE Reham Khalaf (Cairo, Egypt) | 08:30 - 08:30 |
| B355 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC HEMOGLOBINOPATHIES: LONG-TERM OUTCOMES IN A LARGE SINGLE-CENTER COHORT Patrizia Comoli (Pavia, Italy) | 08:30 - 08:30 |
| B356 | RELIABLE ENGRAFTMENT AND COMPARABLE OUTCOMES ACROSS DONOR SOURCES WITH BUSULFAN65-FLUDARABINE-THIOTEPA CONDITIONING IN PAEDIATRIC SICKLE CELL DISEASE Anna-Lisa Lanz (Munich, Germany) | 08:30 - 08:30 |
| B358 | THE IMPACT OF TREOSULPHAN-BASED CONDITIONING AND INTEGRATED FOLLOW UP IMPROVES EVENT FREE SURVIVAL IN CHILDREN UNDERGOING HSCT FOR SICKLE CELL DISEASE Revathi Raj (Chennai, India) | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| B360 | LONG TERM FOLLOW-UP OF THALASSEMIA PATIENTS SHOWS REASONABLE OUTCOMES AFTER TRANSPLANTATION- A SINGLE CENTER EXPERIENCE FROM INDIA Rohan Halder (New Delhi, India) | 08:30 - 08:30 |
| B361 | TREOSULFAN BASED MYELOABLATIVE CONDITIONING IN ADOLESCENT AND ADULT PATIENTS WITH HEMOGLOBINOPATHY Stephanie Leszczak (Regensburg, Germany) | 08:30 - 08:30 |
| B362 | ESTABLISHING PRE-TRANSPLANT AUTOMATED RED CELL EXCHANGE FOR SICKLE CELL DISEASE: SAFETY AND FEASIBILITY RESULTS FROM A START-UP HSCT PROGRAM IN TANZANIA Antonella Capasso (Monza, Italy) | 08:30 - 08:30 |
| B363 | HIGH PLATELET TRANSFUSION BURDEN FLAGS ENDOTHELIAL RISK BUT NOT GVHD, AFTER PEDIATRIC SICKLE CELL HSCT Hailey Tinsley (Houston, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B364 | 63 HLA-IDENTICAL RELATED HAEMOTOPOIETIC STEM CELL TRANSPLANTS IN SICKLE CELL DISEASE Eduardo J. Bardón-Cancho (Madrid, Spain) | 08:30 - 08:30 |
| B365 | CORRELATION OF HB S LEVEL WITH CHIMERISM POST BONE MARROW TRANSPLANT IN PATIENT WITH SICKLE CELL DISEASE | 08:30 - 08:30 |
| B366 | DIFFERENT APPROACHES TO HSCT IN TRANSFUSION-DEPENDENT B-THALASSEMIA Gleb Bronin (Tashkent, Uzbekistan) | 08:30 - 08:30 |
| B367 | THIRTY YEARS LATER: UNEXPECTED, UNHERALDED, AND UNEXPLAINED RE-EMERGENCE OF THALASSEMIA FOLLOWING LONG-TERM ALLOGENEIC ENGRAFTMENT Valeria Maria Pinto (Genoa, Italy) | 08:30 - 08:30 |
| B368 | HLA-MATCHED RELATED DONOR TRANSPLANTATION IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSAEMIA: A SINGLE-CENTRE EXPERIENCE IN A RESOURCE-LIMITED SETTING - LADY RIDGEWAY HOSPITAL FOR CHILDREN, SRI LANKA Shanika Vitharana (Colombo, Sri Lanka) | 08:30 - 08:30 |
| B369 | HAPLOIDENTICAL STEM CELL TRANSPLANTATION AS A CURATIVE STRATEGY FOR SEVERE SICKLE CELL DISEASE: A SINGLE-CENTER REPORT Teresa Martín Aláez (Madrid, Spain) | 08:30 - 08:30 |
| P266 | HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC UNSTABLE HEMOGLOBINOPATHIES: TWO RARE CASES WITH SUSTAINED DONOR CHIMERISM AND LONG-TERM FOLLOW-UP Luiz Guilherme Darrigo Jr (Ribeirão Preto, Brazil) | 08:30 - 08:30 |
| P268 | EVALUATING THE SAFETY, EFFICACY, AND OUTCOMES OF A TARGETED INVASIVE PRENATAL SCREENING PROGRAM FOR HEMOGLOBINOPATHIES IN RURAL AND SEMI-URBAN INDIA | 08:30 - 08:30 |

ePoster

08:30 - 18:00

R20

Nurses Posters - Paediatric

| | | |
|------|---|---------------|
| NP30 | ESTABLISHING THE FIRST PEDIATRIC BONE MARROW TRANSPLANT NURSING PROGRAM IN THE UAE: A MODEL FOR COMPETENCY BASED EDUCATION AND INTERNATIONAL COLLABORATION | 08:30 - 08:30 |
|------|---|---------------|

| | | |
|-------|---|---------------|
| | Dina El Mouzain (Abu Dhabi, United Arab Emirates (the)) | |
| NP31 | IMPLEMENTATION OF NEUTROPENIA PATHWAY TO IMPROVE ANTIBIOTIC TURNAROUND TIME IN PEDIATRIC BMT PATIENTS AT ABU DHABI BONE MARROW TRANSPLANT PROGRAM, CENTER OF EXCELLENCE (UAE) Dina El Mouzain (Abu Dhabi, United Arab Emirates (the)) | 08:30 - 08:30 |
| NP32 | GLOBAL NURSING EXCHANGE: EXPERIENCES FROM THE "HOW DO YOU DO IT" ONLINE SESSIONS BY THE EBMT NURSES GROUP PAEDIATRIC COMMITTEE Ida Bremer Ophorst (Utrecht, Netherlands (the)) | 08:30 - 08:30 |
| NP33 | ASSESSING THE TOLERANCE OF FIBRE BASED FEEDS FOR PAEDIATRIC PATIENTS DURING AN ALLOGENEIC STEM CELL TRANSPLANT Chloe Elliott (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP34 | PREVENTION AND MANAGEMENT OF ORAL MUCOSITIS IN PEDIATRIC ONCO-IMMUNO-HEMATOLOGICAL PATIENTS: A SCOPING REVIEW Silvia Gneccchi (Milan, Italy) | 08:30 - 08:30 |
| NP35 | ROLE OF TANZANIAN NURSES IN OPENING A PEDIATRIC BONE MARROW TRANSPLANT UNIT AND NURSING CARE IN SICKLE CELL PATIENTS AT BENJAMIN MKAPA HOSPITAL IN DODOMA Silvia Gneccchi (Milan, Italy) | 08:30 - 08:30 |
| NP36 | EXPLORING DETERMINANTS OF STAFF RETENTION IN PAEDIATRIC BONE MARROW TRANSPLANT NURSING Charlotte Rigby (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP37 | PERCEIVED BARRIERS AND FACILITATORS OF FAMILY-CENTERED ROUNDS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, A HEALTH CARE PROFESSIONALS SURVEY Madelief Sterre Hübner (Leiden, Netherlands (the)) | 08:30 - 08:30 |
| NP103 | ADMINISTRATION OF GRAFALON® (ATLG) WITH A GRADUALLY INCREASING INFUSION RATE: IMPACT ON TOLERABILITY IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION Simona Calza (Genoa, Italy) | 08:30 - 08:30 |
| NP104 | NURSING PRACTICE AND SAFETY IN ANTI-CD19 CAR-T CELL THERAPY FOR PEDIATRIC REFRACTORY SLE: A CASE SERIES OF 10 PATIENTS Xiaoyuan Wu (Beijing, China) | 08:30 - 08:30 |
| NP105 | NURSING MANAGEMENT OF A COMPLEX PEDIATRIC ALLO-HSCT CASE FOR BETA-THALASSEMIA MAJOR WITH MULTIPLE SEVERE POST-TRANSPLANT COMPLICATIONS Thi Dung Tran (Hanoi, Viet Nam) | 08:30 - 08:30 |
| NP106 | DIGESTIVE AND SYSTEMIC PROPHYLAXIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): A NATIONAL SURVEY IN FRANCE Cécile RENARD (lyon, France) | 08:30 - 08:30 |
| NP108 | EVALUATION OF NURSE CASE MANAGER FOLLOW-UP IN PEDIATRIC POST-HSCT PATIENTS Laura Jiménez Prat (Esplugues de Llobregat, Spain) | 08:30 - 08:30 |
| NP109 | NURSE-LED INITIATIVE SKIN CARE GUIDELINE TO MINIMIZE TREOSULFAN RELATED SKIN TOXICITY AMONG PAEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT IN NATIONAL UNIVERSITY HOSPITAL, SINGAPORE | 08:30 - 08:30 |

| | | |
|---------------------------------|--|---------------|
| | Cing Khan Lian (Singapore, Singapore) | |
| NP110 | NURSE LEADERSHIP IN MANAGING ATG REACTIONS IN PEDIATRIC ONCOLOGY: "KOV IN THE LEAD" Kirsten Madeleine van der Peijl (Utrecht, Netherlands (the)) | 08:30 - 08:30 |
| NP111 | NURSING TRAINING IN A PEDIATRIC HSCT UNIT: IMPLEMENTATION, SATISFACTION OUTCOMES AND EVALUATION FRAMEWORK IN RABAT (MOROCCO) Eugenia Trigos (Valencia, Spain) | 08:30 - 08:30 |
| NP112 | "LIGHTING THE WAY" -ENABLERS OF IMPLEMENTING PHOTOBIO-MODULATION THERAPY FOR MUCOSITIS IN PAEDIATRIC HSCT Elaine Smyth (Dublin, Ireland) | 08:30 - 08:30 |
| NP113 | PHOTOBIO-MODULATION IN THE TREATMENT OF ORAL MUCOSITIS IN THE TRANSPLANT SETTING FOR CHILDREN AND YOUNG PEOPLE Sarah Davies (Sutton, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP114 | COMPREHENSIVE SYMPTOM MANAGEMENT AND SUPPORTIVE NURSING CARE IN A PRETERM TODDLER UNDERGOING HSCT FOR PYRUVATE KINASE DEFICIENCY Thi Dung Tran (Hanoi, Viet Nam) | 08:30 - 08:30 |
| NP115 | PLATELET-RICH GEL PROMOTES RAPID WOUND HEALING IN SEVERE CUTANEOUS GRAFT-VERSUS-HOST DISEASE Veronica Fernandez Angulo (Barcelona, Spain) | 08:30 - 08:30 |
| NP116 | COMPLEXITIES IN GENE THERAPY- MANUFACTURING DELAYS AND THE IMPACTS OF THIS ON THE PATIENTS AND THEIR FAMILIES Kiera Whitworth (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| | | |
| <i>ePoster</i> 08:30 - 18:00 | | R20 |
| ePoster Viewing | | |
| | | |
| <i>ePoster</i> 08:30 - 18:00 | | R20 |
| Nurses Posters - Adult | | |
| NP01 | GLOBAL COLLABORATION AND AI-ENHANCED ONLINE EDUCATION FOR UKRAINIAN HCT NURSES IN WARTIME Oleksandr Istomin (Kyiv, Ukraine) | 08:30 - 08:30 |
| NP02 | BUILDING A SKILLED AND CONFIDENT CAR-T NURSING WORKFORCE: ASSESSING THE IMPACT OF NURSE-LED CAR-T EDUCATION Cassandra Abbott (Melbourne, Australia) | 08:30 - 08:30 |
| NP03 | OPTIMISATION OF CAR-T LEUKAPHERESIS USING A MONONUCLEAR CELL-BASED PREDICTIVE COLLECTION TOOL: A SINGLE-CENTRE EXPERIENCE Clair Scott (Murdoch, Australia) | 08:30 - 08:30 |
| NP04 | QUALITY OF LIFE, ANXIETY AND DEPRESSION IN HSCT RECIPIENTS. A 12-MONTH LONGITUDINAL STUDY Arianna Rosich Soteras (Barcelona, Spain) | 08:30 - 08:30 |
| NP05 | OPTIMIZING CRS AND ICANS MANAGEMENT IN CAR-T CELL THERAPY: IMPACT OF A NURSE-LED STRUCTURED WORKFLOW ON EARLY RECOGNITION AND MANAGEMENT OF CRS AND | 08:30 - 08:30 |

| ICANS | | |
|--------------|--|---------------|
| | Kwee Cheng Chia (Singapore, Singapore) | |
| NP06 | WHEN KNOWLEDGE AND ATTITUDES DO NOT TRANSLATE INTO PRACTICE: PILOT INSIGHTS FROM HEMATOLOGY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION NURSES' SEXUAL HEALTH CARE Meng-Kuan Chiang (Taipei, Taiwan (Province of China)) | 08:30 - 08:30 |
| NP07 | EXPERIENCES OF AT-HOME AUTOLOGOUS STEM CELL TRANSPLANTATION IN SPAIN: CURRENT OVERVIEW AND IMPROVEMENT AREAS Cristina Gallego Miralles (Barcelona, Spain) | 08:30 - 08:30 |
| NP10 | MONITORING TOXICITY-RELATED COMPLICATIONS IN PATIENTS UNDERGOING CAR-T: OBSERVATIONAL, PROSPECTIVE STUDY Francesca Palmisano (Alessandria, Italy) | 08:30 - 08:30 |
| NP11 | TRANSPLANT @ HOME: A SINGLE CENTRE EXPERIENCE IN HOME-BASED CARE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION Hui Li Lim (Singapore, Singapore) | 08:30 - 08:30 |
| NP12 | APPLICATION OF LONG PERIPHERAL CANNULA IN DONOR APHERESIS - EXPERIENCE OF ONE CENTER Petra Vodickova (Plzen, Czechia) | 08:30 - 08:30 |
| NP13 | COULD PROPHYLACTIC NASOGASTRIC TUBE FEEDING REDUCE WEIGHT LOSS FOR PATIENTS UNDERGOING HIGH-TOXICITY CONDITIONING REGIMENS DURING AUTOLOGOUS STEM CELL TRANSPLANT? Hannah van Tromp (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP14 | GUIDING NURSING-LED STRATEGIES TO PREVENT CATHETER-RELATED BLOODSTREAM INFECTIONS DURING ALLOGENEIC HSCT: INFLUENCE OF CATHETER TYPE AND TIMING Maria Teran-Diaz (Santander, Spain) | 08:30 - 08:30 |
| NP15 | LATE TOXICITIES AND QUALITY OF LIFE AFTER VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL): THE ROLE OF ADVANCED PRACTICE NURSING Mercedes Montoro-Lorite (Barcelona, Spain) | 08:30 - 08:30 |
| NP16 | IMPLEMENTING STRUCTURED EDUCATION IN APHERESIS: A COMPARATIVE EVALUATION OF TRAINING EFFICIENCY AND LEARNER PERCEPTIONS Cara Cunningham (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP17 | ASSESSMENT AND MONITORING OF NUTRITIONAL STATUS IN ONCO-HEMATOLOGICAL PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): TOOLS, SCALES AND MULTIDISCIPLINARY APPROACH Alice Passoni (Milan, Italy) | 08:30 - 08:30 |
| NP18 | THE EXPERIENCE OF PATIENTS UNDERGOING CAR T CELL THERAPY: A PHENOMENOLOGICAL-INTERPRETATIVE STUDY Alfonso Parisi (Milano, Italy) | 08:30 - 08:30 |
| NP19 | A NURSING ROLE IN IMPROVING OPERATIONAL EFFICIENCY IN CELLULAR THERAPY CLINICAL TRIALS Soyoung Park (Seattle, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| NP20 | PATIENT SATISFACTION OF A NURSE-LED BONE MARROW ASPIRATION (BMA) SERVICE Sophie Bertorelli (Cardiff, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| NP21 | COMMUNICATION COMPETENCE, SELF-EFFICACY, AND SPIRITUAL INTELLIGENCE: EVIDENCE FROM NURSES WORKING IN BMT UNIT Komal Mundhe (Navi Mumbai, India) | 08:30 - 08:30 |
| NP22 | CONTINUOUS CARE UNIT: A FEASIBLE MODEL TO OPTIMIZE URGENT MANAGEMENT IN HAEMATOLOGICAL MALIGNANCIES, TRANSPLANTATION AND CAR-T PATIENTS Renato Luna Liendo (Barcelona, Spain) | 08:30 - 08:30 |
| NP23 | HEALTHCARE PROFESSIONALS' AND MANAGERS' EXPERIENCES AND PERCEPTIONS OF IMPLEMENTING CHANGE - IN THE CONTEXT OF ALLOGENEIC STEMCELL TRANSPLANTATION Anna O'Sullivan (Stockholm, Sweden) | 08:30 - 08:30 |
| NP24 | MONITORING STRESS AND WORKLOAD IN PRIMARY CAREGIVERS OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION: A ONE-YEAR SINGLE-CENTER EXPERIENCE Sara Marcos Asensio (Salamanca, Spain) | 08:30 - 08:30 |
| NP25 | EARLY NURSING ASSESSMENT AND MANAGEMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE IN TAIWANESE LONG-TERM ALLO-HSCT SURVIVORS: A TWO-YEAR RETROSPECTIVE STUDY Chiao-Fang Chang (Taipei, Taiwan (Province of China)) | 08:30 - 08:30 |
| NP26 | FOSCARNET SODIUM ENEMA FOR REFRACTORY CMV GASTROENTERITIS AFTER HAPLOIDENTICAL HSCT: A CASE SERIES Mengjing Li (Hangzhou, China) | 08:30 - 08:30 |
| NP27 | THE IMPACT OF DOSE REDUCTION OF POST-TRANSPLANT CYCLOPHOSPHAMIDE TO 70 MG/KG ON EARLY TOXICITY: A SINGLE-CENTRE EXPERIENCE Vanessa Magerová (Prague, Czechia) | 08:30 - 08:30 |
| NP28 | IMPLEMENTATION OF A MENTORSHIP PROGRAMME FOR NEWLY HIRED NURSES IN ONCO-HEMATOLOGY AND BONE MARROW TRANSPLANT UNIT AT SAN RAFFAELE HOSPITAL, MILAN Davide Bonomi (Milan, Italy) | 08:30 - 08:30 |
| NP29 | IMPACT OF THE ETAPES-ONCO PEER SUPPORT PROGRAM ON THE NEEDS OF HEMATOLOGY-ONCOLOGY PATIENTS WHO HAVE UNDERGONE CELLULAR THERAPY: PRELIMINARY RESULTS Catherine Paquette-Gascon (Montreal, Canada) | 08:30 - 08:30 |
| NP50 | AN OBJECTIVE PATIENT NEEDS-BASED ACUITY TOOL FOR THE STEM CELL TRANSPLANT PATIENT POPULATION Jill Trzaska (Chicago, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| NP53 | SECONDARY CANCERS AFTER STEM CELL/BONE MARROW TRANSPLANT: INCIDENCE, SCREENING, AND EDUCATION IN A SINGLE-CENTRE REVIEW Paul Hickey (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP54 | ESTABLISHING A NURSE-LED BONE MARROW ASPIRATION (BMA) SERVICE POST-HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): SHARING EXPERTISE TO IMPROVE PATIENT EXPERIENCE AND SERVICE DELIVERY Sophie Bertorelli (Cardiff, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP55 | EMERGENCY: IEC-COLITIS POST CAR-T CELL THERAPY IN MULTIPLE MYELOMA Daniel Verina (New York, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| NP56 | NURSE LED HOLISTIC NEEDS REVIEW CLINIC 100 DAYS POST | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | ALLOGENEIC STEM CELL TRANSPLANT: A SERVICE EVALUATION Aileen Nield (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | |
| NP57 | NURSES' AWARENESS AND READINESS TOWARD FUTURE USE OF ARTIFICIAL INTELLIGENCE (AI) TOOLS IN PREDICTING GVHD AND INFECTION IN HSCT PATIENTS: A CROSS-SECTIONAL STUDY AT ACTREC Amish Kale (Navi Mumbai, India) | 08:30 - 08:30 |
| NP58 | ASSESSMENT OF EXERCISE TOLERANCE IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION DURING HOSPITALIZATION: AN OBSERVATIONAL STUDY Rossella Raffo (Alessandria, Italy) | 08:30 - 08:30 |
| NP59 | CENTRAL VENOUS CATHETER MANAGEMENT AND REMOVAL PATTERNS IN ALLOGENEIC HSCT: INSIGHTS FOR NURSING PRACTICE Maria Teran-Diaz (Santander, Spain) | 08:30 - 08:30 |
| NP62 | REDUCING INPATIENT BED UTILISATION BY DELIVERING CAR-T LYMPHODEPLETION CHEMOTHERAPY IN AN AMBULATORY SETTING AT SHEFFIELD TEACHING HOSPITALS Alexandra Bamford (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP65 | CHALLENGES OF LAUNCHING AN AT-HOME HOSPITALIZATION PROGRAM: THE "SANT PAU A CASA" HOSPITAL-AT-HOME EXPERIENCE Alba Pla Bou (Barcelona, Spain) | 08:30 - 08:30 |
| NP66 | A NURSING LED QUALITY IMPROVEMENT INITIATIVE SUSTAINING ZERO CLABSI IN A ABU DHABI BONE MARROW TRANSPLANT PROGRAM, CENTER OF EXCELLENCE IN THE UNITED ARAB EMIRATES Dina El Mouzain (Abu Dhabi, United Arab Emirates (the)) | 08:30 - 08:30 |
| NP68 | IMPLEMENTING A NURSE-LED CAR-T PATIENT CARE PATHWAY IN A DISTRICT GENERAL HOSPITAL: ENHANCING PRE- AND POST-TREATMENT SUPPORT THROUGH ADVANCED CLINICAL PRACTICE Nicola Knightly (Swindon, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP69 | BEYOND THE PCR: CMV PNEUMONIA DESPITE NEGATIVE SERUM AND BRONCHIAL LAVAGE CMV VIRAL LOAD - CHALLENGE FOR ADVANCED NURSE PRACTITIONER Hsin-Ju Yeh (Taipei, Taiwan (Province of China)) | 08:30 - 08:30 |
| NP70 | PATIENT REPORTED EXPERIENCE OF BONE MARROW ASPIRATE AND TREPINE BIOPSY. A NURSE LED SERVICE ESTABLISHMENT AND IMPROVEMENT PROJECT Sara Main (Southampton, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP71 | HAEMATOPOIETIC, CELL THERAPY AND TRANSPLANT PREPARATIVE TRAINING FOR REGISTERED NURSES IN SINGHEALTH, SINGAPORE Chung Cheng Jordan Hwang (Singapore, Singapore) | 08:30 - 08:30 |
| NP72 | SETTING UP A PRE AND POST ALLOGENIC BONE MARROW TRANSPLANT (BMT) OUTPATIENT PHYSIOTHERAPY SERVICE IN A UK TERTIARY HOSPITAL SETTING - INITIAL RESULTS AND REFLECTIONS Emma Nicholls (Oxford, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP73 | COUNT THEM IN: RECOGNISING DUFFY NULL NEUTROPENIA IN AFRO-CARIBBEAN POPULATION WITH THE AIM TO BROADEN DONOR INCLUSION. CASE REVIEW OF A NEUTROPAENIC DONOR James Oppong (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| NP74 | NEW THERAPIES, NEW DEMANDS: A NURSING PERSPECTIVE ON PATIENT CARE TRANSFORMATION Zvonimir Kralj (Zagreb, Croatia) | 08:30 - 08:30 |
| NP75 | KNOWLEDGE AND SKILLS OF NURSES IN RECOGNIZING EARLY SIGNS OF VENO-OCCLUSIVE DISEASE (VOD) AMONG HSCT PATIENTS: A CROSS-SECTIONAL STUDY AT ACTREC Suman Kubal (Navi Mumbai, India) | 08:30 - 08:30 |
| NP77 | IMPLEMENTATION OF THE INCIDENTS NEWSLETTER "LEARNING SHARE TO IMPROVE CARE" IN HAEMATOLOGY AND DAY UNIT TRANSPLANT (HTDU) AND IN AMBULATORY CARE/ WITHINGTON WARD (WW) Irina Pitacas (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP78 | A STUDY TO ASSESS NURSES' KNOWLEDGE ON CYTOKINE RELEASE SYNDROME IN HAPLOIDENTICAL HSCT: A CROSS-SECTIONAL STUDY AT TERTIARY CARE CENTRE, INDIA Ramineni Anjaneyulu (Navi Mumbai, India) | 08:30 - 08:30 |
| NP79 | PATIENT INFORMATION VIDEOS: ENHANCING EXPERIENCE IN AUTOLOGOUS STEM CELL TRANSPLANTATION Claire Wood (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP81 | NURSING ASPECTS AND OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A FIVE-YEAR RETROSPECTIVE STUDY (2020-2024) Lucija Kralj (Zagreb, Croatia) | 08:30 - 08:30 |
| NP82 | BUILDING INCLUSIVE CLINICAL CULTURES: SUPPORTING NEURODIVERSE STAFF IN A SPECIALIST HAEMATOLOGY AND TRANSPLANT SETTING Arlene Bamforth (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP84 | CONFIDENCE IN A BOX: NURSE-SUPPORTED MEDICATION SELF-MANAGEMENT FOR PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Constance Klaasse (Utrecht, Netherlands (the)) | 08:30 - 08:30 |
| NP87 | PSYCHOLOGICAL IMPACT OF LAST MINUTE SCHEDULING CHANGES ON RELATED DONORS Laura Baines (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP89 | POST-TRAUMATIC STRESS DISORDER SCREENING FOR PRE-HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS Keiko Wahlin (New York City, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| NP90 | NUTRITION IMPACT SYMPTOMS AND NUTRITIONAL STATUS IN ADULT ALLO-HSCT RECIPIENTS DURING 1-YEAR FOLLOW-UP Sebastian Sundsbarm (Oslo, Norway) | 08:30 - 08:30 |
| NP91 | COLLABORATION BETWEEN TRUSTS TO MAINTAIN CONTINUITY OF AUTOLOGOUS STEM CELL TRANSPLANTATION DURING SERVICE DISRUPTION Sheila Fox (Bristol, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP93 | ASSESSMENT OF NUTRITIONAL STATUS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Sara Marcos Asensio (Salamanca, Spain) | 08:30 - 08:30 |
| NP94 | IMPROVING DELIVERY AND DOCUMENTATION OF JACIE-REQUIRED EDUCATION AND COMPETENCIES IN AN ADULT AUTOLOGOUS TRANSPLANT SERVICE Hayley Aplin (Swindon, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |

| | | |
|----------------------------------|---|---------------|
| NP95 | IN HOUSE EDUCATION PROGRAMME 15 YEARS LATER: WHERE ARE WE NOW? Hannah Kenyon-Smith (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP96 | IMPACT OF SWITCHING FROM SODIUM CITRATE AND TAUROLIDINE TO 4% TETRASODIUM EDTA AS A CATHETER LOCK SOLUTION IN HEMATOLOGY PATIENTS Georgeta Tudor (Bucharest, Romania) | 08:30 - 08:30 |
| NP97 | NURSE-DRIVEN INTERVENTIONS LEAD TO NEAR-ZERO CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTION RATES IN ADULT STEM CELL TRANSPLANT PATIENTS: A RETROSPECTIVE OBSERVATIONAL STUDY Francisco Vicente Lopez (Taguig City, Philippines (the)) | 08:30 - 08:30 |
| NP98 | GRAFT VS. HOST DISEASE - ADVANCED PRACTICE NURSE. A POTENTIAL KEY ROLE IN THE INTERPROFESSIONAL CARE OF PATIENTS WITH GVHD Talea Jacobsen (Cologne, Germany) | 08:30 - 08:30 |
| NP99 | WHEN INFECTION DELAYS TRANSPLANTATION - A CASE REPORT OF A PATIENT WITH NECK WOUND INFECTION AND SEPSIS Ajna Džanić (Zagreb, Croatia) | 08:30 - 08:30 |
| <i>ePoster</i> 08:30 - 18:00 | | R20 |
| Nurses Posters - Research | | |
| NP38 | PSYCHOSOCIAL ASSESSMENT OF PATIENTS AND CAREGIVERS UNDERGOING AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION AT HOME Ana Rodriguez Calvo-Parra (Madrid, Spain) | 08:30 - 08:30 |
| NP39 | EFFICACY OF ACUPOINT APPLICATION COMBINED WITH HERBAL FUMIGATION AND WASH IN PREVENTING DIARRHEA AND PERIANAL INFECTION IN PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Liyuan Qin (Shanghai, China) | 08:30 - 08:30 |
| NP40 | FINANCIAL TOXICITY AND ITS INFLUENCING FACTORS IN PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHINA: A CROSS-SECTIONAL STUDY Liyuan Qin (Shanghai, China) | 08:30 - 08:30 |
| NP41 | READINESS FOR DISCHARGE - HOLISTIC UNDERSTANDING OF THE PATIENT JOURNEY FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION Lubna Khatib (Haifa, Israel) | 08:30 - 08:30 |
| NP42 | THE POTENTIAL OF AI CHATBOTS AS CLINICAL DECISION-SUPPORT TOOLS IN NURSING: AN EVALUATION OF SYMPTOM MANAGEMENT RECOMMENDATIONS DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Aysenur Cetin Uceriz (Istanbul, Turkey) | 08:30 - 08:30 |
| NP43 | AN APPLIED STUDY OF STEPWISE EXERCISE NURSING PROGRAM FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS Mengjing Li (Hangzhou, China) | 08:30 - 08:30 |
| NP45 | INVESTIGATION OF THE ACCEPTANCE AND APPLICABILITY OF ACCELEROMETRIC MEASUREMENT OF PHYSICAL ACTIVITY BEFORE, DURING, AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Aleksandra Trojan (Köln, Germany) | 08:30 - 08:30 |

| | | |
|---------------------------------|---|---------------|
| NP46 | LIVED EXPERIENCES AND PERCEIVED QUALITY OF CARE IN ALLO-HSCT: A QUALITATIVE SUBSTUDY OF THE PHARALLO PROGRAMME Paula Guijarro Martínez (Madrid, Spain) | 08:30 - 08:30 |
| NP47 | EVALUATION OF THE EFFICACY OF ULTRASOUND-GUIDED MEDIUM-LENGTH CATHETERS IN THE COLLECTION OF PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS FROM HEALTHY DONORS Fengwei Du (Hangzhou, China) | 08:30 - 08:30 |
| NP118 | APPLICATION OF FAMILY CONSTRUCTION MODEL IN HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH CAR-T CELL THERAPY IN PATIENTS WITH LYMPHOMA Shasha Li (Chongqing, China) | 08:30 - 08:30 |
| NP119 | DEVELOPMENT AND USABILITY TESTING OF A CAR-T THERAPY E-LEARNING RESOURCE FOR HEALTHCARE PROFESSIONALS: A QUALITATIVE THINK-ALOUD STUDY Emily John (Cardiff, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP124 | COMMON ORGAN DYSFUNCTIONS AMONGST POST CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY PATIENTS: A SINGLE CENTRE SURVEY Kevin Aguilar (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| NP126 | SIDE EFFECTS AND LONG-TERM EFFECTS - THE EXPERIENCES OF PATIENTS WITH CAR T-CELL THERAPY. A SCOPING REVIEW Verena Leinemann (Salzburg, Austria) | 08:30 - 08:30 |
| NP132 | NURSING CARE OF A PATIENT WITH REFRACTORY HEMOPHAGOCYTIC SYNDROME UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION Liwei Xu (Hangzhou, China) | 08:30 - 08:30 |
| NP133 | A DESCRIPTIVE NURSING STUDY ON GUT MICROBIOTA AND GRAFT-VERSUS-HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Rosalba Daniela Minniti (Reggio Calabria, Italy) | 08:30 - 08:30 |
| <i>ePoster</i> 08:30 - 18:00 | | R20 |
| Pharmacology | | |
| P385 | OPEN WIDE: EXPLORING SALIVA AS A NON-INVASIVE TOOL FOR POSACONAZOLE LEVELS IN CHILDREN Heather Weerdenburg (Melbourne, Australia) | 08:30 - 08:30 |
| P386 | ANTIFUNGAL PROPHYLAXIS PATTERNS AND INVASIVE FUNGAL INFECTIONS OUTCOMES IN PAEDIATRIC ALLOGENIC HCT: A MULTICENTRE COHORT STUDY Hyatt Assafiri (Melbourne, Australia) | 08:30 - 08:30 |
| P387 | A UK RETROSPECTIVE ANALYSIS OF THE USE OF BELUMOSUDIL IN THE MANAGEMENT OF CHRONIC GRAFT VERSUS HOST DISEASE Siobhan Smith (Cardiff, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P388 | EVALUATING THE IMPACT OF A DEDICATED OUTPATIENT PHARMACY CLINIC ON MEDICATION SAFETY AND TRANSITIONS OF CARE FOR PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION Karim Ibrahim (Darlinghurst, Australia) | 08:30 - 08:30 |
| P390 | POSACONAZOLE IN PAEDIATRICS: ARE WE HITTING THE MARK | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | OR MISSING THE TARGET? | |
| | Heather Weerdenburg (Melbourne, Australia) | |
| P391 | AN EVALUATION OF COMPLIANCE WITH A VACCINATION PROGRAMME FOR PATIENTS WHO HAVE UNDERGONE ALLOGENEIC STEM CELL TRANSPLANTATION OR CAR T-CELL THERAPY | 08:30 - 08:30 |
| | Vaishali Dulobdas (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | |
| P392 | A PROSPECTIVE STUDY EVALUATING THE ROLE OF NOVEL PLATELET-DERIVED MICRORNAS IN MEGAKARYOCYTE DIFFERENTIATION | 08:30 - 08:30 |
| | Aashal Bhavesh Shah (Surat, India) | |
| P393 | IMPACT OF LOW DOSE ANTI-T-LYMPHOCYTE GLOBULIN ON CLINICAL OUTCOMES IN THE ERA OF POST-TRANSPLANT CYCLOPHOSPHAMIDE | 08:30 - 08:30 |
| | Oktay Bilgir (Izmir, Turkey) | |
| P394 | ANTICIPATION OF PHARMACOTHERAPEUTIC PROBLEMS PRIOR TO ALLO HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH CO-MORBIDITIES: A TWO YEARS EXPERIENCE REVIEW | 08:30 - 08:30 |
| | Léonardo Magro (Lille, France) | |
| P395 | TACROLIMUS C/D RATIO-BASED METABOLIZER PHENOTYPE: A POTENTIAL PREDICTOR OF ACUTE KIDNEY INJURY IN HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS | 08:30 - 08:30 |
| | Luiz Carlos da Costa-Junior (São Paulo, Brazil) | |
| P396 | CLINICAL, LABORATORY, AND PHARMACOLOGICAL FACTORS INFLUENCING CALCINEURIN INHIBITOR PLASMA LEVELS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS | 08:30 - 08:30 |
| | Luiz Carlos da Costa-Junior (São Paulo, Brazil) | |
| P397 | IMPACT OF ANTIBIOTIC PROPHYLAXIS ON GRAM-NEGATIVE INFECTION RATES IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS | 08:30 - 08:30 |
| | Estela Moreno Martinez (Barcelona, Spain) | |
| P398 | VANCOMYCIN PROPHYLAXIS IN PAEDIATRIC UMBILICAL CORD BLOOD TRANSPLANTS: A SINGLE CENTRE SERVICE EVALUATION | 08:30 - 08:30 |
| | Rebecca O'Neill (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| P399 | RETROSPECTIVE REVIEW OF LETERMОВIR FOR CYTOMEGALOVIRUS PROPHYLAXIS IN PAEDIATRIC ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS | 08:30 - 08:30 |
| | Yi Xuan Chua (Singapore, Singapore) | |
| P400 | SUBTHERAPEUTIC CYCLOSPORINE CONCENTRATIONS DESPITE STANDARD DOSING IN HSCT PRACTICE | 08:30 - 08:30 |
| | Tsung Yu Pai (Taipei, Taiwan (Province of China)) | |
| P401 | RISK VS BENEFIT: CIPROFLOXACIN PROPHYLAXIS IN HIGH DOSE MELPHALAN AUTOLOGOUS SCT - A SINGLE CENTRE EXPERIENCE | 08:30 - 08:30 |
| | Elizabeth Davies (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| P402 | AWARENESS OF EXTRAVASATION MANAGEMENT FOR CYTOSTATIC AND NON-CYTOSTATIC DRUGS AMONG HEMATOLOGISTS IN THE CZECH REPUBLIC | 08:30 - 08:30 |
| | Jana Vedrová (Praha, Czechia) | |
| P403 | RISK ASSESSMENT OF HERPESVIRUS REACTIVATION IN CHILDREN UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH PROPHYLACTIC USE OF LETEMOVIR: | 08:30 - 08:30 |

A RETROSPECTIVE SINGLE CENTER OBSERVATIONAL STUDY

Shaoyan Hu (Suzhou, China)

ePoster

08:30 - 18:00

R20

Psychological Issues

- P375 **PSYCHOSOCIAL WELL-BEING IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) AND THEIR CAREGIVERS: A PROSPECTIVE STUDY** 08:30 - 08:30
Mirko Farina (Brescia, Italy)
- P376 **LEVEL 1 PSYCHOLOGICAL SKILLS TRAINING FOR HSCT STAFF** 08:30 - 08:30
Anna Lagerdahl (Swindon, United Kingdom of Great Britain and Northern Ireland (the))
- P379 **COMBINING VIRTUAL NATURE EXPOSURE AND HYPNOSIS TO IMPROVE QUALITY OF LIFE IN PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION: FEASIBILITY AND EFFICACY OUTCOMES** 08:30 - 08:30
Valentyn Fournier (Montréal, Canada)
- P380 **PIONEERING PSYCHOSOCIAL SUPPORT FOR BONE MARROW TRANSPLANT PATIENTS: A DESCRIPTIVE CROSS-SECTIONAL SURVEY STUDY AT ABU DHABI BONE MARROW TRANSPLANT PROGRAM, CENTER OF EXCELLENCE** 08:30 - 08:30
Rahma Almheiri (Abu Dhabi, United Arab Emirates (the))
- P381 **CHRONIC FATIGUE SYNDROME AND PSYCHOSOCIAL FACTORS IN ADULT PATIENTS BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION** 08:30 - 08:30
Ivan Moiseev (Saint Petersburg, Russian Federation (the))
- P382 **CELL THERAPIES AND PSYCHOLOGICAL WELLBEING: ASSESSING IMPACTS AND IMPROVING SUPPORT IN THE UK** 08:30 - 08:30
Nele Gewert (London, United Kingdom of Great Britain and Northern Ireland (the))
- P383 **PSYCHOLOGICAL RISKS AND SUPPORT NEEDS IN HSCT: PILOT STUDY FINDINGS** 08:30 - 08:30
Volha Mishkova (Borovlyany, Belarus)
- P384 **ASSESSING PSYCHOSOCIAL NEEDS OF RELATED STEM CELL DONORS: STAFF PERSPECTIVES FROM A UK REGIONAL STEM CELL CENTRE** 08:30 - 08:30
Jonathan Harrold (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))

ePoster

08:30 - 18:00

R20

Patient Advocacy: Patients' Reported Outcome and Expectations

- P365 **VARIANCES IN PATIENT EXPERIENCES WITH SHARED DECISION-MAKING BY TREATMENT IN PATIENTS WITH LBCL: ANALYSIS OF LYMPHOMA COALITION'S 2024 GLOBAL PATIENT SURVEY ON LYMPHOMAS AND CLL** 08:30 - 08:30
Lorna Warwick (Etobicoke, Canada)
- P366 **EXPLORING DEATH, GRIEF AND BEREAVEMENT AT ANTHONY NOLAN: THE IMPORTANCE OF STRUCTURED INVOLVEMENT TO IMPROVE SUPPORT FOR BEREAVED LOVED ONES** 08:30 - 08:30
Liam Rooney (London, United Kingdom of Great Britain and Northern Ireland (the))
- P368 **THE NEW EU REGULATION ON SOHO: STRENGTHENING THE PROTECTION OF DONORS, RECIPIENTS AND OFFSPRING** 08:30 - 08:30
Aurélie Mahalatchimy (Aix-en-Provence, France)

| | | |
|-------------------------------------|---|---------------|
| P369 | DESIGNING LIFE AFTER CAR-T: EXPLORING PATIENT UNCERTAINTY AND EDUCATION NEEDS IN POST-CAR-T THERAPY LIFE Ahmed El-Naas (Doha, Qatar) | 08:30 - 08:30 |
| P370 | CAREGIVERS' PROXY ASSESSMENTS OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES Yajing Xu (Changsha, China) | 08:30 - 08:30 |
| P371 | QUALITY OF LIFE TRAJECTORIES IN THE YEAR FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT: A MIXED-METHODS STUDY Christina Yiallouridou (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P372 | SUPPORTING PATIENTS WITH LIMITED OR NO ENGLISH TO PARTICIPATE IN RESEARCH: A NATIONAL SURVEY OF LANGUAGE AND TRANSLATION SUPPORT IN UK ALLOGENEIC TRANSPLANT CENTRES Tomos Lloyd-Roberts (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P373 | SCALING SOCIOECONOMIC AND QUALITY OF LIFE DATA COLLECTION AMONG HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS IN THE UK: SEQOL STUDY PROGRESS AND SAMPLE SIZE FORECAST Christina Yiallouridou (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P374 | CLINICAL PROFILE AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH SICKLE CELL DISEASE WHO RECEIVED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS IN THE UNITED STATES Duncan Brown (Boston, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| <i>ePoster</i> 08:30 - 18:00 | | R20 |
| Quality Management and JACIE | | |
| P341 | QM EXPERIENCE OF THE ROME TRANSPLANT NETWORK (RTN): OPTIMIZING AND HARMONIZING QUALITY, CONSISTENCY, AND DONOR-PATIENT SAFETY ACROSS A METROPOLITAN PROGRAM Gabriella Peluso Cassese (Rome, Italy) | 08:30 - 08:30 |
| P342 | IMPROVING JACIE INSPECTOR EDUCATION WEBINAR ATTENDANCE THROUGH STRUCTURED PERFORMANCE IMPROVEMENT Stuart Kennedy (Oxford, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P343 | THROUGH THE EYES OF A QUALITY MANAGER: MANAGING THE REGULATORY AND INSPECTION BURDEN OF MULTIPLE INSPECTIONS IN A STEM CELL TRANSPLANT CENTER Halima Begum (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P344 | ATMP MANUFACTURING INSIDE A JACIE-ACCREDITED FACILITY: MISSION IMPOSSIBLE OR THE NEW STANDARD? Peter Sahlström (Stockholm, Sweden) | 08:30 - 08:30 |
| P345 | JOINT INSPECTIONS FOR INSTITUTIONAL AND JACIE CERTIFICATIONS: THE ITALIAN EXPERIENCE Benedetta Mazzanti (Rome, Italy) | 08:30 - 08:30 |
| P346 | A PATIENT-CENTERED, END-TO-END DIGITAL PLATFORM FOR HSCT AND CAR T-CELL THERAPY: A PROCESS-ENGINEERING APPROACH Lisandra Priscilla Hernández Morales (Madrid, Spain) | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| P347 | SMART, SIMPLE, STREAMLINED: USING MS FORMS TO IMPROVE COMPETENCY MONITORING IN A BUSY BMT UNIT Samah Ali (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P348 | IMPLEMENTING JACIE QUALITY STANDARDS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE MANDATORY AUDIT OF EARLY OUTCOMES Donya Qattan (Riyadh, Saudi Arabia) | 08:30 - 08:30 |
| P349 | IMPLEMENTING A MULTI-LEVEL DASHBOARD TO IMPROVE QUALITY, TRACEABILITY AND COMPLIANCE IN CELLULAR THERAPY PROCESSES: A BLOOD BANK'S EXPERIENCE Valentino Granero (Turin, Italy) | 08:30 - 08:30 |
| P350 | JACIE QUALITY COORDINATION IN A ADULT/PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELL THERAPY PROGRAM Iván López-Torija (Barcelona, Spain) | 08:30 - 08:30 |
| P351 | DEVELOPING EXCELLENCE: HOW A STRATEGIC QUALITY FRAMEWORK LAUNCHED A CUTTING-EDGE CELL COLLECTION CENTRE Hirasine Sengomona (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P352 | VALIDATION OF EXTRACORPOREAL PHOTOPHERESIS USING THE THERAKOS™ CELLEX™ PHOTOPHERESIS SYSTEM: A MULTICENTER EUROPEAN PROJECT Federica Zunino (Staines upon Thames, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P353 | SUSTAINING QUALITY IN A COMBINED JACIE-ACCREDITED CENTRE: TWO DECADES OF CONTINUOUS IMPROVEMENT INCLUDING IEC ACCREDITATION Katerina Steinerova (Pilsen, Czechia) | 08:30 - 08:30 |
| P354 | DISPOSAL OF HEMATOPOIETIC STEM CELLS IN A PEDIATRIC TRANSPLANT UNIT OVER 10 YEARS IN ARGENTINA: A QUALITY MANAGEMENT OPPORTUNITY FOR PROCESS OPTIMIZATION Daniela Iglesias (La Plata, Argentina) | 08:30 - 08:30 |
| P355 | THE REGULATION OF CLINICAL TRIALS WITH HEMATOPOIETIC STEM CELL PREPARATIONS: CHALLENGES AND PERSPECTIVES IN THE CONTEXT OF REGULATION (EU) NO. 536/2014 Susanne Ellinger (Regensburg, Germany) | 08:30 - 08:30 |
| P357 | WHO IS CURRENTLY OCCUPYING THE BMT QUALITY MANGER CHAIR, MULTI-CENTER DESCRIPTIVE USING LINKEDIN® WEBSITE Dina El Mouzain (Abu Dhabi, United Arab Emirates (the)) | 08:30 - 08:30 |
| P358 | BUILDING A COST-EFFICIENT, JACIE-ALIGNED GMP FACILITY FOR CAR-T MANUFACTURING WITH SCALABLE EXPANSION TO CELL AND GENE THERAPIES IN AN LMIC SETTING: EXPERIENCE FROM CARTOGENE THERAPEUTICS Anupam Chhabra (Gurgaon, India) | 08:30 - 08:30 |
| P359 | MICROBIAL CONTAMINATION OF CELLULAR THERAPY PRODUCTS: A DECADE OF SUCCESS OF SINGLE CENTER EXPERIENCE IN THE MENA REGION Manal Yaghmour (Doha, Qatar) | 08:30 - 08:30 |
| P360 | REGULATORY MODELS FOR CAR-T CENTER QUALIFICATION IN ITALY AND SWITZERLAND: IMPLICATIONS FOR CLINICAL RESPONSIBILITIES AND QUALITY GOVERNANCE Vincenzo Iaconianni (Sesto San Giovanni, Italy) | 08:30 - 08:30 |
| P361 | 30 YEARS OF THE NHS CORD BANK - MAINTAINING A STABLE | 08:30 - 08:30 |

INVENTORY

| | | |
|------|--|---------------|
| P362 | DISPOSAL OF AUTOLOGOUS HEMATOPOIETIC STEM CELL ALIQUOTS: A REGULATORY AND ETHICAL ANALYSIS FROM THE SAN GIOVANNI ADDOLORATA PROCESSING FACILITY Gabriella Peluso Cassese (Rome, Italy) | 08:30 - 08:30 |
| P363 | GLOBALIZING PSIRF Oseyae Eboiyehi (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P364 | GAPP-PRO JOINT ACTION: LATEST UPDATE Ruth Barrio (Barcelona, Spain) | 08:30 - 08:30 |

ePoster

08:30 - 18:00

R20

Conditioning Regimens and lymphodepletion

| | | |
|------|---|---------------|
| B152 | IMPACT OF ONE VERSUS TWO INDUCTIONS TO ATTAIN FIRST COMPLETE REMISSION IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE: FROM THE ALWP/EBMT Arnon Nagler (Ramat Gan, Israel) | 08:30 - 08:30 |
| B153 | POST-TRANSPLANT CYCLOPHOSPHAMIDE COMPARED WITH OTHER GVHD PROPHYLAXIS STRATEGIES IN REDUCED-INTENSITY ALLOGENEIC TRANSPLANTATION FOR AML AND MDS: AN SFGM-TC REGISTRY STUDY Tereza Coman (Villejuif, France) | 08:30 - 08:30 |
| B154 | ARCHIVE CONDITIONING (ALKYLATING AGENTS, CYTARABINE, CLADRIBINE, HYPOMETHYLATING AGENTS, AND VENETOCLAX) FOR UPFRONT ALLOGENEIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED OR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA Lukas Kevličius (Vilnius, Lithuania) | 08:30 - 08:30 |
| B155 | REJECTION PROPHYLAXIS IN AUTOLOGOUS GENE THERAPY PROTOCOLS: CHOOSING AN ALEMTUZUMAB DOSE Nathan Jeffreys (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B156 | VENETOCLAX-ENHANCED REDUCED-INTENSITY CONDITIONING IN ELDERLY PATIENTS WITH HIGH-RISK MYELOID MALIGNANCIES UNDERGOING ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION: A PHASE II STUDY Jie Gao (Shanghai, China) | 08:30 - 08:30 |
| B160 | VENETOCLAX-AUGMENTED CONDITIONING REGIMENS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOID NEOPLASMS: A SCOPING REVIEW AND EVIDENCE LANDSCAPE Afraa Fadul (Doha, Qatar) | 08:30 - 08:30 |
| B161 | FLUDARABINE AUC EXPOSURE IS NOT PREDICTIVE OF MORTALITY IN THE CONTEXT OF FLUDARABINE BUSULFAN AND ATG CONDITIONED TRANSPLANTATION Alexander Glover (Nottingham, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B162 | SUPERIORITY OF TBI-BASED COMPARED TO MELPHALAN-BASED CONDITIONING REGIMEN IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: COMPARISON BETWEEN DIFFERENT APPROACHES OF TWO MAJOR PEDIATRIC TRANSPLANTATION UNITS Tim Flaadt (Tübingen, Germany) | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| B163 | EFFICACY AND SAFETY OF MELPHALAN/TBI-BASED CONDITIONING REGIMENS (MCAC/TCAC) FOR AUTOLOGOUS HSCT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTICENTER, PROSPECTIVE COHORT STUDY Jieya Luo (Tianjin, China) | 08:30 - 08:30 |
| B164 | COMBINATION OF 7.5 MG/KG ATG WITH BASILIXIMAB AS AN EFFECTIVE REGIMEN FOR PATIENTS WITH SEVERE INFUSIONAL SIDE EFFECTS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION Tingting Han (Beijing, China) | 08:30 - 08:30 |
| B165 | FROM PBPB TO BEDSIDE: VIRTUAL TWIN-GUIDED FLUDARABINE DOSING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Mourad Mseddi (Geneva, Switzerland) | 08:30 - 08:30 |
| B166 | A SIMULATED PK/PD INVESTIGATION OF RATG, FLUDARABINE, AND THIOTEPA IN HAPLO-IDENTICAL TRANSPLANT FOR SICKLE CELL DISEASE; A VANDERBILT GLOBAL HAPLO-IDENTICAL BMT LEARNING COLLABORATIVE (VGC²) ANALYSIS Jaap-Jan Boelens (New York, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| B167 | ASSOCIATION BETWEEN BUSULFAN EXPOSURE AND OVERALL SURVIVAL AND TOXICITY IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT WITH MYELOABLATIVE CONDITIONING - A PROSPECTIVE, MULTICENTRE ANALYSIS Annabelle Robinson (Sydney, Australia) | 08:30 - 08:30 |
| B168 | LONG-TERM FOLLOW-UP WITH TREOSULFAN BASED CONDITIONING REGIMEN IN HEMATOLOGICAL MALIGNANCIES: A SINGLE CENTER EXPERIENCE Anna Paola Iori (Rome, Italy) | 08:30 - 08:30 |
| B169 | HAPLOIDENTICAL HCT IN ADULTS WITH A NON-TBI CONDITIONING REGIMEN: A 10-YEAR SINGLE-CENTER COHORT Fernando Barroso Duarte (Fortaleza, Brazil) | 08:30 - 08:30 |
| B171 | CLADRIBINE WITH TOTAL BODY IRRADIATION AS A STRATEGY TO OPTIMIZE CONDITIONING REGIMEN IN AML AND MDS: A PROSPECTIVE STUDY OF THE POLISH ADULT LEUKEMIA GROUP Malgorzata Sobczyk-Kruszelnicka (Gliwice, Poland) | 08:30 - 08:30 |
| B172 | IMPACT OF TMLI VERSUS TBI CONDITIONING ON TOXICITY, OUTCOMES, AND RELAPSE IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA María Panizo-Inogés (Pamplona, Spain) | 08:30 - 08:30 |
| B173 | OUTCOMES OF ALLOGENIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE: A 5 YEAR SINGLE CENTRE EXPERIENCE Yashashree Gupta (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| B174 | FLUDARABINE PLUS TREOSULFAN CONDITIONING FOR OLDER AND COMORBID PATIENTS BEFORE ALLOGENEIC HSCT - A RETROSPECTIVE ANALYSIS IN A REAL-WORLD COHORT Hanna A. Knaus (Vienna, Austria) | 08:30 - 08:30 |
| B175 | A FAVORABLE EFFICACY-SAFETY PROFILE: TREOSULFAN-BASED CONDITIONING IMPROVES OVERALL SURVIVAL AND LOWERS RELAPSE RISK COMPARED TO BUSULFAN IN RIC ALLO-HSCT Vera Radici (Brescia, Italy) | 08:30 - 08:30 |
| B176 | COMPARISON OF CARMUSTINE-, LOMUSTINE-, AND NITROSOUREA-FREE CONDITIONING REGIMENS FOR | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN LYMPHOMA: RESULTS FROM THE BRAZILIAN REGISTRY Fernando Barroso Duarte (Fortaleza, Brazil) | |
| B178 | FLUDARABINE AND TREOSULFAN MYELOABLATIVE CONDITIONING LEADS TO HIGH OS AND LOW NRM Chiara Bernardi (Geneva, Switzerland) | 08:30 - 08:30 |
| B179 | CLINICAL STUDY OF THE TBFPTCY REGIMEN AS A CONDITIONING REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN MYELOID MALIGNANCIES Ping Zhang (Ningbo, China) | 08:30 - 08:30 |
| B180 | COMPARISON OF TOTAL NODAL IRRADIATION (6.0-7.5 GY) VS LOW-DOSE TOTAL BODY IRRADIATION (2 GY) IN EX VIVO TCRB-DEPLETED HAPLOIDENTICAL TRANSPLANTATION IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES Koh Liang Piu (Singapore, Singapore) | 08:30 - 08:30 |
| B181 | COMPARISON OF TREOSULFAN-THIOTEPA-FLUDARABINE VS FLUDARABINE-TREOSULFAN CONDITIONING FOR ALLOGENEIC HCT IN AML AND MDS: A SINGLE-CENTER RETROSPECTIVE EXPERIENCE Fabio Serpenti (Milan, Italy) | 08:30 - 08:30 |
| B182 | IMLIFIDASE EFFICIENTLY ABROGATES THE EFFECT OF ATLG AND THYMOGLOBULIN ON T- AND NK-CELL VIABILITY AND FUNCTION Claus-Philipp Maier (Tuebingen, Germany) | 08:30 - 08:30 |
| B184 | SALVAGE ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AML: CLADRIBINE-BASED INTENSIVE CONDITIONING VERSUS STANDARD MYELOABLATIVE REGIMENS Wenyi Wang (Hangzhou, China) | 08:30 - 08:30 |
| B185 | TRANSFUSION BURDEN UNDER ATG AND PTCY IN ACUTE LEUKEMIA PATIENTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION Jette Luedersen (Hamburg, Germany) | 08:30 - 08:30 |
| P195 | TOTAL BODY IRRADIATION, BUSULFAN, FLUDARABINE WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION Jae Won Yoo (Seoul, Korea (the Republic of)) | 08:30 - 08:30 |
| P196 | 'IMPROVING TRANSPLANT PLATFORMS': REAL-LIFE EXPERIENCE OF TREOSULFAN AS CONDITIONING FOR ALLO-HSCT IN AML AND MDS María del Mar Perera Álvarez (Las Palmas de Gran Canaria, Spain) | 08:30 - 08:30 |
| P197 | THIOTEPA, CYCLOPHOSPHAMIDE AND FLUDARABINE CONDITIONING REGIMEN FOR ADULT PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: IMPACT OF DONOR MISMATCH ON OUTCOME Massimo Moratti (Udine, Italy) | 08:30 - 08:30 |
| P198 | ENGRAFTMENT KINETICS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPACT OF CONDITIONING INTENSITY AND EARLY POST-TRANSPLANT EVENTS Manuela Estrada-Schweineberg (Bogotá, Colombia) | 08:30 - 08:30 |
| P199 | MYELOABLATIVE CONDITIONING FOR MYELOID MALIGNANCIES WITH THIOTEPA, BUSULFAN, FLUDARABINE WITH ANTI-THYMOCYTE GLOBULIN OR POST TRANSPLANT | 08:30 - 08:30 |

| | | |
|------------------------|--|---------------|
| | CYCLOPHOSPHAMIDE (TBF-ATG OR TBF-PTCY) - A SINGLE CENTRE EXPERIENCE | |
| | Alexander Bashford (Nottingham, United Kingdom of Great Britain and Northern Ireland (the)) | |
| P200 | FLUDARABINE AUGMENTED REDUCED INTENSITY CONDITIONING IMPROVES ENGRAFTMENT AND OUTCOMES IN ADVANCE CUTANEOUS T-CELL LYMPHOMA | 08:30 - 08:30 |
| | Yashashree Gupta (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the)) | |
| P202 | TREOSULFAN-BASED CONDITIONING REGIMEN IS ASSOCIATED WITH AN INCREASED RISK OF EARLY TOXICITY AND RELAPSE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | 08:30 - 08:30 |
| | Nour Ben Abdeljelil (Tunis, Tunisia) | |
| P203 | SUCCESSFUL ABTCR-DEPLETED HAPLOIDENTICAL HSCT AFTER MINIMAL TOXICITY CONDITIONING IN AN HEAVILY PRETREATED DOWN'S SYNDROME PATIENT WITH R/R BCP-ALL | 08:30 - 08:30 |
| | Kateryna Venger (Aachen, Germany) | |
| P204 | OUTCOME OF TREOSULFAN-FLUDARABINE CONDITIONING REGIMENS: A SINGLE CENTER EXPERIENCE | 08:30 - 08:30 |
| | Elsa Masedu (Monza, Italy) | |
| P205 | CONDITIONING WITH FLUDARABINE, CYTARABINE, VENETOCLAX, ETOPOSIDE FOR ALLOGENEIC STEM CELL TRANSPLANT IN PATIENTS WITH ACTIVE ACUTE MYELOID LEUKEMIA | 08:30 - 08:30 |
| | Nikhil Vasudeva (New Delhi, India) | |
| P206 | THE EFFICACY AND SAFETY OF COMBINED FLUDARABINE, BUSULFAN, AND MELPHALAN REDUCED-INTENSITY CONDITIONING (RIC) REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULTS WITH HEMATOLOGIC MALIGNANCY DISEASES | 08:30 - 08:30 |
| | Sunatcha Coratat (Chiang Mai, Thailand) | |
| <i>ePoster</i> | | |
| | 08:30 - 18:00 | R20 |
| Stem cell donor | | |
| A317 | DIFFERENTIAL IMPACT OF FIRST-FIELD AND SECOND-FIELD HLA MISMATCHES IN 9/10 VERSUS 10/10 MATCHED UNRELATED HSCT, AN ANALYSIS OF GERMAN REGISTRY DATA, DRST | 08:30 - 08:30 |
| | Aysenur Arslan (Ulm, Germany) | |
| A318 | MODELING SUFFICIENCY AND GROWTH OF THE AUSTRALIAN AND NEW ZEALAND HSC DONOR REGISTRIES TO MEET PATIENT POPULATION REQUIREMENTS IN AN ERA OF MISMATCHED TRANSPLANTATION | 08:30 - 08:30 |
| | Garth Healey (Sydney, Australia) | |
| A319 | DEMOGRAPHICS MATTER: VARIATION IN DONOR AVAILABILITY DURING CONFIRMATORY TYPING | 08:30 - 08:30 |
| | Ute Verena Solloch (Tübingen, Germany) | |
| A320 | PAROUS FEMALE DONOR REDUCES RELAPSE RISK IN HIGH-RISK AML/MDS AFTER HAPLOIDENTICAL PBSCT WITH ATG/PTCY COMBINATION FOR GVHD PROPHYLAXIS | 08:30 - 08:30 |
| | Huiying Qiu (Shanghai, China) | |
| A321 | OLDER DONOR AGE IS NOT ASSOCIATED WITH INFERIOR SURVIVAL IN CONTEMPORARY HAPLOIDENTICAL TRANSPLANTATION | 08:30 - 08:30 |
| | Yosra Aljawai (Houston, United States Minor Outlying Islands (the)) | |

| | | |
|------|--|---------------|
| A323 | THE IMPACT OF INDIRECT ALLORECOGNITION IN TRANSPLANT OUTCOMES AFTER UNRELATED DONOR TRANSPLANTATION FOR NONMALIGNANT DISEASES Carmem Bonfim (Durham, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A324 | EVALUATION OF RECOVERY AND ADVERSE EVENTS IN 1,638 HEALTHY ANTHONY NOLAN DONORS Tania Dexter (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A325 | INTEGRATING NGS-BASED GERMLINE MUTATION DETECTION INTO DONOR EVALUATION ENHANCES MYELOID NEOPLASM RISK STRATIFICATION Eleni Gavriilaki (Thessaloniki, Greece) | 08:30 - 08:30 |
| A326 | HAPLOIDENTICAL SCT INDUCES LONG-TERM REMISSION IN PATIENTS WITH BPDCN FengRong Wang (Beijing, China) | 08:30 - 08:30 |
| A327 | PROBABLE DONOR - RECIPIENT TRANSMISSION OF HEPATITIS E VIRUS WITH A HAEMATOPOIETIC STEM CELL TRANSPLANT. WMDA RECOMMENDATIONS ON HEV ASSESSMENT IN DONORS AND RECIPIENTS Tigran Torosian (Warsaw, Poland) | 08:30 - 08:30 |
| A329 | CLINICAL PERSPECTIVES ON GERMLINE VARIANTS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: A NATIONWIDE SURVEY IN JAPAN Mizuki Watanabe (Tokyo, Japan) | 08:30 - 08:30 |
| A330 | AGE-DEPENDENT CHANGES IN LYMPHOCYTE COMPOSITION OF PERIPHERAL BLOOD STEM CELL GRAFTS FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION M Queralt Salas (Barcelona, Spain) | 08:30 - 08:30 |
| A331 | CLINICAL VALUE OF ROUTINE BONE MARROW EXAMINATION IN RELATED STEM CELL DONORS Anders Lillemoen Drivenes (Oslo, Norway) | 08:30 - 08:30 |
| A332 | NOT ALL LOW PLATELET COUNTS ARE SPURIOUS: DUTY OF CARE IN CORD BLOOD BANKING Rachel Pawson (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A333 | FEMALE DONORS IMPROVE SURVIVAL OUTCOMES IN HIGH-RISK MALE RECIPIENTS UNDERGOING BONE MARROW TRANSPLANTATION Junko Takeshita (Saitama, Japan) | 08:30 - 08:30 |
| A335 | TRANSIENT ACUTE MYOCARDIAL INJURY DURING G-CSF MOBILIZATION IN HEALTHY PERIPHERAL STEM CELL DONORS: A CASE SERIES Anna Colpo (Padova, Italy) | 08:30 - 08:30 |
| A336 | EVALUATION OF RELATED HEMATOPOIETIC STEM CELL DONORS IN THE CONTEXT OF FACT-JACIE STANDARDS IMPLEMENTATION Leandro Castellanos (Córdoba, Argentina) | 08:30 - 08:30 |
| A337 | SERIOUS ADVERSE REACTIONS AND EVENTS IN RELATED HAEMATOPOIETIC CELLS DONORS - WMDA COMMUNICATION AND RECOMMENDATIONS ON RELATED DONORS FOLLOW UP AND REPORTING OF SAE Grzegorz Hensler (Leiden, Netherlands (the)) | 08:30 - 08:30 |
| A338 | EVOLUTION OF UNRELATED DONOR ACTIVITY IN CHILE: RETROSPECTIVE ANALYSIS OF DKMS DONOR SEARCHES FROM 2018 - 2024 Lorena Cerda (Tuebingen, Germany) | 08:30 - 08:30 |

| | | |
|---|---|---------------|
| A339 | EXPANDING DONOR ACCESS IN DEVELOPING COUNTRIES: EXPERIENCE WITH PEDIATRIC HAPLOIDENTICAL STEM CELL TRANSPLANTATION AT A PRIVATE CENTER IN JORDAN Ayad Ahmed Hussein (Amman, Jordan) | 08:30 - 08:30 |
| A340 | IDENTIFYING REASONS FOR LOCAL VS INTERNATIONAL UNRELATED DONOR SELECTION IN HEMATOPOIETIC CELL TRANSPLANT IN CANADA Matthew Seftel (Vancouver, Canada) | 08:30 - 08:30 |
| A341 | AN INTERSTING CASE OF DONOR DERIVED LEUKAEMIA POST CORD BLOOD TRANSPLANT Ememobong Eno Uoro (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P109 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION USING DECEASED DONOR DERIVED CRYOPRESERVED BONE MARROW: A POTENTIAL ALTERNATIVE GRAFT SOURCE FOR PATIENTS WITH UNMET NEED Sagar Munjal (San Fransisco, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| P110 | FIRST REPORT OF SUCCESSFUL, LIFESAVING AND TIMELY GRAFT RESCUE USING AN OFF-THE-SHELF CRYOPRESERVED, CADAVERIC MARROW IN TRANSPLANT FOLLOWING UNAVAILABILITY OF A LIVING MATCHED UNRELATED DONOR Sagar Munjal (San Fransisco, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| P111 | OUTCOMES AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: A RETROSPECTIVE SINGLE-CENTER COHORT STUDY Jean Gabriel Caurette (Berlin, Germany) | 08:30 - 08:30 |
| P112 | MANAGEMENT OF GROUP B STREPTOCOCCUS IDENTIFIED DURING STERILITY TESTING OF CORD BLOOD UNITS Ulrike Paulus (Bristol/Filton, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| <i>ePoster</i> | | |
| 08:30 - 18:00 | | R20 |
| Stem cell source, mobilization, collection and engineering | | |
| A286 | HEMATOPOIETIC STEM CELL DONATION IN FAMILY DONORS UNDER 18 YEARS OF AGE. EXPERIENCE OF THE ITALIAN SECOND OPINION COMMITTEE SIMTI / SIDEM FOR DONOR PROTECTION Aurora Vassanelli (Verona, Italy) | 08:30 - 08:30 |
| A287 | LONG-TERM CRYOPRESERVATION CHANGES THE IMMUNE EFFECTOR CELL COMPOSITION OF PERIPHERAL BLOOD STEM CELL GRAFTS Elke Ruecker-Braun (Dresden, Germany) | 08:30 - 08:30 |
| A288 | MYELOID EXPANSION VELOCITY: A NOVEL KINETIC BIOMARKER FOR PREDICTING HEMATOPOIETIC STEM CELL MOBILIZATION FAILURE IN ACUTE LEUKEMIA Erlic Jiang (Tianjin, China) | 08:30 - 08:30 |
| A290 | TRANSFORMING TIMELY ACCESS TO STEM CELL COLLECTIONS: EARLY IMPACT OF ANTHONY NOLAN'S FIRST DEDICATED CELL COLLECTION CENTRE Dawn Hart (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A291 | TYPE OF INDUCTION CHEMOTHERAPY INFLUENCES STEM CELL MOBILIZATION CAPACITY IN MULTIPLE MYELOMA PATIENTS - COMPARISON OF VCD VS DARA-VTD IN A LARGE MULTICENTER COHORT | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | Christa Unger (Rostock, Germany) | |
| A292 | LESS INFLAMMATION, SAME SURVIVAL: PLERIXAFOR MOBILIZATION REDUCES ENGRAFTMENT CRS IN PAEDIATRIC HSCT COMPARED TO GCSF ALONE Revathi Raj (Chennai, India) | 08:30 - 08:30 |
| A293 | THE SIBCORD SURVEY: ASSESSING CURRENT PRACTICES IN SIBLING CORD BLOOD USE FOR PEDIATRIC HCT ACROSS EBMT CENTERS Benedetta Elena Di Majo (Monza, Italy) | 08:30 - 08:30 |
| A294 | WORLD MARROW DONOR ASSOCIATION WORLDWIDE SURVEY ON PLERIXAFOR USE IN HEALTHY RELATED AND UNRELATED DONORS Tania Dexter (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A295 | CENTER- AND DEVICE-RELATED VARIABILITY IN TCRAB/CD19 DEPLETION OF HEMATOPOIETIC PROGENITOR CELL APHERESIS PRODUCTS Miguel Blanquer (Murcia, Spain) | 08:30 - 08:30 |
| A296 | SAFE EMERGENCY TRANSFER OF CORD BLOOD UNITS AFTER CRYOGENIC TANK MALFUNCTION: A RARE OPERATIONAL EVENT Jesus Fernandez-Sojo (Barcelona, Spain) | 08:30 - 08:30 |
| A297 | FROM ACCESS TO YIELD: PROCEDURAL INSIGHTS INTO PAEDIATRIC STEM CELL APHERESIS Andrea Espasa (Barcelona, Spain) | 08:30 - 08:30 |
| A298 | UNIVERSAL GENERIC PLERIXAFOR FOR STEM CELL MOBILIZATION IN MULTIPLE MYELOMA: CLINICAL OUTCOMES COMPARISON WITH RISK-ADAPTED STRATEGY AND INTERNATIONAL BENCHMARKS Sreeraj Vasudevan (Thrissur, India) | 08:30 - 08:30 |
| A299 | IMPACT OF VENOUS ACCESS IN THE APHERESIS PERFORMANCE Sara Lopes (Porto, Portugal) | 08:30 - 08:30 |
| A301 | OUTCOMES AND PREDICTORS OF HEMATOPOIETIC STEM CELL MOBILIZATION STRATEGIES IN AUTOLOGOUS TRANSPLANTATION: A REAL-WORLD ANALYSIS Manuela Estrada-Schweineberg (Bogotá, Colombia) | 08:30 - 08:30 |
| A302 | POOR MOBILIZATION IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: CLINICAL CHARACTERIZATION, RESCUE STRATEGIES, AND THE LIMITED UTILITY OF CONVENTIONAL PREDICTORS Erlic Jiang (Tianjin, China) | 08:30 - 08:30 |
| A303 | MANUAL RED CELL DEPLETION IN PAEDIATRIC BONE MARROW TRANSPLANTATION: APPLICATIONS IN ALLOGENEIC AND AUTOLOGOUS SETTINGS Ivana Ferrero (Turin, Italy) | 08:30 - 08:30 |
| A304 | IMPACT OF PRIOR DARATUMUMAB USE ON CD34+ CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION: SINGLE-CENTER EXPERIENCE Carmen Gil Barroso (Huelva, Spain) | 08:30 - 08:30 |
| A306 | ALLOGENEIC BONE MARROW HARVEST IN ADULT AND PEDIATRIC DONORS: A SINGLE-CENTRE EXPERIENCE Jorge Verdejo de Antonio (Madrid, Spain) | 08:30 - 08:30 |
| A307 | THE ROLE OF GRAFT CD3 AND TNC DOSES IN TRANSPLANT OUTCOMES: DOES IT STILL MATTER IN THE PTCY ERA? | 08:30 - 08:30 |

| | | |
|------|--|---------------|
| | Emine Merve Savaş (Ankara, Turkey) | |
| A308 | COMPARATIVE EVALUATION OF ADAMII IMAGE CYTOMETRY WITH TWO FLOW CYTOMETRY PLATFORMS FOR CD34+ HEMATOPOIETIC STEM CELL ENUMERATION Mirjana Milinković (Belgrade, Serbia) | 08:30 - 08:30 |
| A309 | DONOR SELECTION FOR HLA HAPLOTYPE-HOMOZYGOUS PATIENTS UNDERGOING CORD BLOOD TRANSPLANTATION Noriyoshi Yoshinaga (Kyoto, Japan) | 08:30 - 08:30 |
| A310 | COMPARATIVE CHARACTERISTICS OF CD3 DEPLETION AND ALPHA/BETA T CELL DEPLETION AS A GRAFT MANUFACTURING PLATFORM Svetlana Glushkova (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| A311 | ANALYSIS OF CLINICAL AND PROCEDURAL FACTORS ASSOCIATED WITH SUCCESSFUL COLLECTION OF CD34+ HEMATOPOIETIC PROGENITOR CELLS Carmen Gil Barroso (Huelva, Spain) | 08:30 - 08:30 |
| A312 | DIRECTED SIBLING CORD BLOOD BANKING : FOURTEEN YEAR EXPERIENCE IN NHS BLOOD AND TRANSPLANT (NHSBT) Rachel Pawson (London, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| A313 | COMPARATIVE ANALYSIS OF MOBILIZATION REGIMENS AND THEIR IMPACT ON STEM CELL YIELD AND ENGRAFTMENT KINETICS IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY Bushra Ahsan (Lahore, Pakistan) | 08:30 - 08:30 |
| A314 | LEUKAPHERESIS FOR PROGENITOR CELL COLLECTIONS IN LOW WEIGHT CHILDREN: REPORT FROM A SINGLE PEDIATRIC CENTER Jorge Verdejo de Antonio (Madrid, Spain) | 08:30 - 08:30 |
| A315 | NO SIGNIFICANT IMPACT OF GRAFT CD34+/CD3+ RATIO ON TRANSPLANT OUTCOMES AFTER POST-TRANSPLANTATION CYCLOPHOSPHAMIDE-BASED HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION Nadia Bambace (Miami, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A316 | IMPACT OF CD34+ CELL DOSE AND GROWTH FACTOR SUPPORT ON EARLY MORBIDITY AND NON-RELAPSE MORTALITY AFTER AUTOLOGOUS STEM CELL TRANSPLANT FOR LYMPHOMA Shahjehan Hanif (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 08:30 - 08:30 |
| P099 | MOTIXAFORTIDE AND G-CSF TO MOBILIZE HEMATOPOIETIC STEM CELLS FOR AUTOLOGOUS TRANSPLANTATION IN HIGH-RISK MULTIPLE MYELOMA: TWO CASES CLINICAL REPORT Min Dong (Haikou, China) | 08:30 - 08:30 |
| P100 | THE COMPARISON OF BONE MARROW PLUS PERIPHERAL BLOOD VERSUS PERIPHERAL BLOOD AS GRAFT SOURCE IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PATIENTS ≥55 YEARS Yuqian Sun (Beijing, China) | 08:30 - 08:30 |
| P101 | QUALITATIVE AND QUANTITATIVE CHARACTERISTICS OF CD34+ HEMATOPOIETIC STEM CELLS AND THEIR ASSOCIATION WITH HEMATOPOIETIC RECOVERY FOLLOWING ASCT Anamarija Vrkljan Vuk (Zagreb, Croatia) | 08:30 - 08:30 |
| P102 | INTRA-APHERESIS RECRUITMENT OF CD34+ CELLS IN G-CSF VERSUS G-CSF PLUS PLERIXAFOR MOBILIZATION: ASSOCIATION WITH COLLECTION EFFICIENCY AND FINAL HPC(A) YIELD | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | Yandy Marx Castillo-Aleman (Abu Dhabi, United Arab Emirates (the)) | |
| P103 | CANNABIS USE AND ITS RELATIONSHIP WITH MOBILIZATION EFFICIENCY TIME AFTER HSCT IN PATIENTS WITH MULTIPLE SCLEROSIS. A SINGLE CENTER EXPERIENCE IN MEXICO Guillermo J. Ruiz-Argüelles (Puebla, Mexico) | 08:30 - 08:30 |
| P104 | HEMATOLOGIC SHIFTS DURING HPC(A) AND THEIR INFLUENCE ON COLLECTION EFFICIENCY AND CD34⁺ CELL YIELD Yandy Marx Castillo-Aleman (Abu Dhabi, United Arab Emirates (the)) | 08:30 - 08:30 |
| P105 | EFFICACY AND SAFETY OF PLERIXAFOR SALVAGE HEMATOPOIETIC STEM CELL MOBILIZATION IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY OF HETEROGENEOUS RESPONSES Erlic Jiang (Tianjin, China) | 08:30 - 08:30 |
| P106 | INCREASED RISK OF POOR MOBILIZATION AFTER QUADRUPLE THERAPY IN MULTIPLE MYELOMA Alina Tănase (Bucharest, Romania) | 08:30 - 08:30 |
| P107 | SUCCESS OF HEMATOPOIETIC ENGRAFTMENT AFTER LONG-TERM CRYOPRESERVATION OF PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS Marta Fonseca Santos (Salamanca, Spain) | 08:30 - 08:30 |
| P108 | MANAGING STEM CELL MOBILISATION FAILURE: LITERATURE REVIEW AND A CASE OF HIGH-DOSE PLERIXAFOR WITH TWICE DAILY G-CSF MOBILISATION STRATEGY FOR AUTOLOGOUS STEM CELL TRANSPLANTATION Linda Lingxu Li (Auckland, New Zealand) | 08:30 - 08:30 |

ePoster

08:30 - 18:00

R20

Transplant and Cellular Therapies - Basic and Translational

| | | |
|------|--|---------------|
| A001 | PULMONARY AND SYSTEMIC IMMUNE PROFILING REVEALS JAK-STAT SIGNALLING AS A MEDIATOR OF POST-HCT LUNG COMPLICATIONS IN CHILDREN Hannah Walker (Melbourne, Australia) | 08:30 - 08:30 |
| A002 | VERSATILE ALLOGENEIC VIRUS-SPECIFIC CAR-T CELLS FOR HEMATOLOGIC MALIGNANCIES Maria Val-Casals (Barcelona, Spain) | 08:30 - 08:30 |
| A003 | IMMUNE MODULATION BY CAR-T CELLS: EXTRACELLULAR VESICLES AND SECRETOME AS DRIVERS OF MONOCYTE ACTIVATION Besjana Khahysa (Brescia, Italy) | 08:30 - 08:30 |
| A004 | LARGE SCALE MANUFACTURING OF GMP GRADE CORD BLOOD DERIVED MEGAKARYOCYTES FOR CHEMOTHERAPY INDUCED THROMBOCYTOPENIA Yosra Aljawai (Houston, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A005 | GENETIC MECHANISMS UNDERLYING CLONAL EVOLUTION DURING RELAPSE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA Jing Zheng (Hangzhou, China) | 08:30 - 08:30 |
| A006 | GRAFT PLATFORM AND VIRAL REACTIVATION IMPRINT LONG-TERM ALPHABETA AND GAMMADelta T-CELL CLONAL AND TRANSCRIPTIONAL REMODELING AFTER ALLO-HSCT Anniek Stuuut (Utrecht, Netherlands (the)) | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| A007 | ACCELERATING PATIENT CRITICAL TIME METRICS VIA RAPID POINT-OF-CARE MANUFACTURING OF LEUKAPHERESIS-FREE THIRD-GENERATION CD19 CAR-T CELLS Maria Giannaki (Thessaloniki, Greece) | 08:30 - 08:30 |
| A008 | OPTIMIZING CONDITIONING REGIMENS FOR HSCT: TMLI AS AN ORGAN-SPARING ALTERNATIVE TO TBI Alena Zverava (Minsk, Belarus) | 08:30 - 08:30 |
| A009 | SEQUENTIAL MONITORING OF EXTRACELLULAR VESICLES UNCOVERS EARLY ENDOTHELIAL PERTURBATIONS ASSOCIATED WITH ACUTE GVHD Luisa Giaccone (Torino, Italy) | 08:30 - 08:30 |
| A010 | RESTORATION OF PULMONARY ENDOTHELIAL HEALTH AND OVERALL SURVIVAL FOLLOWING ALLOGENEIC HSCT THROUGH MINICIRCLE FOXF1 MRNA NANOPARTICLE THERAPY IN JUVENILE MICE Clayton Long (Phoenix, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A011 | PHARMACOLOGICAL MODULATION OF CAR30 AND CAR19 T CELL STEMNESS AND EX VIVO EXPANSION WITH PI3K AND CBP/P300 INHIBITION Irene Pascual-Latorre (Barcelona, Spain) | 08:30 - 08:30 |
| A012 | INFLAMMATORY AND STROMAL ALTERATIONS OF THE HEMATOPOIETIC NICHE ASSOCIATED WITH POST-CAR-T CYTOPENIAS Carmen Santos Marcos (Salamanca, Spain) | 08:30 - 08:30 |
| A013 | EVALUATION OF THE STATUS OF THE HEMATOPOIETIC NICHE PRE-LYMPHODEPLETION IN THE DEVELOPMENT OF POST-CAR-T HEMATOTOXICITY Carmen Santos Marcos (Salamanca, Spain) | 08:30 - 08:30 |
| A014 | CLINICAL RELEVANCE OF NON-HLA REGIONS DIFFERENCES IN ADDITION TO HLA MOLECULAR MISMATCHES BETWEEN DONOR AND RECIPIENT IN HAPLO-HSCT USING PTCY Francisco Javier Gil-Etayo (Salamanca, Spain) | 08:30 - 08:30 |
| A015 | CD33-CAR INKT CELLS MITIGATE THE IMPACT OF ANTIGENIC HETEROGENEITY IN ACUTE MYELOID LEUKEMIA THROUGH DIRECT CYTOTOXICITY AND ACTIVATION OF CONVENTIONAL T CELLS Sisi Wang (Geneva, Switzerland) | 08:30 - 08:30 |
| A017 | HLA-KIR INTERACTIONS AS PREDICTIVE BIOMARKERS OF NK ALLOREACTIVITY IN HAPLOIDENTICAL TRANSPLANTATION WITH PTCY Francisco Javier Gil-Etayo (Salamanca, Spain) | 08:30 - 08:30 |
| A018 | OVERCOMING MHC-I LIMITATIONS AND ENHANCING ADOPTIVE T CELL FUNCTIONALITY THROUGH DUAL CAR-TCR ENGINEERING Matthias Eyrich (Würzburg, Germany) | 08:30 - 08:30 |
| A019 | EXTRACELLULAR VESICLES AS NONINVASIVE BIOMARKERS OF IMMUNE AND ENDOTHELIAL ACTIVATION IN CAR T-CELL THERAPY RECIPIENTS Luisa Giaccone (Torino, Italy) | 08:30 - 08:30 |
| A020 | SHORT-TERM POST-TRANSPLANT PROTEOMICS REVEAL TEMPORAL AND DISEASE-SPECIFIC TRAJECTORIES IN MYELOID MALIGNANCIES Anniek Stuuut (Utrecht, Netherlands (the)) | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| A021 | IMMUNE PROFILE AND PROTEOME OF PLASMA EXTRACELLULAR VESICLES REVEAL A MYELOID-DRIVEN SIGNATURE ASSOCIATED WITH THE RISK OF RELAPSE AFTER CD19.CAR-T CELL THERAPY Serena De Matteis (Bologna, Italy) | 08:30 - 08:30 |
| A022 | A MULTI-DISEASE SINGLE-CELL ATLAS OF CEREBROSPINAL FLUID IN NEUROINFLAMMATORY RELATED CONDITIONS REVEALS CONSERVED AND CONTEXT-SPECIFIC PATHOGENIC HALLMARKS Xia Li (Hangzhou, China) | 08:30 - 08:30 |
| A023 | IMPACT OF CELLULAR COMPOSITION OF LEUKAPHERESIS PRODUCT ON OVERALL NUCLEATED CELL VIABILITY AFTER CRYOPRESERVATION Vadim Spitsyn (Moscow, Russian Federation (the)) | 08:30 - 08:30 |
| A024 | THE IMPACT OF INFUSED LYMPHOCYTES SUBSETS ON CLINICAL OUTCOMES IN MUD/HAPLO HCT SETTING WITH CD34+ POSITIVE SELECTION AND COINFUSION OF A CONTROLLED NUMBER OF CD3+ Marianna Maffeis (Brescia, Italy) | 08:30 - 08:30 |
| A025 | RELEVANCE OF HLA-B LEADER DIMORPHISM AND MOLECULAR COMPATIBILITY IN HAPLOIDENTICAL HSCT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: EXPERIENCE OF A SPANISH COHORT Francisco Javier Gil-Etayo (Salamanca, Spain) | 08:30 - 08:30 |
| A026 | GENERATION OF CHIMERIC ANTIGEN RECEPTORS AGAINST MURINE CD123 ALLOWS BIOLOGIC ASSESSMENTS IN IMMUNOLOGICALLY COHERENT IN VIVO SYSTEMS Martin Sauer (Hannover, Germany) | 08:30 - 08:30 |
| A027 | THE RATIO THAT MATTERS - HOW CD4:CD8 BALANCE SHAPES CAR T-CELL EFFICACY AND SAFETY Bastian Zinkel (Erlangen, Germany) | 08:30 - 08:30 |
| A028 | TRANSFORMING CAR-T ACCESSIBILITY: A PATHWAY TO AFFORDABLE CELL THERAPY FOR B-CELL MALIGNANCIES IN INDIA AND OTHER LMICS Anupam Chhabra (Gurgaon, India) | 08:30 - 08:30 |
| A029 | COMPARATIVE IN VITRO EXPANSION OF REGULATORY T CELLS FROM CORD BLOOD AND MOBILIZED PERIPHERAL BLOOD STEM CELLS WITH RAPAMYCIN BibiShahin Shamsian (Tehran, Iran (Islamic Republic of)) | 08:30 - 08:30 |
| A030 | THE INFLUENCE OF LUSPATERCEPT ON BONE MARROW MESENCHYMAL STROMAL CELLS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND ACUTE MYELOID LEUKEMIA Nikolai Tsvetkov (St. Petersburg, Russian Federation (the)) | 08:30 - 08:30 |
| A032 | DEMONSTRATING THE FEASIBILITY OF REFREEZING PREVIOUSLY CRYOPRESERVED BONE MARROW FOLLOWING REPROCESSING Erik Woods (San Fransisco, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| A033 | EXTRACORPOREAL PHOTOPHERESIS FOR DELAYED NEUROTOXICITY SYNDROME AFTER BCMA CAR T-CELL THERAPY Philipp Gödel (Cologne, Germany) | 08:30 - 08:30 |
| A034 | SINGLE-CELL MAPPING PORTRAYS THE LINEAGE SPECTRUM OF EPSTEIN-BARR VIRUS INFECTION AND UNVEILS CLINICAL IMPLICATIONS OF CD70 IN PATIENTS WITH PTLD | 08:30 - 08:30 |

| | | |
|------|---|---------------|
| | Jinsong Yan (Dalian, China) | |
| A035 | IMMUNE RECONSTITUTION AFTER CAR-T AND ALLOGENEIC HCT: LONGITUDINAL MULTI-OMICS INSIGHTS INTO PERSISTENT IMMUNE DYSFUNCTION Marjorie Batista (São Paulo, Brazil) | 08:30 - 08:30 |
| A036 | DECIPHERING THE HDAC6-MEDIATED REGULATION OF MLLT3 IN MYELOID PROGENITOR CELL FATE: INSIGHTS INTO STEM CELL DIFFERENTIATION DYNAMICS Anil Aribandi (Hyderabad, India) | 08:30 - 08:30 |
| P001 | PATENTING CORD BLOOD CELLS: AN HISTORICAL PERSPECTIVE Antonio Bruno (Rome, Italy) | 08:30 - 08:30 |
| P002 | ALTERED PRE-TRANSPLANT GUT MICROBIOTA PROFILES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: TOWARD MICROBIOTA-INFORMED RISK STRATIFICATION Lavinia-Eugenia Lipan (Bucharest, Romania) | 08:30 - 08:30 |
| P003 | THE ROLE OF SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY AML IN NON REMISSION: INSIGHTS FROM REAL-WORLD EXPERIENCE Seungah Cha (Seoul, Korea (the Republic of)) | 08:30 - 08:30 |
| P004 | PERSONALIZED THERAPY GUIDED BY EX VIVO DRUG RESPONSE PROFILING ENABLES ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN RELAPSED/REFRACTORY ACUTE LEUKEMIA WITH IMMATURE PHENOTYPE Lucia Prezioso (Parma, Italy) | 08:30 - 08:30 |
| P005 | RETHINKING CONTAMINATION CONTROLS IN CHIMERISM TESTING: THE CASE AGAINST NTCS Thierry Viard (Brisbane, United States Minor Outlying Islands (the)) | 08:30 - 08:30 |
| P006 | TRACKING BACK INNOVATION IN DIFFERENT CLASSES OF NEWLY-DEVELOPED MEDICINAL PRODUCTS THROUGH THE LINKAGE BETWEEN NOBEL AND GALIEN PRIZES SUPPORTS A SPECIFIC STATUS FOR ADVANCED THERAPIES Christian Chabannon (Marseille, France) | 08:30 - 08:30 |
| P007 | HARVESTING CD3 POSITIVE LYMPHOCYTES IN PEDIATRIC PATIENTS FOR CAR-T CELL MANUFACTURING Volker Witt (Vienna, Austria) | 08:30 - 08:30 |

Statistics

09:00 - 12:00

R17

STATS-C1 - Basic course in Statistics 1

Jacques - Emmanuel Galimard (PARIS, France)

| | | |
|------------|---|---------------|
| STATS-C1-1 | Protocol of a study: A study from the "idea" to the analysis plan Jacques - Emmanuel Galimard (PARIS, France) | 09:00 - 09:00 |
| STATS-C1-2 | Data collection and checking Jacques - Emmanuel Galimard (PARIS, France) | 09:00 - 09:00 |
| STATS-C1-3 | Descriptive statistics Jacques - Emmanuel Galimard (PARIS, France) | 09:00 - 09:00 |
| STATS-C1-4 | Comparison of groups for continuous data Jacques - Emmanuel Galimard (PARIS, France) | 09:00 - 09:00 |
| STATS-C1-5 | Comparison of groups for qualitative data Jacques - Emmanuel Galimard (PARIS, France) | 09:00 - 09:00 |

| | | |
|------------|---|---------------|
| STATS-C1-6 | Correlation and linear regression analyses Jacques - Emmanuel Galimard (PARIS, France) | 09:00 - 09:00 |
| STATS-C1-7 | Logistic regression Jacques - Emmanuel Galimard (PARIS, France) | 09:00 - 09:00 |
| STATS-C1-8 | Description for time to event outcome (without competition): The Kaplan Meier method Patrick Gilbert (Barcelona, Spain) | 09:00 - 09:00 |
| STATS-C1-9 | Comparison of time to event outcome (without competition): The logrank test Patrick Gilbert (Barcelona, Spain) | 09:00 - 09:00 |

Patient, Family, and Donor Day

09:00 - 10:20

NOVOTEL CAMPO DE LAS NACIONES

PFDD1 - Patient, Family, and Donor Day 1 | Inside the Transplant Journey: Patient-Led Navigation of Bone Marrow Transplant

Andrea Linke (Berlin, Germany)

Guy Bouguet (Paris, France)

| | | |
|---------|---|---------------|
| PFDD1-0 | Welcome | 09:00 - 09:05 |
| PFDD1-1 | Fundación Josep Carreras: A Community Making Transplant Possible Marta Fernandez (Barcelona, Spain) | 09:05 - 09:20 |
| PFDD1-2 | Introduction | 09:20 - 09:25 |
| PFDD1-3 | Panel Discussion: The ride of my life - How to navigate through HCT - Patients' and health care professionals' perspectives Kirsti Scheffel (Bonn, Germany) Carolina Garcez Martins (Braga, Portugal) Hilda Mekelenkamp (Leiden, Netherlands (the)) Helen Aiston (Southampton, United Kingdom of Great Britain and Northern Ireland (the)) | 09:25 - 10:10 |
| PFDD1-4 | Q&A | 10:10 - 10:20 |

Breaks

10:00 - 10:30

R1

Coffee Break, ePoster Viewing, Visit Exhibition*Meetings*

10:00 - 12:30

R9

IM-1 - EBMT Nurses Exam*Industry Symposium*

10:30 - 12:00

R1

IS07 - What's New in GVHD? | Sanofi

Mohamad Mohty (Paris, France)

| | | |
|--------|---|---------------|
| IS07-1 | Opening Remarks Mohamad Mohty (Paris, France) | 10:30 - 10:35 |
| | Part I: Presentation 'What's New in GVHD?' | 10:35 - 10:35 |
| IS07-2 | Advancing Care Through an Evolving Understanding of Adult cGVHD Robert Zeiser (Freiburg, Germany) | 10:35 - 10:50 |
| IS07-3 | Pediatric cGVHD: A Distinct Disease Course Informing New | 10:50 - 11:05 |

| | | |
|-------------------------------|---|---------------|
| | Directions in Care | |
| | Andy Harris (New York, United States of America (the)) | |
| | Part II: Panel Discussion | 11:05 - 11:05 |
| IS07-4 | Introduction: Setting the Stage for Panel Discussion | 11:05 - 11:10 |
| | Miguel Angel Perales (New York, United States of America (the)) | |
| IS07-5 | Turning Insights Into Impact for GVHD Patients | 11:10 - 11:55 |
| | Miguel Angel Perales (New York, United States of America (the)) | |
| | Mohamad Mohty (Paris, France) | |
| | Robert Zeiser (Freiburg, Germany) | |
| | José Antonio Pérez Simón (Sevilla, Spain) | |
| | Andy Harris (New York, United States of America (the)) | |
| | Helene Schoemans (Leuven, Belgium) | |
| | XiaoJun Huang (Beijing, China) | |
| | Meredith Cowden (Akron, United States of America (the)) | |
| | Michelle Kenyon (LONDON, United Kingdom of Great Britain and Northern Ireland (the)) | |
| IS07-6 | Closing Remarks | 11:55 - 12:00 |
| | Mohamad Mohty (Paris, France) | |
| <i>Industry Symposium</i> | | |
| | 10:30 - 12:00 | R4 |
| | IS09 - Illuminated Constellations: How Diverse Experiences Guide Practical CMV Management Takeda | |
| | Rafael Duarte (Madrid, Spain) | |
| IS09-1 | Welcome and Introductions | 10:30 - 10:35 |
| | Rafael Duarte (Madrid, Spain) | |
| IS09-2 | Unmet Need & Burden of Refractory/Resistant CMV: An Introductory Video | 10:35 - 10:38 |
| IS09-3 | Effectively Identifying and Treating Patients with Cytomegalovirus: A Panel Discussion | 10:38 - 11:38 |
| | Rafael Duarte (Madrid, Spain) | |
| | Eva Wagner-Drouet (Mainz, Germany) | |
| | Johan Maertens (Leuven, Belgium) | |
| IS09-4 | Audience Q&A - All | 11:38 - 11:58 |
| | Rafael Duarte (Madrid, Spain) | |
| IS09-5 | Concluding Remarks | 11:58 - 12:00 |
| | Rafael Duarte (Madrid, Spain) | |
| <i>Nurses Group</i> | | |
| | 10:30 - 12:00 | R7 |
| | NG02 - Nurses Education Day 2: Advancing the art of nursing care in HSCT and cell therapy Innovations in patient centered care | |
| | Marijke Quaghebeur (Ghent, Belgium) | |
| | Isabel Salcedo (Madrid, Spain) | |
| NG02-1 | Health coaching in HCT and cellular therapy | 10:30 - 10:51 |
| | Sarah Calvin (Marseille, France) | |
| NG02-2 | Implementation of nutritional guidance and supporting nutritional goals | 10:51 - 11:12 |
| | Amanda Casirati (Genoa, Italy) | |
| NG02-3 | Preserving the oral mucosa with photobiomodulation | 11:12 - 11:33 |
| | Tamara Jimenez (Madrid, Spain) | |
| NG02-4 | The Microbiota Bundle Care: basic, balanced and consistent nursing care in TPH | 11:33 - 11:54 |

| | | |
|--|--|-------------------------------|
| | Esther Martínez Miguel (Madrid, Spain) | |
| NG02-5 | Q&A | 11:54 - 12:00 |
| <i>Trainee Day</i> | | |
| 10:30 - 11:45 | | R12 |
| TD1 - Trainee Day 1 Fast and furious CARTs | | |
| Esra Gulderen (Helsinki, Finland) | | |
| Alex Rampotas (London, United Kingdom of Great Britain and Northern Ireland (the)) | | |
| TD1-1 | Welcome | 10:30 - 10:35 |
| | Esra Gulderen (Helsinki, Finland) | |
| | Alex Rampotas (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| TD1-2 | 1st gen to TRUCKs | 10:35 - 10:50 |
| | Alex Rampotas (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| TD1-3 | Harnessing CAR-T cells to tackle aging | 10:50 - 11:05 |
| | Corina Amor Vegas (Cold Spring Harbor, United States of America (the)) | |
| TD1-4 | Emerging T-cell therapies for B-ALL | 11:05 - 11:20 |
| | Aida Falgas (Barcelona, Spain) | |
| TD1-5 | CAR-T Cells for HCC | 11:20 - 11:35 |
| | Harriet Roddy (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| TD1-6 | Q&A - Panel discussion | 11:35 - 11:45 |
| <i>Psy Day</i> | | |
| 10:30 - 11:45 | | R13 |
| PSY1 - Psy Day Session 1 Supportive care interventions (I) | | |
| Anna Barata (Boston, United States of America (the)) | | |
| PSY1-1 | Implementing a frailty program in a transplant unit: challenges and opportunities | 10:30 - 10:50 |
| | M Queralt Salas (Barcelona, Spain) | |
| PSY1-2 | Virtual reality interventions to improve mental health and well-being in patients receiving palliative care | 10:50 - 11:10 |
| | Michael Baliouis (Nottingham, United Kingdom of Great Britain and Northern Ireland (the)) | |
| PSY1-3 | Preparing patients and their families for transplant: patient perception on the design and implementation of a new "preparing for transplant" seminar | 11:10 - 11:30 |
| | Jenna Love (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| PSY1-4 | Q&A | 11:30 - 11:45 |
| <i>Patient, Family, and Donor Day</i> | | |
| 10:45 - 12:00 | | NOVOTEL CAMPO DE LAS NACIONES |
| PFDD2 - Patient, Family, and Donor Day 2 Beyond Survival: Strategies for Post-Transplant Health Improvement | | |
| Tone Hansen (Tønsberg, Norway) | | |
| Riikka-Leena Manninen (Ylöjärvi, Finland) | | |
| PFDD2-0 | Introduction | 10:45 - 10:50 |
| PFDD2-1 | Why to keep fit after transplant? | 10:50 - 11:10 |
| | Fabio Turazza (Florence, Italy) | |
| PFDD2-2 | Making changes in life | 11:10 - 11:30 |

| | | |
|--|---|---------------|
| | Alice Polomeni (PARIS, France) | |
| PFDD2-3 | How little can be enough Alexander Varjord (Bergen, Norway) | 11:30 - 11:50 |
| PFDD2-4 | Discussion - Q&A | 11:50 - 12:00 |
| <i>Breaks</i> | | |
| 12:00 - 12:30 | | R1 |
| Break, ePoster Viewing, Visit Exhibition | | |
| <i>Industry Symposium</i> | | |
| 12:30 - 14:00 | | R2 |
| IS10 - Breaking barriers in cell therapy: innovative approaches from transplantation to CAR T evolution Miltenyi Biotec | | |
| José Antonio Pérez Simón (Sevilla, Spain) | | |
| IS10-1 | Welcome & introduction José Antonio Pérez Simón (Sevilla, Spain) | 12:30 - 12:40 |
| IS10-2 | Haploidentical transplantation with TCR$\alpha\beta$-depleted graft and upfront memory T cell add-back in adults with haematological malignancies Koh Liang Piu (Singapore, Singapore) | 12:40 - 13:00 |
| IS10-3 | Navigating graft-versus-leukemia and GvHD: adoptive infusion of T-allo10 after $\alpha\beta$ T-cell depleted haploidentical HSCT Alica Bertaina (Stanford, United States of America (the)) | 13:00 - 13:20 |
| IS10-4 | Beyond CD19: the potential of tandem CD19/CD22 CAR T-cells in high-risk B-ALL Antonio Pérez Martínez (Madrid, Spain) | 13:20 - 13:40 |
| IS10-5 | CAR-T-cells for B-cell mediated autoimmune disease Fabian Müller (Erlangen, Germany) | 13:40 - 14:00 |
| <i>Industry Symposium</i> | | |
| 12:30 - 14:00 | | R3 |
| IS11 - Induction, maintenance and beyond: advancing outcomes in TE NDMM Johnson & Johnson | | |
| Jesús San-Miguel (Pamplona, Spain) | | |
| IS11-1 | Welcome and introduction Jesús San-Miguel (Pamplona, Spain) | 12:30 - 12:35 |
| IS11-2 | 3, 2, 1... lift off! Starting strong with anti-CD38 induction and consolidation Jesús San-Miguel (Pamplona, Spain) | 12:35 - 12:50 |
| IS11-3 | Going the distance: enhancing outcomes with Daratumumab-Lenalidomide maintenance Maria Gavriatopoulou (Athens, Greece) | 12:50 - 13:05 |
| IS11-4 | A journey through the myeloma case galaxy: discussion and Q&A - All faculty Mohamad Mohty (Paris, France) | 13:05 - 13:55 |
| IS11-5 | Summary and close Jesús San-Miguel (Pamplona, Spain) | 13:55 - 14:00 |

Industry Symposium

12:30 - 14:00

R4

IS12 - Advancing Management of Steroid-Refractory aGvHD with GI involvement: From Unmet Need to a Potential third-line option | Clinigen

Florent Malard (Paris, France)

Fabio Ciceri (Milano, Italy)

| | | |
|--------|---|---------------|
| IS12-1 | Introduction & Welcome Florent Malard (Paris, France) Fabio Ciceri (Milano, Italy) | 12:30 - 12:35 |
| IS12-2 | Unmet Medical Need in aGvHD in 3L Setting Zinaida Peric (Rijeka, Croatia) | 12:35 - 12:50 |
| IS12-3 | Scientific Rationale for Targeting the Gut Microbiome in aGvHD Ernst Holler (Regensburg, Germany) | 12:50 - 13:05 |
| IS12-4 | Clinical Evidence Supporting MaaT013 in aGvHD Florent Malard (Paris, France) | 13:05 - 13:20 |
| IS12-5 | Clinical Case Highlights: MaaT013 in Real World Practice Jaime Sanz (Valencia, Spain) | 13:20 - 13:35 |
| IS12-6 | Panel Discussion & Q&A Fabio Ciceri (Milano, Italy) | 13:35 - 13:55 |
| IS12-7 | Closing Remarks Florent Malard (Paris, France) Fabio Ciceri (Milano, Italy) | 13:55 - 14:00 |

Nurses Group

12:30 - 14:00

R7

NG03 - Nurses Education Day 3: Advancing the art of nursing care in HSCT and cell therapy | Challenge to nursing of novel therapeutics

Marijke Quaghebeur (Ghent, Belgium)

Julia Ruiz Pato (Madrid, Spain)

| | | |
|--------|--|---------------|
| NG03-1 | The challenges of delivering universal allogeneic CAR-T cell therapy Deborah Yallop (London, United Kingdom of Great Britain and Northern Ireland (the)) | 12:30 - 12:51 |
| NG03-2 | The impact of novel therapeutics on clinical nurse education Silvia Gneccchi (Milan, Italy) | 12:51 - 13:12 |
| NG03-3 | The impact of novel therapeutics on interdisciplinary care Christien Oudbier (Utrecht, Netherlands (the)) | 13:12 - 13:33 |
| NG03-4 | The financial and psychosocial burden of novel therapeutics Mercedes Montoro-Lorite (Barcelona, Spain) | 13:33 - 13:54 |
| NG03-5 | Q&A | 13:54 - 14:00 |

Trainee Day

12:30 - 13:45

R12

TD2 - Trainee Day 2 | Cellular therapies beyond cancer

Catherine Mhando (DODOMA, Tanzania, United Republic of)

Fabio Andreozzi (Brussels-Leuven, Belgium)

Benedetta Elena Di Majo (Monza, Italy)

| | | |
|-------|--|---------------|
| TD2-1 | Novel targeted therapies in IEI: Bridge or alternative to HCT? Carsten Speckmann (Freiburg, Germany) | 12:30 - 12:50 |
| TD2-2 | Curative strategies in Sickle cell disease Mohsin Badat (London, United Kingdom of Great Britain and Northern Ireland (the)) | 12:50 - 13:10 |

| | | |
|--|---|-------------------------------|
| TD2-3 | Rewiring immunity in Autoimmune Disease Raffaella Greco (Milano, Italy) | 13:10 - 13:30 |
| TD2-4 | Q&A - Panel discussion | 13:30 - 13:45 |
| <i>Psy Day</i> | | |
| 12:30 - 13:45 | | R13 |
| PSY2 - Psy Day Session 2 Patient and caregiver-reported outcomes | | |
| Michael Baliouis (Nottingham, United Kingdom of Great Britain and Northern Ireland (the)) | | |
| PSY2-1 | Patient-reported and cognitive outcomes after CAR-T cell therapy Anna Barata (Boston, United States of America (the)) | 12:30 - 12:50 |
| PSY2-2 | Patient-reported psychosocial distress and cognitive function in allogeneic SCT survivors: associations with return to work and daily activities - The SOPRALLO Project Yana Stepanishyna (Brussels, Belgium) | 12:50 - 13:10 |
| PSY2-3 | Caregiver burden and psychosocial distress when undergoing inpatient or at-home HCT Arianna Rosich Soteras (Barcelona, Spain) | 13:10 - 13:30 |
| PSY2-4 | Q&A | 13:30 - 13:45 |
| <i>Statistics</i> | | |
| 12:30 - 15:45 | | R17 |
| STATS-C2 - Basic course in Statistics 2 | | |
| Jacques - Emmanuel Galimard (PARIS, France) | | |
| STATS-C2-1 | Theory: The survival function and the hazard function Jacques - Emmanuel Galimard (PARIS, France) | 12:30 - 12:30 |
| STATS-C2-2 | The Cox model and multivariable methods Luuk Gras (Amsterdam, Netherlands (the)) | 12:30 - 12:30 |
| STATS-C2-3 | Competing events and the cumulative incidence method Luuk Gras (Amsterdam, Netherlands (the)) | 12:30 - 12:30 |
| STATS-C2-4 | Comparison of time to event outcome with competition: The Gray test Luuk Gras (Amsterdam, Netherlands (the)) | 12:30 - 12:30 |
| STATS-C2-5 | Stat issues in Hematologic Studies Allain-Thibeault Ferhat (Paris, France) | 12:30 - 12:30 |
| <i>Patient, Family, and Donor Day</i> | | |
| 13:30 - 14:45 | | NOVOTEL CAMPO DE LAS NACIONES |
| PFDD3 - Patient, Family, and Donor Day 3 Reprogramming the Immune System: Autologous Transplant and CAR-T Cells in Autoimmune Diseases (AIDs) | | |
| Noelle Tassy (Marseilles, France) | | |
| Abdelfatah Ibrahim (London, United Kingdom of Great Britain and Northern Ireland (the)) | | |
| PFDD3-0 | Introduction Abdelfatah Ibrahim (London, United Kingdom of Great Britain and Northern Ireland (the)) | 13:30 - 13:35 |
| PFDD3-1 | 30 years of autologous HCT in Multiple Sclerosis Richard Burt (La Jolla, United States of America (the)) | 13:35 - 13:50 |
| PFDD3-2 | Let's debunk HCT for multiple sclerosis! Noelle Tassy (Marseilles, France) | 13:50 - 14:00 |
| PFDD3-3 | Autologous HCT for people with MS: a patient experience 11 years | 14:00 - 14:10 |

| | | |
|---|--|---------------|
| | post | |
| | Sigbjørn Rogne (Tromsø, Norway) | |
| PFDD3-4 | CAR-T cells for multiple sclerosis Johanna Richter (Hamburg, Germany) | 14:10 - 14:25 |
| PFDD3-5 | Discussion - Q&A | 14:25 - 14:45 |
| | | |
| <i>Breaks</i> | | |
| 14:00 - 14:30 | | R1 |
| Break, ePoster Viewing, Visit Exhibition | | |
| | | |
| <i>Industry Symposium</i> | | |
| 14:30 - 16:00 | | R2 |
| IS13 - CAR T in DLBCL: Overcoming misconceptions for better patient outcomes Gilead & Kite | | |
| Anna Sureda (Barcelona, Spain) | | |
| IS13-1 | Welcome and introduction Anna Sureda (Barcelona, Spain) | 14:30 - 14:35 |
| IS13-2 | Misconception #1: My patient isn't the 'right' patient for CAR T Anna Sureda (Barcelona, Spain) | 14:35 - 14:50 |
| IS13-3 | Panel discussion - All faculty Anna Sureda (Barcelona, Spain) | 14:50 - 15:00 |
| IS13-4 | Misconception #2: The CAR T journey is too long for my patient to complete Samuel Yamshon (New York, United States of America (the)) | 15:00 - 15:15 |
| IS13-5 | Panel discussion - All faculty Anna Sureda (Barcelona, Spain) | 15:15 - 15:25 |
| IS13-6 | Misconception #3: The side effects of CAR T are too severe Birte Friedrichs (Düsseldorf, Germany) | 15:25 - 15:40 |
| IS13-7 | Panel discussion - All faculty Anna Sureda (Barcelona, Spain) | 15:40 - 15:50 |
| IS13-8 | Audience Q&A - All faculty Anna Sureda (Barcelona, Spain) | 15:50 - 15:55 |
| IS13-9 | Conclusion and closing remarks Anna Sureda (Barcelona, Spain) | 15:55 - 16:00 |
| | | |
| <i>Industry Symposium</i> | | |
| 14:30 - 16:00 | | R3 |
| IS14 - Comprehensive Care of FLT3+ AML Patients: Pre-Transplant Assessment and Post-Transplant Management Daiichi Sankyo | | |
| Jordi Esteve (Barcelona, Spain) | | |
| IS14-1 | Welcome and Introduction Jordi Esteve (Barcelona, Spain) | 14:30 - 14:40 |
| IS14-2 | Individualising Care Through Pre-Transplant Assessment Jurjen Versluis (Rotterdam, Netherlands (the)) | 14:40 - 15:00 |
| IS14-3 | Optimising Outcomes in the Post-Transplant Setting Alessandro Isidori (Italy) | 15:00 - 15:20 |
| IS14-4 | Real-World Check With Patient Cases - All | 15:20 - 15:40 |

IS14-5 **Panel Discussion and Closing Remarks - All** 15:40 - 16:00

Industry Symposium

14:30 - 16:00

R4

**IS15 - Optimizing the Transplant Experience: Patient Journey Through Conditioning and GvHD Management | MEDSCAPE Education Global
Supported by an Education Grant from Medac**

Daniele Avenoso (Brescia, Italy)

IS15-1 **Setting the Stage: The Modern Transplant Odyssey** 14:30 - 14:35

Daniele Avenoso (Brescia, Italy)

IS15-2 **The Balancing Act: Tailoring Conditioning for the Complex Patient** 14:35 - 15:00

Daniele Avenoso (Brescia, Italy)

Mareike Verbeek (Munich, Germany)

Robert Zeiser (Freiburg, Germany)

Filippo Milano (Seattle, United States of America (the))

IS15-3 **Maximum Intent: Myeloablative Strategies in High-Risk Disease** 15:00 - 15:25

Daniele Avenoso (Brescia, Italy)

Filippo Milano (Seattle, United States of America (the))

Mareike Verbeek (Munich, Germany)

Robert Zeiser (Freiburg, Germany)

IS15-4 **Navigating the Storm: Managing Steroid-Refractory GvHD** 15:25 - 15:50

Robert Zeiser (Freiburg, Germany)

IS15-5 **Key Takeaways and Future Horizons** 15:50 - 16:00

Daniele Avenoso (Brescia, Italy)

Industry Symposium

14:30 - 16:00

R5

IS16 - Optimizing CMV management in pediatric and adult HSCT: Recent evidence and clinical implications | MSD

Rafael de la Cámara (Madrid, Spain)

IS16-1 **Welcome, introductions, and opening remarks** 14:30 - 14:35

Rafael de la Cámara (Madrid, Spain)

IS16-2 **The burden of CMV in transplantation: Past lessons and major milestones** 14:35 - 14:55

Rafael de la Cámara (Madrid, Spain)

IS16-3 **Evolving strategies and remaining challenges in CMV management in adult HSCT** 14:55 - 15:15

Per Ljungman (Stockholm, Sweden)

IS16-4 **From evidence to practice: Advancing CMV management in pediatric HSCT** 15:15 - 15:35

Dina Averbuch (Jerusalem, Israel)

IS16-5 **Panel discussion and Q&A - All** 15:35 - 15:55

Rafael de la Cámara (Madrid, Spain)

IS16-6 **Closing remarks** 15:55 - 16:00

Rafael de la Cámara (Madrid, Spain)

Nurses Group

14:30 - 16:00

R7

NG04 - Nurses Education Day 4: Advancing the art of nursing care in HSCT and cell therapy | Advances in not so rare complications

Marijke Quaghebeur (Ghent, Belgium)

Julia Ruiz Pato (Madrid, Spain)

| | | |
|--------|--|---------------|
| NG04-1 | Advances in diagnosis and care of hemorrhagic cystitis Anna Serrahima (Girona, Spain) | 14:30 - 14:51 |
| NG04-2 | Advances in care of severe skin toxicity and skin GVHD Giulia Colombo (Milano, Italy) | 14:51 - 15:12 |
| NG04-3 | Advances in prevention detection and treatment of graft failure William George Giusti Fischer (London, United Kingdom of Great Britain and Northern Ireland (the)) | 15:12 - 15:33 |
| NG04-4 | Advances in prevention, detection and treatment of viral complications Cecile Pochon (NANCY, France) | 15:33 - 15:54 |
| NG04-5 | Q&A | 15:54 - 16:00 |

Industry Symposium

14:30 - 16:00

R8

IS08 - Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy | Omeros "Due to Italian regulatory requirements, this session is not available to delegates joining from Italy"

Rafael Duarte (Madrid, Spain)

Mohamad Mohty (Paris, France)

| | | |
|--------|---|---------------|
| IS08-1 | Welcome & Introductions Rafael Duarte (Madrid, Spain) Mohamad Mohty (Paris, France) | 14:30 - 14:35 |
| IS08-2 | Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA): Pathophysiology-Guided Diagnosis Michelle L Schoettler (Atlanta, United States of America (the)) | 14:35 - 14:45 |
| IS08-3 | The Role of Complement in TA-TMA: Recent Clinical Data Miguel Angel Perales (New York, United States of America (the)) Michelle L Schoettler (Atlanta, United States of America (the)) | 14:45 - 15:05 |
| IS08-4 | Panel Discussion #1 | 15:05 - 15:15 |
| IS08-5 | Narsoplimab: Clinical Evidence in TA-TMA Response Rate & Survival vs External Control Miguel Angel Perales (New York, United States of America (the)) | 15:15 - 15:25 |
| IS08-6 | Narsoplimab: Survival Data from Expanded Access Program (EAP) Michelle L Schoettler (Atlanta, United States of America (the)) | 15:25 - 15:35 |
| IS08-7 | Narsoplimab: Case Series Rafael Duarte (Madrid, Spain) | 15:35 - 15:45 |
| IS08-8 | Panel Discussion #2 | 15:45 - 15:55 |
| IS08-9 | Closing Remarks & Q&A | 15:55 - 16:00 |

Trainee Day

14:30 - 15:45

R12

TD3 - Trainee Day 3 | Access and innovation

Giorgio Orofino (Milan, Italy)

Aleksandra Oszer (Lodz, Poland)

| | | |
|-------|--|---------------|
| TD3-1 | Could allogeneic CAR-T cells reduce costs and increase global | 14:30 - 14:50 |
|-------|--|---------------|

| | | |
|--|--|-------------------------------|
| | access to cellular therapy? | |
| | Paul Maciocia (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| TD3-2 | Innovative strategies for Haploidentical transplantation in thalassaemia Mohana Reddy (Bengaluru, India) | 14:50 - 15:10 |
| TD3-3 | Should pharmacogenomics impact global chemotherapy prescriptions practices - Focus on underrepresented population groups Jatinder Lamba (United States of America (the)) | 15:10 - 15:30 |
| TD3-4 | Q&A - Panel discussion | 15:30 - 15:45 |
| | | |
| <i>Psy Day</i> | | |
| 14:30 - 15:45 | | R13 |
| PSY3 - Psy Day Session 3 Pediatrics and childhood survivors | | |
| Alice Polomeni (PARIS, France) | | |
| PSY3-1 | Mental health, quality of life and unmet informational needs among childhood cancer survivors (cohort 2017-2020) Elena Valero (Robledo de Chavela, Spain) | 14:30 - 14:50 |
| PSY3-2 | Beyond treatment: prevalence, predictors, and changes in anxiety and depression among parents of childhood cancer survivors Laura Inhestern (Hamburg, Germany) | 14:50 - 15:10 |
| PSY3-3 | Ethical challenges when consenting minor donor siblings Marina Bonfill (Barcelona, Spain) | 15:10 - 15:30 |
| PSY3-4 | Q&A | 15:30 - 15:45 |
| | | |
| <i>Lab Scientists Day</i> | | |
| 14:30 - 15:45 | | R14 |
| LS1 - Lab Scientists Day 1 HSCT Lab in Transition - Novel therapies, SoHO compliance, and laboratory best practices | | |
| María Esther Martínez Muñoz (Madrid, Spain) | | |
| LS1-1 | Adoptive CD45RA- T cell therapy for severe refractory infections Antonio Pérez Martínez (Madrid, Spain) | 14:30 - 14:55 |
| LS1-2 | Aiming to harmonize processing laboratory practices for HCT Jesus Fernandez-Sojo (Barcelona, Spain) | 14:55 - 15:20 |
| LS1-3 | What the new SoHO regulation means for the transplant processing laboratory Dolores Hernández Maraver (MADRID, Spain) | 15:20 - 15:45 |
| | | |
| <i>Patient, Family, and Donor Day</i> | | |
| 15:15 - 16:45 | | NOVOTEL CAMPO DE LAS NACIONES |
| PFDD4 - Patient, Family, and Donor Day 4 The Gift of a Lifetime: Sibling and Recipients Perspectives on Transplant | | |
| Jacqueline Del Castillo (London, United Kingdom of Great Britain and Northern Ireland (the)) | | |
| Celia Marin (Murcia, Spain) | | |
| PFDD4-0 | Opening the Conversation - The Human Side of Transplantation Celia Marin (Murcia, Spain) | 15:15 - 15:20 |
| PFDD4-1 | Two Sides of the Same Transplant: A Sister's Story Noelia Quintero Montiel (Leon, Spain) María Eugenia Quintero Montiel (Leon, Spain) | 15:20 - 15:40 |
| PFDD4-2 | Quimera: Screening and presentation of the documentary film | 15:40 - 16:10 |

| | | |
|--|---|---------------|
| | Willy Ormaetxea (Barcelona, Spain) | |
| PFDD4-3 | Discussion - Q&A | 16:10 - 16:40 |
| | Celia Marin (Murcia, Spain) | |
| | María Eugenia Quintero Montiel (Leon, Spain) | |
| | Noelia Quintero Montiel (Leon, Spain) | |
| | Willy Ormaetxea (Barcelona, Spain) | |
| | Marta Fernandez (Barcelona, Spain) | |
| | Jacqueline Del Castillo (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| | | |
| <i>Meetings</i> | | |
| | 15:30 - 18:00 | R9 |
| IM-2 - EBMT Physicians Exam | | |
| | | |
| <i>Breaks</i> | | |
| | 16:00 - 16:30 | R1 |
| Coffee Break, ePoster Viewing, Visit Exhibition | | |
| | | |
| <i>Industry Symposium</i> | | |
| | 16:30 - 18:00 | R4 |
| IS17 - Understanding the unmet clinical need in GvHD management Therakos | | |
| Hildegard Greinix (Vienna, Austria) | | |
| IS17-1 | Introduction | 16:30 - 16:35 |
| | Hildegard Greinix (Vienna, Austria) | |
| IS17-2 | NIH chronic GvHD consensus conference 2025 update - what are the unmet clinical needs? | 16:35 - 17:00 |
| | Stephanie Lee (Seattle, United States of America (the)) | |
| IS17-3 | Biology of GvHD in light of novel composite endpoints | 17:00 - 17:25 |
| | Kirk Schultz (Vancouver, Canada) | |
| IS17-4 | Combination therapy to address the unmet clinical needs in GvHD in 2026 | 17:25 - 17:50 |
| | Robert Zeiser (Freiburg, Germany) | |
| IS17-5 | Q&A session | 17:50 - 18:00 |
| | | |
| <i>Industry Symposium</i> | | |
| | 16:30 - 18:00 | R5 |
| IS18 - Longevity and innovation: Charting the future of CAR T cell therapy in hematologic malignancies Bristol Myers Squibb | | |
| Catherine Thieblemont (Paris, France) | | |
| IS18-1 | Welcome and introductions | 16:30 - 16:35 |
| | Catherine Thieblemont (Paris, France) | |
| IS18-2 | Why CAR T changes the game: Long-term data and real-world evidence in LBCL | 16:35 - 17:15 |
| | Jeremy Abramson (Boston, United States of America (the)) | |
| IS18-3 | Re-defining the treatment of Multiple Myeloma: Perspectives on the future of CAR T | 17:15 - 17:55 |
| | María Victoria Mateos (Salamanca, Spain) | |
| IS18-4 | Q&A Session and Adjournment - All faculty | 17:55 - 18:00 |

Industry Symposium

16:30 - 18:00

R7

IS19 - Pathways to Optimise Care: Clinical Collaboration in the Evolving Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent β -thalassemia (TDT) | Vertex

Mattia Algeri (Rome, Italy)

| | | |
|--------|---|---------------|
| IS19-1 | Welcome and introductions Mattia Algeri (Rome, Italy) | 16:30 - 16:40 |
| IS19-2 | Coordinating clinical management in the advanced treatment of SCD and TDT Mattia Algeri (Rome, Italy) | 16:40 - 17:00 |
| IS19-3 | Early multidisciplinary discussions to optimise patient referral and treatment outcomes in SCD Sultan Almutairi (Jeddah, Saudi Arabia) | 17:00 - 17:20 |
| IS19-4 | Transplanter-referrer collaboration in the selection of patients with TDT for advanced therapies Perla Eleftheriou (London, United Kingdom of Great Britain and Northern Ireland (the)) | 17:20 - 17:40 |
| IS19-5 | Panel discussion and audience Q&A - All faculty Mattia Algeri (Rome, Italy) | 17:40 - 17:55 |
| IS19-6 | Final panel reflection and closing remarks Mattia Algeri (Rome, Italy) | 17:55 - 18:00 |

Joint Sessions

16:30 - 17:45

R12

JS01 - Joint Session EBMT Trainee Committee & YoungEHA

Anna Sureda (Barcelona, Spain)

Konstanze Döhner (Ulm, Germany)

| | | |
|--------|--|---------------|
| JS01-1 | Opening Anna Sureda (Barcelona, Spain) Konstanze Döhner (Ulm, Germany) | 16:30 - 16:35 |
| JS01-2 | The EBMT Trainee Committee: What We Are and What We Do Alex Rampotas (London, United Kingdom of Great Britain and Northern Ireland (the)) Esra Gulderen (Helsinki, Finland) | 16:35 - 16:50 |
| JS01-3 | Young EHA: What We Are and What We Do Nuno Borges (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the)) | 16:50 - 17:05 |
| JS01-4 | Keynote: How to develop a career in cellular therapies Jane Apperley (United Kingdom of Great Britain and Northern Ireland (the)) | 17:05 - 17:35 |
| JS01-5 | Q&A - Discussion | 17:35 - 17:45 |

Psy Day

16:30 - 17:45

R13

PSY4 - Psy Day Session 4 | Psychosocial innovations in HCT and cellular therapy

Elena Valero (Robledo de Chavela, Spain)

| | | |
|--------|--|---------------|
| PSY4-1 | Psychosocial care following allo-HCT Alice Polomeni (PARIS, France) | 16:30 - 16:50 |
| PSY4-2 | Development of a patient question prompt list for after-care following allogeneic hematopoietic stem cell transplantation Daniel Wolff (Regensburg, Germany) | 16:50 - 17:10 |
| PSY4-3 | A PROTOCOL FOR ASSESSING PSYCHOLOGICAL READINESS FOR HEMATOPOIETIC STEM CELL TRANSPLANT AND GENE THERAPY IN SICKLE CELL DISEASE | 17:10 - 17:30 |

| | | |
|--|--|---------------|
| | Dana Footer (Washington, United States Minor Outlying Islands (the)) | |
| PSY4-4 | Q&A | 17:30 - 17:45 |
| | | |
| <i>Lab Scientists Day</i> | | |
| 16:30 - 17:45 | | R14 |
| LS2 - Lab Scientists Day 2 ATMP Manufacturing: challenges and new strategies | | |
| Joaquim Vives Armengol (Barcelona, Spain) | | |
| LS2-1 | Technological challenges in VST production Anastasia Papadopoulou (Thessaloniki, Greece) | 16:30 - 16:55 |
| LS2-2 | Scale up bioprocessing of ATMPs Margarida Serra (Oeiras, Portugal) | 16:55 - 17:20 |
| LS2-3 | Smart ATMP manufacturing strategies Ioannis Papantoniou (Belgium) | 17:20 - 17:45 |
| | | |
| <i>Nurses Group</i> | | |
| 16:30 - 18:00 | | R17 |
| NG05 - Nurses Group Workshop Research - Please Mind the Gap: Bridging research and practice with implementation science | | |
| Annika Kisch (Lund, Sweden) | | |
| Ozgun Gokmen Kaya (Istanbul, Turkey) | | |
| NG05-1 | From Evidence to Practice: Advancing Clinical Care Through Implementation Science Sabina de Geest (BASEL, Switzerland) | 16:30 - 17:00 |
| NG05-2 | Applying Implementation Science Methods in Stem Cell Transplantation - a practical example Sabine Valenta (Tübingen, Germany) Lynn Leppla (Freiburg, Germany) | 17:00 - 17:15 |
| NG05-3 | Implementation Science in Action - Practical Application on Examples | 17:15 - 18:00 |
| | | |
| <i>Breaks</i> | | |
| 18:00 - 18:15 | | R1 |
| Break | | |
| | | |
| <i>General</i> | | |
| 18:15 - 19:30 | | R1 |
| GS1 - EBMT 2026 Opening Ceremony | | |
| Anna Sureda (Barcelona, Spain) | | |
| Rafael Duarte (Madrid, Spain) | | |
| GS1-1 | Welcome and introduction Anna Sureda (Barcelona, Spain) | 18:15 - 18:20 |
| GS1-2 | Welcome and introduction to the conference Rafael Duarte (Madrid, Spain) | 18:20 - 18:25 |
| GS1-3 | EBMT Patient Advocacy Committee: Welcome note Natacha Bolaños (Madrid, Spain) | 18:25 - 18:30 |
| GS1-4 | Welcome from the Nurses Group Hilda Mekelenkamp (Leiden, Netherlands (the)) | 18:30 - 18:35 |
| GS1-5 | Honorary Members 2026 | 18:35 - 18:55 |

| | | |
|-------|--|---------------|
| | Mary Horowitz (United States of America (the)) Dan Engelhard (Israel) Jakob Passweg (Basel, Switzerland) | |
| GS1-6 | Introduction of the Keynote speaker Rafael Duarte (Madrid, Spain) | 18:55 - 19:00 |
| GS1-7 | Keynote Lecture: From Subjects to Stakeholders - Patient Partnership in Multidisciplinary Cancer Care Lola Manterola (Madrid, Spain) | 19:00 - 19:30 |

Monday, 23. March 2026*Meetings*

07:00 - 08:45

R13

BM-SAAWP - Business Meeting of the Severe Aplastic Anaemia Working Party

Antonio M. Risitano (Avellino, Italy)

Meetings

07:00 - 08:45

R14

BM-CMWP - Business Meeting of the Chronic Malignancies Working Party

Donal McLornan (London, United Kingdom of Great Britain and Northern Ireland (the))

Meetings

07:00 - 08:45

R16

BM-IDWP - Business Meeting of the Infectious Diseases Working Party

Dina Averbuch (Jerusalem, Israel)

Meet the Expert

07:45 - 08:45

R18

QM-MTE-1 - Quality Management Meet-the-Expert: Change control - What Is It and How to Get It Right

QM-MTE-1

Change control - What Is It and How to Get It Right

07:45 - 08:45

Olivier Urbain (Brussels, Belgium)

Carlos Torrico (Barcelona, Spain)

Meet the Expert

07:45 - 08:45

R18

MTE-05 - Meet-the-Expert: Inside JACIE - Practical guidance for a successful Certification journey

MTE-5

Inside JACIE - Practical guidance for a successful Certification journey

07:45 - 08:45

Lynn Manson (Edinburgh, United Kingdom of Great Britain and Northern Ireland (the))

Nina Worel (Vienna, Austria)

Meet the Expert

07:45 - 08:45

R18

MTE-04 - Meet-the-Expert: GVHD in Practice - Expert insights into diagnosis, management, and controversies

MTE-4

GVHD in Practice - Expert insights into diagnosis, management, and controversies

07:45 - 08:45

Olaf Penack (Berlin, Germany)

Hildegard Greinix (Vienna, Austria)

Meet the Expert

07:45 - 08:45

R18

MTE-01 - Meet-the-Expert: Infection prevention and management in HCT and Cell Therapy - Practical questions, real-world answers

MTE-1

Infection prevention and management in HCT and Cell Therapy - Practical questions, real-world answers

07:45 - 08:45

Oliver Cornely (Cologne, Germany)

Patricia Muñoz (Madrid, Spain)

Meet the Expert
07:45 - 08:45 R18

MTE - Breakfast Meet the Expert - Monday

Meet the Expert
07:45 - 08:45 R18

MTE-03 - Meet-the-Expert: How to predict and manage CAR-T failure in lymphoma

MTE-3 **How to predict and manage CAR-T failure in lymphoma** 07:45 - 08:45
Miguel Angel Perales (New York, United States of America (the))
Margarita Sánchez-Beato (Madrid, Spain)

Meet the Expert
07:45 - 08:45 R18

MTE-02 - Meet-the-Expert: Cord blood as a source for HCT - Ready to pull the plug?

MTE-2 **Cord blood as a source for HCT - Ready to pull the plug?** 07:45 - 08:45
Sergi Querol (Barcelona, Spain)
Annalisa Ruggeri (Milano, Italy)

ePoster
08:30 - 18:00 R20

ePoster Viewing

Plenary Session
09:00 - 10:30 R1

P01 - Plenary | Artificial Intelligence in Hematology and Cell Therapy - Shaping clinical research and practice for 2026

Rafael Duarte (Madrid, Spain)

Isabel Sánchez-Ortega (Barcelona, Spain)

P01-1 **Introduction** 09:00 - 09:05

P01-2 **AI-driven advances in Hematology diagnostics** 09:05 - 09:20
Claudia Haferlach (Munich, Germany)

P01-3 **Synthetic data generation with AI in the context of HCT/CT in Hematology** 09:20 - 09:35
Matteo Della Porta (Milan, Italy)

P01-4 **AI in Cellular Therapy** 09:35 - 09:50
Roni Shouval (New York, United States of America (the))

P01-5 **AI-driven innovation in Hematology - Transforming Transplantation and Cellular Therapy** 09:50 - 10:05
Federico Alvarez (Madrid, Spain)

P01-6 **Panel discussion on AI in Hematology and Cell Therapy, and what these tools can offer to shape clinical research and practice in this field, and Q&A** 10:05 - 10:30

Workshop
09:00 - 10:30 R2

W01 - Workshop | HCT to induce immunotolerance to SOT - Has the concept come of age?

Cristina Díaz de Heredia (Barcelona, Spain)

Katharina Kleinschmidt (Regensburg, Germany)

W01-1 **Introduction** 09:00 - 09:05

W01-2 **Achieving xenograft tolerance** 09:05 - 09:20

| | | |
|-------|--|---------------|
| | Megan Sykes (New York, United States of America (the)) | |
| W01-3 | The case for cardiac transplantation Rafael Correa (Madrid, Spain) | 09:20 - 09:35 |
| W01-4 | The case of kidney transplantation Thomas Wekerle (Vienna, Austria) | 09:35 - 09:50 |
| W01-5 | The case of multivisceral transplantation Antonio Pérez Martínez (Madrid, Spain) | 09:50 - 10:05 |
| W01-6 | Panel discussion on the state of the field: progress, challenges, and future directions | 10:05 - 10:30 |

Cell Therapy Day

09:00 - 10:20

R3

CTD1 - Cell Therapy Day 1 | CAR-T cells

Jurgen Kuball (Utrecht, Netherlands (the))

Ana Alarcón Tomás (Madrid, Spain)

| | | |
|--------|---|---------------|
| CTD1-0 | Welcome | 09:00 - 09:05 |
| CTD1-1 | In-vivo B-cell maturation antigen CAR-T-cell therapy for relapsed or refractory multiple myeloma Heng Mei (Wuhan, China) | 09:05 - 09:30 |
| CTD1-2 | Repurposing base editors for targeted knock-in and simultaneous knockouts to generate multiplex-edited allogeneic CAR-T cells with minimal translocations Dimitrios Laurin Wagner (Houston, United States of America (the)) | 09:30 - 09:55 |
| CTD1-3 | Comparing safety of CD19-CAR T cell therapy in SLE and NHL: learning through patient trajectories Fabian Müller (Erlangen, Germany) | 09:55 - 10:20 |

Educational

09:00 - 10:30

R4

E01 - Educational | Infections after HCT/CT - Classical issues and new challenges

Jan Styczynski (Bydgoszcz, Poland)

Martin Hoenigl (Graz, Austria)

| | | |
|-------|---|---------------|
| E01-1 | Introduction | 09:00 - 09:05 |
| E01-2 | When fever isn't an infection - Rethinking diagnostic assumptions Rodrigo Martino (Barcelona, Spain) | 09:05 - 09:20 |
| E01-3 | When fever signals infection - How to select empirical antibiotic therapy Dina Averbuch (Jerusalem, Israel) | 09:20 - 09:37 |
| E01-4 | New antifungals in the horizon - Expanding the armamentarium Livio Pagano (ROMA, Italy) | 09:37 - 09:52 |
| E01-6 | New antivirals and unmet challenges Carlos Solano (Valencia, Spain) | 09:52 - 10:07 |
| E01-6 | Panel discussion on new challenges in anti-infective management in adult and paediatric patients, and Q&A | 10:07 - 10:30 |

Oral Session

09:00 - 10:15

R5

OS01 - Oral Session 1 | MDS & MPN

Donal McLornan (London, United Kingdom of Great Britain and Northern Ireland (the))

Gunnar Weise (Hamburg, Germany)

- | | | |
|---------|--|---------------|
| OS01-01 | ROLE OF GENETIC ALTERATIONS IN PATIENTS TRANSPLANTED FOR CMML: AN ANALYSIS OF A FRENCH COHORT, ON BEHALF OF THE SFGM-TC Laetitia Souchet (Paris, France) | 09:00 - 09:09 |
| OS01-02 | COMPARISON OF GVHD PROPHYLAXIS STRATEGIES IN MYELOFIBROSIS PATIENTS UNDERGOING ALLOGENEIC CELL TRANSPLANTATION FROM MATCHED RELATED DONORS: A STUDY BY THE EBMT CHRONIC MALIGNANCIES WORKING PARTY Patrizia Chiusolo (Roma, Italy) | 09:09 - 09:18 |
| OS01-03 | PHASE II SINGLE-CENTER PROSPECTIVE STUDY OF RUXOLITINIB ADMINISTERED BEFORE, DURING AND AFTER STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS Rachel Salit (Seattle, United States of America (the)) | 09:18 - 09:27 |
| OS01-04 | THE RECENT DEVELOPED AND MULTI-CENTER VALIDATED CONCISE OBJECTIFIABLE RISK EVALUATION (CORE) SCORE PREDICTS NRM RISK PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS PATIENTS Gunnar Weise (Hamburg, Germany) | 09:27 - 09:36 |
| OS01-05 | OLVEREMBATINIB-MEDIATED DEEP REMISSION IMPROVES ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOME IN PATIENTS WITH BLAST CRISIS CHRONIC MYELOID LEUKEMIA: THE FIRST REAL-WORLD PRACTICE Xiaoyu Zhang (Tianjin, China) | 09:36 - 09:45 |
| OS01-06 | COMPARING THE MTSS AND MYELOFIBROSIS ALLORISK STRATIFIER SCORES FOR PREDICTING EARLY MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE Daniele Sannipoli (Milano, Italy) | 09:45 - 09:54 |
| OS01-07 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN HYPOPLASTIC MYELODYSPLASTIC SYNDROME FROM A LATIN AMERICAN MULTICENTER STUDY Fernando Barroso Duarte (Fortaleza, Brazil) | 09:54 - 10:03 |
| OS01-08 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC CHRONIC MYELOID LEUKEMIA IN THE TKI ERA: AN EBMT PEDIATRIC DISEASES WORKING PARTY ANALYSIS Herbert Pichler (Vienna, Austria) | 10:03 - 10:12 |

Oral Session

09:00 - 10:15

R6

OS02 - Oral Session 2 | Lymphomas

Ali Bazarbachi (Beirut, Lebanon)

Jan Christian Schroeder (Tübingen, Germany)

- | | | |
|---------|---|---------------|
| OS02-01 | DISEASE STATUS AT LYMPHODEPLETION RATHER THAN BRIDGING MODALITY PREDICTS OUTCOMES FOLLOWING CD19-DIRECTED CAR T-CELL THERAPY IN LARGE B-CELL LYMPHOMA Philipp Berning (Muenster, Germany) | 09:00 - 09:09 |
| OS02-02 | THREE-YEAR EFFICACY AND LONGITUDINAL SAFETY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH | 09:09 - 09:18 |

| | | |
|--|--|---------------|
| | THIRD-LINE OR LATER (3L+) FOLLICULAR LYMPHOMA (FL) FROM TRANSCEND FL | |
| | Alejandro Martin Garcia-Sancho (Salamanca, Spain) | |
| OS02-03 | AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH CAR-T CELL THERAPY SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL IN RELAPSED REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA | 09:18 - 09:27 |
| | Yan Gao (Beijing, China) | |
| OS02-04 | OUTCOMES AFTER ANTI-CD19 CAR T-CELL THERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A LARGE REAL-WORLD REGISTRY ANALYSIS FROM THE EBMT LYMPHOMA WORKING PARTY | 09:27 - 09:36 |
| | Remy Dulery (Paris, France) | |
| OS02-05 | IMPACT OF PRIOR B-CELL-DIRECTED IMMUNOTHERAPY ON THE OUTCOME OF CD19 CAR T-CELL THERAPY IN AGGRESSIVE B-CELL LYMPHOMA | 09:36 - 09:45 |
| | Jan Christian Schroeder (Tübingen, Germany) | |
| OS02-06 | EARLY ALLOGENEIC TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN HIGH-RISK T-CELL LYMPHOMA: RESULTS OF A PROSPECTIVE PHASE 2 STUDY | 09:45 - 09:54 |
| | FengRong Wang (Beijing, China) | |
| OS02-07 | AVOIDING SALVAGE CHEMOTHERAPY IN EARLY PD-1 INHIBITOR RESPONDERS: OUTCOMES OF LOW-DOSE NIVOLUMAB-BASED SECOND-LINE THERAPY (NICE-40) FOR HODGKIN LYMPHOMA | 09:54 - 10:03 |
| | Polina Kotselyabina (Saint Petersburg, Russian Federation (the)) | |
| OS02-08 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER FAILING CAR-T THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GETH-TC/GELTAMO STUDY | 10:03 - 10:12 |
| | Leyre Bento (Palma de Mallorca, Spain) | |
| <i>Nurses Group</i> | | |
| | 09:00 - 10:30 | R7 |
| NG06 - Nurses Group Opening Session | | |
| | Hilda Mekelenkamp (Leiden, Netherlands (the)) | |
| | Julia Ruiz Pato (Madrid, Spain) | |
| | Isabel Salcedo (Madrid, Spain) | |
| NG06-1 | Welcome and overview | 09:00 - 09:10 |
| NG06-2 | Welcome to Madrid | 09:10 - 09:15 |
| NG06-3 | Presentation of the 18th Distinguished Merit Award & Honorary Member Award | 09:15 - 09:30 |
| | Jacqui Stringer (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| | Michelle Kenyon (LONDON, United Kingdom of Great Britain and Northern Ireland (the)) | |
| NG06-4 | Keynote lecture I - Advancing the image of nursing in 2026 and beyond | 09:30 - 10:00 |
| | Hildegart González (Navarra, Spain) | |
| NG06-5 | Keynote lecture II - Future proofing nursing | 10:00 - 10:30 |
| | Adelaida Zabalegui (Barcelona, Spain) | |

Joint Sessions

09:00 - 10:30

R8

JS03 - Joint Session EBMT - ASTCT - CIBMTR - APBMT - LABMT | Donor Selection in Allo-HCT: How Geography Shapes Choices and Outcomes

Anna Sureda (Barcelona, Spain)

Juliana Martinez Rolon (Buenos Aires, Argentina)

Alok Srivastava (Bengaluru, India)

Bronwen Shaw (Milwaukee, United States of America (the))

Richard Maziarz (Portland, United States of America (the))

| | | |
|----------|--|---------------|
| JS03-1 | Introduction | 09:00 - 09:05 |
| JS03-2.1 | Donor Selection - The Asia Pacific Perspective: Interplay of geography, ethnicity and preferences Alok Srivastava (Bengaluru, India) | 09:05 - 09:09 |
| JS03-2.2 | Trends of donor choice and related outcomes for allo-SCT in National Taiwan University Hospital, a major HCT center in Taiwan Bor-Sheng Ko (Taipei, Taiwan (Province of China)) | 09:09 - 09:17 |
| JS03-3 | Donor alternatives and unmet transplant necessities in Latin America Gregorio Jaimovich (Buenos Aires, Argentina) | 09:17 - 09:29 |
| JS03-4 | From Data to Decisions: U.S. donor selection guided by research but influenced by local pressures and/or bias Bronwen Shaw (Milwaukee, United States of America (the)) Richard Maziarz (Portland, United States of America (the)) | 09:29 - 09:41 |
| JS03-5 | Donor Selection in Allo-HCT: EBMT experience Alienor Xhaard (Paris, France) | 09:41 - 09:53 |
| JS03-6 | Haploidentical stem cell transplantation: the chance to expand access to allogeneic donor pool Fabio Ciceri (Milano, Italy) | 09:53 - 10:05 |
| JS03-7 | Panel Discussion | 10:05 - 10:30 |

Joint Sessions

09:00 - 10:30

R9

JS02 - Joint Session CTIWP, PDWP, EUROCORD, and the Cord Blood Association

Robert Wynn (Manchester, United Kingdom of Great Britain and Northern Ireland (the))

Joanne Kurtzberg (Durham, United States of America (the))

| | | |
|--------|--|---------------|
| JS02-1 | Non HLA matched pooled UCBT Filippo Milano (Seattle, United States of America (the)) | 09:00 - 09:25 |
| JS02-2 | Evolution overtime of CBT, practice and results Eliane Gluckman (Paris, France) | 09:25 - 09:50 |
| JS02-3 | CB banking activity in Spain Sergi Querol (Barcelona, Spain) | 09:50 - 10:15 |
| JS02-4 | Round Table: Rejuvenating the cord blood transplantation Eliane Gluckman (Paris, France) Robert Wynn (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) Filippo Milano (Seattle, United States of America (the)) Sergi Querol (Barcelona, Spain) Joanne Kurtzberg (Durham, United States of America (the)) Petra Gesine Koegler (Düsseldorf, Germany) Vanderson Rocha (SÃO PAULO, Brazil) Annalisa Ruggeri (Milano, Italy) Krzysztof Kalwak (Wroclaw, Poland) Tomasz Baran (Warsaw, Poland) | 10:15 - 10:30 |

Pharmacists Day

09:00 - 10:30

R10

Pharm1 - Pharmacists Day 1 | Clinical update

Nick Duncan (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))

Estela Moreno Martinez (Barcelona, Spain)

| | | |
|----------|--|---------------|
| Pharm1-1 | Welcome from the EBMT Pharmacist Committee | 09:00 - 09:05 |
| | Nick Duncan (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | |
| Pharm1-2 | Welcome from the Spanish cancer pharmacy group | 09:05 - 09:10 |
| | Garbiñe Lizeaga (San Sebastian, Spain) | |
| Pharm1-3 | New Developments in management of GVHD | 09:10 - 09:35 |
| | Irene García-Cadenas (Barcelona, Spain) | |
| Pharm1-4 | Beyond CMV - management of viral infections in the transplant setting | 09:35 - 10:00 |
| | Rafael de la Cámara (Madrid, Spain) | |
| Pharm1-5 | Dosing of anti-infectives in renally impaired HCT patients | 10:00 - 10:25 |
| | Eva-Maria Wansing (Hamburg, Germany) | |

Data Management

09:00 - 10:25

R11

DM1 - Data Management Session 1 | The EBMT Registry: what's new and how to stay compliant

Annelot van Amerongen (Leiden, Netherlands (the))

Julia Lee (London, United Kingdom of Great Britain and Northern Ireland (the))

| | | |
|-------|---|---------------|
| DM1-1 | Welcome | 09:00 - 09:10 |
| | Annelot van Amerongen (Leiden, Netherlands (the)) | |
| DM1-2 | EBMT Registry new functionalities presentation | 09:10 - 09:30 |
| | Nadiia Dyba (Barcelona, Spain) | |
| DM1-3 | EBMT Registry tools introduction | 09:30 - 09:50 |
| | Ignacio García (Eindhoven, Netherlands (the)) | |
| DM1-4 | QA refresher | 09:50 - 10:10 |
| | Iris Bargallo (Barcelona, Spain) | |
| DM1-5 | Q&A | 10:10 - 10:25 |

How do I... ?

09:00 - 10:15

R12

HDI1 - How Do I treat GVHD - Role of the multi-disciplinary team in the treatment of Chronic GVHD? | Supported through an unrestricted educational grant by Sanofi

Zinaida Peric (Rijeka, Croatia)

Steven Pavletic (Rockville, United States of America (the))

| | | |
|--------|--|---------------|
| HDI1-1 | The dermatologist's perspective | 09:00 - 09:20 |
| | Alina Markova (New York, United States of America (the)) | |
| HDI1-2 | The ophthalmologist's perspective | 09:20 - 09:40 |
| | Sandeep Jain (Chicago, United States of America (the)) | |
| HDI1-3 | The gynecologist's perspective | 09:40 - 10:00 |
| | Rebecca Moffat (Olten, Switzerland) | |
| HDI1-4 | Q&A - Discussion | 10:00 - 10:15 |

Working Party Session

09:00 - 10:15

R13

SAAWP - Severe Aplastic Anaemia Working Party Session | Advances in treatment of acquired and inherited aplastic anemia

Austin Kulasekararaj (London, United Kingdom of Great Britain and Northern Ireland (the))

Camila Frieri (Avellino, Italy)

| | | |
|---------|---|---------------|
| SAAWP-1 | SAAWP activities, projects and studies Antonio M. Risitano (Avellino, Italy) | 09:00 - 09:10 |
| SAAWP-2 | HCT for Dyskeratosis Congenita: an updated study from the SAAWP Fabiana Cacace (Naples, Italy) | 09:10 - 09:25 |
| SAAWP-3 | Critical decision points in acquired Aplastic Anemia: Diagnosis, therapy selection, and IST management Phillip Scheinberg (Sao Paulo, Brazil) | 09:25 - 09:40 |
| SAAWP-4 | Q&A | 09:40 - 09:50 |
| SAAWP-5 | Gene therapy for inherited bone marrow failure syndromes Paula Rio (Madrid, Spain) | 09:50 - 10:05 |
| SAAWP-6 | Q&A | 10:05 - 10:15 |

Special Session

09:00 - 10:30

R14

SS01 - Equality, Diversity, and Inclusion Session

Silvia Montoto (London, United Kingdom of Great Britain and Northern Ireland (the))

John Snowden (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))

| | | |
|--------|--|---------------|
| SS01-1 | Impaired access to cellular therapy treatment and clinical trials in LMIC: impact on women Candice Hendricks (Pretoria, South Africa) | 09:00 - 09:20 |
| SS01-2 | Management of LGBTQ+ patients with cancer Alison Berner (London, United Kingdom of Great Britain and Northern Ireland (the)) | 09:20 - 09:40 |
| SS01-3 | Black Women in UK STEM Higher Education: Challenges and Change Vanessa Apea (London, United Kingdom of Great Britain and Northern Ireland (the)) | 09:40 - 10:00 |
| SS01-4 | Panel Discussion | 10:00 - 10:15 |

Patient Advocacy Session

09:00 - 10:15

R16

PAS1 - Patient Advocacy Committee Session 1 | Does Autoimmune Diseases stem cell based care need "undisciplined" medicine?

Noelle Tassy (Marseilles, France)

Natacha Bolaños (Madrid, Spain)

| | | |
|--------|--|---------------|
| PAS1-1 | Introduction | 09:00 - 09:05 |
| PAS1-2 | The PACIFIC initiative: Towards an Integrated Research and Care Center in Auto and Allo Immunity in France Seiamak Bahram (Strasbourg, France) | 09:05 - 09:20 |
| PAS1-3 | Autologous BMT for AIDs: Advancing the Interface between Hematology and Disease-specific specialties Richard Burt (La Jolla, United States of America (the)) | 09:20 - 09:40 |
| PAS1-4 | The Multidisciplinary Model for Optimal Management of Multiple Sclerosis Abdelfatah Ibrahim (London, United Kingdom of Great Britain and Northern Ireland (the)) | 09:40 - 09:55 |

| | | |
|---|--|---------------|
| PAS1-5 | Discussion - Q&A | 09:55 - 10:15 |
| <i>Special Session</i> | | |
| 09:00 - 10:00 | | R17 |
| SS02 - Special Session From Page to Podium: mastering publication and presentation in Hematology | | |
| Mohamad Mohty (Paris, France) | | |
| SS02-1 | From page to podium: mastering publication and presentation in Hematology | 09:00 - 10:00 |
| | Mohamad Mohty (Paris, France) Yishan Ye (Hangzhou, China) | |
| <i>Breaks</i> | | |
| 10:30 - 11:00 | | R1 |
| Coffee Break, ePoster Viewing, Visit Exhibition | | |
| <i>Workshop</i> | | |
| 11:00 - 12:30 | | R1 |
| W02 - Workshop GVHD beyond immunosuppression - Regulation, repair, and innovation | | |
| Guillermo Orti Pascual (Barcelona, Spain) Zinaida Peric (Rijeka, Croatia) | | |
| W02-1 | Introduction | 11:00 - 11:05 |
| W02-2 | Current state of microbiota transplantation in allogeneic HCT | 11:05 - 11:20 |
| | Florent Malard (Paris, France) | |
| W02-3 | Potential new regulators of GVHD from basic studies | 11:20 - 11:35 |
| | Simon Mendez-Ferrer (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | |
| W02-4 | From bench to bedside - Emerging therapeutic strategies in GVHD | 11:35 - 11:50 |
| | José Antonio Pérez Simón (Sevilla, Spain) | |
| W02-5 | Key updates from the NIH Chronic GVHD Consensus Project | 11:50 - 12:05 |
| | Steven Pavletic (Rockville, United States of America (the)) | |
| W02-6 | Panel discussion on novel strategies beyond immunosuppression to help the management of acute and chronic GVHD, and Q&A | 12:05 - 12:30 |
| <i>Workshop</i> | | |
| 11:00 - 12:30 | | R2 |
| W03 - Workshop A focus on allogeneic HCT in myelodysplastic neoplasms | | |
| Donal McLornan (London, United Kingdom of Great Britain and Northern Ireland (the)) | | |
| W03-1 | Introduction | 11:00 - 11:05 |
| W03-2 | Harnessing machine learning to improve outcomes of allogeneic HCT in MDS | 11:05 - 11:20 |
| | Adrián Mosquera Orgueira (Santiago de Compostela, Spain) | |
| W03-3 | Contemporary approaches to VEXAS | 11:20 - 11:35 |
| | Fabio Ciceri (Milano, Italy) | |
| W03-4 | Allogeneic HCT in MDS/MPN overlap syndromes | 11:35 - 11:50 |
| | Kavita Raj (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| W03-5 | Management of MDS relapse after allogeneic HCT | 11:50 - 12:05 |
| | Marie Robin (Paris, France) | |
| W03-6 | Panel discussion on allogeneic HCE in MDS, and Q&A | 12:05 - 12:30 |

Cell Therapy Day

11:00 - 12:15

R3

CTD2 - Cell Therapy Day 2 | alloHCT and HLA

Annalisa Ruggeri (Milano, Italy)

Federico Simonetta (Genève, Switzerland)

| | | |
|--------|---|---------------|
| CTD2-1 | Does registry growth still matter in 2025 - importance to increase the ethnical diversity of the donors on the registry? Effie Petersdorf (Seattle, United States of America (the)) | 11:00 - 11:25 |
| CTD2-2 | Impact of KIR and HLA gene polymorphisms on anti-leukemic NK responses after haploHCT with PTCy Katia Gagne (Nantes, France) | 11:25 - 11:50 |
| CTD2-3 | The use of expanded cord in patients with high risk malignancies Guy Sauvageau (Montreal, Canada) | 11:50 - 12:15 |

Educational

11:00 - 12:30

R4

E02 - Educational | Advances in Hemoglobinopathies in the era of transplantation and gene therapy

Abdul Hakim Al Rawas (Muscat, Oman)

Cristina Beléndez (Madrid, Spain)

| | | |
|-------|---|---------------|
| E02-1 | Introduction | 11:00 - 11:05 |
| E02-2 | Definition of clinical outcome for transplantation and gene therapy in Thalassemia and Sickle cell disease Valeria Maria Pinto (Genoa, Italy) | 11:05 - 11:20 |
| E02-3 | Transplantation in adult Thalassemia Emanuele Angelucci (Genova, Italy) | 11:20 - 11:35 |
| E02-4 | A track of the clones: Novel tracking tools in sickle cell gene therapy David Kent (York, United Kingdom of Great Britain and Northern Ireland (the)) | 11:35 - 11:50 |
| E02-5 | Use of chimerism in transplantation for hemoglobinopathies Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the)) | 11:50 - 12:05 |
| E02-6 | Panel discussion on advances in hemoglobinopathies in the era of transplantation and gene therapy, and Q&A | 12:05 - 12:30 |

Oral Session

11:00 - 12:15

R5

OS03 - Oral Session 3 | Acute Leukaemia (I)

Eolia Brissot (Paris, France)

| | | |
|---------|--|---------------|
| OS03-01 | PHASE 1 EVALUATION OF THE SAFETY AND EFFICACY OF RAPCABTAGENE AUTOLEUCEL (YTB323) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) Alessandro Rambaldi (Bergamo, Italy) | 11:00 - 11:09 |
| OS03-02 | OPTIMIZING TRANSPLANT OUTCOMES IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH PRE-TRANSPLANT SECOND- AND THIRD-GENERATION TKIS AND POST-TRANSPLANT PROPHYLACTIC MAINTENANCE: A STUDY FROM THE EBMT ALWP Iman Abou Dalle (Beirut, Lebanon) | 11:09 - 11:18 |
| OS03-03 | CLINICAL OUTCOMES IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL) WHO ACHIEVED REMISSION FOLLOWING TREATMENT WITH OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN | 11:18 - 11:27 |

THE FELIX STUDY

Manuel Guerreiro (Valencia, Spain)

- | | | |
|---------|--|---------------|
| OS03-04 | DECITABINE PREVENTS POST-TRANSPLANT RELAPSE IN ACUTE MYELOID LEUKEMIA BY IMMUNOMETABOLIC REPROGRAMMING OF MACROPHAGES VIA THE H3K4ME3-ACOD1-ITACONATE AXIS Yutong Xie (Chongqing, China) | 11:27 - 11:36 |
| OS03-05 | CHANGING LANDSCAPE OF HAPLOIDENTICAL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A TEN-YEAR ANALYSIS OF PRACTICES AND OUTCOMES - A STUDY FROM THE ALWP/EBMT Eolia Brissot (Paris, France) | 11:36 - 11:45 |
| OS03-06 | OLDER MATCHED SIBLING DONOR VS YOUNG HAPLOIDENTICAL DONOR FOR ALLOGENEIC TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN SECONDARY ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ALWP/EBMT Arnon Nagler (Ramat Gan, Israel) | 11:45 - 11:54 |
| OS03-07 | UM171-EXPANDED CORD BLOOD AS A SAFE AND POTENT GRAFT SOURCE FOR HIGH-RISK LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES WITH DURABLE LONG-TERM SURVIVAL Sandra Cohen (Montréal, Canada) | 11:54 - 12:03 |
| OS03-08 | DO 2 YEAR PATIENT OUTCOMES DIFFER BY DONOR TYPE USING CONTEMPORARY GRAFT VS HOST DISEASE PROPHYLAXIS POST-TRANSPLANT? A CIBMTR RETROSPECTIVE ANALYSIS Steven M. Devine (Minneapolis, United States Minor Outlying Islands (the)) | 12:03 - 12:12 |

Oral Session

11:00 - 12:15

R6

OS04 - Oral Session 4 | Non-infective complications other than GVHD

Rosamaria Nitti (Milan, Italy)

- | | | |
|---------|--|---------------|
| OS04-01 | RAVULIZUMAB PLUS BEST SUPPORTIVE CARE IN PEDIATRIC PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY: 52-WEEK RESULTS FROM A PHASE 3 TRIAL David Bueno Sánchez (Madrid, Spain) | 11:00 - 11:09 |
| OS04-02 | UPDATED INTERIM ANALYSIS-POEM MULTI-CENTER STUDY: TOWARDS A SEQUENTIAL TIME ADJUSTED RISK MODEL FOR PREDICTION OF ENDOTHELIOPATHIES POST-HCT Kris Michael Mahadeo (Durham, United States of America (the)) | 11:09 - 11:18 |
| OS04-03 | ORAL IPTACOPAN DEMONSTRATES EFFICACY AS SALVAGE THERAPY FOR HIGH-RISK TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: FIRST REAL-WORLD EXPERIENCE Fei Gao (Hangzhou, China) | 11:18 - 11:27 |
| OS04-04 | PERI-TRANSPLANT GUT MICROBIOME INJURY AND ENTEROCOCCUS FAECIUM DOMINATION ARE ASSOCIATED WITH INCREASED MORTALITY IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Enrico Velardi (Rome, Italy) | 11:27 - 11:36 |
| OS04-05 | BASILINE LIVER ELASTOGRAPHY PREDICTS THE RISK OF SOS/VOD IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Lorenzo Lazzari (Milano, Italy) | 11:36 - 11:45 |
| OS04-06 | PENTRAXIN 3 AS EARLY BIOMARKER TO PREDICT ACUTE GRAFT-VERSUS-HOST DISEASE AND TRANSPLANT-RELATED MORTALITY | 11:45 - 11:54 |

| | | |
|---|--|---------------|
| | Rosamaria Nitti (Milan, Italy) | |
| OS04-07 | POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IS ASSOCIATED WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE USE AND DELAYED B AND T-CELL IMMUNE RECOVERY Davide Murgia (Bergamo, Italy) | 11:54 - 12:03 |
| OS04-08 | RISK FACTORS FOR HEPATIC VENO-OCCLUSIVE DISEASE AFTER ALLO-HSCT IN ACUTE LEUKEMIA PATIENTS TREATED WITH ANTIBODY-DRUG CONJUGATES Zhemal Rakhmanova (Saint-Petersburg, Russian Federation (the)) | 12:03 - 12:12 |
| <i>Nurses Group</i> | | |
| 11:00 - 12:30 | | R7 |
| NG07 - Nurses Group Oral Adult - Best Abstract Award Finalist | | |
| Elin Ofverberg (Gothenburg, Sweden) Sara Marcos Asensio (Salamanca, Spain) | | |
| NG07-01 | JOURNEY MAPPING AS A METHOD TO EXPLORE THE ADOPTIVE CELL THERAPY EXPERIENCE OF PATIENTS, INFORMAL CAREGIVERS, AND HEALTHCARE PROFESSIONALS Nina Canova (Lausanne, Switzerland) | 11:00 - 11:15 |
| NG07-02 | VITAMIN D MONITORING AND REPLACEMENT IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A CLINICAL AUDIT OF PRACTICE AGAINST REGIONAL GUIDELINES Maeve O'Shea (London, United Kingdom of Great Britain and Northern Ireland (the)) | 11:15 - 11:30 |
| NG07-03 | ENHANCING PREPAREDNESS AND WELL-BEING IN ALLOGENEIC STEM CELL TRANSPLANTATION: A MIXED-METHODS EVALUATION AND OPTIMISATION OF THE NURSE-LED ANIMO SUPPORT NETWORK Alexandra Iosif (Munich, Germany) | 11:30 - 11:45 |
| NG07-04 | GENDER MATTERS: UNDERSTANDING RETURN-TO-WORK EXPERIENCES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Karine Bilodeau (Montreal, Canada) | 11:45 - 12:00 |
| NG07-05 | IMPACT OF A STRUCTURED PRE-TRANSPLANT NUTRITION PROGRAM WITHIN A FRAILTY-PREHABILITATION STRATEGY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Maria Cancio-Solé (Barcelona, Spain) | 12:00 - 12:15 |
| <i>Working Party Session</i> | | |
| 11:00 - 12:15 | | R8 |
| LWP - Lymphoma Working Party Session | | |
| Ali Bazarbachi (Beirut, Lebanon) Charalampia Kyriakou (London, United Kingdom of Great Britain and Northern Ireland (the)) | | |
| LWP1-1 | Report of LWP activities & introduction Jian Jian Luan award Ali Bazarbachi (Beirut, Lebanon) | 11:00 - 11:15 |
| LWP1-2 | COMPARATIVE EFFICACY OF AXICABTAGENE CILOLEUCEL AND LISOCABTAGENE MARALEUCEL IN SECOND LINE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA - AN EBMT ANALYSIS Anna Ossami Saidy (Berlin, Germany) | 11:15 - 11:30 |
| LWP1-3 | EBMT Consensus on transplantation in Hodgkin lymphoma Anna Sureda (Barcelona, Spain) | 11:30 - 11:40 |
| LWP1-4 | EBMT Consensus on transplant and cellular therapy in Mantle cell | 11:40 - 11:50 |

| | | |
|---|--|---------------|
| | lymphoma | |
| | Peter Dreger (Heidelberg, Germany) | |
| LWP1-5 | Controversy on CAR-T versus Bispecifics for follicular lymphoma | 11:50 - 11:50 |
| LWP1-5.1 | In favor of CAR-T | 11:50 - 11:57 |
| | Yasmina Serroukh (Rotterdam, Netherlands (the)) | |
| LWP1-5.2 | In favor of bispecifics | 11:57 - 12:04 |
| | Kim Linton (United Kingdom of Great Britain and Northern Ireland (the)) | |
| LWP1-5.3 | Discussion | 12:04 - 12:10 |
| | | |
| <i>Oral Session</i> | | |
| 11:00 - 12:15 | | |
| | | R9 |
| OS05 - Oral Session 5 Immune reconstitution and chimerism | | |
| Ismael Buño (Madrid, Spain) | | |
| Rebecca Goodhew (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | | |
| OS05-01 | COMBINED TRANSPLANTS (HEMATOPOIETIC STEM CELL AND SOLID ORGAN) TO ACHIEVE IMMUNE TOLERANCE: A EUROPEAN PEDIATRIC STUDY | 11:00 - 11:09 |
| | Pietro Merli (Rome, Italy) | |
| OS05-02 | EARLY IMMUNE RECOVERY IN MISMATCHED UNRELATED DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION USING REDUCED-DOSE POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: RESULTS FROM THE OPTIMIZE TRIAL | 11:09 - 11:18 |
| | Jeffery J. Auletta (Minneapolis, United States Minor Outlying Islands (the)) | |
| OS05-03 | SYSTEMS BIOLOGY APPROACH REVEALS BDNF AS A DRIVER OF B-CELL REGENERATION | 11:18 - 11:27 |
| | Neta Nevo (Haifa, Israel) | |
| OS05-04 | COMPARISON OF IMMUNE RECONSTITUTION AND INFECTION-RELATED OUTCOMES WITH PT-CY VERSUS ATG AFTER MUD TRANSPLANTATION FOR HIGH-RISK MYELOID MALIGNANCIES | 11:27 - 11:36 |
| | Giulia Furnari (Milan, Italy) | |
| OS05-05 | THREE-MONTH CHIMERISM-TRIGGERED PRE-EMPTIVE DONOR LYMPHOCYTE INFUSIONS IMPROVE OUTCOMES IN T-CELL-DEPLETED ALLOGENEIC STEM CELL TRANSPLANTS FOR HAEMATOLOGICAL MALIGNANCIES | 11:36 - 11:45 |
| | Rebecca Goodhew (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | |
| OS05-06 | EVALUATION OF FACTORS THAT MAY INFLUENCE CHIMERISM IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SICKLE CELL DISEASE | 11:45 - 11:54 |
| | Teresa Martín Aláez (Madrid, Spain) | |
| OS05-07 | LOW T-CELL RESPONSES TO PHYTOHEMAGGLUTININ ARE ASSOCIATED WITH INCREASED RELAPSE AND MORTALITY AT 1-YEAR POST-CAR-T CELL THERAPY | 11:54 - 12:03 |
| | Francesco Peracchi (Milan, Italy) | |
| OS05-08 | PHARMACOLOGICAL MODULATION OF PROTEOSTASIS AS A STRATEGY TO BOOST THYMIC REGENERATION AND T CELL IMMUNITY | 12:03 - 12:12 |
| | Shirley Genah (Rome, Italy) | |

Pharmacists Day

11:00 - 12:15

R10

Pharm2 - Pharmacists Day 2 | Education and Training and Research

Vera Domingos (Lisbon, Portugal)

Vera Pires (Lisbon, Portugal)

| | | |
|----------|--|---------------|
| Pharm2-1 | JACIE Standards for Pharmacists Tiene Bauters (Ghent, Belgium) | 11:00 - 11:25 |
| Pharm2-2 | ENABLING MODEL INFORMED PRECISION DOSING OF BUSULFAN IN HSCT PATIENTS: AN EXTERNAL MODEL EVALUATION Sandra Witta (Hamburg, Germany) | 11:25 - 11:40 |
| Pharm2-3 | HIGHER INFLIXIMAB EXPOSURE IS ASSOCIATED WITH IMPROVED RESPONSE IN PEDIATRIC STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE: DO WE NEED THERAPEUTIC DRUG MONITORING? Shaden Mahmmod (Utrecht, Netherlands (the)) | 11:40 - 11:55 |
| Pharm2-5 | Q&A | 12:10 - 12:15 |

Data Management

11:00 - 12:05

R11

DM2 - Data Management Session 2 | Data reporting: core, extended and study-specific data

Emmanuelle Polge (PARIS, France)

Nikolaos Glentis (Utrecht, Netherlands (the))

| | | |
|-------|--|---------------|
| DM2-1 | Data collection form updates 2026 Alina Kuliesh (Leiden, Netherlands (the)) | 11:00 - 11:15 |
| DM2-2 | The EBMT Registry Study Manager for data collection William Boreland (Paris, France) | 11:15 - 11:30 |
| DM2-3 | How to count the number of treatment lines in acute leukemia Alessandro Criscimanna (Milan, Italy) Aleksandra Gavrilina (Paris, France) | 11:30 - 11:50 |
| DM2-4 | Q&A | 11:50 - 12:05 |

How do I... ?

11:00 - 12:15

R12

HDI2 - How Do I...CAR T-cell counseling and caregiver support | Supported through an unrestricted educational grant by Gilead and Kite

Michelle Kenyon (LONDON, United Kingdom of Great Britain and Northern Ireland (the))

María Soledad Jiménez Picazo (Córdoba, Spain)

| | | |
|--------|---|---------------|
| HDI2-1 | CAR T-cell counseling and decision making Britt Snoek (Rotterdam, Netherlands (the)) | 11:00 - 11:20 |
| HDI2-2 | Supporting caregivers of adults receiving CAR T-cell therapy Maxime Berquier (PARIS, France) | 11:20 - 11:40 |
| HDI2-3 | Supporting caregivers of children receiving CAR T-cell therapy Marieke Van der Vlugt (Utrecht, Netherlands (the)) | 11:40 - 12:00 |
| HDI2-4 | Panel Discussion | 12:00 - 12:15 |

Nurses Group

11:00 - 12:30

R13

NG08 - Nurses Group | Global Education

Julia Ruiz Pato (Madrid, Spain)

Liana Abu Rumieleh (Jerusalem, Israel)

| | | |
|--------|--|---------------|
| NG08-1 | Empowering Nurses for Sustainable Healthcare Futures Kim Verhaegh (Leiden, Netherlands (the)) | 11:00 - 11:21 |
| NG08-2 | Recommendations for equitable, diverse and Inclusive Cancer Care in Europe. Katie Rizvi (Budapest, Hungary) | 11:21 - 11:42 |
| NG08-3 | Outreach project: EBMT Middle-Income Countries Paediatric Advanced Care Training Lawrence Faulkner (Florence, Italy) | 11:42 - 12:03 |
| NG08-4 | Collaborative pathways in HCT and cell therapy: Training nurses in South Africa Sithembiso Cyril Mthimkhulu (Johannesburg, South Africa) | 12:03 - 12:24 |
| NG08-5 | Q&A | 12:24 - 12:29 |

Statistics

11:00 - 12:00

R14

STATS1 - Statistical Symposium | Regression modelling for competing risks

Liesbeth de Wreede (Leiden, Netherlands (the))

Simona Iacobelli (Rome, Italy)

| | | |
|----------|---|---------------|
| STATS1-1 | Regression modelling for competing risks: cause-specific hazards model versus the Fine-Gray model Kwang Woo Ahn (Milwaukee, United States of America (the)) | 11:00 - 11:15 |
| STATS1-2 | The Fine-Gray model and the problem of total failure probability larger than one Hein Putter (Leiden, Netherlands (the)) | 11:15 - 11:30 |
| STATS1-3 | Matched time-to-event analysis of competing risks outcomes of haploidentical transplants: why, what, how? Jan Beyersmann (Ulm, Germany) | 11:30 - 11:45 |
| STATS1-4 | Q&A | 11:45 - 12:00 |

Patient Advocacy Session

11:00 - 12:15

R16

PAS2 - Patient Advocacy Committee Session 2 | The next evolution of the EBMT Registry: Patient-Reported Outcomes in the era of patient experience data

Natacha Bolaños (Madrid, Spain)

John Snowden (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))

| | | |
|--------|--|---------------|
| PAS2-1 | The Patient Perspective in the Era of Patient Experience Data Lorna Warwick (Etobicoke, Canada) | 11:00 - 11:10 |
| PAS2-2 | Why Regulators and Health Systems Need Registry-Based PROs Roberto Nuño (Bilbao, Spain) | 11:10 - 11:20 |
| PAS2-3 | Panel Discussion - Operationalising PRO Collection within the EBMT Registry and expectations for registries as evidence generators Lorna Warwick (Etobicoke, Canada) Roberto Nuño (Bilbao, Spain) Per Ljungman (Stockholm, Sweden) John Snowden (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | 11:20 - 12:15 |

| | | |
|--|---|---------------|
| | Treatment of Transplant-Eligible NDMM Philippe Moreau (Nantes, France) | |
| IS20-3 | Maximizing Patient Outcomes With Novel Administration Methods and Strategies for Supportive Care Meletios-Athanasios C. Dimopoulos (Athens, Greece) | 13:35 - 13:50 |
| IS20-4 | Final Audience Q&A - All Faculty | 13:50 - 14:00 |
| <i>Industry Symposium</i> | | |
| 13:00 - 14:00 | | R3 |
| IS21 - Global perspectives on optimising the patient HCT journey in haemoglobinopathies Vertex | | |
| Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the)) | | |
| IS21-1 | Welcome and introduction Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the)) | 13:00 - 13:10 |
| IS21-2 | Patient selection: Lessons from real-world HCT practice Mohammed Essa (Riyadh, Saudi Arabia) | 13:10 - 13:25 |
| IS21-3 | Optimising the patient journey: Learnings from clinical experience in gene therapies Rabi Hanna (Cleveland, United States of America (the)) | 13:25 - 13:40 |
| IS21-4 | Panel discussion and clinical perspectives - All faculty Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the)) | 13:40 - 14:00 |
| <i>Meetings</i> | | |
| 13:00 - 14:00 | | R13 |
| BM-NG - EBMT Nurses Group overview opportunities and networking | | |
| <i>Industry Meet the Expert</i> | | |
| 13:00 - 14:00 | | R18 |
| S-MTE - Clinical Experiences with Engineered Cell Therapy Orca-T in Allogeneic HCT Orca Bio | | |
| Lori Muffly (Stanford, United States of America (the)) Alexandra Gomez Arteaga (New York, United States of America (the)) | | |
| <i>Industry Meet the Expert</i> | | |
| 13:00 - 14:00 | | R18 |
| S-MTE - Meet the Expert | | |
| <i>Industry Theatre</i> | | |
| 13:10 - 13:45 | | R19 |
| IT1 - Choosing allogeneic cell therapy in 2026: From decision to impact Pierre Fabre | | |
| Anna Sureda (Barcelona, Spain) | | |
| IT1-1 | Welcome Anna Sureda (Barcelona, Spain) | 13:10 - 13:13 |
| IT1-2 | Speaker Presentation Anna Sureda (Barcelona, Spain) | 13:13 - 13:18 |
| IT1-3 | Speaker Presentation Christof Scheid (Cologne, Germany) | 13:18 - 13:38 |
| IT1-4 | Discussion & Q&A Anna Sureda (Barcelona, Spain) Christof Scheid (Cologne, Germany) | 13:38 - 13:43 |

| | | |
|--------|--|---------------|
| CTD3-1 | New tools for prediction and treatment of CRS and ICANS Marion Subklewe (Munich, Germany) | 14:30 - 14:55 |
| CTD3-2 | Eligibility criteria for patients receiving CAR-T for DLBCL Annalisa Ruggeri (Milano, Italy) | 14:55 - 15:20 |
| CTD3-3 | CAR-T as outpatient program Christof Scheid (Cologne, Germany) | 15:20 - 15:45 |

Working Party Session

14:30 - 15:45

R4

IDWP - Infectious Diseases Working Party Session

Jan Styczynski (Bydgoszcz, Poland)

| | | |
|--------|---|---------------|
| IDWP-1 | Refractory/ resistant HSV and CMV - an underestimated problem? Per Ljungman (Stockholm, Sweden) | 14:30 - 14:48 |
| IDWP-2 | Specifics of infections management in patients following post-transplantation cyclophosphamide Montserrat Rovira (Barcelona, Spain) | 14:48 - 15:06 |
| IDWP-3 | Antifungal/antiviral/antibacterial prophylaxis update: who, what, how long? Dionysios Neofytos (Geneva, Switzerland) | 15:06 - 15:24 |
| IDWP-4 | Top 10 papers 2025-2026 on new antibiotics and other infectious topics Malgorzata Mikulska (Genova, Italy) | 15:24 - 15:42 |

Educational

14:30 - 16:00

R5

E04 - Educational | Beware of the Donor - Beyond compatibility in allogeneic HCT

Alejandro Madrigal (LONDON, United Kingdom of Great Britain and Northern Ireland (the))

Bronwen Shaw (Milwaukee, United States of America (the))

| | | |
|-------|---|---------------|
| E04-1 | Introduction | 14:30 - 14:35 |
| E04-2 | Molecular diagnosis of germline leukemias Carmelo Gurnari (Rome, Italy) | 14:35 - 14:50 |
| E04-3 | Donor-derived leukemias after allogeneic HCT Bipin Savani (Nashville, United States of America (the)) | 14:50 - 15:05 |
| E04-4 | Germline leukemias and donor selection Jordi Esteve (Barcelona, Spain) | 15:05 - 15:20 |
| E04-5 | Beyond HLA, how to identify the best allogeneic donor? The value of biorepositories to explore other biomarkers Stephen R. Spellman (Minneapolis, United States Minor Outlying Islands (the)) | 15:20 - 15:35 |
| E04-6 | Panel discussion on germline hematologic malignancies, donor risk and impact on donor selection, and Q&A | 15:35 - 16:00 |

Oral Session

14:30 - 15:45

R6

OS06 - Oral Session 6 | Conditioning regimen

Kim Orchard (Southampton, United Kingdom of Great Britain and Northern Ireland (the))

Julia Katharina Scholz (Erlangen, Germany)

| | | |
|---------|--|---------------|
| OS06-01 | PICKING STRONG BRIDGING REGIMENS BEFORE CD19 CAR-T CELL THERAPY OF LARGE B CELL LYMPHOMA - HOW HISTOLOGY AND HIGH LDH IMPACT LONG-TERM OUTCOMES | 14:30 - 14:39 |
|---------|--|---------------|

| | | |
|---------|---|---------------|
| | Julia Katharina Scholz (Erlangen, Germany) | |
| OS06-02 | MYELOABLATIVE IS NOT ALWAYS BETTER: DISMANTLING THE ONE-SIZE-FITS-ALL APPROACH TO HAPLOIDENTICAL CONDITIONING INTENSITY Yosra Aljawai (Houston, United States Minor Outlying Islands (the)) | 14:39 - 14:48 |
| OS06-03 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH BRIQUILIMAB ANTI-CD117 ANTIBODY-BASED NONMYELOABLATIVE CONDITIONING FOR GATA2 DEFICIENCY Danielle Arnold (Bethesda, United States Minor Outlying Islands (the)) | 14:48 - 14:57 |
| OS06-04 | CAN WE ELIMINATE TBI/BUSULFAN AND GVHD IN FANCONI ANEMIA TRANSPLANTATION? RESULTS FROM A PROSPECTIVE HAPLOIDENTICAL TRANSPLANT APPROACH Alice Bertaina (Palo Alto, United States Minor Outlying Islands (the)) | 14:57 - 15:06 |
| OS06-05 | EFFICACY OF A LOW-DOSE ATG-CONTAINING CONDITIONING REGIMEN FOR UMBILICAL CORD BLOOD TRANSPLANTATION IN SEVERE APLASTIC ANEMIA: A PROSPECTIVE, SINGLE-ARM CLINICAL TRIAL Yue Wu (Hefei, China) | 15:06 - 15:15 |
| OS06-06 | TREOSULFAN MODEL INFORMED PRECISION DOSING FOR OPTIMIZED CLINICAL OUTCOME IN CHILDREN AT HIGH RISK FOR OVER- OR UNDEREXPOSURE UNDERGOING ALLOGENEIC HSCT FOR NON-MALIGNANT DISEASES Dirk Jan A.R. Moes (Leiden, Netherlands (the)) | 15:15 - 15:24 |
| OS06-07 | ANTIBODY TARGETED RADIOTHERAPY CONDITIONING PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION: LONG-TERM FOLLOW-UP OF 40 PATIENTS WHO RECEIVED YTTRIUM-90 ANTI-CD66 IN A PHASE I/II TRIAL Kim Orchard (Southampton, United Kingdom of Great Britain and Northern Ireland (the)) | 15:24 - 15:33 |
| OS06-08 | TOTAL MARROW AND LYMPHOID IRRADIATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS CONFERS FAVORABLE GVHD/RELAPSE-FREE SURVIVAL AND QUALITY-OF-LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN REMISSION Anthony Stein (Duarte, CA, United States Minor Outlying Islands (the)) | 15:33 - 15:42 |

Nurses Group

14:30 - 16:00

R7

NG09 - Joint Session Nurses Group with the Patient Advocacy Committee | How to talk about female sexuality after transplant?

Angela Leather (Manchester, United Kingdom of Great Britain and Northern Ireland (the))

Jacqueline Del Castillo (London, United Kingdom of Great Britain and Northern Ireland (the))

| | | |
|--------|--|---------------|
| NG09-1 | Introduction | 14:30 - 14:35 |
| NG09-2 | Breaking the silence on female sexuality after transplant: my body, my voice Kirsti Scheffel (Bonn, Germany) | 14:35 - 14:45 |
| NG09-3 | Panel Discussion and Q&A | 14:45 - 14:55 |
| NG09-4 | Empowering women's health: Strategies for prevention and care Laurence Quarez-Blaise (Marseille, France) | 14:55 - 15:05 |
| NG09-5 | Panel Discussion and Q&A | 15:05 - 15:15 |
| NG09-6 | Transforming recovery: A nurse-led approach to women's health post-transplant Jacqui Stringer (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 15:15 - 15:25 |

| | | |
|--------|---|---------------|
| NG09-7 | Panel Discussion and Q&A | 15:25 - 15:35 |
| NG09-8 | The Mind-Body struggle: The psychosocial impact of altered sexuality and sexual function Anna Barata (Boston, United States of America (the)) | 15:35 - 15:45 |
| NG09-9 | Panel Discussion and Q&A | 15:45 - 15:55 |

Joint Sessions

14:30 - 15:45

R8

JS04 - Joint Session EBMT - EHA | The Microbiome and Immune Modulation: From Transplantation to Novel Therapies

Anna Sureda (Barcelona, Spain)

Konstanze Döhner (Ulm, Germany)

| | | |
|--------|--|---------------|
| JS04-1 | Microbiome and vaccines Vanessa Harris (Amsterdam, Netherlands (the)) | 14:30 - 14:50 |
| JS04-2 | Microbiome Modulation in Immune-Based and Targeted Therapies Hendrik Poeck (Regensburg, Germany) | 14:50 - 15:10 |
| JS04-3 | Panel Discussion | 15:10 - 15:40 |

How do I... ?

14:30 - 15:45

R9

HDI3 - How Do I... Treat first-line patients with high-risk BCL? | Supported through an unrestricted educational grant by Novartis

Alberto Mussetti (barcelona, Spain)

| | | |
|--------|--|---------------|
| HDI3-1 | From R-CHOP to Personalized First-Line Regimens: Evidence and Emerging Approaches Raúl Córdoba (Madrid, Spain) | 14:30 - 14:50 |
| HDI3-2 | Immunotherapy Frontiers: CAR-T and Immune-Based First-Line Strategies in High-Risk BCL Alberto Mussetti (barcelona, Spain) | 14:50 - 15:10 |
| HDI3-3 | Balancing Efficacy and Safety: Managing Cytokine Release Syndrome and Neurotoxicity Ana Alarcón Tomás (Madrid, Spain) | 15:10 - 15:30 |
| HDI3-4 | Q&A | 15:30 - 15:45 |

Pharmacists Day

14:30 - 15:45

R10

Pharm3 - Pharmacists Day 3 | Paediatrics and novel therapies

Rick Admiraal (Utrecht, Netherlands (the))

Claudia Langebrake (Hamburg, Germany)

| | | |
|----------|---|---------------|
| Pharm3-1 | Exa-cel for sickle cell anaemia and beta-thalassaemia Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the)) | 14:30 - 15:00 |
| Pharm3-2 | Paediatric Hematopoietic Cell Transplantation Conditioning: Infants to Adolescence - UK and US perspectives Vinita Pai (Columbus, United States of America (the)) Poonam Lumb (London, United Kingdom of Great Britain and Northern Ireland (the)) | 15:00 - 15:45 |

Data Management

14:30 - 15:45

R11

DM3 - Data Management Session 3 | EBMT Registry: hands-on training with the registry team

Igor Ariz (Barcelona, Spain)

Hendrikus Bouwman (Hilversum, Netherlands (the))

| | | |
|-------|--|---------------|
| DM3-1 | Training Opening Nadiia Dyba (Barcelona, Spain) | 14:30 - 14:45 |
| DM3-2 | Hands-on training - Part 1 Ignacio García (Eindhoven, Netherlands (the)) | 14:45 - 15:05 |
| DM3-3 | Hands-on training - Part 2 Nikolaos Glentis (Utrecht, Netherlands (the)) | 15:05 - 15:25 |
| DM3-4 | Q&A | 15:25 - 15:40 |

Working Party Session

14:30 - 15:45

R12

TCWP - Transplant Complications Working Party Session

Olaf Penack (Berlin, Germany)

Lars Klingen Gjørde (Copenhagen, Denmark)

| | | |
|--------|--|---------------|
| TCWP-1 | Introduction Olaf Penack (Berlin, Germany) | 14:30 - 14:35 |
| TCWP-2 | Expert recommendations on management of ruxolitinib-refractory GVHD Guillermo Orti Pascual (Barcelona, Spain) | 14:35 - 14:50 |
| TCWP-3 | Neurologic complications after alloSCT and CAR-T - EBMT guidelines and harmonization committee Roser Velasco (Barcelona, Spain) | 14:50 - 15:05 |
| TCWP-4 | Functional recovery post HCT or CART: Why exercise matters more than ever Eva Michel (MONTROUGE, France) | 15:05 - 15:20 |
| TCWP-5 | Palliative care in alloSCT and cellular therapies - EBMT guidelines and harmonization committee Michelle Kenyon (LONDON, United Kingdom of Great Britain and Northern Ireland (the)) | 15:20 - 15:35 |
| TCWP-6 | Q&A | 15:35 - 15:45 |

Nurses Group

14:30 - 16:00

R13

NG10 - Nurses Group | Oral Paediatric - Best Abstract Award Finalist

Ida Bremer Ophorst (Utrecht, Netherlands (the))

Maria Finch (London, United Kingdom of Great Britain and Northern Ireland (the))

| | | |
|---------|---|---------------|
| NG10-01 | PAIN MANAGEMENT PRACTICES DURING PAEDIATRIC ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE COHORT STUDY Karin Plummer (Gold Coast, Australia) | 14:30 - 14:45 |
| NG10-02 | SAFETY PROFILES OF TWO ANTI-THYMOCYTE GLOBULIN FORMULATIONS IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION: IMPLICATIONS FOR NURSING CARE Isabel Salcedo (Madrid, Spain) | 14:45 - 15:00 |
| NG10-03 | LISTENING TO THE YOUNG: EMPOWERING CHILDREN AND ADOLESCENTS IN SHAPING HEALTHCARE PLANNING Julia Ruiz Pato (Madrid, Spain) | 15:00 - 15:15 |

| | | |
|---------|---|---------------|
| NG10-04 | LEXI'S LEGACY - A LETTER TO HEALTHCARE PROFESSIONALS Karen Nicholson (London, United Kingdom of Great Britain and Northern Ireland (the)) | 15:15 - 15:30 |
| NG10-05 | SERVICE EVALUATION OF 'READY STEADY GO' TRANSITION QUESTIONNAIRE IN POST-CD34+ EX-VIVO GENE THERAPY PAEDIATRIC PATIENTS Rima Ahmed (London, United Kingdom of Great Britain and Northern Ireland (the)) | 15:30 - 15:45 |

Oral Session

14:30 - 15:45

R14

OS07 - Oral Session 7 | Predictive scores for relapse and complications

Thomas Luft (Heidelberg, Germany)

Natalia Tijaro Ovalle (New York, United States Minor Outlying Islands (the))

| | | |
|---------|---|---------------|
| OS07-01 | NOVEL COMPOSITE END-POINTS TOXICITY/PROGRESSION-FREE SURVIVAL (TFPFS) AND TOXICITY-FREE COMPLETE REMISSION (TFCR) AFTER CART19 CELL THERAPY FOR LARGE B CELL LYMPHOMA (LBCL): CELL THERAPY CONSORTIUM ANALYSIS Veronika Bachanova (Minneapolis, United States Minor Outlying Islands (the)) | 14:30 - 14:39 |
| OS07-02 | FRAILTY ASSESSMENT AND THEIR PROGNOSTIC SIGNIFICANCE IN CAR T-CELL THERAPY. RESULTS FROM A PROSPECTIVE AND LONGITUDINAL SINGLE-CENTER STUDY Rubén Solís Armenta (Barcelona, Spain) | 14:39 - 14:48 |
| OS07-03 | THE INFLAMIX SCORE PREDICTS VERY SEVERE CRS AND ICU ADMISSION, AS WELL AS PROGNOSIS, IN PATIENTS WITH LBCL TREATED WITH CAR-T THERAPY Eugenio Galli (Rome, Italy) | 14:48 - 14:57 |
| OS07-04 | A BASELINE INFLAMMATORY SIGNATURE IDENTIFIES IMPAIRED CD8+ T-CELL RECONSTITUTION AND RELAPSE RISK AFTER ALLOHCT IN AML, INDEPENDENT OF TP53 MUTATION AND MRD Natalia Tijaro Ovalle (New York, United States Minor Outlying Islands (the)) | 14:57 - 15:06 |
| OS07-05 | CARE-BMT RISK SCORE: CARDIOVASCULAR RISK STRATIFICATION IN 104 CONSECUTIVE PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Ambra Fumagalli (Milan, Italy) | 15:06 - 15:15 |
| OS07-06 | MULTIMODAL PREDICTION OF EARLY CARDIOVASCULAR TOXICITY AFTER CAR-T THERAPY Roni Shouval (New York, United States of America (the)) | 15:15 - 15:24 |
| OS07-07 | EXTERNAL VALIDATION OF THE ORIGINAL AND REFINED CARE-BMT SCORES FOR THE PREDICTION OF CARDIAC EVENTS AFTER ALLOGENEIC TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA Arnau Torrent-Rodríguez (Barcelona, Spain) | 15:24 - 15:33 |
| OS07-08 | SYSTEMATIC LIVER STIFFNESS MEASUREMENT FOR DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE IN ADULT PATIENTS UNDERGOING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE REAL-WORLD SINGLE-CENTRE EXPERIENCE Gianmario Pasqualone (Rome, Italy) | 15:33 - 15:42 |

Special Session

14:30 - 16:00

R16

SS04 - Special Session | The integration of patient voices in HCT/CT research and practice

Helene Schoemans (Leuven, Belgium)

Natacha Bolaños (Madrid, Spain)

| | | |
|--------|---------------------|---------------|
| SS04-1 | Introduction | 14:30 - 14:35 |
|--------|---------------------|---------------|

| | | |
|--------|--|---------------|
| SS04-2 | Physician perspective Helene Schoemans (Leuven, Belgium) | 14:35 - 14:55 |
| SS04-3 | Nurse perspective Paula González (Madrid, Spain) | 14:55 - 15:15 |
| SS04-4 | Patient perspective David Aguilar Prieto (Barcelona, Spain) | 15:15 - 15:35 |
| SS04-5 | Panel discussion on common strategies to further the integration of patient voices in research in HCT and CT, and Q&A | 15:35 - 16:00 |

Working Party Session

14:30 - 15:45

R17

JACIE WP - JACIE Working Party Session | Role of Accreditation in Cellular Therapies

Charles Crawley (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))

Richard Olaussen (Oslo, Norway)

| | | |
|-----------|--|---------------|
| JACIEWP-1 | The first year of JACIE Working Party Charles Crawley (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | 14:30 - 14:40 |
| JACIEWP-2 | Role of Accreditation in a changing landscape: The US Perspective Joseph Schwartz (Fort Lee, United States Minor Outlying Islands (the)) | 14:40 - 14:55 |
| JACIEWP-3 | Role of Accreditation in a changing landscape: The European Perspective Christian Chabannon (Marseille, France) | 14:55 - 15:10 |
| JACIEWP-4 | Beyond Europe: LMIC Task Force Sandra Loaiza (London, United Kingdom of Great Britain and Northern Ireland (the)) | 15:10 - 15:18 |
| JACIEWP-5 | Update on Quality Managers Committee Anne Emmett (London, United Kingdom of Great Britain and Northern Ireland (the)) | 15:18 - 15:26 |
| JACIEWP-6 | Update on the Inspector Committee Dania Arabi (Jeddah, Saudi Arabia) | 15:26 - 15:34 |
| JACIEWP-7 | Q&A | 15:34 - 15:44 |

Breaks

16:00 - 16:30

R1

Coffee Break, ePoster Viewing, Visit Exhibition*General*

16:30 - 18:00

R1

GS2 - Presidential Symposium

Anna Sureda (Barcelona, Spain)

Rafael Duarte (Madrid, Spain)

| | | |
|-------|---|---------------|
| GS2-1 | Van Bekkum Award - Introduction | 16:30 - 16:33 |
| GS2-2 | HIGH-THROUGHPUT DEEP LEARNING-BASED PROFILING OF CAR-T IMMUNE DYNAMICS FROM ROUTINE PERIPHERAL BLOOD SMEARS Roni Shouval (New York, United States of America (the)) | 16:33 - 16:48 |
| GS2-3 | Basic Science Award - Introduction | 16:48 - 16:51 |
| GS2-4 | CD19/CD84 IF-BETTER DUAL CAR T CELLS DEMONSTRATE SUPERIOR CONTROL OF CD19-LOW B-ALL THAN SINGLE CART19 Ane Altuna Mongelos (Barcelona, Spain) | 16:51 - 17:06 |

| | | |
|--------|--|---------------|
| GS2-5 | DURABLE CLINICAL BENEFITS WITH EXAGAMGLOGENE AUTOTEMCEL FOR GREATER THAN 6 YEARS OF FOLLOW-UP IN TRANSFUSION-DEPENDENT THALASSEMIA AND SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES Franco Locatelli (Rome, Italy) | 17:06 - 17:15 |
| GS2-6 | NON-RELAPSE MORTALITY FOLLOWING CAR-T CELL THERAPY: A STUDY BY THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY Charlotte E. Graham (London, United Kingdom of Great Britain and Northern Ireland (the)) | 17:15 - 17:24 |
| GS2-7 | NANOBODY-DERIVED CD19/CD22 TANDEM CAR-T THERAPY AS SALVAGE TREATMENT FOR IMMUNOTHERAPY-REFRACTORY B-ALL AFTER BLINATUMOMAB, INOTUZUMAB, OR PRIOR SINGLE-TARGET CAR-T: PHASE 1A DOSE FINDING AND RP2D EVALUATION Yi-Han Yang (Beijing, China) | 17:24 - 17:33 |
| GS2-8 | MAAT013 FOR RUXOLITINIB-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE WITH GASTROINTESTINAL INVOLVEMENT: FINAL RESULTS FROM THE ARES PHASE III TRIAL Florent Malard (Paris, France) | 17:33 - 17:42 |
| GS2-9 | SAFETY AND EFFICACY OF LENTIVIRAL HEMATOPOIETIC STEM AND PROGENITOR CELL GENE THERAPY WITH ETUVETIDIGENE AUTOTEMCEL FOR THE TREATMENT OF WISKOTT-ALDRICH SYNDROME Francesca Ferrua (Milan, Italy) | 17:42 - 17:51 |
| GS2-10 | LONG TERM EVALUATION OF EFFICACY AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS - NISSC-1 LONG TERM EXTENSION Joerg Henes (Tuebingen, Germany) Dominique Farge (Paris, France) | 17:51 - 18:00 |

Cell Therapy Day

16:30 - 17:45

R3

CTD4 - Cell Therapy Day 4 | New cellular therapy

Christian Chabannon (Marseille, France)

Marion Subklewe (Munich, Germany)

| | | |
|--------|---|---------------|
| CTD4-1 | Autologous T cell therapy for PRAME+ advanced solid tumors Martin Wermke (Dresden, Germany) | 16:30 - 16:55 |
| CTD4-2 | TIL and oncolytic viruses in melanoma Tine Monberg (Herlev, Denmark) | 16:55 - 17:20 |
| CTD4-3 | New targets and migration clues in solid cancer for natural and engineered immune cells Dorine de Bont (Utrecht, Netherlands (the)) | 17:20 - 17:45 |

Nurses Group

16:30 - 18:00

R7

NG11 - Nurses Group | Cell and Gene Therapy

Kelly Hennessy (London, United Kingdom of Great Britain and Northern Ireland (the))

Eugenia Trigoso (Valencia, Spain)

| | | |
|--------|---|---------------|
| NG11-1 | Does CAR-T cell change the landscape of multiple myeloma? Anneleen Vanhellefont (Leuven, Belgium) | 16:30 - 16:51 |
| NG11-2 | Does CAR-T cell change the landscape of autoimmune diseases? Claudia Boglione (Florence, Italy) | 16:51 - 17:12 |

| | | |
|---|---|---------------|
| NG11-3 | Does Gene Therapy change the landscape of sickle cell disease? Sandrine Bremathas (London, United Kingdom of Great Britain and Northern Ireland (the)) | 17:12 - 17:33 |
| NG11-4 | Does gene therapy change the landscape of immune deficiencies? Jinhua Xu-Bayford (London, United Kingdom of Great Britain and Northern Ireland (the)) | 17:33 - 17:54 |
| NG11-5 | Q&A | 17:54 - 18:00 |
| <i>Pharmacists Day</i> | | |
| 16:30 - 17:45 | | R10 |
| Pharm4 - Pharmacists Day 4 Service delivery - joint session with EBMT Nurses Group | | |
| Katerina Nezvalova Henriksen (Oslo, Norway) Marijke Quaghebeur (Ghent, Belgium) | | |
| Pharm4-1 | Novel models of care for transplant delivery Aleksandra Trojan (Köln, Germany) | 16:30 - 16:40 |
| Pharm4-1.1 | Experience with particular delivery models - Pharmacist experience Estela Moreno Martinez (Barcelona, Spain) | 16:40 - 16:55 |
| Pharm4-1.2 | Experience with particular delivery models - Nurse experience Efstathia Sarla (Stockholm, Sweden) | 16:55 - 17:10 |
| Pharm4-2 | Pharmaceutical aspects of delivering transplant treatments Mathias Buaas Austli (Oslo, Norway) | 17:10 - 17:25 |
| Pharm4-3 | Panel discussion | 17:25 - 17:45 |
| <i>Data Management</i> | | |
| 16:30 - 17:45 | | R11 |
| DM4 - Data Management Session 4 How to report: cell therapies and treatment histories | | |
| Steffie van der Werf (Leiden, Netherlands (the)) Jacques - Emmanuel Galimard (PARIS, France) | | |
| DM4-1 | How do I add TIL therapies (Tumor Infiltrating Lymphocytes) or VST therapies (Virus-specific T-cells) into the EBMT Registry Patrizia Comoli (Pavia, Italy) Jeroen Knippenberg (Leiden, Netherlands (the)) | 16:30 - 16:50 |
| DM4-2 | How to define hematological relapse of AML Giorgio Orofino (Milan, Italy) Pascale Ambron (Paris, France) | 16:50 - 17:10 |
| DM4-3 | How to count the number of treatment lines pre HCT/CT in myeloma Patrick Hayden (Dublin, Ireland) Joe Tuffnell (Rotterdam, Netherlands (the)) | 17:10 - 17:30 |
| DM4-4 | Q&A | 17:30 - 17:45 |
| <i>Nurses Group</i> | | |
| 16:30 - 18:00 | | R13 |
| NG12 - Nurses Group Oral Session I | | |
| Cristina Gallego Miralles (Barcelona, Spain) Anna Serrahima (Girona, Spain) | | |
| NG12-04 | THE CURRENT SITUATION OF STRESS AND MENTAL HEALTH INTERVENTION OF HEMATOPOIETIC STEM CELL TRANSPLANT CAREGIVERS Shasha Li (Chongqing, China) Yuqing Liu (China) | 16:30 - 16:45 |
| NG12-02 | HIGH LEVELS OF SYMPTOMS ARE LINKED TO STRONGER SELF- | 16:45 - 17:00 |

CARE MANAGEMENT IN ALLO-HCT SURVIVORS

Cecilia Engberg de Carvalho (Lund, Sweden)

- NG12-01 **CLOSING THE GAP IN DONOR CARE: A RETROSPECTIVE AUDIT OF RELATED STEM CELL DONOR FOLLOW-UP** 17:15 - 17:30
Patricia Cardoso (London, United Kingdom of Great Britain and Northern Ireland (the))
- NG12-05 **PERCEIVED BURDEN IN PRIMARY CAREGIVERS FOR AT-HOME HOSPITALIZATION AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE** 17:30 - 17:45
Marta Yusta Arnal (Barcelona, Spain)

Printed Poster

18:00 - 19:00

R1

Nurses Posters- Research

- NP38 **PSYCHOSOCIAL ASSESSMENT OF PATIENTS AND CAREGIVERS UNDERGOING AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION AT HOME** 18:00 - 18:00
Ana Rodriguez Calvo-Parra (Madrid, Spain)
- NP39 **EFFICACY OF ACUPOINT APPLICATION COMBINED WITH HERBAL FUMIGATION AND WASH IN PREVENTING DIARRHEA AND PERIANAL INFECTION IN PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION** 18:00 - 18:00
Liyuan Qin (Shanghai, China)
- NP40 **FINANCIAL TOXICITY AND ITS INFLUENCING FACTORS IN PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHINA: A CROSS-SECTIONAL STUDY** 18:00 - 18:00
Liyuan Qin (Shanghai, China)
- NP41 **READINESS FOR DISCHARGE - HOLISTIC UNDERSTANDING OF THE PATIENT JOURNEY FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION** 18:00 - 18:00
Lubna Khatib (Haifa, Israel)
- NP42 **THE POTENTIAL OF AI CHATBOTS AS CLINICAL DECISION-SUPPORT TOOLS IN NURSING: AN EVALUATION OF SYMPTOM MANAGEMENT RECOMMENDATIONS DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION** 18:00 - 18:00
Aysenur Cetin Uceriz (Istanbul, Turkey)
- NP43 **AN APPLIED STUDY OF STEPWISE EXERCISE NURSING PROGRAM FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS** 18:00 - 18:00
Mengjing Li (Hangzhou, China)
- NP45 **INVESTIGATION OF THE ACCEPTANCE AND APPLICABILITY OF ACCELEROMETRIC MEASUREMENT OF PHYSICAL ACTIVITY BEFORE, DURING, AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION** 18:00 - 18:00
Aleksandra Trojan (Köln, Germany)
- NP46 **LIVED EXPERIENCES AND PERCEIVED QUALITY OF CARE IN ALLO-HSCT: A QUALITATIVE SUBSTUDY OF THE PHARALLO PROGRAMME** 18:00 - 18:00
Paula Guijarro Martínez (Madrid, Spain)
- NP47 **EVALUATION OF THE EFFICACY OF ULTRASOUND-GUIDED MEDIUM-LENGTH CATHETERS IN THE COLLECTION OF PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS FROM HEALTHY DONORS** 18:00 - 18:00
Fengwei Du (Hangzhou, China)

Printed Poster

18:00 - 19:00

R1

Nurses Posters - Adult

| | | |
|------|--|---------------|
| NP01 | GLOBAL COLLABORATION AND AI-ENHANCED ONLINE EDUCATION FOR UKRAINIAN HCT NURSES IN WARTIME Oleksandr Istomin (Kyiv, Ukraine) | 18:00 - 18:00 |
| NP02 | BUILDING A SKILLED AND CONFIDENT CAR-T NURSING WORKFORCE: ASSESSING THE IMPACT OF NURSE-LED CAR-T EDUCATION Cassandra Abbott (Melbourne, Australia) | 18:00 - 18:00 |
| NP03 | OPTIMISATION OF CAR-T LEUKAPHERESIS USING A MONONUCLEAR CELL-BASED PREDICTIVE COLLECTION TOOL: A SINGLE-CENTRE EXPERIENCE Clair Scott (Murdoch, Australia) | 18:00 - 18:00 |
| NP04 | QUALITY OF LIFE, ANXIETY AND DEPRESSION IN HSCT RECIPIENTS. A 12-MONTH LONGITUDINAL STUDY Arianna Rosich Soteras (Barcelona, Spain) | 18:00 - 18:00 |
| NP05 | OPTIMIZING CRS AND ICANS MANAGEMENT IN CAR-T CELL THERAPY: IMPACT OF A NURSE-LED STRUCTURED WORKFLOW ON EARLY RECOGNITION AND MANAGEMENT OF CRS AND ICANS Kwee Cheng Chia (Singapore, Singapore) | 18:00 - 18:00 |
| NP06 | WHEN KNOWLEDGE AND ATTITUDES DO NOT TRANSLATE INTO PRACTICE: PILOT INSIGHTS FROM HEMATOLOGY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION NURSES' SEXUAL HEALTH CARE Meng-Kuan Chiang (Taipei, Taiwan (Province of China)) | 18:00 - 18:00 |
| NP07 | EXPERIENCES OF AT-HOME AUTOLOGOUS STEM CELL TRANSPLANTATION IN SPAIN: CURRENT OVERVIEW AND IMPROVEMENT AREAS Cristina Gallego Miralles (Barcelona, Spain) | 18:00 - 18:00 |
| NP10 | MONITORING TOXICITY-RELATED COMPLICATIONS IN PATIENTS UNDERGOING CAR-T: OBSERVATIONAL, PROSPECTIVE STUDY Francesca Palmisano (Alessandria, Italy) | 18:00 - 18:00 |
| NP11 | TRANSPLANT @ HOME: A SINGLE CENTRE EXPERIENCE IN HOME-BASED CARE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION Hui Li Lim (Singapore, Singapore) | 18:00 - 18:00 |
| NP12 | APPLICATION OF LONG PERIPHERAL CANNULA IN DONOR APHERESIS - EXPERIENCE OF ONE CENTER Petra Vodickova (Plzen, Czechia) | 18:00 - 18:00 |
| NP13 | COULD PROPHYLACTIC NASOGASTRIC TUBE FEEDING REDUCE WEIGHT LOSS FOR PATIENTS UNDERGOING HIGH-TOXICITY CONDITIONING REGIMENS DURING AUTOLOGOUS STEM CELL TRANSPLANT? Hannah van Tromp (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| NP14 | GUIDING NURSING-LED STRATEGIES TO PREVENT CATHETER-RELATED BLOODSTREAM INFECTIONS DURING ALLOGENEIC HSCT: INFLUENCE OF CATHETER TYPE AND TIMING Maria Teran-Diaz (Santander, Spain) | 18:00 - 18:00 |
| NP15 | LATE TOXICITIES AND QUALITY OF LIFE AFTER VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL): THE ROLE OF ADVANCED PRACTICE NURSING | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | Mercedes Montoro-Lorite (Barcelona, Spain) | |
| NP16 | IMPLEMENTING STRUCTURED EDUCATION IN APHERESIS: A COMPARATIVE EVALUATION OF TRAINING EFFICIENCY AND LEARNER PERCEPTIONS Cara Cunningham (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| NP17 | ASSESSMENT AND MONITORING OF NUTRITIONAL STATUS IN ONCO-HEMATOLOGICAL PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): TOOLS, SCALES AND MULTIDISCIPLINARY APPROACH Alice Passoni (Milan, Italy) | 18:00 - 18:00 |
| NP18 | THE EXPERIENCE OF PATIENTS UNDERGOING CAR T CELL THERAPY: A PHENOMENOLOGICAL-INTERPRETATIVE STUDY Alfonso Parisi (Milano, Italy) | 18:00 - 18:00 |
| NP19 | A NURSING ROLE IN IMPROVING OPERATIONAL EFFICIENCY IN CELLULAR THERAPY CLINICAL TRIALS Soyoung Park (Seattle, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| NP20 | PATIENT SATISFACTION OF A NURSE-LED BONE MARROW ASPIRATION (BMA) SERVICE Sophie Bertorelli (Cardiff, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| NP21 | COMMUNICATION COMPETENCE, SELF-EFFICACY, AND SPIRITUAL INTELLIGENCE: EVIDENCE FROM NURSES WORKING IN BMT UNIT Komal Mundhe (Navi Mumbai, India) | 18:00 - 18:00 |
| NP22 | CONTINUOUS CARE UNIT: A FEASIBLE MODEL TO OPTIMIZE URGENT MANAGEMENT IN HAEMATOLOGICAL MALIGNANCIES, TRANSPLANTATION AND CAR-T PATIENTS Renato Luna Liendo (Barcelona, Spain) | 18:00 - 18:00 |
| NP23 | HEALTHCARE PROFESSIONALS' AND MANAGERS' EXPERIENCES AND PERCEPTIONS OF IMPLEMENTING CHANGE - IN THE CONTEXT OF ALLOGENEIC STEMCELL TRANSPLANTATION Anna O'Sullivan (Stockholm, Sweden) | 18:00 - 18:00 |
| NP24 | MONITORING STRESS AND WORKLOAD IN PRIMARY CAREGIVERS OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION: A ONE-YEAR SINGLE-CENTER EXPERIENCE Sara Marcos Asensio (Salamanca, Spain) | 18:00 - 18:00 |
| NP25 | EARLY NURSING ASSESSMENT AND MANAGEMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE IN TAIWANESE LONG-TERM ALLO-HSCT SURVIVORS: A TWO-YEAR RETROSPECTIVE STUDY Chiao-Fang Chang (Taipei, Taiwan (Province of China)) | 18:00 - 18:00 |
| NP26 | FOSCARNET SODIUM ENEMA FOR REFRACTORY CMV GASTROENTERITIS AFTER HAPLOIDENTICAL HSCT: A CASE SERIES Mengjing Li (Hangzhou, China) | 18:00 - 18:00 |
| NP27 | THE IMPACT OF DOSE REDUCTION OF POST-TRANSPLANT CYCLOPHOSPHAMIDE TO 70 MG/KG ON EARLY TOXICITY: A SINGLE-CENTRE EXPERIENCE Vanessa Magerová (Prague, Czechia) | 18:00 - 18:00 |
| NP28 | IMPLEMENTATION OF A MENTORSHIP PROGRAMME FOR NEWLY HIRED NURSES IN ONCO-HEMATOLOGY AND BONE MARROW TRANSPLANT UNIT AT SAN RAFFAELE HOSPITAL, MILAN Davide Bonomi (Milan, Italy) | 18:00 - 18:00 |
| NP29 | IMPACT OF THE ETAPES-ONCO PEER SUPPORT PROGRAM ON | 18:00 - 18:00 |

THE NEEDS OF HEMATOLOGY-ONCOLOGY PATIENTS WHO HAVE UNDERGONE CELLULAR THERAPY: PRELIMINARY RESULTS

Catherine Paquette-Gascon (Montreal, Canada)

Printed Poster

18:00 - 19:00

R1

Gene Therapy - Basic and Translational

| | | |
|------|---|---------------|
| A273 | PHARMACODYNAMIC INSIGHTS INTO ADAPTER CAR TECHNOLOGIES Patrick Schlegel (Regensburg, Germany) | 18:00 - 18:00 |
| A274 | A SINGLE-STEP STRATEGY FOR SIMULTANEOUS T-CELL ACTIVATION AND B-CELL ELIMINATION IN CAR-T PRODUCTION USING BISPECIFIC ANTIBODIES Ivan Gaponenko (Saint Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| A275 | SYSTEMATIC TARGET ANTIGEN VALIDATION AND ANTIBODY VALIDATION FOR CELLULAR IMMUNOTHERAPY Patrick Schlegel (Regensburg, Germany) | 18:00 - 18:00 |
| A276 | A COMPARATIVE PHENOTYPIC AND FUNCTIONAL STUDY OF WT-1 AND TERT SPECIFIC TCR-ENGINEERED T CELLS WITH MODULAR RECEPTOR DESIGNS Emilia Jaskuła (Wroclaw, Poland) | 18:00 - 18:00 |
| A277 | IMPROVING LENTIVIRAL TRANSDUCTION EFFICIENCY OF CD34+ HEMATOPOIETIC STEM CELLS USING POLOXAMERS OR LENTIBLAST PREMIUM®: OPTIMIZATION TOWARD A GENE THERAPY PROCEDURE FOR SICKLE CELL DISEASE Elisa Magrin (Paris, France) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Gene Therapy - Clinical

| | | |
|------|---|---------------|
| A278 | LONG-TERM CLINICAL OUTCOMES OF ATIDARSAGENE AUTOTEMCEL, AUTOLOGOUS HEMATOPOIETIC STEM CELL GENE THERAPY (HSC-GT) FOR EARLY-ONSET METACHROMATIC LEUKODYSTROPHY, WITH UP TO 13 YEARS OF FOLLOW-UP Salvatore Recupero (Milan, Italy) | 18:00 - 18:00 |
| A279 | REFRAMING PAIN AND VOES AFTER TRANSFORMATIVE THERAPIES FOR SICKLE CELL DISEASE: INSIGHTS FROM GENE THERAPY WITH LOVOTIBEGLOGENE AUTOTEMCEL Julie Kanter (Birmingham, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A280 | FIRST-IN-WORLD EXPERIENCE OF IMMUNOMODULATION TO PROMOTE RECIPIENT TOLERANCE TO GENE MODIFIED AUTOLOGOUS STEM CELL TRANSPLANT FOR MPS II Nathan Jeffreys (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A281 | GALLBLADDER ABNORMALITIES IN METACHROMATIC LEUKODYSTROPHY: PRELIMINARY ANALYSIS IN PATIENTS TREATED WITH HEMATOPOIETIC STEM CELL GENE THERAPY AND UNTREATED PATIENTS Salvatore Recupero (Milan, Italy) | 18:00 - 18:00 |
| A282 | BRIDGING READINESS AND REALITY: U.S. PEDIATRIC HEMATOLOGISTS' PERSPECTIVES ON GENE THERAPY FOR SICKLE CELL DISEASE IN THE POST-APPROVAL ERA Alexander Ngwube (Houston, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A283 | A CASE OF LACK OF ENGRAFTMENT OF GENE-CORRECTED | 18:00 - 18:00 |

CELLS AFTER LENTIVIRAL HEMATOPOIETIC STEM CELL GENE THERAPY FOR METACHROMATIC LEUKODYSTROPHY: AN INTEGRATED CLINICAL AND IMMUNOLOGICAL INVESTIGATION

Valeria Calbi (Milan, Italy)

- A284 **STEM CELL MOBILISATION FOR GENE THERAPY IN ADOLESCENT PATIENTS WITH SICKLE CELL DISEASE: EXPERIENCE FROM THE FIRST THREE PATIENTS IN THE UK** 18:00 - 18:00
Sarah Lawson (Birmingham, United Kingdom of Great Britain and Northern Ireland (the))
- A285 **THE USE OF GCSF FOR STEM CELLS MOBILIZATION IN PATIENTS WITH SICKLE CELL DISEASE TREATED WITH GENE THERAPY** 18:00 - 18:00
Mohammed Essa (Riyadh, Saudi Arabia)

Printed Poster

18:00 - 19:00

R1

Stem cell source, mobilization, collection and engineering

- A286 **HEMATOPOIETIC STEM CELL DONATION IN FAMILY DONORS UNDER 18 YEARS OF AGE. EXPERIENCE OF THE ITALIAN SECOND OPINION COMMITTEE SIMTI / SIDEM FOR DONOR PROTECTION** 18:00 - 18:00
Aurora Vassanelli (Verona, Italy)
- A287 **LONG-TERM CRYOPRESERVATION CHANGES THE IMMUNE EFFECTOR CELL COMPOSITION OF PERIPHERAL BLOOD STEM CELL GRAFTS** 18:00 - 18:00
Elke Ruecker-Braun (Dresden, Germany)
- A288 **MYELOID EXPANSION VELOCITY: A NOVEL KINETIC BIOMARKER FOR PREDICTING HEMATOPOIETIC STEM CELL MOBILIZATION FAILURE IN ACUTE LEUKEMIA** 18:00 - 18:00
Erjie Jiang (Tianjin, China)
- A290 **TRANSFORMING TIMELY ACCESS TO STEM CELL COLLECTIONS: EARLY IMPACT OF ANTHONY NOLAN'S FIRST DEDICATED CELL COLLECTION CENTRE** 18:00 - 18:00
Dawn Hart (London, United Kingdom of Great Britain and Northern Ireland (the))
- A291 **TYPE OF INDUCTION CHEMOTHERAPY INFLUENCES STEM CELL MOBILIZATION CAPACITY IN MULTIPLE MYELOMA PATIENTS - COMPARISON OF VCD VS DARA-VTD IN A LARGE MULTICENTER COHORT** 18:00 - 18:00
Christa Unger (Rostock, Germany)
- A292 **LESS INFLAMMATION, SAME SURVIVAL: PLERIXAFOR MOBILIZATION REDUCES ENGRAFTMENT CRS IN PAEDIATRIC HSCT COMPARED TO GCSF ALONE** 18:00 - 18:00
Revathi Raj (Chennai, India)
- A293 **THE SIBCORD SURVEY: ASSESSING CURRENT PRACTICES IN SIBLING CORD BLOOD USE FOR PEDIATRIC HCT ACROSS EBMT CENTERS** 18:00 - 18:00
Benedetta Elena Di Majo (Monza, Italy)
- A294 **WORLD MARROW DONOR ASSOCIATION WORLDWIDE SURVEY ON PLERIXAFOR USE IN HEALTHY RELATED AND UNRELATED DONORS** 18:00 - 18:00
Tania Dexter (London, United Kingdom of Great Britain and Northern Ireland (the))
- A295 **CENTER- AND DEVICE-RELATED VARIABILITY IN TCRAB/CD19 DEPLETION OF HEMATOPOIETIC PROGENITOR CELL APHERESIS PRODUCTS** 18:00 - 18:00
Miguel Blanquer (Murcia, Spain)

| | | |
|------|---|---------------|
| A296 | SAFE EMERGENCY TRANSFER OF CORD BLOOD UNITS AFTER CRYOGENIC TANK MALFUNCTION: A RARE OPERATIONAL EVENT Jesus Fernandez-Sojo (Barcelona, Spain) | 18:00 - 18:00 |
| A297 | FROM ACCESS TO YIELD: PROCEDURAL INSIGHTS INTO PAEDIATRIC STEM CELL APHERESIS Andrea Espasa (Barcelona, Spain) | 18:00 - 18:00 |
| A298 | UNIVERSAL GENERIC PLERIXAFOR FOR STEM CELL MOBILIZATION IN MULTIPLE MYELOMA: CLINICAL OUTCOMES COMPARISON WITH RISK-ADAPTED STRATEGY AND INTERNATIONAL BENCHMARKS Sreeraj Vasudevan (Thrissur, India) | 18:00 - 18:00 |
| A299 | IMPACT OF VENOUS ACCESS IN THE APHERESIS PERFORMANCE Sara Lopes (Porto, Portugal) | 18:00 - 18:00 |
| A301 | OUTCOMES AND PREDICTORS OF HEMATOPOIETIC STEM CELL MOBILIZATION STRATEGIES IN AUTOLOGOUS TRANSPLANTATION: A REAL-WORLD ANALYSIS Manuela Estrada-Schweineberg (Bogotá, Colombia) | 18:00 - 18:00 |
| A302 | POOR MOBILIZATION IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: CLINICAL CHARACTERIZATION, RESCUE STRATEGIES, AND THE LIMITED UTILITY OF CONVENTIONAL PREDICTORS Erlic Jiang (Tianjin, China) | 18:00 - 18:00 |
| A303 | MANUAL RED CELL DEPLETION IN PAEDIATRIC BONE MARROW TRANSPLANTATION: APPLICATIONS IN ALLOGENEIC AND AUTOLOGOUS SETTINGS Ivana Ferrero (Turin, Italy) | 18:00 - 18:00 |
| A304 | IMPACT OF PRIOR DARATUMUMAB USE ON CD34+ CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION: SINGLE-CENTER EXPERIENCE Carmen Gil Barroso (Huelva, Spain) | 18:00 - 18:00 |
| A306 | ALLOGENEIC BONE MARROW HARVEST IN ADULT AND PEDIATRIC DONORS: A SINGLE-CENTRE EXPERIENCE Jorge Verdejo de Antonio (Madrid, Spain) | 18:00 - 18:00 |
| A307 | THE ROLE OF GRAFT CD3 AND TNC DOSES IN TRANSPLANT OUTCOMES: DOES IT STILL MATTER IN THE PTCY ERA? Emine Merve Savaş (Ankara, Turkey) | 18:00 - 18:00 |
| A308 | COMPARATIVE EVALUATION OF ADAMII IMAGE CYTOMETRY WITH TWO FLOW CYTOMETRY PLATFORMS FOR CD34+ HEMATOPOIETIC STEM CELL ENUMERATION Mirjana Milinković (Belgrade, Serbia) | 18:00 - 18:00 |
| A309 | DONOR SELECTION FOR HLA HAPLOTYPE-HOMOZYGOUS PATIENTS UNDERGOING CORD BLOOD TRANSPLANTATION Noriyoshi Yoshinaga (Kyoto, Japan) | 18:00 - 18:00 |
| A310 | COMPARATIVE CHARACTERISTICS OF CD3 DEPLETION AND ALPHA/BETA T CELL DEPLETION AS A GRAFT MANUFACTURING PLATFORM Svetlana Glushkova (Moscow, Russian Federation (the)) | 18:00 - 18:00 |
| A311 | ANALYSIS OF CLINICAL AND PROCEDURAL FACTORS ASSOCIATED WITH SUCCESSFUL COLLECTION OF CD34+ HEMATOPOIETIC PROGENITOR CELLS Carmen Gil Barroso (Huelva, Spain) | 18:00 - 18:00 |

| | | |
|--|--|---------------|
| A312 | DIRECTED SIBLING CORD BLOOD BANKING : FOURTEEN YEAR EXPERIENCE IN NHS BLOOD AND TRANSPLANT (NHSBT) Rachel Pawson (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A313 | COMPARATIVE ANALYSIS OF MOBILIZATION REGIMENS AND THEIR IMPACT ON STEM CELL YIELD AND ENGRAFTMENT KINETICS IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY Bushra Ahsan (Lahore, Pakistan) | 18:00 - 18:00 |
| A314 | LEUKAPHERESIS FOR PROGENITOR CELL COLLECTIONS IN LOW WEIGHT CHILDREN: REPORT FROM A SINGLE PEDIATRIC CENTER Jorge Verdejo de Antonio (Madrid, Spain) | 18:00 - 18:00 |
| A315 | NO SIGNIFICANT IMPACT OF GRAFT CD34+/CD3+ RATIO ON TRANSPLANT OUTCOMES AFTER POST-TRANSPLANTATION CYCLOPHOSPHAMIDE-BASED HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION Nadia Bambace (Miami, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A316 | IMPACT OF CD34+ CELL DOSE AND GROWTH FACTOR SUPPORT ON EARLY MORBIDITY AND NON-RELAPSE MORTALITY AFTER AUTOLOGOUS STEM CELL TRANSPLANT FOR LYMPHOMA Shahjehan Hanif (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| <i>Printed Poster</i> 18:00 - 19:00 | | R1 |
| Stem cell donor | | |
| A317 | DIFFERENTIAL IMPACT OF FIRST-FIELD AND SECOND-FIELD HLA MISMATCHES IN 9/10 VERSUS 10/10 MATCHED UNRELATED HSCT, AN ANALYSIS OF GERMAN REGISTRY DATA, DRST Aysenur Arslan (Ulm, Germany) | 18:00 - 18:00 |
| A318 | MODELING SUFFICIENCY AND GROWTH OF THE AUSTRALIAN AND NEW ZEALAND HSC DONOR REGISTRIES TO MEET PATIENT POPULATION REQUIREMENTS IN AN ERA OF MISMATCHED TRANSPLANTATION Garth Healey (Sydney, Australia) | 18:00 - 18:00 |
| A319 | DEMOGRAPHICS MATTER: VARIATION IN DONOR AVAILABILITY DURING CONFIRMATORY TYPING Ute Verena Solloch (Tübingen, Germany) | 18:00 - 18:00 |
| A320 | PAROUS FEMALE DONOR REDUCES RELAPSE RISK IN HIGH-RISK AML/MDS AFTER HAPLOIDENTICAL PBSCT WITH ATG/PTCY COMBINATION FOR GVHD PROPHYLAXIS Huiying Qiu (Shanghai, China) | 18:00 - 18:00 |
| A321 | OLDER DONOR AGE IS NOT ASSOCIATED WITH INFERIOR SURVIVAL IN CONTEMPORARY HAPLOIDENTICAL TRANSPLANTATION Yosra Aljawai (Houston, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A323 | THE IMPACT OF INDIRECT ALLORECOGNITION IN TRANSPLANT OUTCOMES AFTER UNRELATED DONOR TRANSPLANTATION FOR NONMALIGNANT DISEASES Carmem Bonfim (Durham, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A324 | EVALUATION OF RECOVERY AND ADVERSE EVENTS IN 1,638 HEALTHY ANTHONY NOLAN DONORS Tania Dexter (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| A325 | INTEGRATING NGS-BASED GERMLINE MUTATION DETECTION INTO DONOR EVALUATION ENHANCES MYELOID NEOPLASM RISK STRATIFICATION Eleni Gavriilaki (Thessaloniki, Greece) | 18:00 - 18:00 |
| A326 | HAPLOIDENTICAL SCT INDUCES LONG-TERM REMISSION IN PATIENTS WITH BPDCN FengRong Wang (Beijing, China) | 18:00 - 18:00 |
| A327 | PROBABLE DONOR - RECIPIENT TRANSMISSION OF HEPATITIS E VIRUS WITH A HAEMATOPOIETIC STEM CELL TRANSPLANT. WMDA RECOMMENDATIONS ON HEV ASSESSMENT IN DONORS AND RECIPIENTS Tigran Torosian (Warsaw, Poland) | 18:00 - 18:00 |
| A329 | CLINICAL PERSPECTIVES ON GERMLINE VARIANTS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: A NATIONWIDE SURVEY IN JAPAN Mizuki Watanabe (Tokyo, Japan) | 18:00 - 18:00 |
| A330 | AGE-DEPENDENT CHANGES IN LYMPHOCYTE COMPOSITION OF PERIPHERAL BLOOD STEM CELL GRAFTS FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION M Queralt Salas (Barcelona, Spain) | 18:00 - 18:00 |
| A331 | CLINICAL VALUE OF ROUTINE BONE MARROW EXAMINATION IN RELATED STEM CELL DONORS Anders Lillemoen Drivenes (Oslo, Norway) | 18:00 - 18:00 |
| A332 | NOT ALL LOW PLATELET COUNTS ARE SPURIOUS: DUTY OF CARE IN CORD BLOOD BANKING Rachel Pawson (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A333 | FEMALE DONORS IMPROVE SURVIVAL OUTCOMES IN HIGH-RISK MALE RECIPIENTS UNDERGOING BONE MARROW TRANSPLANTATION Junko Takeshita (Saitama, Japan) | 18:00 - 18:00 |
| A335 | TRANSIENT ACUTE MYOCARDIAL INJURY DURING G-CSF MOBILIZATION IN HEALTHY PERIPHERAL STEM CELL DONORS: A CASE SERIES Anna Colpo (Padova, Italy) | 18:00 - 18:00 |
| A336 | EVALUATION OF RELATED HEMATOPOIETIC STEM CELL DONORS IN THE CONTEXT OF FACT-JACIE STANDARDS IMPLEMENTATION Leandro Castellanos (Córdoba, Argentina) | 18:00 - 18:00 |
| A337 | SERIOUS ADVERSE REACTIONS AND EVENTS IN RELATED HAEMATOPOIETIC CELLS DONORS - WMDA COMMUNICATION AND RECOMMENDATIONS ON RELATED DONORS FOLLOW UP AND REPORTING OF SAE Grzegorz Hensler (Leiden, Netherlands (the)) | 18:00 - 18:00 |
| A338 | EVOLUTION OF UNRELATED DONOR ACTIVITY IN CHILE: RETROSPECTIVE ANALYSIS OF DKMS DONOR SEARCHES FROM 2018 - 2024 Lorena Cerda (Tuebingen, Germany) | 18:00 - 18:00 |
| A339 | EXPANDING DONOR ACCESS IN DEVELOPING COUNTRIES: EXPERIENCE WITH PEDIATRIC HAPLOIDENTICAL STEM CELL TRANSPLANTATION AT A PRIVATE CENTER IN JORDAN Ayad Ahmed Hussein (Amman, Jordan) | 18:00 - 18:00 |
| A340 | IDENTIFYING REASONS FOR LOCAL VS INTERNATIONAL UNRELATED DONOR SELECTION IN HEMATOPOIETIC CELL TRANSPLANT IN CANADA | 18:00 - 18:00 |

| | | |
|---|--|---------------|
| | Matthew Seftel (Vancouver, Canada) | |
| A341 | AN INTERSTING CASE OF DONOR DERIVED LEUKAEMIA POST CORD BLOOD TRANSPLANT | 18:00 - 18:00 |
| | Ememobong Eno Usoro (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| <i>Printed Poster</i> | | |
| | 18:00 - 19:00 | R1 |
| Nurses Posters- Paediatric | | |
| NP30 | ESTABLISHING THE FIRST PEDIATRIC BONE MARROW TRANSPLANT NURSING PROGRAM IN THE UAE: A MODEL FOR COMPETENCY BASED EDUCATION AND INTERNATIONAL COLLABORATION | 18:00 - 18:00 |
| | Dina El Mouzain (Abu Dhabi, United Arab Emirates (the)) | |
| NP31 | IMPLEMENTATION OF NEUTROPENIA PATHWAY TO IMPROVE ANTIBIOTIC TURNAROUND TIME IN PEDIATRIC BMT PATIENTS AT ABU DHABI BONE MARROW TRANSPLANT PROGRAM, CENTER OF EXCELLENCE (UAE) | 18:00 - 18:00 |
| | Dina El Mouzain (Abu Dhabi, United Arab Emirates (the)) | |
| NP32 | GLOBAL NURSING EXCHANGE: EXPERIENCES FROM THE "HOW DO YOU DO IT" ONLINE SESSIONS BY THE EBMT NURSES GROUP PAEDIATRIC COMMITTEE | 18:00 - 18:00 |
| | Ida Bremer Ophorst (Utrecht, Netherlands (the)) | |
| NP33 | ASSESSING THE TOLERANCE OF FIBRE BASED FEEDS FOR PAEDIATRIC PATIENTS DURING AN ALLOGENEIC STEM CELL TRANSPLANT | 18:00 - 18:00 |
| | Chloe Elliott (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| NP34 | PREVENTION AND MANAGEMENT OF ORAL MUCOSITIS IN PEDIATRIC ONCO-IMMUNO-HEMATOLOGICAL PATIENTS: A SCOPING REVIEW | 18:00 - 18:00 |
| | Silvia Gneccchi (Milan, Italy) | |
| NP35 | ROLE OF TANZANIAN NURSES IN OPENING A PEDIATRIC BONE MARROW TRANSPLANT UNIT AND NURSING CARE IN SICKLE CELL PATIENTS AT BENJAMIN MKAPA HOSPITAL IN DODOMA | 18:00 - 18:00 |
| | Silvia Gneccchi (Milan, Italy) | |
| NP36 | EXPLORING DETERMINANTS OF STAFF RETENTION IN PAEDIATRIC BONE MARROW TRANSPLANT NURSING | 18:00 - 18:00 |
| | Charlotte Rigby (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| NP37 | PERCEIVED BARRIERS AND FACILITATORS OF FAMILY-CENTERED ROUNDS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, A HEALTH CARE PROFESSIONALS SURVEY | 18:00 - 18:00 |
| | Madelief Sterre Hübner (Leiden, Netherlands (the)) | |
| <i>Printed Poster</i> | | |
| | 18:00 - 19:00 | R1 |
| Non-infectious Early Complications | | |
| A379 | DEFINING AND VALIDATING THE CD34+ CELL DOSE THRESHOLD REQUIRED FOR STEM CELL BOOST IN CHILDREN WITH POOR GRAFT FUNCTION. A REPORT FROM THE GETH-TC | 18:00 - 18:00 |
| | Maria Isabel Benitez Carabante (Barcelona, Spain) | |
| A380 | ENGRAFTMENT SYNDROME IN PEDIATRIC ALLOGENEIC HSCT: RISK FACTORS AND OUTCOMES | 18:00 - 18:00 |
| | Anne B. Verbeek (Leiden, Netherlands (the)) | |

| | | |
|------|---|---------------|
| A381 | INCIDENCE OF VOD AND LONGITUDINAL DYNAMICS OF EASIX AND ENDOTHELIAL BIOMARKERS AFTER ALLO-HCT WITH PTCY Blanca De Moner Rafel (Barcelona, Spain) | 18:00 - 18:00 |
| A382 | SECOND ALLOGENEIC STEM CELL TRANSPLANTATION TO TREAT PRIMARY AND SECONDARY GRAFT FAILURE: A SINGLE CENTRE EXPERIENCE Ignacio Gómez-Centurión (Madrid, Spain) | 18:00 - 18:00 |
| A383 | REDUCED EARLY POST-TRANSPLANT GLUTAMINE LEVELS ARE ASSOCIATED WITH SYSTEMIC INFLAMMATION AND SEVERE AGVHD Sarah Weischendorff (Copenhagen, Denmark) | 18:00 - 18:00 |
| A384 | COMPARISON OF THE INFECTIOUS AND IMMUNOLOGICAL SAFETY OF A LOW-BACTERIAL AND MODIFIED DIET IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS Alexander Kulagin (Saint Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| A385 | NON-INFECTIOUS NON CARDIOGENIC INTERSTITIAL LUNG DISEASE-RELATED ACUTE RESPIRATORY FAILURE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE FRENCH MULTICENTER EXPERIENCE Jebnoun Naïm (Créteil, France) | 18:00 - 18:00 |
| A386 | INCIDENCE AND RISK FACTORS OF NON-INFECTIOUS PULMONARY COMPLICATIONS FOLLOWING LOW-DOSE-RATE TOTAL BODY IRRADIATION Zixuan Jin (Kyoto, Japan) | 18:00 - 18:00 |
| A387 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF CURCUMIN TO REDUCE MUCOSITIS IN AUTOLOGOUS TRANSPLANT SETTING Sachin Punatar (Navi Mumbai, India) | 18:00 - 18:00 |
| A388 | COMPREHENSIVE PAIN MANAGEMENT IN PAEDIATRIC ALLOGENIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): RETROSPECTIVE AUDIT OF SPECIALIST PAIN TEAM REFERRALS AND DEVELOPMENT OF A PILOT PAIN-MANAGEMENT PATHWAY Akshay Deshpande (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A389 | EARLY ACUTE KIDNEY INJURY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A 634-RECIPIENT COHORT STUDY Luiz Carlos da Costa-Junior (São Paulo, Brazil) | 18:00 - 18:00 |
| A390 | A PHASE 1 DOSE-ESCALATION STUDY OF UMBILICAL CORD BLOOD MONONUCLEAR CELL INFUSION FOR SECONDARY POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Erlic Jiang (Tianjin, China) | 18:00 - 18:00 |
| A391 | THE ROLE OF DEFIBROTIDE AS PROPHYLAXIS FOR VENOCCLUSIVE DISEASE IN PEDIATRIC THALASSEMIA STEM CELL TRANSPLANTATION USING IV BUSULFAN CONDITIONING. A RETROSPECTIVE SINGLE-CENTER 10-YEAR EXPERIENCE Abdullah Alharbi (Riyadh, Saudi Arabia) | 18:00 - 18:00 |
| A392 | IMPACT OF ANTIBIOTIC USE IN EARLY FEVER AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE María José Llácer Ferrandis (Madrid, Spain) | 18:00 - 18:00 |
| A393 | AUTOIMMUNE-LIKE HEPATITIS OF ALLOGENIC ORIGIN: A RARE | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | BUT DISTINCT ENTITY IN POST-TRANSPLANT LIVER DYSFUNCTION | |
| | Claudia Mosquera Rubal (Madrid, Spain) | |
| A394 | TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY: INCIDENCE AND MANAGEMENT IN SETTINGS WITH LIMITED BIOMARKERS AND NO ACCESS TO TARGETED THERAPIES | 18:00 - 18:00 |
| | Nour Ben Abdeljelil (Tunis, Tunisia) | |
| A395 | NARSOPLIMAB IN CRITICALLY ILL PATIENTS WITH TA-TMA REQUIRING INTENSIVE CARE: A SINGLE CENTER STUDY | 18:00 - 18:00 |
| | Ana Belén Bocanegra (Madrid, Spain) | |
| A396 | RESELECT1&AMP;2: INTERVENTIONAL STUDIES FOR THE TREATMENT OF POOR GRAFT FUNCTION POST ALLOGENEIC STEM CELL TRANSPLANTATION | 18:00 - 18:00 |
| | Daniel North (Melbourne, Australia) | |
| A397 | HEPATIC VENOUS PRESSURE GRADIENT TO DIAGNOSE VENO-OCCLUSIVE DISEASE AFTER HEMATOPOIETIC BONE MARROW TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS | 18:00 - 18:00 |
| | Luigi Colecchia (Bologna, Italy) | |
| A400 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) IS AN EARLY BIOMARKER OF SEVERE SINUSOIDAL OBSTRUCTION SYNDROME AFTER PEDIATRIC HSCT | 18:00 - 18:00 |
| | Karoline Juul Grube (Copenhagen, Denmark) | |
| A401 | DEFIBROTIDE RESCUE FOR PEDIATRIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME; A SINGLE-CENTER 10-YEAR EXPERIENCE | 18:00 - 18:00 |
| | Dua'a Zandaki (Amman, Jordan) | |
| A402 | ASSESSMENT OF CARDIOVASCULAR RISK BURDEN AND ITS IMPACT ON OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | 18:00 - 18:00 |
| | Panagiota Gianni (Ulm, Germany) | |
| A403 | TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY CLINICAL CHARACTERISTIC, RISK FACTORS, THERAPEUTIC MANAGEMENT AND OUTCOME: A SINGLE CENTER RETROSPECTIVE COHORT STUDY | 18:00 - 18:00 |
| | Memon Shahbaz (Riyadh, Saudi Arabia) | |
| A404 | REAL-WORLD EFFICACY AND SAFETY OF DEFIBROTIDE FOR SINUSOIDAL OBSTRUCTION SYNDROME - NATIONWIDE SURVEY | 18:00 - 18:00 |
| | Souichi Shiratori (Sapporo, Japan) | |
| A405 | EASIX SCORE AS A PREDICTOR FOR TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY IN PAEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | 18:00 - 18:00 |
| | Maria Isabel Benitez Carabante (Barcelona, Spain) | |
| A406 | POSITIVE OUTCOMES AMONG PEDIATRIC HCT PATIENTS TREATED WITH DARATUMUMAB FOR AUTO-IMMUNE HEMOLYTIC ANEMIA | 18:00 - 18:00 |
| | Lauren Stafford (Durham, United States Minor Outlying Islands (the)) | |
| A408 | DAY 0 EASIX SCORE PREDICTS NON-RELAPSE MORTALITY, BUT NOT GRAFT-VERSUS HOST DISEASE OR RELAPSE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER REAL-WORLD ANALYSIS | 18:00 - 18:00 |
| | Ion Antohe (Iasi, Romania) | |

| | | |
|--|--|---------------|
| A409 | ANAKINRA AS TREATMENT FOR SECONDARY HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS FOLLOWING ALLOGENIC STEM CELL TRANSPLANT: A RETROSPECTIVE ANALYSIS IN A UNIVERSITY HOSPITAL TRANSPLANT CENTRE Hwai Jing Hiew (Southampton, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A410 | EARLY POST-TRANSPLANT ELECTROLYTE DISTURBANCES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: INCIDENCE AND SEVERITY Luiz Carlos da Costa-Junior (São Paulo, Brazil) | 18:00 - 18:00 |
| A411 | HEMOSTATIC ALTERATIONS AND HISTOPATHOLOGICAL FINDINGS OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HSCT FROM A REFERENCE CENTER IN LATIN AMERICA Severiano Baltazar Arellano (Monterrey, Mexico) | 18:00 - 18:00 |
| A412 | THE CLINICAL SIGNIFICANCE AND SAFETY OF BRONCHOSCOPY AFTER ALLO-HSCT Seiya Bamba (Kyoto, Japan) | 18:00 - 18:00 |
| A413 | COLD AGGLUTININ SYNDROME FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Trym Døvik (Oslo, Norway) | 18:00 - 18:00 |
| <i>Printed Poster</i> 18:00 - 19:00 | | R1 |
| Graft-versus-host Disease - Basic and Translational | | |
| A360 | ATG EXPOSURE AND IMMUNE RECONSTITUTION IN CHILDREN WITH HEMOGLOBINOPATHIES FOLLOWING HSCT: DIFFERENT PATTERNS FOR ATG-GRAPALON AND THYMOGLOBULINE Ysabel Alessa Schwietzer (Hamburg, Germany) | 18:00 - 18:00 |
| A361 | SKIN TAPE STRIPPING ENABLES NON-INVASIVE MONITORING OF INFLAMMATORY CYTOKINES IN ACUTE SKIN GVHD Nakisa Kamari-Kany (Copenhagen, Denmark) | 18:00 - 18:00 |
| A363 | THERAPEUTIC TARGETING OF CCR7 IMPROVES OUTCOMES IN A PRECLINICAL MODEL OF ACUTE GRAFT-VERSUS-HOST DISEASE Andrea Hoyos Domingo (Madrid, Spain) | 18:00 - 18:00 |
| A364 | PRE-TRANSPLANT T/NK-LIKE DERIVED EXTRACELLULAR VESICLES ASSOCIATE WITH GVHD AND DISTINCT IMMUNE RECONSTITUTION PATTERNS, INFLUENCED BY GUT MICROBIOME AND CHEMOTHERAPY EXPOSURE IN PEDIATRIC STEM CELL TRANSPLANTATION Francesca Gottardi (Bologna, Italy) | 18:00 - 18:00 |
| A365 | HIGH THROUGHPUT METABOLIC ANALYSES DEMONSTRATE AMINO ACID PATHWAY PERTURBATIONS IN ACUTE GRAFT-VERSUS-HOST DISEASE Dan Le (Melbourne, Australia) | 18:00 - 18:00 |
| A369 | COMPARATIVE ANALYSIS OF GRAFT-VERSUS-HOST DISEASE INCIDENCE AND PATTERNS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS STANDARD PROPHYLAXIS M Queralt Salas (Barcelona, Spain) | 18:00 - 18:00 |
| A371 | IMPAIRED CIRCULATING T_{FH} SUBSETS AS EARLY INDICATORS OF CHRONIC GVHD PATHOGENESIS Silvia Spoerl (Erlangen, Germany) | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| A372 | PERTURBATIONS IN THE MICROBIAL DERIVED TRYPTOPHAN METABOLITES UNDERLIE ACUTE GRAFT-VERSUS-HOST DISEASE Dan Le (Melbourne, Australia) | 18:00 - 18:00 |
| A374 | PRE-TRANSPLANT TREC LEVELS MODULATE POST-TRANSPLANT GUT INTRINSIC DNA-DAMAGE AND IMMUNE RESPONSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Adam Kuba (Olomouc, Czechia) | 18:00 - 18:00 |
| A375 | SYNERGISTIC EFFECTS OF AXATILIMAB AND RUXOLITINIB IN AN INFLAMMATORY IN VITRO MODEL OF GVHD Shannon Kahan (Wilmington, DE, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A376 | VON WILLEBRAND FACTOR-ENHANCED EASIX FORMULA CORRELATES WITH CGVHD SEVERITY IN THE INFLAMMATORY CGVHD PHENOTYPE AND CYTOKINE CONCENTRATIONS Ana Zelić Kerep (Zagreb, Croatia) | 18:00 - 18:00 |
| A377 | THE INTERPLAY BETWEEN CYTOMEGALOVIRUS REACTIVATION, CONDITIONING REGIMENS, AND GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HSCT: A 10-YEAR RETROSPECTIVE ANALYSIS FROM RESOURCE-LIMITED SETTING Bushra Ahsan (Lahore, Pakistan) | 18:00 - 18:00 |
| A378 | SINGLE-AGENT CSF-1R OR JAK INHIBITION REDUCES FIBROSIS IN A MURINE MODEL OF CHRONIC GRAFT-VERSUS-HOST DISEASE Paul Wilson (Wilmington, DE, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Poster Session in Hall 9*Printed Poster*

18:00 - 19:00

R1

Transplant and Cellular Therapies - Basic and Translational

| | | |
|------|--|---------------|
| A001 | PULMONARY AND SYSTEMIC IMMUNE PROFILING REVEALS JAK-STAT SIGNALLING AS A MEDIATOR OF POST-HCT LUNG COMPLICATIONS IN CHILDREN Hannah Walker (Melbourne, Australia) | 18:00 - 18:00 |
| A002 | VERSATILE ALLOGENEIC VIRUS-SPECIFIC CAR-T CELLS FOR HEMATOLOGIC MALIGNANCIES Maria Val-Casals (Barcelona, Spain) | 18:00 - 18:00 |
| A003 | IMMUNE MODULATION BY CAR-T CELLS: EXTRACELLULAR VESICLES AND SECRETOME AS DRIVERS OF MONOCYTE ACTIVATION Besjana Xhahysa (Brescia, Italy) | 18:00 - 18:00 |
| A004 | LARGE SCALE MANUFACTURING OF GMP GRADE CORD BLOOD DERIVED MEGAKARYOCYTES FOR CHEMOTHERAPY INDUCED THROMBOCYTOPENIA Yosra Aljawai (Houston, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A005 | GENETIC MECHANISMS UNDERLYING CLONAL EVOLUTION DURING RELAPSE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA Jing Zheng (Hangzhou, China) | 18:00 - 18:00 |
| A006 | GRAFT PLATFORM AND VIRAL REACTIVATION IMPRINT LONG- | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | TERM ALPHABETA AND GAMMADelta T-CELL CLONAL AND TRANSCRIPTIONAL REMODELING AFTER ALLO-HSCT | |
| | Anniek StuuT (Utrecht, Netherlands (the)) | |
| A007 | ACCELERATING PATIENT CRITICAL TIME METRICS VIA RAPID POINT-OF-CARE MANUFACTURING OF LEUKAPHERESIS-FREE THIRD-GENERATION CD19 CAR-T CELLS | 18:00 - 18:00 |
| | Maria Giannaki (Thessaloniki, Greece) | |
| A008 | OPTIMIZING CONDITIONING REGIMENS FOR HSCT: TMLI AS AN ORGAN-SPARING ALTERNATIVE TO TBI | 18:00 - 18:00 |
| | Alena Zverava (Minsk, Belarus) | |
| A009 | SEQUENTIAL MONITORING OF EXTRACELLULAR VESICLES UNCOVERS EARLY ENDOTHELIAL PERTURBATIONS ASSOCIATED WITH ACUTE GVHD | 18:00 - 18:00 |
| | Luisa Giaccone (Torino, Italy) | |
| A010 | RESTORATION OF PULMONARY ENDOTHELIAL HEALTH AND OVERALL SURVIVAL FOLLOWING ALLOGENEIC HSCT THROUGH MINICIRCLE FOXF1 MRNA NANOPARTICLE THERAPY IN JUVENILE MICE | 18:00 - 18:00 |
| | Clayton Long (Phoenix, United States Minor Outlying Islands (the)) | |
| A011 | PHARMACOLOGICAL MODULATION OF CAR30 AND CAR19 T CELL STEMNESS AND EX VIVO EXPANSION WITH PI3K AND CBP/P300 INHIBITION | 18:00 - 18:00 |
| | Irene Pascual-Latorre (Barcelona, Spain) | |
| A012 | INFLAMMATORY AND STROMAL ALTERATIONS OF THE HEMATOPOIETIC NICHE ASSOCIATED WITH POST-CAR-T CYTOPENIAS | 18:00 - 18:00 |
| | Carmen Santos Marcos (Salamanca, Spain) | |
| A013 | EVALUATION OF THE STATUS OF THE HEMATOPOIETIC NICHE PRE-LYMPHODEPLETION IN THE DEVELOPMENT OF POST-CAR-T HEMATOTOXICITY | 18:00 - 18:00 |
| | Carmen Santos Marcos (Salamanca, Spain) | |
| A014 | CLINICAL RELEVANCE OF NON-HLA REGIONS DIFFERENCES IN ADDITION TO HLA MOLECULAR MISMATCHES BETWEEN DONOR AND RECIPIENT IN HAPLO-HSCT USING PTCY | 18:00 - 18:00 |
| | Francisco Javier Gil-Etayo (Salamanca, Spain) | |
| A015 | CD33-CAR INKT CELLS MITIGATE THE IMPACT OF ANTIGENIC HETEROGENEITY IN ACUTE MYELOID LEUKEMIA THROUGH DIRECT CYTOTOXICITY AND ACTIVATION OF CONVENTIONAL T CELLS | 18:00 - 18:00 |
| | Sisi Wang (Geneva, Switzerland) | |
| A017 | HLA-KIR INTERACTIONS AS PREDICTIVE BIOMARKERS OF NK ALLOREACTIVITY IN HAPLOIDENTICAL TRANSPLANTATION WITH PTCY | 18:00 - 18:00 |
| | Francisco Javier Gil-Etayo (Salamanca, Spain) | |
| A018 | OVERCOMING MHC-I LIMITATIONS AND ENHANCING ADOPTIVE T CELL FUNCTIONALITY THROUGH DUAL CAR-TCR ENGINEERING | 18:00 - 18:00 |
| | Matthias Eyrich (Würzburg, Germany) | |
| A019 | EXTRACELLULAR VESICLES AS NONINVASIVE BIOMARKERS OF IMMUNE AND ENDOTHELIAL ACTIVATION IN CAR T-CELL THERAPY RECIPIENTS | 18:00 - 18:00 |
| | Luisa Giaccone (Torino, Italy) | |
| A020 | SHORT-TERM POST-TRANSPLANT PROTEOMICS REVEAL | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | TEMPORAL AND DISEASE-SPECIFIC TRAJECTORIES IN MYELOID MALIGNANCIES | |
| | Anniek Stuut (Utrecht, Netherlands (the)) | |
| A021 | IMMUNE PROFILE AND PROTEOME OF PLASMA EXTRACELLULAR VESICLES REVEAL A MYELOID-DRIVEN SIGNATURE ASSOCIATED WITH THE RISK OF RELAPSE AFTER CD19.CAR-T CELL THERAPY | 18:00 - 18:00 |
| | Serena De Matteis (Bologna, Italy) | |
| A022 | A MULTI-DISEASE SINGLE-CELL ATLAS OF CEREBROSPINAL FLUID IN NEUROINFLAMMATORY RELATED CONDITIONS REVEALS CONSERVED AND CONTEXT-SPECIFIC PATHOGENIC HALLMARKS | 18:00 - 18:00 |
| | Xia Li (Hangzhou, China) | |
| A023 | IMPACT OF CELLULAR COMPOSITION OF LEUKAPHERESIS PRODUCT ON OVERALL NUCLEATED CELL VIABILITY AFTER CRYOPRESERVATION | 18:00 - 18:00 |
| | Vadim Spitsyn (Moscow, Russian Federation (the)) | |
| A024 | THE IMPACT OF INFUSED LYMPHOCYTES SUBSETS ON CLINICAL OUTCOMES IN MUD/HAPLO HCT SETTING WITH CD34+ POSITIVE SELECTION AND COINFUSION OF A CONTROLLED NUMBER OF CD3+ | 18:00 - 18:00 |
| | Marianna Maffeis (Brescia, Italy) | |
| A025 | RELEVANCE OF HLA-B LEADER DIMORPHISM AND MOLECULAR COMPATIBILITY IN HAPLOIDENTICAL HSCT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: EXPERIENCE OF A SPANISH COHORT | 18:00 - 18:00 |
| | Francisco Javier Gil-Etayo (Salamanca, Spain) | |
| A026 | GENERATION OF CHIMERIC ANTIGEN RECEPTORS AGAINST MURINE CD123 ALLOWS BIOLOGIC ASSESSMENTS IN IMMUNOLOGICALLY COHERENT IN VIVO SYSTEMS | 18:00 - 18:00 |
| | Martin Sauer (Hannover, Germany) | |
| A027 | THE RATIO THAT MATTERS - HOW CD4:CD8 BALANCE SHAPES CAR T-CELL EFFICACY AND SAFETY | 18:00 - 18:00 |
| | Bastian Zinkel (Erlangen, Germany) | |
| A028 | TRANSFORMING CAR-T ACCESSIBILITY: A PATHWAY TO AFFORDABLE CELL THERAPY FOR B-CELL MALIGNANCIES IN INDIA AND OTHER LMICS | 18:00 - 18:00 |
| | Anupam Chhabra (Gurgaon, India) | |
| A029 | COMPARATIVE IN VITRO EXPANSION OF REGULATORY T CELLS FROM CORD BLOOD AND MOBILIZED PERIPHERAL BLOOD STEM CELLS WITH RAPAMYCIN | 18:00 - 18:00 |
| | BibiShahin Shamsian (Tehran, Iran (Islamic Republic of)) | |
| A030 | THE INFLUENCE OF LUSPATERCEPT ON BONE MARROW MESENCHYMAL STROMAL CELLS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND ACUTE MYELOID LEUKEMIA | 18:00 - 18:00 |
| | Nikolai Tsvetkov (St. Petersburg, Russian Federation (the)) | |
| A032 | DEMONSTRATING THE FEASIBILITY OF REFREEZING PREVIOUSLY CRYOPRESERVED BONE MARROW FOLLOWING REPROCESSING | 18:00 - 18:00 |
| | Erik Woods (San Fransisco, United States Minor Outlying Islands (the)) | |
| A033 | EXTRACORPOREAL PHOTOPHERESIS FOR DELAYED NEUROTOXICITY SYNDROME AFTER BCMA CAR T-CELL THERAPY | 18:00 - 18:00 |
| | Philipp Gödel (Cologne, Germany) | |

| | | |
|------|---|---------------|
| A034 | SINGLE-CELL MAPPING PORTRAYS THE LINEAGE SPECTRUM OF EPSTEIN-BARR VIRUS INFECTION AND UNVEILS CLINICAL IMPLICATIONS OF CD70 IN PATIENTS WITH PTLD Jinsong Yan (Dalian, China) | 18:00 - 18:00 |
| A035 | IMMUNE RECONSTITUTION AFTER CAR-T AND ALLOGENEIC HCT: LONGITUDINAL MULTI-OMICS INSIGHTS INTO PERSISTENT IMMUNE DYSFUNCTION Marjorie Batista (São Paulo, Brazil) | 18:00 - 18:00 |
| A036 | DECIPHERING THE HDAC6-MEDIATED REGULATION OF MLLT3 IN MYELOID PROGENITOR CELL FATE: INSIGHTS INTO STEM CELL DIFFERENTIATION DYNAMICS Anil Aribandi (Hyderabad, India) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Transplant and Cellular Therapies - Clinical

| | | |
|------|--|---------------|
| A037 | EMAPALUMAB INDUCES RAPID, DURABLE RESPONSES AND RELIABLE BRIDGING TO CURATIVE HSCT IN PATIENTS WITH PRIMARY HLH: POOLED ANALYSIS OF PROSPECTIVE TRIALS NI-0501-04, NI-0501-05 AND NI-0501-09 Franco Locatelli (Rome, Italy) | 18:00 - 18:00 |
| A038 | INTERIM CLINICAL OUTCOMES IN ORCA-T WITH REDUCED INTENSITY CONDITIONING: AN OBSERVATIONAL COMPARISON TO REGISTRY-BASED POST-TRANSPLANT CYCLOPHOSPHAMIDE PATIENTS Anna Pavlova (Menlo Park, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A039 | CONTEMPORARY CAUSES OF ACUTE TRANSPLANT-RELATED MORTALITY (TRM) AFTER ALLOGRAFT IN A COHORT OF 2312 PAEDIATRIC PATIENTS: A REPORT FROM THE BSBMTCT, PAEDIATRIC GROUP Gustavo de Oliveira Canedo (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A040 | CLINICAL BENEFITS OF RUXOLITINIB IN MODERATE-TO-SEVERE CRS: REDUCED SEVERE ICANS AND STEROID USE WITH PRESERVED SURVIVAL AFTER PEDIATRIC CAR-T THERAPY Shaoyan Hu (Suzhou, China) | 18:00 - 18:00 |
| A041 | RELAPSED OR REFRACTORY POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: REAL-LIFE MULTICENTER ITALIAN EXPERIENCE WITH TABELCLEUCEL Chiara Consoli (Torino, Italy) | 18:00 - 18:00 |
| A042 | LISOCABTAGENE MARALEUCEL VERSUS AXICABTAGENE CILOLEUCEL IN R/R LARGE B-CELL LYMPHOMA: A META-ANALYSIS OF REAL-WORLD COMPARATIVE STUDIES Fernando Gibran-Nunes (São Paulo, Brazil) | 18:00 - 18:00 |
| A043 | PRELIMINARY SAFETY AND EFFICACY OF MYELOABLATIVE ORCA-Q IN PATIENTS WITH HAPLOIDENTICAL DONORS Amandeep Salhotra (Duarte, United States of America (the)) | 18:00 - 18:00 |
| A044 | FIRST-LINE ANAKINRA FOR CYTOKINE RELEASE SYNDROME AFTER ANTI-CD19 CAR-T CELLS: A SINGLE-CENTER EXPERIENCE | 18:00 - 18:00 |
| A045 | CAR-T-CELL-INDUCED PSEUDOPROGRESSION (CARTIPP): AN EBMT TCWP STUDY Torsten Schroeder (Kiel, Germany) | 18:00 - 18:00 |
| A046 | CLINICAL BIOMARKERS FOR EARLY RECOGNITION OF SUBOPTIMAL ECULIZUMAB RESPONSE IN TRANSPLANT- | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | ASSOCIATED THROMBOTIC MICROANGIOPATHY | |
| | Kristie Ramos (Cincinnati, United States Minor Outlying Islands (the)) | |
| A047 | B CELL APLASIA POST CD28 AND 41BB CONTAINING CD19 TARGETING CAR-T CELL THERAPY - SINGLE CENTRE RETROSPECTIVE EXPERIENCE | 18:00 - 18:00 |
| | Nida Shafique (Sutton, United Kingdom of Great Britain and Northern Ireland (the)) | |
| A048 | LONG-TERM CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA TREATED WITH PRIZLONCABTAGENE AUTOLEUCEL | 18:00 - 18:00 |
| | Aibin Liang (Shanghai, China) | |
| A049 | OUTCOME OF AGGRESSIVE B-CELL LYMPHOMA ADMINISTERED WITH CAR T-CELL ALONE OR IN COMBINATION WITH ASCT: A PROPENSITY SCORE MATCHING COHORT STUDY | 18:00 - 18:00 |
| | Yan Gao (Beijing, China) | |
| A050 | INFLUENCE OF THE HLA MISMATCHED LOCUS ON OUTCOMES IN MISMATCHED UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE GVHD PROPHYLAXIS: A CIBMTR RETROSPECTIVE ANALYSIS | 18:00 - 18:00 |
| | Stephen R. Spellman (Minneapolis, United States Minor Outlying Islands (the)) | |
| A051 | DONOR SELECTION AND CLINICAL OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS OLDER THAN 50 YEARS - A SINGLE CENTRE RETROSPECTIVE REVIEW | 18:00 - 18:00 |
| | Thomas Chan (Hong Kong, China) | |
| A052 | BCMA CAR T-CELL THERAPY DEMONSTRATES EARLY SAFETY AND EFFICACY SIGNALS IN REFRACTORY SYSTEMIC SCLEROSIS AND ANTIPHOSPHOLIPID SYNDROME: PHASE I RESULTS IN AUTOIMMUNE DISEASES | 18:00 - 18:00 |
| | Shlomo Elias (Jerusalem, Israel) | |
| A053 | CAR⁺ EXTRACELLULAR VESICLES PREDICT ANTI-CD19 CAR-T CELL THERAPY RESPONSE IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS | 18:00 - 18:00 |
| | Margherita Ursi (Bologna, Italy) | |
| A054 | FLUDARABINE EXPOSURE IMPACTS BCMA-DIRECTED CAR-T THERAPY EFFICACY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA | 18:00 - 18:00 |
| | Eugene Brailovski (New York City, United States Minor Outlying Islands (the)) | |
| A055 | OUTCOME OF CAR-T CELL THERAPY IN OLDER PATIENTS. A STUDY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY | 18:00 - 18:00 |
| | Guillaume Dachy (Brussels, Belgium) | |
| A056 | HAPLOIDENTICAL DONOR-DERIVED CAR-T CELLS CO-INFUSED WITH THE ALLOGENIC GRAFT ON THE PLATFORM OF T CELL DEPLETION OR POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN WITH ADVANCED B-CELL NEOPLASMS | 18:00 - 18:00 |
| | Larisa Shelikhova (Moscow, Russian Federation (the)) | |
| A059 | COMPARATIVE VALIDATION OF NEUTROPHIL-BASED MODELS (CAR-HEMATOTOX, ALL-HEMATOTOX, AND E-IPM) FOR PREDICTING EARLY T-ICAH-T-DEFINED PLATELET RECOVERY AFTER CAR-T THERAPY | 18:00 - 18:00 |
| | Meng Lv (Beijing, China) | |
| A060 | IMPACT OF THIOTEPA-BUSULFAN CONDITIONING ON CMML TRANSPLANT SCORE PERFORMANCE | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | Maraike Harfmann (Hamburg, Germany) | |
| A061 | TRUNCATING GENE ALTERATIONS AND PROMOTER HYPERMETHYLATION DRIVE CD7⁻ RELAPSE AFTER CD7 CAR-T THERAPY: A PATIENT-INFORMED MECHANISM STUDY Rongrong Chen (Hangzhou, China) | 18:00 - 18:00 |
| A062 | BU/CY/FLU-ATG VERSUS BU/CY-ATG CONDITIONING REGIMEN IN HAPLOIDENTICAL CELL TRANSPLANTATION FOR SEVERE ACQUIRED APLASTIC ANEMIA Zhengli Xu (Beijing, China) | 18:00 - 18:00 |
| A063 | THE CAST STRATEGY (CAR-T/ASCT/SEQUENTIAL CAR-T) WITH LOW-DOSE FRACTIONATED RT BRIDGING IN HEAVILY PRE-TREATED R/R CNSL □A PROOF-OF-CONCEPT STUDY Yajing Zhang (Beijing, China) | 18:00 - 18:00 |
| A064 | L-IPM: A NOVEL SCORE SYSTEM FOR PREDICTING LATE IMMUNE EFFECTOR CELL-ASSOCIATED HEMATOTOXICITY (ICAH) AFTER CAR-T THERAPY AND COMPARISON WITH CAR-HEMATOTOX, ALL-HEMATOTOX, AND E-IPM Meng Lv (Beijing, China) | 18:00 - 18:00 |
| A065 | IMPACT OF TREATMENT SEQUENCE OF GLOFITAMAB AND CAR-T THERAPY ON EFFICACY, SURVIVAL, AND TARGET ANTIGEN EXPRESSION IN RELAPSED/REFRACTORY B-NHL Yan Gao (Beijing, China) | 18:00 - 18:00 |
| A066 | CD19 CAR-T THERAPY IN TRANSFORMED FOLLICULAR LYMPHOMA: A REAL-WORLD COHORT OF 43 PATIENTS Yan Gao (Beijing, China) | 18:00 - 18:00 |
| A067 | ANTIBIOTIC TIMING AND IMPACT ON SURVIVAL OUTCOMES IN ANTI-CD19 AND ANTI-BCMA CAR-T CELL THERAPY Uroosa Ibrahim (New York, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A068 | IMMUNOGENETIC AND CLINICAL DETERMINANTS OF CYTOKINE RELEASE SYNDROME AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POSTTRANSPLANTATION CYCLOPHOSPHAMIDE Rodrigo Gil Manso (Salamanca, Spain) | 18:00 - 18:00 |
| A070 | SALVAGE STRATEGIES AND OUTCOMES AFTER EARLY-LINE CD19 CAR T-CELL THERAPY FAILURE IN LARGE B-CELL LYMPHOMA Silvia Escribano Serrat (New York, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A071 | INCIDENCE OF SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSED BY DOPPLER ULTRASOUND/LIVER ELASTOGRAPHY IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Maud D'Aveni (Nancy, France) | 18:00 - 18:00 |
| A072 | PERI-TRANSPLANT PALLIATIVE CARE AND/OR COMORBIDITY MANAGEMENT FOR OLDER, MEDICALLY INFIRM, AND/OR FRAIL RECIPIENTS OF ALLOGENEIC TRANSPLANTS - PHASE II AND INTERIM PHASE III TRIAL ANALYSES Mohamed Sorrow (Seattle, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A073 | POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSE REDUCTION ENABLES FASTER GRANULOCYTE ENGRAFTMENT WHILE MAINTAINING EFFICACY IN PREVENTING GVHD Václav Heřman (Prague, Czechia) | 18:00 - 18:00 |
| A075 | OUTCOME OF PATIENTS TREATED FOR T-ALL WITH HSCT IN THE FORUM-1 STUDY Jeanne Martin (Paris, France) | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| A076 | AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (AUTOHCT) FOR PLASMA BLASTIC LYMPHOMA (PBL): AN EBMT LYMPHOMA WORKING PARTY STUDY Peter Dreger (Heidelberg, Germany) | 18:00 - 18:00 |
| A077 | EXCELLENT OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC AND ADULT NUP98-REARRANGED ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER REAL-WORLD STUDY Baiqing Sun (Langfang, China) | 18:00 - 18:00 |
| A078 | OUTCOMES OF ALLO-HCT IN AML PATIENTS HARBORING NUP98 REARRANGEMENTS: A STUDY OF THE EBMT GLOBAL COMMITTEE, ACUTE LEUKEMIA WORKING PARTY, AND PEDIATRIC DISEASES WORKING PARTY Lin Li (Hangzhou, China) | 18:00 - 18:00 |
| A079 | IMPORTANCE OF GRAFT COMPOSITION ON EBV REACTIVATION RISK FOLLOWING MODERN GVHD PROPHYLAXIS Jean Roy (Montréal, Canada) | 18:00 - 18:00 |
| A080 | PATIENTS WITH RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS ACHIEVE DEEP HEMATOLOGIC AND ORGAN RESPONSES WITH THE NOVEL MDC-CAR-BCMA001 Kiavasch Mohammad Nejad Farid (Heidelberg, Germany) | 18:00 - 18:00 |
| A081 | PRE-LYMPHODEPLETION CIRCULATING MICRORNA SIGNATURES PREDICT OUTCOMES OF PATIENTS TREATED WITH ANTI-CD19 CAR-T CELL THERAPY Margherita Ursi (Bologna, Italy) | 18:00 - 18:00 |
| A082 | ARE TRANSPLANT-DERIVED COMORBIDITY INDICES FIT FOR CAR-T THERAPY? A MULTICENTER COMPARATIVE ANALYSIS Silvia Escribano Serrat (New York, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A083 | INCIDENCE AND RISK FACTORS OF PRIMARY GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Tatiana Rudakova (St.Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| A085 | CLINICAL OUTCOMES IN MYELODYSPLASTIC SYNDROME PATIENTS TREATED WITH ORCA-T OR POST-TRANSPLANT CYCLOPHOSPHAMIDE PATIENTS: A REGISTRY-BASED COMPARISON Arpita Gandhi (Portland, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A086 | MACROPHAGE ACTIVATION BEFORE LYMPHODEPLETION CAN PREDICT CRS, ICANS, AND LATE CYTOPENIA AFTER CD19 CAR-T CELL THERAPY FOR HEMATOLOGICAL CANCER Monica Da-My Tran (Copenhagen, Denmark) | 18:00 - 18:00 |
| A087 | CAR-T BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA Xiaoxi Lu (Chengdu, China) | 18:00 - 18:00 |
| A088 | OUTCOMES OF DONOR LYMPHOCYTE INFUSION FOR MEASURABLE RESIDUAL DISEASE AND RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE RETROSPECTIVE ANALYSIS Safia Belbachir (Murdoch, Australia) | 18:00 - 18:00 |
| A089 | SECONDARY MALIGNANCY RISK AFTER ALLOGENEIC HSCT WITH PTCY OR ATG PROPHYLAXIS: A RETROSPECTIVE STUDY Daniele Mannina (Rozzano, Italy) | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| A090 | NOVEL PRECISION ALEMTUZUMAB DOSING RESULTS IN BETTER DAY 0 TARGET RANGE ACHIEVEMENT AND IMPROVED HSCT OUTCOMES IN IEI PATIENTS Pooja Khandelwal (Cincinnati, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A091 | PRELIMINARY BASIS FOR A PREDICTIVE ALGORITHM OF REHABILITATION REQUIREMENTS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS Riccardo Marmoni (Brescia, Italy) | 18:00 - 18:00 |
| A092 | EMAPALUMAB IS ASSOCIATED WITH RAPID AND SUSTAINED BENEFITS IN PHLH SUBGROUPS, INCLUDING CNS INVOLVEMENT AND PREVIOUSLY UNTREATED PATIENTS: ANALYSIS OF TRIALS NI-0501-04, NI-0501-05 AND NI-0501-09 Franco Locatelli (Rome, Italy) | 18:00 - 18:00 |
| A093 | MAAT033 FOR GUT MICROBIOTA OPTIMIZATION TO IMPROVE SURVIVAL AFTER ALLOGENEIC HCT: THE PHOEBUS TRIAL Natalia Gemperle Ortiz (Lyon, France) | 18:00 - 18:00 |
| A094 | DYNAMIC MONITORING OF THE PROGNOSTIC NUTRITIONAL INDEX (PNI) IN CAR-T THERAPY FOR RELAPSED/REFRACTORY LYMPHOMA: A RETROSPECTIVE STUDY Jing Liu (Beijing, China) | 18:00 - 18:00 |
| A095 | CIRCULATING TUMOR DNA (CTDNA) AND IL-10 OR IL-10/IL-6 RATIO DYNAMIC MONITORING FOR PREDICTING RELAPSE IN RELAPSED/REFRACTORY CNS LYMPHOMA: A RETROSPECTIVE COHORT STUDY Yan Gao (Beijing, China) | 18:00 - 18:00 |
| A096 | A FIRST-IN-HUMAN STUDY OF HLA-PARTIALLY TO FULLY MATCHED ALLOGENEIC CRYOPRESERVED DECEASED DONOR BONE MARROW TRANSPLANTATION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES Sagar Munjal (San Francisco, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A097 | UPFRONT TRANSPLANTATION VS. INTENSIVE REMISSION INDUCTION IN MDS/AML, MDS-EB AND OLIGOBLASTIC AML - LIMITED PREDICTIVE VALUE OF BLAST COUNT AT DIAGNOSIS Lisa-Marie Necke (Tübingen, Germany) | 18:00 - 18:00 |
| A098 | IMPACT OF POST-TRANSPLANT INTRATHECAL THERAPY ON CENTRAL NERVOUS SYSTEM RELAPSE IN ACUTE LYMPHOBLASTIC LEUKEMIA Julia Bannatyne Undabeitia (Santander, Spain) | 18:00 - 18:00 |
| A099 | TIMING OF CALCINEURIN INHIBITOR-MMF AFTER HAPLOIDENTICAL TRANSPLANTATION WITH PTCY: RESULTS OF A PHASE II RANDOMIZED STUDY Mithun Abraham Prakash (Ranipet, India) | 18:00 - 18:00 |
| A101 | HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACQUIRED APLASTIC ANEMIA IN 2024: A CROSS-SECTIONAL STUDY FROM THE CHINESE BLOOD AND MARROW TRANSPLANTATION REGISTRY GROUP (CBMTRG) Zhengli Xu (Beijing, China) | 18:00 - 18:00 |
| A103 | IRON OVERLOAD (IO) IS ASSOCIATED WITH AN INCREASED RISK OF INFECTIOUS COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) WITH POST TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) BASED PROPHYLAXIS Monzr Al Malki (Duarte, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A106 | OPTIMIZING ALTERNATIVE DONOR SELECTION IN ALLOGENEIC | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | HSCT: DISEASE- AND CONDITIONING-SPECIFIC ADVANTAGES OF UMBILICAL CORD BLOOD TRANSPLANTS | |
| | Eun-Jeong Jeong (Seongnam-si, Korea (the Republic of)) | |
| A107 | INFLUENCE OF TIME-OF-DAY OF GRAFT INFUSION ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES: A VALIDATION COHORT STUDY | 18:00 - 18:00 |
| | Chiara Bernardi (Geneva, Switzerland) | |
| A108 | CLINICAL CHARACTERISTICS, PROGNOSTIC FACTORS, AND TRANSPLANT OUTCOMES IN HEMATOLOGICAL MALIGNANCIES WITH BEHÇET'S DISEASE: A RETROSPECTIVE STUDY OF 114 PATIENTS | 18:00 - 18:00 |
| | Xiaoyu Cao (Hangzhou, China) | |
| A109 | CUMULATIVE CYCLOSPORINE A EXPOSURE AND LONG-TERM OUTCOMES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA | 18:00 - 18:00 |
| | Hauke Wilcken (Freiburg, Germany) | |
| A110 | ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ACUTE LEUKEMIA: LESSONS TO LEARN FROM MULTIMODAL CLUSTERING | 18:00 - 18:00 |
| | Thomas Luft (Heidelberg, Germany) | |
| A111 | TRANSPLANT OUTCOMES WITH SPANISH CORD BLOOD UNITS: SIGNIFICANT IMPROVEMENT OVER TIME | 18:00 - 18:00 |
| | Sergi Querol (Barcelona, Spain) | |
| A112 | EFFICACY OF THE TRIPLET THERAPY WITH VENETOCLAX, AZACITIDINE AND GILTERITINIB FOR THE TREATMENT OF FLT3-ITD MUTATED R/R AML PATIENTS BRIDGING TO ALLOGENEIC STEM CELL TRANSPLANTATION | 18:00 - 18:00 |
| | Chen Liang (Tianjin, China) | |
| A113 | THE EFFICACY OF MEMORY T CELL DONOR LYMPHOCYTE INFUSION IN AUGMENTING IMMUNE FUNCTION FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION | 18:00 - 18:00 |
| | Jiayu Huang (Shanghai, China) | |
| A114 | LONG-TERM SURVIVAL AND HIGH-RISK DETERMINANTS FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT IN MANTLE CELL LYMPHOMA | 18:00 - 18:00 |
| | Muhammad Azeem Khan (Rochester, United States Minor Outlying Islands (the)) | |
| A115 | LINK BETWEEN NON DONOR-SPECIFIC ANTI-HLA ANTIBODIES AND INFERIOR KEY OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION -THE "LAIKA" STUDY- | 18:00 - 18:00 |
| | Roberto Crocchiolo (Milano, Italy) | |
| A116 | V-DELTA-2 UNCONVENTIONAL T CELLS IN THE DONOR GRAFT ARE ASSOCIATED WITH IMPROVED OVERALL SURVIVAL AFTER UNRELATED DONOR ALLO-HCT FOR AML AND MDS | 18:00 - 18:00 |
| | Kate A. Markey (Seattle, United States Minor Outlying Islands (the)) | |
| A117 | DAN-CART 1901: PRELIMINARY RESULTS OF SAFE AND FEASIBLE ADMINISTRATION OF THE FRESH AUTOLOGOUS ANTI-CD19 CAR-T PRODUCT DK-CLIC-1901 | 18:00 - 18:00 |
| | Katrine Kielsen (Copenhagen, Denmark) | |
| A118 | OUTCOMES OF CRYOPRESERVED VERSUS NON-CRYOPRESERVED STEM CELL ALLOGRAFTS: A COMPARATIVE ANALYSIS | 18:00 - 18:00 |
| | Jenny Miethke (Jena, Germany) | |
| A119 | COMPARISON OF OUTCOMES OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR ALK-POSITIVE | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | AND ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: AN ANALYSIS OF THE EBMT LWP Evgenii Shumilov (Muenster, Germany) | |
| A120 | TREATMENT OUTCOMES WITH OUT-OF-SPECIFICATION PRODUCTS AND REMANUFACTURING SUCCESS IN CAR T-CELL THERAPY FOR AGGRESSIVE B-CELL LYMPHOMAS: A MULTICENTRE REAL-WORLD STUDY GETH/GELTAMO Lucía Lopez Corral (Salamanca, Spain) | 18:00 - 18:00 |
| A122 | INCIDENCE AND RISK FACTORS FOR POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN A MULTICENTER COHORT Olivia Gelo (Buenos Aires, Argentina) | 18:00 - 18:00 |
| A123 | ALLOGENEIC STEM CELL TRANSPLANTATION WITH 3-DAYS BUSULFAN PLUS FLUDARABINE AS CONDITIONING REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY T- AND NK/T-CELL LYMPHOMAS Ji Hyun Lee (Busan, Korea (the Republic of)) | 18:00 - 18:00 |
| A124 | THE IMPACT OF HLA-DPB1 PERMISSIVE AND NON-PERMISSIVE MISMATCH ON OUTCOMES IN MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THALASSEMIA Mohana Reddy (Bengaluru, India) | 18:00 - 18:00 |
| A125 | CLINICAL OUTCOMES OF FULLY HLA-MATCHED SIBLING VERSUS PARENTAL HSCT IN CHILDREN WITH HEMOGLOBINOPATHIES | 18:00 - 18:00 |
| A126 | PATIENTS WITH HIGH GRADE TRANSFORMATION OF WALDENSTRÖM'S MACROGLOBULINEMIA CAN BE RESCUED WITH TRANSPLANTATION. REPORT FROM THE LYMPHOMA WORKING PARTY OF THE EBMT Charalampia Kyriakou (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A128 | IMPACT OF PRE-APHERESIS HOLDING THERAPY ON EFFICACY AND HEMATOLOGIC TOXICITY AFTER CD19 CAR T-CELL THERAPY IN LARGE B-CELL LYMPHOMA Marina Gomez-Llobell (New York, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A129 | EFFECT OF DEFERASIROX INITIATED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ON OUTCOMES IN AML AND MDS: A PROSPECTIVE OBSERVATIONAL STUDY WITH PROPENSITY-SCORE MATCHED CONTROLS Mauricette Michallet (Lyon, France) | 18:00 - 18:00 |
| A130 | HIGHER BODY MASS INDEX IS ASSOCIATED WITH IMPROVED OUTCOMES AFTER CAR-T CELL THERAPY IN PATIENTS WITH LARGE B-CELL LYMPHOMA Mirko Farina (Brescia, Italy) | 18:00 - 18:00 |
| A131 | POPULATION PHARMACOKINETICS AND OPTIMAL EXPOSURE OF ANTI-THYMOCYTE GLOBULIN IN MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION Hamid Ghazal (Calgary, Canada) | 18:00 - 18:00 |
| A132 | EXPLORING BASELINE COGNITIVE FUNCTION ASSESSMENTS AS A PREDICTOR OF ICANS IN CAR-T CELL THERAPY PATIENTS Safia Belbachir (Murdoch, Australia) | 18:00 - 18:00 |
| A133 | EASIX OUTPERFORMS EBMT AND CIBMTR RISK MODELS IN PREDICTING VOD/SOS DESPITE DEFIBROTIDE USE IN ALLOGENEIC HSCT Güldane Cengiz Seval (Ankara, Turkey) | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| A134 | NON-CRYOPRESERVED HEMATOPOIETIC STEM CELLS FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA: REDUCED TOXICITY AND DISTINCT INFLAMMATORY PROFILE AS COMPARED TO CRIOPRESERVED PRODUCTS Mauricio Sarmiento Maldonado (Santiago, Chile) | 18:00 - 18:00 |
| A136 | CLINICAL OUTCOMES OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN YOUNGER PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) Miguel Angel Perales (New York, United States of America (the)) | 18:00 - 18:00 |
| A137 | OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN T-CELL NON-HODGKIN LYMPHOMA EXPERIENCE AT UNIVESITARY HOSPITAL OF SALAMANCA-SPAIN Jaime Daniel Pallo Espinoza (Salamanca, Spain) | 18:00 - 18:00 |
| A139 | "REAL WORLD" INCIDENCE AND CHARACTERISTICS OF IMMUNE EFFECTOR CELL-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTOCYTOSIS: A GOCART COALITION STUDY ON BEHALF OF THE EBMT ADWP, CTIWP AND TCWP Matteo Doglio (Milan, Italy) | 18:00 - 18:00 |
| A140 | RISK STRATIFICATION FOR HIGHER GRADE ICANS IN ANTI CD19 CAR T-CELL THERAPY TO GUIDE MANAGEMENT OF HIGH RISK PATIENTS Jonas Wißkirchen (Mainz, Germany) | 18:00 - 18:00 |
| A141 | VENETOCLAX PLUS HIGH-DOSE CYTARABINE AND MITOXANTRONE (HAM-VEN) AS BRIDGE TO OR SALVAGE THERAPY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY AML Sara Jennrich (Essen, Germany) | 18:00 - 18:00 |
| A142 | SARCOPENIA ASSESSMENT BY BIOELECTRICAL IMPEDANCE AND FUNCTIONAL TESTS PREDICTS CLINICAL OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Silvia Zanon (Brescia, Italy) | 18:00 - 18:00 |
| A143 | POOR GRAFT FUNCTION AND GRAFT FAILURE AFTER ALLOGENEIC HSCT: FOCUS ON CELLULAR THERAPY. A RETROSPECTIVE SINGLE-CENTER ANALYSIS Natalia Zubarovskaya (Vienna, Austria) | 18:00 - 18:00 |
| A145 | SCALABLE MANUFACTURING AND NATIONWIDE DISTRIBUTION OF ORCA-T: A PRECISION-ENGINEERED ALLOGENEIC IMMUNE CELL THERAPY Anna Pavlova (Menlo Park, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A146 | OUTCOMES AFTER STANDARD- VS. REDUCED-DOSE TREOSULFAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Johanne Schovsbo (Copenhagen, Denmark) | 18:00 - 18:00 |
| A147 | REAL-WORLD EXPERIENCE WITH TABELLECLEUCEL Kiavasch Mohammad Nejad Farid (Heidelberg, Germany) | 18:00 - 18:00 |
| A148 | MESENCHYMAL STEM CELLS DERIVED FROM DIFFERENT SOURCES AND THEIR SECRETOMES IN MULTIPLE SCLEROSIS THERAPY: A SINGLE CENTER EXPERIENCE Ahmad Ibrahim (Beirut, Lebanon) | 18:00 - 18:00 |
| A149 | TREOSULFAN-FLUDARABINE AS A REDUCED INTENSITY CONDITIONING ALTERNATIVE TO BUSULFAN-FLUDARABINE FOR ADULT ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE-CENTER, EARLY REAL-LIFE CLINICAL AND ECONOMICAL COMPARATIVE OUTCOMES | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | Clémence Delaye (Villejuif, France) | |
| A150 | CD72-GATED PRE-CAR-T MRD AS A NOVEL PREDICTOR OF POST-TRANSPLANT OUTCOMES IN R/R B-ALL ACHIEVING MRD-NEGATIVE REMISSION AFTER CD19 CAR-T THERAPY Man Chen (Beijing, China) | 18:00 - 18:00 |
| A151 | NON-MYELOABLATIVE CONDITIONING FLUCYTBI WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IS SAFE AND EFFECTIVE FOR BOTH HAPLOIDENTICAL AND UNRELATED DONOR ALLOGENEIC TRANSPLANTATION IN OLDER PATIENTS WITH AML OR MDS Charlotte Nykolyszyn (Marseille, France) | 18:00 - 18:00 |
| A152 | HYPOMETHYLATING AGENTS PLUS VENETOCLAX VS INTENSIVE CHEMOTHERAPY PRIOR TO TRANSPLANT IN HIGH-RISK ACUTE MYELOID LEUKEMIA Charlotte Nykolyszyn (Marseille, France) | 18:00 - 18:00 |
| A153 | PROGNOSIS ANALYSIS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF MYELOID SARCOMA: A SINGLE-CENTER STUDY Na Zhang (Beijing, China) | 18:00 - 18:00 |
| A154 | PATTERNS AND PREDICTORS OF HEMATOLOGIC TOXICITY AFTER BCMA- AND CD19-TARGETED CAR-T THERAPY Shlomo Elias (Jerusalem, Israel) | 18:00 - 18:00 |
| A156 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA: A RETROSPECTIVE STUDY ON PROGNOSTIC FACTORS AND A NOVEL SCORING SYSTEM Na Tao (Hangzhou, China) | 18:00 - 18:00 |
| A157 | OUTCOME OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) AFTER PEMBROLIZUMAB IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS: A RETROSPECTIVE ANALYSIS OF THE KING HUSSEIN CANCER CENTER Khalid Halahleh (Amman, Jordan) | 18:00 - 18:00 |
| A158 | A PILOT RANDOMIZED CLINICAL TRIAL OF A VIRTUAL REALITY SUPPORTIVE CARE INTERVENTION FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION Hermioni Amonoo (Boston, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A161 | HARMONIZING HAPLOIDENTICAL STRATEGIES: A FOUR-YEAR COMPARATIVE ANALYSIS OF T-CELL-DEPLETED AND REPLETE PEDIATRIC TRANSPLANTS FROM A DEVELOPING COUNTRY Chintan Tarunkumar Vyas (Mumbai, India) | 18:00 - 18:00 |
| A164 | PERFORMANCE AND VALIDATION OF THE SIMPLIFIED COMORBIDITY INDEX IN PREDICTING NON-RELAPSE MORTALITY AFTER ALLOGENEIC HCT IN THE CURRENT ERA Omar Eduardo Fernandes Vargas (Montreal, Canada) | 18:00 - 18:00 |
| A165 | GRAFT-VERSUS-HOST DISEASE, RELAPSE, AND A SIMPLE GRFS RISK GROUPING IN HAPLOIDENTICAL TRANSPLANTATION WITH PTCY Gonzalo Bentolila (Ciudad Autonoma de Buenos Aires, Argentina) | 18:00 - 18:00 |
| A166 | CD45RA-DEPLETED T-CELL ADOPTIVE CELL THERAPY FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS WITH REFRACTORY/RESISTANT EBV INFECTIONS: A MULTICENTER, RETROSPECTIVE STUDY Chuanhe Jiang (Shanghai, China) | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| A167 | HCT-CI FAILS TO PREDICT OUTCOMES OR TOXICITY IN A LARGE REAL-WORLD LBCL COHORT TREATED WITH AXICABTAGENE CILOLEUCEL: THE AUSTRALIAN CAR-T REAL-WORLD CONSORTIUM EXPERIENCE Safia Belbachir (Murdoch, Australia) | 18:00 - 18:00 |
| A169 | SURVIVAL OUTCOMES FOLLOWING ALLOGENEIC TRANSPLANT FOR TP53-MUTATED MYELOID MALIGNANCY IN IRELAND Sarah Kelliher (Dublin, Ireland) | 18:00 - 18:00 |
| A170 | OUTCOME AND TOXICITY PROFILE OF CAR T-CELL THERAPY IN PEDIATRIC RELAPSED/REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE-CENTER EXPERIENCE FROM SAUDI ARABIA Alaa Alzahrani (Riyadh, Saudi Arabia) | 18:00 - 18:00 |
| A171 | INDIVIDUALIZED BUSULFAN COMPARED TO FIXED-DOSE IN HEMATOPOIETIC STEM CELL TRANSPLANT FOR AML/MDS: RESULTS FROM A SINGLE CENTER Roberto Bono (Palermo, Italy) | 18:00 - 18:00 |
| A172 | IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) IN PAEDIATRIC PATIENTS FOLLOWING CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY: EXPERIENCE FROM A TERTIARY CARE CENTER Nazaret Sanchez-Sierra (Barcelona, Spain) | 18:00 - 18:00 |
| A173 | A SINGLE CENTRE RETROSPECTIVE REVIEW OF DONOR LYMPHOCYTE INFUSION - INDICATIONS, OUTCOMES AND TOXICITY Catharina Tao (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A174 | REAL-WORLD OUTCOMES OF AUTOLOGOUS BONE MARROW TRANSPLANTATION IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER RETROSPECTIVE ANALYSIS FROM THE UKRAINIAN NATIONAL BMT REGISTRY Serhii Horbachov (Cherkasy, Ukraine) | 18:00 - 18:00 |
| A175 | TREOSULFAN COMPARED WITH BUSULFAN-BASED CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HEMATOLOGICAL MALIGNANCIES Anna Czyż (Wrocław, Poland) | 18:00 - 18:00 |
| A176 | UTILIZING GVHD BIOMARKERS TO PREDICT POOR ENGRAFTMENT: THE GOLDILOCKS PHENOMENON OF ALLOREACTIVE T CELLS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION Clayton Long (Phoenix, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A177 | IMMUNE EFFECTOR CELL ASSOCIATED HAEMATOTOXICITY (ICAHT) AND CORRELATION WITH CLINICAL OUTCOMES POST CD19 CAR-T; A SINGLE CENTRE RETROSPECTIVE EXPERIENCE FROM THE ROYAL MARSDEN HOSPITAL Nida Shafique (Sutton, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A178 | DUAL T-CELL DEPLETION WITH ANTITHYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PERIPHERAL BLOOD ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME Soyean Kwon (Seoul, Korea (the Republic of)) | 18:00 - 18:00 |
| A179 | IMPACT OF HLA B LEADER GENOTYPE ON SINGLE HLA MISMATCHED ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER COHORT STUDY Elcin Erdogan Yucel (Izmir, Turkey) | 18:00 - 18:00 |
| A180 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION USING | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | DECEASED DONOR DERIVED CRYOPRESERVED BONE MARROW: A FIRST-IN-HUMAN REPORT OF SUCCESSFUL ENGRAFTMENT IN PRESERVE 1 | |
| | Sagar Munjal (San Francisco, United States Minor Outlying Islands (the)) | |
| A181 | EFFICACY OF UNRELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SEVERE APLASTIC ANEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY OF 206 PATIENTS | 18:00 - 18:00 |
| | Jinrong Zhao (Guangzhou, China) | |
| A184 | UMBILICAL CORD BLOOD MICROTRANSPLANTATION PLUS CHEMOTHERAPY FOR AML AND HIGH-RISK MDS POST-CR1 | 18:00 - 18:00 |
| | Jing Zheng (Hangzhou, China) | |
| A185 | CLINICAL IMPACT OF IN-SILICO HISTOCOMPATIBILITY ALGORITHMS IN 9/10 MISMATCHED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATIO | 18:00 - 18:00 |
| | Rodrigo Gil Manso (Salamanca, Spain) | |
| A186 | INTRARENAL ARTERIAL INFUSION OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF TRANSPLANTATION-ASSOCIATED ACUTE RENAL FAILURE: A CASE REPORT | 18:00 - 18:00 |
| | Yuanying Zeng (Dongguan, China) | |
| A187 | CLINICAL STUDY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION PLUS UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR THE RELAPSED AND REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA | 18:00 - 18:00 |
| | Zhengchang He (Chongqing, China) | |
| A188 | POST-TRANSPLANT MONITORING OF NGS-BASED MINIMAL RESIDUAL DISEASE AND DONOR CHIMERISM AS A PROGNOSTIC TOOL IN OLDERLY PATIENTS WITH AML/MDS | 18:00 - 18:00 |
| | Seong Kyu Park (Bucheon-Si, Korea (the Republic of)) | |
| A189 | PTCY VERSUS ATLG IN ALLOGENEIC HSCT FOR ACUTE LEUKEMIA WITH HIGH DISEASE BURDEN: A REAL-WORLD STUDY | 18:00 - 18:00 |
| | Minglu Li (Beijing, China) | |
| A190 | ADMISSION TO INTENSIVE CARE UNIT (ICU) OF ADULT HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE CENTER EXPERIENCE | 18:00 - 18:00 |
| | Laura Contreras Rujas (Madrid, Spain) | |
| A191 | DETERMINANTS OF GVHD AND SURVIVAL AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER ANALYSIS OF 169 PATIENTS | 18:00 - 18:00 |
| | Fei Pan (Beijing, China) | |
| A192 | A RETROSPECTIVE ANALYSIS OF THE CLINICAL CHARACTERISTICS, RISK FACTORS, AND PROGNOSIS OF FUSARIUM INFECTION IN HEMATOLOGIC PATIENTS BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION | 18:00 - 18:00 |
| | JiCong Liu (LangFang, China) | |
| A193 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR THERAPY-RELATED MYELOID NEOPLASMS: LONG-TERM OUTCOMES AND PROGNOSTIC DETERMINANTS FROM A SINGLE-CENTER COHORT | 18:00 - 18:00 |
| | Yunsuk Choi (Seoul, Korea (the Republic of)) | |
| A194 | EFFICACY AND SAFETY OF COMBINING BCL-2 INHIBITORS WITH HYPOMETHYLATING AGENTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME AFTER | 18:00 - 18:00 |

| ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | | |
|---|---|---------------|
| | Larisa Kuzmina (Moscow, Russian Federation (the)) | |
| A195 | SECONDARY MYELODYSPLASTIC SYNDROME AFTER CAR-T THERAPY: AN EMERGING LATE TOXICITY Juliana Bosco Santos (São Paulo, Brazil) | 18:00 - 18:00 |
| A196 | EARLY CYCLOSPORINE TAPERING AND PROPHYLACTIC DONOR LYMPHOCYTE INFUSION FOR POST-TRANSPLANT IMMUNOMODULATION IN HIGH-RISK HEMATOLOGIC MALIGNANCIES: A SINGLE-CENTER FEASIBILITY STUDY Roberto Bono (Palermo, Italy) | 18:00 - 18:00 |
| A198 | LONG-TERM OUTCOMES OF ADULT PH+ ALL TREATED WITH DASATINIB OR IMATINIB BEFORE THE BLINATUMOMAB ERA: A RETROSPECTIVE ANALYSIS OF 250 PATIENTS FROM THE PALG REGISTRY Ugo Giordano (Wroclaw, Poland) | 18:00 - 18:00 |
| A199 | OVERCOMING ULTIMATE RESISTANCE: EFFICACY AND SAFETY OF RECIPIENT-DERIVED (DONOR-CHIMERIC) CAR-T THERAPY COMBINED WITH MULTIMODAL STRATEGIES FOR EARLY RELAPSE POST-ALLO-HSCT: A SINGLE-CENTER CASE SERIES Yajing Zhang (Beijing, China) | 18:00 - 18:00 |
| A200 | GEMTUZUMAB OZOGAMICIN ENABLES BRIDGING TO 2ND/3RD ALLO-HSCT WITH FAVORABLE OUTCOMES IN CD33-HIGH RELAPSED/REFRACTORY AML WITH POST-ALLO-HSCT RELAPSE Xiaohong Liu (Beijing, China) | 18:00 - 18:00 |
| A201 | LONGITUDINAL IMPROVEMENT IN SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A 15-YEAR SINGLE-CENTRE EVALUATION OF QUALITY INITIATIVES Safia Belbachir (Murdoch, Australia) | 18:00 - 18:00 |
| A202 | THROMBOTIC MICROANGIOPATHY FOLLOWING CAR T-CELL THERAPY: A CASE SERIES FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY Guillaume Dachy (Brussels, Belgium) | 18:00 - 18:00 |
| A203 | THE IMPACT OF PRE-TRANSPLANT ISOAGGLUTININ REDUCTION IN MAJOR AND BIDIRECTIONAL ABO-MISMATCHED ALLOGENEIC STEM CELL TRANSPLANTATION - A TWO CENTRE COMPARISON Safia Belbachir (Murdoch, Australia) | 18:00 - 18:00 |
| A204 | SAFETY AND EMERGING CLINICAL IMPACT OF CD19 CAR T-CELL THERAPY IN SEVERE AUTOIMMUNE RHEUMATIC DISEASES: A SINGLE-CENTRE CASE SERIES Aitomi Bittner (Berlin, Germany) | 18:00 - 18:00 |
| A205 | SINGLE CENTRE EXPERIENCE OF USING A THERAPEUTIC PLATELET REGIME DURING AUTOLOGOUS STEM CELL TRANSPLANT Malik Saeed (Nottingham, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A206 | ALLOGENEIC HSCT FOR ADVANCED STAGE AND RELAPSED/REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA (ENKTCL): A SINGLE INSTITUTION EXPERIENCE IN L-ASPARAGINASE ERA Thomas Chan (Hong Kong, China) | 18:00 - 18:00 |
| A207 | EFFICACY AND SAFETY OF CD20XCD3 BISPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMAS: A SYSTEMATIC REVIEW AND META-ANALYSIS Fernando Gibran-Nunes (São Paulo, Brazil) | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| A208 | ACCESS TO CAR-T CELL THERAPY IN CENTRAL AND EASTERN EUROPE (CEE) - PERSISTENT DISPARITIES Karolina Liszka (Wrocław, Poland) | 18:00 - 18:00 |
| A209 | EFFICACY AND SAFETY ANALYSIS OF PD-1 INHIBITORS IN ACUTE LEUKEMIA PATIENTS WITH MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION BiXin Li (Langfang, China) | 18:00 - 18:00 |
| A211 | HYPOFIBRINOGENEMIA AND SYSTEMIC INFLAMMATION FOLLOWING BCMA-DIRECTED CAR-T THERAPY: A RETROSPECTIVE STUDY Almudena Zaratiegui (Madrid, Spain) | 18:00 - 18:00 |
| A212 | SURVIVAL AND OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER, DECADE-LONG ANALYSIS Noa Holtzman (Miami, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A213 | AGE AT TRANSPLANT DETERMINES OUTCOME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MITOCHONDRIAL NEURO-GASTROINTESTINAL ENCEPHALOPATHY (MNGIE) Patel Zeeshan Jameel (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A214 | LONG-TERM OUTCOMES OF HAPLOIDENTICAL AND MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN COMPLETE REMISSION NON-DS-AMKL: A SINGLE-CENTER COHORT STUDY Fei Pan (Beijing, China) | 18:00 - 18:00 |
| A215 | IMPACT OF HEPATITIS E VIRUS INFECTION ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CURRENT TREATMENT STATUS Ting Liu (Langfang City, China) | 18:00 - 18:00 |
| A216 | IMPACT OF THERAPEUTIC PLASMA EXCHANGE ON PAN-REACTIVE HLA ANTIBODY TITRES IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA UNDERGOING MATCHED RELATED DONOR HSCT: A SINGLE-CENTRE STUDY Santanu Sen (Mumbai, India) | 18:00 - 18:00 |
| A217 | RISK FACTORS FOR REFRACTORY CYTOMEGALOVIRUS INFECTION IN HEMATOPOIETIC STEM CELL AND SOLID ORGAN TRANSPLANT RECIPIENTS Shunqing Wang (Guangzhou, China) | 18:00 - 18:00 |
| A218 | PROGNOSTIC AND SAFETY PREDICTIVE VALUE OF THE SYSTEMIC IMMUNE-INFLAMMATION INDEX IN R/R B-CELL LYMPHOMA PATIENTS UNDERGOING CAR-T CELL THERAPY Jing Liu (Beijing, China) | 18:00 - 18:00 |
| A219 | BONE MARROW TRANSPLANTATION IN SICKLE, ACCORDING TO DONOR STATUS: COMPARISON AND DIFFERENCES IN CLINICAL OUTCOMES Eduardo J. Bardón-Cancho (Madrid, Spain) | 18:00 - 18:00 |
| A220 | THE PROGNOSTIC IMPACT OF CEBPA MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Erlic Jiang (Tianjin, China) | 18:00 - 18:00 |
| A221 | MESENCHYMAL STEM CELL TRANSPLANTATION IN PATIENTS WITH GRAFT HYPOFUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | Tatsiana Talako (Minsk, Belarus) | |
| A222 | REFINING HLA-DPB1 MISMATCH (PERMISSIVENESS/NON PERMISSIVENESS) ASSESSMENT IN ALLOGENEIC STEM CELL TRANSPLANTATION Chiara Camerini (Florence, Italy) | 18:00 - 18:00 |
| A223 | DYNAMIC CHANGES IN PHASE ANGLE ASSESSED BY BIOELECTRICAL IMPEDANCE ANALYSIS AS A MARKER OF TOXICITY IN PATIENTS UNDERGOING CAR-T CELL THERAPY Mirko Farina (Brescia, Italy) | 18:00 - 18:00 |
| A224 | HYPOMETHYLATING AGENTS AND VENETOCLAX FOR RELAPSE PREVENTION IN PATIENTS WITH HIGH-RISK MYELOID MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Huiying Qiu (Shanghai, China) | 18:00 - 18:00 |
| A225 | A SIMPLIFIED APPROACH TO GENERATE TREG-ENRICHED GRAFT: TECHNICAL AND EARLY CLINICAL DEVELOPMENT OF CD3-DEPLETION AND CD25-SELECTION Dmitry Pershin (Moscow, Russian Federation (the)) | 18:00 - 18:00 |
| A226 | REAL-WORLD OVERALL SURVIVAL OUTCOMES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA: EXPERIENCE FROM A MEXICAN CENTER Rosa Adriana Alvidrez-González (Mexico City, Mexico) | 18:00 - 18:00 |
| A227 | EFFICACY AND SAFETY OF GRANULOCYTE COLONY STIMULATING FACTOR (GCSF) USE FOLLOWING CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY (CAR-T): A SYSTEMATIC REVIEW Xiao Ran Luo (Singapore, Singapore) | 18:00 - 18:00 |
| A228 | COMPUTED TOMOGRAPHY-DERIVED MUSCLE QUALITY PREDICTS LENGTH OF HOSPITALIZATION AFTER STEM CELL TRANSPLANTATION Christianne Bourlon-De los Ríos (Mexico City, Mexico) | 18:00 - 18:00 |
| A229 | THE ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA Nikolai Tsvetkov (St. Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| A230 | TRANSITIONING CAR-T CELL THERAPY FOR MYELOMA TO THE OUTPATIENT SETTING: FIRST EXPERIENCE FROM A GERMAN CENTER Philipp Gödel (Cologne, Germany) | 18:00 - 18:00 |
| A231 | THE PRACTICAL DIFFICULTIES OF DLI THERAPY: A SINGLE-CENTRE AUDIT OF DLI COLLECTION AND USE William George Giusti Fischer (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A232 | EARLY STEROID PROPHYLAXIS AS A STRATEGY TO REDUCE CAR T-CELL TOXICITIES WITHOUT AFFECTING EFFICACY Simona Sammassimo (Milan, Italy) | 18:00 - 18:00 |
| A233 | SEQUENTIAL IMMUNOMODULATION WITH PRE-APHERESIS PRIMING AND POST-INFUSION BOOST TO RESTORE T-CELL FITNESS AND IMPROVE ANTI-CD19 CAR-T EXPANSION IN BENDAMUSTINE-EXPOSED R/R B-NHL: A PILOT STUDY Yajing Zhang (Beijing, China) | 18:00 - 18:00 |
| A234 | REDEFINING CURATIVE HORIZONS IN THALASSEMIA MAJOR: 100% SURVIVAL FOLLOWING ALTERNATIVE DONOR HSCT IN A RESOURCE-LIMITED SETTING | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | Chintan Tarunkumar Vyas (Mumbai, India) | |
| A235 | EXPERIENCE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH GATA2 MUTATION Larisa Kuzmina (Moscow, Russian Federation (the)) | 18:00 - 18:00 |
| A236 | ALLOGENEIC HSCT WITH MYELOABLATIVE CONDITIONING IN SICKLE CELL DISEASE: A SINGLE-CENTER EXPERIENCE Akif Yesilipek (Antalya, Turkey) | 18:00 - 18:00 |
| A238 | SHOULD FRAILTY SCORES BE CONSIDERED WHEN ASSESSING ELIGIBILITY FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION? THE EXPERIENCE OF THE SOUTH WALES BLOOD AND MARROW TRANSPLANT PROGRAMME Wendy Ingram (Cardiff, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A239 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF 38 PATIENTS Yang He (Langfang, China) | 18:00 - 18:00 |
| A240 | IS HLA MISMATCHING BECOMING A HISTORY IN THE ERA OF POST-TRANSPLANT CYCLOPHOSPHAMIDE? Elcin Erdogan Yucel (Izmir, Turkey) | 18:00 - 18:00 |
| A241 | INDUCING KETOSIS WITH B-HYDROXYBUTYRATE SUPPLEMENTATION DURING CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN RELAPSED/REFRACTORY INFANT ACUTE LYMPHOBLASTIC LEUKEMIA Patrizia Lehr (Freiburg, Germany) | 18:00 - 18:00 |
| A243 | OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY IN ADOLESCENTS AND YOUNG ADULTS: A SINGLE-CENTRE EXPERIENCE Yazeed Bajuaifer (Riyadh, Saudi Arabia) | 18:00 - 18:00 |
| A244 | CD34⁺ CELL DOSE ABOVE 10 MILLION PER KILOGRAM ON THE OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE Lun-Wei Chiou (Taipei, Taiwan (Province of China)) | 18:00 - 18:00 |
| A245 | OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN ACUTE LEUKEMIAS IN ECUADOR Luis Martillo-Maldonado (Guayaquil, Ecuador) | 18:00 - 18:00 |
| A246 | EVALUATING THE ROLE OF ELTROMBOPAG IN POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS WITH HEMATOLOGIC DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS April Joy Ong (Manila City, Philippines (the)) | 18:00 - 18:00 |
| A247 | TREATMENT OF RELAPSED/REFRACTORY HIGH-GRADE B-CELL LYMPHOMAS WITH POINT-OF-CARE MANUFACTURED ANTI-CD-MB-19.1 -CART-CELLS: A SINGLE CENTER, INTERIM ANALYSIS OF A PHASE 2 TRIAL FROM JORDAN Khalid Halahleh (Amman, Jordan) | 18:00 - 18:00 |
| A248 | FEASIBILITY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH MYELOID NEOPLASMS: SINGLE-CENTER EXPERIENCE Natalia López Esteban (Las Palmas de Gran Canaria, Spain) | 18:00 - 18:00 |
| A249 | OUTCOMES OF CORD BLOOD TRANSPLANTATION FOR AML-MR: PROGRESS AND REMAINING CHALLENGES Shunsuke Nishino (Minato-Ku, Tokyo, Japan) | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| A250 | HAPLOIDENTICAL VERSUS FULLY MATCHED RELATED DONOR STEM CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULTS WITH SEVERE APLASTIC ANEMIA: A SINGLE-CENTER EXPERIENCE FROM A RESOURCE-LIMITED SETTING Daniella Hodroj (Beirut, Lebanon) | 18:00 - 18:00 |
| A251 | PROGNOSTIC FACTORS FOR CYTOKINE RELEASE SYNDROME (CRS) AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY: A SINGLE-CENTER EXPERIENCE Aikaterini Benekou (Athens, Greece) | 18:00 - 18:00 |
| A252 | WHEN COMBINING ATG WITH PTCY, HIGHER ATG EXPOSURE MAY RESULT IN HIGHER SURVIVAL Hamid Ghazal (Calgary, Canada) | 18:00 - 18:00 |
| A253 | IMPACT OF CORTICOSTEROID THERAPY ON CLINICAL OUTCOMES, TOXICITY, AND CAR T-CELL KINETICS IN PATIENTS TREATED WITH ACADEMIC ANTI-BCMA CAR T CELLS (HBI0101) Sigal Grisariu (Jerusalem, Israel) | 18:00 - 18:00 |
| A254 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION POST-CAR-T THERAPY IN CHILDREN WITH PRE-B ACUTE LYMPHOBLASTIC LEUKAEMIA: NATIONAL POLISH EXPERIENCE Karolina Liszka (Wroclaw, Poland) | 18:00 - 18:00 |
| A256 | MULTICENTER PILOT CLINICAL TRIAL OF OLUTASIDENIB AS MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH AML/MDS CARRYING IDH1 MUTATIONS Amandeep Salhotra (Duarte, United States of America (the)) | 18:00 - 18:00 |
| A257 | A SINGLE CENTRE EXPERIENCE OF ALLOGENEIC STEM CELL TRANSPLANT IN PATIENTS OVER 70 Catharina Tao (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A258 | LOW-LEVEL PRETRANSPLANT CMV DNAEMIA IS ALREADY A RISK FACTOR FOR POSTTRANSPLANT CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Dionysios Neofytos (Geneva, Switzerland) | 18:00 - 18:00 |
| A259 | ASSESSMENT OF COMPLEMENT PATHWAY DYNAMICS AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT: RESULTS FROM A MONOCENTRIC LONGITUDINAL MONITORING PROGRAM Camille Malbrun (Vandoeuvre-Les-Nancy, France) | 18:00 - 18:00 |
| A260 | HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR MALIGNANT AND NON-MALIGNANT HEMATOLOGIC DISORDERS: A REAL-WORLD EXPERIENCE FROM QATAR Afraa Fadul (Doha, Qatar) | 18:00 - 18:00 |
| A261 | OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHRONIC MYELOID LEUKEMIA IN TYROSINE KINASE INHIBITORS ERA: A SINGLE CENTRE STUDY FROM PAKISTAN Bushra Ahsan (Lahore, Pakistan) | 18:00 - 18:00 |
| A262 | ABT/CD19 DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION IS A SAFE AND EFFECTIVE SALVAGE THERAPY IN HEAVILY PRETREATED RELAPSED/REFRACTORY PATIENTS WITH HODGKIN LYMPHOMA Lucia Prezioso (Parma, Italy) | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| A264 | FACTORS AFFECTING QUALITY OF BONE MARROW HARVESTING: AN ANALYSIS OF ANTHONY NOLAN DONORS FROM 2019-2024 Tania Dexter (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A265 | FOR CAR T CELL, SIZE DOES SEEM TO MATTER! Susana Couto Irving (Porto, Portugal) | 18:00 - 18:00 |
| A267 | IMPACT OF SOCIODEMOGRAPHIC AND CLINICAL FACTORS ON ACCESS TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY FROM MEXICO Rosa Adriana Alvidrez-González (Mexico City, Mexico) | 18:00 - 18:00 |
| A268 | SINGLE-CENTER RETROSPECTIVE CLINICAL STUDY ON THE CONDITIONING REGIMEN OF DECITABINE, THIOTEPA, BUSULFAN, AND FLUDARABINE (DTBF) COMBINED WITH ATG/PTCY FOR ALTERNATIVE DONOR TRANSPLANTATION IN MYELODYSPLASTIC NEOPLASMS Yajing Xu (Changsha, China) | 18:00 - 18:00 |
| A269 | CONDITIONING MATTERS: A RETROSPECTIVE COMPARISON OF BUCY AND FLUBU IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Mistral Castellanos-Mares (Mexico City, Mexico) | 18:00 - 18:00 |
| A270 | MULTI-VIRUS SPECIFIC MEMORY T CELLS TARGETING CMV, BKV, AND EBV IN POST-HSCT VIRAL INFECTIONS Seok-Goo Cho (Seoul, Korea (the Republic of)) | 18:00 - 18:00 |
| A271 | LONG-TERM OUTCOMES OF HAPLOIDENTICAL, MATCHED SIBLING, AND MATCHED UNRELATED DONOR HSCT IN 133 ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A SINGLE-CENTER COMPARATIVE STUDY Yanli Zhao (Langfang, China) | 18:00 - 18:00 |
| A272 | ALEMTUZUMAB PROVIDES DURABLE DEPLETION OF CIRCULATING CAR-T CELLS IN A PATIENT WITH HYPOKINETIC MOVEMENT DISORDERS AFTER BCMA-TARGETING CAR-T CELL THERAPY Lea Miebach (Greifswald, Germany) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Relapse and Graft-versus-Leukemia

| | | |
|------|--|---------------|
| A342 | MUTATIONAL LANDSCAPE CHANGES OF AML IN PATIENTS RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Kristina Maas-Bauer (Freiburg, Germany) | 18:00 - 18:00 |
| A343 | GRANULOCYTE TRANSFUSION DURING CORD-BLOOD TRANSPLANT PRODUCES EARLY, REPRODUCIBLE, EFFECTOR MEMORY CD8+ T-CELL EXPANSION WITH CLINICALLY SIGNIFICANT CLINICAL RESPONSES IN REFRACTORY AML Nathan Jeffreys (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A345 | PROGNOSTIC IMPACT OF PRE-TRANSPLANT MEASURABLE RESIDUAL DISEASE AND GVHD PROPHYLAXIS IN AML PATIENTS UNDERGOING ALLO-HCT Huxlhey Cabrera-García (Medellín, Colombia) | 18:00 - 18:00 |
| A346 | AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HIGH-RISK AML: A SINGLE-CENTER RETROSPECTIVE STUDY Sadia Falcioni (Bologna, Italy) | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| A348 | CLINICAL OUTCOMES OF AZACITIDINE-VENETOCLAX IN RELAPSED AML AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE ASOVASNA CELLULAR THERAPY GROUP Maria de la Cruz Viguria (San Sebastián, Spain) | 18:00 - 18:00 |
| A349 | OUTCOMES OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE AND A DIFFERENT DONOR AFTER RELAPSE FOLLOWING A FIRST ALLOGRAFT: A SINGLE-CENTER RETROSPECTIVE STUDY Lucia Castilla-Garcia (Madrid, Spain) | 18:00 - 18:00 |
| A350 | DONOR DERIVED LEUKEMIA, SINGLE CENTRE EXPERIENCE Markéta Šťastná Marková (Praha 2, Czechia) | 18:00 - 18:00 |
| A351 | EFFICACY AND TOXICITY OF DONOR LYMPHOCYTE INFUSION IN A FIXED-DOSE COHORT: CLINICAL OUTCOMES AND PATIENT-REPORTED BURDEN Julian Greß (Munich, Germany) | 18:00 - 18:00 |
| A352 | EFFECT OF MINIMAL RESIDUAL DISEASE GUIDED POSTTRANSPLANT 6-MERCAPTOPYRIMIDINE AND METHOTREXATE MAINTENANCE ON PROGNOSIS OF HIGH-RISK PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE Zühre Kaya (Ankara, Turkey) | 18:00 - 18:00 |
| A353 | CLINICAL COURSE AND SURVIVAL OF AML PATIENTS WITH CLONAL EVOLUTION AT RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Lukas Schaefer (Berlin, Germany) | 18:00 - 18:00 |
| A355 | MONOCYTE-T CELLS CROSSTALK ORCHESTRATES EARLY GRAFT-VERSUS-LEUKEMIA IMMUNITY IN AML PATIENTS AFTER TRANSPLANTATION Sha Hao (Tianjin, China) | 18:00 - 18:00 |
| A356 | APPLICATION OF PLASMA FOURIER-TURNED INFRARED SPECTROSCOPY (FT-IR) FOR MONITORING OF ACUTE MYELOID LEUKEMIA AND EXTRAMEDULLARY RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Besjana Khahysa (Brescia, Italy) | 18:00 - 18:00 |
| A357 | REFINED DISEASE RISK INDEX OUTWEIGHS PRE-TRANSPLANT RESPONSE IN PREDICTING RELAPSE AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULTS FROM THE NATIONAL CANCER INSTITUTE IN LIMA, PERÚ Naty López-Córdova (Lima, Peru) | 18:00 - 18:00 |
| A358 | VENETOCLAX AND HYPOMETHYLATING AGENT WITH DONOR LYMPHOCYTE INFUSION FOR RELAPSED ACUTE MYELOID LEUKAEMIA POST ALLOGENEIC STEM CELL TRANSPLANTATION William George Giusti Fischer (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Late complications, quality of life, fertility and survivorship

| | | |
|------|--|---------------|
| A414 | CARDIOVASCULAR HEALTH OF HAEMATOPOIETIC STEM CELL TRANSPLANT SURVIVORS IN THE UK BIOBANK Dorina-Gabriela Condurache (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| A415 | SOCIAL IMPACT AND PATIENT-CAREGIVER EXPERIENCE IN CHRONIC GVHD: RESULTS FROM A NATIONAL SURVEY IN SPAIN | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | Marta Fernandez (Barcelona, Spain) | |
| A416 | SURVEY ON FERTILITY MANAGEMENT AND OUTCOMES AFTER CAR T, ON BEHALF OF THE EBMT CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY Giorgio Orofino (Milan, Italy) | 18:00 - 18:00 |
| A417 | SECOND PRIMARY MALIGNANCIES AFTER T-CELL ENGAGING BISPECIFIC ANTIBODY THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS Jaromir Tomasik (Warsaw, Poland) | 18:00 - 18:00 |
| A418 | QUALITY OF LIFE RECOVERY FOLLOWING CHRONIC GRAFT-VERSUS-HOST DISEASE RESOLUTION IN LONG-TERM ALLOGENEIC TRANSPLANT SURVIVORS Genevieve Douglas (Melbourne, Australia) | 18:00 - 18:00 |
| A419 | LONGITUDINAL ASSESSMENT OF FRAILTY AND FUNCTIONAL RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE PROPHYLAXIS Adriana Cuartas (Barcelona, Spain) | 18:00 - 18:00 |
| A420 | EXTENSIVE OR SEVERE CHRONIC GVHD IS ASSOCIATED WITH SUSTAINED AND WORSENING IMPAIRMENTS IN SYMPTOMS AND WELL-BEING UP TO 5 YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Pleun Schonewille (Utrecht, Netherlands (the)) | 18:00 - 18:00 |
| A421 | SIGNIFICANT IMPROVEMENT OF SURVIVAL AND GVHD- AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OVER TIME Hanna A. Knaus (Vienna, Austria) | 18:00 - 18:00 |
| A422 | POST-HCT EMPLOYMENT AND ASSOCIATED FACTORS AMONG CHILDHOOD, ADOLESCENT, AND YOUNG ADULT PATIENTS AT THE TIME OF TRANSPLANTATION Saiko Kurosawa (Nagano, Japan) | 18:00 - 18:00 |
| A423 | GONADAL FUNCTION OF CHILDREN AND ADOLESCENTS AFTER ALLOGENEIC HSCT WITH TREOSULFAN- AND TBI-BASED CONDITIONING Susanna Arakelyan (Moscow, Russian Federation (the)) | 18:00 - 18:00 |
| A424 | LONG-TERM SURVIVAL AND QUALITY OF LIFE IN OLDER ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANT Kyra A. Oosterink (Leiden, Netherlands (the)) | 18:00 - 18:00 |
| A425 | GONADAL TOXICITY AND PREMATURE OVARIAN INSUFFICIENCY AFTER HEMATOPOIETIC STEM CELL GENE-THERAPY IN FEMALE PATIENTS WITH METACHROMATIC LEUKODYSTROPHY Salvatore Recupero (Milan, Italy) | 18:00 - 18:00 |
| A426 | MAPPING QUALITY OF LIFE OVER TIME: INSIGHTS FROM THE ACCESS TRIAL USING MISMATCHED UNRELATED DONORS Rachel Cusatis (Milwaukee, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| A427 | EVALUATING THE POTENTIAL OF E-HEALTH TO IMPROVE POST-TRANSPLANT CARE: PRELIMINARY RESULTS OF THE MY-MEDULA RANDOMIZED TRIAL Irene García-Cadenas (Barcelona, Spain) | 18:00 - 18:00 |
| A429 | IMPACT OF REDUCED-INTENSITY CONDITIONING REGIMENS ON FEMALE GONADAL FUNCTION IN SICKLE CELL DISEASE | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | Tamara Diesch-Furlanetto (Basel, Switzerland) | |
| A430 | NOT JUST SURVIVING BUT THRIVING - A PEDSQL-MEASURED QUALITY OF LIFE IN LONG TERM SURVIVORS WHO UNDERWENT HSCT FOR IBMFS Krithika Krishnakumar (Chennai, India) | 18:00 - 18:00 |
| A431 | INCIDENCE, RISK FACTORS AND OUTCOMES OF AVASCULAR NECROSIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS DEVELOPING GRAFT-VERSUS-HOST DISEASE Rohan Jacob Verghese (Navi Mumbai, India) | 18:00 - 18:00 |
| A432 | SECOND PRIMARY MALIGNANCY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION - LONG-TERM FOLLOW-UP AT A SINGLE INSTITUTE EXPERIENCE Lun-Wei Chiou (Taipei, Taiwan (Province of China)) | 18:00 - 18:00 |
| A433 | NON-INFECTIOUS COMPLICATIONS AFTER CAR-T CELL THERAPY Juan Manuel Cerezo-Martín (Santander, Spain) | 18:00 - 18:00 |
| A434 | FROM CHILDHOOD TO ADOLESCENCE: LONG-TERM RISKS AND RECOVERY MORE THAN FIVE YEARS AFTER NON-TBI HSCT Amir Ali Hamidieh (Tehran, Iran (Islamic Republic of)) | 18:00 - 18:00 |
| A435 | BRONCHIOLITIS OBLITERANS SYNDROME AFTER PAEDIATRIC ALLOGENEIC HSCT: A SYSTEMATIC REVIEW OF THERAPEUTIC STRATEGIES Hannah Walker (Melbourne, Australia) | 18:00 - 18:00 |
| A436 | LATE MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION SURVIVORS Yun-Jung Huang (Taipei, Taiwan (Province of China)) | 18:00 - 18:00 |

Tuesday, 24. March 2026*General*

07:45 - 08:45

R14

GS3 - EBMT General Assembly

Anna Sureda (Barcelona, Spain)

| | | |
|-------|---|---------------|
| GS3-1 | President's Report Anna Sureda (Barcelona, Spain) | 07:45 - 08:10 |
| GS3-2 | Treasurer's Financial Report Mette Hazenberg (Amsterdam, Netherlands (the)) | 08:10 - 08:20 |
| G3-3 | Secretary's Report Raffaella Greco (Milano, Italy) | 08:20 - 08:30 |
| GS3-4 | Election Results 2026 Raffaella Greco (Milano, Italy) | 08:30 - 08:35 |
| GS3-5 | Outgoing Board Members Anna Sureda (Barcelona, Spain) | 08:35 - 08:40 |
| GS3-6 | Q&A | 08:40 - 08:45 |

Meet the Expert

07:45 - 08:45

R18

MTE-07 - Meet-the-Expert: How I Approach VOD in 2026 - Evolving strategies in diagnosis and care

| | | |
|-------|--|---------------|
| MTE-7 | How I Approach VOD in 2026 - Evolving strategies in diagnosis and care Monica Cabrero (Salamanca, Spain) | 07:45 - 08:45 |
|-------|--|---------------|

Meet the Expert

07:45 - 08:45

R18

QM-MTE-3 - Quality Management Meet-the-Expert: Managing Audit outcomes, occurrences and adverse events - closing the loop

| | | |
|----------|---|---------------|
| QM-MTE-3 | Managing Audit outcomes, occurrences and adverse events - closing the loop Lea Brandt Kristensen (Aarhus, Denmark) Rachel Luke (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the)) | 07:45 - 08:45 |
|----------|---|---------------|

Meet the Expert

07:45 - 08:45

R18

MTE-09 - Meet-the-Expert: MDS and Transplantation - How to decide who and when

| | | |
|-------|--|---------------|
| MTE-9 | MDS and Transplantation - How to decide who and when David Valcárcel (Barcelona, Spain) Marie Robin (Paris, France) | 07:45 - 08:45 |
|-------|--|---------------|

Meet the Expert

07:45 - 08:45

R18

MTE-10 - Meet-the-Expert: HCT and CAR-T: Let's talk about access, equity, and global implementation

| | | |
|--------|--|---------------|
| MTE-10 | HCT and CAR-T: Let's talk about access, equity, and global implementation Gregorio Jaimovich (Buenos Aires, Argentina) Nelson Hamerschlak (São Paulo- SP, Brazil) | 07:45 - 08:45 |
|--------|--|---------------|

Meet the Expert

07:45 - 08:45

R18

MTE - Breakfast Meet the Expert - Tuesday*Meet the Expert*

07:45 - 08:45

R18

MTE-06 - Meet-the-Expert: CMV in 2026 - Evolving strategies for diagnosis and management

MTE-6

CMV in 2026 - Evolving strategies for diagnosis and management

07:45 - 08:45

Per Ljungman (Stockholm, Sweden)

David Navarro (Valencia, Spain)

Meet the Expert

07:45 - 08:45

R18

MTE-08 - Meet-the-Expert: Delivering HCT and Cell Therapy in the outpatient setting

MTE-8

Delivering HCT and Cell Therapy in the outpatient setting

07:45 - 08:45

Francesc Fernández-Avilés (Barcelona, Spain)

Lone Friis (Copenhagen, Denmark)

ePoster

08:30 - 18:00

R20

ePoster Viewing*Plenary Session*

09:00 - 10:30

R1

P03 - Plenary | The Myeloma Paradox - In search of precision sequencing for a crowded innovation landscape

Joaquín Martínez (MAdrid, Spain)

Meral Beksac (Ankara, Turkey)

P03-1

Introduction

09:00 - 09:05

P03-2

Sequencing of conventional drugs and monoclonal antibodies

09:05 - 09:20

María Victoria Mateos (Salamanca, Spain)

P03-3

Sequencing of bispecifics and CAR-T

09:20 - 09:35

Mohamad Mohty (Paris, France)

P03-4

Sequencing HCT, early and/or in relapse, in the therapeutic strategy

09:35 - 09:50

Marc Raab (Heidelberg, Germany)

P03-5

Failure after CAR-T: does the sequence end or what are the options?

09:50 - 10:05

Hermann Einsele (Würzburg, Germany)

P03-6

Panel discussion on innovation and sequencing in the MM crowded landscape, and Q&A

10:05 - 10:30

Paediatrics Day

09:00 - 10:15

R2

Paed1 - Paediatrics Diseases Working Party Session

Krzysztof Kalwak (Wroclaw, Poland)

Katharina Kleinschmidt (Regensburg, Germany)

Paed1-1

FORUM1/FORUM2 initiative update

09:00 - 09:15

Christina Peters (Austria)

Franco Locatelli (Rome, Italy)

Paed1-2

NGS-MRD monitoring pre- and post-HCT and CAR T in pB-ALL--can

09:15 - 09:30

| | | |
|---|---|---------------|
| | we use it to improve outcomes? | |
| | Michael Pulsipher (Salt Lake City, United States of America (the)) | |
| Paed1-3 | Treatment of T-ALL with CAR T cells: the London perspective Robert Chiesa (London, United Kingdom of Great Britain and Northern Ireland (the)) | 09:30 - 09:45 |
| Paed1-4 | Treatment of T-ALL with CAR T cells: the Rome perspective Franco Locatelli (Rome, Italy) Francesca Del Bufalo (Rome, Italy) | 09:45 - 10:00 |
| Paed1-5 | Dietrich Niethammer Award - Introduction Supported by Miltenyi Katharina Kleinschmidt (Regensburg, Germany) Krzysztof Kalwak (Wroclaw, Poland) | 10:00 - 10:06 |
| Paed1-6 | Dietrich Niethammer Award Franco Locatelli (Rome, Italy) | 10:06 - 10:15 |
| | | |
| <i>Working Party Session</i> | | |
| 09:00 - 10:20 | | R3 |
| CTIWP - Cellular Therapy & Immunobiology Working Party Session | | |
| Annalisa Ruggeri (Milano, Italy) Florent Malard (Paris, France) | | |
| CTIWP-1 | Introduction of the Jon J. Van Rood Award | 09:00 - 09:05 |
| CTIWP-2 | Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury Julius Fischer (Germany) | 09:05 - 09:25 |
| CTIWP-3 | Introduction Plenary Lecture Jurgen Kuball (Utrecht, Netherlands (the)) | 09:25 - 09:30 |
| CTIWP-4 | TCR engineering for solid tumors Chiara Bonini (Milan, Italy) | 09:30 - 10:15 |
| CTIWP-5 | Q&A | 10:15 - 10:20 |
| | | |
| <i>Oral Session</i> | | |
| 09:00 - 10:15 | | R4 |
| OS08 - Oral Session 8 Acute Leukaemia (II) | | |
| Fabio Ciceri (Milano, Italy) Jaime Sanz (Valencia, Spain) | | |
| OS08-01 | DISTINCT PROGNOSIS AND TRANSPLANT TIMING IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA Chuanhe Jiang (Shanghai, China) | 09:00 - 09:09 |
| OS08-02 | A COMPARISON OF FLUDARABINE MELPHALAN AND FLUDARABINE TREOSULFAN FOR ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA.A STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT Daniele Avenoso (Brescia, Italy) | 09:09 - 09:18 |
| OS08-03 | ADULT ACUTE MYELOID LEUKEMIA WITH FUS::<i>ERG</i> FUSION: A NATIONAL, RETROSPECTIVE, MULTI-CENTER STUDY Jiayu Huang (Shanghai, China) | 09:18 - 09:27 |
| OS08-04 | CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS GENERATED USING A PIGGYBAC TRANSPOSON VECTOR FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE I STUDY Kotaro Narita (Nagoya, Japan) | 09:27 - 09:36 |
| OS08-05 | CD7-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL | 09:36 - 09:45 |

| | | |
|---------|---|---------------|
| | THERAPY SHOWS GOOD EFFICACY AND SAFETY IN REFRACTORY/RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL) | |
| | Peihua Lu (Langfang, China) | |
| OS08-06 | LONG-TERM OUTCOMES OF SEQUENTIAL CD7 CAR-T THERAPY AND SECOND ALLOGENEIC TRANSPLANTATION FOR T-ALL/LBL RELAPSED AFTER A PRIOR ALLO-TRANSPLANT | 09:45 - 09:54 |
| | XINGYU Cao (Langfang, China) | |
| OS08-07 | TREOSULFAN - BASED CONDITIONING IN ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION; LONG-TERM FOLLOW-UP | 09:54 - 10:03 |
| | Avichai Shimoni (Tel-Hashomer, Israel) | |
| OS08-08 | FIRST-IN-HUMAN TRIAL OF IL15-ACTIVATED CIK CELL THERAPY POST-HCT: DURABLE REMISSION AND SEROTHERAPY-ASSOCIATED IMMUNE RECONSTITUTION IN HIGH-RISK HEMATOLOGIC MALIGNANCIES | 10:03 - 10:12 |
| | Eva Rettinger (Frankfurt, Germany) | |

Educational

09:00 - 10:30

R5

E05 - Educational | Evolving standards in Severe Aplastic Anemia - Matching the right therapy to the right patient

Austin Kulasekararaj (London, United Kingdom of Great Britain and Northern Ireland (the))

Lucrecia Yañez (Santander, Spain)

| | | |
|-------|---|---------------|
| E05-1 | Introduction | 09:00 - 09:05 |
| E05-2 | Long-term outcomes of SAA patients treated with triple therapy | 09:05 - 09:25 |
| | Emma Groarke (Bethesda, United States of America (the)) | |
| E05-3 | Which donor should we use in the absence of a matched sibling? | 09:25 - 09:45 |
| | Juan Montoro (Valencia, Spain) | |
| E05-4 | Guidelines and key determinants for treatment choice across SAA patient profiles | 09:45 - 10:05 |
| | Antonio M. Risitano (Avellino, Italy) | |
| E05-5 | Q&A and Roundtable | 10:05 - 10:30 |

Oral Session

09:00 - 10:15

R6

OS09 - Oral Session 9 | Infections - Viral

Rafael de la Cámara (Madrid, Spain)

Claire Horgan (Manchester, United Kingdom of Great Britain and Northern Ireland (the))

| | | |
|---------|---|---------------|
| OS09-01 | CYTOMEGALOVIRUS CELL-MEDIATED IMMUNITY GUIDED LETERMOVIR PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL | 09:00 - 09:09 |
| | Xiaoxia Hu (Shanghai, China) | |
| OS09-02 | PREDICTORS OF PROTECTIVE ANTIBODY LEVELS IN ALLOGENEIC HCT RECIPIENTS FOLLOWING A STANDARDIZED POST-TRANSPLANT VACCINATION SERIES INCLUDING TWO DOSES OF MMR | 09:09 - 09:18 |
| | Kareem Jamani (Calgary, Canada) | |
| OS09-03 | OUTCOME OF ADULT PATIENTS WITH HIV UNDERGOING AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY OF THE IDWP | 09:18 - 09:27 |

| | | |
|---------|---|---------------|
| | Annalisa Paviglianiti (Barcelona, Spain) | |
| OS09-04 | PRITELIVIR DEMONSTRATED SUPERIOR EFFICACY COMPARED TO INVESTIGATOR'S CHOICE TREATMENT FOR REFRACTORY HERPES SIMPLEX VIRUS INFECTIONS IN IMMUNOCOMPROMISED PATIENTS: PRIOH-1, PHASE 3 SAFETY AND EFFICACY | 09:27 - 09:36 |
| | Genovefa Papanicolaou (New York, United States Minor Outlying Islands (the)) | |
| OS09-05 | LETTERMOVIR USE IN PEDIATRIC HSCT PATIENTS UNDER 12 YEARS OLD: UPDATED DATA FROM A RETROSPECTIVE MULTICENTER STUDY OF THE PDWP AND IEWP OF THE EBMT | 09:36 - 09:45 |
| | Claire Horgan (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| OS09-06 | IMPACT OF CMV INFECTION IN PATIENTS WITH LYMPHOMA AFTER CAR-T THERAPY. AN INTERNATIONAL STUDY ON BEHALF OF IDWP, LWP, AND CTIWP OF EBMT | 09:45 - 09:54 |
| | Rafael de la Cámara (Madrid, Spain) | |
| OS09-07 | INTRAVENOUS BRINCIDOFVIR EFFECTIVELY REDUCES CMV DNAEMIA IN ANTIVIRAL EXPERIENCED IMMUNOCOMPROMISED PATIENTS: RESULTS OF A PHASE 2A CLINICAL TRIAL | 09:54 - 10:03 |
| | Genovefa Papanicolaou (New York, United States Minor Outlying Islands (the)) | |
| OS09-08 | MARIBAVIR FOR CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE INTERNATIONAL REAL-WORLD STUDY OF IDWP OF EBMT | 10:03 - 10:12 |
| | Annalisa Paviglianiti (Barcelona, Spain) | |

Nurses Group

09:00 - 10:30

R7

NG13 - Nurses Group | Silent dysfunction, managing endocrine complications after transplantation

Sophie Van Lancker (Ghent, Belgium)

Francisco Xosé Roman Losada (Vigo, Spain)

| | | |
|--------|--|---------------|
| NG13-1 | Fertility preservation and premature ovarion failure | 09:00 - 09:21 |
| | Iebe De Quick (Brussels, Belgium) | |
| NG13-2 | Fertility preservation and premature male gonadal failure | 09:21 - 09:42 |
| | Nathalie Peters (Ghent, Belgium) | |
| NG13-3 | Growth and puberty | 09:42 - 10:03 |
| | Joëll Bense (Leiden, Netherlands (the)) | |
| NG13-4 | Metabolic syndrome | 10:03 - 10:24 |
| | Anne Nissen (Copenhagen, Denmark) | |
| NG13-5 | Q&A | 10:24 - 10:30 |

Workshop

09:00 - 10:30

R8

W04 - Workshop | Decades of impact - EBMT's role in advancing Transplantation and Cellular Therapy

Anna Sureda (Barcelona, Spain)

Rafael Duarte (Madrid, Spain)

| | | |
|-------|--|---------------|
| W04-1 | Introduction | 09:00 - 09:05 |
| W04-2 | Decades of impact from the EBMT activity survey | 09:05 - 09:20 |
| | Jakob Passweg (Basel, Switzerland) | |
| W04-3 | Tracing the EBMT footprint in the evolution of HCT and CT | 09:20 - 09:35 |
| | Isabel Sánchez-Ortega (Barcelona, Spain) | |

| | | |
|-------|--|---------------|
| W04-4 | Sister society collaborations: learning from CIBMTR trackrecord and the PRO as a source Bronwen Shaw (Milwaukee, United States of America (the)) | 09:35 - 09:50 |
| W04-5 | From the harmonisation project to future decades of EBMT impact in advancing our field Ibrahim Yakoub-Agha (Lille, France) | 09:50 - 10:05 |
| W04-6 | Q&A - Panel discussion | 10:05 - 10:30 |

JACIE Quality Management

09:00 - 10:15

R9

QM1 - JACIE Quality Management 1 | Perspectives on JACIECharles Crawley (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))
Dania Arabi (Jeddah, Saudi Arabia)

| | | |
|-------|--|---------------|
| QM1-1 | Competent Authority Perspective: The Spanish Experience Dolores Hernández Maraver (MADRID, Spain) | 09:00 - 09:15 |
| QM1-2 | Professional Development and the role of the JACIE Inspector Ivana Ferrero (Turin, Italy) | 09:15 - 09:30 |
| QM1-3 | How to keep the inspection team happy: preparing your centre for the inspection days Deborah Richardson (Southampton, United Kingdom of Great Britain and Northern Ireland (the)) | 09:30 - 09:45 |
| QM1-4 | A WORKFLOW-INTEGRATED DIGITAL PLATFORM FOR PROCEDURE PLANNING AND REAL-TIME CAPTURE OF JACIE-REQUIRED KPIS IN APHERESIS UNITS AND CELL THERAPY PROCESSING AND CRYOPRESERVATION LABORATORIES Lisandra Priscilla Hernández Morales (Madrid, Spain) | 09:45 - 10:00 |
| QM1-5 | Q&A | 10:00 - 10:15 |

Educational

09:00 - 10:30

R10

E06 - Educational | Cellular therapies for Autoimmune Diseases - International guidance meets clinical controversyElisa Roldán-Galván (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))
Christina Bergmann (Erlangen, Germany)

| | | |
|-------|---|---------------|
| E06-1 | Introduction | 09:00 - 09:05 |
| E06-2 | Harmonization guidelines for AD: a focus on systemic sclerosis Raffaella Greco (Milano, Italy) | 09:05 - 09:35 |
| E06-3 | Controversies in systemic sclerosis: the case for BITEs Tobias Alexander (Berlin, Germany) | 09:35 - 09:50 |
| E06-4 | Controversies in systemic sclerosis: the case for CARTs Christina Bergmann (Erlangen, Germany) | 09:50 - 10:05 |
| E06-5 | Panel discussion on recommendations and controversies on cellular therapies for AD and SS, and Q&A | 10:05 - 10:30 |

Transplant and Search Coordinators Day

09:00 - 10:15

R11

TSCD1 - EBMT-WMDA Transplant and Search Coordinators Day 1 | From search to survival - When time is of the essenceAlicia Venter (Leiden, Netherlands (the))
Nicolaus Kröger (Essen, Germany)

| | | |
|---------|---|---------------|
| TSCD1-1 | The clinician's perspective - What makes a match "good enough" | 09:00 - 09:20 |
|---------|---|---------------|

| | | |
|---------|---|---------------|
| | when time is short? | |
| | Nicolaus Kröger (Essen, Germany) | |
| TSCD1-2 | The donor registry perspective - Why a global community of donor registries is still needed in times of Advanced Therapies and use of PtCy | 09:20 - 09:40 |
| | Ann O'Leary (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| TSCD1-3 | The donor center perspective - Optimizing the pathway from search to collection in Hematopoietic Stem Cell Transplantation | 09:40 - 10:00 |
| | Jan Markert (Tübingen, Germany) | |
| TSCD1-4 | Q&A | 10:00 - 10:15 |
| | | |
| | <i>How do I... ?</i> | |
| | 09:00 - 10:15 | R12 |
| | HDI5 - How do I treat GVHD, from routine management to treatment of atypical manifestations - A focus on ECP Supported through an unrestricted educational grant by Therakos | |
| | Francesca Kinsella (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | |
| | Daniel Wolff (Regensburg, Germany) | |
| HDI5-1 | Acute GVHD | 09:00 - 09:20 |
| | Monia Marchetti (Alessandria, Italy) | |
| HDI5-1 | Chronic GVHD | 09:20 - 09:40 |
| | Elisa Sala (Ulm, Germany) | |
| HDI5-3 | Combination of ECP with other strategies | 09:40 - 10:00 |
| | Ivan Moiseev (Saint Petersburg, Russian Federation (the)) | |
| HDI5-4 | Q&A - Discussion | 10:00 - 10:15 |
| | | |
| | <i>Nurses Group</i> | |
| | 09:00 - 10:30 | R13 |
| | NG14 - Nurses Group New technologies supporting future care | |
| | Annika Kisch (Lund, Sweden) | |
| | Lidia Hurtado (Barcelona, Spain) | |
| NG14-1 | Empowering Patients Through e-Health: Advancing Integrated Symptom Assessment, Monitoring, and Care | 09:00 - 09:21 |
| | Sabine Valenta (Tübingen, Germany) | |
| NG14-2 | The use of AI in enhancing the art of patient care | 09:21 - 09:42 |
| | Alberto Mussetti (barcelona, Spain) | |
| NG14-3 | The use of monitoring devices in ambulatory transplantation | 09:42 - 10:03 |
| | Simona Calza (Genoa, Italy) | |
| NG14-4 | The use of machine learning in prediction patient death in HCT | 10:03 - 10:24 |
| | Erik von Asmuth (Leiden, Netherlands (the)) | |
| NG14-5 | Q&A | 10:24 - 10:30 |
| | | |
| | <i>Special Session</i> | |
| | 09:00 - 10:30 | R14 |
| | SS05 - Joint Physician-Nurse Session The right to be forgotten in Europe: ending financial discrimination for cancer survivors | |
| | Valle Gómez-García de Soria (Madrid, Spain) | |
| | Hilda Mekelenkamp (Leiden, Netherlands (the)) | |
| SS05-1 | Opening & Welcome | 09:00 - 09:05 |

| | | |
|--|--|---------------|
| SS05-2 | The right to be forgotten in Europe. Implications for cancer and HCT survivors Françoise Meunier (Brussels, Belgium, Belgium) | 09:05 - 09:30 |
| SS05-3 | Panel Discussion Helene Schoemans (Leuven, Belgium) Carlos Esquivias Escobar (Madrid, Spain) Françoise Meunier (Brussels, Belgium, Belgium) Elordi García (Madrid, Spain) | 09:30 - 10:20 |
| SS05-4 | Q&A | 10:20 - 10:30 |
| <i>How do I... ?</i> | | |
| 09:00 - 10:15 | | R16 |
| HDI4 - How Do I... Continue to improve the management of SOS/VOD? Jazz Pharmaceuticals has provided funding for this session and has not been involved in any aspect of this activity | | |
| Michelle Kenyon (LONDON, United Kingdom of Great Britain and Northern Ireland (the)) Selim Corbacioglu (Regensburg, Germany) | | |
| HDI4-1 | Prophylaxis in pediatrics: from the Harmony Trial to the recent EBMT recommendations Selim Corbacioglu (Regensburg, Germany) | 09:00 - 09:20 |
| HDI4-2 | Early intervention in Adults since the EBMT 2023 refined criteria Monica Cabrero (Salamanca, Spain) | 09:20 - 09:40 |
| HDI4-3 | Multidisciplinary clinical intervention: physician's and nurse's perspectives Daniele Avenoso (Brescia, Italy) Michelle Kenyon (LONDON, United Kingdom of Great Britain and Northern Ireland (the)) | 09:40 - 10:00 |
| HDI4-4 | Panel discussion | 10:00 - 10:15 |
| <i>Pharmacists Day</i> | | |
| 09:00 - 10:30 | | R17 |
| Pharm5 - Pharmacists Training Session | | |
| Nick Duncan (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | | |
| <i>Breaks</i> | | |
| 10:30 - 11:00 | | R1 |
| Coffee Break, ePoster Viewing, Visit Exhibition | | |
| <i>Workshop</i> | | |
| 11:00 - 12:30 | | R1 |
| W05 - Workshop Improving outcomes of allogeneic HCT in Acute Leukemias | | |
| Fabio Ciceri (Milano, Italy) María Jesús Pascual (MÁLAGA, Spain) | | |
| W05-1 | Introduction | 11:00 - 11:05 |
| W05-2 | Improving outcomes of allogeneic HCT for ALL Eolia Brissot (Paris, France) | 11:05 - 11:25 |
| W05-3 | Optimizing transplant conditioning for AML Arnon Nagler (Ramat Gan, Israel) | 11:25 - 11:45 |
| W05-4 | Novel frailty tools to improve allogeneic HCT outcomes in elderly patients M Queralt Salas (Barcelona, Spain) | 11:45 - 12:05 |
| W05-5 | Panel discussion on strategies to improve outcomes of allogeneic HCT in acute leukemias, and Q&A | 12:05 - 12:30 |

Paediatrics Day

11:00 - 12:15

R2

Paed2 - Inborn Errors Working Party Session | Setting-up a site for novel therapy clinical trials

Claire Booth (London, United Kingdom of Great Britain and Northern Ireland (the))

Maria Ester Bernardo (Milano, Italy)

| | | |
|---------|--|---------------|
| Paed2-1 | HSC-GT setting: the journey to set-up a HSC-GT trial in Fanconi anemia and most recent results Julian Sevilla (Madrid, Spain) | 11:00 - 11:20 |
| Paed2-2 | Allo-HCT setting: the journey to set-up a trial on adoptive cellular therapy with CD45RO+ memory T-cell addback Mary Slatter (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the)) | 11:20 - 11:40 |
| Paed2-3 | Allo-HCT setting: cellular therapies based on Virus Specific T-cells in HCT and most recent results Tobias Feuchtinger (Freiburg, Germany) | 11:40 - 12:00 |
| Paed2-4 | Regulatory progress and accessibility in HSC-GT Claire Booth (London, United Kingdom of Great Britain and Northern Ireland (the)) | 12:00 - 12:10 |

Workshop

11:00 - 12:30

R3

W06 - Workshop | Infections after CAR-T therapy: shall we?

Ana Alarcón Tomás (Madrid, Spain)

Rafael de la Cámara (Madrid, Spain)

| | | |
|-------|--|---------------|
| W06-1 | Introduction | 11:00 - 11:05 |
| W06-2 | Shall we treat febrile patients following CAR-T infusion with antibiotics? Eleftheria Kampouri (Lausanne, Switzerland) | 11:05 - 11:20 |
| W06-3 | Shall we worry about fungal infections in CAR-T patients? Lidia Gil (Poznan, Poland) | 11:20 - 11:35 |
| W06-4 | Shall we monitor viral infections in CAR-T recipients and which ones? Rafael de la Cámara (Madrid, Spain) | 11:35 - 11:50 |
| W06-5 | Shall we vaccinate after CAR-T to prevent delayed infections? Malgorzata Mikulska (Genova, Italy) | 11:50 - 12:05 |
| W06-6 | Panel discussion on current status of infections management in CAR-T recipients, and Q&A | 12:05 - 12:30 |

Oral Session

11:00 - 12:15

R4

OS10 - Oral Session 10 | Stem cell donor and source

Alessandro Criscimanna (Milan, Italy)

Rocio Parody (Jerez de la Frontera, Spain)

| | | |
|---------|---|---------------|
| OS10-01 | COMPARISON OF UD9/10 WITH DQB1 MISMATCHES VS UD10/10 IN PATIENTS WITH AML TRANSPLANTED IN CR, A STUDY ON BEHALF ON THE ALWP Alessandro Criscimanna (Milan, Italy) | 11:00 - 11:09 |
| OS10-02 | A MACHINE LEARNING APPROACH COMBINING HLA AND NON-HLA FACTORS TO SUPPORT SELECTING THE "BEST" DONOR: ANALYSIS ON 7,609 TRANSPLANTS AND A READY-TO-USE INTERACTIVE TOOL Roberto Crocchiolo (Milano, Italy) | 11:09 - 11:18 |
| OS10-03 | HEALTHY POOR MOBILIZERS RELATED AND UNRELATED ADULT | 11:18 - 11:27 |

| | | |
|--|---|---------------|
| | AND PEDIATRIC DONORS: NATIONWIDE SPANISH EXPERIENCE WITH AND WITHOUT PLERIXAFOR | |
| | Rocio Parody (Jerez de la Frontera, Spain) | |
| OS10-04 | MATCHED UNRELATED VS. HAPLOIDENTICAL DONOR FOR ALLOGENEIC HSCT IN PATIENTS WITH ACUTE LEUKEMIA WITH IDENTICAL GVHD PROPHYLAXIS - A RANDOMIZED PROSPECTIVE EBMT LABELED TRIAL | 11:27 - 11:36 |
| | Nicolaus Kröger (Essen, Germany) | |
| OS10-05 | EXPANDING ACCESS TO HAPLOIDENTICAL TRANSPLANTATION: CLINICAL FEASIBILITY OF A CENTRALIZED NATIONWIDE DISTRIBUTION MODEL FOR FRESH TCRA/B-DEPLETED GRAFTS IN FRANCE | 11:36 - 11:45 |
| | Ugo Chartral (Paris, France) | |
| OS10-06 | LETERMOVIR ELIMINATES SURVIVAL DIFFERENCES ACROSS RECIPIENT/DONOR CMV SEROLOGY COMBINATIONS IN MATCHED UNRELATED DONOR ALLOGENEIC STEM CELL TRANSPLANTATION | 11:45 - 11:54 |
| | Radwan Massoud (Hamburg, Germany) | |
| OS10-07 | IMPACT OF DONOR CHARACTERISTICS ON THE OUTCOMES FOLLOWING HAPLO-HSCT IN PATIENTS AGED 55 YEARS AND OLDER | 11:54 - 12:03 |
| | Wei Zhao (Beijing, China) | |
| OS10-08 | HLA-DRB1 MISMATCHING ENHANCES GVL EFFECT IN PEDIATRIC ACUTE LEUKEMIA UNDERGOING G-CSF/ATG-BASED HAPLOIDENTICAL TRANSPLANTATION : THE CRITICAL ROLE OF POSITION 86 DIMORPHISM | 12:03 - 12:12 |
| | Xiangjun Liu (Beijing, China) | |
| <i>Workshop</i> | | |
| | 11:00 - 12:30 | R5 |
| W07 - Workshop GVHD prophylaxis in SAA - Can one size really fit all? | | |
| | Béatrice Drexler (Basel, Switzerland) | |
| | Antonio M. Risitano (Avellino, Italy) | |
| W07-1 | Introduction | 11:00 - 11:05 |
| W07-2 | The case for ATG | 11:05 - 11:20 |
| | Regis Peffault de Latour (Paris, France) | |
| W07-3 | The case for Alemtuzumab | 11:20 - 11:35 |
| | Austin Kulasekararaj (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| W07-4 | The case for PTCy | 11:35 - 11:50 |
| | Andrea Bacigalupo (Roma, Italy) | |
| W07-5 | The case for ex vivo TCD | 11:50 - 12:05 |
| | Jaime Sanz (Valencia, Spain) | |
| W07-6 | Panel discussion on the state of the field: progress, challenges and future directions, and Q&A | 12:05 - 12:30 |
| <i>Educational</i> | | |
| | 11:00 - 12:30 | R6 |
| E07 - Educational The evolving role of HCT in lymphoma | | |
| | Ali Bazarbachi (Beirut, Lebanon) | |
| | Carmen Martínez (Barcelona, Spain) | |
| E07-1 | Introduction | 11:00 - 11:05 |

| | | |
|-------|---|---------------|
| E07-2 | Is autologous HCT still relevant in DLBCL? Leyre Bento (Palma de Mallorca, Spain) | 11:05 - 11:20 |
| E07-3 | Allogeneic HCT for CTCL: evolving evidence and EBMT recommendations Francesco Onida (Milano, Italy) | 11:20 - 11:35 |
| E07-4 | Integrating bispecifics in the transplant strategy Anna Sureda (Barcelona, Spain) | 11:35 - 11:50 |
| E07-5 | The role of allogeneic HCT and other immune therapies following CART in lymphoma Ali Bazarbachi (Beirut, Lebanon) | 11:50 - 12:05 |
| E07-6 | Panel discussion on the evolving role of HCT in less common indications and amidst other innovative therapies, and Q&A | 12:05 - 12:30 |

Nurses Group
11:00 - 12:30

R7

NG15 - Nurses Group | Next Generation

Nilufar Sommerfeld (Freiburg, Germany)
Thomas Jezequel (Nantes, France)

| | | |
|--------|--|---------------|
| NG15-1 | Can the next generation change a leadership narrative? Elin Ofverberg (Gothenburg, Sweden) | 11:00 - 11:21 |
| NG15-2 | Leading with the authority in daily practice Marijke Quaghebeur (Ghent, Belgium) | 11:21 - 11:42 |
| NG15-3 | Mentorship matters bridging the generation gaps Davide Bonomi (Milan, Italy) | 11:42 - 12:03 |
| NG15-4 | Coping worklife balance in high stress environment Salla Lehvonen (Helsinki, Finland) | 12:03 - 12:24 |
| NG15-5 | Q&A | 12:24 - 12:30 |

Oral Session
11:00 - 12:15

R8

OS11 - Oral Session 11 | GVHD Basic & Translational

Simon Mendez-Ferrer (Cambridge, United Kingdom of Great Britain and Northern Ireland (the))
Lena Riegler (Freiburg, Germany)

| | | |
|---------|---|---------------|
| OS11-01 | TGF-B-ENRICHED ENTERAL NUTRITION MODULATES SYSTEMIC INFLAMMATION IN ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE Lena Riegler (Freiburg, Germany) | 11:00 - 11:09 |
| OS11-02 | ASCC1 DEFICIENCY IN DONOR T CELLS AGGRAVATES AGVHD THROUGH TRANSCRIPTIONAL DOWNREGULATION OF IL-10 Min Ling (Beijing, China) | 11:09 - 11:18 |
| OS11-03 | T CELL RESISTANCE TO GLUCOCORTICOIDS IN GRAFT-VERSUS-HOST DISEASE Andrew McIntyre (Oxford, United Kingdom of Great Britain and Northern Ireland (the)) | 11:18 - 11:27 |
| OS11-04 | HOW DOES A SINGLE PRETRANSPLANT ORAL HIGH DOSE OF VITAMIN A PREVENT CHRONIC GRAFT VERSUS HOST DISEASE? TRANSCRIPTOMIC INSIGHTS INTO MECHANISM Pooja Khandelwal (Cincinnati, United States Minor Outlying Islands (the)) | 11:27 - 11:36 |
| OS11-05 | MICROBIOTA-DERIVED PROPIONATE INDUCES DELETIONAL TOLERANCE AND DECREASES GRAFT-VERSUS-HOST DISEASE | 11:36 - 11:45 |

| | | |
|---------|---|---------------|
| | Kate A. Markey (Seattle, United States Minor Outlying Islands (the)) | |
| OS11-06 | TISSUE-RESIDENT MEMORY T CELLS PREDICT STEROID-REFRACTORY COURSE IN ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE Lukas Gaksch (Graz, Austria) | 11:45 - 11:54 |
| OS11-07 | IDENTIFICATION OF A PLASMA IMMUNE MARKER PANEL FOR EARLY DETECTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN CHILDREN Coco de Koning (Utrecht, Netherlands (the)) | 11:54 - 12:03 |
| OS11-08 | RESTRICTION OF SLC7A5-MEDIATED L-LEU UPTAKE IN ALLOGENIC T CELLS EFFICIENTLY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AND MAINTAINS GRAFT-VERSUS-TUMOUR RESPONSE Danay Cibrian Vera (Madrid, Spain) | 12:03 - 12:12 |

JACIE Quality Management

11:00 - 12:15

R9

QM2 - JACIE Quality Management 2 | Managing Risks, Incidents and Validation in HCT & Cell Therapy

Rachel Luke (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the))

Eugenia Trigoso (Valencia, Spain)

| | | |
|-------|---|---------------|
| QM2-1 | Anticipating Risks: Proactive Approaches Evi Sprangers (Gent, Belgium) | 11:00 - 11:15 |
| QM2-2 | Impact Assessment: Identifying Critical Equipment, Processes, and Systems Olga López (Salamanca, Spain) | 11:15 - 11:30 |
| QM2-3 | How Do You Validate? Key Considerations on Equipment, Personnel, Procedure, and Software Validation Barbara Loconte (Bellinzona, Switzerland) Silvia Bisin (Florence, Italy) | 11:30 - 11:45 |
| QM2-4 | Learning from incidents: Root Cause Analysis in Practice Renza Monteleone (Palermo, Italy) | 11:45 - 12:00 |
| QM2-5 | Q&A | 12:00 - 12:15 |

Workshop

11:00 - 12:30

R10

W08 - Workshop | Harnessing HCT and CAR-T cells for Autoimmune Disease

Tobias Alexander (Berlin, Germany)

Montserrat Rovira (Barcelona, Spain)

| | | |
|-------|---|---------------|
| W08-1 | Introduction | 11:00 - 11:05 |
| W08-2 | Autologous HCT for multiple sclerosis - A European perspective Paolo Muraro (London, United Kingdom of Great Britain and Northern Ireland (the)) | 11:05 - 11:20 |
| W08-3 | Autologous HCT for multiple sclerosis - México experience Guillermo J. Ruiz-Argüelles (Puebla, Mexico) | 11:20 - 11:35 |
| W08-4 | Local immune effector cell-associated toxicity syndrome (LICATS) in autoimmune patients undergoing CAR-T cell therapy Melanie Hagen (Erlangen, Germany) | 11:35 - 11:50 |
| W08-5 | Outcomes and specific management of CAR-T for autoimmune diseases Elisa Roldán-Galván (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | 11:50 - 12:05 |
| W08-6 | Panel discussion on harnessing HCT and CAR-T cells in | 12:05 - 12:30 |

autoimmune diseases, and Q&A*Transplant and Search Coordinators Day*

11:00 - 12:15

R11

TSCD2 - EBMT-WMDA Transplant and Search Coordinators Day 2 | Accelerating timelines to transplant

Ann O'Leary (London, United Kingdom of Great Britain and Northern Ireland (the))

Ibrahim Yakoub-Agha (Lille, France)

| | | |
|---------|---|---------------|
| TSCD2-1 | Do patient appeals recruit committed donors? Evaluating the impact on donor registration and long-term commitment Felipe Macias (Barcelona, Spain) Sergi Querol (Barcelona, Spain) | 11:00 - 11:20 |
| TSCD2-2 | Safety first: the importance of SPEAR reporting Gayathri Nair (Liebefeld, Switzerland) | 11:20 - 11:40 |
| TSCD2-3 | Accelerating time to transplant Alison Logan (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 11:40 - 12:00 |
| TSCD2-4 | Q&A | 12:00 - 12:15 |

Working Party Session

11:00 - 12:15

R12

CMWP - Chronic Malignancies Working Party Session

Donal McLornan (London, United Kingdom of Great Britain and Northern Ireland (the))

Fernando Barroso Duarte (Fortaleza, Brazil)

| | | |
|--------|--|---------------|
| CMWP-1 | Introduction: Bridging Continents, Aligning Missions: The SBTMO-EBMT CMWP Partnership Fernando Barroso Duarte (Fortaleza, Brazil) | 11:00 - 11:05 |
| CMWP-2 | Defining Remission and Relapse After Allo-HCT in MDS/MPN Overlap Syndromes and Optimization of Transplantation Outcomes: recommendations from the EBMT practice harmonisation and guidelines committee Donal McLornan (London, United Kingdom of Great Britain and Northern Ireland (the)) | 11:05 - 11:15 |
| CMWP-3 | Donor Derived Myeloid Neoplasms: Best practice guidelines on behalf of the EBMT Carmelo Gurnari (Rome, Italy) | 11:15 - 11:25 |
| CMWP-4 | Allogeneic HCT for Myelofibrosis in Brazil: Contemporary considerations and outcomes on behalf of the SBTMO Vaneuza Funke (Curitiba, Brazil) | 11:25 - 11:35 |
| CMWP-5 | DDX41-mutated Myeloid Neoplasms: considerations to allo-HCT in 2026 Joanna Drozd-Sokolowska (Warsaw, Poland) | 11:35 - 11:45 |
| CMWP-6 | Should we consider PTCy for all donor types in chronic myeloid malignancies in 2026? Yves Chalandon (Geneva, Switzerland) | 11:45 - 11:55 |
| CMWP-7 | Utilization and outcomes of Autologous HCT in Multiple Myeloma: Insights from the South African Registry Estelle Verburgh (Cape Town, South Africa) | 11:55 - 12:05 |
| CMWP-8 | Q&A | 12:05 - 12:15 |

Nurses Group

11:00 - 12:30

R13

NG16 - Nurses Group | Best Research Abstracts Finalists

Isabel Salcedo (Madrid, Spain)

Simona Calza (Genoa, Italy)

| | | |
|---------|--|---------------|
| NG16-01 | LATE EFFECTS AND SYMPTOM BURDEN AMONG LONG-TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A NATIONWIDE CROSS-SECTIONAL STUDY Mette Schaufuss Engedal (Copenhagen, Denmark) | 11:00 - 11:15 |
| NG16-02 | EMOTIONAL BURDEN PREDICTS MORTALITY 5 YEARS AFTER ADULT HEMATOPOIETIC CELL TRANSPLANTATION: THE PROSPECTIVE SWISS TRANSPLANT COHORT STUDY Sabine Valenta (Tübingen, Germany) | 11:15 - 11:30 |
| NG16-03 | IMPROVING CHRONIC GVHD CARE: DEVELOPMENT OF A CHRONIC GVHD-MODULE WITHIN AN EHEALTH FACILITATED INTEGRATED CARE MODEL: SMILE Tabea Sommer (Freiburg, Germany) | 11:30 - 11:45 |
| NG16-04 | A MULTIMODAL APPROACH TO SEXUAL FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: A RANDOMIZED CONTROLLED STUDY Kristina Holmegaard Nørskov (Copenhagen, Denmark) | 11:45 - 12:00 |
| NG16-05 | DIGITAL HEALTH STRATEGIES FOR PATIENT EDUCATION IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A SCOPING REVIEW Ozgun Gokmen Kaya (Istanbul, Turkey) | 12:00 - 12:15 |

Joint Sessions

11:00 - 12:30

R14

JS05 - Joint Session EBMT - EFI | HLA and beyond in contemporary HCT

Mette Hazenberg (Amsterdam, Netherlands (the))

Jean Villard (Geneva, Switzerland)

| | | |
|--------|--|---------------|
| JS05-1 | HLA genes, structure and function John Trowsdale (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | 11:00 - 11:25 |
| JS05-2 | Donor selection 2026 - have we overcome the HLA barrier? Katharina Fleischhauer (Essen, Germany) | 11:25 - 11:50 |
| JS05-3 | Beyond the HLA criteria, what does matter for the clinical outcome in HSCT Luca Vago (Milano, Italy) | 11:50 - 12:15 |
| JS05-4 | Q&A - Discussion | 12:15 - 12:30 |

GoCART Coalition

11:00 - 12:15

R16

GCC1 - GoCART Coalition 1 | Scientific Excellence Session: Presentation of clinical studies selected and supported by the GoCART Coalition

Annalisa Ruggeri (Milano, Italy)

Christian Chabannon (Marseille, France)

| | | |
|--------|--|---------------|
| GCC1-1 | Data harmonization and the impact in clinical studies in the future, a GoCART - T2Evolve initiative Björn Chapuy (Berlin, Germany) | 11:00 - 11:15 |
| GCC1-2 | Assessing the efficacy and tolerance of anti-CD19 CAR-T cells in immunosuppressed patients with and history of solid organ transplantation (SOT) or HIV and suffering from haematological B-cell malignancies | 11:15 - 11:30 |

| | | |
|--|---|---------------|
| | Laure Ricard (Paris, France) | |
| GCC1-3 | Non-ICANS neurotoxicities (NINTs) following BCMA targeted CAR-T cell therapy Charlotte E. Graham (London, United Kingdom of Great Britain and Northern Ireland (the)) | 11:30 - 11:45 |
| GCC1-4 | Observatory study in quest of the best third line therapeutic option after Diffuse Large B Cells Lymphoma (DLBCL) failure to second line CAR-T cell therapy in the EBMT registry (OSCAR-T) Hyacinthe Johnson-Ansah (CAEN, France) | 11:45 - 12:00 |
| GCC1-5 | Q&A | 12:00 - 12:15 |
| <i>Nurses Group</i> | | |
| | 11:00 - 12:30 | R17 |
| NG17 - Nurses Group Workshop Apheresis | | |
| Natalia Lorente Del Río (Madrid, Spain) | | |
| Angela Leather (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | | |
| María Jesús Mustieles Ezquerro (Barcelona, Spain) | | |
| NG17-0 | Introduction | 11:00 - 11:00 |
| NG17-1 | Patient preparation - consider counselling/information giving, patient timings and planning Natalia Lorente Del Río (Madrid, Spain) | 11:00 - 11:00 |
| NG17-2 | Clinical Management - Venous access/Citrate toxicity María Jesús Mustieles Ezquerro (Barcelona, Spain) | 11:00 - 11:00 |
| NG17-3 | Capacity and Scheduling - increasing demand and activity Angela Leather (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 11:00 - 11:00 |
| NG17-4 | Education and training - networking opportunities | 11:00 - 11:00 |
| <i>Breaks</i> | | |
| | 12:30 - 13:00 | R1 |
| Lunch Break, ePoster Viewing, Visit Exhibition | | |
| <i>Meetings</i> | | |
| | 12:45 - 14:00 | R10 |
| BM-ADWP - Business Meeting of the Autoimmune Diseases Working Party | | |
| Tobias Alexander (Berlin, Germany) | | |
| <i>Meetings</i> | | |
| | 12:45 - 14:00 | R12 |
| BM-ALWP - Business Meeting of the Acute Leukaemia Working Party | | |
| Fabio Ciceri (Milano, Italy) | | |
| <i>Meetings</i> | | |
| | 12:45 - 14:00 | R14 |
| BM-HWP - Business Meeting of the Haemoglobinopathies Working Party | | |
| Emanuele Angelucci (Genova, Italy) | | |
| <i>Meetings</i> | | |
| | 12:45 - 14:00 | R16 |
| BM-CTIWP - Business Meeting of the Cellular Therapy & Immunobiology Working Party | | |
| Annalisa Ruggeri (Milano, Italy) | | |

Industry Symposium

13:00 - 14:00

R7

IS23 - Focusing GvHD care through the eyes of providers and patients: Practical insights on ECP | Delivered by Know-GvHD.com/GvHDHub.com - Supported through an unrestricted educational grant by Therakos

Hildegard Greinix (Vienna, Austria)

| | | |
|--------|---|---------------|
| IS23-1 | Welcome and introductions Hildegard Greinix (Vienna, Austria) | 13:00 - 13:05 |
| IS23-2 | The role of nurses within the multidisciplinary GvHD care team Michelle Kenyon (LONDON, United Kingdom of Great Britain and Northern Ireland (the)) | 13:05 - 13:15 |
| IS23-3 | Physician's perspective: How I treat GvHD with ECP Hildegard Greinix (Vienna, Austria) | 13:15 - 13:30 |
| IS23-4 | Patient's perspective: My journey with GvHD Matea Meden (Croatia) | 13:30 - 13:45 |
| IS23-5 | Panel discussion: Clinical considerations, challenges, and best practices - All (led by Chair) | 13:45 - 13:55 |
| IS23-6 | Closing remarks, post-activity quiz, and evaluation Hildegard Greinix (Vienna, Austria) | 13:55 - 14:00 |

Industry Theatre

13:10 - 13:45

R19

IT2 - Advances in Engineered Cell Therapy to Improve Outcomes in Allogeneic HCT | Orca Bio

Lori Muffly (Stanford, United States of America (the))

Breaks

14:00 - 14:30

R1

Break, ePoster Viewing, Visit Exhibition*Plenary Session*

14:30 - 16:00

R1

P04 - Plenary | Next-Gen CAR Therapies - Smarter designs, broader impact

Anna Sureda (Barcelona, Spain)

Ibrahim Yakoub-Agha (Lille, France)

| | | |
|-------|---|---------------|
| P04-1 | Introduction | 14:30 - 14:35 |
| P04-2 | Next-Gen CAR strategies to address myelotoxicity in AML Nela Klein-González (Barcelona, Spain) | 14:35 - 14:50 |
| P04-3 | Next-Gen CARs are TRUCKs Hinrich Abken (Regensburg, Germany) | 14:50 - 15:05 |
| P04-4 | Allogeneic genome edited universal Next-Gen CAR-T cells Waseem Qasim (London, United Kingdom of Great Britain and Northern Ireland (the)) | 15:05 - 15:20 |
| P04-5 | Armored and in vivo Next-Gen CARs He Huang (Hangzhou, China) | 15:20 - 15:35 |
| P04-6 | Q&A - Panel discussion | 15:35 - 16:00 |

Paediatrics Day

14:30 - 15:45

R2

Paed3 - Paediatric Diseases Oral Session

Adriana Balduzzi (Desio, Italy)

Elif Ince (Ankara, Turkey)

| | | |
|----------|---|---------------|
| Paed3-01 | COMPARATIVE OUTCOMES AFTER SEROTHERAPY WITH ATLG- GRAFALON OR ATG-THYMOGLOBULIN IN PEDIATRIC ALL PATIENTS GIVEN MUD ALLOGENEIC HSCT: FINDINGS FROM THE INTERNATIONAL PROSPECTIVE FORUM STUDY Laura M. Moser* (Frankfurt, Germany) | 14:30 - 14:39 |
| Paed3-02 | HIGH INCIDENCE OF RELAPSE AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION CONFERS A POOR PROGNOSIS IN PAEDIATRIC GLIS2+ AML- AN EBMT PAEDIATRIC DISEASES WORKING PARTY STUDY Krzysztof Kalwak (Wroclaw, Poland) | 14:39 - 14:48 |
| Paed3-03 | REGISTRY-BASED, PAIR-MATCHED ANALYSIS COMPARING A/B T-/CD19-CELL DEPLETION AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA-HAPLOIDENTICAL HSCT FOR CHILDREN WITH ACUTE LEUKEMIA: AN EBMT PDWP STUDY Daria Pagliara (Roma, Italy) | 14:48 - 14:57 |
| Paed3-04 | SEROTHERAPY IN CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH MALIGNANCIES: RESULTS OF A RETROSPECTIVE MULTICENTER STUDY BY AIEOP (ASSOCIAZIONE ITALIANA ONCOEMATOLOGIA PEDIATRICA) Francesco Saglio (Torino, Italy) | 14:57 - 15:06 |
| Paed3-05 | IMPROVED ENGRAFTMENT FOLLOWING A TREOSULFAN- FLUDARABINE CONDITIONING REGIMEN COMPARED TO THIOTEPA-FLUDARABINE IN PATIENTS WITH REFRACTORY CYTOPENIA OF CHILDHOOD Brigitte Strahm (Freiburg, Germany) | 15:06 - 15:15 |
| Paed3-06 | IMPACT OF EX-VIVO T-CELL DEPLETION IN UNRELATED DONOR HSCT FOR PEDIATRIC MALIGNANT DISEASES: A MULTICENTER RETROSPECTIVE COMPARATIVE STUDY ON BEHALF OF SPANISH GETH-TC PED GROUP Luisa Sisinni (Madrid, Spain) | 15:15 - 15:24 |
| Paed3-07 | REAL-WORLD OUTCOMES OF MESENCHYMAL STROMAL CELL THERAPY IN HEAVILY PRE-TREATED PAEDIATRIC PATIENTS WITH REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE Peter Bader (Frankfurt am Main, Germany) | 15:24 - 15:33 |
| Paed3-08 | ADAPT TO ENDURE: SUSTAINING PEDIATRIC HCT THROUGH WARTIME DISRUPTION IN UKRAINE Oleksandr Lysytsia (Kyiv, Ukraine) | 15:33 - 15:42 |

Educational
14:30 - 16:00

R3

E08 - Educational | Integrating novel agents and allogeneic HCT in chronic malignancies

Kavita Raj (London, United Kingdom of Great Britain and Northern Ireland (the))
Valentín García (Madrid, Spain)

| | | |
|-------|---|---------------|
| E08-1 | Introduction | 14:30 - 14:35 |
| E08-2 | In myelofibrosis Juan Carlos Hernandez-Boluda (Valencia, Spain) | 14:35 - 14:50 |
| E08-3 | In chronic myeloid leukemia Chris Armstrong (Dublin, Ireland) | 14:50 - 15:05 |
| E08-4 | In non-classical MPNs Nicola Polverelli (Pavia, Italy) | 15:05 - 15:20 |
| E08-5 | In chronic lymphocytic leukemia Michel van Gelder (Maastricht, Netherlands (the)) | 15:20 - 15:35 |

E08-5 **Panel discussion on the integration of novel agents and allogeneic HCT in standard of care management of chronic malignancies, and Q&A** 15:35 - 16:00

Oral Session

14:30 - 15:45

R4

OS12 - Oral Session 12 | Acute GVHD - Clinical

Olaf Penack (Berlin, Germany)

Kristie Ramos (Cincinnati, United States Minor Outlying Islands (the))

OS12-01 **HUMAN MILK OLIGOSACCHARIDE (2'-FUCOSYLLACTOSE) MODIFIES THE GUT MICROBIOME AND REDUCES ACUTE GI GVHD: RESULTS OF A PROSPECTIVE, FIRST IN-PEDIATRICS PHASE II STUDY** 14:30 - 14:39

Kristie Ramos (Cincinnati, United States Minor Outlying Islands (the))

OS12-02 **COST-EFFECTIVENESS OF ORCA-T VS ALLO-HCT WITH CONVENTIONAL GVHD PROPHYLAXIS FOR THE TREATMENT OF ADVANCED HEMATOLOGIC MALIGNANCIES IN THE UNITED STATES** 14:39 - 14:48

Rawan Faramand (Tampa, United States Minor Outlying Islands (the))

OS12-03 **ITACITINIB IN COMBINATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND TACROLIMUS (ICT) AS GVHD PROPHYLAXIS FOR REDUCED INTENSITY MATCHED DONOR HEMATOPOIETIC CELL TRANSPLANTATION (HCT): FINAL ANALYSIS** 14:48 - 14:57

Monzr Al Malki (Duarte, United States Minor Outlying Islands (the))

OS12-04 **ENDOTHELIAL DYSFUNCTION AND IMMUNE ACTIVATION INTERACT AND DETERMINE MORTALITY IN ACUTE GRAFT-VERSUS-HOST DISEASE** 14:57 - 15:06

Thomas Luft (Heidelberg, Germany)

OS12-05 **VEDOLIZUMAB FOR TREATING STEROID-REFRACTORY LOWER GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE: A SINGLE-CENTER REAL-WORLD STUDY** 15:06 - 15:15

Jieya Luo (Tianjin, China)

OS12-06 **RISE OF CIRCULATING ENDOTHELIAL CELLS AT ENGRAFTMENT IS A HALLMARK OF STEROID-REFRACTORY GVHD** 15:15 - 15:24

Polona Novak (Ljubljana, Slovenia)

OS12-07 **POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSE REDUCTION WITHIN AN ENTIRELY CALCINEURIN AND MTOR INHIBITOR-FREE GVHD PROPHYLAXIS REGIMEN: INTERIM RESULTS OF THE ABC PHASE I-IIb TRIAL** 15:24 - 15:33

A Samer Al-Homsi (Hempstead, United States Minor Outlying Islands (the))

OS12-08 **PREDICTIVE, TARGETABLE, SCALABLE: SIGNALING LYMPHOCYTE ACTIVATION MOLECULE FAMILY 7 (SLAMF7) IS DIFFERENTIALLY EXPRESSED AT SITES OF ACUTE GRAFT-VERSUS-HOST DISEASE AND CONFERS A FAVORABLE CLINICAL OUTCOME** 15:33 - 15:42

Simon Weisemann (Hamburg, Germany)

Working Party Session

14:30 - 15:45

R5

HWP - Haemoglobinopathies Working Party Session

Fabio Giglio (MILANO, Italy)

Abdul Hakim Al Rawas (Muscat, Oman)

HWP-1 **Introduction** 14:30 - 14:31

| | | |
|-------|---|---------------|
| HWP-2 | Non-genotoxic conditioning for curative cellular therapies in haemoglobinopathies Roland Meisel (Duesseldorf, Germany) | 14:31 - 14:46 |
| HWP-3 | HCT for SCD in Tanzania Stella Malangahe (Tanzania, Tanzania, United Republic of) | 14:46 - 15:01 |
| HWP-4 | Optimising mobilisation and stem cell collection in Genetherapy Mohammed Essa (Riyadh, Saudi Arabia) | 15:01 - 15:16 |
| HWP-5 | Real life experience of gene therapy, Regent Consortium view Sonali Chaudhury (Chicago, United States of America (the)) | 15:16 - 15:31 |
| HWP-6 | Q&A | 15:31 - 15:45 |

Working Party Session

14:30 - 15:45

R6

ALWP - Acute Leukaemia Working Party Session

Fabio Ciceri (Milano, Italy)

Simona Piemontese (Milan, Italy)

| | | |
|--------|---|---------------|
| ALWP-0 | Introduction | 14:30 - 14:45 |
| ALWP-1 | Bridging AML to transplant: is 3+7 becoming obsolete in the azacitidine-venetoclax era? Gesine Bug (Frankfurt, Germany) | 14:45 - 15:00 |
| ALWP-2 | MRD in allo-HCT for AML: where do we stand? Alexandros Spyridonidis (Patras, Greece) | 15:00 - 15:15 |
| ALWP-3 | Ph+ ALL in the age of immunotherapy: is allogeneic transplant still justified? Eolia Brissot (Paris, France) | 15:15 - 15:30 |
| ALWP-4 | How to chose a Haplo-donor Jaime Sanz (Valencia, Spain) | 15:30 - 15:45 |

Nurses Group

14:30 - 16:00

R7

NG18 - Nurses Group | Back to basics. Understanding...

Ariadna Domènech (Barcelona, Spain)

Lynn Leppla (Freiburg, Germany)

| | | |
|--------|---|---------------|
| NG18-1 | HLA in hematopoietic donor selection Antonio Balas (Madrid, Spain) | 14:30 - 14:51 |
| NG18-2 | Principles of MRD Michelle Lannon (Newcastle Upon Tyne, United Kingdom of Great Britain and Northern Ireland (the)) | 14:51 - 15:12 |
| NG18-3 | Managing complications of cell infusion Miranda van Harmelen (Leiden, Netherlands (the)) | 15:12 - 15:33 |
| NG18-4 | Engraftment syndrome and its management Misha Srour (lille, France) | 15:33 - 15:54 |
| NG18-5 | Q&A | 15:54 - 16:00 |

Joint Sessions

14:30 - 16:00

R8

JS06 - Joint Session EBMT - WBMT | Global perspective in cellular and gene therapy

Damiano Rondelli (Chicago, United States of America (the))

Annalisa Ruggeri (Milano, Italy)

| | | |
|--------|---|---------------|
| JS06-1 | Opportunities and results of CAR-T cell therapies worldwide Christian Chabannon (Marseille, France) Riad El Fakih (Saudi Arabia) | 14:30 - 14:55 |
| JS06-2 | Global gene therapy initiatives: A WBMT perspective Carmem Bonfim (Durham, United States Minor Outlying Islands (the)) | 14:55 - 15:20 |
| JS06-3 | CART19 or CARTBCMA for chronic Graft-versus-Host Disease: a WBMT project Dietger Niederwieser (Leipzig, Germany) | 15:20 - 15:45 |
| JS06-4 | Q&A | 15:45 - 16:00 |

JACIE Quality Management
14:30 - 15:45

R9

QM3 - JACIE Quality Management 3 | Implementing Standards

Richard Olaussen (Oslo, Norway)
Anne Emmett (London, United Kingdom of Great Britain and Northern Ireland (the))

| | | |
|-------|--|---------------|
| QM3-1 | Changes to 9th Edition HCT /3rd Edition IEC Collection Standards and practical implications Nina Worel (Vienna, Austria) | 14:30 - 14:45 |
| QM3-2 | IEC Pathway for non -HCT Centres Carla Sánchez (Barcelona, Spain) | 14:45 - 15:00 |
| QM3-3 | Managing complex applications: multiple sites, minimum activity and other challenges Charles Crawley (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | 15:00 - 15:15 |
| QM3-4 | Implementing JACIE: South African experience | 15:15 - 15:30 |
| QM3-5 | Q&A | 15:30 - 15:45 |

Working Party Session
14:30 - 15:45

R10

ADWP - Autoimmune Diseases Working Party Session

Tobias Alexander (Berlin, Germany)
Elisa Roldán-Galván (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))

| | | |
|--------|--|---------------|
| ADWP-1 | Welcome | 14:30 - 14:35 |
| ADWP-2 | Patient selection and optimal conditioning for HCT in MS Alice Mariottini (Florence, Italy) | 14:35 - 14:50 |
| ADWP-3 | CAR-T in MS Johanna Richter (Hamburg, Germany) | 14:50 - 15:05 |
| ADWP-4 | 30 Years of HCT for SSc Richard Burt (La Jolla, United States of America (the)) | 15:05 - 15:20 |
| ADWP-5 | Expanding CAR-T beyond rheumatology to other autoimmune diseases Fabian Müller (Erlangen, Germany) | 15:20 - 15:35 |
| ADWP-6 | Q&A | 15:35 - 15:45 |

Transplant and Search Coordinators Day
14:30 - 15:45

R11

TSCD3 - EBMT-WMDA Transplant and Search Coordinators Day 3 | Best practices in urgent searches

Gabi Rall (Tübingen, Germany)
Lydia Foeken (Leiden, Netherlands (the))

| | | |
|---------|---|---------------|
| TSCD3-1 | The clinician's perspective - Critical failure point: donor withdrawal post-conditioning and its clinical impact (case study) Nicoletta Sacchi (Genova, Italy) | 14:30 - 14:50 |
| TSCD3-2 | The donor registry perspective - Critical failure point: donor withdrawal post-conditioning (case study) Kalinga Perera (Llantrisant, United Kingdom of Great Britain and Northern Ireland (the)) | 14:50 - 15:10 |
| TSCD3-3 | Registry of unmet need - When there is no HLA matched donor for your patient Alicia Venter (Leiden, Netherlands (the)) | 15:10 - 15:30 |
| TSCD3-4 | Q&A | 15:30 - 15:45 |

Oral Session

14:30 - 15:45

R12

OS13 - Oral Session 13 | CAR-T

Valentín Ortiz-Maldonado (Barcelona, Spain)

Igor Kos (Homburg, Germany)

| | | |
|---------|--|---------------|
| OS13-01 | REAL-WORLD EVIDENCE FOR THE SAFETY AND EFFICACY OF GLOFITAMAB COMBINED WITH CAR-T THERAPY IN RELAPSED/REFRACTORY B-CELL LYMPHOMA Jia Wei (Wuhan, China) | 14:30 - 14:39 |
| OS13-02 | HIGH TUMOR MUTATIONAL BURDEN DEFINES AN IMMUNE-EVASIVE STATE LIMITING CD19 CAR-T EFFICACY IN LARGE B-CELL LYMPHOMA Sandeep Raj (New York, United States Minor Outlying Islands (the)) | 14:39 - 14:48 |
| OS13-03 | HOSPITAL EXEMPTION FOR HEIDAGENLEUCEL (HEIDI-CEL), A THIRD GENERATION CD19.CAR T CELL PRODUCT IN GERMANY Michael Schmitt (Heidelberg, Germany) | 14:48 - 14:57 |
| OS13-04 | CELLULAR THERAPIES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: REAL-WORLD EBMT OUTCOMES WITH CAR-T CELLS AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT Igor Kos (Homburg, Germany) | 14:57 - 15:06 |
| OS13-05 | COMPARATIVE OUTCOMES OF LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS AN EXTERNAL CONTROL ARM (ECA) IN PATIENTS WITH THIRD-LINE OR LATER (3L+) RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) M. Lia Palomba (New York, United States Minor Outlying Islands (the)) | 15:06 - 15:15 |
| OS13-06 | OUTPATIENT USE OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): REAL-WORLD DATA FROM THE CIBMTR REGISTRY Mino Battiwalla (Nashville, United States Minor Outlying Islands (the)) | 15:15 - 15:24 |
| OS13-07 | QUANTIFYING DAY-TO-DAY RISK OF CYTOKINE RELEASE SYNDROME (CRS) AND NEUROLOGICAL EVENTS (NE) AFTER LISOCABTAGENE MARALEUCEL (LISO-CEL) INFUSION: POOLED ANALYSIS FROM 7 CLINICAL TRIALS Valentín Ortiz-Maldonado (Barcelona, Spain) | 15:24 - 15:33 |
| OS13-08 | HEPATOTOXICITY AFTER CAR-T CELL THERAPY IN LYMPHOMA: A MULTICENTER REAL-WORLD STUDY OF OVER 1,000 PATIENTS Sigrun Einarsdottir (New York, United States Minor Outlying Islands (the)) | 15:33 - 15:42 |

Nurses Group

14:30 - 16:00

R13

NG19 - Nurses Group | Paediatric Session

Ida Bremer Ophorst (Utrecht, Netherlands (the))

Salla Lehtonen (Helsinki, Finland)

| | | |
|--------|--|---------------|
| NG19-1 | When Treatment Hurts: Improving Pain Care in Pediatric Stem Cell Transplantation Emma de Ruiter (Utrecht, Netherlands (the)) | 14:30 - 14:55 |
| NG19-2 | The World in Between: Navigating the PICU for the HCT Child Liana Abu Rumieleh (Jerusalem, Israel) | 14:55 - 15:20 |
| NG19-3 | A Parent's Story: The World of Differences between the SCT unit and the PICU Ricardo, Thinka & Izze van Wijk (Hoogblokland, Netherlands (the)) | 15:20 - 15:40 |
| NG19-4 | Panel Discussion and Q&A | 15:40 - 16:00 |

Statistics

14:30 - 15:30

R14

STATS2 - Statistical Workshop | Use of AI with EBMT dataset

Jarl Mooyaart (Voorschoten, Netherlands (the))

Mathilde Fekom (Paris, France)

| | | |
|----------|--|---------------|
| STATS2-1 | Use of ML for Risk Prediction with EBMT Data Mouad Abouqateb (Paris, France) | 14:30 - 14:45 |
| STATS2-2 | Application of machine learning to case mix stratification Erik von Asmuth (Leiden, Netherlands (the)) Stijn Halkes (Leiden, Netherlands (the)) | 14:45 - 15:20 |
| STATS2-3 | Q&A | 15:20 - 15:30 |

GoCART Coalition

14:30 - 15:45

R16

GCC2 - GoCART Coalition 2 | Access to Immune Effector Cell Therapies

Jurgen Kuball (Utrecht, Netherlands (the))

Chiara Bonini (Milan, Italy)

| | | |
|--------|--|---------------|
| GCC2-1 | Operational burden and fragmented implementation in CAR-T cell therapy: insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee Nick Van Sinderen (Cologne, Germany) | 14:30 - 14:45 |
| GCC2-2 | The JANE-2 EU Joint Action Working Group on high-tech medical technologies Julie Gehl (Copenhagen, Denmark) | 14:45 - 15:00 |
| GCC2-3 | The IQVIA Institute report on achieving CAR-T cell therapy health system readiness: An assessment of barriers and opportunities Murray Aitken (Parsippany, United States of America (the)) | 15:00 - 15:15 |
| GCC2-4 | Clinical development success rates for durable cell and gene therapies Mark Trusheim (Boston, United States of America (the)) | 15:15 - 15:30 |
| GCC2-5 | Academic production capacities for viral vectors and ATMPs in Europe: a NxtGen, DARE-NL, T2Evolve, GoCART survey Trudy Straetemans (Utrecht, Netherlands (the)) | 15:30 - 15:45 |

Nurses Group

14:30 - 16:00

R17

NG20 - Nurses Group Workshop | Ethics | No patient left behind: Ethics and equity for our vulnerable patients

Davide Bonomi (Milan, Italy)

Solveig Adalsteinsdottir (Stockholm, Sweden)

| | | |
|--------|--|---------------|
| NG20-1 | A changing world - Impact on HCT nursing practice Marjola Gjergji (Roma, Italy) | 14:30 - 14:50 |
| NG20-2 | Cultural Competence in Swedish Pediatric Hospital Care Azar Tavallali (Stockholm, Sweden) | 14:50 - 15:10 |
| NG20-3 | Bridging cultures: transcultural mediation at the bedside Maria Luz Uria Oficialdegui (Barcelona, Spain) | 15:10 - 15:30 |
| NG20-4 | Panel Discussion and Q&A | 15:30 - 16:00 |

Breaks

16:00 - 16:30

R1

Coffee Break, ePoster Viewing, Visit Exhibition*Educational*

16:30 - 18:00

R1

E09 - Educational | The PTCy paradox - Transformative in haplo, yet marginal gain in matched

Bronwen Shaw (Milwaukee, United States of America (the))

| | | |
|-------|--|---------------|
| E09-1 | Introduction | 16:30 - 16:35 |
| E09-2 | PTCy dose reductions and partners - One strategy for all donors and degrees of mismatch? Giorgia Battipaglia (Naples, Italy) | 16:35 - 16:55 |
| E09-3 | Biomarker-driven management of stem cell transplant using PTCy Ismael Buño (Madrid, Spain) | 16:55 - 17:15 |
| E09-4 | Why the PTCY paradox? When better matched HCT fail to replicate haplo success Leo Luznik (Houston, United States of America (the)) | 17:15 - 17:35 |
| E09-5 | Panel discussion and Q&A | 17:35 - 18:00 |

Paediatrics Day

16:30 - 17:45

R2

Paed4 - Inborn Errors Oral Session

Benedicte Neven (Paris, France)

Michael Albert (Munich, Germany)

| | | |
|----------|--|---------------|
| Paed4-01 | HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 752 CHILDREN WITH OSTEOPELOSIS: A STUDY OF THE INBORN ERRORS WORKING PARTY OF THE EBMT Robert Chiesa (London, United Kingdom of Great Britain and Northern Ireland (the)) | 16:30 - 16:39 |
| Paed4-02 | EARLY ACCESS EXPERIENCE OF LENTIVIRAL HEMATOPOIETIC STEM AND PROGENITOR CELL GENE THERAPY (ETUVETIDIGENE-AUTOTEMCEL) IN PATIENTS AFFECTED BY WISKOTT-ALDRICH SYNDROME Sabina Cenciarelli (Milan, Italy) | 16:39 - 16:48 |
| Paed4-03 | ENDOTHELIAL BIOMARKER DYNAMICS IN SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING PEDIATRIC ALLOGENEIC HSCT Katrine Kielsen (Copenhagen, Denmark) | 16:48 - 16:57 |

| | | |
|----------|--|---------------|
| Paed4-04 | PHASE 1 GENE THERAPY FOR PATIENTS WITH IPEX SYNDROME: PRELIMINARY IN VIVO DATA OF THE TREATMENT WITH ENGINEERED TREG-LIKE CELL CD4^{L_VFOXP3} | 16:57 - 17:06 |
| | Jessie L. Alexander (Stanford, United States Minor Outlying Islands (the)) | |
| Paed4-05 | EXTENSIVE METABOLIC CORRECTION AND FAVOURABLE NEUROLOGICAL OUTCOMES MAINTAINED 5 YEARS AFTER TREATMENT WITH AUTOLOGOUS HAEMATOPOIETIC STEM CELL GENE THERAPY (OTL-203) IN MUCOPOLYSACCHARIDOSIS TYPE-I HURLER | 17:06 - 17:15 |
| | Francesca Tucci (Milan, Italy) | |
| Paed4-06 | MANAGEMENT AND OUTCOMES OF PEDIATRIC TA-TMA AFTER ALLOGENEIC HCT: A UK MULTICENTER RETROSPECTIVE STUDY | 17:15 - 17:24 |
| | Milena Balasch Carulla (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| Paed4-07 | TREOSULFAN-BASED REDUCED-TOXICITY CONDITIONING IN CHILDREN WITH INBORN ERRORS OF IMMUNITY: REPORT OF RETROSPECTIVE STUDY FROM A SINGLE CENTER IN CANADA | 17:24 - 17:33 |
| | Ayshah AlOtaibi (Toronto, Canada) | |
| Paed4-08 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ATAXIA-TELANGIECTASIA - A MULTICENTER STUDY BY EBMT/IEWP | 17:33 - 17:42 |
| | Shahrzad Bakhtiar (Frankfurt/Main, Germany) | |

Educational

16:30 - 18:00

R3

E10 - Educational | Beware of unusual infections: a case-based educational discussion

Rafael de la Cámara (Madrid, Spain)

Malgorzata Mikulska (Genova, Italy)

| | | |
|-------|--|---------------|
| E10-1 | Introduction | 16:30 - 16:35 |
| E10-2 | MDR bacterial infections | 16:35 - 16:50 |
| | Carlota Gudiol (Barcelona, Spain) | |
| E10-3 | Rare fungal infections after HCT/CT (<i>Fusarium</i>, <i>Scedosporium</i>...) | 16:50 - 17:05 |
| | Jon Salmanton-García (Cologne, Germany) | |
| E10-4 | Mycobacterial infections after HCT/CT (<i>TB</i> and <i>non-TB</i>) | 17:05 - 17:20 |
| | Joanna Drozd-Sokolowska (Warsaw, Poland) | |
| E10-5 | Rare viral infections after HCT/CT (<i>parvovirus</i>, <i>HHV8</i>, <i>JC virus</i>...) | 17:20 - 17:35 |
| | José Luis Piñana (VALENCIA, Spain) | |
| E10-6 | Panel discussion on unusual infections, and Q&A | 17:35 - 18:00 |

Educational

16:30 - 18:00

R4

E11 - Educational | Neurologic complications across immunotherapies - A comparative perspective

Olaf Penack (Berlin, Germany)

Ana Alarcón Tomás (Madrid, Spain)

| | | |
|-------|--|---------------|
| E11-1 | Introduction | 16:30 - 16:35 |
| E11-2 | Neurologic complications of allogeneic HCT | 16:35 - 16:50 |
| | Petra Hühnchen (Berlin, Germany) | |
| E11-3 | Neurologic complications of CAR-T therapy | 16:50 - 17:05 |
| | Charlotte E. Graham (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| E11-4 | Neurologic complications of bispecific antibodies and other | 17:05 - 17:20 |

| | | |
|---|---|---------------|
| | immunotherapies | |
| | Roser Velasco (Barcelona, Spain) | |
| E11-5 | Neurologic (CNS) infections | 17:20 - 17:35 |
| | Dionysios Neofytos (Geneva, Switzerland) | |
| E11-6 | Panel discussion on neurologic complications of major immunotherapies, highlighting shared and distinct pathways and clinical presentations, and Q&A | 17:35 - 18:00 |
| | | |
| <i>How do I... ?</i> | | |
| 16:30 - 17:45 | | |
| R5 | | |
| HDI6 - How Do I... Use new combinations in follicular lymphoma Supported through an unrestricted educational grant by Genmab | | |
| Ali Bazarbachi (Beirut, Lebanon) | | |
| HDI6-1 | Bispecific antibodies vs CAR-T cells in R/R follicular lymphoma: complementary or competing strategies? | 16:30 - 16:50 |
| | Yasmina Serroukh (Rotterdam, Netherlands (the)) | |
| HDI6-2 | Moving Bispecifics Earlier: First and second-line follicular lymphoma | 16:50 - 17:10 |
| | Lorenzo Falchi (New York, United States of America (the)) | |
| HDI6-3 | Managing toxicities of bispecific antibodies in follicular lymphoma in the real-world setting | 17:10 - 17:30 |
| | Patricia Lopez-Pereira (Barcelona, Spain) | |
| HDI6-4 | Q&A - Discussion | 17:30 - 17:45 |
| | | |
| <i>Joint Sessions</i> | | |
| 16:30 - 18:00 | | |
| R6 | | |
| JS07 - Joint Session EBMT - ISCT Advanced Therapies: From New Clinical Indications to Product Definition and Health System Integration | | |
| Dominique Farge (Paris, France) | | |
| Raffaella Greco (Milano, Italy) | | |
| JS07-1 | Advanced therapies beyond hematology: current evidence and challenges in autoimmune diseases | 16:30 - 16:50 |
| | Raffaella Greco (Milano, Italy) | |
| JS07-2 | Potency assays in advanced therapies: linking product characterization to clinical outcome | 16:50 - 17:10 |
| | Joaquim Vives Armengol (Barcelona, Spain) | |
| JS07-3 | ISCT/EBMT in cell and gene therapy success - past, present & future | 17:10 - 17:30 |
| | Mark Lowdell (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| JS07-4 | Q&A | 17:30 - 18:00 |
| | | |
| <i>Nurses Group</i> | | |
| 16:30 - 18:00 | | |
| R7 | | |
| NG21 - Nurses Group GVHD | | |
| Klára Kabátová Maxová (Pilsen, Czechia) | | |
| Chiara Giacon (Pavia, Italy) | | |
| NG21-1 | GVHD assessment and implications | 16:30 - 16:51 |
| | Michelle Kenyon (LONDON, United Kingdom of Great Britain and Northern Ireland (the)) | |
| NG21-2 | Pulmonary GVHD | 16:51 - 17:12 |
| | Louise Bondeelle (Geneva, Switzerland) | |

| | | |
|--------|--|---------------|
| NG21-3 | Ocular GVHD Tessa Kerre (Gent, Belgium) | 17:12 - 17:33 |
| NG21-4 | The impact of the GVHD treatment Stephano Botti (Reggio Emilia, Italy) | 17:33 - 17:54 |
| NG21-5 | Q&A | 17:54 - 18:00 |

Workshop

16:30 - 18:00

R8

W09 - Workshop | HCT immunobiology and immunotherapy beyond CARs

Valle Gómez-García de Soria (Madrid, Spain)

Rafael Duarte (Madrid, Spain)

| | | |
|-------|---|---------------|
| W09-1 | Introduction | 16:30 - 16:35 |
| W09-2 | Dissecting the basis of graft versus leukemia responses Nicoletta Cieri (Boston, United States of America (the)) | 16:35 - 16:50 |
| W09-3 | Novel Strategies for HLA-mismatched Transplantation and Cell Therapy for EAML - From micro-transplantation to super-transplantation Yajing Huang (Beijing, China) | 16:50 - 17:05 |
| W09-4 | MSCs and ECVs - An old cellular tool with a new edge Fermín Sánchez-Guijo (Salamanca, Spain) | 17:05 - 17:20 |
| W09-5 | New approaches to generate potent anti-tumour NK cells: BCG priming and a specific cytokine cocktail Mar Vales-Gomez (Madrid, Spain) | 17:20 - 17:35 |
| W09-6 | Q&A - Panel discussion | 17:35 - 18:00 |

JACIE Quality Management

16:30 - 17:45

R9

QM4 - JACIE Quality Management 4 | Leveraging JACIE in CAR-T

Nick Van Sinderen (Cologne, Germany)

Lea Brandt Kristensen (Aarhus, Denmark)

| | | |
|-------|---|---------------|
| QM4-1 | Managing the inspection burden: the Dutch experience Suzanne Van Dorp (Nijmegen, Netherlands (the)) | 16:30 - 16:45 |
| QM4-2 | Site Qualifications: Working with manufacturers to reduce audit time Christof Scheid (Cologne, Germany) | 16:45 - 17:00 |
| QM4-3 | GoCART: Focus in education Christian Chabannon (Marseille, France) | 17:00 - 17:15 |
| QM4-4 | Implementing CAR-Ts: A Nursing Perspective Hanne Gronlund Lind (Aarhus, Denmark) | 17:15 - 17:30 |
| QM4-5 | Q&A | 17:30 - 17:45 |

How do I... ?

16:30 - 17:45

R10

HDI7 - How do I... Prepare SCD patients for curative options | Supported through an unrestricted educational grant by Vertex

Donatella Baronciani (Pesaro, Italy)

Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the))

| | | |
|--------|--|---------------|
| HDI7-1 | How do I select patients with sickle cell disease for transplant or gene therapy Valeria Maria Pinto (Genoa, Italy) | 16:30 - 16:55 |
| HDI7-2 | How do I perform sickle cell mobilization and apheresis in preparation for sickle cell gene therapy Mohammed Essa (Riyadh, Saudi Arabia) | 16:55 - 17:20 |
| HDI7-3 | Discussion | 17:20 - 17:45 |

Transplant and Search Coordinators Day

16:30 - 17:45

R11

TSCD4 - EBMT-WMDA Transplant and Search Coordinators Day 4 | Emerging Trends: Cell & Gene Therapy - Implications for the Search & Transplant Coordinators

Eva Frevel (Cologne, Germany)

Annalisa Ruggeri (Milano, Italy)

| | | |
|---------|---|---------------|
| TSCD4-1 | Rethinking the donor registry: evolving roles in the area of Cell & Gene Therapy Anaily Valderrama (London, United Kingdom of Great Britain and Northern Ireland (the)) | 16:30 - 16:50 |
| TSCD4-2 | Cord blood at the crossroads: a revival through innovation Belen Alvarez Palomo (Barcelona, Spain) | 16:50 - 17:10 |
| TSCD4-3 | Clinical readiness: integrating new therapies into patient pathways Nina Worel (Vienna, Austria) | 17:10 - 17:30 |
| TSCD4-4 | Q&A | 17:30 - 17:45 |

Special Session

16:30 - 18:00

R12

SS06 - 7th Global Committee Scientific Session | How to cope globally with unmet needs

Norbert-Claude Gorin (Paris, France)

John Snowden (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))

| | | |
|-------|--|---------------|
| SS6-0 | Welcome Norbert-Claude Gorin (Paris, France) | 16:30 - 16:33 |
| SS6-1 | EBMT IDWP project on neglected tropical diseases (NTD) and related diseases: progress so far and plans Vivak Parkash (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | 16:33 - 16:48 |
| SS6-2 | Hemoglobinopathies: evolving new therapies and global challenges in high-burden, low-resource settings Miguel R. Abboud (Beirut, Lebanon) | 16:48 - 17:03 |
| SS6-3 | Hematopoietic stem cell transplant for sickle cell disease: experience from Tanzania Stella Malangahe (Tanzania, Tanzania, United Republic of) | 17:03 - 17:18 |
| SS6-4 | Haploidentical hematopoietic stem cell transplantation for rare diseases (Huang XiaoJun, CN) XiaoJun Huang (Beijing, China) | 17:18 - 17:33 |
| SS6-5 | CAR-Ts in new geographies: opportunities and barriers - The Mexican experience Alejandro Madrigal (LONDON, United Kingdom of Great Britain and Northern Ireland (the)) | 17:33 - 17:48 |
| SS6-6 | Conclusion Anna Sureda (Barcelona, Spain) Ibrahim Yakoub-Agha (Lille, France) | 17:48 - 18:00 |

Nurses Group

16:30 - 18:00

R13

NG22 - Nurses Group | Apheresis

Natalia Lorente Del Río (Madrid, Spain)

Valentina de Cecco (Roma, Italy)

| | | |
|--------|--|---------------|
| NG22-1 | Meeting the challenges of venous access and poor mobilizers in apheresis Katarina Olsson Lundberg (Gothenburg, Sweden) | 16:30 - 16:51 |
| NG22-2 | Usual and unusual side effects of GCSF Angela Leather (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 16:51 - 17:12 |
| NG22-3 | Enhancing the therapeutic relationship in the apheresis unit Meriam Grootes (The Hague, Netherlands (the)) | 17:12 - 17:33 |
| NG22-4 | The role of plasma exchange Rebekah Horler (Bristol, United Kingdom of Great Britain and Northern Ireland (the)) | 17:33 - 17:54 |
| NG22-4 | Q&A | 17:54 - 18:00 |

Special Session

16:30 - 17:45

R14

SS07 - EBMT Contest III - How an allogeneic stem cell transplant can cure your cancer

Esra Gulderen (Helsinki, Finland)

Alex Rampotas (London, United Kingdom of Great Britain and Northern Ireland (the))

Benedetta Elena Di Majo (Monza, Italy)

| | | |
|--------|---|---------------|
| SS07-1 | A Second Chance at Life: How Donated Stem Cells Heal Nida Malik (Halesowen, United Kingdom of Great Britain and Northern Ireland (the)) | 16:30 - 16:45 |
| SS07-2 | A Hero in Every Cell: How Donor Stem Cells Fight Blood Cancer Pinelopi Samara (Athens, Greece) | 16:45 - 17:00 |
| SS07-3 | From Conflict to Cure: Harnessing Alloreactivity in Allogeneic Stem Cell Transplant Khushnuma Mullanfiroze (London, United Kingdom of Great Britain and Northern Ireland (the)) | 17:00 - 17:15 |
| SS07-4 | Come Sit With Me. A poem about how an allogeneic stem cell transplant can cure your cancer Sara Main (Southampton, United Kingdom of Great Britain and Northern Ireland (the)) | 17:15 - 17:30 |
| SS07-5 | Audience voting & Winner announcement | 17:30 - 17:45 |

GoCART Coalition

16:30 - 17:45

R16

GCC3 - GoCART Coalition 3 | The Power of Real-World Education and Real-World Data

Marion Subklewe (Munich, Germany)

Julio Delgado (Barcelona, Spain)

| | | |
|--------|--|---------------|
| GCC3-1 | The GoCART Observership Programme Marion Subklewe (Munich, Germany) | 16:30 - 16:45 |
| GCC3-2 | Optimizing patient registries for regulatory decision making - key learnings from an HMA/EMA multistakeholder workshop Juan José Abellán (Amsterdam, Netherlands (the)) | 16:45 - 17:00 |
| GCC3-3 | The role of RWE in medicine regulatory settings Juan José Abellán (Amsterdam, Netherlands (the)) | 17:00 - 17:15 |
| GCC4-4 | Linking a national registry electronically to the EBMT registry, challenges and opportunities, an Oncode-Accelerator and EBMT initiative Margot Jak (Utrecht, Netherlands (the)) | 17:15 - 17:30 |

GCC4-5 **EU regulation on SoHO: potential consequences on the generation of real-world data** 17:30 - 17:45

Aur lie Mahalatchimy (Aix-en-Provence, France)

Nurses Group

16:30 - 18:00

R17

NG23 - Nurses Group Workshop | Prehabilitation matters: preparing patients for stronger treatment outcomes

Maaik  de Ruijter (Amsterdam, Netherlands (the))

Elin Ofverberg (Gothenburg, Sweden)

NG23-1 **Psychological and social factors in prehabilitation for stem cell transplant patients** 16:30 - 16:45

Krist n Hulda G slad ttir (Reykjav k, Iceland)

NG23-2 **PROPEL: Randomised comparison of personalised prehabilitation to standard of care in treatment of AML/High risk MDS** 16:45 - 17:00

Ching Ting (Justin) Loke (Manchester, United Kingdom of Great Britain and Northern Ireland (the))

NG23-3 **Physical - Psychosocial - Nutrition** 17:00 - 17:30

Ida Bremer Ophorst (Utrecht, Netherlands (the))

Maria Finch (London, United Kingdom of Great Britain and Northern Ireland (the))

Ozgun Gokmen Kaya (Istanbul, Turkey)

NG23-4 **Panel Discussion and Q&A** 17:30 - 18:00

Printed Poster

18:00 - 19:00

R1

Aplastic Anaemia

B320 **PREVIOUS ANTITHYMOCYTE-BASED IMMUNOSUPPRESSIVE THERAPY INCREASED THE RISK OF VIRUS REACTIVATION IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA** 18:00 - 18:00

Zhengli Xu (Beijing, China)

B321 **IMPROVING THE OUTCOME OF STEM CELL TRANSPLANTATION IN PATIENTS WITH SEVERE APLASTIC ANEMIA** 18:00 - 18:00

Sabrina Giammarco (Rome, Italy)

B323 **ASSESSMENT OF DONOR ENGRAFTMENT KINETICS FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT OF SEVERE APLASTIC ANEMIA** 18:00 - 18:00

Ganesh Raman (Seattle, United States Minor Outlying Islands (the))

B324 **QUALITY OF LIFE IN PATIENTS WITH APLASTIC ANEMIA IMPROVES DURING IMMUNOSUPPRESSIVE THERAPY AND CORRELATES WITH DEPTH OF RESPONSE: ANALYSIS OF THE SAAWP EBMT RACE STUDY** 18:00 - 18:00

Iris Lommerse (Leiden, Netherlands (the))

B325 **QUALITATIVE ASSESSMENT OF PREDICTORS OF RESPONSE TO IMMUNOSUPPRESSIVE THERAPY IN APLASTIC ANAEMIA: A SYSTEMATIC LITERATURE REVIEW** 18:00 - 18:00

Phillip Scheinberg (Sao Paulo, Brazil)

B326 **AB T-CELL DEPLETION VERSUS PTCY IN UNRELATED DONOR HSCT FOR PEDIATRIC PATIENTS WITH APLASTIC ANEMIA** 18:00 - 18:00

Daria Shasheleva (Moscow, Russian Federation (the))

B327 **EXCELLENT OUTCOMES AFTER HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT** 18:00 - 18:00

| | | |
|------|--|---------------|
| | CYCLOPHOSPHAMIDE IN CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA SUPPORT EARLY TRANSPLANTATION Gisele Loth (Curitiba, Brazil) | |
| B328 | AN EPIGENOME-WIDE ASSOCIATION (EWAS) STUDY IN FANCONI ANEMIA AND APLASTIC ANEMIA Maura Faraci (Genova, Italy) | 18:00 - 18:00 |
| B329 | HIGH CD34+ CELL DOSE SIGNIFICANTLY REDUCES EBV REACTIVATION AND IMPROVES SURVIVAL IN APLASTIC ANEMIA PATIENTS UNDERGOING UCBT Jing Long (Beijing, China) | 18:00 - 18:00 |
| B330 | A SYSTEMATIC REVIEW OF REAL-WORLD EVIDENCE ON THERAPIES FOR MODERATE APLASTIC ANAEMIA Britta Hoechsmann (Ulm, Germany) | 18:00 - 18:00 |
| B331 | HAPLOIDENTICAL VS MATCHED UNRELATED DONOR TRANSPLANTATION IN SEVERE APLASTIC ANEMIA: A SINGLE-CENTER COHORT Mohamed I. Sharif (Toronto, Canada) | 18:00 - 18:00 |
| B332 | THIOTEPA-BASED BUSULFAN-SPARING CONDITIONING OPTIMIZES ENGRAFTMENT AND MITIGATES CHRONIC GVHD IN PEDIATRIC HAPLOIDENTICAL HSCT FOR SAA: A MATCHED CASE-CONTROL STUDY Shaoyan Hu (Suzhou, China) | 18:00 - 18:00 |
| B333 | SECOND ALLOGENEIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA: REAL-WORLD OUTCOMES FROM A SINGLE CENTRE IN PAKISTAN Bushra Ahsan (Lahore, Pakistan) | 18:00 - 18:00 |
| | <i>Printed Poster</i> 18:00 - 19:00 | R1 |
| | Poster Session in Hall 9 | |
| | <i>Printed Poster</i> 18:00 - 19:00 | R1 |
| | Nurses Posters - Adult | |
| NP01 | GLOBAL COLLABORATION AND AI-ENHANCED ONLINE EDUCATION FOR UKRAINIAN HCT NURSES IN WARTIME Oleksandr Istomin (Kyiv, Ukraine) | 18:00 - 18:00 |
| NP02 | BUILDING A SKILLED AND CONFIDENT CAR-T NURSING WORKFORCE: ASSESSING THE IMPACT OF NURSE-LED CAR-T EDUCATION Cassandra Abbott (Melbourne, Australia) | 18:00 - 18:00 |
| NP03 | OPTIMISATION OF CAR-T LEUKAPHERESIS USING A MONONUCLEAR CELL-BASED PREDICTIVE COLLECTION TOOL: A SINGLE-CENTRE EXPERIENCE Clair Scott (Murdoch, Australia) | 18:00 - 18:00 |
| NP04 | QUALITY OF LIFE, ANXIETY AND DEPRESSION IN HSCT RECIPIENTS. A 12-MONTH LONGITUDINAL STUDY Arianna Rosich Soteras (Barcelona, Spain) | 18:00 - 18:00 |
| NP05 | OPTIMIZING CRS AND ICANS MANAGEMENT IN CAR-T CELL THERAPY: IMPACT OF A NURSE-LED STRUCTURED WORKFLOW ON EARLY RECOGNITION AND MANAGEMENT OF CRS AND ICANS Kwee Cheng Chia (Singapore, Singapore) | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| NP06 | WHEN KNOWLEDGE AND ATTITUDES DO NOT TRANSLATE INTO PRACTICE: PILOT INSIGHTS FROM HEMATOLOGY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION NURSES' SEXUAL HEALTH CARE Meng-Kuan Chiang (Taipei, Taiwan (Province of China)) | 18:00 - 18:00 |
| NP07 | EXPERIENCES OF AT-HOME AUTOLOGOUS STEM CELL TRANSPLANTATION IN SPAIN: CURRENT OVERVIEW AND IMPROVEMENT AREAS Cristina Gallego Miralles (Barcelona, Spain) | 18:00 - 18:00 |
| NP10 | MONITORING TOXICITY-RELATED COMPLICATIONS IN PATIENTS UNDERGOING CAR-T: OBSERVATIONAL, PROSPECTIVE STUDY Francesca Palmisano (Alessandria, Italy) | 18:00 - 18:00 |
| NP11 | TRANSPLANT @ HOME: A SINGLE CENTRE EXPERIENCE IN HOME-BASED CARE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION Hui Li Lim (Singapore, Singapore) | 18:00 - 18:00 |
| NP12 | APPLICATION OF LONG PERIPHERAL CANNULA IN DONOR APHERESIS - EXPERIENCE OF ONE CENTER Petra Vodickova (Plzen, Czechia) | 18:00 - 18:00 |
| NP13 | COULD PROPHYLACTIC NASOGASTRIC TUBE FEEDING REDUCE WEIGHT LOSS FOR PATIENTS UNDERGOING HIGH-TOXICITY CONDITIONING REGIMENS DURING AUTOLOGOUS STEM CELL TRANSPLANT? Hannah van Tromp (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| NP14 | GUIDING NURSING-LED STRATEGIES TO PREVENT CATHETER-RELATED BLOODSTREAM INFECTIONS DURING ALLOGENEIC HSCT: INFLUENCE OF CATHETER TYPE AND TIMING Maria Teran-Diaz (Santander, Spain) | 18:00 - 18:00 |
| NP15 | LATE TOXICITIES AND QUALITY OF LIFE AFTER VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL): THE ROLE OF ADVANCED PRACTICE NURSING Mercedes Montoro-Lorite (Barcelona, Spain) | 18:00 - 18:00 |
| NP16 | IMPLEMENTING STRUCTURED EDUCATION IN APHERESIS: A COMPARATIVE EVALUATION OF TRAINING EFFICIENCY AND LEARNER PERCEPTIONS Cara Cunningham (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| NP17 | ASSESSMENT AND MONITORING OF NUTRITIONAL STATUS IN ONCO-HEMATOLOGICAL PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): TOOLS, SCALES AND MULTIDISCIPLINARY APPROACH Alice Passoni (Milan, Italy) | 18:00 - 18:00 |
| NP18 | THE EXPERIENCE OF PATIENTS UNDERGOING CAR T CELL THERAPY: A PHENOMENOLOGICAL-INTERPRETATIVE STUDY Alfonso Parisi (Milano, Italy) | 18:00 - 18:00 |
| NP19 | A NURSING ROLE IN IMPROVING OPERATIONAL EFFICIENCY IN CELLULAR THERAPY CLINICAL TRIALS Soyoung Park (Seattle, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| NP20 | PATIENT SATISFACTION OF A NURSE-LED BONE MARROW ASPIRATION (BMA) SERVICE Sophie Bertorelli (Cardiff, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| NP21 | COMMUNICATION COMPETENCE, SELF-EFFICACY, AND SPIRITUAL INTELLIGENCE: EVIDENCE FROM NURSES WORKING IN BMT UNIT | 18:00 - 18:00 |

| | | |
|-----------------------------------|---|---------------|
| | Komal Mundhe (Navi Mumbai, India) | |
| NP22 | CONTINUOUS CARE UNIT: A FEASIBLE MODEL TO OPTIMIZE URGENT MANAGEMENT IN HAEMATOLOGICAL MALIGNANCIES, TRANSPLANTATION AND CAR-T PATIENTS Renato Luna Liendo (Barcelona, Spain) | 18:00 - 18:00 |
| NP23 | HEALTHCARE PROFESSIONALS' AND MANAGERS' EXPERIENCES AND PERCEPTIONS OF IMPLEMENTING CHANGE - IN THE CONTEXT OF ALLOGENEIC STEMCELL TRANSPLANTATION Anna O'Sullivan (Stockholm, Sweden) | 18:00 - 18:00 |
| NP24 | MONITORING STRESS AND WORKLOAD IN PRIMARY CAREGIVERS OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION: A ONE-YEAR SINGLE-CENTER EXPERIENCE Sara Marcos Asensio (Salamanca, Spain) | 18:00 - 18:00 |
| NP25 | EARLY NURSING ASSESSMENT AND MANAGEMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE IN TAIWANESE LONG-TERM ALLO-HSCT SURVIVORS: A TWO-YEAR RETROSPECTIVE STUDY Chiao-Fang Chang (Taipei, Taiwan (Province of China)) | 18:00 - 18:00 |
| NP26 | FOSCARNET SODIUM ENEMA FOR REFRACTORY CMV GASTROENTERITIS AFTER HAPLOIDENTICAL HSCT: A CASE SERIES Mengjing Li (Hangzhou, China) | 18:00 - 18:00 |
| NP27 | THE IMPACT OF DOSE REDUCTION OF POST-TRANSPLANT CYCLOPHOSPHAMIDE TO 70 MG/KG ON EARLY TOXICITY: A SINGLE-CENTRE EXPERIENCE Vanessa Magerová (Prague, Czechia) | 18:00 - 18:00 |
| NP28 | IMPLEMENTATION OF A MENTORSHIP PROGRAMME FOR NEWLY HIRED NURSES IN ONCO-HEMATOLOGY AND BONE MARROW TRANSPLANT UNIT AT SAN RAFFAELE HOSPITAL, MILAN Davide Bonomi (Milan, Italy) | 18:00 - 18:00 |
| NP29 | IMPACT OF THE ETAPES-ONCO PEER SUPPORT PROGRAM ON THE NEEDS OF HEMATOLOGY-ONCOLOGY PATIENTS WHO HAVE UNDERGONE CELLULAR THERAPY: PRELIMINARY RESULTS Catherine Paquette-Gascon (Montreal, Canada) | 18:00 - 18:00 |
| <i>Printed Poster</i> | | |
| 18:00 - 19:00 | | R1 |
| Nurses Posters- Paediatric | | |
| NP30 | ESTABLISHING THE FIRST PEDIATRIC BONE MARROW TRANSPLANT NURSING PROGRAM IN THE UAE: A MODEL FOR COMPETENCY BASED EDUCATION AND INTERNATIONAL COLLABORATION Dina El Mouzain (Abu Dhabi, United Arab Emirates (the)) | 18:00 - 18:00 |
| NP31 | IMPLEMENTATION OF NEUTROPENIA PATHWAY TO IMPROVE ANTIBIOTIC TURNAROUND TIME IN PEDIATRIC BMT PATIENTS AT ABU DHABI BONE MARROW TRANSPLANT PROGRAM, CENTER OF EXCELLENCE (UAE) Dina El Mouzain (Abu Dhabi, United Arab Emirates (the)) | 18:00 - 18:00 |
| NP32 | GLOBAL NURSING EXCHANGE: EXPERIENCES FROM THE "HOW DO YOU DO IT" ONLINE SESSIONS BY THE EBMT NURSES GROUP PAEDIATRIC COMMITTEE Ida Bremer Ophorst (Utrecht, Netherlands (the)) | 18:00 - 18:00 |
| NP33 | ASSESSING THE TOLERANCE OF FIBRE BASED FEEDS FOR PAEDIATRIC PATIENTS DURING AN ALLOGENEIC STEM CELL | 18:00 - 18:00 |

TRANSPLANT

Chloe Elliott (London, United Kingdom of Great Britain and Northern Ireland (the))

- | | | |
|------|---|---------------|
| NP34 | PREVENTION AND MANAGEMENT OF ORAL MUCOSITIS IN PEDIATRIC ONCO-IMMUNO-HEMATOLOGICAL PATIENTS: A SCOPING REVIEW Silvia Gneccchi (Milan, Italy) | 18:00 - 18:00 |
| NP35 | ROLE OF TANZANIAN NURSES IN OPENING A PEDIATRIC BONE MARROW TRANSPLANT UNIT AND NURSING CARE IN SICKLE CELL PATIENTS AT BENJAMIN MKAPA HOSPITAL IN DODOMA Silvia Gneccchi (Milan, Italy) | 18:00 - 18:00 |
| NP36 | EXPLORING DETERMINANTS OF STAFF RETENTION IN PAEDIATRIC BONE MARROW TRANSPLANT NURSING Charlotte Rigby (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| NP37 | PERCEIVED BARRIERS AND FACILITATORS OF FAMILY-CENTERED ROUNDS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, A HEALTH CARE PROFESSIONALS SURVEY Madelief Sterre Hübner (Leiden, Netherlands (the)) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Nurses Posters- Research

- | | | |
|------|--|---------------|
| NP38 | PSYCHOSOCIAL ASSESSMENT OF PATIENTS AND CAREGIVERS UNDERGOING AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION AT HOME Ana Rodriguez Calvo-Parra (Madrid, Spain) | 18:00 - 18:00 |
| NP39 | EFFICACY OF ACUPOINT APPLICATION COMBINED WITH HERBAL FUMIGATION AND WASH IN PREVENTING DIARRHEA AND PERIANAL INFECTION IN PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Liyuan Qin (Shanghai, China) | 18:00 - 18:00 |
| NP40 | FINANCIAL TOXICITY AND ITS INFLUENCING FACTORS IN PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHINA: A CROSS-SECTIONAL STUDY Liyuan Qin (Shanghai, China) | 18:00 - 18:00 |
| NP41 | READINESS FOR DISCHARGE - HOLISTIC UNDERSTANDING OF THE PATIENT JOURNEY FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION Lubna Khatib (Haifa, Israel) | 18:00 - 18:00 |
| NP42 | THE POTENTIAL OF AI CHATBOTS AS CLINICAL DECISION-SUPPORT TOOLS IN NURSING: AN EVALUATION OF SYMPTOM MANAGEMENT RECOMMENDATIONS DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Aysenur Cetin Uceriz (Istanbul, Turkey) | 18:00 - 18:00 |
| NP43 | AN APPLIED STUDY OF STEPWISE EXERCISE NURSING PROGRAM FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS Mengjing Li (Hangzhou, China) | 18:00 - 18:00 |
| NP45 | INVESTIGATION OF THE ACCEPTANCE AND APPLICABILITY OF ACCELEROMETRIC MEASUREMENT OF PHYSICAL ACTIVITY BEFORE, DURING, AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Aleksandra Trojan (Köln, Germany) | 18:00 - 18:00 |
| NP46 | LIVED EXPERIENCES AND PERCEIVED QUALITY OF CARE IN ALLO-HSCT: A QUALITATIVE SUBSTUDY OF THE PHARALLO | 18:00 - 18:00 |

PROGRAMME

Paula Guijarro Martínez (Madrid, Spain)

- NP47 **EVALUATION OF THE EFFICACY OF ULTRASOUND-GUIDED MEDIUM-LENGTH CATHETERS IN THE COLLECTION OF PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS FROM HEALTHY DONORS** 18:00 - 18:00

Fengwei Du (Hangzhou, China)

Printed Poster

18:00 - 19:00

R1

Bone Marrow Failure

- B334 **EFFICACY AND SAFETY OF IPTACOPAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REAL-WORLD STUDY OF 37 PATIENTS IN CHINA** 18:00 - 18:00

- B335 **T CELL-DEPLETED HAPLOIDENTICAL AND MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION REPRESENT SAFE AND EFFICIENT THERAPEUTIC APPROACHES FOR PEDIATRIC PATIENTS WITH BONE MARROW FAILURE SYNDROMES** 18:00 - 18:00

Anja Troeger (Regensburg, Germany)

Printed Poster

18:00 - 19:00

R1

Autoimmune Diseases

- B337 **REAL-WORLD ANALYSIS OF RAVULIZUMAB SAFETY AND EFFECTIVENESS IN ADVANCED AGE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: INSIGHTS FROM THE INTERNATIONAL PNH REGISTRY** 18:00 - 18:00

Philippe Gustovic (Baar, Switzerland)

- B338 **DANICOPAN ADD-ON THERAPY DEMONSTRATES POSITIVE EFFICACY AND SAFETY IN ADVANCED AGE ADULTS WITH PNH AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS: PHASE 3 ALPHA TRIAL SUB-ANALYSIS** 18:00 - 18:00

Austin Kulasekararaj (London, United Kingdom of Great Britain and Northern Ireland (the))

- B339 **HETEROGENEOUS NON-HEMATOLOGIC AUTOIMMUNE COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC LEUKEMIA: INCIDENCE, SPECTRUM, AND OUTCOMES IN A SINGLE-CENTER COHORT** 18:00 - 18:00

Amir Ali Hamidieh (Tehran, Iran (Islamic Republic of))

- B340 **FROM VISION TO REALITY: EVALUATING SAFETY OF THE FIRST IN HOUSE IMPLEMENTED CD19 CAR-T IN UNITED ARAB EMIRATES FOR SLE PATIENTS** 18:00 - 18:00

Mohamed Abu-Haleeqa (Abu Dhabi, United Arab Emirates (the))

- B341 **REDUCTION OF INTERLEUKIN-6 AND INTERLEUKIN-8-MEDIATED INFLAMMATION AND PROLIFERATION IN SKIN FIBROBLASTS IN SYSTEMIC SCLEROSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION MEASURED BY GENE EXPRESSION ANALYSES** 18:00 - 18:00

Gunter Assmann (Minden, Germany)

- B342 **SAFETY OF RAVULIZUMAB USE IN PREGNANCY: INSIGHTS FROM A GLOBAL PHARMACOVIGILANCE ANALYSIS** 18:00 - 18:00

Cory Williams (New Haven, United States Minor Outlying Islands (the))

- B343 **MMR SEROLOGIC STATUS IN MULTIPLE SCLEROSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION** 18:00 - 18:00

| | | |
|------|--|---------------|
| | Edoardo Simonetti (Florence, Italy) | |
| B344 | INFECTIOUS COMPLICATIONS IN DUTCH MS-PATIENTS WITHIN THE FIRST YEAR AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A FOREIGN COUNTRY Lara Suzanne Oosterom (Groningen, Netherlands (the)) | 18:00 - 18:00 |
| B345 | NUMBER OF CD34 CELLS EMPLOYED IN AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR PERSONS WITH MULTIPLE SCLEROSIS IS NOT RELATED TO THE NEUROLOGICAL OUTCOME OF THE PROCEDURE Guillermo J. Ruiz-Argüelles (Puebla, Mexico) | 18:00 - 18:00 |
| B346 | BEYOND STEM CELLS; DUAL NK-CELL POPULATION IN STEM CELL GRAFT MAY CONTRIBUTE TO IMMUNE RESET POST AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS Shahna Barrett (Kingston, Jamaica) | 18:00 - 18:00 |
| B347 | AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ANTI-SYNTHEASE SYNDROME: LONG-TERM OUTCOMES FROM TWO REFRACTORY CASES Michel Lu (Sydney, Australia) | 18:00 - 18:00 |
| B348 | OUTCOMES OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE SCLEROSIS: EXPERIENCE FROM SOUTH AFRICA Adam Setzer (Johannesburg, South Africa) | 18:00 - 18:00 |
| B349 | ANTI-CD38 MONOCLONAL ANTIBODY FOR TREATING IMMUNE THROMBOCYTOPENIA: A CASE REPORT | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Paediatrics - Basic and translational

| | | |
|------|---|---------------|
| B268 | PRE-TRANSPLANT RESISTOME DISRUPTION PREDICTS ESBL GENE ACCUMULATION IN PEDIATRIC TRANSPLANT RECIPIENTS: A PROSPECTIVE MULTI-CENTER STUDY Edoardo Muratore (Bologna, Italy) | 18:00 - 18:00 |
| B269 | REGULATORY T CELL RECONSTITUTION IS ASSOCIATED WITH ONSET AND SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC AND YOUNG ADULT HCT RECIPIENTS Jaap-Jan Boelens (New York, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B270 | CAR-T PHENOTYPE AND HOST IMMUNE PROFILES AT APHERESIS AND POST-INFUSION DRIVE CD19 CAR-T PERSISTENCE IN PAEDIATRIC B ALL | 18:00 - 18:00 |
| B272 | ROLE OF PHARMACOGENETICS IN THE EFFICACY OF LOW-DOSE METHOTREXATE ADMINISTERED AS GVHD PROPHYLAXIS IN PEDIATRIC ALL PATIENTS: A FORUM STUDY Yvonne Gloor (Geneva, Switzerland) | 18:00 - 18:00 |
| B273 | POTENTIAL FOR PHARMACOGENOMICS TO IMPROVE MEDICATION SAFETY AND EFFICACY IN AUSTRALIAN HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS Hannah Walker (Melbourne, Australia) | 18:00 - 18:00 |
| B274 | HEMATOPOIETIC STEM CELL TRANSPLANTATION AND GUT MICROBIOME DIVERSITY IN CHILDREN Gustav Ørting Jørgensen (Copenhagen, Denmark) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Conditioning Regimens and lymphodepletion

- | | | |
|------|---|---------------|
| B152 | IMPACT OF ONE VERSUS TWO INDUCTIONS TO ATTAIN FIRST COMPLETE REMISSION IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE: FROM THE ALWP/EBMT Arnon Nagler (Ramat Gan, Israel) | 18:00 - 18:00 |
| B153 | POST-TRANSPLANT CYCLOPHOSPHAMIDE COMPARED WITH OTHER GVHD PROPHYLAXIS STRATEGIES IN REDUCED-INTENSITY ALLOGENEIC TRANSPLANTATION FOR AML AND MDS: AN SFGM-TC REGISTRY STUDY Tereza Coman (Villejuif, France) | 18:00 - 18:00 |
| B154 | ARCHIVE CONDITIONING (ALKYLATING AGENTS, CYTARABINE, CLADRIBINE, HYPOMETHYLATING AGENTS, AND VENETOCLAX) FOR UPFRONT ALLOGENEIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED OR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA Lukas Kevličius (Vilnius, Lithuania) | 18:00 - 18:00 |
| B155 | REJECTION PROPHYLAXIS IN AUTOLOGOUS GENE THERAPY PROTOCOLS: CHOOSING AN ALEMTUZUMAB DOSE Nathan Jeffreys (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B156 | VENETOCLAX-ENHANCED REDUCED-INTENSITY CONDITIONING IN ELDERLY PATIENTS WITH HIGH-RISK MYELOID MALIGNANCIES UNDERGOING ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION: A PHASE II STUDY Jie Gao (Shanghai, China) | 18:00 - 18:00 |
| B160 | VENETOCLAX-AUGMENTED CONDITIONING REGIMENS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOID NEOPLASMS: A SCOPING REVIEW AND EVIDENCE LANDSCAPE Afraa Fadul (Doha, Qatar) | 18:00 - 18:00 |
| B161 | FLUDARABINE AUC EXPOSURE IS NOT PREDICTIVE OF MORTALITY IN THE CONTEXT OF FLUDARABINE BUSULFAN AND ATG CONDITIONED TRANSPLANTATION Alexander Glover (Nottingham, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B162 | SUPERIORITY OF TBI-BASED COMPARED TO MELPHALAN-BASED CONDITIONING REGIMEN IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: COMPARISON BETWEEN DIFFERENT APPROACHES OF TWO MAJOR PEDIATRIC TRANSPLANTATION UNITS Tim Flaadt (Tübingen, Germany) | 18:00 - 18:00 |
| B163 | EFFICACY AND SAFETY OF MELPHALAN/TBI-BASED CONDITIONING REGIMENS (MCAC/TCAC) FOR AUTOLOGOUS HSCT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTICENTER, PROSPECTIVE COHORT STUDY Jieya Luo (Tianjin, China) | 18:00 - 18:00 |
| B164 | COMBINATION OF 7.5 MG/KG ATG WITH BASILIXIMAB AS AN EFFECTIVE REGIMEN FOR PATIENTS WITH SEVERE INFUSIONAL SIDE EFFECTS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION Tingting Han (Beijing, China) | 18:00 - 18:00 |
| B165 | FROM PBPK TO BEDSIDE: VIRTUAL TWIN-GUIDED FLUDARABINE DOSING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | Mourad Mseddi (Geneva, Switzerland) | |
| B166 | A SIMULATED PK/PD INVESTIGATION OF RATG, FLUDARABINE, AND THIOTEPA IN HAPLO-IDENTICAL TRANSPLANT FOR SICKLE CELL DISEASE; A VANDERBILT GLOBAL HAPLO-IDENTICAL BMT LEARNING COLLABORATIVE (VGC²) ANALYSIS Jaap-Jan Boelens (New York, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B167 | ASSOCIATION BETWEEN BUSULFAN EXPOSURE AND OVERALL SURVIVAL AND TOXICITY IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT WITH MYELOABLATIVE CONDITIONING - A PROSPECTIVE, MULTICENTRE ANALYSIS Annabelle Robinson (Sydney, Australia) | 18:00 - 18:00 |
| B168 | LONG-TERM FOLLOW-UP WITH TREOSULFAN BASED CONDITIONING REGIMEN IN HEMATOLOGICAL MALIGNANCIES: A SINGLE CENTER EXPERIENCE Anna Paola Iori (Rome, Italy) | 18:00 - 18:00 |
| B169 | HAPLOIDENTICAL HCT IN ADULTS WITH A NON-TBI CONDITIONING REGIMEN: A 10-YEAR SINGLE-CENTER COHORT Fernando Barroso Duarte (Fortaleza, Brazil) | 18:00 - 18:00 |
| B171 | CLADRIBINE WITH TOTAL BODY IRRADIATION AS A STRATEGY TO OPTIMIZE CONDITIONING REGIMEN IN AML AND MDS: A PROSPECTIVE STUDY OF THE POLISH ADULT LEUKEMIA GROUP Malgorzata Sobczyk-Kruszelnicka (Gliwice, Poland) | 18:00 - 18:00 |
| B172 | IMPACT OF TMLI VERSUS TBI CONDITIONING ON TOXICITY, OUTCOMES, AND RELAPSE IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA María Panizo-Inogés (Pamplona, Spain) | 18:00 - 18:00 |
| B173 | OUTCOMES OF ALLOGENIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE: A 5 YEAR SINGLE CENTRE EXPERIENCE Yashashree Gupta (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B174 | FLUDARABINE PLUS TREOSULFAN CONDITIONING FOR OLDER AND COMORBID PATIENTS BEFORE ALLOGENEIC HSCT - A RETROSPECTIVE ANALYSIS IN A REAL-WORLD COHORT Hanna A. Knaus (Vienna, Austria) | 18:00 - 18:00 |
| B175 | A FAVORABLE EFFICACY-SAFETY PROFILE: TREOSULFAN-BASED CONDITIONING IMPROVES OVERALL SURVIVAL AND LOWERS RELAPSE RISK COMPARED TO BUSULFAN IN RIC ALLO-HSCT Vera Radici (Brescia, Italy) | 18:00 - 18:00 |
| B176 | COMPARISON OF CARMUSTINE-, LOMUSTINE-, AND NITROSOUREA-FREE CONDITIONING REGIMENS FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN LYMPHOMA: RESULTS FROM THE BRAZILIAN REGISTRY Fernando Barroso Duarte (Fortaleza, Brazil) | 18:00 - 18:00 |
| B178 | FLUDARABINE AND TREOSULFAN MYELOABLATIVE CONDITIONING LEADS TO HIGH OS AND LOW NRM Chiara Bernardi (Geneva, Switzerland) | 18:00 - 18:00 |
| B179 | CLINICAL STUDY OF THE TBFPTCY REGIMEN AS A CONDITIONING REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN MYELOID MALIGNANCIES Ping Zhang (Ningbo, China) | 18:00 - 18:00 |
| B180 | COMPARISON OF TOTAL NODAL IRRADIATION (6.0-7.5 GY) VS LOW-DOSE TOTAL BODY IRRADIATION (2 GY) IN EX VIVO TCRAB-DEPLETED HAPLOIDENTICAL TRANSPLANTATION IN ADULTS | 18:00 - 18:00 |

WITH HEMATOLOGICAL MALIGNANCIES

Koh Liang Piu (Singapore, Singapore)

- | | | |
|------|--|---------------|
| B181 | COMPARISON OF TREOSULFAN-THIOTEPA-FLUDARABINE VS FLUDARABINE-TREOSULFAN CONDITIONING FOR ALLOGENEIC HCT IN AML AND MDS: A SINGLE-CENTER RETROSPECTIVE EXPERIENCE Fabio Serpenti (Milan, Italy) | 18:00 - 18:00 |
| B182 | IMLIFIDASE EFFICIENTLY ABROGATES THE EFFECT OF ATLG AND THYMOGLOBULIN ON T- AND NK-CELL VIABILITY AND FUNCTION Claus-Philipp Maier (Tuebingen, Germany) | 18:00 - 18:00 |
| B184 | SALVAGE ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AML: CLADRIBINE-BASED INTENSIVE CONDITIONING VERSUS STANDARD MYELOABLATIVE REGIMENS Wenyi Wang (Hangzhou, China) | 18:00 - 18:00 |
| B185 | TRANSFUSION BURDEN UNDER ATG AND PTCY IN ACUTE LEUKEMIA PATIENTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION Jette Luedersen (Hamburg, Germany) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Infections and vaccination - Basic and Translational

- | | | |
|------|--|---------------|
| B070 | IMMUNOGENICITY AND REACTOGENICITY OF REPEATED COVID-19 VACCINATION IN IMMUNOCOMPROMISED PATIENTS (AUTO-COVID-VACC): PRELIMINARY RESULTS FROM A MULTICENTRE, PROSPECTIVE, NON-INTERVENTIONAL STUDY Louise M. Cremer (Cologne, Germany) | 18:00 - 18:00 |
| B071 | IMPACT OF EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV-PTLD) ON DONOR T-CELL CHIMERISM IN ALLOGRAFT RECIPIENTS RECEIVING THYMOGLOBULIN AS GVHD PROPHYLAXIS Kirsty Sharplin (Oxford, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Infections and vaccination - Clinical

- | | | |
|------|---|---------------|
| B072 | RISK STRATIFICATION SYSTEM FOR CMV MONITORING AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION Alicja Sadowska-Klasa (Seattle, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B073 | REAL-WORLD USE, EFFECTIVENESS AND SAFETY OF MARIBAVIR IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT CMV OR INTOLERANCE TO ANTI-CMV AGENTS: INTERIM ARISE RESULTS Johan Maertens (Leuven, Belgium) | 18:00 - 18:00 |
| B074 | INFECTION BURDEN IN MISMATCHED UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION USING REDUCED-DOSE POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: RESULTS FROM THE OPTIMIZE TRIAL Jeffery J. Auletta (Minneapolis, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B075 | RISK STRATIFICATION FOR EARLY EBV REACTIVATION AFTER PEDIATRIC ALLO-HSCT: DEVELOPMENT OF A CLINICAL SCORING SYSTEM | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | Shaoyan Hu (Suzhou, China) | |
| B076 | ADENOVIRUS IN THE ERA OF INCREASING ALTERNATE DONOR HSCT: OUTCOMES, PREDICTORS, AND THERAPEUTIC RESPONSE OVER THE LAST DECADE Krithika Krishnakumar (Chennai, India) | 18:00 - 18:00 |
| B077 | IMPACT OF INTERLEUKIN-6 DYNAMICS ON INFECTION SEVERITY AND CLINICAL OUTCOMES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES UNDERGOING INTENSIVE THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION Ben-Niklas Baermann (Düsseldorf, Germany) | 18:00 - 18:00 |
| B078 | PRE-TRANSPLANT CLOSTRIDIODES DIFFICILE INFECTION: A TIMING-DEPENDENT PREDICTOR OF GI GVHD AND EARLY MORTALITY IN ALLOGENEIC HSCT RECIPIENTS Wenyi Wang (Hangzhou, China) | 18:00 - 18:00 |
| B079 | HHV-6B INFECTION ADVERSELY IMPACTS OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTICENTER, CASE-CONTROL STUDY Jiayu Huang (Shanghai, China) | 18:00 - 18:00 |
| B080 | VIROLOGIC OUTCOMES BY BASELINE CMV VIRAL LOAD IN HCT RECIPIENTS TREATED WITH MARIBAVIR: POST HOC ANALYSIS OF PHASE 2 AND 3 TRIALS Genovefa Papanicolaou (New York, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B081 | PROGNOSTIC IMPLICATIONS OF CMV INFECTION/DISEASE AND HHV-6 ENCEPHALITIS IN CORD BLOOD TRANSPLANT RECIPIENTS RECEIVING FOSCARNET Shogo Matsui (Tokyo, Japan) | 18:00 - 18:00 |
| B082 | BRONCHOALVEOLAR LAVAGE PRACTICES IN ALLO-HCT RECIPIENTS WITH LOWER RESPIRATORY TRACT INFECTIONS: A SURVEY OF INFECTIOUS DISEASES WORKING PARTY (IDWP) EBMT Agnieszka Piekarska (Gdansk, Poland) | 18:00 - 18:00 |
| B083 | MOST PATIENTS DON'T NEED COMPLETE REVACCINATION AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION Sabine Dressler (Nürnberg, Germany) | 18:00 - 18:00 |
| B084 | OUTCOME OF CMV PNEUMONIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION IN THE ERA OF MODERN TRANSPLANTATION AND CMV PREVENTION PRACTICES Alicja Sadowska-Klasa (Seattle, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B086 | EBV REACTIVATION AND PTLD IN THE LETERMОВIR ERA: BEYOND ANTIVIRAL PROPHYLAXIS Ilaria Cutini (Florence, Italy) | 18:00 - 18:00 |
| B087 | IMPACT OF EBMT 2025 DEFINITIONS ON THE IDENTIFICATION OF CATHETER-RELATED BLOODSTREAM INFECTIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Juan Manuel Cerezo-Martín (Santander, Spain) | 18:00 - 18:00 |
| B089 | INCREASED INCIDENCE OF INFECTIONS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS IN MATCHED SIBLING AND UNRELATED DONOR STEM CELL TRANSPLANTATION Athanasios Gakopoulos (Athens, Greece) | 18:00 - 18:00 |
| B090 | EFFICACY AND SAFETY OF MARIBAVIR IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS BY BASELINE NEUTROPENIA STATUS: A POST HOC ANALYSIS OF PHASE 2 AND 3 CLINICAL TRIALS | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | Alicja Sadowska-Klasa (Seattle, United States Minor Outlying Islands (the)) | |
| B091 | THE ORAL MICROBIOME IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS Rajinder Bajwa (Columbus, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B092 | SURVEY BY THE INFECTIOUS DISEASES WORKING PARTY OF EBMT ON THE USE OF RECOMBINANT HERPES ZOSTER VACCINE AFTER AUTOLOGOUS AND ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANTATION Maria Stamouli (Athens, Greece) | 18:00 - 18:00 |
| B093 | ANAKINRA TO REDUCE FEVER DURING NEUTROPENIA AND MUCOSITIS IN MULTIPLE MYELOMA PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER HIGH-DOSE MELPHALAN - A RANDOMIZED CONTROLLED TRIAL Eva Molendijk (Nijmegen, Netherlands (the)) | 18:00 - 18:00 |
| B094 | THE IMPACT OF CMV-SEROPOSITIVITY ON OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF LETERMOVIR IN AML AND MDS PATIENTS Lina Kolloch (Muenster, Germany) | 18:00 - 18:00 |
| B095 | MARIBAVIR FOR TREATMENT OF REFRACTORY/RECURRENT CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HSCT RECIPIENTS Aleksandr Siniaev (St. Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| B096 | EFFECTIVENESS OF A STRUCTURED PREVENTION STRATEGY FOR HBV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING HBSAG-POSITIVE DONORS Jinya Lin (Hangzhou, China) | 18:00 - 18:00 |
| B097 | LETERMOVIR PRIMARY PROPHYLAXIS IS A PROTECTIVE FACTOR FOR SURVIVAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS. DATA FROM THE FIRST PROSPECTIVE MULTICENTER STUDY IN LATIN AMERICA Fabian Herrera (Buenos Aires, Argentina) | 18:00 - 18:00 |
| B098 | SAFETY OF OMITTING ANTIBACTERIAL PROPHYLAXIS IN ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: EXPERIENCE FROM A SINGLE CANADIAN CENTER Omar Eduardo Fernandes Vargas (Montreal, Canada) | 18:00 - 18:00 |
| B099 | EARLY ADMINISTRATION OF LETERMOVIR PROPHYLAXIS POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IS ASSOCIATED WITH DELAYED ENGRAFTMENT Dionysios Neofytos (Geneva, Switzerland) | 18:00 - 18:00 |
| B100 | EXHALED-BREATH VOLATILE MARKERS OF INVASIVE PULMONARY ASPERGILLOSIS IN PEDIATRIC CANCER AND STEM CELL TRANSPLANT PATIENTS: A PILOT STUDY Laura Rotte (Utrecht, Netherlands (the)) | 18:00 - 18:00 |
| B101 | CMV INFECTION AFTER ALLOGENEIC HSCT IN SERONEGATIVE RECIPIENTS TRANSPLANTED FROM A SEROPOSITIVE DONOR: A MONOCENTRIC RETROSPECTIVE STUDY Alienor Xhaard (Paris, France) | 18:00 - 18:00 |
| B103 | CYTOMEGALOVIRUS REACTIVATION IN A SINGLE CENTER PAEDIATRIC COHORT UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION AND USE OF LETERMOVIR Teresa Martín Aláez (Madrid, Spain) | 18:00 - 18:00 |
| B104 | PRESERVATION OF ADAPTIVE IMMUNITY AFTER NONMYELOABLATIVE HEMATOPOIETIC CELL | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | TRANSPLANTATION IN ADULTS WITH SICKLE CELL DISEASE (PROTECT STUDY) Erfan Nur (Amsterdam, Netherlands (the)) | |
| B105 | CAN RECTAL SWABS PREDICT POST-HCT PSEUDOMONAS AERUGINOSA INFECTIONS? - A PRELIMINARY SINGLE-CENTER ANALYSIS Giovanni Grillo (Milan, Italy) | 18:00 - 18:00 |
| B106 | INTRODUCING MIPI-RADS, MOLD-ASSOCIATED INVASIVE PULMONARY INFECTION - REPORTING AND DATA SYSTEM, FOR UNIFORM ASSESSMENT AND REPORTING OF CHEST CT-IMAGING OF PULMONARY INVASIVE MOULD INFECTIONS Elizabeth De Kort (Nijmegen, Netherlands (the)) | 18:00 - 18:00 |
| B107 | HUMAN HERPES VIRUS 6 INFECTION IN ALLOGENEIC STEM CELL TRANSPLANTATION RECEIVING POST-TRASPLANT CYCLOPHOSPHAMIDE Maria Suárez-Lledó (Barcelona, Spain) | 18:00 - 18:00 |
| B108 | IMPACT OF DONOR CMV-SPECIFIC HUMORAL AND CELL-MEDIATED IMMUNITY ON CMV-IMMUNE RECONSTITUTION AND INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION Guillermo Ramos Moreno (Madrid, Spain) | 18:00 - 18:00 |
| B109 | INCIDENCE OF EBV DNAEMIA AND POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) AMONG HCT WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE (PTCY). A SINGLE CENTER EXPERIENCE Genovefa Papanicolaou (New York, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B110 | MONITORING MATTERS - SUPRATHERAPEUTIC LEVEL OF TACROLIMUS IS A PREDICTOR OF BK VIRUS REACTIVATION IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION Revathi Raj (Chennai, India) | 18:00 - 18:00 |
| B111 | ERAVACYCLINE IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS: A REAL-WORLD STUDY OF DRUG-DRUG INTERACTIONS WITH CYCLOSPORINE/TACROLIMUS AND ANTI-INFECTIVE EFFICACY Jieya Luo (Tianjin, China) | 18:00 - 18:00 |
| B112 | GASTROINTESTINAL MUCOSITIS AS CONTRIBUTOR TO FEVER IN AUTOLOGOUS STEM CELL TRANSPLANT RECIPIENTS CONDITIONED WITH HIGH-DOSE MELPHALAN Björn Reijnders (Nijmegen, Netherlands (the)) | 18:00 - 18:00 |
| B113 | CMV AND EBV REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES Yuqing Tu (Suzhou, China) | 18:00 - 18:00 |
| B114 | EARLY DISCONTINUATION OF EMPIRIC ANTIBIOTIC THERAPY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Aleksandr Siniaev (St. Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| B116 | THE ROLE OF PCR DETECTION OF CARBAPENEMASE GENES IN NATIVE SPECIMENS FOR ROUTINE COLONIZATION SCREENING IN THE EARLY POST-ALLO-HCT PERIOD Aleksandr Siniaev (St. Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| B117 | CURRENT TRENDS IN THE MANAGEMENT OF CYTOMEGALOVIRUS IN CELL THERAPIES RECIPIENTS IN SPAIN: | 18:00 - 18:00 |

| RESULTS OF THE 2025 GETH-TC SURVEY | | |
|---|--|---------------|
| | Irene García-Cadenas (Barcelona, Spain) | |
| B118 | RISK OF BACTEREMIA IN LEVOFLOXACIN-RESISTANT EXTENDED-SPECTRUM B-LACTAMASE-PRODUCING ENTEROBACTERIALES COLONIZED RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT Dario Schiavo (Treviso, Italy) | 18:00 - 18:00 |
| B120 | DETERMINANTS OF EARLY AND LATE INFECTIONS AFTER CAR-T IN SECOND- AND THIRD-LINE LBCL Ilaria Cutini (Florence, Italy) | 18:00 - 18:00 |
| B121 | MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY Francesco Paolo Tambaro (Naples, Italy) | 18:00 - 18:00 |
| B122 | SURGICAL TREATMENT OF PULMONARY INVASIVE FUNGAL DISEASE IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Alexander Kulagin (Saint Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| B123 | NOT ALL AUTOLOGOUS TRANSPLANTS ARE LOW RISK: DELAYED PLATELET ENGRAFTMENT SIGNALS THE NEED FOR CMV MONITORING Ibrahim Ethem Pinar (Bursa, Turkey) | 18:00 - 18:00 |
| B124 | RESPIRATORY VIRAL INFECTIONS AND NONINFECTIOUS PULMONARY COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Frédéric Rivière (Caen, France) | 18:00 - 18:00 |
| B125 | HHV6 MONITORING AND DONOR ASSESSMENT IN PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANT - A SINGLE CENTRE PROSPECTIVE STUDY Antonio Grasso (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B126 | CHANGES IN ANTIBODY TITERS AND PREDICTIVE FACTORS FOR SEROCONVERSION FOLLOWING LIVE VACCINATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS Misaki Hada (Kyoto, Japan) | 18:00 - 18:00 |
| B127 | MANAGEMENT OF CMV INFECTION WITH MARIBAVIR IN PATIENTS TREATED WITH CAR-T THERAPY Cristian Gutierrez-Padilla (Madrid, Spain) | 18:00 - 18:00 |
| B128 | NORMAL IGG DOES NOT EQUATE TO IMMUNE COMPETENCE AFTER HSCT IN PEDIATRIC SICKLE CELL DISEASE Alexander Ngwube (Houston, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B129 | PHYSICIAN SURVEY OF REAL-WORLD MARIBAVIR USE AND TREATMENT DECISION MAKING IN REFRACTORY CYTOMEGALOVIRUS INFECTION AFTER TRANSPLANTATION Johan Maertens (Leuven, Belgium) | 18:00 - 18:00 |
| B130 | COMPARATIVE ANALYSIS OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL VS MATCHED SIBLING DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Marco Alejandro Jiménez-Ochoa (Mexico City, Mexico) | 18:00 - 18:00 |
| B131 | HOSPITAL EXEMPTION USE OF VIRUS-SPECIFIC T-LYMPHOCYTES IN CHILDREN: EARLY EXPERIENCE WITHIN THE ALLOVISTA FRAMEWORK | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | Marek Ussowicz (Wrocław, Poland) | |
| B132 | IMPACT OF LETERMIVIR PROPHYLAXIS ON CYTOMEGALOVIRUS EVENTS AND RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR AML AND MDS Sin Young Park (Seoul, Korea (the Republic of)) | 18:00 - 18:00 |
| B133 | ADDITION OF ANTITHYMOCYTE GLOBULIN TO CYCLOSPORIN AND MYCOPHENOLATE IN UNMANIPULATED HAPLO-TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN AND TEENAGERS. RESULTS OF A SERIE OF 40 PATIENTS Angela Trujillo-Gaviria (Medellin, Colombia) | 18:00 - 18:00 |
| B134 | OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS REQUIRING INTENSIVE CARE: A RETROSPECTIVE COHORT STUDY Andrés Yesid Bonilla-Salcedo (Mexico City, Mexico) | 18:00 - 18:00 |
| B135 | LONG TERM COVID-19 VACCINE EFFECTIVENESS AND ANTY-SARS-COV-2 IGG DYNAMICS IN CHILDREN AND YOUNG ADULTS AFTER ALLOGENEIC HSCT Marek Ussowicz (Wrocław, Poland) | 18:00 - 18:00 |
| B136 | RISK OF INFECTIONS AFTER CAR-T CELLS IS HIGH AND DIFFICULT-TO-PREDICT Héctor Cruz Barquín (Santander, Spain) | 18:00 - 18:00 |
| B137 | METAGENOMIC NEXT-GENERATION SEQUENCING AS A DIAGNOSTIC TOOL TO DETECT PATHOGENS IN IMMUNOCOMPROMISED PATIENTS WITH PULMONARY INFECTIONS - A SINGLE CENTER PROSPECTIVE STUDY Anna Ruckdeschel (Würzburg, Germany) | 18:00 - 18:00 |
| B139 | TRANSPLANTING THROUGH UNCERTAINTY: SINGLE CENTER EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SEVERE APLASTIC ANEMIA AND POSSIBLE PULMONARY INVASIVE FUNGAL INFECTION Ayad Ahmed Hussein (Amman, Jordan) | 18:00 - 18:00 |
| B140 | ACCURATE CMV IGG DETECTION USING BUCCAL SWABS IN STEM CELL DONOR SCREENING Alejandra Martinez Trillos (Barcelona, Spain) | 18:00 - 18:00 |
| B141 | LATE CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HSCT PERSISTS IN THE ERA OF LETERMIVIR PROPHYLAXIS - A SINGLE-CENTRE REAL WORLD STUDY Kirsty Sharplin (Oxford, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B142 | IMPACT OF HUMAN PARVOVIRUS B19 INFECTION ON THE OUTCOME OF PEDIATRIC HCT FOR HEMOGLOBINOPATHIES AND OTHER HEREDITARY ANEMIAS Stella Muscianisi (Pavia, Italy) | 18:00 - 18:00 |
| B143 | COMPARATIVE STUDY OF RESPIRATORY SYNCYTIAL VIRUS BURDEN AND TREATMENT POLICIES IN HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Justin du Toit (Johannesburg, South Africa) | 18:00 - 18:00 |
| B144 | HOW DO DEFINITIONS FOR NOSOCOMIAL INVASIVE ASPERGILLOSIS PERFORM IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS? Paulina Vega (Seattle, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B145 | CANADIAN SURVEY ON ANTIBACTERIAL PROPHYLAXIS AND FEBRILE NEUTROPENIA MANAGEMENT IN ADULT ALLOGENEIC | 18:00 - 18:00 |

HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS

Omar Eduardo Fernandes Vargas (Montreal, Canada)

- | | | |
|------|--|---------------|
| B146 | MANAGEMENT OF PROTRACTED CLOSTRIDIODES DIFFICILE INFECTION IN CHILDREN WITH GI-GVHD AFTER ALLOGENEIC HSCT: A SINGLE-CENTER PEDIATRIC EXPERIENCE Jaroslava Adamčáková (Bratislava, Slovakia) | 18:00 - 18:00 |
| B147 | MICAFUNGIN AS ANTIFUNGAL PROPHYLAXIS DURING THE PRE-ENGRAFTMENT PERIOD OF ALLO-HSCT. ANALYSIS OF A 450-PATIENT COHORT Bernardo Soto Román (Madrid, Spain) | 18:00 - 18:00 |
| B148 | SEROPREVALENCE OF HBV IN UNRELATED DONORS AT CONFIRMATORY TYPING STAGE AND ITS IMPACT ON THE CHOICE OF HEMATOPOIETIC CELL DONOR - DATA OF DKMS POLAND Przemyslaw Szymanski (Warsaw, Poland) | 18:00 - 18:00 |
| B149 | EPIDEMIOLOGY OF CATHETER-RELATED BLOODSTREAM INFECTIONS IN STEM CELL TRANSPLANTATION Elba Vélez Blanco (Santander, Spain) | 18:00 - 18:00 |
| B150 | REAL-WORLD UTILIZATION AND EFFICACY OF BIOEQUIVALENT GENERIC LETERMОВIR PROPHYLAXIS IN ALLOGENEIC HSCT RECIPIENTS: PEDIATRIC SUBGROUP ANALYSIS FROM DEFENDER STUDY Santanu Sen (Mumbai, India) | 18:00 - 18:00 |
| B151 | LETERMОВIR CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENIC HEMATOPOIETIC-CELL TRANSPLANTATION: REAL-WORLD EVIDENCE FROM HIGH-ENDEMIC REGION Vaibhav Chadha (New Delhi, India) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Graft-versus-host Disease - Clinical

- | | | |
|------|---|---------------|
| B001 | LOW-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FROM AN 10/10 HLA-IDENTICAL DONOR: A NEW PARADIGM? STUDY CONDUCTED ON BEHALF OF GETH-TC B. Herruzo (Málaga, Spain) | 18:00 - 18:00 |
| B002 | DECODING LONG-TERM IMMUNE SIGNATURE THROUGH AUTOANTIBODY EXPRESSION AS PERSISTENT IMMUNE SIGNALS IN POST-TRANSPLANT PAEDIATRIC ALL Anita Lawitschka (Vienna, Austria) | 18:00 - 18:00 |
| B003 | DUPILUMAB: EFFECTIVE AND SAFE ADDITION TO THE THERAPEUTIC ARMAMENTARIUM FOR PAEDIATRIC SKIN GVHD - A SINGLE CENTRE EXPERIENCE Kalasekhar Vijaya Sekharan (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B004 | REAL-WORLD RESULTS ON THE USE OF BELUMOSUDIL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC GVHD: THE ITALIAN RETROSPECTIVE ANALYSIS Francesca Bonifazi (Bologna, Italy) | 18:00 - 18:00 |
| B005 | KEY RESULTS FROM THE CHRONOS MULTICENTRE RETROSPECTIVE COHORT STUDY DESCRIBING PATIENT OUTCOMES IN THIRD-LINE ACUTE GASTROINTESTINAL GVHD Johannes Clausen (Linz, Austria) | 18:00 - 18:00 |
| B006 | PHASE 2 STUDY OF EXTRACORPOREAL PHOTOPHERESIS WITH | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | UVADEX™ PLUS STANDARD STEROID TREATMENT FOR HIGH-RISK ACUTE GRAFT-VERSUS-HOST DISEASE | |
| | Francis Ayuketang Ayuk (Hamburg, Germany) | |
| B007 | CLINICAL OUTCOMES AMONG PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE TREATED WITH AXATILIMAB: ANALYSIS OF AN EXPANDED ACCESS PROGRAM | 18:00 - 18:00 |
| | Anthony Stein (Duarte, CA, United States Minor Outlying Islands (the)) | |
| B008 | TWO-AGENT GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS WITH CYCLOPHOSPHAMIDE AND RUXOLITINIB: EXPERIENCE BEYOND THE CLINICAL TRIALS | 18:00 - 18:00 |
| | Ivan Moiseev (Saint Petersburg, Russian Federation (the)) | |
| B009 | ABATACEPT REDUCES ACUTE GVHD INCIDENCE AND IMPROVES GRFS IN PEDIATRIC PATIENTS TRANSPLANTED FROM AN HLA-MISMATCHED DONOR: A REAL-WORLD, MULTICENTER, RETROSPECTIVE STUDY | 18:00 - 18:00 |
| | Pietro Merli (Rome, Italy) | |
| B011 | A MULTICENTRE STUDY ON IN VIVO T-CELL DEPLETION PLATFORMS IN REDUCED-INTENSITY ALLOGENEIC STEM CELL TRANSPLANTS FOR HAEMATOLOGICAL MALIGNANCIES | 18:00 - 18:00 |
| | Rebecca Goodhew (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B012 | RESULTS OF ABATACEPT ADDITION TO POST TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS IN ALLOGENEIC HEMATOPOYETIC STEM CELL TRANSPLANTATION | 18:00 - 18:00 |
| | Lucia Castilla-Garcia (Madrid, Spain) | |
| B013 | BELUMOSUDIL FOR ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE: A SINGLE-CENTER REAL-WORLD STUDY OF EFFICACY AND SAFETY | 18:00 - 18:00 |
| | Heng Mei (Wuhan, China) | |
| B014 | REAL-WORLD SINGLE-CENTER EXPERIENCE OF ANTI-THYMOCYTE/ ANTI-T-LYMPHOCYTE GLOBULINS IN POST-TRANSPLANT CYCLOPHOSPHAMIDE CONDITIONINGS OF HAPLOIDENTICAL AND UNRELATED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SAFETY, EFFICACY, AND ENDOTHELIAL INJURY PROFILE | 18:00 - 18:00 |
| | Eleni Gavriilaki (Thessaloniki, Greece) | |
| B015 | ASSOCIATION BETWEEN ORAL CHRONIC GRAFT-VERSUS-HOST DISEASE AND THE GRAFT-VERSUS-LEUKEMIA EFFECT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE, SINGLE-CENTER OBSERVATIONAL STUDY | 18:00 - 18:00 |
| | Michael Loschi (Nice, France) | |
| B016 | THE COMBINATION OF RUXOLITINIB AND EXTRACORPOREAL PHOTOPHERESIS IS A HIGHLY EFFECTIVE SECOND LINE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 18:00 - 18:00 |
| | Nikolett Wohner (Budapest, Hungary) | |
| B017 | OUTCOMES IN TCRAB-DEPLETED HAPLOIDENTICAL TRANSPLANTATION WITH UPFRONT CD45RA-DEPLETED MEMORY T-CELL ADD-BACK: ANALYSIS OF 127 ADULTS WITH HEMATOLOGICAL MALIGNANCIES TREATED AT NATIONAL UNIVERSITY CANCER INSTITUTE, SINGAPORE | 18:00 - 18:00 |
| | Victor Wei Teik Ling (Singapore, Singapore) | |
| B018 | MESENCHYMAL STROMAL CELLS FOR THE TREATMENT STEROID REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN | 18:00 - 18:00 |
| | Krzysztof Czyzewski (Bydgoszcz, Poland) | |

| | | |
|------|---|---------------|
| B019 | BEYOND STATIC SNAPSHOTS: A DYNAMIC PREDICTION MODEL FOR ACUTE GRAFT-VERSUS-HOST DISEASE INTEGRATING SERIAL MEASUREMENTS OF SIX INFLAMMATORY BIOMARKERS Xiaoyu Zhang (Tianjin, China) | 18:00 - 18:00 |
| B020 | THE ROLE OF ADDING ANTITHYMOCYTE GLOBULIN TO STANDARD GVHD PROPHYLAXIS IN HLA ONE-LOCUS-MISMATCHED UNRELATED BONE MARROW TRANSPLANTATION: A RANDOMIZED MULTICENTER PHASE III TRIAL Junya Kanda (Kyoto, Japan) | 18:00 - 18:00 |
| B021 | 3X3 COMPARISON OF TACROLIMUS, SIROLIMUS AND MYCOPHENOLATE MOPHETIL (MMF) VS POSTRASPLANT CYCLOPHOSPHAMIDE (PT-CY), TACROLIMUS AND MMF VS PT-CY, SIROLIMUS AND MMF. A RETROSPECTIVE ANALYSIS (GETH-TC) José Antonio Pérez Simón (Sevilla, Spain) | 18:00 - 18:00 |
| B022 | ST2 AND REG3A IN GRAFT VERSUS HOST DISEASE Dan Le (Melbourne, Australia) | 18:00 - 18:00 |
| B023 | GRAFT-VERSUS-HOST DISEASE IN THE CENTRAL NERVOUS SYSTEM - EMERGING PROBLEM OF MODERN HSCT TECHNOLOGY Natalia Bronina (Moscow, Russian Federation (the)) | 18:00 - 18:00 |
| B024 | SKIN RESPONSES USING MODIFIED CRITERIA AMONG PATIENTS WITH SCLEROTIC CHRONIC GRAFT-VERSUS-HOST DISEASE TREATED WITH AXATILIMAB IN THE AGAVE-201 TRIAL Britnie Thomas (Wilmington, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B028 | A MODIFIED PEDIATRIC DAY 100 SCORE TO PREDICT MODERATE TO SEVERE CGVHD, TRANSPLANT-RELATED MORTALITY, AND OUTCOME AFTER HEMATOPOIETIC CELL TRANSPLANTATION Sonia Bonanomi (Monza, Italy) | 18:00 - 18:00 |
| B029 | SERUM CHOLINESTERASE AS A LOW-COST, ROUTINELY AVAILABLE BIOMARKER FOR ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE IN CHILDREN Wiebke Jünemann (Hamburg, Germany) | 18:00 - 18:00 |
| B030 | HUMANIZED ANTI-CD25 MONOCLONAL ANTIBODY FOR GVHD PROPHYLAXIS IN ELDERLY HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION: A PHASE II STUDY Xiaoyu Zhang (Tianjin, China) | 18:00 - 18:00 |
| B031 | ABSOLUTE LYMPHOCYTE COUNT AT ANTI-T-LYMPHOCYTE GLOBULIN DOES NOT PREDICT GVHD INCIDENCE AND GVHD/RELAPSE FREE SURVIVAL AFTER MATCHED UNRELATED DONOR TRANSPLANTATION: A TWO-CENTER VALIDATION STUDY Radwan Massoud (Hamburg, Germany) | 18:00 - 18:00 |
| B033 | SAFETY AND FEASIBILITY OF 0.6 MG/KG EVERY 4 WEEKS DOSING OF AXATILIMAB IN PATIENTS TREATED IN THE AGAVE-201 STUDY María Sola Soto (Barcelona, Spain) | 18:00 - 18:00 |
| B034 | ASSESSMENTS OF BONE HEALTH AMONG PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE RECEIVING AXATILIMAB IN THE AGAVE-201 TRIAL Doris M. Ponce (New York, NY, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B035 | OUTCOMES OF PATIENTS DIAGNOSED WITH STEROID-REFRACTORY OR DEPENDENT ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE RESISTANT OR INTOLERANT TO SECOND- | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | LINE RUXOLITINIB: A RETROSPECTIVE STUDY FROM THE GETH-TC | |
| | María Sola Soto (Barcelona, Spain) | |
| B036 | IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSE REDUCTION ON THE INCIDENCE OF COMPLICATIONS AND RELAPSE AFTER ALLOGENEIC TRANSPLANTATION | 18:00 - 18:00 |
| | María Panizo-Inogés (Pamplona, Spain) | |
| B037 | MISSED AND DELAYED GENITAL GVHD: ORAL INVOLVEMENT AS A CLINICAL BIOMARKER FOR EARLY DETECTION | 18:00 - 18:00 |
| | Valle Gómez-García de Soria (Madrid, Spain) | |
| B039 | REDUCED-DOSE POST TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: LEARNINGS FOR THE FUTURE | 18:00 - 18:00 |
| | Rohan Halder (New Delhi, India) | |
| B042 | A SINGLE TRANSPLANT PROGRAM EXPERIENCE IN TERMS OF GVHD PROPHYLAXIS: IS LESS DOSES OF METHOTREXATE BETTER THAN MORE? | 18:00 - 18:00 |
| | Cristina Luise (Naples, Italy) | |
| B043 | SYSTEMIC TREATMENT WITH THE ROCK2 INHIBITOR BELUMOSUDIL IN OCULAR CHRONIC GRAFT VERSUS HOST DISEASE | 18:00 - 18:00 |
| | Yibo Wu (Hangzhou, China) | |
| B044 | DONOR- AND DOSE- SPECIFIC ENDOTHELIAL ACTIVATION AND CLINICAL OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE | 18:00 - 18:00 |
| | M Queralt Salas (Barcelona, Spain) | |
| B045 | EFFICACY OF CNI-FREE GVHD PROPHYLAXIS IN PEDIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER PRIOR MONOCLONAL ANTIBODY THERAPY | 18:00 - 18:00 |
| | Tatiana Bykova (Saint-Petersburg, Russian Federation (the)) | |
| B046 | VIRAL INFECTION WITHIN STEROID REFRACTORY/DEPENDENT GVHD PATIENTS TREATED WITH RUXOLITINIB: A SINGLE CENTER ANALYSIS | 18:00 - 18:00 |
| | Silvia Zanon (Brescia, Italy) | |
| B047 | BENEFITS OF A MULTIDISCIPLINARY COMMITTEE FOR THE TREATMENT OF CHRONIC GVHD: CASE REPORTS AS A PARADIGM FOR COLLABORATIVE CARE | 18:00 - 18:00 |
| | David Gomez Rocha (Madrid, Spain) | |
| B048 | EFFICACY AND SAFETY OF BELUMOSUDIL-ECP (EXTRACORPOREAL PHOTOPHERESIS) COMBINATION THERAPY IN REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AND CORRELATION WITH CYTOKIN KINETIC: A SINGLE-CENTER RETROSPECTIVE STUDY | 18:00 - 18:00 |
| | Patrizia Chiusolo (Roma, Italy) | |
| B049 | BELUMOSUDIL TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: REAL-WORLD CLINICAL DATA FROM FRANCE | 18:00 - 18:00 |
| | Florent Malard (Paris, France) | |
| B050 | MORTALITY BY ORGAN-SPECIFIC FIBROTIC MANIFESTATIONS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE IN THE UNITED STATES | 18:00 - 18:00 |
| | Alyshah Abdul Sultan (Morristown, United States Minor Outlying Islands (the)) | |

| | | |
|------|--|---------------|
| B051 | SAFETY AND TOLERABILITY OF A CANNABIS-BASED OIL EXTRACT IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION - A PHASE I STUDY Juliana Matos Pessôal (São Paulo, Brazil) | 18:00 - 18:00 |
| B052 | PROPHYLACTIC TOCILIZUMAB FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN MATERNAL HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-ARM STUDY Yibo Wu (Hangzhou, China) | 18:00 - 18:00 |
| B053 | ABATACEPT FOR GVHD PROPHYLAXIS IN PEDIATRIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM SAUDI ARABIA Hawazen Alsaedi (Riyadh, Saudi Arabia) | 18:00 - 18:00 |
| B054 | PET-CT AND CHRONIC GVHD: A DIAGNOSTIC TOOL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ? A PROSPECTIVE INTERVENTIONAL STUDY WITHIN CHU CAEN NORMANDY, FRANCE Quentin Levesque (Caen, France) | 18:00 - 18:00 |
| B055 | REAL-WORLD EFFICACY AND TOXICITY PROFILE OF RUXOLITINIB IN PEDIATRIC ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE: A MULTICENTER RETROSPECTIVE STUDY Andrea Buonsante (Monza, Italy) | 18:00 - 18:00 |
| B056 | "EFFECT OF REDUCING THE DOSES OF CYCLOPHOSPHAMIDE ON OUTCOMES AND ON IMMUNE RECOVERY" Francisco Manuel Martín Domínguez (Seville, Spain) | 18:00 - 18:00 |
| B057 | RUXOLITINIB UTILIZATION IN STEROID-REFRACTORY GVHD DURING THE PTCY ERA: A COMPARATIVE ANALYSIS WITH AN HISTORICAL ATG COHORT Riccardo Marmoni (Brescia, Italy) | 18:00 - 18:00 |
| B058 | CLINICAL FEATURES AND OUTCOME OF CHRONIC GVHD IN PEDIATRIC PATIENTS: A MULTICENTER STUDY ON BEHALF OF THE SPANISH GROUP FOR HEMATOPOIETIC TRANSPLANTATION AND CELL THERAPY(GETH-TC) Laura Alonso Garcia (Barcelona, Spain) | 18:00 - 18:00 |
| B059 | CHARACTERISTICS OF CLINICAL TRIALS IN GRAFT-VERSUS-HOST DISEASE: LANDSCAPE OF STUDY DRUGS AND ASSESSMENT OF OUTCOME MEASURES Hanna A. Knaus (Vienna, Austria) | 18:00 - 18:00 |
| B060 | IMPACT OF ANTI-T-LYMPHOCYTE GLOBULIN DOSING ON GRAFT VERSUS HOST DISEASE IN MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION Radwan Massoud (Hamburg, Germany) | 18:00 - 18:00 |
| B061 | SAFETY AND EFFICACY OF ABATACEPT IN THE MANAGEMENT OF STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE. A SINGLE CENTER EXPERIENCE Panagiotis Dolgyras (Thessaloniki, Greece) | 18:00 - 18:00 |
| B064 | OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS WITH PERI-TRANSPLANT-RUXOLITINIB PROPHYLAXIS Miriam Mozaffari Jovein (Freiburg im Breisgau, Germany) | 18:00 - 18:00 |
| B065 | IMPACT OF PULMONARY FUNCTION TESTING ON BRONCHIOLITIS OBLITERANS SYNDROME AND OUTCOME AFTER | 18:00 - 18:00 |

| | | |
|--|--|---------------|
| | HEMATOPOIETIC STEM CELL TRANSPLANT Rosa De Francesco (Tricase, Italy) | |
| B066 | LOW-DOSE WEEKLY CIDOFOVIR AS AN EFFECTIVE PROPHYLACTIC ALTERNATIVE TO LETERMOVIR FOR PRE-ENGRAFTMENT CMV IN ALLOGENEIC HSCT Santanu Sen (Mumbai, India) | 18:00 - 18:00 |
| B067 | DESCRIPTION OF CHRONIC GRAFT VERSUS HOST DISEASE USING AN INNOVATIVE ARTIFICIAL INTELLIGENCE NATURAL LANGUAGE PROCESSING ON ELECTRONIC MEDICAL RECORDS FROM 8 CENTERS IN FRANCE Darko Kiprijanovski (Paris, France) | 18:00 - 18:00 |
| B068 | EFFECTIVENESS AND SAFETY OF BELUMOSUDIL FOR CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE STUDY FROM CHINA Hailong Yuan (Xinjiang, China) | 18:00 - 18:00 |
| B069 | EARLY RUXOLITINIB USE IN MODERATE-TO-SEVERE PULMONARY CHRONIC GRAFT-VERSUS-HOST DISEASE: A CASE SERIES Andrés Yesid Bonilla-Salcedo (Mexico City, Mexico) | 18:00 - 18:00 |
| <i>Printed Poster</i> 18:00 - 19:00 | | R1 |
| Myelofibrosis, Chronic Myeloid Leukaemia and Other Myeloproliferative Disorders | | |
| B422 | PELABRESIB PLUS RUXOLITINIB AS BRIDGING THERAPY TO HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: INSIGHTS FROM MANIFEST AND MANIFEST-2 STUDIES Michael Loschi (Nice, France) | 18:00 - 18:00 |
| B424 | HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MYELOFIBROSIS: A CHINESE MULTICENTER RETROSPECTIVE STUDY Yuqian Sun (Beijing, China) | 18:00 - 18:00 |
| B425 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS: PATTERNS AND OUTCOME AFTER RELAPSE AND LONG-TERM FOLLOW UP Avichai Shimoni (Tel-Hashomer, Israel) | 18:00 - 18:00 |
| B426 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELOFIBROSIS USING POST-TRANSPLANT CYCLOPHOSPHAMIDE: PRELIMINARY RESULTS FROM THE GETH-TC CLINICAL PRACTICE PROTOCOL Juan Carlos Hernandez-Boluda (Valencia, Spain) | 18:00 - 18:00 |
| B427 | MTSS PREDICTS OUTCOME OF HAPLO-SCT IN MYELOFIBROSIS Judith Metzdorf (Essen, Germany) | 18:00 - 18:00 |
| B428 | LONG-TERM MINIMAL RESIDUAL DISEASE MONITORING BY DIGITAL DROPLET PCR AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS IS PREDICTIVE OF RELAPSE: A RETROSPECTIVE AND PROSPECTIVE STUDY Maria Chiara Finazzi (Bergamo, Italy) | 18:00 - 18:00 |
| B429 | HAPLOIDENTICAL STEM CELL TRANSPLANTATION USING NOVEL PROTOCOL DEMONSTRATED EXCELLENT OUTCOMES FOR PATIENTS WITH MYELOFIBROSIS Yuqian Sun (Beijing, China) | 18:00 - 18:00 |
| B430 | THE EFFICACY AND SAFETY OF PD-1 MONOCLONAL ANTIBODY | 18:00 - 18:00 |

| | | |
|-------------------------|--|---------------|
| | IN THE TREATMENT OF HEMOPHAGOCYTIC SYNDROME □ SYSTEMATIC REVIEW | |
| | Shaoyan Hu (Suzhou, China) | |
| B431 | INCIDENCE, CLINICAL OUTCOME, AND THERAPEUTIC IMPLICATIONS OF RELAPSE AFTER ALLOGENIC STEM CELL TRANSPLANTATION FOR PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS | 18:00 - 18:00 |
| | Chiara Camerini (Florence, Italy) | |
| B432 | REDUCED-INTENSITY HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH ADVANCED MYELOFIBROSIS | 18:00 - 18:00 |
| | Monzr Al Malki (Duarte, United States Minor Outlying Islands (the)) | |
| B433 | INFLUENCE OF HLA-DPB MATCHING ON OUTCOMES AFTER ALLO-HSCT FOR MYELOFIBROSIS | 18:00 - 18:00 |
| | Mathias Schäfersküpfer (Hamburg, Germany) | |
| B434 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS: A SINGLE-CENTER RETROSPECTIVE STUDY | 18:00 - 18:00 |
| B435 | POOR GRAFT FUNCTION FOLLOWING ALLOGENIC STEM CELL TRANSPLANTATION FOR PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: INCIDENCE, RISK FACTORS, AND PROGNOSTIC IMPLICATIONS FROM A SINGLE-CENTER EXPERIENCE | 18:00 - 18:00 |
| | Edoardo Simonetti (Florence, Italy) | |
| <i>Printed Poster</i> | | |
| | 18:00 - 19:00 | R1 |
| Multiple Myeloma | | |
| B406 | INTENSIFIED CONSOLIDATION WITH TANDEM AUTOLOGOUS VERSUS AUTOLOGOUS/REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION FROM RELATED OR UNRELATED DONORS IN FIRST-LINE THERAPY IN 149 HIGH-RISK MYELOMA PATIENTS | 18:00 - 18:00 |
| | Song-Yau Wang (Leipzig, Germany) | |
| B407 | UPDATED EXPLORATORY MULTIVARIABLE ANALYSES DEMONSTRATE DIFFERENTIAL IMPACT OF DUFFY GENOTYPE ON PROGRESSION-FREE SURVIVAL WITH LENALIDOMIDE-BORTEZOMIB-DEXAMETHASONE (RVD) ALONE OR RVD+ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) | 18:00 - 18:00 |
| | Paul G. Richardson (Boston, United States Minor Outlying Islands (the)) | |
| B408 | SOLUBLE BCMA AS AN EMERGING BIOMARKER IN BCMA T-CELL-REDIRECTING THERAPIES | 18:00 - 18:00 |
| | Adolfo Fernández Sánchez (Salamanca, Spain) | |
| B409 | THE EXPERIENCE OF AUTOSCT IN PATIENTS WITH MULTIPLE MYELOMA ON DIALYSIS | 18:00 - 18:00 |
| | Ekaterina Karimova (Moscow, Russian Federation (the)) | |
| B410 | BORTEZOMIB MAINTENANCE AFTER ALLOGENEIC TRANSPLANT IN NEWLY DIAGNOSED MYELOMA PATIENTS: LESS CHRONIC GVHD BUT NO IMPACT ON SURVIVAL | 18:00 - 18:00 |
| | Jean Roy (Montréal, Canada) | |
| B411 | AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: A 10-YEAR SINGLE-CENTER EXPERIENCE | 18:00 - 18:00 |
| | Evgeniia Zhelnova (Moscow, Russian Federation (the)) | |

| | | |
|--|---|---------------|
| B412 | PROGNOSTIC DIFFERENCES AMONG PATIENTS WITH MULTIPLE MYELOMA UNDERGOING UPFRONT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPAN, TAIWAN, AND MALAYSIA: IMPACT OF PRE-TRANSPLANT PI/IMID-BASED THERAPIES Hiroyuki Takamatsu (Kanazawa, Japan) | 18:00 - 18:00 |
| B413 | COMPARISON OF DARA-VTD AND TRIPLE THERAPY AS INDUCTION REGIMENS PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA Maciej Sławomir Tomasiewicz (Wrocław, Poland) | 18:00 - 18:00 |
| <i>Printed Poster</i> | | |
| 18:00 - 19:00 | | |
| Solid Tumours | | |
| B436 | SEQUENCE ORDER IN BU MEL CONDITIONING FAILS TO PREDICT SURVIVAL: PK AND OUTCOME DATA FROM A PEDIATRIC NEUROBLASTOMA AND EWING SARCOMA COHORT Srijib Mukherjee (Westmead, Australia) | 18:00 - 18:00 |
| <i>Printed Poster</i> | | |
| 18:00 - 19:00 | | |
| Chronic Lymphocytic Leukemia | | |
| B405 | OUTCOME OF SINGLE- AND DOUBLE-REFRACTORY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): THE IMPACT OF CELLULAR THERAPY Peter Dreger (Heidelberg, Germany) | 18:00 - 18:00 |
| <i>Printed Poster</i> | | |
| 18:00 - 19:00 | | |
| Immune Reconstitution and Chimerism | | |
| B186 | IMMUNE RECONSTITUTION DURING MAINTENANCE THERAPY WITH AZACITIDINE AFTER ALLOGENEIC HCT Laura Pedretti (Bologna, Italy) | 18:00 - 18:00 |
| B187 | PREVALENCE AND LONG-TERM CLINICAL IMPACT OF SELECTIVE IGA DEFICIENCY FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY: A RETROSPECTIVE COHORT ANALYSIS Sravani Vemuri (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B188 | CHARACTERIZING THERAPEUTIC ENDPOINTS AND EFFICACY OF PRE-EMPTIVE DONOR LYMPHOCYTE INFUSION FOR MIXED LYMPHOID CHIMERISM POST-ALLOGENEIC STEM CELL TRANSPLANT: A FOUR-YEAR SINGLE-CENTRE RETROSPECTIVE ANALYSIS Kinda Al-Hourani (Glasgow, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B189 | BONE MARROW ASPIRATIONS (BMAS) AFTER DONOR LYMPHOCYTE INFUSION (DLI): ARE ROUTINE FOLLOW-UPS NECESSARY FOR ALL PATIENTS? Sophie Bertorelli (Cardiff, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B190 | LETERMOVIR PROPHYLAXIS RESHAPES EARLY IMMUNE RECONSTITUTION AND CMV/EBV REACTIVATION DYNAMICS AFTER ALLOGENEIC HSCT Wei Zhao (Beijing, China) | 18:00 - 18:00 |
| B191 | DEEP IMMUNOPHENOTYPING IDENTIFIES DIFFERENTIAL | 18:00 - 18:00 |

IMMUNE PROFILES IN RECIPIENTS OF DONOR LYMPHOCYTE INFUSIONS

Jennifer Vidler (London, United Kingdom of Great Britain and Northern Ireland (the))

- | | | |
|------|---|---------------|
| B192 | BONE MARROW GRAFTS SUPPORT BROADER EARLY T-CELL AND ANTIVIRAL REPERTOIRE RECOVERY AFTER HAPLOIDENTICAL HSCT WITH PTCY | 18:00 - 18:00 |
| | Amandine Pradier (Geneva, Switzerland) | |
| B193 | A RANDOMIZED PILOT TRIAL OF CLOSTRIDIUM BUTYRICUM MIYARI 588 IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS | 18:00 - 18:00 |
| | Ryotaro Nakamura (Duarte, United States Minor Outlying Islands (the)) | |
| B194 | DETERMINANTS OF ENGRAFTMENT INSTABILITY IN SICKLE CELL DISEASE: IDENTIFYING MODIFIABLE AND EARLY PREDICTORS OF MIXED CHIMERISM AFTER CURATIVE TRANSPLANTATION | 18:00 - 18:00 |
| | Alexander Ngwube (Houston, United States Minor Outlying Islands (the)) | |
| B195 | DIFFERENTIAL IMMUNE RECONSTITUTION ACROSS AGE GROUPS AFTER ALLO-HSCT: A LONGITUDINAL ANALYSIS OF PEDIATRIC, ADULT, AND ELDERLY PATIENTS | 18:00 - 18:00 |
| | Wei Zhao (Beijing, China) | |
| B196 | IMMUNE RECONSTITUTION AFTER HAPLOIDENTICAL PBSCT IN PAEDIATRIC B AND T-ALL: A COMPARATIVE STUDY OF PATIENTS WITH AND WITHOUT PRIOR CAR-T THERAPY | 18:00 - 18:00 |
| | Jann Adriel Sy (Singapore, Singapore) | |
| B197 | DAY 30 MIXED DONOR CHIMERISM DOES NOT PREDICT RELAPSE IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML AND MDS | 18:00 - 18:00 |
| | Carol Herrera Hernández (Las Palmas de Gran Canaria, Spain) | |
| B198 | PROLONGED HYPOGAMMAGLOBULINEMIA IN PATIENTS WITH INBORN ERRORS OF IMMUNITY (IEI) AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) | 18:00 - 18:00 |
| | Yulia Rodina (Moscow, Russian Federation (the)) | |
| B199 | THREE-MONTH WHOLE BLOOD AND T-CELL CHIMERISM INDEPENDENTLY PREDICT RELAPSE AND SURVIVAL FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTS FOR HAEMATOLOGICAL CANCERS: A MULTICENTRE ANALYSIS | 18:00 - 18:00 |
| | Rebecca Goodhew (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B200 | SUCCESSFUL TREATMENT OF TRANSPLANTED PID PATIENTS WITH SPLIT CHIMERISM USING CD34+POSITIVELY-SELECTED HSPCS AFTER CONDITIONING WITH REDUCED-TOXICITY TARGETED BUSULFAN ALONE | 18:00 - 18:00 |
| | Pik Ki Chan (Zurich, Switzerland) | |
| B201 | FROM IMMUNODEFICIENCY TO MALIGNANCY: SUCCESSFUL ALLOGENEIC HSCT IN NIJMEGEN BREAKAGE SYNDROME WITH LATE RELAPSE T-ALL | 18:00 - 18:00 |
| | Sabina Kardovskaya (Moscow, Russian Federation (the)) | |
| B202 | CLINICAL SIGNIFICANCE OF DONOR-RECIPIENT ABO MISMATCH IN SURVIVAL AND IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - SINGLE CENTRE EXPERIENCE (CIC 1085) | 18:00 - 18:00 |
| | Yavor Petrov (Varna, Bulgaria) | |

Printed Poster

18:00 - 19:00

R1

B cell Non Hodgkin Lymphoma

- B394 **PHASE 2 ELARA TRIAL FINAL ANALYSIS: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)** 18:00 - 18:00
Joaquín Martínez (Madrid, Spain)
- B395 **REAL-WORLD STUDY OF SECOND-LINE LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL EFFECTIVENESS, SAFETY, AND HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA** 18:00 - 18:00
Farah Toron (Uxbridge, United Kingdom of Great Britain and Northern Ireland (the))
- B396 **ALLOGENEIC TRANSPLANTATION AFTER FAILURE OF CAR-T CELLS AND EXPOSURE TO BISPECIFIC ANTIBODIES: FEASIBILITY, SAFETY AND SURVIVAL OUTCOMES** 18:00 - 18:00
Giorgia Gobbi
- B397 **ALLOGENEIC TRANSPLANTATION OUTCOMES IN PATIENTS WITH HIGH-GRADE LYMPHOMA AFTER RELAPSE FOLLOWING CAR-T THERAPY: A MULTICENTER RETROSPECTIVE COMPARATIVE STUDY** 18:00 - 18:00
Araceli Salamanca Cuenca (Jerez de la Frontera, Spain)
- B398 **AUTOLOGOUS STEM CELL TRANSPLANTATION WITH REDUCED-DOSE THIOTEPA CONDITIONING IN PRIMARY CNS LYMPHOMA: SAFETY AND OUTCOMES IN A REAL-WORLD COHORT** 18:00 - 18:00
Giovanni Grillo (Milan, Italy)
- B400 **POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD): RESULTS OF THE MULTICENTER OBSERVATIONAL RETROSPECTIVE COHORT STUDY OF THE ITALIAN LYMPHOMA FOUNDATION (FIL_PTLD)** 18:00 - 18:00
Chiara Consoli (Torino, Italy)
- B401 **PREDOMINANCE OF CD4+ T-CELLS IS ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL** 18:00 - 18:00
Jorge Illarramendi (Pessac, France)
- B402 **EFFICACY AND SAFETY OF ENSARTINIB-BASED REGIMENS IN ALK-POSITIVE LYMPHOMA: A REAL-WORLD RETROSPECTIVE STUDY** 18:00 - 18:00
Xiaorui Fu (Zhengzhou, China)
- B403 **LONG-TERM FOLLOW-UP OF CD19 CAR-T FOR R/R B-NHL: KI-67 AS A PROGNOSTIC FACTOR FOR SUSTAINED REMISSION** 18:00 - 18:00
Yinghui Yu (Hangzhou, China)

Printed Poster

18:00 - 19:00

R1

Inborn error of immunity, hematopoiesis and metabolism

- B370 **HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCIES IN CHILDREN: THE UKRAINIAN EXPERIENCE (2018-2025)** 18:00 - 18:00
Oleksandr Istomin (Kyiv, Ukraine)
- B371 **OUTCOMES OF ALLOGENEIC HSCT IN NIJMEGEN BREAKAGE SYNDROME WITH TREOSULFAN-BASED CONDITIONING REGIMEN - A MULTICENTER STUDY** 18:00 - 18:00
Alexandra Laberko (Saint-Petersburg, Russian Federation (the))

| | | |
|------|---|---------------|
| B372 | FACTORS ASSOCIATED WITH MIXED CHIMERISM IN CHILDREN WITH NON-MALIGNANT DISEASES TRANSPLANTED WITH A TREOSULFAN- BASED REGIMEN Etai Adam (Tel Aviv, Israel) | 18:00 - 18:00 |
| B373 | MULTICENTER EXPERIENCE OF HSCT IN RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISEASE (RALD) - IEWP EBMT STUDY Alexandra Laberko (Saint-Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| B374 | OUTCOMES OF LATE-ONSET KRABBE DISEASE TREATED WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE-CENTRE EXPERIENCE Callum Fernando (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B375 | HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IN NEUROPATHIC MUCOPOLYSACCHARIDOSIS TYPE-II (MPS-II) PRESERVES NEURODEVELOPMENT AND SHOULD BE ROUTINE PRACTICE Osama Mansour (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B376 | IMPAIRED P53-MEDIATED DNA DAMAGE RESPONSE IN A HUMAN ETV6::RUNX1 IPSC MODEL SHOWS GENOMIC INSTABILITY IN PRE-LEUKEMIC CELLS Petra Gesine Koegler (Düsseldorf, Germany) | 18:00 - 18:00 |
| B377 | GLOBALISING HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY: A UK-INDIA MULTICENTRE EXPERIENCE Divij Sachdeva (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B378 | FIRST REPORTED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) FOR RAD50 DEFICIENCY: INITIAL CLINICAL EXPERIENCE IN TWO PEDIATRIC PATIENTS Alexandra Shutova (Moscow, Russian Federation (the)) | 18:00 - 18:00 |
| B379 | SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH WOLMAN DISEASE REFRACTORY TO HIGH-DOSE ENZYME REPLACEMENT THERAPY: COMPLETE DONOR CHIMERISM AND SUSTAINED METABOLIC RECOVERY Burcu Akıncı (İstanbul, Turkey) | 18:00 - 18:00 |
| B380 | HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY: IMPACT OF CONDITIONING REGIMENS Gizem Zengin Ersoy (İstanbul, Turkey) | 18:00 - 18:00 |
| B381 | ALLOGENEIC STEM CELL TRANSPLANTATION AS A CURATIVE STRATEGY FOR PYRUVATE KINASE DEFICIENCY: A SINGLE-CENTER EXPERIENCE Anna Osipova (Saint-Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| B383 | SUCCESSFUL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH IMMUNODEFICIENCY ASSOCIATED WITH ITGB4 MUTATION: EXPANDING THE PHENOTYPE Neeraj Teotia (Gurugram, India) | 18:00 - 18:00 |
| B384 | SINGLE CENTER EXPERIENCE OF ALLOGENEIC HSCT WITH POSTTRANPLANT CYCLOPHOSPHAMIDE IN INBORN ERRORS OF IMMUNITY Alexandra Laberko (Saint-Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| B385 | CLINICAL PICTURE AND IMMUNE RECONSTITUTION POST-HAEMATOPOIETIC CELL TRANSPLANTATION IN PAEDIARIC PATIENTS WITH CHRONIC GRANULOMATOUS DISEASE - LATIN | 18:00 - 18:00 |

AMERICAN SINGLE EXPERIENCE

Maria Pilar Tejada (Ciudad Autónoma de Buenos Aires, Argentina)

- B386 **SUCCESSFUL CORD BLOOD TRANSPLANTATION IN AN INFANT WITH LEUKOCYTE ADHESION DEFICIENCY TYPE III: A CASE REPORT AND 1 YEAR FOLLOW-UP** 18:00 - 18:00
Marianna Maffeis (Brescia, Italy)

Printed Poster

18:00 - 19:00

R1

Haemoglobinopathies

- B350 **THE NEED FOR A SUBSEQUENT HCT IS A LATE & CONTINUOUS RISK AND WITH SIGNIFICANT IMPACT IN OVERALL SURVIVAL IN HAEMOGLOBINOPATHIES: AN ANALYSIS OF HWP** 18:00 - 18:00
Josu de la Fuente (London, United Kingdom of Great Britain and Northern Ireland (the))
- B351 **EARLY DETECTION OF CLONAL HEMATOPOIESIS IN SICKLE CELL DISEASE: RESULTS FROM AN ACTIVELY MONITORED COHORT** 18:00 - 18:00
Alice Corsia (Paris, France)
- B352 **TREOSULFAN-BASED CONDITIONING IS ASSOCIATED WITH BETTER OUTCOMES IN ADOLESCENTS AND YOUNG ADULTS UNDERGOING MATCHED RELATED DONOR TRANSPLANTATION FOR THALASSEMIA MAJOR** 18:00 - 18:00
Mithun Abraham Prakash (Ranipet, India)
- B354 **POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS ATG AS GVHD PROPHYLAXIS IN MATCHED SIBLING DONOR PBSC TRANSPLANTATION FOR B-THALASSEMIA MAJOR - A SINGLE CENTER EXPERIENCE** 18:00 - 18:00
Reham Khalaf (Cairo, Egypt)
- B355 **ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC HEMOGLOBINOPATHIES: LONG-TERM OUTCOMES IN A LARGE SINGLE-CENTER COHORT** 18:00 - 18:00
Patrizia Comoli (Pavia, Italy)
- B356 **RELIABLE ENGRAFTMENT AND COMPARABLE OUTCOMES ACROSS DONOR SOURCES WITH BUSULFAN65-FLUDARABINE-THIOTEPA CONDITIONING IN PAEDIATRIC SICKLE CELL DISEASE** 18:00 - 18:00
Anna-Lisa Lanz (Munich, Germany)
- B358 **THE IMPACT OF TREOSULPHAN-BASED CONDITIONING AND INTEGRATED FOLLOW UP IMPROVES EVENT FREE SURVIVAL IN CHILDREN UNDERGOING HSCT FOR SICKLE CELL DISEASE** 18:00 - 18:00
Revathi Raj (Chennai, India)
- B360 **LONG TERM FOLLOW-UP OF THALASSEMIA PATIENTS SHOWS REASONABLE OUTCOMES AFTER TRANSPLANTATION- A SINGLE CENTER EXPERIENCE FROM INDIA** 18:00 - 18:00
Rohan Halder (New Delhi, India)
- B361 **TREOSULFAN BASED MYELOABLATIVE CONDITIONING IN ADOLESCENT AND ADULT PATIENTS WITH HEMOGLOBINOPATHY** 18:00 - 18:00
Stephanie Leszczak (Regensburg, Germany)
- B362 **ESTABLISHING PRE-TRANSPLANT AUTOMATED RED CELL EXCHANGE FOR SICKLE CELL DISEASE: SAFETY AND FEASIBILITY RESULTS FROM A START-UP HSCT PROGRAM IN TANZANIA** 18:00 - 18:00
Antonella Capasso (Monza, Italy)

| | | |
|------|---|---------------|
| B363 | HIGH PLATELET TRANSFUSION BURDEN FLAGS ENDOTHELIAL RISK BUT NOT GVHD, AFTER PEDIATRIC SICKLE CELL HSCT Hailey Tinsley (Houston, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B364 | 63 HLA-IDENTICAL RELATED HAEMOTOPOIETIC STEM CELL TRANSPLANTS IN SICKLE CELL DISEASE Eduardo J. Bardón-Cancho (Madrid, Spain) | 18:00 - 18:00 |
| B365 | CORRELATION OF HB S LEVEL WITH CHIMERISM POST BONE MARROW TRANSPLANT IN PATIENT WITH SICKLE CELL DISEASE | 18:00 - 18:00 |
| B366 | DIFFERENT APPROACHES TO HSCT IN TRANSFUSION-DEPENDENT B-THALASSEMIA Gleb Bronin (Tashkent, Uzbekistan) | 18:00 - 18:00 |
| B367 | THIRTY YEARS LATER: UNEXPECTED, UNHERALDED, AND UNEXPLAINED RE-EMERGENCE OF THALASSEMIA FOLLOWING LONG-TERM ALLOGENEIC ENGRAFTMENT Valeria Maria Pinto (Genoa, Italy) | 18:00 - 18:00 |
| B368 | HLA-MATCHED RELATED DONOR TRANSPLANTATION IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSAEMIA: A SINGLE-CENTRE EXPERIENCE IN A RESOURCE-LIMITED SETTING - LADY RIDGEWAY HOSPITAL FOR CHILDREN, SRI LANKA Shanika Vitharana (Colombo, Sri Lanka) | 18:00 - 18:00 |
| B369 | HAPLOIDENTICAL STEM CELL TRANSPLANTATION AS A CURATIVE STRATEGY FOR SEVERE SICKLE CELL DISEASE: A SINGLE-CENTER REPORT Teresa Martín Aláez (Madrid, Spain) | 18:00 - 18:00 |

Printed Poster

18:00 - 19:00

R1

Hodgkin Lymphoma and T cell Lymphoma

| | | |
|------|---|---------------|
| B387 | PD-1 INHIBITOR PROLGOLIMAB ACHIEVES HIGH RESPONSE RATE BUT AUTO-HCT REMAINS ESSENTIAL FOR SUSTAINED PROLONGED REMISSION IN SECOND-LINE TREATMENT OF RELAPSED/REFRACTORY HODGKIN LYMPHOMA (PROLGO-HL) Liudmila Fedorova (St. Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| B388 | FIVE-YEAR FOLLOW-UP OF NIVOLUMAB-BASED COMBINATIONS AND TRANSPLANT STRATEGY AFTER PD-1 INHIBITOR FAILURE IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA Liudmila Fedorova (St. Petersburg, Russian Federation (the)) | 18:00 - 18:00 |
| B389 | AUTOLOGOUS TRANSPLANT IN T-CELL LYMPHOMAS Cristian Rodriguez (Córdoba, Argentina) | 18:00 - 18:00 |
| B391 | THE ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADVANCED PRIMARY CUTANEOUS T-CELL LYMPHOMA - A MULTICENTER RETROSPECTIVE ANALYSIS Moritz Schmidt (Munich, Germany) | 18:00 - 18:00 |
| B392 | A COMPARATIVE ANALYSIS OF TRANSFORMED HODGKIN'S LYMPHOMAS FROM MARGINAL ZONE LYMPHOMA: A POPULATION-BASED COHORT STUDY Rongrong Chen (Hangzhou, China) | 18:00 - 18:00 |
| B393 | ROLE OF TARGETED IMMUNE THERAPIES IN RELAPSED/REFRACTORY LYMPHOMA (HODGKINS): A MULTICENTER EXPERIENCE FROM VARIOUS TRANSPLANT CENTERS IN PAKISTAN. A LOWER MIDDLE INCOME COUNTRY PERSPECTIVE | 18:00 - 18:00 |

Bushra Ahsan (Lahore, Pakistan)

Printed Poster

18:00 - 19:00

R1

Acute Leukaemia

- | | | |
|------|---|---------------|
| B281 | A NOVEL RISK STRATIFICATION FRAMEWORK FOR CEBPA MUTANT AML BASED ON CEBPA BZIP IN-FRAME INSERTION/DELETION AND NRAS/CSF3R CO-MUTATIONS Zhile Chen (Hangzhou, China) | 18:00 - 18:00 |
| B282 | ALLOGENEIC TRANSPLANTATION OUTCOMES OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES AND COMPLEX KARYOTYPE: A STUDY FROM THE ALWP/EBMT Arnon Nagler (Ramat Gan, Israel) | 18:00 - 18:00 |
| B283 | SURVIVAL BENEFIT OF ALLOGENEIC TRANSPLANT IN TP53-MUTATED AML ACROSS SINGLE- AND DOUBLE-HIT DISEASE Jaime Andres Suarez-Londono (Hempstead, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B284 | INOTUZUMAB OZOGAMICIN AS A BRIDGE TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN RELAPSED/REFRACTORY B-ALL: A STUDY ON BEHALF OF GETH-TC Aitana Balaguer Rosello (Valencia, Spain) | 18:00 - 18:00 |
| B285 | "LESS IS MORE"? PTCY+CNI WITH VS WITHOUT MMF IN 10/10 MUD HCT FOR AML IN CR1. FROM THE GLOBAL COMMITTEE AND ALWP OF EBMT Jia Chen (Suzhou, China) | 18:00 - 18:00 |
| B286 | IMPACT OF INDUCTION RESPONSE AND CO-MUTATIONS ON TRANSPLANT OUTCOMES IN AML WITH MYELODYSPLASIA-RELATED GENE MUTATIONS: A MULTICENTER RETROSPECTIVE STUDY Xiaoxia Hu (Shanghai, China) | 18:00 - 18:00 |
| B287 | TREOSULFAN-BASED CONDITIONING WITH PTCY IN AML: A COMPARISON BETWEEN HAPLOIDENTICAL AND 9/10 MUD TRANSPLANTS. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT Daniele Avenoso (Brescia, Italy) | 18:00 - 18:00 |
| B288 | RESULTS OF ALLOGENEIC HSCT IN CR1 FOR PEDIATRIC PATIENTS WITH <i>DE NOVO</i>, HIGH-RISK, ACUTE MYELOID LEUKEMIA (AML): A REPORT FROM AIEOP Pietro Merli (Rome, Italy) | 18:00 - 18:00 |
| B289 | MAINTENANCE THERAPY POST HEMATOPOIETIC STEM CELL TRANSPLANT IN ACUTE MYELOID LEUKEMIA WITH FLT3 INHIBITORS AND HYPOMETHYLATING AGENTS: INSIGHTS FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY Nour Moukalled (Beirut, Lebanon) | 18:00 - 18:00 |
| B290 | SUCCESSFUL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED AND RELAPSED/REFRACTORY ACUTE MYELOBLASTIC LEUKEMIA FOLLOWING A HIGHLY EFFICIENT REGIMEN, FLAG-MITOXANTRONE WITH LOW-DOSE 7 DAYS VENETOCLAX Ahmad Ibrahim (Beirut, Lebanon) | 18:00 - 18:00 |
| B291 | POST-TRANSPLANT OUTCOMES IN ACUTE MYELOID LEUKEMIA HARBORING NRAS AND/OR KRAS MUTATIONS: A STUDY ON BEHALF OF EBMT-ALWP | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | Iman Abou Dalle (Beirut, Lebanon) | |
| B292 | "STICK TO THE STANDARD": ADDITION OF THIOTEPA TO FLU/BU INCREASES NRM IN MSD/URD TRANSPLANTS FOR MRD+CR1 AML. FROM THE GLOBAL COMMITTEE AND ALWP OF EBMT Yuhua Ru (Suzhou, China) | 18:00 - 18:00 |
| B293 | COMBINED PRE-TRANSPLANT MRD DETECTION BY FACS AND NGS MAY ENHANCE RELAPSE PREDICTION IN AML PATIENTS RECEIVING ALLO-SCT IN COMPLETE REMISSION Evgeny Klyuchnikov (Hamburg, Germany) | 18:00 - 18:00 |
| B294 | ALLOGENEIC TRANSPLANTATION IN SECONDARY COMPARED TO DE NOVO ACUTE MYELOID LEUKEMIA- THE IMPACT OF NEXT-GENERATION SEQUENCING BASED MUTATION PROFILE: A STUDY FROM THE ALWP/EBMT Arnon Nagler (Ramat Gan, Israel) | 18:00 - 18:00 |
| B295 | OBECABTAGENE AUTOLEUCCEL (OBE-CEL) IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL): LONG-TERM CLINICAL OUTCOMES IN ADULTS STRATIFIED BY AGE SUBGROUPS OF INTEREST | 18:00 - 18:00 |
| B296 | ICT01/IPN60340-AZACITIDINE-VENETOCLAX INDUCES HIGH REMISSION RATE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 1/2 STUDY EVICTION Sylvain Garciaz (Marseille, France) | 18:00 - 18:00 |
| B299 | FLAMSA-BASED CONDITIONING IS ASSOCIATED WITH LOWER NRM AND HIGHER SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY AML Evgeny Klyuchnikov (Hamburg, Germany) | 18:00 - 18:00 |
| B300 | OUTCOMES OF MORPHOLOGICAL VERSUS MINIMAL RESIDUAL DISEASE (MRD) RELAPSE AFTER ALLOGENEIC TRANSPLANTATION (ALLO-HCT) FOR ACUTE MYELOID LEUKEMIA (AML) Hassan B. Alkhateeb (Rochester, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B301 | PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKAEMIA UNDERGOING UNMANIPULATED G-CSF-PRIMED HAPLOIDENTICAL BONE MARROW TRANSPLANTATION: FAVOURABLE LONG-TERM OUTCOME IN FIRST REMISSION WITH POSITIVE MEASURABLE RESIDUAL DISEASE Gottardo De Angelis (Rome, Italy) | 18:00 - 18:00 |
| B302 | SYSTEMIC EVALUATION FOR EXTRAMEDULLARY DISEASE AND TREATMENT OUTCOMES IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Ruifeng Hou (Beijing, China) | 18:00 - 18:00 |
| B303 | SUPERIOR GVHD-FREE/RELAPSE-FREE SURVIVAL WITH HAPLOIDENTICAL TRANSPLANTATION USING TCRAB/CD45RA-DEPLETED GRAFTS IN AML: A COMPARATIVE ANALYSIS WITH MATCHED DONORS Huirong Han (Singapore, Singapore) | 18:00 - 18:00 |
| B304 | SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM DIFFERENT DONOR FOR PATIENTS WITH ACUTE LEUKEMIA RELAPSED AFTER FIRST TRANSPLANTATION—A SINGLE CENTER REAL WORLD STUDY Yue Lu (Langfang, China) | 18:00 - 18:00 |
| B305 | ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION MAY OVERCOME THE ADVERSE PROGNOSTIC IMPACT OF IKZF1 | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | ALTERATIONS IN ADULT PRECURSOR B-ALL Veronika Valkova (Prague, Czechia) | |
| B306 | DEPTH OF REMISSION PREDICTS OUTCOME AFTER ALLOGENEIC HSCT FOR AML: A SINGLE-CENTER STUDY OF 263 PATIENTS Anna Maria Raiola (GE, Italy) | 18:00 - 18:00 |
| B307 | REAL-WORLD EXPERIENCE WITH GILTERITINIB MAINTENANCE FOLLOWING ALLOGENEIC TRANSPLANTATION IN RELAPSED/REFRACTORY AML PATIENTS HARBORING <i>FLT3</i> MUTATIONS Xavier Cheng-Hong Tsai (Taipei, Taiwan (Province of China)) | 18:00 - 18:00 |
| B309 | REAL-WORLD OUTCOMES OF DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC HCT FOR ACUTE LEUKEMIA: A 20-YEAR MULTICENTER STUDY Anna Paola Iori (Rome, Italy) | 18:00 - 18:00 |
| B310 | AGE OVER SIBLING: YOUNGER UNRELATED DONORS PROVIDE SUPERIOR OUTCOMES COMPARED TO SIBLING DONORS IN FULLY MATCHED HCT IN OLDER AML/MDS PATIENTS Jan Maciej Zaucha (Gdansk, Poland) | 18:00 - 18:00 |
| B311 | CHARACTERISTICS AND OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULTS WITH PHILADELPHIA-LIKE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER ANALYSIS Noa Holtzman (Miami, United States Minor Outlying Islands (the)) | 18:00 - 18:00 |
| B312 | ALLOGENEIC STEM CELL TRANSPLANTATION DURING FIRST REMISSION IMPROVES SURVIVAL IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA Congxiao Zhang (Hangzhou, China) | 18:00 - 18:00 |
| B313 | FACTORS PREDICTING OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH ACTIVE DISEASE UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Raffaella Cerretti (Rome, Italy) | 18:00 - 18:00 |
| B314 | AN EARLY MYELOID STEM CELLS-BASED IMMUNOPHENOTYPIC PANEL CAN RAPIDLY AND EFFICIENTLY DISTINGUISH APL FROM APL-LIKE Man Chen (Beijing, China) | 18:00 - 18:00 |
| B315 | STUDY OF BONE MARROW-INFILTRATING NK CELLS (BINK) AND PERIPHERAL BLOOD NK CELL (PBNK) IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA Antonio Pérez Martínez (Madrid, Spain) | 18:00 - 18:00 |
| B316 | EARLY TRANSPLANTATION FOLLOWING INDUCTION CHEMOTHERAPY IN ADULT AML PATIENTS WITH A <i>NUP98</i> REARRANGEMENTS LEADS TO MRD-NEGATIVE REMISSION Hannah Al-Yousuf (London, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B317 | OUTCOMES OF SECOND ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA AT THE IRISH NATIONAL ADULT STEM CELL TRANSPLANT UNIT James Dillon (Dublin, Ireland) | 18:00 - 18:00 |
| B318 | EFFICACY AND SAFETY OF BLINATUMOMAB AS COMBINATION OF INDUCTION OR EARLY CONSOLIDATION THERAPY IN NEWLY DIAGNOSED B CELL ACUTE LEUKEMIA Fang Xu (Lang Fang, China) | 18:00 - 18:00 |
| B319 | PROGNOSTIC FACTORS FOR EARLY LEUKEMIA-FREE SURVIVAL IN NPM1-MUTATED AML UNDERGOING ALLOGENEIC | 18:00 - 18:00 |

TRANSPLANTATION WITH ACTIVE DISEASE

Alessia Fraccaroli (Munich, Germany)

Printed Poster

18:00 - 19:00

R1

Artificial Intelligence and Computational Approaches

- B275 **HLA STRUCTURAL PROFILES IDENTIFIED BY PROTEIN LANGUAGE MODELS PREDICT GRAFT FAILURE IN HAPLOIDENTICAL TRANSPLANTATION** 18:00 - 18:00
Rui Ma (Beijing, China)
- B276 **MINOR HISTOCOMPATIBILITY ANTIGEN BURDEN AS A RISK FACTOR FOR ACUTE GVHD AFTER HLA-IDENTICAL UNRELATED DONOR TRANSPLANT** 18:00 - 18:00
Javier Sevilla-Montero (Madrid, Spain)
- B277 **STACKED MACHINE-LEARNING SURVIVAL MODELING FOR MYELODYSPLASTIC SYNDROMES UNDERGOING ALLOGENEIC TRANSPLANTATION: AN EBMT REGISTRY STUDY** 18:00 - 18:00
Carmelo Gurnari (Rome, Italy)
- B278 **PROTEIN LANGUAGE MODEL-DERIVED FUNCTIONAL DIVERSITY METRIC OF HLA ALLELES BETWEEN DONOR AND RECIPIENT PREDICTS GRAFT FAILURE IN SALVAGE SECOND HAPLO-HSCT USING THE SAME DONORS** 18:00 - 18:00
Rui Ma (Beijing, China)
- B279 **AUTOMATED EXTRACTION AND VISUALIZATION OF PEDIATRIC BMT CLINICAL NOTES USING A COST-EFFICIENT GPT-4.1-MINI PIPELINE** 18:00 - 18:00
Dua'a Zandaki (Amman, Jordan)
- B280 **CREATING A POOL OF READY-TO-USE CORD BLOOD UNITS BY SELECTING DONORS USING HLA-INFORMED ALGORITHMS** 18:00 - 18:00
Maude Dumont-Lagacé (Montréal, Canada)

Printed Poster

18:00 - 19:00

R1

Myelodysplastic Syndromes

- B414 **IMPACT OF CONCURRENT GENETIC ALTERATIONS ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH TP53-MUTATED AML/MDS: A MULTI-CENTER COHORT STUDY** 18:00 - 18:00
Zhengli Xu (Beijing, China)
- B415 **A NOVEL TARGETED NGS ASSAY FOR TP53 LOH DETECTION FACILITATES ROUTINE MULTI-HIT CLASSIFICATION AND REFINES RISK STRATIFICATION IN MYELOID NEOPLASMS** 18:00 - 18:00
Yanmin Zhao (Hangzhou, China)
- B416 **RISK-ADAPTED CONDITIONING REGIMEN IN MYELODYSPLASIA NEOPLASMS: A MULTICENTER STUDY USING THE TRANSPLANT CONDITIONING INTENSITY (TCI) SCORE** 18:00 - 18:00
- B419 **COMPARATIVE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS AND OTHER MYELODYSPLASTIC SYNDROMES: BRAZILIAN SBTMO/CIBMTR REGISTRY ANALYSIS** 18:00 - 18:00
Fernando Barroso Duarte (Fortaleza, Brazil)
- B420 **OUTCOME OF UNRELATED AND HAPLOIDENTICAL HSCT AMONG** 18:00 - 18:00

CHILDREN WITH MYELODYSPLASTIC SYNDROME

Mariya Ilyushina (Moscow, Russian Federation (the))

Printed Poster

18:00 - 19:00

R1

Paediatrics - Clinical

- | | | |
|------|--|---------------|
| B203 | COMPARATIVE ANALYSIS ON ANTI-THYMOCYTE GLOBULIN (ATG) VS ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) IN PEDIATRIC PATIENTS WITH MALIGNANT DISEASES RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY Francesco Saglio (Torino, Italy) | 18:00 - 18:00 |
| B204 | PRETRANSPLANT ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) PREDICTS NON-RELAPSE MORTALITY AFTER ALLO-HSCT IN A MULTICENTRIC PEDIATRIC ALL COHORT WITH INCREASING RISK FOR OLDER PATIENTS Dorothea Bauer (Vienna, Austria) | 18:00 - 18:00 |
| B205 | IMPACT OF RECIPIENT AGE AND CYCLOSPORIN A TARGET LEVEL ON MIXED CHIMERISM AFTER TREOSULFAN-BASED MATCHED FAMILY DONOR HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE Barbara Meissner (Hannover, Germany) | 18:00 - 18:00 |
| B206 | OUTCOMES OF PATIENTS WITH AML UNDER 18 YEARS WHO RELAPSE WITHIN 6 MONTHS FROM ALLOGENEIC HSCT- A RETROSPECTIVE STUDY FROM THE EBMT PDWP Claire Horgan (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B207 | COMPARISON OF BONE MARROW VS PERIPHERAL BLOOD STEM CELLS FOR HAPLOIDENTICAL HSCT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN: A CIBMTR ANALYSIS Joerg Krueger (Toronto, Canada) | 18:00 - 18:00 |
| B208 | EFFICACY ANALYSIS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA: A 15-YEAR CLINICAL STUDY FROM CHINA Shaoyan Hu (Suzhou, China) | 18:00 - 18:00 |
| B209 | THE COMBINATION OF VENETOCLAX AND DECITABINE AS MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH VERY HIGH-RISK ACUTE MYELOID LEUKEMIA Jonathan P. Gross (Berlin, Germany) | 18:00 - 18:00 |
| B210 | MMUD VS MATCHED DONORS IN PEDIATRIC HSCT SETTING: TIME TO RE-THINK GVHD PROPHYLAXIS STRATEGIES? Chiara Mainardi (Padova, Italy) | 18:00 - 18:00 |
| B211 | BELUMOSUDIL USE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN: EXPERIENCE FROM THE PEDIATRIC SUBCOMMITTEE OF THE SPANISH GROUP FOR HSCT AND CELL THERAPY (GETH) Marta González (Madrid, Spain) | 18:00 - 18:00 |
| B212 | A PILOT MULTICENTRE FEASIBILITY STUDY OF REAL-TIME PHARMACOKINETIC-GUIDED FLUDARABINE DOSING IN CHILDREN RECEIVING CD19-DIRECTED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL LEUKAEMIA Emma Barlow (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B213 | SURFACTANT PROTEIN D IN PLASMA MAY PREDICT BRONCHIOLITIS OBLITERANS AFTER PEDIATRIC HSCT | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | Amalie Christence Sennels (Copenhagen, Denmark) | |
| B214 | HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN USING CD3/CD19 DEPLETED GRAFTS: RESULTS OF A MULTICENTRE PHASE I/II STUDY Thomas Eichholz (Tuebingen, Germany) | 18:00 - 18:00 |
| B215 | EMAPALUMAB FOR THE TREATMENT OR PROPHYLAXIS FOR GRAFT FAILURE AFTER HSCT IN CHILDREN Blanca Molina (Madrid, Spain) | 18:00 - 18:00 |
| B216 | TREOSULFAN OR BUSULFAN: DETERMINANTS OF RELAPSE RISK WITH DIFFERENT CONDITIONING REGIMEN IN CHILDREN WITH ACUTE MYELOID LEUKEMIA Emanuele Lanino (Monza, Italy) | 18:00 - 18:00 |
| B217 | PROADRENOMEDULLIN (PRO-ADM) FOR EARLY IDENTIFICATION OF INFECTIOUS AND TRANSPLANT-RELATED COMPLICATIONS AFTER PEDIATRIC HCT: A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY Manuela Spadea (Turin, Italy) | 18:00 - 18:00 |
| B218 | REAL-WORLD EXPERIENCE WITH ISAVUCONAZOLE IN ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS IN SPAIN Blanca Molina (Madrid, Spain) | 18:00 - 18:00 |
| B219 | BANDICOOT: AN ADAPTIVE PLATFORM TRIAL DESIGNED TO IMPROVE THE COMPLICATIONS, COST-EFFECTIVENESS AND HEALTH OUTCOMES FOR CHILDREN RECEIVING A STEM CELL TRANSPLANT Hannah Walker (Melbourne, Australia) | 18:00 - 18:00 |
| B220 | ORAL SUPPLEMENTATION VS ENTERAL VIA NASO-GASTRIC TUBE VS PARENTERAL NUTRITION AS NUTRITIONAL SUPPORT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY Francesco Paolo Tambaro (Naples, Italy) | 18:00 - 18:00 |
| B221 | POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC PATIENTS RECEIVING LETERMОВIR AS CMV INFECTION PROPHYLAXIS Katarzyna Smalisz (Cracow, Poland) | 18:00 - 18:00 |
| B222 | TREOSULFAN-BASED CONDITIONING REGIMENS ARE SAME EFFECTIVE, BUT LESS TOXIC IN COMPARISON WITH BUSULFAN-BASED IN PEDIATRIC SOLID TUMORS: RESULTS OF RETROSPECTIVE ANALYSIS FROM 148 PATIENTS Teimur Aliev (Moscow, Russian Federation (the)) | 18:00 - 18:00 |
| B223 | COMPARATIVE STUDY OF CORD BLOOD TRANSPLANTATION FOR PEDIATRIC ACUTE LEUKEMIA: JOINT ANALYSIS BY EUROCORD AND JSTCT Itaru Kato (Kyoto, Japan) | 18:00 - 18:00 |
| B225 | ENTERAL VERSUS PARENTERAL NUTRITION IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE EVALUATION OF FEASIBILITY, CLINICAL OUTCOMES, AND RESOURCE UTILIZATION Hawazen Alsaedi (Riyadh, Saudi Arabia) | 18:00 - 18:00 |
| B227 | DAY +60 B LYMPHOCYTES POST-TRANSPLANT AS AN EARLY PREDICTOR OF CHRONIC GVHD Marta González (Madrid, Spain) | 18:00 - 18:00 |
| B228 | CURRENT USE OF BELUMOSUDIL FOR PEDIATRIC STEROID-REFRACTORY CHRONIC GVHD IN EUROPE: RESULTS OF | 18:00 - 18:00 |

| | | |
|------|--|---------------|
| | RETROSPECTIVE SURVEY OF THE PEDIATRIC DISEASES WORKING PARTY (PDWP) OF THE EBMT | |
| | Kirill Kirgizov (Moscow, Russian Federation (the)) | |
| B229 | THE DONOR'S FINGERPRINT: PEDIATRIC DONOR CELL LEUKEMIA | 18:00 - 18:00 |
| | Aharon Gefen (Haifa, Israel) | |
| B230 | REAL-WORLD EXPERIENCE WITH BELUMOSUDIL FOR STEROID-REFRACTORY CHRONIC GVHD IN CHILDREN: A MULTICENTER STUDY ON BEHALF OF RUSBMT PAEDIATRIC WORKING PARTY | 18:00 - 18:00 |
| | Tatiana Bykova (Saint-Petersburg, Russian Federation (the)) | |
| B231 | PLATFORM-SPECIFIC PATTERNS OF IMMUNE RECONSTITUTION AFTER PEDIATRIC ALLOGENEIC HSCT: COMPARATIVE ANALYSIS OF TCRAB/CD19+ DEPLETION AND POST-TRANSPLANT CYCLOPHOSPHAMIDE | 18:00 - 18:00 |
| | Larisa Vakhonina (Ekaterinburg, Russian Federation (the)) | |
| B233 | ROMIPLOSTIM IN PEDIATRIC PATIENTS POST HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR EARLY PLATELET ENGRAFTMENT- AN OPEN LABEL RANDOMISED CONTROLLED TRIAL | 18:00 - 18:00 |
| | Sanjana Sarangarajan (New Delhi, India) | |
| B234 | ACUTE GRAFT-VERSUS-HOST DISEASE REQUIRING SECOND-LINE THERAPY AFTER PEDIATRIC ALLOGENEIC HCT IN THE PRE-RUXOLITINIB ERA: A RETROSPECTIVE AIEOP ANALYSIS | 18:00 - 18:00 |
| | Stella Boghen (Pavia, Italy) | |
| B235 | POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC HEMOGLOBINOPATHIES: EXPANDING ACCESS TO ALLOGENEIC STEM CELL TRANSPLANTATION | 18:00 - 18:00 |
| | Manon Queudeville (Hamburg, Germany) | |
| B236 | MULTIFACETED ROLE OF ELTROMBOPAG FOR POOR GRAFT FUNCTION IN PEDIATRIC ALLOGENEIC HSCT RECIPIENTS | 18:00 - 18:00 |
| | Natalia Maximova (Trieste, Italy) | |
| B237 | HIGH VIRAL LOAD BK VIRURIA IS COMMON AFTER PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANT AND DOES NOT PREDICT SYMPTOMATIC HAEMORRHAGIC CYSTITIS | 18:00 - 18:00 |
| | Hilary Cahill (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B238 | DONOR SELECTION STRATEGY IS CRITICAL IN DETERMINING OUTCOMES OF HIGH-RISK, PAEDIATRIC, RELAPSED, MRD POSITIVE T-ALL HSCT | 18:00 - 18:00 |
| | Srividhya Senthil (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B239 | BORN TO HEAL? PSYCHOSOCIAL AND ETHICAL DIMENSIONS OF SAVIOR SIBLINGS AND RECIPIENT CHILDREN IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | 18:00 - 18:00 |
| | İbrahim Eker (Afyonkarahisar, Turkey) | |
| B240 | SECONDARY MALIGNANCIES IN SURVIVORS OF CHILDHOOD CANCER | 18:00 - 18:00 |
| | Hilary Cahill (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| B241 | PERI-TRANSPLANT RUXOLITINIB FOR GRAFT-VS-HOST-DISEASE (GVHD) PREVENTION IN PEDIATRIC AND YOUNG ADULT PATIENTS UNDERGOING MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION (HCT): INTERIM ANALYSIS | 18:00 - 18:00 |
| | Nicole Karras (Duarte, United States Minor Outlying Islands (the)) | |
| B242 | PROPHYLACTIC DLI IN PEDIATRIC PATIENTS WITH HIGH RISK HEMATOLOGICAL MALIGNANCIES - A SINGLE CENTER | 18:00 - 18:00 |

| | | |
|------|---|---------------|
| | EXPERIENCE | |
| | Denise Epple (Munich, Germany) | |
| B243 | FEASIBILITY OF CADAVERIC DONOR-DERIVED HEMATOPOIETIC GRAFTS TO INDUCE MIXED CHIMERISM AS A STRATEGY TO ACHIEVE TOLERANCE IN MULTIVISCERAL TRANSPLANTATION | 18:00 - 18:00 |
| | Antonio Pérez Martínez (Madrid, Spain) | |
| B244 | IMPACT OF ANTI-THYMOCYTE GLOBULIN DOSE ON SURVIVAL, RELAPSE AND IMMUNE RECOVERY IN PEDIATRIC ALLOGENEIC HSCT FOR MYELOID MALIGNANCIES | 18:00 - 18:00 |
| | Marek Ussowicz (Wrocław, Poland) | |
| B245 | THE EFFECT OF ALLOGENEIC HSCT ON PEDIATRIC NON-DOWN SYNDROME AMKL: RESULTS FROM A MULTICENTER CALD-AMKL-18 TRIAL | 18:00 - 18:00 |
| | Shaoyan Hu (Suzhou, China) | |
| B246 | PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN BRAZIL: A REGIONAL CHALLENGE | 18:00 - 18:00 |
| | Beatrice Duarte (São Paulo, Brazil) | |
| B247 | DOSE REDUCTION IMPROVES THE OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH WILMS TUMOR: DATA FROM RETROSPECTIVE TRIAL FROM TWO CENTRS | 18:00 - 18:00 |
| | Teimur Aliev (Moscow, Russian Federation (the)) | |
| B248 | NEUROIMMUNOLOGICAL MORBIDITY AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER ANALYSIS ON BEHALF OF THE PEDIATRIC SUBCOMMITTEE OF GETH (GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO) | 18:00 - 18:00 |
| | Angelica Villanueva-Freije (Madrid, Spain) | |
| B249 | THE RESULTS OF ALLOGENIC HSCT IN PAEDIATRIC PATIENTS DIAGNOSED WITH MYELOID SARCOMA - A SINGLE CENTRE EXPERIENCE | 18:00 - 18:00 |
| | Jacek Wachowiak (Poznań, Poland) | |
| B250 | POPULATION PHARMACOKINETIC EVALUATION OF EXTENDED INFUSION ACYCLOVIR IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS | 18:00 - 18:00 |
| | Natalia Maximova (Trieste, Italy) | |
| B251 | EXCELLENT OUTCOMES OF UNMANIPULATED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS AFTER MINIMALLY INTENSIVE CONDITIONING FOR SALVAGE HSCT IN CHILDREN | 18:00 - 18:00 |
| | Ulrike Zeilhofer (Zurich, Switzerland) | |
| B252 | EFFICACY OF PROPHYLACTIC LEVOFLOXACIN IN PEDIATRIC AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER, RETROSPECTIVE ANALYSIS | 18:00 - 18:00 |
| | Melanie Klemond (Rochester, United States Minor Outlying Islands (the)) | |
| B254 | POST-TRANSPLANT COMPLICATIONS AND MAINTENANCE THERAPY IN CHILDREN UNDERGOING AUTOHSCT DUE TO RELAPSE/PROGRESSION OF HODGKIN'S LYMPHOMA | 18:00 - 18:00 |
| | Katarzyna Smalisz (Cracow, Poland) | |
| B255 | LYMPHOMATOID GRANULOMATOSIS OF A CENTRAL NERVOUS SYSTEM AS THE ONLY MANIFESTATION OF POST- TRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A PEDIATRIC CASE REPORT | 18:00 - 18:00 |
| | Maria Polacik (Dresden, Germany) | |

| | | |
|------|--|---------------|
| B256 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A POLISH PEDIATRIC EXPERIENCE Jowita Fraczkiewicz (Wroclaw, Poland) | 18:00 - 18:00 |
| B257 | MANAGEMENT OF TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IN CHILDREN AFTER HSCT WITH RAVULIZUMAB: SINGLE CENTER EXPERIENCE Irina Kostareva (Moscow, Russian Federation (the)) | 18:00 - 18:00 |
| B258 | OUTCOME OF SALVAGE SECOND HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CHILDREN WITH HIGH-RISK HEMATOLOGICAL DISORDERS: A SINGLE CENTER EXPERIENCE FROM JORDAN Ayad Ahmed Hussein (Amman, Jordan) | 18:00 - 18:00 |
| B259 | CMV AND BK VIRUS REACTIVATION AFTER ALLOGENEIC HSCT ACCORDING TO DONOR TYPE: A SINGLE-CENTER PEDIATRIC EXPERIENCE Cristina Jercan (Bucharest, Romania) | 18:00 - 18:00 |
| B260 | THE CLINICAL COURSE OF HAPLOHSCT + DINUTUXIMAB BETA IMMUNOTHERAPY IN POLISH CHILDREN WITH RELAPSING NEUROBLASTOMA Katarzyna Smalisz (Cracow, Poland) | 18:00 - 18:00 |
| B261 | ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH DIAMOND-BLACKFAN ANAEMIA: A SINGLE-CENTER EXPERIENCE Renata Formankova (Prague, Czechia) | 18:00 - 18:00 |
| B262 | CHRONIC GRAFT VERSUS HOST DISEASE DURING 20-YEAR OF MONOCENTRIC EXPERIENCE Maura Faraci (Genova, Italy) | 18:00 - 18:00 |
| B263 | THE ACHILLES HEEL OF KMT2A-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA IN INFANTS Larisa Fechina (Ekaterinburg, Russian Federation (the)) | 18:00 - 18:00 |
| B264 | EXTRACORPOREAL PHOTOPHERESIS IN WITH DIFFERENT SYSTEMS PERFORMED; A REAL WORLD SINGLE CENTER REPORT Volker Witt (Vienna, Austria) | 18:00 - 18:00 |
| B265 | TACKLING MIXED CHIMERISM WITH WHOLE BLOOD DONOR LYMPHOCYTE INFUSION IN RESOURCE LIMITED SETTING - CASE SERIES Ranjit Kumar Chatada Srivaishnava (Hyderabad, India) | 18:00 - 18:00 |
| B266 | DEVELOPMENT OF A NOVEL SCORING INDEX TO QUANTIFY THE NEED FOR NUTRITIONAL SUPPORT INTERVENTIONS DURING STEM CELL TRANSPLANT AND GENE THERAPY IN CHILDREN Gerard Gurumurthy (Cambridge, United Kingdom of Great Britain and Northern Ireland (the)) | 18:00 - 18:00 |
| B267 | POOR OUTCOMES FOR CHILDREN WITH REFRACTORY POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER Hannah Walker (Melbourne, Australia) | 18:00 - 18:00 |

Wednesday, 25. March 2026*Educational*

08:30 - 10:00

R4

E12 - Educational | Haploidentical HCT in paediatric patients - PTCy vs TCD platforms in malignant and non-malignant indications

Krzysztof Kalwak (Wroclaw, Poland)

Marta González (Madrid, Spain)

| | | |
|-------|--|---------------|
| E12-1 | Introduction | 08:30 - 08:35 |
| E12-2 | For PTCy in malignant indications Jean Hugues Dalle (Paris, France) | 08:35 - 08:50 |
| E12-3 | PTCy vs TCD approaches for HLA-haploidentical HCT in malignant disorders Franco Locatelli (Rome, Italy) | 08:50 - 09:05 |
| E12-4 | For PTCy in non-malignant indications Carmem Bonfim (Durham, United States Minor Outlying Islands (the)) | 09:05 - 09:20 |
| E12-5 | TCD platforms in non-malignant indications Carlo Dufour (Genoiva, Italy) | 09:20 - 09:35 |
| E12-6 | Roundtable discussion and debate on PTCy vs TCD platforms in these paediatric settings | 09:35 - 10:00 |

Educational

08:30 - 10:00

R5

E13 - Educational | Endothelial dysfunction syndromes - A focus on TA-TMA

Rafael Duarte (Madrid, Spain)

Eleni Gavriilaki (Thessaloniki, Greece)

| | | |
|-------|---|---------------|
| E13-1 | Introduction | 08:30 - 08:35 |
| E13-2 | From pathophysiology to criteria for diagnosis, severity scoring and assessment of response Eleni Gavriilaki (Thessaloniki, Greece) | 08:35 - 08:50 |
| E13-3 | Current Consensus Criteria: Is there really a consensus? - Perspectives from a pediatric nephrologist Sangeeta Hingorani (Seattle, WA US, United States of America (the)) | 08:50 - 09:05 |
| E13-4 | Current consensus criteria: an adult physician's perspective Alessandro Rambaldi (Bergamo, Italy) | 09:05 - 09:20 |
| E13-5 | Harmonization criteria in the real world: Results from the MIDAS consortium Sumithira Vasu (Columbus, United States Minor Outlying Islands (the)) | 09:20 - 09:35 |
| E13-6 | Panel discussion on criteria for diagnosis and severity scoring of TA-TMA and their implementation in clinical practice, and Q&A | 09:35 - 10:00 |

Workshop

08:30 - 10:00

R6

W10 - Workshop | CAR-T Cell Therapy - Complications, innovation and the road ahead

Valentín Ortiz-Maldonado (Barcelona, Spain)

Manel Juan Otero (Barcelona, Spain)

| | | |
|-------|---|---------------|
| W10-1 | Introduction | 08:30 - 08:35 |
| W10-2 | What have we learnt so far about short and long-term CAR-T | 08:35 - 08:55 |

| | | |
|---|--|---------------|
| | complications? From recommendations to clinical practice | |
| | Jurgen Kuball (Utrecht, Netherlands (the)) | |
| W10-3 | Secondary malignancies after CAR-T: should we start worrying? | 08:55 - 09:15 |
| | Annalisa Ruggeri (Milano, Italy) | |
| W10-4 | Academic CAR development: how far can we go? The Barcelona pathway. | 09:15 - 09:35 |
| | Manel Juan Otero (Barcelona, Spain) | |
| W10-5 | Q&A - Panel discussion | 09:35 - 10:00 |
| <i>Nurses Group</i> | | |
| | 08:30 - 10:00 | R7 |
| NG24 - Nurses Group Infections | | |
| | Mathias Hellberg Naegele (St. Gallen, Switzerland) | |
| | Sara Marcos Asensio (Salamanca, Spain) | |
| NG24-1 | Curing the incurable stem cell transplantation for HIV | 08:30 - 08:51 |
| | Olaf Penack (Berlin, Germany) | |
| NG24-2 | How to prevent and manage antibiotic resistance in cellular therapy | 08:51 - 09:12 |
| | Alexander Schauwvlieghe (Brugge, Belgium) | |
| NG24-3 | How donor registries can prepare for an endemic or pandemic virus | 09:12 - 09:33 |
| | Nuria Marieges (Barcelona, Spain) | |
| NG24-4 | Challenges and treat of fungal infection | 09:33 - 09:54 |
| | Dilnasheen Safdar (Lahore, Pakistan) | |
| NG24-5 | Q&A | 09:54 - 10:00 |
| <i>Educational</i> | | |
| | 08:30 - 10:00 | R8 |
| E14 - Educational Fungal infections after HCT | | |
| | Catherine Cordonnier (Créteil, France) | |
| | Jon Salmanton-García (Cologne, Germany) | |
| E14-1 | Introduction | 08:30 - 08:35 |
| E14-2 | Growing global concern over the spread of Aspergillus resistance | 08:35 - 08:50 |
| | Paul Verweij (Nijmegen, Netherlands (the)) | |
| E14-3 | What a HCT physician needs to know about fungal diagnosis | 08:50 - 09:05 |
| | Ana Alastruey-Izquierdo (Majadahonda, Spain) | |
| E14-4 | Antifungal therapy in practice: when is it time to change? | 09:05 - 09:20 |
| | Johan Maertens (Leuven, Belgium) | |
| E14-5 | Fungal infections after HCT: what's new? | 09:20 - 09:35 |
| | Martin Hoenigl (Graz, Austria) | |
| E14-6 | Q&A - Panel discussion | 09:35 - 10:00 |
| <i>Oral Session</i> | | |
| | 08:30 - 09:45 | R12 |
| OS14 - Oral Session 14 Graft manipulation and conditioning | | |
| | Bronwen Shaw (Milwaukee, United States of America (the)) | |
| | Ajmeera Azeez (Bangalore, India) | |
| OS14-01 | ORCA-T DEMONSTRATES FAVORABLE QUALITY OF LIFE AND | 08:30 - 08:39 |

| | | |
|---|--|---------------|
| | HEALTHCARE RESOURCE USE COMPARED TO STANDARD ALLOHSCT PLUS TAC/MTX FOR GVHD PREVENTION IN RANDOMIZED PHASE3 CLINICAL TRIAL (PRECISION-T) | |
| | Arpita Gandhi (Portland, United States Minor Outlying Islands (the)) | |
| OS14-02 | CLINICAL OUTCOMES IN ORCA-T AND REGISTRY-BASED POST-TRANSPLANT CYCLOPHOSPHAMIDE PATIENTS: AN OBSERVATIONAL COMPARISON | 08:39 - 08:48 |
| | Amandeep Salhotra (Duarte, United States of America (the)) | |
| OS14-03 | POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER MISMATCHED UNRELATED DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION - 2-YEAR OUTCOMES FROM THE NMDP-SPONSORED ACCESS TRIAL | 08:48 - 08:57 |
| | Monzr Al Malki (Duarte, United States Minor Outlying Islands (the)) | |
| OS14-04 | TCR ALPHA/BETA DEPLETION IN HAPLOIDENTICAL TRANSPLANTATION FOR PEDIATRIC PATIENTS | 08:57 - 09:06 |
| | Ajmeera Azeez (Bangalore, India) | |
| OS14-05 | BETTER OUTCOMES WITH HAPLOIDENTICAL THAN MATCHED SIBLING DONORS FOR AML PATIENTS TRANSPLANTED IN MRD+ CR: A STUDY FROM GLOBAL COMMITTEE AND ALWP OF THE EBMT | 09:06 - 09:15 |
| | Yishan Ye (Hangzhou, China) | |
| OS14-06 | IMPACT OF ABO COMPATIBILITY ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ALL: RESULTS FROM FORUM | 09:15 - 09:24 |
| | Julia Fekadu-Siebold (Frankfurt, Germany) | |
| OS14-07 | REFINING THE TRANSPLANT CONDITIONING INTENSITY (TCI) INDEX BY INTEGRATING POST-TRANSPLANT CYCLOPHOSPHAMIDE: A RETROSPECTIVE ANALYSIS IN ALLO-HCT | 09:24 - 09:33 |
| | Cristian Alberdi-Lema (Barcelona, Spain) | |
| OS14-08 | ALLOGENEIC STEM CELLS TRANSPLANTATION IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS PREVIOUSLY TREATED BY TISAGENLEUCCEL FOR B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A FRENCH RETROSPECTIVE SFGM-TC STUDY | 09:33 - 09:42 |
| | Marie Parreillet (Paris, France) | |
| | | |
| <i>Nurses Group</i> | | |
| 08:30 - 10:00 | | |
| | | R13 |
| NG25 - Nurses Group Disease update | | |
| Cristina Baiana (Yvoir, Belgium) | | |
| Seher Yaprak (Kocaeli, Turkey) | | |
| NG25-1 | Recent updates in Hodgkin Lymphoma | 08:30 - 08:51 |
| | Izaskun Zeberio Etxetkipia (Donostia, Spain) | |
| NG25-2 | Blastic Plasmacytoid Dendritic Cell Neoplasm | 08:51 - 09:12 |
| | Pramila Krishnamurthy (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| NG25-3 | Solid malignancies | 09:12 - 09:33 |
| | Juan Añon Hidalgo (Madrid, Spain) | |
| NG25-4 | Updates on Allo-HCT in Myelofibrosis | 09:33 - 09:54 |
| | Donal McLornan (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| NG25-5 | Q&A | 09:54 - 10:00 |

ePoster

08:30 - 12:00

R20

ePoster Viewing*Breaks*

10:00 - 10:30

R1

Coffee Break, ePoster Viewing, Visit Exhibition*Oral Session*

10:30 - 11:45

R4

OS15 - Oral Session 15 | Multiple Myeloma

Meral Beksac (Ankara, Turkey)

Laurent Garderet (PARIS 13EME ARRONDISSEMENT, France)

| | | |
|---------|--|---------------|
| OS15-01 | LONG-TERM PROGRESSION-FREE SURVIVAL BENEFIT WITH CILTACABTAGENE AUTOLEUCEL IN STANDARD-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA Albert Oriol (Barcelona, Spain) | 10:30 - 10:39 |
| OS15-02 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA Joaquín Martínez (MAdrid, Spain) | 10:39 - 10:48 |
| OS15-07 | MODELING LONG-TERM PROGRESSION-FREE SURVIVAL IN TRANSPLANT-ELIGIBLE AND TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE Mohamad Mohty (Paris, France) | 10:48 - 10:57 |
| OS15-04 | REAL-WORLD COMPARISON OF STANDARD-OF-CARE IDECABTAGENE VICLEUCEL AND CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE-MYELOMA: A STUDY ON BEHALF OF THE CTIWP AND THE CMWP OF THE EBMT Florent Malard (Paris, France) | 10:57 - 11:06 |
| OS15-05 | OUTCOMES OF PATIENTS WITH T(4;14) MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION: A REPORT BY THE EBMT CHRONIC MALIGNANCIES WORKING PARTY Joanna Drozd-Sokolowska (Warsaw, Poland) | 11:06 - 11:15 |
| OS15-06 | CILTACABTAGENE AUTOLEUCEL OUT-OF-SPECIFICATION MANUFACTURING OUTCOMES IMPROVE WITH EARLIER LINES OF THERAPY Hannelore Van Eeckhoutte (New Brunswick, United States Minor Outlying Islands (the)) | 11:15 - 11:24 |
| OS15-03 | DARATUMUMAB/BORTEZOMIB/LENALIDOMIDE/DEXAMETHASON E WITH DARATUMUMAB/LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN THE PHASE 3 PERSEUS TRIAL Meral Beksac (Ankara, Turkey) | 11:24 - 11:33 |
| OS15-08 | THE EBMT MULTIPLE MYELOMA EARLY RELAPSE (ER) SCORE IDENTIFIES FUNCTIONALLY HIGH RISK PATIENTS ACROSS CYTOGENETIC SUBGROUPS IN THE CURRENT ERA OF INDUCTIONS. AN EBMT-CMWP REPORT Meral Beksac (Ankara, Turkey) | 11:33 - 11:42 |

Workshop

10:30 - 11:45

R5

W11 - Workshop | Novel data on intestinal GVHD - Which are the practical implications of supportive care?

Grzegorz Basak (Warsaw, Poland)

Arancha Bermúdez (Santander, Spain)

| | | |
|-------|--|---------------|
| W11-1 | Introduction | 10:30 - 10:35 |
| W11-2 | Protective Intestinal metabolites as a novel approach Hendrik Poeck (Regensburg, Germany) | 10:35 - 10:55 |
| W11-3 | Practical implications on nutrition and supplementation Zinaida Peric (Rijeka, Croatia) | 10:55 - 11:15 |
| W11-4 | Antibiotics and intestinal GVHD - friend or foe? Robert Jenq (Los Angeles, United States of America (the)) | 11:15 - 11:35 |
| W11-5 | Panel discussion | 11:35 - 11:45 |

Workshop

10:30 - 11:45

R6

W12 - Workshop | CAR-T Cell Therapy for other forms of lymphoma

Charalampia Kyriakou (London, United Kingdom of Great Britain and Northern Ireland (the))

Alberto Mussetti (barcelona, Spain)

| | | |
|-------|--|---------------|
| W12-1 | Introduction | 10:30 - 10:35 |
| W12-2 | Classical Hodgkin's disease Javier Briones (Barcelona, Spain) | 10:35 - 10:50 |
| W12-3 | T-cell & T-cell rich lymphomas Miguel Angel Perales (New York, United States of America (the)) | 10:50 - 11:05 |
| W12-4 | Chronic lymphocytic leukemia and Richter's syndrome Julio Delgado (Barcelona, Spain) | 11:05 - 11:20 |
| W12-5 | Primary CNS lymphoma Anna Ossami Saidy (Berlin, Germany) | 11:20 - 11:35 |
| W12-6 | Q&A - Panel discussion | 11:35 - 11:45 |

Nurses Group

10:30 - 11:45

R7

NG26 - Nurses Group | Ethics of evolving therapies

Hilda Mekelenkamp (Leiden, Netherlands (the))

Michelle Kenyon (LONDON, United Kingdom of Great Britain and Northern Ireland (the))

| | | |
|--------|---|---------------|
| NG26-1 | Case presentation Ruth Clout (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) Michelle Kenyon (LONDON, United Kingdom of Great Britain and Northern Ireland (the)) | 10:30 - 10:35 |
| NG26-2 | Growth of advanced therapy usages : challenges to the healthcare system Christian Chabannon (Marseille, France) | 10:35 - 10:45 |
| NG26-4 | Equity, Access, and Capacity - the ethical debate Hilda Mekelenkamp (Leiden, Netherlands (the)) | 10:55 - 11:05 |
| NG26-5 | Advocacy lens on ethics of evolving therapies | 11:05 - 11:15 |

| | | |
|--|--|---------------|
| | Jonathan Clark (Hilversum, Netherlands (the)) | |
| NG26-6 | Panel Discussion - Q&A | 11:15 - 11:45 |
| <i>Joint Sessions</i> | | |
| 10:30 - 11:30 | | R8 |
| JS08 - Joint Session EBMT - KSBMT Up-Front Allogeneic HCT for Aplastic Anemia: Europe vs. Korea | | |
| Anna Sureda (Barcelona, Spain) | | |
| Kyung-Nam Koh (Seoul, Korea (the Republic of)) | | |
| JS08-1 | Up-Front Allogeneic HCT for Aplastic Anemia: European perspective | 10:30 - 10:50 |
| | Antonio M. Risitano (Avellino, Italy) | |
| JS08-2 | Up-Front Allogeneic HCT for Aplastic Anemia: Korean perspective | 10:50 - 11:10 |
| | Hoon Kook (Gwangju, Korea (the Republic of)) | |
| JS08-3 | Panel Discussion | 11:10 - 11:30 |
| | Hoon Kook (Gwangju, Korea (the Republic of)) | |
| | Antonio M. Risitano (Avellino, Italy) | |
| | Kyung-Nam Koh (Seoul, Korea (the Republic of)) | |
| | Anna Sureda (Barcelona, Spain) | |
| <i>Special Session</i> | | |
| 10:30 - 11:45 | | R12 |
| SS08 - EBMT Benchmarking Session - A key tool for quality improvement | | |
| Carlos Solano (Valencia, Spain) | | |
| Lynn Manson (Edinburgh, United Kingdom of Great Britain and Northern Ireland (the)) | | |
| SS08-1 | Introduction | 10:30 - 10:35 |
| SS08-2 | Methodological choices for EBMT benchmarking | 10:35 - 10:55 |
| | Liesbeth de Wreede (Leiden, Netherlands (the)) | |
| SS08-3 | Current experience and results so far | 10:55 - 11:15 |
| | John Snowden (Sheffield, United Kingdom of Great Britain and Northern Ireland (the)) | |
| SS08-4 | Next steps to further improve EBMT benchmarking | 11:15 - 11:35 |
| | Nina Worel (Vienna, Austria) | |
| SS08-5 | Panel discussion on the future of benchmarking and it's influence on the need for accreditation | 11:35 - 11:45 |
| <i>Nurses Group</i> | | |
| 10:30 - 11:45 | | R13 |
| NG27 - Nurses Group Oral Adult Session II | | |
| Polona Klanscek (Ljubljana, Slovenia) | | |
| Thomas Jezequel (Nantes, France) | | |
| NG27-01 | DEFINING NATIONAL RESEARCH PRIORITIES IN HSCT NURSING USING THE DONABEDIAN MODEL, DELPHI METHODOLOGY, AND CONSENSUS RATIFICATION | 10:30 - 10:38 |
| | Ozgun Gokmen Kaya (Istanbul, Turkey) | |
| NG27-02 | BRIDGING THE EDUCATIONAL GAP: A NATIONAL, NURSE-LED ONLINE APHERESIS COURSE TO ENHANCE QUALITY IN HSCT AND CELLULAR THERAPY | 10:38 - 10:46 |
| | Natalia Lorente Del Río (Madrid, Spain) | |
| NG27-03 | QUALITY OF LIFE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADOLESCENTS AND YOUNG ADULTS: INSIGHTS FROM A DANISH CROSS-SECTIONAL STUDY USING | 10:46 - 10:54 |

| | | |
|---|--|---------------|
| | THE EORTC QLQ AYA QUESTIONNAIRE | |
| | Nanna Randrup Madsen (Copenhagen, Denmark) | |
| NG27-04 | EVERY MINUTE COUNTS: DO THAW-TO-INFUSION INTERVALS AND INFUSION TIME OF DAY INFLUENCE CRS ONSET AND HOSPITAL STAY IN CAR-T THERAPY? A NURSE-LED RETROSPECTIVE REAL-WORLD ANALYSIS | 10:54 - 11:02 |
| | Donna Walsh (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | |
| NG27-05 | ECP 2.0: TECHNICAL, ORGANIZATIONAL AND PATIENT-CENTERED EVALUATION OF HIGH-FLOW VENOUS PORTS AS SYSTEMATIC ACCESS FOR POST-TRANSPLANT EXTRACORPOREAL PHOTOPHERESIS | 11:02 - 11:10 |
| | Barbara Loconte (Bellinzona, Switzerland) | |
| NG27-06 | DIFFERENCES BETWEEN PHYSICIANS' AND NURSES' PERSPECTIVES IN DEFINING CORE NURSING-SENSITIVE OUTCOMES IN ADULT HSCT AND CAR-T THERAPY: AN INTERDISCIPLINARY ITALIAN DELPHI CONSENSUS | 11:10 - 11:18 |
| | Marco Cioce (Rome, Italy) | |
| NG27-07 | PREPPING WITH PREHAB: A PHYSICAL ACTIVITY FOCUSED "PREHABILITATION" PILOT WITHIN THE ALLOGENEIC BMT PATHWAY | 11:18 - 11:26 |
| | Katie Booth (Glasgow, United Kingdom of Great Britain and Northern Ireland (the)) | |
| NG27-08 | A FAIR MATCH? AUDIT OF GEOGRAPHIC INEQUITY IN RELATIVES TISSUE TYPING TIMELINES | 11:26 - 11:34 |
| | Monica Blasco Gomez (London, United Kingdom of Great Britain and Northern Ireland (the)) | |
| <i>Breaks</i> | | |
| | 11:45 - 12:30 | R1 |
| Lunch Break, ePoster Viewing, Visit Exhibition | | |
| <i>Oral Session</i> | | |
| | 12:30 - 13:45 | R4 |
| OS16 - Oral Session 16 Chronic GVHD - Clinical | | |
| | Steven Pavletic (Rockville, United States of America (the)) | |
| | Rafael Duarte (Madrid, Spain) | |
| OS16-01 | BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN UNDER 12: A RETROSPECTIVE ANALYSIS OF EFFECTIVENESS AND SAFETY | 12:30 - 12:39 |
| | Jianyun Liao (Guangdong Province, Dongguan City, China) | |
| OS16-02 | EFFICACY AND SAFETY OF AXATILIMAB IN JAPANESE PATIENTS WITH RECURRENT OR REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER AT LEAST 2 PRIOR LINES OF SYSTEMIC THERAPY | 12:39 - 12:48 |
| | Yoshihiro Inamoto (Toyoake, Japan) | |
| OS16-03 | IMPACT OF GRAFT-VERSUS-HOST DISEASE ON THE MAIN OUTCOMES FOLLOWING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION BASED ON EX-VIVO ALPHA BETTA T CELL DEPLETION | 12:48 - 12:57 |
| | Michael Maschan (Moscow, Russian Federation (the)) | |
| OS16-04 | AXATILIMAB IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC GRAFT-VERSUS-HOST DISEASE: UPDATED SAFETY ANALYSIS OF A RANDOMIZED, PHASE 2 STUDY | 12:57 - 13:06 |
| | Amandeep Salhotra (Duarte, United States of America (the)) | |
| OS16-05 | EFFICACY AND SAFETY OF THE ROCK2-INHIBITOR | 13:06 - 13:15 |

| | | |
|--|---|---------------|
| | BELUMOSUDIL FOR CHRONIC GVHD: UPDATE FROM A MULTICENTER RETROSPECTIVE ANALYSIS OF A LARGE GERMAN-AUSTRIAN COHORT OF THE BELUMOSUDIL MAP | |
| | Udo Holtick (Cologne, Germany) | |
| OS16-06 | A COMPREHENSIVE ANALYSIS OF AXATILIMAB IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE AND RELATED BRONCHIOLITIS OBLITERANS SYNDROME: INTEGRATED ANALYSIS FROM 2 CLINICAL STUDIES | 13:15 - 13:24 |
| | Zachariah DeFilipp (Boston, United States of America (the)) | |
| OS16-07 | CHRONIC GRAFT-VERSUS-HOST DISEASE: REAL-WORLD OUTCOMES AND EFFICACY OF RUXOLITINIB COMPARED WITH CONVENTIONAL TREATMENTS | 13:24 - 13:33 |
| | Thomas Chan (Hong Kong, China) Garret Leung (Hong Kong, China) | |
| OS16-08 | CHGVHD IMMUNE RECONSTITUTION-SCORE: INTEGRATING IMMUNOLOGICAL AND CLINICAL FEATURES TO PREDICT OUTCOMES IN CHRONIC GVHD | 13:33 - 13:42 |
| | Maria Helena Parrinello (Milan, Italy) | |
| <i>Oral Session</i> | | |
| 12:30 - 13:45 | | R5 |
| OS17 - Oral Session 17 Relapse and Graft-versus-Leukaemia | | |
| | Angelica Villanueva-Freije (Madrid, Spain) Jordi Esteve (Barcelona, Spain) | |
| OS17-01 | VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN ACUTE MYELOID LEUKEMIA RELAPSING POST ALLOGENEIC STEM CELL TRANSPLANT: EBMT ALWP REAL-WORLD EVIDENCE | 12:30 - 12:39 |
| | Nour Moukalled (Beirut, Lebanon) | |
| OS17-02 | TP53 VARIANT ALLELE FREQUENCY AS A GENETIC MRD MARKER PREDICTS RELAPSE AND GUIDES SUBTYPE-SPECIFIC THERAPY IN TP53-MUTATED AML/MDS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION | 12:39 - 12:48 |
| | Yanmin Zhao (Hangzhou, China) | |
| OS17-03 | ALLOHEME SURVEILLANCE ENABLES EARLY DETECTION OF RELAPSE IN POST-HCT AML AND MDS PATIENTS | 12:48 - 12:57 |
| | Monzr Al Malki (Duarte, United States Minor Outlying Islands (the)) | |
| OS17-04 | PROGNOSTIC VALUE OF PERI-TRANSPLANT MOLECULAR MRD MONITORING BY TARGETED NGS FOR ALLO-HCT RECIPIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA: A MULTICENTER STUDY OF TROPHY GROUP | 12:57 - 13:06 |
| | Yeqian Zhao (Hangzhou, China) | |
| OS17-05 | BEYOND PROGNOSTIC RISK: TIME-DEPENDENT INTERACTION ANALYSIS IDENTIFIES ASXL1, RUNX1, AND A MUTATED ASXL1/RUNX1/BCOR/BCORL1 CLUSTER AS PREDICTORS OF TRANSPLANT BENEFIT IN AML IN FIRST REMISSION | 13:06 - 13:15 |
| | Ayman Sayyed (Toronto, Canada) | |
| OS17-06 | PROPHYLACTIC MEMORY DLI ENHANCES IMMUNE RECOVERY AND DISEASE-FREE SURVIVAL AFTER ALLOGENEIC HCT | 13:15 - 13:24 |
| | Angelica Villanueva-Freije (Madrid, Spain) | |
| OS17-07 | REGULATING VERY EARLY CICLOSPORIN IS CRITICAL IN DETERMINING DISEASE RESPONSE EARLY AFTER CORD BLOOD TRANSPLANT FOR HIGH-RISK PAEDIATRIC AML | 13:24 - 13:33 |
| | Srividhya Senthil (Manchester, United Kingdom of Great Britain and Northern Ireland (the)) | |
| OS17-08 | TEN YEARS OF POST-ALLOGENEIC HSCT HEALTHCARE | 13:33 - 13:42 |

UTILIZATION IN FRANCE: A NATIONWIDE POPULATION-BASED STUDY (2013-2023)

Monia Zidane (Paris, France)

Oral Session

12:30 - 13:45

R6

OS18 - Oral Session 18 | CAR-T and other Cellular Therapies

Margot Jak (Utrecht, Netherlands (the))

Aibin Liang (Shanghai, China)

- | | | |
|---------|---|---------------|
| OS18-01 | ULTRA-LOW-DOSE IL-10-EXPRESSING CAR-T CELLS ACHIEVE ROBUST COMPLETE REMISSION IN R/R DLBCL: RESULTS UPDATE OF A PHASE I TRIAL Shan Fu (Hangzhou, China) | 12:30 - 12:39 |
| OS18-02 | A GLOBAL PHASE 1B STUDY OF PRIZLO-CEL, A DUAL TARGETING CD20/CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA Margot Jak (Utrecht, Netherlands (the)) | 12:39 - 12:48 |
| OS18-03 | PHASE I/IIA MULTICENTER TRIAL OF NON-VIRAL SLEEPING BEAUTY TRANSPOSON-ENGINEERED CD19 CAR-T CELLS (TRANPOCART19) IN RELAPSED/REFRACTORY B-CELL LYMPHOMAS: RESULTS FROM DOSE LEVELS 1 AND 2 Lucía Lopez Corral (Salamanca, Spain) | 12:48 - 12:57 |
| OS18-04 | MYELOID DERIVED SUPPRESSOR CELLS (MDSC) AFFECT IMMEDIATE EFFICACY AND ACUTE TOXICITIES OF ANTI-CD19 CAR-T IN PATIENTS WITH LARGE B-CELL LYMPHOMA Eugenio Galli (Rome, Italy) | 12:57 - 13:06 |
| OS18-05 | THE IMPACT OF TIME IN PATIENTS WITH LARGE B CELL LYMPHOMA CANDIDATES FOR AXI-CEL THERAPY: SPANISH MULTICENTER GETH-TC/GELTAMO STUDY Leyre Bento (Palma de Mallorca, Spain) | 13:06 - 13:15 |
| OS18-06 | IMMUNE CELL THERAPY AFTER TCRA⁺/CD19⁺-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED HIGH-RISK NEUROBLASTOMA: A PHASE 2 SINGLE-CENTER STUDY Stefano Giardino (Genova, Italy) | 13:15 - 13:24 |
| OS18-07 | EXTENDED CLINICAL AND GENOMIC EVALUATION OF CTX130, A CD70-DIRECTED ALLOGENEIC CAR T THERAPY, IN ADULT T-CELL LEUKEMIA/LYMPHOMA: RESULTS FROM THE FIRST-IN-HUMAN COBALT-LYM PHASE I TRIAL R. Alejandro Sica (New York City, United States Minor Outlying Islands (the)) | 13:24 - 13:33 |
| OS18-08 | ADOPTIVE TRANSFER OF MULTIVIRUS-SPECIFIC T CELLS AGAINST REFRACTORY CMV, ADV AND EBV INFECTIONS AFTER STEM CELL TRANSPLANTATION - INTERIM RESULTS FROM THE "TRACE" PHASE-III TRIAL Theresa Kaeuferle (Freiburg, Germany) | 13:33 - 13:42 |

Nurses Group

12:30 - 13:55

R7

NG28 - Nurses Group | Late effects & Closing session

Hilda Mekelenkamp (Leiden, Netherlands (the))

Britt Snoek (Rotterdam, Netherlands (the))

- | | | |
|--------|--|---------------|
| NG28-1 | Cognitive impairment after cell therapies Ksenia Boriskina (Stockholm, Sweden) | 12:30 - 12:50 |
|--------|--|---------------|

| | | |
|--------|---|---------------|
| NG28-2 | Late cardiac toxicities Beatriz Vergara (Madrid, Spain) | 12:50 - 13:10 |
| NG28-3 | The patient experience Sofia Moreno (Madrid, Spain) | 13:10 - 13:30 |
| NG28-4 | Best of the best | 13:30 - 13:40 |
| NG28-5 | Highlights of physicians sessions | 13:40 - 13:50 |
| NG28-6 | Presentations of Annual Meeting 2027 Britt Snoek (Rotterdam, Netherlands (the)) | 13:50 - 13:55 |

Oral Session

12:30 - 13:45

R8

OS19 - Oral Session 19 | Infections - Bacterial, fungal, and vaccines

Mathilde Ruggiu-Goirand (Paris, France)

| | | |
|---------|--|---------------|
| OS19-01 | TOXOPLASMOSIS SCREENING, PROPHYLAXIS AND TREATMENT PRACTICES ACROSS EBMT CENTERS: A SURVEY ON BEHALF OF THE INFECTIOUS DISEASES WORKING PARTY Fabio Andreozzi (Brussels-Leuven, Belgium) | 12:30 - 12:39 |
| OS19-02 | PROGNOSIS OF INVASIVE ASPERGILLOSIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Mathilde Ruggiu-Goirand (Paris, France) | 12:39 - 12:48 |
| OS19-03 | INFECTION RATES ACROSS THE FIRST-YEAR POST-TRANSPLANT IN PTCY AND NON-PTCY-BASED GVHD PROPHYLAXIS: A POST-HOC ANALYSIS OF A RANDOMIZED PHASE II STUDY Jennifer I. Jensen (Seattle, United States of America (the)) | 12:48 - 12:57 |
| OS19-04 | VACCINATION STRATEGY IN PATIENTS UNDERGOING CAR-T THERAPIES - AN IDWP AND CTIWP EBMT SURVEY Agnieszka Piekarska (Gdansk, Poland) | 12:57 - 13:06 |
| OS19-05 | INCIDENCE AND OUTCOME OF INFECTIONS AFTER TREATMENT WITH CAR-T CELLS VERSUS BISPECIFIC ANTIBODIES IN PATIENTS AFFECTED BY HEMATOLOGICAL MALIGNANCIES Daniele Mannina (Rozzano, Italy) | 13:06 - 13:15 |
| OS19-06 | MANAGEMENT OF BLOODSTREAM INFECTION SECONDARY TO BACTERIAL TRANSLOCATION DURING THE NEUTROPENIC PHASE OF STEM CELL TRANSPLANT. A NO-CENTRAL LINE REMOVAL STRATEGY IN 73 EPISODES Angela Trujillo-Gaviria (Medellin, Colombia) | 13:15 - 13:24 |
| OS19-07 | THIRD PARTY FUNGUS-SPECIFIC T CELL THERAPY FOR INVASIVE FUNGAL INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION David Gottlieb (Sydney, Australia) | 13:24 - 13:33 |
| OS19-08 | PRE-TRANSPLANT ASPERGILLOSIS IS ASSOCIATED WITH REDUCED POST-TRANSPLANT SURVIVAL OF CHILDREN WITH LEUKEMIA: SUBGROUP ANALYSIS OF A PROSPECTIVE STUDY ON BEHALF OF IDWP, PDWP AND ALWP-EBMT Jop Jans (Utrecht, Netherlands (the)) | 13:33 - 13:42 |

Oral Session

12:30 - 13:45

R12

OS20 - Oral Session 20 | Aplastic Anaemia & Autoimmune Diseases

Antonio M. Risitano (Avellino, Italy)

Jingjing Feng (Hangzhou, China)

| | | |
|---------|---|---------------|
| OS20-01 | CO-INFUSION OF ANTI-CD19 AND ANTI-BCMA CAR-T CELLS FOR RELAPSED OR REFRACTORY NMOSD: A PHASE 1 CLINICAL TRIAL AND MECHANISTIC INSIGHTS Jingjing Feng (Hangzhou, China) | 12:30 - 12:39 |
| OS20-02 | CSMD1 IS THE MOST COMMONLY MUTATED GENE IN APLASTIC ANEMIA PATIENTS TREATED WITH IMMUNO-SUPPRESSIVE THERAPY: EVIDENCE OF IN VIVO PRUNING SELECTION OF HEMATOPOIETIC CELLS Antonio M. Risitano (Avellino, Italy) | 12:39 - 12:48 |
| OS20-03 | CAR-T ACTIVITY FOR AUTOIMMUNE DISEASES ACROSS EBMT CENTERS IN 2025: A SURVEY ON BEHALF OF EBMT ADWP AND CTIWP Giorgio Orofino (Milan, Italy) | 12:48 - 12:57 |
| OS20-04 | EXPANDING DONOR OPTIONS: RETROSPECTIVE REVIEW OF PRACTICE AND OUTCOMES FOR MISMATCHED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PAEDIATRIC ACQUIRED SEVERE APLASTIC ANAEMIA (SAA) Akshay Deshpande (Birmingham, United Kingdom of Great Britain and Northern Ireland (the)) | 12:57 - 13:06 |
| OS20-05 | THE "WINDOW OF OPPORTUNITY" IN CAR-T FOR LUPUS NEPHRITIS: AUTOLOGOUS BISPECIFIC CD19/BCMA RESCUE IN PATIENTS REFRACTORY TO UNIVERSAL-CD19 CAR-T — A TALE OF TWO BIOPSIES Yajing Zhang (Beijing, China) | 13:06 - 13:15 |
| OS20-06 | GENOMIC INSTABILITY AND HIGH MUTATION BURDEN IN FIBROBLASTS OF SYSTEMIC SCLEROSIS PATIENTS ARE IMPROVED IN CLINICAL RESPONDERS TO AUTOLOGOUS HSCT Jan Storek (Calgary, Canada) | 13:15 - 13:24 |
| OS20-07 | ALEMTUZUMAB-CONDITIONED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION CONFERS EXCELLENT SURVIVAL WITH LIMITED GVHD IN FANCONI ANEMIA Rafaella Muratori (Curitiba, Brazil) | 13:24 - 13:33 |
| OS20-08 | DISEASE STATUS AND HIGH TOXICITY INFLUENCE OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADOLESCENTS AND ADULTS WITH FANCONI ANEMIA: A SPANISH MULTICENTER EXPERIENCE M. Luz Uria Oficialdegui (Barcelona, Spain) | 13:33 - 13:42 |

Oral Session
12:30 - 13:45

R13

OS21 - Oral Session 21 | Hemoglobinopathies & Inborn Errors

Vaibhav Chadha (New Delhi, India)

| | | |
|---------|---|---------------|
| OS21-01 | HAPLOIDENTICAL STEM CELL TRANSPLANT WITH TCR-ALPHA/BETA DEPLETION IN TRANSFUSION DEPENDENT THALASSEMIA POST PRE TRANSPLANT IMMUNOSUPPRESSION Sunil Bhat (Bangalore, India) | 12:30 - 12:39 |
| OS21-02 | ASS-T CELL DEPLETED HAPLOIDENTICAL HSCT FOR PEDIATRIC AND ADULT PATIENTS WITH SICKLE CELL DISEASE: INTERIM ANALYSIS OF THE T-HAPLO-HSCT FOR SCD TRIAL (NCT04201210) Selim Corbacioglu (Regensburg, Germany) | 12:39 - 12:48 |
| OS21-03 | ATIDARSAGENE AUTOTEMCEL IN METACHROMATIC LEUKODYSTROPHY: SAFETY CONSIDERATIONS FROM REAL-WORLD PRACTICE Valeria Calbi (Milan, Italy) | 12:48 - 12:57 |

| | | |
|---------|--|---------------|
| OS21-04 | A DECADE OLD EXPERIENCE OF OPTIMISING CONDITIONING TO IMPROVE HEMATOPOIETIC STEM CELL TRANSPLANTS OUTCOMES IN SICKLE CELL DISEASE Vaibhav Chadha (New Delhi, India) | 12:57 - 13:06 |
| OS21-05 | PROSPECTIVE MULTICENTRE ANALYSIS OF FLUDARABINE EXPOSURE IN CHILDREN RECEIVING FLUDARABINE-TREOSULFAN-THIOTEPA FOR NON-SCID INBORN ERRORS OF IMMUNITY: PRELIMINARY FINDINGS FROM HAPLO+4KIDS Emma Barlow (Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland (the)) | 13:06 - 13:15 |
| OS21-06 | LOWER GVHD RATES IN MISMATCHED DONORS WITH PTCY AS COMPARED TO MATCHED UNRELATED DONORS WITHOUT PTCY AFTER PEDIATRIC FULL BONE MARROW HSCT FOR HEMOGLOBINOPATHIES Gertjan Lugthart (Leiden, Netherlands (the)) | 13:15 - 13:24 |
| OS21-07 | PATIENT-CENTERED, MULTIDISCIPLINARY DELPHI PROCESS TO DEVELOP EUROPEAN CONSENSUS FOR LATE EFFECTS POST-HSCT FOR PATIENTS WITH INBORN ERRORS OF IMMUNITY ON BEHALF OF IEWP AND ESID Reem Elfeky (London, United Kingdom of Great Britain and Northern Ireland (the)) | 13:24 - 13:33 |
| OS21-08 | EXAGAMGLOGENE AUTOTEMCEL FOR SICKLE CELL DISEASE AND TRANSFUSION DEPENDENT BETA THALASSEMIA: REAL WORLD DATA, SINGLE CENTER EXPERIENCE Mohammed Essa (Riyadh, Saudi Arabia) | 13:33 - 13:42 |

General

14:00 - 14:30

R4

GS4 - EBMT 2026 Closing Session

Anna Sureda (Barcelona, Spain)

Rafael Duarte (Madrid, Spain)

| | | |
|-------|---|---------------|
| GS4-1 | Presentation of the Springer Nature Poster Awards Anna Sureda (Barcelona, Spain) | 14:00 - 14:05 |
| GS4-2 | Best Young Abstracts Mette Hazenberg (Amsterdam, Netherlands (the)) | 14:05 - 14:10 |
| GS4-3 | Congress President's closing remarks Rafael Duarte (Madrid, Spain) | 14:10 - 14:15 |
| GS4-4 | Presentation of the 53rd Annual Meeting of the EBMT Annoek Broers (Netherlands (the)) Jurjen Versluis (Rotterdam, Netherlands (the)) | 14:15 - 14:20 |
| GS4-5 | EBMT President's closing remarks Anna Sureda (Barcelona, Spain) | 14:20 - 14:25 |
| GS4-6 | New EBMT President Induction: Passing of the hammer Anna Sureda (Barcelona, Spain) Ibrahim Yakoub-Agha (Lille, France) | 14:25 - 14:30 |